<SEC-DOCUMENT>0001640334-20-000582.txt : 20200323
<SEC-HEADER>0001640334-20-000582.hdr.sgml : 20200323
<ACCEPTANCE-DATETIME>20200320213752
ACCESSION NUMBER:		0001640334-20-000582
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		78
CONFORMED PERIOD OF REPORT:	20191231
FILED AS OF DATE:		20200323
DATE AS OF CHANGE:		20200320

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Emerald Bioscience, Inc.
		CENTRAL INDEX KEY:			0001516551
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				450692882
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-55136
		FILM NUMBER:		20733427

	BUSINESS ADDRESS:	
		STREET 1:		130 NORTH MARINA DRIVE
		CITY:			LONG BEACH
		STATE:			CA
		ZIP:			90803
		BUSINESS PHONE:		(949) 336-3443

	MAIL ADDRESS:	
		STREET 1:		130 NORTH MARINA DRIVE
		CITY:			LONG BEACH
		STATE:			CA
		ZIP:			90803

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Nemus Bioscience, Inc.
		DATE OF NAME CHANGE:	20141030

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LOAD GUARD LOGISTICS, INC.
		DATE OF NAME CHANGE:	20121107

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LOAD GUARD TRANSPORTATION, INC.
		DATE OF NAME CHANGE:	20110324
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>embi_10k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<html><head><title>embi_10k.htm</title><!--Document Created by EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman; MARGIN: 0px 7%"><body style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman; MARGIN: 0px 7%" scroll="yes"><table style="border-collapse:collapse;font-size:1px;width:100%"> <tr> <td style="BORDER-BOTTOM: 5px solid;"></td></tr> <tr> <td style="BORDER-BOTTOM: 2px solid;"></td></tr></table> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:center;"><font style="font-size:12pt"><strong>UNITED STATES</strong></font></p> <p style="MARGIN: 0px; text-align:center;"><font style="font-size:12pt"><strong>SECURITIES AND EXCHANGE COMMISSION</strong></font></p> <p style="MARGIN: 0px; text-align:center;"><font style="font-size:12pt"><strong>Washington, D.C. 20549</strong></font></p> <p style="MARGIN: 0px; text-align:center;">&#160;</p> <p style="MARGIN: 0px; text-align:center;"><font style="font-size:18pt"><strong>FORM 10-K</strong></font></p> <p style="MARGIN: 0px; text-align:center;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong><font style="font-size:10pt">&#9746;&#160;&#160; </font>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</strong></p> <p style="MARGIN: 0px; text-align:center;">&#160;</p> <p style="MARGIN: 0px; text-align:center;">For the fiscal year ended <strong><u>December 31, 2019</u></strong></p> <p style="MARGIN: 0px; text-align:center;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong><font style="font-size:10pt">&#9744;&#160;&#160; </font>TRANSITION</strong><strong> </strong><strong>REPORT</strong><strong> </strong><strong>PURSUANT</strong><strong> </strong><strong>TO</strong><strong> </strong><strong>SECTION</strong><strong> </strong><strong>13</strong><strong> </strong><strong>OR</strong><strong> </strong><strong>15(d)</strong><strong> </strong><strong>OF</strong><strong> </strong><strong>THE</strong><strong> </strong><strong>SECURITIES</strong><strong> </strong><strong>EXCHANGE</strong><strong> </strong><strong>ACT</strong><strong> </strong><strong>OF</strong><strong> </strong><strong>1934</strong></p> <p style="MARGIN: 0px; text-align:center;">&#160;</p> <p style="MARGIN: 0px; text-align:center;">For the transition period from __________ to __________</p> <p style="MARGIN: 0px; text-align:center;">&#160;</p> <p style="MARGIN: 0px; text-align:center;">Commission File Number: <strong><u>000-55136</u></strong></p> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;margin-left:auto;margin-right:auto;width:50%"> <tr> <td style="BORDER-BOTTOM: black 1px solid;"> <p style="MARGIN: 0px; text-align:center;"><font style="font-size:18pt;margin:0px"><strong>Emerald Bioscience, Inc.</strong></font> </p></td></tr> <tr> <td> <p style="MARGIN: 0px; text-align:center;">(Exact name of registrant as specified in its charter)</p></td></tr></table> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"> <tr> <td style="BORDER-BOTTOM: black 1px solid;width:45%;"> <p style="MARGIN: 0px; text-align:center;"><strong>Nevada</strong></p></td> <td style="width:10%;"> <p style="MARGIN: 0px; text-align:center;">&#160;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:45%;"> <p style="MARGIN: 0px; text-align:center;"><strong>45-0692882</strong></p></td></tr> <tr> <td> <p style="MARGIN: 0px; text-align:center;">(State or other jurisdiction </p> <p style="MARGIN: 0px; text-align:center;">of incorporation or organization)</p></td> <td> <p style="MARGIN: 0px; text-align:center;">&#160;</p></td> <td> <p style="MARGIN: 0px; text-align:center;">(I.R.S. Employer</p> <p style="MARGIN: 0px; text-align:center;">Identification No.)</p></td></tr> <tr> <td> <p style="MARGIN: 0px; text-align:center;">&#160;</p></td> <td> <p style="MARGIN: 0px; text-align:center;">&#160;</p></td> <td> <p style="MARGIN: 0px; text-align:center;">&#160;</p></td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid;"> <p style="MARGIN: 0px; text-align:center;"><strong>130 North Marina Drive, Long Beach, CA</strong></p></td> <td> <p style="MARGIN: 0px; text-align:center;">&#160;</p></td> <td style="BORDER-BOTTOM: black 1px solid;"> <p style="MARGIN: 0px; text-align:center;"><strong>90803</strong></p></td></tr> <tr> <td> <p style="MARGIN: 0px; text-align:center;">(Address of principal executive offices)&#160;</p></td> <td> <p style="MARGIN: 0px; text-align:center;">&#160;</p></td> <td> <p style="MARGIN: 0px; text-align:center;">(Zip Code) </p></td></tr></table> <p style="MARGIN: 0px">&#160; &#160;</p> <p style="MARGIN: 0px; text-align:center;">Registrant&#8217;s telephone number, including area code: <strong><u>(949) 336-3443</u></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:center;">Securities registered pursuant to Section 12(b) of the Act:</p> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"> <tr> <td style="BORDER-BOTTOM: black 1px solid;width:45%;"> <p style="MARGIN: 0px; text-align:center;">Title of each class:</p></td> <td style="width:10%;"> <p style="MARGIN: 0px; text-align:center;">&#160;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:45%;"> <p style="MARGIN: 0px; text-align:center;">Name of each exchange on which registered:</p></td></tr> <tr> <td> <p style="MARGIN: 0px; text-align:center;"><strong>None</strong></p></td> <td> <p style="MARGIN: 0px; text-align:center;">&#160;</p></td> <td> <p style="MARGIN: 0px; text-align:center;"><strong>None</strong></p></td></tr></table> <p style="MARGIN: 0px">&#160; &#160;</p> <p style="MARGIN: 0px; text-align:center;">Securities registered pursuant to Section 12(g) of the Act:</p> <p style="MARGIN: 0px; text-align:center;">&#160;</p> <p style="MARGIN: 0px; text-align:center;"><strong><u>Common Stock, Par Value $0.001</u></strong></p> <p style="MARGIN: 0px; text-align:center;">(Title of Class)</p> <p style="MARGIN: 0px; text-align:center;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">Indicate by check mark if registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. <font style="font-family:wingdings;display:inline"><font style="font-family:wingdings">&#168;</font></font> Yes&#160;&#160;&#160;&#160; <font style="font-family:wingdings;display:inline">x</font> No </p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">Indicate by check mark if registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. <font style="font-family:wingdings;display:inline"><font style="font-family:wingdings">&#168;</font></font> Yes&#160;&#160;&#160;&#160; <font style="font-family:wingdings;display:inline">x</font> No </p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <font style="font-family:wingdings;display:inline">x</font> Yes&#160;&#160;&#160; <font style="font-family:wingdings;display:inline"><font style="font-family:wingdings">&#168;</font></font> No</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <font style="font-family:wingdings;display:inline">x</font> Yes&#160;&#160;&#160;&#160; <font style="font-family:wingdings;display:inline"><font style="font-family:wingdings">&#168;</font></font> No</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (&#167; 229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant&#8217;s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. <font style="font-family:wingdings;display:inline">x</font><font style="font-family:wingdings;display:inline"></font></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"> <tr> <td style="width:30%;"> <p style="MARGIN: 0px">Large accelerated filer</p></td> <td style="width:20%;"> <p style="MARGIN: 0px"><font style="font-size:10pt">&#9744;</font></p></td> <td style="width:30%;"> <p style="MARGIN: 0px">Accelerated filer</p></td> <td style="width:20%;"> <p style="MARGIN: 0px"><font style="font-size:10pt">&#9744;</font></p></td></tr> <tr> <td> <p style="MARGIN: 0px">Non-accelerated filer</p></td> <td> <p style="MARGIN: 0px"><font style="font-size:10pt">&#9746;</font></p></td> <td> <p style="MARGIN: 0px">Smaller reporting company</p></td> <td> <p style="MARGIN: 0px"><font style="font-size:10pt">&#9746;</font></p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">Emerging growth company</p></td> <td> <p style="MARGIN: 0px"><font style="font-size:10pt">&#9744;</font></p></td></tr></table> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <font style="font-family:wingdings;display:inline"><font style="font-family:wingdings">&#168;</font></font> </p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). <font style="font-family:wingdings;display:inline"><font style="font-family:wingdings">&#168;</font></font> Yes&#160;&#160;&#160;&#160; <font style="font-family:wingdings;display:inline">x</font> No </p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">The aggregate market value of the voting and non-voting common equity held by non-affiliates was approximately $17,116,620 as of June 28, 2019, based upon the closing price of $.29 per share of the registrant&#8217;s common stock on the OTCQB on June 28, 2019, the last business day of the registrant&#8217;s most recently completed second fiscal quarter.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">As of March 16, 2020, there were 183,207,747 shares of the registrant&#8217;s common stock issued and outstanding.</p> <p style="MARGIN: 0px">&#160; </p> <table style="border-collapse:collapse;font-size:1px;width:100%"> <tr> <td style="BORDER-BOTTOM: 2px solid;"></td></tr> <tr> <td style="BORDER-BOTTOM: 5px solid;"></td></tr></table> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr></table> <p style="MARGIN: 0px; text-align:center;"><strong style="MARGIN: 0px"></strong>&#160;</p> <p style="MARGIN: 0px; text-align:center;"><strong style="MARGIN: 0px"><a name="toc1">TABLE</a></strong><strong> </strong><strong>OF</strong><strong> </strong><strong>CONTENTS</strong></p> <p style="MARGIN: 0px">&#160;&#160; </p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="width:9%;"> <p style="MARGIN: 0px">&#160;</p></td> <td></td> <td style="width:1%;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:9%;"> <p style="MARGIN: 0px; text-align:center;"><strong>PAGE</strong></p></td> <td style="width:1%;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td colspan="5"> <p style="MARGIN: 0px; text-align:center;"><a href="#part1"><strong>PART</strong><strong> </strong><strong>I</strong></a></p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td> <p style="MARGIN: 0px"><a href="#item1">Item 1. </a></p></td> <td> <p style="MARGIN: 0px"><a href="#item1">Business</a></p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px; text-align:right;">3</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td> <p style="MARGIN: 0px"><a href="#item1a">Item 1A.</a></p></td> <td> <p style="MARGIN: 0px"><a href="#item1a">Risk Factors</a></p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px; text-align:right;">16</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td> <p style="MARGIN: 0px"><a href="#item1b">Item 1B. </a></p></td> <td> <p style="MARGIN: 0px"><a href="#item1b">Unresolved Staff Comments</a></p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px; text-align:right;">35</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td> <p style="MARGIN: 0px"><a href="#item2">Item 2. </a></p></td> <td> <p style="MARGIN: 0px"><a href="#item2">Properties</a></p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px; text-align:right;">35</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td> <p style="MARGIN: 0px"><a href="#item3">Item 3.</a></p></td> <td> <p style="MARGIN: 0px"><a href="#item3">Legal Proceedings</a></p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px; text-align:right;">35</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td> <p style="MARGIN: 0px"><a href="#item4">Item 4.</a></p></td> <td> <p style="MARGIN: 0px"><a href="#item4">Mine Safety Disclosures</a></p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px; text-align:right;">35</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td colspan="5" style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;"><strong><a href="#part2">PART II</a></strong></p></td></tr> <tr style="background-color:#ffffff;"> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><a href="#item5">Item 5.</a></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><a href="#item5">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity</a></p> <p style="MARGIN: 0px"><a href="#item5">Securities</a></p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:right;">36</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><a href="#item6">Item 6.</a></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><a href="#item6">Selected Financial Data</a></p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:right;">37</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><a href="#item7">Item 7.</a></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><a href="#item7">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:right;">37</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><a href="#item7a">Item 7A.</a></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><a href="#item7a">Quantitative and Qualitative Disclosures About Market Risk</a></p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:right;">42</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><a href="#item8">Item 8.</a></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><a href="#item8">Financial Statements and Supplementary Data</a></p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:right;">43</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><a href="#item9">Item 9.</a></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><a href="#item9">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:right;">43</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><a href="#item9a">Item 9A.</a></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><a href="#item9a">Controls and Procedures</a></p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:right;">43</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><a href="#item9b">Item 9B.</a></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><a href="#item9b">Other Information</a></p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:right;">43</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td colspan="5" style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;"><strong><a href="#part3">PART III</a></strong></p></td></tr> <tr style="background-color:#ffffff;"> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><a href="#item10">Item 10.</a></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><a href="#item10">Directors, Executive Officers and Corporate Governance</a></p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:right;">44</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><a href="#item11">Item 11.</a></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><a href="#item11">Executive Compensation</a></p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:right;">47</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><a href="#item12">Item 12.</a></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><a href="#item12">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:right;">50</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><a href="#item13">Item 13.</a></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><a href="#item13">Certain Relationships and Related Transactions, and Director Independence</a></p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:right;">51</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><a href="#item14">Item 14.</a></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><a href="#item14">Principal Accountant Fees and Services</a></p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:right;">54</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td colspan="5" style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;"><strong><a href="#part4">PART IV</a></strong></p></td></tr> <tr style="background-color:#ffffff;"> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><a href="#item15">Item 15.</a></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><a href="#item15">Exhibits, Financial Statement Schedules</a></p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:right;">55</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><a href="#item16">Item 16.</a></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><a href="#item16">Form 10-K Summary</a></p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:right;">57</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr></table> <p style="MARGIN: 0px">&#160;&#160; </p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">2</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc1">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:center;"><strong><a name="part1">PART</a> I</strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><em>As used in this report, unless otherwise indicated, the terms &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Company&#8221; and &#8220;Emerald Bioscience&#8221; refer to Emerald Bioscience, Inc., a Nevada corporation formerly known as Nemus Bioscience, Inc. and Load Guard Logistics, Inc., together with its wholly-owned subsidiaries, Nemus, a California corporation, and EMBI Australia Pty Ltd, an Australian proprietary limited company.</em></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong><u><a name="item1">Item</a> 1. Business</u></strong><strong>. </strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong>History</strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">We were incorporated in the State of Nevada on March 16, 2011 as Load Guard Transportation, Inc., and subsequently changed our name to Load Guard Logistics, Inc. in 2012.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">On October 31, 2014, Load Guard Logistics, Inc. (&#8220;LGL&#8221;) closed an Agreement and Plan of Merger, dated October 17, 2014 (the &#8220;Merger Agreement&#8221;), with Nemus Acquisition Corp. (&#8220;Acquisition Sub&#8221;), Nemus Bioscience, Inc. (&#8220;Name Change Merger Sub&#8221;), and Nemus (&#8220;Nemus&#8221;), pursuant to which Acquisition Sub merged with and into Nemus and Nemus survived as a wholly-owned subsidiary of LGL (the &#8220;Merger&#8221;). On November 3, 2014, LGL changed its name to &#8220;Nemus Bioscience, Inc.&#8221; by merging with Name Change Merger Sub.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">On October 31, 2014, immediately prior to the consummation of the Merger, we entered into an Assignment and Assumption Agreement with LGT, Inc., a wholly owned subsidiary, pursuant to which we transferred all of its assets and liabilities to LGT.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">On October 31, 2014, we entered into a Share Repurchase and Cancellation Agreement with LGT, Yosbani Mendez and Francisco Mendez, pursuant to which we repurchased 5,431,460 shares of our common stock from Yosbani Mendez and Francisco Mendez for a repurchase price of all of the issued and outstanding shares of LGT. Upon the repurchase, we cancelled all of such repurchased shares.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">Prior to the Merger, we were a transportation and logistics company engaged primarily in hauling truckload shipments of general commodities in both interstate and intrastate commerce. Following the Merger, we became a biopharmaceutical company focused on the discovery, development and commercialization of cannabinoid-based therapeutics.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">In January 2018, we entered into a securities purchase agreement with Emerald Health Sciences, Inc. (&#8220;Emerald Health Sciences&#8221;), pursuant to which Emerald Health Sciences purchased a majority of the outstanding equity in us, resulting in a change in control of the Company. As part of the transaction, the members of Board of Directors of the Company (the &#8220;Board&#8221;), with the exception of Dr. Brian Murphy, our CEO, tendered their resignation, and Emerald Health Sciences appointed two nominees to the Board. </p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">In October 2018, the Board appointed Dr. Avtar Dhillon, the Chairman, CEO and President of Emerald Health Sciences, as the Executive Chairman of the Board. On December 17, 2019, the Board accepted the resignation of Dr. Avtar Dhillon, who offered his resignation as the Executive Chairman of the Board and the position of Chairman of the Finance and Business Development Committee of the Board. The Board also appointed Punit Dhillon, an existing member of the Board, as Chairman of the Board and as Chairman of the Finance and Business Development Committee of the Board, to fill the vacancies in such offices created by the resignation of Dr. Dhillon. </p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">Effective March 25, 2019, we changed our name to Emerald Bioscience, Inc.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">In August 2019, we formed a new subsidiary in Australia, EMBI Australia Pty Ltd. in order to qualify for the Australian government&#8217;s research and development tax credit for research and development dollars spent in Australia. The primary purpose of EMBI Australia Pty Ltd. is to conduct clinical trials for our product candidates.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">As of December 31, 2019, we have devoted substantially all of our efforts to securing product licenses, carrying out research and development activities, building infrastructure and raising capital. We have not yet realized revenue from our planned principal operations.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong>Business Overview</strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">We are a biopharmaceutical company targeting the discovery, development and commercialization of cannabinoid-based therapeutics through a number of license agreements with the University of Mississippi (&#8220;UM&#8221;). UM holds the only contract to cultivate cannabis for research purposes on behalf of the Federal Government of the United States and has held that federal license since 1968, and it has significant expertise in cannabis cultivation and the extraction, separation, processing and manufacture of cannabis extracts as well as the chemistry and physiology of cannabinoid molecules. We were established as, and continue to be, a development and commercialization partner of UM, working to bring the University&#8217;s proprietary cannabinoid molecules through the development process.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong>Our Strategic Partnership</strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">In July 2013, we entered into a Memorandum of Understanding (the &#8220;MOU&#8221;), with UM to engage in joint research of extracting, manipulating, and studying cannabinoids in certain forms to develop intellectual property with the intention of creating and commercializing therapeutic medicines. The MOU provided that we own all intellectual property developed solely by our employees and will jointly own all intellectual property developed jointly between Emerald Bioscience and UM employees. The term of the MOU was five years and the parties agreed to enter into separate research agreements upon the identification of patentable technologies. This MOU resulted in us entering into several licenses and research agreements with UM related to a prodrug of tetrahydrocannabinol (&#8220;THC&#8221;) and an analog of cannabidiol (&#8220;CBD&#8221;). The term of the MOU expired in 2018 and was not renewed because we and UM had entered into a number of licenses for the aforementioned compounds.</p> <p style="MARGIN: 0px">&#160; </p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">3</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc1">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160; &#160;</p> <p style="MARGIN: 0px"><strong><em>UM 5050 Pro-Drug Agreements and UM 8930 Analog Agreements</em></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">In July 2018, we renewed the ocular licenses for UM 5050, related to the proprietary pro-drug formulation of tetrahydrocannabinol (&#8220;THC&#8221;), and UM 8930, related to an analog formulation of cannabidiol (&#8220;CBD&#8221;). On May 24, 2019, the ocular delivery licenses were replaced by &#8220;all fields of use&#8221; licenses for both UM 5050 and UM 8930 (the &#8220;License Agreements&#8221;). Pursuant to these license agreements, UM granted us an exclusive, perpetual license, including, with the prior written consent of UM, the right to sublicense, the intellectual property related to UM 5050 for tetrahydrocannabinol-valine-hemisuccinate (&#8220;THCVHS&#8221;) and UM 8930 for cannabidiol-valine-hemisuccinate (&#8220;CBDVHS&#8221;) for all fields of use.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">The all fields of use licenses contain certain milestone payments, royalty and sublicensing fees payable by us, as defined therein. Each License Agreement provides for an annual maintenance fee of $75,000 payable on the anniversary of the effective date. The upfront payment for UM 5050 is $100,000 and the upfront payment for UM 8930 is $200,000. Additionally, there is also a $200,000 fee due within 30 days upon receipt of the first United States Patent and Trademark Office Notice of Allowance for UM 8930. The milestone payments payable for each license are as follows:</p> <p style="MARGIN: 0px">&#160;&#160; </p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="width:4%;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">$100,000 paid within 30 days following the submission of the first Investigational New Drug Application to the Food and Drug Administration or an equivalent application to a regulatory agency anywhere in the world, for a product&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">$200,000 paid within 30 days following the first submission of a NDA, or an equivalent application to a regulatory agency anywhere in the world, for each product that is administered in a different route of administration from that of the early submitted product(s)&#894; and</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">$400,000 paid within 30 days following the approval of a NDA, or an equivalent application to a regulatory agency anywhere in the world, for each product that is administered in a different route of administration from that of the early approved product(s).</td></tr></table> <p style="MARGIN: 0px">&#160; </p> <p style="MARGIN: 0px">The royalty percentage due on net sales under each License Agreement is in the mid-single digits. We must also pay to UM a portion of all licensing fees received from any sublicensees, subject to a minimum royalty on net sales, and we are required to reimburse patent costs incurred by UM related to the licensed products. The royalty obligations apply by country and by licensed product, and end upon the later of the date that no valid claim of a licensed patent covers a licensed product in a given country, or ten years after the first commercial sale of such licensed product in such country.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">Each License Agreement continues, unless terminated, until the later of the expiration of the last to expire of the patents or patent applications within the licensed technology or the expiration of our payment obligations under the License Agreement. UM may terminate each License Agreement, by giving written notice of termination, upon our material breach and of the License Agreements, including failure to make payments or satisfy covenants, representations or warranties without cure, noncompliance, a bankruptcy event, our dissolution or cessation of operations, our failure to make reasonable efforts to commercialize at least one product or failure to keep at least one product on the market after the first commercial sale for a continuous period of one year, other than for reasons outside our control, or our failure to meet certain pre-established development milestones. We may terminate each License Agreement upon 60 days&#8217; written notice to UM.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong><em>UM 5070 License Agreement</em></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">In January 2017, we entered into a license agreement with UM pursuant to which UM granted us an exclusive, perpetual license, including the right to sublicense, the intellectual property related to a platform of cannabinoid-based molecules (&#8220;UM 5070&#8221;), to research, develop and commercialize products for the treatment of infectious diseases. The license agreement culminates roughly one year of screening and target molecule identification studies especially focused on therapy-resistant infectious organisms like Methicillin-resistant Staphylococcus aureus (&#8220;MRSA&#8221;).</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">We paid UM an upfront license fee under the license agreement. Under the license agreement, we are also responsible for annual maintenance fees that will be credited against royalties in the current fiscal year, contingent milestone payments upon achievement of development and regulatory milestones, and royalties on net sales of licensed products sold for commercial use. The aggregate milestone payments due under the license agreement if all of the milestones are achieved is $700,000 and the royalty percentage due on net sales is in the mid-single digits. We must also pay to UM a percentage of all licensing fees we receive from any sublicensees, subject to a minimum royalty on net sales by such sublicensees. Our royalty obligations apply on a country by country and licensed product by licensed product basis, and end upon the later of the date that no valid claim of a licensed patent covers a licensed product in a given country, or ten years after first commercial sale of such licensed product in such country.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">The license agreement continues, unless terminated, until the later of the expiration of the last to expire of the patents or patent applications within the licensed technology or expiration of our payment obligations under the license. UM may terminate the license agreement, effective with the giving of notice, if: (a) we fail to pay any material amount payable to UM under the license agreement and do not cure such failure within 60 days after UM notifies us of such failure, (b) we materially breach any covenant, representation or warranty in the license agreement and do not cure such breach within 60 days after UM notifies us of such breach, (c) we fail to comply in any material respect with the terms of the license and do not cure such noncompliance within 60 days after UM notifies us of such failure, (d) we are subject to a bankruptcy event, (e) we dissolve or cease operations or (f) if after the first commercial sale of a product during the term of the license agreement, we materially fail to make reasonable efforts to commercialize at least one product or fail to keep at least one product on the market after the first commercial sale for a continuous period of 1 year, other than for reasons outside our control. We may terminate the license agreement upon 60 days&#8217; written notice to UM.</p> <p style="MARGIN: 0px">&#160; </p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">4</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc1">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160; </p> <p style="MARGIN: 0px"><strong>Our Product Candidates</strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">Cannabinoids are a class of chemically diverse compounds that are mainly found in extracts from the cannabis plant. These compounds express their physiological response by binding to specific cannabinoid receptors (CB1 and CB2), which are found throughout the body. Some cannabinoids have been observed to exert multiple effects on the human body, including, but not limited to: impacting the immune response, nervous system function and repair, gastrointestinal maintenance and motility, motor function in muscles, pancreatic functionality, modulating inflammation and tissue repair, blood sugar regulation, and integrity of function in the eye (including the optic nerve). Cannabis and specific cannabinoids have been studied widely, with limited published data suggesting the potential for these compounds to be used in treating many disorders or alleviating disease-associated symptoms. </p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">We are focused on the development of early stage cannabinoid product candidates. The following table summarizes certain information regarding our cannabinoid product candidates:</p> <p style="MARGIN: 0px">&#160; </p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="BORDER-BOTTOM: 1px solid;width:15%;vertical-align:top;"> <p style="MARGIN: 0px"><strong>Product Candidate</strong></p></td> <td style="width:2%;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:28%;vertical-align:top;"> <p style="MARGIN: 0px"><strong>Indication</strong></p></td> <td style="width:2%;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:31%;vertical-align:top;"> <p style="MARGIN: 0px"><strong>Development Status</strong></p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px">NB1111</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px">Glaucoma</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px">Preclinical</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px">NB2222</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px">Multiple Ocular Targets</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px">Preclinical</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px">NB3111</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px">MRSA</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px">Research</p></td></tr></table> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong><em>NB1111</em></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">Glaucoma is an ocular neuropathy associated with the initiation of programmed cell death, known as apoptosis, of the retinal ganglion cells (&#8220;RGCs&#8221;) of the optic nerve, resulting in progressive and irreversible loss of vision. Intraocular pressure (&#8220;IOP&#8221;) has been identified as an important risk factor in the pathogenesis of this disease. Elevated IOP can lead to damage of RGC axons through vascular ischemia by compromising blood flow to the cells, and physical crush injury as the elevated ocular pressure compresses these delicate cells. Cannabinoid receptors are highly concentrated in the eye, especially in organs of the anterior compartment that help regulate IOP, and the posterior compartment in the area of the retina and optic nerve. Stimulation of cannabinoid receptors by THC has been previously shown to lower IOP in both animal and human studies.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">Our lead ocular compound is NB1111, a prodrug of THC. The molecule has been formulated to make the usually lipophilic THC more hydrophilic to allow for improved transport across membranes. In 2013 and 2014, UM conducted studies of the formulation in the rabbit ocular model which showed that the molecule was able to penetrate all chambers of the eye which could potentially broaden the proposed therapeutic indications of interest to diseases in the posterior compartment of the eye that affect the retina and optic nerve, such as macular degeneration or diabetic retinopathy. These studies also revealed that the formulation was able to achieve potentially therapeutic concentrations in the anterior compartment, vitreous humor, and posterior compartment of the normal rabbit eye, which is very similar to the human eye in anatomy and physiology. The rabbit ocular model is an accepted animal model for regulatory agencies when considering a candidate drug for human testing and this data will be submitted as part of the investigational new drug application (&#8220;IND&#8221;) to the Food and Drug Administration (the &#8220;FDA&#8221;). Additional studies using an alpha-chymotrypsin induced glaucoma model in rabbits were performed by UM in 2013 and 2014 under a grant from the National Institutes of Health (the &#8220;NIH&#8221;). Those studies showed that NB1111 was able to reduce IOP by 45% to 50%. Reduction in IOP was successful in an almost linear dose-responsive manner, with greater decline in IOP associated with higher dosage concentration. The decline in IOP observed in the rabbit model correlated to historical human data when patients were exposed to systemically administered THC via inhalational methods. The human studies were conducted by the NIH and the U.S. Army in the 1970&#8217;s where glaucoma patients for the NIH study and normal volunteers for the U.S. Army study were exposed to THC by smoking marijuana. Patients tested by the NIH exhibited a decline in IOP ranging from 35% to as high as 65%, correlated to the amount of THC in the plasma and relative to their baseline IOP level. Normal volunteers in the U.S. Army study also showed a decrease in IOP of approximately 10% to 20% in a setting of normotension. While THC from smoking marijuana was able to reduce IOP in humans, the effect was short lived given the short half-life of the THC molecule. The half-life of the pro-drug used in the rabbit glaucoma model was longer, but still pointed to the need to formulate the pro-drug in a way to lengthen the half-life that would be consistent with once-daily dosing of a marketed product</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">We examined the compound in further testing using a nanoparticle delivery system to prolong the drug&#8217;s biologic half-life in late 2015 and 2016. The studies were conducted by UM and placed NB1111 into a solid lipid-nanoparticle system (&#8220;SLN&#8221;) to deliver the drug to the eye using topical drop administration. The SLN delivery of NB1111 was administered to rabbits that underwent elevated IOP inducement using the alpha-chymotrypsin model. Data from that experiment confirmed previous studies that showed administration of NB1111 resulted in a 45% reduction in IOP from baseline with a half- life consistent with five to six-times per day dosing. When NB1111 was administered via SLN delivery in a normotensive model, the lower concentration of NB1111 (0.4% equivalent THC) exhibited a decrease in IOP of approximately 20% while the higher concentration of NB1111 (0.6% equivalent THC) lowered IOP by a maximum of 38%. The use of SLN technology lengthened the physiologic half-life of NB1111 equivalent to dosing the drug two to three times a day. Subsequently, the formulation being developed for human studies will involve encapsulating the drug in a nanoemulsion complemented with the use of the viscosity enhancer, Carbopol, to increase the residence time of the drug on the eye. Testing of this formulation in a normotensive animal model revealed statistically significant lowering of the IOP when compared to both latanoprost and timolol, as well as extended pharmacologic activity time that could possibly support once daily dosing.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">Further animal experimentation conducted in 2016-2017 examined both the penetration and concentration of NB1111 in key organs of the eye. The data revealed that IOP declined in a concentration-time dependent manner and could be correlated to the concentration of THC in organs regulating IOP, such as the trabecular meshwork in the anterior compartment and the retina-choroid in the posterior compartment. The data was important for demonstrating a direct causal relationship between the penetration and concentration of THC with IOP-lowering capability and the presence of THC in multiple compartments of the eye. Additionally, neither free-THC nor 11-hydroxy-THC (the main active metabolite of THC) was detected in the peripheral circulation of the test animals, indicating that the topical dosage of the test compound remained restricted to the eye.</p> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">5</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc1">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">In 2019, UM completed experiments showing that NB1111 was statistically superior in lowering IOP compared to the prostaglandin-based therapy, latanoprost, the current standard-of-care for treating glaucoma. Significance was reached across multiple timepoints during a seven-day course of dosing using a validated rabbit normotensive ocular model and NB1111 exerted pharmacologic activity consistent with once-daily to twice-daily dosing. Additionally, Glauconix Biosciences Inc. (&#8220;Glauconix&#8221;) completed their pilot study to research the mechanism of action and IOP-lowering ability of THC when administered into an <em>ex vivo</em> model of a 3D-human trabecular meshwork using both healthy and glaucomatous-derived tissues. The Glauconix study validated the mechanism of action of NB1111 in lowering IOP, a defining disease process of hypertensive glaucoma. Moreover, biomarkers associated with inflammation and fibrosis in both normal and tissues affected by glaucoma were significantly decreased, pointing to anti-inflammatory and anti-fibrotic activities that are often associated with the cannabinoid class of molecules in other disease-states; and data revealed that biomarkers associated with neovascularization, a disease process of new blood vessel formation that can damage the retina in a variety of ocular diseases, was also inhibited by THC, prompting further study for the utility of this drug in diseases of the retina.</p> <p style="MARGIN: 0px">&#160; </p> <p style="MARGIN: 0px; text-align:justify;">The manufacturing of the active pharmaceutical ingredient of NB1111 is conducted in the United States. Formulation of the eye drop for testing is also performed in the United States but can rely on regulatory-accepted excipients that can be sourced from countries outside the United States, such as China. In lieu of the recent pandemic of COVID-19, there could possibly be an impact on sourcing materials that are part of the eye drop formulation, as well as impacting volunteer and/or patient recruitment in Australia for clinical studies. Therefore, we anticipate shifting our first in-human studies of the lead drug candidate, NB1111, from the second half of 2020, to the 2021 timeframe. The first-in-human studies are to be conducted in healthy volunteers and patients with glaucoma and ocular hypertension in Australia (the &#8220;Clinical Trial&#8221;). Initially, we plan to conduct single-ascending dose (&#8220;SAD&#8221;) and multiple-ascending dose (&#8220;MAD&#8221;) studies to establish physiological activity in humans to define a dosing therapeutic window and to validate an ocular formulation for larger follow-on studies. Subsequently, Phase 2 studies will be advanced provided initial human clinical data point to IOP lowering activity balanced by safety parameters. Phase 2 studies in glaucoma/ocular hypertension are expected to be conducted over 7 to 28 days with supporting safety labs monitored concurrently with dosing, including validated assays to detect any evidence of THC in the peripheral circulation of those dosed. Given that IOP data is objectively measured, we will decide whether to conduct a subsequent Phase 2b study or go directly to a larger Phase 3 clinical trial based on the quality of the data collected in the Phase 2a study and the advice provided by the FDA or other regulatory bodies.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px"><strong><em>NB2222</em></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">NB2222 is a prototype ocular formulation of the proprietary Emerald Bioscience CBD analog, CBDVHS. We have embarked on studies with UM exploring the utility of our drug candidate NB2222 as an eye drop emulsion for the potential treatment and management of several eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. Data presented at the American Association of Pharmaceutical Scientists (AAPS) meeting held in November 2017, revealed that this early formulation of the CBD analog was able to penetrate multiple compartments of the eye, including reaching the retina and the optic nerve. Further testing will need to be conducted to assess biomarkers for the possible utility of this compound as a therapeutic agent.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">In 2019, we announced that data generated by Glauconix showed significant anti-inflammatory and anti-fibrotic activity in ocular tissue with CBDVHS, when compared to CBD, indicating therapeutic potential as a neuroprotectant, especially in diseases of the retina. CBDVHS displayed a statistically significant potency when compared to CBD. Additionally, CBDVHS was not associated with elevating IOP at anti-fibrotic concentrations based on biomarker data.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">In 2019, UM also completed pre-clinical experiments showing that NB2222 exhibited an ability to penetrate multiple chambers of the eye and reach the optic nerve. These findings support the therapeutic potential to provide ocular neuroprotection of retinal ganglion cells, an important goal in treating diseases which lead to vision loss. The data were published in the peer-reviewed Journal of Ocular Pharmacology and Therapeutics in a paper titled, &#8220;Analog Derivatization of Cannabidiol for Improved Ocular Permeation&#8221; (2019&#894; volume 35 (5): 1-10).</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">In 2020, we expect to continue to advance our pre-clinical studies related to NB2222 and our proprietary CBD analog. </p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong><em>NB3111</em></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">MRSA was first described in 1961 after the introduction of the antibiotic, methicillin, and since that time, the prevalence of the organism has increased globally in both community and healthcare settings. The prevalence of MRSA in intensive care units in the United States has been estimated to be 60% (Am J Infect Control 2004&#894; 32:470) with more than 90,000 invasive MRSA infections occurring annually in the United States resulting in more than 18,000 deaths (JAMA 2007&#894; 298: 1763-71). Annual costs for treating MRSA in the United States are projected to exceed $4 billion, accounting for a collective eight million extra hospital days annually (ISPOR&#894; 10th Annual Meeting, Wash D.C., May 2005&#894; Pew Foundation Research Brief, April 2012).</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">MRSA is classically resistant to conventional antibiotics to treat staph infections such as fluoroquinolones, beta-lactams, and macrolides. Most patients who develop MRSA infections are usually colonized with either a community acquired strain (CA-MRSA) or healthcare-associated strain (HA-MRSA). Therefore, antibiotic development against MRSA can take three approaches: (a) decolonization, (b) treatment of localized soft tissue infections, or (c) systemic antibiotic for generalized sepsis.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">Cannabinoid molecules have been shown in in vitro studies conducted by third parties to possess anti-infective activity against a variety of MRSA strains. We entered into a research agreement with UM to explore this area in 2015 and have tested a variety of cannabinoids in various strengths, combinations, and delivery systems against a variety of MRSA species found in community, healthcare, and institutional settings such as nursing homes, correctional facilities, and military quarters. As discussed above in &#8220;Our Strategic Partnership - UM 5070 License Agreement,&#8221; in January 2017, we entered into a license agreement with UM pursuant to which UM granted us an exclusive, perpetual license, including the right to sublicense, to intellectual property related to UM 5070, a platform of cannabinoid-based molecules to research, develop and commercialize products for the treatment of infectious diseases.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong><em>Other Potential Products</em></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">We continue to plan to work with UM to explore other potential indications and associated routes of administration based on the expanded UM 5050 and UM 8930 all fields of use licenses. Our decision to advance a potential therapeutic candidate will be influenced by a number of criteria, including but not limited to pre-clinical data, synthesis and formulation capability, as well as prevailing market conditions.</p> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">6</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc1">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">For example, in December 2019, we announced data generated by StemoniX, that CBDVHS was both pharmacologically and therapeutically distinct from CBD when studied in an <em>in vitro</em> human neural tissue model mimicking chemically-induced seizure-like hyperactivity. Additionally, CBDVHS was observed to gain potency in anti-seizure-like activity over the seven-day observation period, whereas the suppressive effect afforded by CBD dissipated by day three. In assessing safety parameters of CBDVHS, the molecule was not found to be toxic to the neurologic cells tested in multiple assays, both in acute and longer-term exposure.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;&#160;&#160; </p> <p style="MARGIN: 0px"><strong>Our Competitive Strengths</strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">Cannabis is subject to strict regulation in the United States. Cannabis and cannabis extracts are classified by the U.S. Drug Enforcement Administration (the &#8220;DEA&#8221;), as a Schedule I substance, which means that, under federal law, it has no established medicinal use and may not be marketed or sold in the United States. In addition, the United States is a party to the Single Convention on Narcotic Drugs, which imposes certain requirements and restrictions on member parties with respect to the cultivation and wholesale trade in cannabis. Since 1968, UM has held the only contract with the Federal Government to cultivate cannabis on its behalf for research purposes and holds the requisite DEA registrations authorizing it to engage in that activity. The contract, which is open for competitive bidding at periodic intervals, is administered by the National Institute on Drug Abuse (&#8220;NIDA&#8221;), an agency within the NIH. UM&#8217;s current contract was awarded in 2015 and runs for a base year of one year with four one-year options. Although in August 2016 the DEA announced that it would consider granting registrations for the cultivation of cannabis for research and development purposes outside of the NIDA contract process, we are not aware of any entity that has received such a registration under this process. As the sole contract holder since 1968, UM has developed significant expertise in the extraction, separation, processing and manufacture of cannabinoids. UM has also engaged in the cultivation of cannabis and the extraction of cannabinoids for purposes of developing drug product candidates apart from its role as NIDA contractor. We have entered into several research and license agreements with UM and view this collaborative association as a significant strategic advantage in the marketplace.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">The only cannabinoid products that are currently approved as drugs in the United States and, to our knowledge, all cannabinoid products in late-stage development, are predominantly orally-delivered products. Cannabinoids, when ingested orally, are subject to significant first pass metabolism by the liver and potential drug-drug interactions, resulting in very high inter-patient and intra-patient variation in bioavailability which can potentially compromise both efficacy and safety. This has been published in the literature and in product labeling by regulatory agencies worldwide. These independent assessments correlate with highly variable response rates and safety profiles which, in some cases, have been deemed to have marginal clinical utility.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">We have licensed from UM the rights to a pro-drug formulation of THC. Data from UM supports the delivery of the pro-drug through absorptive routes other than the gastrointestinal tract, which we believe has the potential to mitigate the issue of first-pass metabolism by the liver, potentially enhancing drug bioavailability and predictive pharmacokinetics.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">We are also working with UM and other parties on methods to formulate and deliver a variety of other pharmaceutical-grade cannabinoids to better manage symptoms and/or treat diseases.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong>Our Business Strategy</strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">Our goal is to become a premier developer of prescriptive cannabinoid-based medicines for global markets with significant unmet medical needs. Our current operating strategy includes:</p> <p style="MARGIN: 0px">&#160; </p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="width:4%;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">selection of potential clinical targets based on internal and external published data, access to appropriate cannabinoids, and the impact of both developmental and market conditions&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">prioritization of product candidates based on the potential clinical utility of associated target indications&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">utilization, where feasible, of naturally-derived drug prototypes leading to synthetically produced cannabinoid derivatives optimized for development and commercialization&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">development and execution of an intellectual property strategy&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">development and advancement of our current product pipeline&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">outsourcing services, such as use of Clinical Research Organizations (&#8220;CROs&#8221;) and contract manufacturers for the API, where possible and appropriate&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">obtaining regulatory approval from the FDA, EMA, and other appropriate regulatory agencies for product candidates&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">research and development of additional target indications for cannabinoid product candidates&#894; and</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">partnering, out-licensing, or selling approved products, if any, to optimize Company efficiencies to bring state-of-the-art therapeutics to patients.</td></tr></table> <p style="MARGIN: 0px">&#160;&#160; </p> <p style="MARGIN: 0px"><strong>Sales and Marketing</strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">We have not established a sales, marketing or product distribution infrastructure because our lead product candidates are still in research, discovery or preclinical development stages. If and when we obtain approval to market any of our product candidates, we will evaluate what we believe to be the optimal commercialization path for the Company, the respective product candidate, and patients. Commercialization paths may include licensing, selling, or partnering with other commercial partners. We may also choose to build a commercial sales and marketing team for some or all of our product candidates.</p> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">7</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc1">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160; </p> <p style="MARGIN: 0px"><strong>Manufacturing</strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">We do not own or operate, and currently have no plans to establish, any manufacturing facilities for final manufacture. We currently rely, and expect to continue to rely, on third parties to manufacture our product candidates for preclinical and clinical testing, as well as for commercial manufacturing of any products that we may commercialize.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">We entered into agreements with Albany Molecular Research Inc. (&#8220;AMRI&#8221;) in February 2016, July 2018 and April 2019 for the development and manufacture of our proprietary cannabinoid- based APIs. In late 2016, we finalized a commitment with Teewinot Life Sciences, working in conjunction with AMRI, to manufacture biosynthetically produced cannabinoids derivatives licensed from UM to be used in clinical trials or commercialized products. It is anticipated that the biosynthetically generated API will eventually form the basis of our drug candidates NB1111 in development for glaucoma and NB2222 for ocular diseases. In August 2019, we terminated our ongoing agreements with AMRI. We entered into an agreement with Noramco Inc. (&#8220;Noramco&#8221;) in February 2019 to develop scale-up synthesis methods and to manufacture the analog derivative, CBDVHS, and amended the agreement in August 2019 to include THCVHS.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">For all of our future product candidates, we aim to identify and qualify manufacturers to provide the API and fill-and-finish services prior to submission of an NDA to the FDA. We expect to continue to develop drug candidates that can be produced cost-effectively at contract manufacturing facilities.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong>Intellectual Property</strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">The success of most of our product candidates will depend in large part on our ability to:</p> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="width:4%;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">obtain and maintain patent and other legal protections for the proprietary technology, inventions and improvements we consider important to our business&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">prosecute our patent applications and defend any issued patents we obtain&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">preserve the confidentiality of our trade secrets&#894; and</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">operate without infringing the patents and proprietary rights of third parties.</td></tr></table> <p style="MARGIN: 0px">&#160;&#160; </p> <p style="MARGIN: 0px">We intend to continue to seek appropriate patent protection for certain of our product candidates, drug delivery systems, molecular modifications, as well as other proprietary technologies and their uses by filing patent applications in the United States and other selected global territories. We intend for these patent applications to cover, where possible, claims for medical uses, processes for isolation and preparation, processes for delivery and formulations.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">As of the date of this Annual Report, we have licensed from UM two U.S. patents as well as foreign counterparts in the United Kingdom, European Union, Japan, Hong Kong, Canada and Australia. The patents that we license cover composition of matter and preparation of delta-9 THC amino acid esters and their methods of use. These patents are expected to expire in 2034. Additionally, in March 2020, we were notified by the United States Patent and Trademark Office, that a notice of allowance has been issued for the proprietary analog of cannabidiol, CBDVHS. Under our license agreements, UM retains ownership over the licensed patents and control over the maintenance and prosecution of the licensed patents and patent applications. We also rely upon unpatented trade secrets and know- how and continuing technological innovation to develop and maintain our proprietary and intellectual property position. We seek to protect our proprietary information, in part, using confidentiality agreements with our collaborators, scientific advisors, employees and consultants, and invention assignment agreements with our employees and selected consultants, scientific advisors and collaborators. The confidentiality agreements are designed to protect our proprietary information and, in the case of agreements or clauses requiring invention assignment, to grant us ownership of technologies that are developed through a relationship with a third-party.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong>Competition</strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">Our industry is characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. We face potential competition from many different sources, such as pharmaceutical companies, including generic drug companies, biotechnology companies, drug delivery companies and academic and research institutions. Many of our potential competitors have substantially greater financial, scientific, technical, intellectual property, regulatory and human resources than we do, and greater experience than we do commercializing products and developing product candidates, including obtaining FDA and other regulatory approvals for product candidates. Consequently, our competitors may develop products for indications we pursue that are more effective, better tolerated, more widely-prescribed or accepted, more useful and less costly, and they may also be more successful in manufacturing and marketing their products. We also face competition from third parties in recruiting and retaining qualified personnel, establishing clinical trial sites and enrolling patients for clinical trials and in identifying and acquiring or in-licensing new products and product candidates.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong>Government Regulation</strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">Government authorities in the United States, at the federal, state and local level, and in other countries, extensively regulate, among other things, the research, development, testing, manufacture, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, import and export of pharmaceutical products such as those we are developing. The processes for obtaining regulatory approvals in the United States and in foreign countries, along with subsequent compliance with applicable statutes and regulations, require the expenditure of substantial time and financial resources. A failure to comply with such laws and regulations or prevail in any enforcement action or litigation related to noncompliance could have a material adverse impact on our business, financial condition and results of operations and could cause the market value of our common stock to decline.</p> <p style="MARGIN: 0px">&#160; </p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">8</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc1">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong><em>Regulation of Cannabis and Cannabinoids</em></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><em>DEA Regulation</em></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">Cannabis, cannabis extracts and some cannabinoids are regulated as &#8220;controlled substances&#8221; as defined in the Controlled Substances Act (the &#8220;CSA&#8221;), which establishes registration, security, recordkeeping, reporting, storage, distribution and other requirements administered by the DEA. The DEA is concerned with the control of handlers of controlled substances, and with the equipment and raw materials used in their manufacture and packaging, in order to prevent loss and diversion into illicit channels of commerce.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">The DEA regulates controlled substances as Schedule I, II, III, IV or V substances. Schedule I substances by definition have no established medicinal use and may not be marketed or sold in the United States. A pharmaceutical product may be listed as Schedule II, III, IV or V, with Schedule II substances considered to present the highest risk of abuse and Schedule V substances the lowest relative risk of abuse among such substances. Cannabis, cannabis extracts and some cannabinoids are listed by the DEA as Schedule I controlled substances under the CSA. Consequently, their manufacture, shipment, storage, sale and use are subject to a high degree of regulation. Annual registration is required for any facility that manufactures, distributes, dispenses, imports or exports any controlled substance. The registration is specific to the particular location, activity and controlled substance schedule. For example, separate registrations are needed for import and manufacturing, and each registration will specify which schedules of controlled substances are authorized.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">The DEA typically inspects a facility to review its security measures prior to issuing a registration. Security requirements vary by controlled substance schedule, with the most stringent requirements applying to Schedule I and Schedule II substances. Required security measures include background checks on employees and physical control of inventory through measures such as cages, surveillance cameras and inventory reconciliations. The registered entity must maintain records for the handling of all controlled substances and must make periodic reports to the DEA. These include, for example, distribution reports for Schedule I and II controlled substances, Schedule III substances that are narcotics, and other designated substances. The registered entity must also report thefts or losses of any controlled substance and obtain authorization to destroy any controlled substance. In addition, special authorization and notification requirements apply to imports and exports.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">In addition, a DEA quota system controls and limits the availability and production of controlled substances in Schedule I or II. Distributions of any Schedule I or II controlled substance must also be accompanied by special order forms, with copies provided to the DEA. The DEA may adjust aggregate production quotas and individual production and procurement quotas from time to time during the year, although the DEA has substantial discretion in whether or not to make such adjustments. To meet its responsibilities, the DEA conducts periodic inspections of registered establishments that handle controlled substances. In the event of non-compliance, the DEA may seek civil penalties, refuse to renew necessary registrations, or initiate proceedings to revoke those registrations. In certain circumstances, violations could lead to criminal prosecution.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">The DEA has conducted a scientific review of the chemical structure of CBDVHS and determined that CBDVHS is not a regulated chemical nor controlled substance under the CSA. This decision by the DEA may help us expand the network of clinical testing sites, permit a greater cross-section of patients to participate in studies of this drug, as well as speed the initiation of clinical trials. THCVHS remains a Schedule I, controlled substance, pending a request to re-schedule after completion of pivotal clinical trials resulting in a drug approval by the FDA.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><em>State Regulation</em></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">The states also maintain separate controlled substance laws and regulations, including licensing, recordkeeping, security, distribution, and dispensing requirements. State authorities, including Boards of Pharmacy, regulate use of controlled substances in each state. Failure to maintain compliance with applicable requirements, particularly as manifested in the loss or diversion of controlled substances, can result in enforcement action that could have a material adverse effect on our business, operations and financial condition.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><em>The Single Convention on Narcotic Drugs 1961</em></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">Many countries, including the United States, are parties to the 1961 Single Convention on Narcotic Drugs (the &#8220;Single Convention&#8221;), which is an international treaty that governs international trade and domestic control of narcotic substances, including cannabis and cannabis extracts. The Single Convention requires all parties to take measures to limit the production, manufacture, export, import, distribution of, trade-in, and use and possession of cannabis exclusively to medical and scientific purposes. In particular, the Single Convention requires member countries to establish a government agency to oversee the cultivation of marijuana and establish a monopoly on the wholesale trade of marijuana, and it provides that this role must be filled by a single government agency if the member country&#8217;s constitution so permits.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">Party members, including the United States, may interpret and implement their treaty obligations in a way that restricts our ability to develop and obtain marketing approval for our product candidates in accordance with our current plans and partnership with UM.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><em>NIDA</em></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">Pursuant to the Single Convention, NIDA oversees the cultivation of research-grade cannabis for medicinal research on behalf of the United States Government. NIDA has historically fulfilled this obligation through a contract that it administers with UM. UM has been the sole NIDA contractor to grow cannabis for research purposes since 1968. The contract is open for competitive bidding at periodic intervals. Since 1999, the term of the contract has been five years. UM engaged in a competitive bidding process for the next contract interval and was awarded the contract in 2015. Under the NIDA contract, UM grows, harvests, stores, ships and analyzes cannabis of different varieties, as NIDA requires. In August 2016, the DEA announced that it would consider granting registrations for the cultivation of cannabis for research and development purposes outside of the NIDA contract process. We are not aware of any entity that has received such a registration under this process to date.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">UM has represented that it also grows cannabis for purposes of researching cannabis extracts, and has in the past grown cannabis, purified cannabis extracts, and distributed extracts for purposes of developing product candidates, separate and apart from its contract with NIDA. UM has indicated that it conducted these activities pursuant to separate registrations from the DEA and that it plans to seek the necessary additional DEA registrations to conduct the contemplated activities in connection with our partnership, in compliance with applicable law and the United States&#8217; obligations under the Single Convention. However, there is a risk that regulatory authorities may disagree and decline to authorize UM to engage in these activities.</p> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">9</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc1">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong><em>U.S. Food and Drug Administration</em></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">In the United States, pharmaceutical products are subject to extensive regulation by the FDA. The FDA regulates drugs under the FDCA and its implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject us to a variety of administrative or judicial sanctions, such as the FDA&#8217;s refusal to approve pending NDAs, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties.</p> <p style="MARGIN: 0px">&#160; </p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="width:4%;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">The process required by the FDA before a drug may be marketed in the United States generally involves the following:</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">completion of preclinical laboratory tests, animal studies and formulation studies in compliance with good laboratory practice (&#8220;GLP&#8221;) regulations&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">submission to the FDA of an IND, which must become effective before human clinical trials may begin&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">approval by an institutional review board (&#8220;IRB&#8221;) at each clinical site before each trial may be initiated&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">performance of adequate and well-controlled human clinical trials in accordance with good clinical practice (&#8220;GCP&#8221;) requirements to establish the safety and efficacy of the proposed drug for each indication&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">submission of a NDA to the FDA&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced to assess compliance with cGMP requirements and to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality and purity&#894; and</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">FDA review and approval of the NDA.</td></tr></table> <p style="MARGIN: 0px">&#160;&#160;&#160; </p> <p style="MARGIN: 0px"><em>Preclinical Studies</em></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">Preclinical studies include laboratory evaluation of product chemistry, toxicity and formulation, as well as animal studies to assess potential safety and efficacy. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data and any available clinical data or literature, among other things, to the FDA as part of an IND. Some preclinical testing may continue even after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA unless, before that time, the FDA raises concerns or questions related to one or more proposed clinical trials and places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><em>Clinical Trials</em></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">Clinical trials involve the administration of the investigational new drug to human subjects under the supervision of qualified investigators in accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent in writing for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, an IRB at each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution. Information about certain clinical trials must be submitted within specific timeframes to the NIH for public dissemination on their <u>www.clinicaltrials.gov</u> website.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">Human clinical trials are typically conducted in three sequential phases, which may overlap or be combined:</p> <p style="MARGIN: 0px">&#160;&#160;&#160; </p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="width:4%;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Phase 1: The drug is initially introduced into healthy human subjects or patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness.</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Phase 2: The drug is administered to a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage.</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px">Phase 3: The drug is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product, and to provide adequate information for the labeling of the product.</p></td></tr></table> <p style="MARGIN: 0px">&#160;&#160; </p> <p style="MARGIN: 0px">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse events occur. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, or at all. Furthermore, the FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients.</p> <p style="MARGIN: 0px">&#160; </p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">10</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc1">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160; </p> <p style="MARGIN: 0px"><em>Marketing Approval</em></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">Assuming successful completion of the required clinical testing, the results of the preclinical and clinical studies, together with detailed information relating to the product&#8217;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of a NDA requesting approval to market the product for one or more indications. In most cases, the submission of a NDA is subject to a substantial application user fee. Under the Prescription Drug User Fee Act (&#8220;PDUFA&#8221;) guidelines that are currently in effect, the FDA has a goal of ten months from the date of &#8220;filing&#8221; of a standard NDA for a new molecular entity to review and act on the submission. This review typically takes at least twelve months from the date the NDA is submitted to the FDA because the FDA has approximately two months to make a &#8220;filing&#8221; decision. However, if issues arise during the review, the FDA may request additional information and the review period may be extended to permit the applicant to provide and the FDA to review that information, which may significantly extend this time period.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">In addition, under the Pediatric Research Equity Act of 2003 (&#8220;PREA&#8221;), as amended and reauthorized, certain NDAs or supplements to a NDA must contain data that is adequate to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">The FDA also may require submission of REMS plan to ensure that the benefits of the drug outweigh its risks. The REMS plan could include medication guides, physician communication plans, assessment plans, and/or elements to assure safe use, such as restricted distribution methods, patient registries, or other risk minimization tools.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">The FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review. The FDA may request additional information rather than accept a NDA for filing. In this event, the application must be resubmitted with the additional information requested. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA reviews a NDA to determine, among other things, whether the drug is safe and effective and whether the facility in which it is manufactured, processed, packaged or held meets standards designed to assure the product&#8217;s continued safety, quality and purity.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">The FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">Before approving a NDA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving a NDA, the FDA may inspect one or more clinical trial sites to assure compliance with GCP requirements.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">The testing and approval process for a NDA requires substantial time, effort and financial resources, and each may take several years to complete. Data obtained from preclinical and clinical testing are not always conclusive and may be susceptible to varying interpretations, which could delay, limit or prevent regulatory approval. The FDA may not grant approval on a timely basis, or at all.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">After evaluating the NDA and all related information, including the advisory committee recommendation, if any, and inspection reports regarding the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a complete response letter. A complete response letter generally contains a statement of specific conditions that must be met in order to secure final approval of the NDA and may require additional clinical or preclinical testing in order for the FDA to reconsider the application. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions have been met to the FDA&#8217;s satisfaction, the FDA will typically issue an approval letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. For some products, such as our product candidates, an additional step of DEA review and scheduling is required.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><em>Post-Approval Requirements</em></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims are subject to prior FDA review and approval. There also are continuing, annual user fee requirements for any marketed products and the establishments at which such products are manufactured, as well as new application fees for supplemental applications with clinical data.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">The FDA may impose a number of post-approval requirements as a condition of approval of a NDA. For example, the FDA may require post-marketing testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state agencies and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP requirements and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance.</p> <p style="MARGIN: 0px">&#160; </p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">11</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc1">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information&#894; imposition of post-market studies or clinical trials to assess new safety risks&#894; or imposition of distribution or other restrictions under a REMS program. </p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">Other potential consequences include, among other things:</p> <p style="MARGIN: 0px">&#160;&#160;&#160; </p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="width:4%;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">fines, warning letters or holds on post-approval clinical trials&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product license approvals&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">product seizure or detention, or refusal to permit the import or export of products&#894; or</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">injunctions or the imposition of civil or criminal penalties.</td></tr></table> <p style="MARGIN: 0px">&#160;&#160;&#160; </p> <p style="MARGIN: 0px">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act (&#8220;PDMA&#8221;), which regulates the distribution of drugs and drug samples at the federal level and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong><em>Exclusivity and Approval of Competing Products</em></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><em>Hatch Waxman Act</em></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">Section 505 of the FDCA describes three types of marketing applications that may be submitted to the FDA to request marketing authorization for a new drug. A Section 505(b)(1) NDA is an application that contains full reports of investigations of safety and efficacy. A 505(b)(2) NDA is an application that contains full reports of investigations of safety and efficacy but where at least some of the information required for approval comes from investigations that were not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use from the person by or for whom the investigations were conducted. This regulatory pathway enables the applicant to rely, in part, on the FDA&#8217;s prior findings of safety and efficacy for an existing product, or published literature, in support of its application. Section 505(j) establishes an abbreviated approval process for a generic version of approved drug products through the submission of an Abbreviated New Drug Application (&#8220;ANDA&#8221;). An ANDA provides for marketing of a generic drug product that has the same active ingredients, dosage form, strength, route of administration, labeling, performance characteristics and intended use, among other things, to a previously approved product. ANDAs are termed &#8220;abbreviated&#8221; because they are generally not required to include preclinical (animal) and clinical (human) data to establish safety and efficacy. Instead, generic applicants must scientifically demonstrate that their product is bioequivalent to, or performs in the same manner as, the innovator drug through in vitro, in vivo, or other testing. The generic version must deliver the same amount of active ingredients into a subject&#8217;s bloodstream in the same amount of time as the innovator drug and can often be substituted by pharmacists under prescriptions written for the reference listed drug.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><em>Hatch Waxman Patent Exclusivity</em></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">In seeking approval for a drug through a NDA, applicants are required to list with the FDA each patent with claims that cover the applicant&#8217;s product or a method of using the product. Upon approval of a drug, each of the patents listed in the application for the drug is then published in the FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. Drugs listed in the Orange Book can, in turn, be cited by potential competitors in support of approval of an ANDA or 505(b)(2) NDA.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">The ANDA or 505(b)(2) NDA applicant is required to certify to the FDA concerning any patents listed for the approved product in the FDA&#8217;s Orange Book, except for patents covering methods of use for which the ANDA applicant is not seeking approval. Specifically, the applicant must certify with respect to each patent that:</p> <p style="MARGIN: 0px">&#160; </p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="width:4%;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">the required patent information has not been filed&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">the listed patent has expired&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">the listed patent has not expired, but will expire on a particular date and approval is sought after patent expiration&#894; or</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">the listed patent is invalid, unenforceable or will not be infringed by the new product.</td></tr></table> <p style="MARGIN: 0px">&#160; </p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">12</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc1">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">Generally, the ANDA or 505(b)(2) NDA cannot be approved until all listed patents have expired, except when the ANDA or 505(b)(2) NDA applicant challenges a listed drug. A certification that the proposed product will not infringe the already approved product&#8217;s listed patents or that such patents are invalid or unenforceable is called a Paragraph IV certification. If the applicant does not challenge the listed patents or indicate that it is not seeking approval of a patented method of use, the ANDA or 505(b)(2) NDA application will not be approved until all the listed patents claiming the referenced product have expired.&#160;&#160;&#160;</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">If the ANDA or 505(b)(2) NDA applicant has provided a Paragraph IV certification to the FDA, the applicant must also send notice of the Paragraph IV certification to the NDA and patent holders once the application has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph IV certification. The filing of a patent infringement lawsuit within 45 days after the receipt of notice of the Paragraph IV certification automatically prevents the FDA from approving the ANDA or 505(b)(2) NDA until the earlier of 30 months, expiration of the patent, settlement of the lawsuit or a decision in the infringement case that is favorable to the ANDA applicant.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><em>Hatch Waxman Non-Patent Exclusivity</em></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">In addition to patent issues, market and data exclusivity provisions under the FDCA can delay the submission or the approval of certain applications for competing products. The FDCA provides a five-year period of non-patent data exclusivity within the United States to the first applicant to gain approval of a NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the activity of the drug substance. During the exclusivity period, the FDA may not accept for review an ANDA or a 505(b)(2) NDA submitted by another company that references the previously approved drug. However, an ANDA or 505(b)(2) NDA may be submitted after four years if it contains a Paragraph IV certification of patent invalidity or non-infringement. The FDCA also provides three years of marketing exclusivity for a NDA, 505(b)(2) NDA, or supplement to an existing NDA or 505(b) NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant, are deemed by the FDA to be essential to the approval of the application or supplement. Three-year exclusivity may be awarded for changes to a previously approved drug product, such as new indications, dosages, strengths or dosage forms of an existing drug.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">This three-year exclusivity covers only the conditions of use associated with the new clinical investigations and, as a general matter, does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for other versions of a drug. Five-year and three- year exclusivity will not delay the submission or approval of a full NDA&#894; however, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><em>Orphan Drug Designation and Exclusivity</em></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a drug intended to treat a disease or condition that affects populations of fewer than 200,000 individuals in the United States or, if it affects more than 200,000 individuals in the United States, there is no reasonable expectation that the cost of developing and making a drug product available in the United States for this type of disease or condition will be recovered from sales of the product. Orphan designation must be requested before submitting a NDA. Orphan designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity or inability to manufacture the product in sufficient quantities. The designation of such drug also entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. Competitors, however, may receive approval of different products for the same indication for which the orphan product has exclusivity or obtain approval for the same product but for a different indication than that for which the orphan product has exclusivity.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong><em>Federal and State Fraud and Abuse and Data Privacy and Security Laws and Regulations</em></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">In addition to FDA restrictions on marketing of pharmaceutical products, federal and state fraud and abuse laws restrict business practices in the pharmaceutical industry. These laws include anti-kickback and false claims laws and regulations as well as data privacy and security laws and regulations.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce or in return for purchasing, leasing, ordering, or arranging for or recommending the purchase, lease, or order of any item or service reimbursable under Medicare, Medicaid or other federal healthcare programs. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value. The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers, and formulary managers on the other. Although there are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, the exemptions and safe harbors are drawn narrowly. Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases, or recommendations may be subject to scrutiny if they do not meet the requirements of a statutory or regulatory exception or safe harbor. Several courts have interpreted the statute&#8217;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, the statute has been violated. In addition, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">The federal False Claims Act prohibits any person from knowingly presenting, or causing to be presented, a false claim for payment to the federal government or knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government. A claim includes &#8220;any request or demand&#8221; for money or property presented to the U.S. government. A violation of the federal Anti-Kickback Statute also constitutes a false or fraudulent claim for purposes of the civil False Claims Act.</p> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">13</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc1">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160; </p> <p style="MARGIN: 0px">Several pharmaceutical and other healthcare companies have been prosecuted under these laws for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. Other companies have been prosecuted for causing false claims to be submitted because of the companies&#8217; marketing of products for unapproved, and thus non-covered, uses. In addition, many states have similar fraud and abuse statutes or regulations that apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">The federal HIPAA also created federal criminal statutes that prohibit knowingly and willfully executing a scheme to defraud any healthcare benefit program, including private third party payors and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the Anti- Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">Pharmaceutical companies are also subject to the civil monetary penalties statute, which imposes penalties against any person who is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">In addition, there has been a recent trend of increased federal and state regulation of payments made to physicians and other health care providers. The Patient Protection and Affordable Care Act, as amended by the ACA, signed into law on March 2010, created new federal requirements for reporting, by applicable manufacturers of covered drugs, payments and other transfers of value to physicians and teaching hospitals. Applicable manufacturers are also required to report annually to the government certain ownership and investment interests held by physicians and their immediate family members. In addition, certain states require implementation of commercial compliance programs and compliance with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, impose restrictions on marketing practices, and/or tracking and reporting of gifts, compensation and other remuneration or items of value provided to physicians and other health care professionals and entities.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">We may also be subject to data privacy and security regulation by both the federal government and the states in which we conduct our business. HIPAA, as amended by the Health Information Technology and Clinical Health Act (&#8220;HITECH&#8221;) and its implementing regulations, imposes specified requirements relating to the privacy, security and transmission of individually identifiable health information. Among other things, HITECH makes HIPAA&#8217;s privacy and security standards directly applicable to &#8220;business associates,&#8221; defined as independent contractors or agents of covered entities that receive or obtain protected health information in connection with providing a service on behalf of a covered entity. HITECH also increased the civil and criminal penalties that may be imposed against covered entities, business associates and possibly other persons, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions. In addition, state laws govern the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same requirements, thus complicating compliance efforts.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">To the extent that any of our product candidates, once approved, are sold in a foreign country, we may be subject to similar foreign laws and regulations, which may include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws, and implementation of corporate compliance programs and reporting of payments or other transfers of value to healthcare professionals.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">The shifting commercial compliance environment and the need to build and maintain robust systems to comply with different compliance and/or reporting requirements in multiple jurisdictions increase the possibility that a healthcare company may violate one or more of the requirements. If our operations are found to be in violation of any of such laws or any other governmental regulations that apply to us, we may be subject to penalties, including, without limitation, civil and criminal penalties, damages, fines, the curtailment or restructuring of our operations, exclusion from participation in federal and state healthcare programs and imprisonment, any of which could adversely affect our ability to operate our business and our financial results.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong><em>Coverage and Reimbursement</em></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">Significant uncertainty exists as to the coverage and reimbursement status of any drug products for which we obtain regulatory approval. In the United States and markets in other countries, sales of any products for which we receive regulatory approval for commercial sale will depend, in part, on the availability of coverage and reimbursement from third-party payors. Third-party payors include government authorities, managed care providers, private health insurers and other organizations. The process for determining whether a payor will provide coverage for a drug product may be separate from the process for setting the reimbursement rate that the payor will pay for the drug product. Third-party payors may limit coverage to specific drug products on an approved list, or formulary, which might not include all of the FDA-approved drugs for a particular indication. A decision by a third-party payor not to cover our products, if approved, could reduce physician utilization of our products once approved and have a material adverse effect on our sales, results of operations and financial condition. Moreover, a payor&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">In addition, the U.S. government, state legislatures and foreign governments have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. By way of example, in the United States, the ACA contains provisions that may reduce the profitability of drug products, including, for example, increased rebates for drugs sold to Medicaid programs, extension of Medicaid rebates to Medicaid managed care plans, mandatory discounts for certain Medicare Part D beneficiaries, and annual fees based on pharmaceutical companies&#8217; share of sales to federal health care programs. In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed bills designed to, among other things, reform government program reimbursement methodologies. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our products once approved or additional pricing pressures.</p> <p style="MARGIN: 0px">&#160; </p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">14</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc1">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160; </p> <p style="MARGIN: 0px; text-align:justify;">We expect that the Trump administration will continue to seek to modify, repeal, or otherwise invalidate all or certain provisions of the ACA. In January 2017, the House and Senate passed a budget resolution that authorizes congressional committees to draft legislation to repeal all or portions of the ACA and permits such legislation to pass with a majority vote in the Senate. President Trump has also recently issued an executive order in which he stated that it is his administration&#8217;s policy to seek the prompt repeal of the ACA and directed executive departments and federal agencies to waive, defer, grant exemptions from, or delay the implementation of the burdensome provisions of the ACA to the maximum extent permitted by law. There is still uncertainty with respect to the impact President Trump&#8217;s administration and the U.S. Congress may have if any. Any changes will likely take time to unfold and could have an impact on coverage and reimbursement for healthcare items and services covered by plans that were authorized by the ACA. As such, we cannot predict what effect the ACA or other healthcare reform initiatives that may be adopted in the future will have on our business.</p> <p style="MARGIN: 0px">&#160;&#160;</p> <p style="MARGIN: 0px"><strong>Foreign Regulation</strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">In order to market any product outside of the United States, we must comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy and governing, among other things, clinical trials and commercial sales and distribution of our products. While our management and many of our consultants are familiar with and have been responsible for gaining marketing approval in many countries, we have not reviewed the specific regulations in countries outside of the United States, as it pertains to cannabinoids.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong>Additional Regulation</strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">We are a reporting company with the Securities and Exchange Commission (the &#8220;SEC&#8221;), and, therefore, subject to the information and reporting requirements of the Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) and other federal securities laws, and the compliance obligations of the Sarbanes-Oxley Act of 2002 (the &#8220;Sarbanes-Oxley Act&#8221;). In addition, our financial reporting is subject to United States generally accepted accounting principles (the &#8220;U.S. GAAP&#8221;), and U.S. GAAP is subject to change over time.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">We are also subject to federal, state and local laws and regulations applied to businesses generally. We believe that we are in conformity with all applicable laws in all relevant jurisdictions.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong>Employees</strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">As of the date of this Annual Report, we have a total of four full-time employees, two of whom have an M.D. degree. None of our employees are represented by a labor union or covered by a collective bargaining agreement. We have not experienced any work stoppages and we consider our relations with our employees to be good.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">We anticipate that we will need to hire approximately four additional employees or independent contractors for our continued development efforts. We also intend to utilize independent contractors and outsourced services, such as CROs, and third-party manufacturers, where possible and appropriate.</p> <p style="MARGIN: 0px">&#160;&#160;</p> <p style="MARGIN: 0px"><strong>Website</strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">Our Internet website, which is located at <u>http://emeraldbio.life</u>, describes our company and our management and provides information about cannabis-based therapeutics. Information contained on our website is not incorporated by reference into, and should not be considered a part of, this Annual Report.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong>FORWARD-LOOKING STATEMENTS</strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">Statements in this Annual Report on Form 10-K that are not descriptions of historical facts are forward-looking statements that are based on management&#8217;s current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition and stock price could be materially and negatively affected. In some cases, you can identify forward-looking statements by terminology including &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;can,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;potential,&#8221; &#8220;predicts,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; or the negative of these terms or other comparable terminology. Factors that could cause actual results to differ materially from those currently anticipated include those set forth in the section below titled &#8220;Risk Factors,&#8221; including, without limitation, risks relating to:</p> <p style="MARGIN: 0px">&#160; </p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="width:4%;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">the results of our research and development activities, including uncertainties relating to the discovery of potential product candidates and the preclinical and clinical testing of our product candidates&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">the early stage of our product candidates presently under development&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">our need for substantial additional funds in order to continue our operations, and the uncertainty of whether we will be able to obtain the funding we need&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">our ability to obtain and, if obtained, maintain regulatory approval of our current product candidates, and any of our other future product candidates, and any related restrictions, limitations, and/or warnings in the label of any approved product candidate&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">our ability to retain or hire key scientific or management personnel&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">our ability to protect our intellectual property rights that are valuable to our business, including patent and other intellectual property rights&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">our dependence on UM, third-party manufacturers, suppliers, research organizations, testing laboratories and other potential collaborators&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">our ability to develop successful sales and marketing capabilities in the future as needed&#894;</td></tr></table> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">15</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc1">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="width:4%;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">the size and growth of the potential markets for any of our approved product candidates, and the rate and degree of market acceptance of any of our approved product candidates&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">competition in our industry&#894; and</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">regulatory developments in the United States and foreign countries.</td></tr></table>&#160;&#160;&#160;&#160;&#160;&#160; <p style="MARGIN: 0px">We operate in a rapidly-changing environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this report may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. The forward-looking statements included in this report speak only as of the date hereof, and except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this report to conform these statements to actual results or to changes in our expectations.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong><u><a name="item1a">Item</a> 1A. Risk Factors.</u></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><em>Any investment in our common stock involves a high degree of risk. Investors should carefully consider the risks described below and all of the information contained in this Annual Report on Form 10-K before deciding whether to purchase our common stock. Our business, financial condition or results of operations could be materially and adversely affected by these risks if any of them actually occur. Our common stock is quoted on the OTCQB under the symbol &#8220;EMBI.&#8221; This market is extremely limited and the prices quoted are not a reliable indication of the value of our common stock. As of the date of this Annual Report, there has been very limited trading of shares of our common stock. If and when our common stock is traded, the trading price could decline due to any of these risks, and an investor may lose all or part of his or her investment. Some of these factors have affected our financial condition and operating results in the past or are currently affecting us. This Annual Report on Form 10-K also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including the risks described below and elsewhere in this Annual report. </em></p> <p style="MARGIN: 0px">&#160;&#160;</p> <p style="MARGIN: 0px"><strong>Risks Related to our Business and Capital Requirements</strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong><em>Since we have a limited operating history in our business, it is difficult for potential investors to evaluate our business.</em></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">Our short operating history may hinder our ability to successfully meet our objectives and makes it difficult for potential investors to evaluate our business or prospective operations. We have not generated any revenues since inception and we are not currently profitable and may never become profitable. As an early-stage company, we are subject to all the risks inherent in the financing, expenditures, operations, complications and delays inherent in a new business. Accordingly, our business and success face risks from uncertainties faced by developing companies in a competitive environment. There can be no assurance that our efforts will be successful or that we will ultimately be able to attain profitability.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong><em>We currently have no product revenues and no products approved for marketing and need substantial additional funding to continue our operations. We may not be able to raise capital when needed, if at all, which would force us to delay, reduce or eliminate our product development programs or commercialization efforts and could cause our business to fail.</em></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">We expect to need substantial additional funding to pursue the clinical development of our product candidates and launch and commercialize any product candidates for which we receive regulatory approval. Our existing cash position is under $1.0 million and we need to bring in additional capital in the near term. We require additional capital for the development and commercialization of our product candidates. Furthermore, we expect to incur additional costs associated with operating as a public company. We may also encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may increase our capital needs and/or cause us to spend our cash resources faster than we expect. Accordingly, we will need to obtain substantial additional funding in order to continue our operations. As noted in our audited financial statements for the years ended December 31, 2019 and 2018, the uncertainties surrounding our ability to fund our operations raise substantial doubt about our ability to continue as a going concern.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">To date, we have financed our operations entirely through investments by founders and other investors. We may seek additional funds through public or private equity or debt financing, via strategic transactions or collaborative arrangements. Additional funding from those or other sources may not be available when or in the amounts needed, on acceptable terms, or at all. If we raise capital through the sale of equity, or securities convertible into equity, it would result in dilution to our then existing stockholders, which could be significant depending on the price at which we may be able to sell our securities. If we raise additional capital through the incurrence of indebtedness, we would likely become subject to covenants restricting our business activities, and holders of debt instruments may have rights and privileges senior to those of our equity investors. In addition, servicing the interest and principal repayment obligations under debt facilities could divert funds that would otherwise be available to support research and development, clinical or commercialization activities. If we obtain capital through collaborative arrangements, these arrangements could require us to relinquish rights to our technology or product candidates and could result in our receipt of only a portion of the revenues associated with the partnered product.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">There are no assurances that future funding will be available on favorable terms or at all. If additional funding is not obtained, we may need to reduce, defer or cancel preclinical and lab work, planned clinical trials, or overhead expenditures to the extent necessary. The failure to fund our operating and capital requirements could have a material adverse effect on our business, financial condition and results of operations.</p> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">16</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc1">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160; </p> <p style="MARGIN: 0px">If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or any future commercialization efforts. Any of these events could significantly harm our business, financial condition and prospects.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong><em>Our independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern. </em></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">Our historical financial statements have been prepared under the assumption that we will continue as a going concern. Our independent registered public accounting firm has issued a report on our audited financial statements for the year ended December 31, 2019 that included an explanatory paragraph referring to our recurring operating losses and expressing substantial doubt in our ability to continue as a going concern. Our ability to continue as a going concern is dependent upon our ability to obtain additional equity financing or other capital, attain further operating efficiencies, reduce expenditures, and, ultimately, generate revenue. Our financial statements do not include any adjustments that might result from the outcome of this uncertainty. However, if adequate funds are not available to us when we need it, we will be required to curtail our operations which would, in turn, further raise substantial doubt about our ability to continue as a going concern. The doubt regarding our potential ability to continue as a going concern may adversely affect our ability to obtain new financing on reasonable terms or at all. Additionally, if we are unable to continue as a going concern, our stockholders may lose some or all of their investment in us.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><em><strong>We rely heavily on UM for our research and development programs, and UM is a joint owner of the intellectual property resulting from its preclinical research and development. </strong></em></p> <p style="MARGIN: 0px">&#160; </p> <p style="MARGIN: 0px">We rely heavily on our relationship with UM for our research and development programs. Under the terms of our agreements with UM, we are required to fund preclinical and clinical trials required for cannabinoid-based products developed by UM. If UM were to terminate one or more of our agreements, we may be required to return or destroy certain materials or data developed during our partnership that is confidential to UM and face substantial delays or possible termination of the affected program.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">In addition, the agreements provide that all intellectual property rights (including any patents and non-manufacturing related know-how) that are conceived by both UM and us during the course of the collaboration are to be jointly owned by UM and us. Because UM exercises some control over this jointly owned intellectual property, we may need to seek UM&#8217;s consent to pursue, use, license and/or enforce some of these intellectual property rights in the future. An unexpected deterioration in our relationship with UM may have a material adverse effect on our business, reputation, results of operations and financial condition.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong><em>We are heavily dependent on the success of our early-stage product candidates, which will require significant additional efforts to develop and may prove not to be viable for commercialization.</em></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">We are very early in our development efforts. We have no products approved for sale and all of our product candidates are in preclinical development, including the development of cannabinoid-based formulations. Further preclinical testing is ongoing and if successful, will be part of a regulatory filing to satisfy Investigational New Drug (&#8220;IND&#8221;) requirements that need to be met in order for the candidate compounds and routes of administration to enter testing in humans. Our ability to generate product revenue, which we do not expect will occur for many years, if ever, will depend heavily on the successful development and commercialization of our product candidates. Our business depends entirely on the successful development, clinical testing, and commercialization of these and any other product candidates we may seek to develop in the future, which may never occur.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px">The success of our product candidates will depend on several factors, any one of which we may not be able to successfully complete, such as:</p> <p style="MARGIN: 0px">&#160; </p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="width:4%;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">receipt of necessary controlled substance registrations from the DEA&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">successful completion of preclinical studies and clinical trials&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">receipt of marketing approvals from the FDA and other applicable regulatory authorities&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">obtaining, maintaining and protecting our intellectual property portfolio, including patents and trade secrets, and regulatory exclusivity for our product candidates&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">identifying, making arrangements and ensuring necessary registrations with third-party manufacturers, or establishing commercial manufacturing capabilities for applicable product candidates&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">launching commercial sales of the products, if and when approved, whether alone or in collaboration with others&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">acceptance of our products, if and when approved, by patients, the medical community and third-party payors&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">effectively competing with other therapies&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">obtaining and maintaining healthcare coverage and adequate reimbursement of our products&#894; and</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">maintaining a continued acceptable safety profile of our products following approval.</td></tr></table> <p style="MARGIN: 0px">&#160; </p> <p style="MARGIN: 0px">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize our product candidates, which would materially harm our business.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">We expect to conduct clinical trials for certain of our product candidates at sites outside the United States, and the FDA may not accept data from trials conducted in such locations. </p> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">17</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc1">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160;&#160; </p> <p style="MARGIN: 0px; text-align:justify;">We expect to conduct one or more of our clinical trials outside the United States. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of this data is subject to certain conditions imposed by the FDA. For example, the clinical trial must be well designed and conducted and performed by qualified investigators in accordance with ethical principles. The trial population must also adequately represent the U.S. population, and the data must be applicable to the U.S. population and U.S. medical practice in ways that the FDA deems clinically meaningful. Generally, the patient population for any clinical trials conducted outside of the United States must be representative of the population for whom we intend to seek approval in the United States. In addition, while these clinical trials are subject to the applicable local laws, FDA acceptance of the data will be dependent upon its determination that the trials also complied with all applicable U.S. laws and regulations. There can be no assurance that the FDA will accept data from trials conducted outside of the United States. If the FDA does not accept the data from any of our clinical trials that we conduct outside the United States, it would likely result in the need for additional trials, which would be costly and time-consuming and delay or permanently halt our development of the product candidate.</p> <p style="MARGIN: 0px">&#160;&#160; </p> <p style="MARGIN: 0px">In addition, the conduct of clinical trials outside the United States could have a significant impact on us. Risks inherent in conducting international clinical trials include:</p> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="width:4%;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">foreign regulatory requirements that could restrict or limit our ability to conduct our clinical trials;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">administrative burdens of conducting clinical trials under multiple foreign regulatory schema;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">foreign exchange fluctuations; and</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">diminished protection of intellectual property in some countries.</td></tr></table>&#160;&#160; <p style="MARGIN: 0px"><strong><em>We conduct certain research and development operations through our Australian wholly-owned subsidiary. If we lose our ability to operate in Australia, or if our subsidiary is unable to receive the research and development tax credit allowed by Australian regulations, our business and results of operations could suffer.</em></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">In August 2019, we formed a wholly-owned Australian subsidiary, EMBI Australia, to conduct various clinical activities for our product candidates in Australia. Due to the geographical distance and lack of employees currently in Australia, as well as our lack of experience operating in Australia, we may not be able to efficiently or successfully monitor, develop and commercialize our lead product candidate in Australia, including conducting clinical trials. Furthermore, we have no assurance that the results of any clinical trials that we conduct for our product candidates in Australia will be accepted by the FDA or foreign regulatory authorities for development and commercialization approvals.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">In addition, current Australian tax regulations provide for a refundable R&amp;D tax credit equal to 43.5% of qualified expenditures. If our subsidiary loses its ability to operate in Australia, or if we are ineligible or unable to receive the R&amp;D tax credit, or the Australian government significantly reduces or eliminates the tax incentive program, our business and results of operation may be adversely affected.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong><em>We may not be successful in our efforts to build a pipeline of product candidates.</em></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">Our strategy is to use and expand our relationship with UM to build a pipeline of cannabinoid-based products. We may not be able to develop product candidates that are safe and effective for all or any of our targets. Even if we are successful in building a product pipeline, the potential product candidates that we identify may not be suitable for clinical development for a number of reasons, including due to harmful side effects or other characteristics that indicate a low likelihood of receiving marketing approval or achieving market acceptance. If our methods of identifying potential product candidates fail to produce a pipeline of potentially viable product candidates, then we may not be able to obtain product revenue in future periods, which would make it unlikely that we would ever achieve profitability.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong><em>We expect to face intense competition, often from companies with greater resources and experience than we have.</em></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">The pharmaceutical industry is highly competitive and subject to rapid change. The industry continues to expand and evolve as an increasing number of competitors and potential competitors enter the market. Many of these competitors and potential competitors have substantially greater financial, technological, managerial and research and development resources and experience than we have. Some of these competitors and potential competitors have more experience than we have in the development of pharmaceutical products, including validation procedures and regulatory matters. In addition, our pipeline products, if successfully developed, will compete with product offerings from large and well-established companies that have greater marketing and sales experience and capabilities than we or our collaboration partners have. If we are unable to compete successfully, we may be unable to grow and sustain our revenue.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong><em>We have substantial capital requirements that, if not met, may hinder our operations.</em></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">We anticipate that we will make substantial capital expenditures for laboratory and preclinical work and for future clinical trials. If we cannot raise sufficient capital, we may have limited ability to expend the capital necessary to undertake or complete laboratory and preclinical work and future clinical trials. There can be no assurance that debt or equity financing will be available or sufficient to meet these requirements or for other corporate purposes, or if debt or equity financing is available, that it will be on terms acceptable to us. Moreover, future activities may require us to alter our capitalization significantly. Our inability to access sufficient capital for our operations could have a material adverse effect on our financial condition, results of operations or prospects.</p> <p style="MARGIN: 0px">&#160; </p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">18</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc1">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160; </p> <p style="MARGIN: 0px"><strong><em>Additional capital may be costly or difficult to obtain.</em></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">Additional capital, whether through the offering of equity or debt securities, may not be available on reasonable terms or at all, especially in light of the recent downturn in the economy and dislocations in the credit and capital markets. If we are unable to obtain required additional capital, we may have to curtail our growth plans or cut back on existing business and, further, we may not be able to continue operating if we do not generate sufficient revenues from operations needed to stay in business. We may incur substantial costs in pursuing future capital financing, including investment banking fees, legal fees, accounting fees, securities law compliance fees, printing and distribution expenses and other costs. We may also be required to recognize non- cash expenses in connection with certain securities we issue, such as convertible notes and warrants, which may adversely impact our financial condition.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong><em>Current global financial conditions have been characterized by increased volatility which could negatively impact our business, prospects, liquidity and </em></strong><strong><em>financial condition.</em></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">Current global financial conditions and recent market events have been characterized by increased volatility and the resulting tightening of the credit and capital markets has reduced the amount of available liquidity and overall economic activity. We cannot guaranty that debt or equity financing and the ability to borrow funds or cash generated by operations will be available or sufficient to meet or satisfy our initiatives, objectives, or requirements. Our inability to access sufficient amounts of capital on terms acceptable to us for our operations will negatively impact our business, prospects, liquidity and financial condition.</p> <p style="MARGIN: 0px">&#160;&#160;</p> <p style="MARGIN: 0px"><strong><em>If we are not able to attract and retain highly qualified personnel, we may not be able to successfully implement our business strategy.</em></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">Our ability to compete in the highly competitive biotechnology and pharmaceuticals industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel. Our success depends in large measure on our key personnel, including Dr. Brian Murphy, our Chief Executive Officer. The loss of the services of Dr. Murphy could significantly hinder our operations. We do not currently have key person insurance in effect for Dr. Murphy. In addition, the competition for qualified personnel in the pharmaceutical industry is intense and there can be no assurance that we will be able to continue to attract and retain all personnel necessary for the development and operation of our business.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong><em>We may be subject to claims by third parties asserting that our employees or we have misappropriated their intellectual property or claiming ownership of what we regard as our own intellectual property.</em></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">Some of our employees were previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees do not use the proprietary information or know-how of others in their work for us, with contractual provisions and other procedures, we may be subject to claims that these employees or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such employee&#8217;s former employers. Litigation may be necessary to defend against any such claims.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">In addition, while it is our policy to require our employees and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact contributes to the development of intellectual property that we regard as our own. Further, the terms of such assignment agreements may be breached and we may not be able to successfully enforce their terms, which may force us to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of intellectual property rights we may regard and treat as our own.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><em><strong>We will need to grow the size of our organization, and we may experience difficulties in managing any growth we may achieve.</strong></em></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">As of the date of this Annual Report, we have four full-time employees. As our development and commercialization plans and strategies develop, we expect to need additional research, development, managerial, operational, sales, marketing, financial, accounting, legal and other resources. Future growth would impose significant added responsibilities on members of management. Our management may not be able to accommodate those added responsibilities, and our failure to do so could prevent us from effectively managing future growth, if any, and successfully growing our company.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong><em>If we breach any of the agreements under which we license from UM the commercialization rights to our product candidates, we could lose license rights that are important to our business and our operations could be materially harmed.</em></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">We license from UM the use, development and commercialization rights for our product candidates. As a result, our current business plans are dependent upon our maintenance of the license agreements and the rights we license under it. If we fail to comply with any of the conditions or obligations or otherwise breach the terms of our license agreement with UM, or any future license agreement we may enter on which our business or product candidates are dependent, UM may have the right to terminate the applicable agreement in whole or in part and thereby extinguish our rights to the licensed technology and intellectual property and/or any rights we have acquired to develop and commercialize certain product candidates. The loss of the rights licensed to us under our license agreement with UM, or any future license agreement that we may enter granting rights on which our business or product candidates are dependent, would eliminate our ability to further develop the applicable product candidates and would materially harm our business, prospects, financial condition and results of operations.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong><em>Our operating activities may be restricted as a result of covenants related to the outstanding indebtedness under our Credit Agreement and we may be required to repay the outstanding indebtedness in an event of default, which could have a material adverse effect on our business.</em></strong></p> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">19</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc1">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">We could default on the payment of our indebtedness under our Multi-Draw Credit Agreement entered into with Emerald Health Sciences, a related party, on October 5, 2018 (the &#8220;Credit Agreement&#8221;), when it comes due which may result in acceleration of all amounts outstanding under our Credit Agreement. Additionally, our Credit Agreement restricts, among other things, our ability to incur debt and requires us to comply with certain covenants. We may not be able to comply with these restrictions and covenants in the future. Our failure to comply with any of the restrictions and covenants under our Credit Agreement could result in an event of default under our Credit Agreement and result in the acceleration of the maturity of the indebtedness under the Credit Agreement. We may not have enough available cash or be able to raise additional funds through equity or debt financings to repay such indebtedness at the time any such event of default occurs. In that case, we may be required to delay, limit, reduce or terminate our product candidate development or commercialization efforts or grant to others rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.&#160; </p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong><em>As our products and company are in a highly regulated industry, significant and unforeseen changes in policy may have material impacts on our business.</em></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">A primary reason for our company to develop the cannabis-derived pharmaceuticals is the changing regulatory and social landscape, in terms of cannabis. State efforts to decriminalize and/or legalize, as well as the growth of state level medical marijuana rulings, have created the opportunity to develop the medical potential for cannabis. However, cannabis is still illegal on a Federal level, outside of the areas described above. We do not know what impact might occur to our development plans, if the Federal law were to change dramatically in the near-term. While we believe the licensed intellectual property, the institutional knowledge, and our management experience will provide us with what is necessary to achieve our goals, we cannot predict the impact of any changes in the current regulatory environment</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong><em>The use of &#8220;medical marijuana&#8221; or &#8220;recreational marijuana&#8221; in the United States may impact our business.</em></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">There is a substantial amount of change occurring in various states of the United States regarding the use of &#8220;medical marijuana.&#8221; While cannabis is a Schedule I substance as defined under federal law, and its possession and use is not permitted in accordance with federal law, a number of individual states have enacted state laws to authorize possession and use of cannabis for medical purposes, and in some states for recreational purposes. While our product candidates are distinct from crude herbal cannabis, our prospects may nevertheless be impacted by these laws at the state level in the United States.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">As with all medicines, it is very difficult to gauge accurately market acceptance of our potential drug candidates. While we are taking and will take significant efforts in selecting drug candidates that we believe represent the best opportunities for market adoption, such as unsatisfied needs, competitive environment, partnering potential, therapeutic potential, and target product profile potential, the ultimate market acceptance of a preclinical candidate is very difficult to predict. The ultimate acceptance will be impacted by the performance in clinical trials (efficacy and safety), reimbursement and development of competitive compounds. Also, the healthcare reimbursement environment has been changing over the recent past and is likely to continue to evolve. If we are unable to gain market acceptance for our product candidates, if approved, then we may not be able to generate substantial product revenues.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong><em>We currently have no marketing and sales experience or capabilities to market and sell our product candidates, if approved. </em></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">We currently do not have experience in the marketing, sales and distribution of any of our product candidates that are able to attain regulatory approval. If our product candidates receive regulatory approval, we will need to establish sales and marketing capabilities to commercialize our product candidates, which will be expensive and time consuming. Any failure or delay in the development of our internal sales and marketing capabilities would adversely impact the commercialization of any of our products that we obtain approval to market. If we are not successful in commercializing our product candidates, either on our own or through collaborations with one or more third parties, our future product revenue will suffer and we may incur significant additional losses.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong><em>Our commercial success depends upon attaining significant market acceptance of our product candidates, if approved, among physicians and patients.</em></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">Even if approved by the FDA, our product candidates may not gain market acceptance among physicians and patients, which is vital to our commercial success. Market acceptance of any product candidate for which we receive approval depends on a number of factors, including:</p> <p style="MARGIN: 0px">&#160;&#160; </p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="width:4%;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">the clinical indications for which the drug is approved and efficacy and safety as demonstrated in clinical trials&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">the timing of market introduction of the product candidate and/or competitive products&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">acceptance of the drug as a safe and effective treatment by physicians and patients&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">the potential and perceived advantages of the product candidate over alternative treatments&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">the cost of treatment in relation to alternative treatments&#894; and</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">the prevalence and severity of adverse side effects.</td></tr></table> <p style="MARGIN: 0px">&#160; </p> <p style="MARGIN: 0px">If our product candidates are approved but fail to achieve an adequate level of acceptance by physicians and patients, we will not be able to generate significant revenues, and we may not become or remain profitable.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong><em>We may expend our limited resources to pursue a particular product candidate or indication and may fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</em></strong></p> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">20</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc1">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160; </p> <p style="MARGIN: 0px">Because we have limited financial and managerial resources, we must focus our efforts on particular research programs and product candidates for specific indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. Any such failure to improperly assess potential product candidates could result in missed opportunities and/or our focus on product candidates with low market potential, which would harm our business and financial condition.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong><em>We engage in transactions with related parties and such transactions present possible conflicts of interest that could have an adverse effect on us.</em></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">We have entered, and may continue to enter, into transactions with Emerald Health Sciences and its affiliates and other related parties for financing, corporate, business development and operational services. Such transactions may not have been entered into on an arm&#8217;s-length basis, and we may have achieved more or less favorable terms because such transactions were entered into with our related parties. We rely, and will continue to rely, on our related parties to maintain these services. If the pricing for these services changes, or if our related parties cease to provide these services, including by terminating agreements with us, we may be unable to obtain replacements for these services on the same terms without disruption to our business. This could have a material effect on our business, results of operations and financial condition. The details of certain of these transactions are set forth in &#8220;Certain Relationships and Related Party Transactions.&#8221; Related party transactions create the possibility of conflicts of interest with regard to our management, including that:</p> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="width:4%;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">we may enter into contracts between us, on the one hand, and related parties, on the other, that are not the result of arm&#8217;s-length transactions&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">our executive officers and directors that hold positions of responsibility with related parties may be aware of certain business opportunities that are appropriate for presentation to us as well as to such other related parties and may present such business opportunities to such other parties&#894; and</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">our executive officers and directors that hold positions of responsibility with related parties may have significant duties with, and spend significant time serving, other entities and may have conflicts of interest in allocating time.</td></tr></table> <p style="MARGIN: 0px">&#160; </p> <p style="MARGIN: 0px">Such conflicts could cause an individual in our management to seek to advance his or her economic interests or the economic interests of certain related parties above ours. Further, the appearance of conflicts of interest created by related party transactions could impair the confidence of our investors. Our audit committee reviews these transactions. Notwithstanding this, it is possible that a conflict of interest could have a material adverse effect on our liquidity, results of operations and financial condition.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><em><strong>We are expecting delays to our NB1111 clinical trial as a result of the COVID-19 and unpredictable business disruptions could seriously harm our future revenues and financial condition, increase our costs and expenses and impact our ability to raise capital.</strong></em></p> <p style="MARGIN: 0px; text-align:justify;">&#160; </p> <p style="MARGIN: 0px; text-align:justify;">Our operations could be subject to unpredictable events, such as earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics such as the COVID-19 outbreak and other natural or manmade disasters or business interruptions, for which we are predominantly self-insured. We do not carry insurance for all categories of risk that our business may encounter. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. Notably, we rely on third-party manufacturers to produce our product candidates. The manufacturing of the active pharmaceutical ingredient of NB1111 is conducted in the United States. Formulation of the eye drop for testing is also performed in the United States but can rely on regulatory-accepted excipients that can be sourced from countries outside the United States, such as China. In lieu of the recent pandemic of COVID-19, there could possibly be an impact on sourcing materials that are part of the eye drop formulation, as well as impacting volunteer and/or patient recruitment in Australia for clinical studies. Therefore, we anticipate shifting our first-in-human studies of the lead drug candidate, NB1111, from the second half of 2020, to the 2021 timeframe. Additionally, COVID-19 has caused significant disruptions to the global financial markets which could impact our ability to raise additional capital. The ultimate impact on us and our significant suppliers and manufacturers is unknown, but our operations and financial condition could suffer in the event of these type of unpredictable events. Further, any significant uninsured liability may require us to pay substantial amounts, which would adversely affect our business, results of operations, financial condition and cash flows from future prospects.</p> <p style="MARGIN: 0px; text-align:justify;">&#160; &#160;&#160;</p> <p style="MARGIN: 0px"><strong>Risks Related to Controlled Substances</strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong><em>The product candidates we are developing will be subject to U.S. controlled substance laws and regulations and failure to comply with these laws and regulations, or the cost of compliance with these laws and regulations, may adversely affect the results of our business operations, both during non-clinical and clinical development and post-approval, and our financial condition.</em></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">The product candidates we plan to develop will contain controlled substances as defined in the CSA. Controlled substances that are pharmaceutical products are subject to a high degree of regulation under the CSA, which establishes, among other things, certain registration, manufacturing quotas, security, recordkeeping, reporting, import, export and other requirements administered by the DEA. The DEA classifies controlled substances into five schedules: Schedule I, II, III, IV or V substances. Schedule I substances by definition have a high potential for abuse, no currently &#8220;accepted medical use&#8221; in the United States, lack accepted safety for use under medical supervision, and may not be prescribed, marketed or sold in the United States. Pharmaceutical products approved for use in the United States may be listed as Schedule II, III, IV or V, with Schedule II substances considered to present the highest potential for abuse or dependence and Schedule V substances the lowest relative risk among such substances. Schedule I and II drugs are subject to the strictest controls under the CSA, including manufacturing and procurement quotas, security requirements and criteria for importation. In addition, dispensing of Schedule II drugs is further restricted. For example, they may not be refilled without a new prescription.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">While cannabis, cannabis extracts, and some cannabinoids are Schedule I controlled substances, products approved for medical use in the United States that contain cannabis, cannabis extracts or some cannabinoids must be placed on Schedules II-V, since approval by the FDA satisfies the &#8220;accepted medical use&#8221; requirement.</p> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">21</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc1">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">If approved by the FDA, we expect the finish dosage forms of our cannabinoid-derived drug product candidates to be listed by the DEA as a Schedule II or III controlled substance. Consequently, their manufacture, importation, exportation, domestic distribution, storage, sale and legitimate use will be subject to a significant degree of regulation by the DEA. In addition, the scheduling process may take one or more years, thereby delaying the launch of the drug product in the United States. Furthermore, if the FDA, DEA, or any foreign regulatory authority determines that any of our drug product candidates may have potential for abuse, it may require us to generate more clinical or other data than we currently anticipate to establish whether or to what extent the substance has an abuse potential, which could increase the cost and/or delay the launch of the drug product.&#160; </p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">Facilities conducting research, manufacturing, distributing, importing or exporting, or dispensing controlled substances must be registered (licensed) to perform these activities and have the security, control, recordkeeping, reporting and inventory mechanisms required by the DEA to prevent drug loss and diversion. All these facilities must renew their registrations annually, except dispensing facilities, which must renew every three years. The DEA conducts periodic inspections of certain registered establishments that handle controlled substances. Obtaining the necessary registrations may result in delay of the manufacturing, development, or distribution of our product candidates. Furthermore, failure to maintain compliance with the CSA, particularly non-compliance resulting in loss or diversion, can result in regulatory action that could have a material adverse effect on our business, financial condition and results of operations. The DEA may seek civil penalties, refuse to renew necessary registrations, or initiate proceedings to restrict, suspend or revoke those registrations. In certain circumstances, violations could lead to criminal proceedings. Individual states have also established controlled substance laws and regulations. Though state- controlled substances laws often mirror federal law, because the states are separate jurisdictions, they may separately schedule our product candidates. While some states automatically schedule a drug based on federal action, other states schedule drugs through rulemaking or a legislative action. State scheduling may delay commercial sale of any product for which we obtain federal regulatory approval and adverse scheduling could have a material adverse effect on the commercial attractiveness of such product. We or our partners or clinical sites must also obtain separate state registrations, permits or licenses in order to be able to obtain, handle, and distribute controlled substances for clinical trials or commercial sale, and failure to meet applicable regulatory requirements could lead to enforcement and sanctions by the states in addition to those from the DEA or otherwise arising under federal law.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">To conduct clinical trials with our product candidates in the United States prior to approval, each of our research sites must obtain and maintain a DEA researcher registration that will allow those sites to handle and dispense the product candidate and to obtain the product. If the DEA delays or denies the grant of a research registration to one or more research sites, the clinical trial could be significantly delayed, and we could lose clinical trial sites.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">Manufacturing of our product candidates is, and, if approved, our commercial products will be subject to the DEA&#8217;s annual manufacturing and procurement quota requirements, if classified as Schedule II. The annual quota allocated to us or our contract manufacturers for the controlled substances in our product candidates may not be sufficient to meet commercial demand or complete clinical trials. Consequently, any delay or refusal by the DEA in establishing our, or our contract manufacturers&#8217;, procurement and/or production quota for controlled substances could delay or stop our clinical trials or product launches, which could have a material adverse effect on our business, financial position and operations.</p> <p style="MARGIN: 0px">&#160;&#160;</p> <p style="MARGIN: 0px">If, upon approval of any of our product candidates, the product is scheduled as Schedule II or III, we would also need to identify wholesale distributors with the appropriate DEA registrations and authority to distribute the product to pharmacies and other health care providers. The failure to obtain, or delay in obtaining, or the loss of any of those registrations could result in increased costs to us. Furthermore, state and federal enforcement actions, regulatory requirements, and legislation intended to reduce prescription drug abuse, such as the requirement that physicians consult a state prescription drug monitoring program may make physicians less willing to prescribe, and pharmacies to dispense, our products, if approved.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong><em>Our ability to research, develop and commercialize our drug product candidates is dependent on our ability to obtain and maintain the necessary controlled substance registrations from the DEA.</em></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">In the United States, the DEA regulates activities relating to the cultivation, possession and supply of cannabis for medical research and/or commercial development, including the requirement to obtain annual registrations to manufacture or distribute pharmaceutical products derived from cannabis extracts. The NIDA also plays a role in oversight of the cultivation of cannabis for medicinal research. We do not currently handle any controlled substances, but we plan to partner with third-parties to engage in the research and development of cannabis-derived compounds for medical purposes. This will require that our third-party contractors obtain and maintain the necessary DEA registrations, and be subject to other regulatory requirements. We plan to develop and manufacture synthetically produced active drug products and in February 2016, July 2018 and April 2019, signed agreements with AMRI to synthetically manufacture our API to be used in our development programs for glaucoma and CINV. In August 2019, we terminated our ongoing agreements with AMRI. We entered into an agreement with Noramco in February 2019 to develop scale-up synthesis methods and to manufacture the analog derivative, CBDVHS, and amended the agreement in August 2019 to include THCVHS.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong><em>The cultivation of cannabis is strictly regulated in the United States under a complex legal framework and our partners may be unable to obtain or maintain the necessary authorizations to cultivate cannabis for the research and development of cannabis-derived compounds.</em></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">We are partnering with UM to research and develop cannabis-derived drug products. Pursuant to that partnership, UM plans to cultivate cannabis and make extracts to conduct or enable our third-party laboratories to conduct early investigations into proof-of-concept studies on the activity of these cannabinoids in various medical conditions. The regulation of cannabis is complex and subject to stringent controls. UM has indicated that its plan for cultivating cannabis for the purification of cannabis extracts is in compliance with applicable law, including the CSA, DEA regulations, and the United States&#8217; obligations under the 1961 Single Convention on Narcotic Drugs. However, there is a risk that regulatory authorities may disagree or may decline to authorize UM to engage in the contemplated activities under the partnership. Interpretations of law that DEA adopted in the past may evolve or change. If UM cannot obtain or maintain the necessary regulatory authorizations that we anticipate will be required for the contemplated development program, our business may suffer and we may not be able to pursue the discovery, research and development of cannabinoids.</p> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">22</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc1">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong>Risks Related to Government Regulation</strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong><em>If we fail to demonstrate the safety and efficacy of any product candidate that we develop to the satisfaction of the FDA or comparable foreign regulatory authorities we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of such product candidate. This would adversely impact our ability to generate revenue, our business and our results of operations.</em></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">We are not permitted to commercialize, market, promote, or sell any product candidate in the United States without obtaining marketing approval from the FDA or in other countries without obtaining approvals from comparable foreign regulatory authorities, such as the European Medicines Agency (the &#8220;EMA&#8221;), and we may never receive such approvals. To gain approval to market a drug product, we must complete extensive preclinical development and clinical trials that demonstrate the safety and efficacy of the product for the intended indication to the satisfaction of the FDA or other regulatory authority.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">We have not previously submitted a new drug application (&#8220;NDA&#8221;) to the FDA, or similar drug approval filings to comparable foreign authorities, for any product candidate, and we cannot be certain that any of our product candidates will be successful in clinical trials or receive regulatory approval. Further, our product candidates may not receive regulatory approval even if they are successful in clinical trials. If we do not receive regulatory approval for our product candidates, we may not be able to continue our operations. Even if we successfully obtain regulatory approval to market our product candidates, our revenue will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval and have commercial rights.&#160; </p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">The FDA or any foreign regulatory bodies could delay, limit or deny approval of our product candidates for many reasons, including:</p> <p style="MARGIN: 0px">&#160;&#160; </p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="width:4%;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">our inability to demonstrate to the satisfaction of the FDA or the applicable foreign regulatory body that the product candidate is safe and effective for the requested indication&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">the FDA&#8217;s or the applicable foreign regulatory agency&#8217;s disagreement with the interpretation of data from preclinical studies or clinical trials&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">our inability to demonstrate that the clinical and other benefits of the product candidate outweigh any safety or other perceived risks&#894;the FDA&#8217;s or the applicable foreign regulatory agency&#8217;s requirement for additional preclinical or clinical studies&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">the FDA&#8217;s or the applicable foreign regulatory agency&#8217;s non-approval of the formulation, labeling or the specifications of the product candidate&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">the FDA&#8217;s or the applicable foreign regulatory agency&#8217;s failure to approve the manufacturing processes or facilities of third-party manufacturers with which we contract&#894; or</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">the potential for approval policies or regulations of the FDA or the applicable foreign regulatory agencies to significantly change in a manner rendering our clinical data insufficient for approval.</td></tr></table> <p style="MARGIN: 0px">&#160; </p> <p style="MARGIN: 0px">Even if we eventually complete clinical testing and receive approval of a NDA or foreign regulatory filing for a product candidate, the FDA or the applicable foreign regulatory agency may grant approval contingent on the performance of costly additional clinical trials which may be required after approval. The FDA or the applicable foreign regulatory agency also may approve the product candidate for a more limited indication or a narrower patient population than we originally requested, and the FDA, or applicable foreign regulatory agency, may not approve the labeling that we believe is necessary or desirable for the successful commercialization of the product. Any delay in obtaining, or inability to obtain, applicable regulatory approval would delay or prevent commercialization of the product candidate and would materially adversely impact our business and prospects.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong><em>Preclinical and clinical drug development involves a lengthy and expensive process with an uncertain outcome. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.</em></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">Clinical testing is expensive and can take several years to complete, and its outcome is inherently uncertain. Moreover, obtaining sufficient quantities of product for clinical testing is subject to regulation by DEA and, in some cases, NIDA. It is impossible to predict when or if any of our product candidates will prove effective or safe in humans or will receive regulatory approval. Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, we must complete preclinical studies and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. A failure of one or more clinical trials can occur at any stage of testing. The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products. We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or subsequently to commercialize our product candidates, including:</p> <p style="MARGIN: 0px">&#160;&#160; </p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="width:4%;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">FDA, DEA or NIDA may not authorize the use and distribution of sufficient quantities of product for clinical testing&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">regulators or independent institutional review boards (IRBs) may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">we may experience delays in reaching, or fail to reach, agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites&#894;</td></tr></table> <p style="MARGIN: 0px">&#160;&#160;&#160;&#160; </p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">23</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc1">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="width:4%;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development programs&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials at a higher rate than we anticipate&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all&#894;</td></tr></table> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="width:4%;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">we may have to suspend or terminate clinical trials of our product candidates for various reasons, including a finding that the participants are being exposed to unacceptable health risks&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">regulators or IRBs may require that we or our investigators suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">the cost of clinical trials of our product candidates may be greater than we anticipate&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate&#894; and</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">our product candidates may have undesirable side effects or other unexpected characteristics, causing us or our investigators, regulators or IRBs to suspend or terminate the trials.</td></tr></table>&#160; <p style="MARGIN: 0px">If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we may:</p> <p style="MARGIN: 0px">&#160;&#160; </p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="width:4%;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">be delayed in obtaining marketing approval for our product candidates&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">not obtain marketing approval at all&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">obtain approval for indications or patient populations that are not as broad as intended or desired&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">be subject to additional post-marketing testing requirements&#894; or</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">have the product removed from the market after obtaining marketing approval.</td></tr></table> <p style="MARGIN: 0px">&#160; </p> <p style="MARGIN: 0px">Our product development costs will also increase if we experience delays in testing or in receiving marketing approvals. We do not know whether any of our preclinical studies or clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Significant preclinical study or clinical trial delays also could allow our competitors to bring products to market before we do and impair our ability to successfully commercialize our product candidates and may harm our business and results of operations.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong><em>If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.</em></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or similar regulatory authorities outside the United States. Our pool of suitable patients may be smaller for some of our product candidates, which will impact our ability to enroll a sufficient number of suitable patients. In addition, some of our competitors have ongoing clinical trials for product candidates that treat the same indications as our product candidates, and patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors&#8217; product candidates. Patient enrollment is affected by other factors including:</p> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="width:4%;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">the severity of the disease under investigation&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">the eligibility criteria for the study in question&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">the perceived risks and benefits of the product candidate under study&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">the efforts to facilitate timely enrollment in clinical trials&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">the patient referral practices of physicians&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">the ability to monitor patients adequately during and after treatment&#894; and</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">the proximity and availability of clinical trial sites for prospective patients.</td></tr></table> <p style="MARGIN: 0px">&#160;&#160; </p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">24</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc1">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">Our inability to enroll a sufficient number of patients for our clinical trials would result in significant delays and could require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our product candidates, which would cause the value of our company to decline and limit our ability to obtain additional financing.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong><em>Our development and commercialization strategy for THCVHS, including NB1111, may depend, in part, on published scientific literature and the FDA&#8217;s prior findings regarding the safety and efficacy of dronabinol, based on data not developed by us, but upon which the FDA may rely in reviewing our NDA.</em></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">The Hatch-Waxman Act added Section 505(b)(2) to the Federal Food, Drug and Cosmetic Act (&#8220;FDCA&#8221;), Section 505(b)(2) permits the filing of a NDA where at least some of the information required for approval comes from investigations that were not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use from the person by or for whom the investigations were conducted. The FDA interprets Section 505(b)(2) of the FDCA, for purposes of approving a NDA, to permit the applicant to rely, in part, upon published literature or the FDA&#8217;s previous findings of safety and efficacy for an approved product. The FDA may also require companies to perform additional clinical trials or measurements to support any deviation from the previously approved product. The FDA may then approve the new product candidate for all or some of the label indications for which the referenced product has been approved, as well as for any new indication sought by the Section 505(b)(2) applicant. The label, however, may require all or some of the limitations, contraindications, warnings or precautions included in the listed product&#8217;s label, including a black box warning, or may require additional limitations, contraindications, warnings or precautions. Depending on guidance from the FDA, we may decide to submit a NDA for NB1111 under Section 505(b) relying, in part, on the FDA&#8217;s previous findings of safety and efficacy from investigations for the approved drug product Dronabinol for which we have not received a right of reference and published scientific literature. Even though we may be able to take advantage of Section 505(b)(2) to support potential U.S. approval, the FDA may require us to perform additional clinical trials or measurements to support approval. In addition, notwithstanding the approval of many products by the FDA pursuant to Section 505(b)(2), over the last few years some pharmaceutical companies and others have objected to the FDA&#8217;s interpretation of Section 505(b)(2). If the FDA changes its interpretation of Section 505(b)(2), or if the FDA&#8217;s interpretation is successfully challenged in court, this could delay or even prevent the FDA from approving any Section 505(b)(2) NDAs that we submit. Such a result could require us to conduct additional testing and costly clinical trials, which could substantially delay or prevent the approval and launch of our product candidates, including NB1111.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong><em>Even if we receive regulatory approval for a product candidate, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and subject us to restrictions, withdrawal from the market, or penalties if we fail to comply with applicable regulatory requirements or if we experience unanticipated problems with our product candidates, when and if approved.</em></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">Once regulatory approval has been granted, the approved product and its manufacturer are subject to continual review by the FDA, DEA and/or non-U.S. regulatory authorities. Any regulatory approval that we receive for our product candidates may be subject to limitations on the indicated uses for which the product may be marketed or contain requirements for potentially costly post-marketing follow-up studies or surveillance to monitor the safety and efficacy of the product. In addition, if the FDA and/or non-U.S. regulatory authorities approve any of our product candidates, we will be subject to extensive and ongoing regulatory requirements by the FDA and other regulatory authorities with regard to labeling, packaging, adverse event reporting, storage, distribution, advertising, promotion, recordkeeping and submission of safety and other post-market information. Manufacturers of our products and manufacturers&#8217; facilities are required to comply with current good manufacturing practice (&#8220;cGMP&#8221;) regulations, which include requirements related to quality control and quality assurance as well as the corresponding maintenance of records and documentation. Further, regulatory authorities must approve these manufacturing facilities before they can be used to manufacture our products, and these facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance with cGMP regulations. Accordingly, we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality control. We will also be required to report certain adverse reactions and production problems, if any, to the FDA and to comply with requirements concerning advertising and promotion for our products. If we, any future collaboration partner or a regulatory authority discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory authority may impose restrictions on that product, the collaboration partner, the manufacturer or us, including requiring withdrawal of the product from the market or suspension of manufacturing. </p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">Any DEA registrations that we receive may also be subject to limitations. For example, if approved, our commercial products will be subject to the DEA&#8217;s annual manufacturing and procurement quota requirements. The annual quota allocated to us or our contract manufacturers for the controlled substances in our product candidates may not be sufficient to meet commercial demand. Our facilities that handle controlled substances, and those of our third-party contractors, will also be subject to registration requirements and periodic inspections. Additionally, if approved by the FDA, the finished dosage forms of our drug product candidates will be subject to the DEA&#8217;s rescheduling process, which may delay product launch and impose additional regulatory burdens. Failure to maintain compliance with the CSA, particularly non-compliance resulting in loss or diversion, can result in regulatory action that could have a material adverse effect on our business, financial condition and results of operations. The DEA may seek civil penalties, refuse to renew necessary registrations, or initiate proceedings to restrict, suspend or revoke those registrations. In certain circumstances, violations could lead to criminal proceedings. For additional information, see Risk Factor, &#8220;<em>The </em><em>product candidates we are developing will be subject to U.S. controlled substance laws and regulations and failure to comply with these laws and regulations, or the cost of compliance with these laws and regulations, may adversely affect the results of our business operations, both during non-clinical and clinical development and post-approval, and our financial condition.</em>&#8221;</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">The FDA closely regulates the post-approval marketing and promotion of drugs to ensure drugs are marketed only for the approved indications and in accordance with the provisions of the approved labeling and regulatory requirements. The FDA also imposes stringent restrictions on manufacturers&#8217; communications regarding off-label use and if we do not restrict the marketing of our products only to their approved indications, we may be subject to enforcement action for off-label marketing. If we, our product candidates or the manufacturing facilities for our product candidates fail to comply with regulatory requirements of the FDA and/or other non-U.S. regulatory authorities, we could be subject to administrative or judicially imposed sanctions, including:</p> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">25</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc1">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="width:4%;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">warning letters or untitled letters&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">mandated modifications to promotional materials or the required provision of corrective information to healthcare practitioners&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">restrictions imposed on the product or its manufacturers or manufacturing processes&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">restrictions imposed on the labeling or marketing of the product&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">restrictions imposed on product distribution or use&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">requirements for post-marketing clinical trials&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">suspension of any ongoing clinical trials&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">suspension of or withdrawal of regulatory approval&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">voluntary or mandatory product recalls and publicity requirements&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">refusal to approve pending applications for marketing approval of new products or supplements to approved applications filed by us&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">restrictions on operations, including costly new manufacturing requirements&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">seizure or detention of our products&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">refusal to permit the import or export of our products&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">required entry into a consent decree, which can include imposition of various fines (including restitution or disgorgement of profits or revenue), reimbursements for inspection costs, required due dates for specific actions and penalties for noncompliance&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">civil or criminal penalties&#894; or</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">injunctions.</td></tr></table> <p style="MARGIN: 0px">&#160;&#160;&#160;&#160;&#160;</p> <p style="MARGIN: 0px">Widely publicized events concerning the safety risk of certain drug products have resulted in the withdrawal of drug products, revisions to drug labeling that further limit use of the drug products and the imposition by the FDA of risk evaluation and mitigation strategies (&#8220;REMS&#8221;), to ensure that the benefits of the drug outweigh its risks. In addition, widely publicized events concerning the safety risk of certain drug products have resulted in the withdrawal of drug products, revisions to drug labeling that further limit use of the drug products and the imposition by the FDA of REMS to ensure that the benefits of the drug outweigh its risks. In addition, because of the serious public health risks of high profile adverse safety events with certain products, the FDA may require, as a condition of approval, costly REMS programs.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">The regulatory requirements and policies may change, and additional government regulations may be enacted for which we may also be required to comply. For example, in December 2016, the 21st Century Cures Act (the &#8220;Cures Act&#8221;) was signed into law. The Cures Act, among other things, is intended to modernize the regulation of drugs and spur innovation, but its ultimate implementation is unclear. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would adversely affect our business, prospects, financial condition and results of operations.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or in other countries. For example, certain regulatory policies of the Trump administration may impact our business and industry in ways that are difficult or impossible to predict. Since the November 2016 U.S. presidential election, the Trump administration has made numerous efforts to reduce regulation and its associated costs, including the issuance of a number of Executive Orders which could impose significant burdens on, or otherwise materially delay, the FDA&#8217;s ability to engage in routine regulatory and oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. In January 2017, President Trump issued Executive Order 13771, applicable to all executive agencies, including the FDA, which requires an agency to repeal two existing rules for each new significant rule or guidance document to be issued, unless otherwise prohibited by law. This &#8220;two-for-one&#8221; policy is aimed at reducing regulatory costs. For fiscal years 2018 and beyond, this Executive Order requires agencies to identify regulations to offset any incremental cost of a new regulation and approximate the total costs or savings associated with each new regulation or repealed regulation. It is difficult to predict the extent to which such regulatory reform initiatives and actions will impact the FDA&#8217;s ability to exercise its regulatory authority. If these executive actions impose constraints on the FDA&#8217;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted. If we or any future collaboration partner are not able to maintain regulatory compliance, we or such collaboration partner, as applicable, will not be permitted to market our future products and our business will suffer.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">26</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc1">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160; </p> <p style="MARGIN: 0px"><strong><em>Serious adverse events or undesirable side effects or other unexpected properties of any of our product candidates may be identified during development or after approval that could delay, prevent or cause the withdrawal of regulatory approval, limit the commercial potential, or result in significant negative consequences following marketing approval.</em></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">Serious adverse events or undesirable side effects caused by, or other unexpected properties of, our product candidates could cause us, an IRB, or regulatory authorities to interrupt, delay or halt our clinical trials and could result in a more restrictive label, the imposition of distribution or use restrictions or the delay or denial of regulatory approval by the FDA or comparable foreign regulatory authorities. If any of our product candidates are associated with serious adverse events or undesirable side effects or have properties that are unexpected, we may need to abandon their development or limit development to certain uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Many compounds that initially showed promise in clinical or earlier stage testing have later been found to cause undesirable or unexpected side effects that prevented further development of the compound.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">Undesirable side effects or other unexpected adverse events or properties of any of our other product candidates could arise or become known either during clinical development or, if approved, after the approved product has been marketed. If such an event occurs during development, our trials could be suspended or terminated and the FDA or comparable foreign regulatory authorities could order us to cease further development of, or deny approval of, our product candidates. If such an event occurs after such product candidates are approved, a number of potentially significant negative consequences may result, including:</p> <p style="MARGIN: 0px">&#160;&#160; </p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="width:4%;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">regulatory authorities may withdraw the approval of such product&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">regulatory authorities may require additional warnings on the label or impose distribution or use restrictions&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">regulatory authorities may require one or more post-market studies&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">we may be required to create a medication guide outlining the risks of such side effects for distribution to patients&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">we could be sued and held liable for harm caused to patients&#894; and</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">our reputation may suffer.</td></tr></table> <p style="MARGIN: 0px">&#160;&#160; </p> <p style="MARGIN: 0px">Any of these events could prevent us from achieving or maintaining market acceptance of the affected product candidate, if approved, or could substantially increase commercialization costs and expenses, which could delay or prevent us from generating revenue from the sale of our products and harm our business and results of operations.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong><em>We expect to rely on third parties, such as CROs, to conduct some or all of our preclinical and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may be unable to obtain regulatory approval for or commercialize any of our product candidates.</em></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">We expect to rely on medical institutions, clinical investigators, contract laboratories and other third parties, such as CROs, to conduct our preclinical and clinical studies on our product candidates in compliance with applicable regulatory requirements. These third parties will not be our employees and, except for restrictions imposed by our contracts with such third parties, we will have limited ability to control the amount or timing of resources that they devote to our programs. Although we expect to rely on these third parties to conduct our preclinical studies and clinical trials, we will remain responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with its investigational plan and protocol and the applicable legal, regulatory, and scientific standards, and our reliance on these third parties will not relieve us of our regulatory responsibilities. These entities must maintain and comply with valid DEA registrations and requirements. The FDA and regulatory authorities in other jurisdictions require us to comply with regulations and standards, commonly referred to as current good clinical practices (&#8220;cGCPs&#8221;) for conducting, monitoring, recording and reporting the results of clinical trials, in order to ensure that the data and results are scientifically credible and accurate and that the trial subjects are adequately informed of the potential risks of participating in clinical trials. If we or any of our third-party contractors fail to comply with applicable cGCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. In addition, we are required to report certain financial interests of our third-party investigators if these relationships exceed certain financial thresholds and meet other criteria. The FDA or comparable foreign regulatory authorities may question the integrity of the data from those clinical trials conducted by principal investigators who previously served or currently serve as scientific advisors or consultants to us from time to time and receive cash compensation in connection with such services. Our clinical trials must also generally be conducted with products produced under cGMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">Some of the third parties with whom we contract may also have relationships with other commercial entities, some of which may compete with us. If the third parties conducting our preclinical studies or our clinical trials do not perform their contractual duties or obligations or comply with regulatory requirements, we may need to enter into new arrangements with alternative third parties. This could be costly, and our preclinical studies or clinical trials may need to be extended, delayed, terminated or repeated, and we may not be able to obtain regulatory approval in a timely fashion, or at all, for the applicable product candidate, or to commercialize such product candidate being tested in such studies or trials. If any of our relationships with these third parties terminate, we may not be able to enter into arrangements with alternative third-party contractors or to do so on commercially reasonable terms. Though we plan to carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong><em>We rely on, and expect to continue relying on, third-party contract manufacturing organizations to manufacture and supply product candidates for us, as well as certain raw materials used in the production thereof. If one of our suppliers or manufacturers fails to perform adequately, we may be required to incur significant delays and costs to find new suppliers or manufacturers.</em></strong></p> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">27</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc1">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160; </p> <p style="MARGIN: 0px">We currently have no experience in, and we do not own facilities for, manufacturing our product candidates. We rely on, and expect to continue relying upon, third-party manufacturing organizations to manufacture and supply our product candidates and certain raw materials used in the production thereof. Some of our key components for the production of our product candidates may have a limited number of suppliers.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">The facilities used by our contract manufacturers to manufacture our product candidates must be approved by the FDA pursuant to inspections that will be conducted after we submit our NDA to the FDA. We expect that we will not control the manufacturing process of, and will be completely dependent on, our contract manufacturing partners for compliance with cGMP requirements, for manufacture of our drug products. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA, DEA or others, they will not be able to secure and/or maintain DEA registrations and regulatory approval for their manufacturing facilities. In addition, we expect that we will have no control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates, or if DEA does not register these facilities for the manufacture of controlled substances, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">We do not have commercial supply agreements with our suppliers. In the event that we and our suppliers cannot agree to the terms and conditions for them to provide clinical and commercial supply needs, we would not be able to manufacture our product or candidates until a qualified alternative supplier is identified, which could also delay the development of, and impair our ability to commercialize, our product candidates.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">The failure of third-party manufacturers or suppliers to perform adequately or the termination of our arrangements with any of them may adversely affect our business.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong><em>We could be subject to costly product liability claims related to our clinical trials and product candidates.</em></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">Because we plan to conduct clinical trials with human subjects, we face the risk that the use of our product candidates may result in adverse side effects to our patients in our clinical trials. We face even greater risks upon any commercialization of our product candidates. An individual may bring a product liability claim against us alleging that one of our product candidates causes, or is claimed to have caused, an injury or is found to be unsuitable for consumer use. Any product liability claim brought against us, with or without merit, could result in:</p> <p style="MARGIN: 0px">&#160;&#160; </p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="width:4%;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">withdrawal of clinical trial volunteers, investigators, patients or trial sites&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">the inability to commercialize our product candidates&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">decreased demand for our product candidates&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">regulatory investigations that could require costly recalls or product modifications&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">loss of revenue&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">substantial costs of litigation&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">liabilities that substantially exceed our product liability insurance, which we would then be required to pay ourselves&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">an increase in our product liability insurance rates or the inability to maintain insurance coverage in the future on acceptable terms, if at all&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">the diversion of management&#8217;s attention from our business&#894; and</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">damage to our reputation and the reputation of our products.</td></tr></table> <p style="MARGIN: 0px">&#160; </p> <p style="MARGIN: 0px">Product liability claims may subject us to the foregoing and other risks, which could have a material adverse effect on our business, results of operations, financial condition, and prospects.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong><em>Our employees, independent contractors, principal investigators, CROs, consultants and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</em></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">We are exposed to the risk that our employees, independent contractors, principal investigators, CROs, consultants and vendors may engage in fraudulent or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violates: (1) FDA regulations, including those laws requiring the reporting of true, complete and accurate information to the FDA&#894; (2) manufacturing standards&#894; (3) federal and state healthcare fraud and abuse laws and regulations&#894; or (4) laws that require the true, complete and accurate reporting of financial information or data. Specifically, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter misconduct by our employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</p> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">28</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc1">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong><em>We are subject to uncertainty relating to coverage and reimbursement policies which, if not favorable to our product candidates, could hinder or prevent our products&#8217; commercial success.</em></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">Our ability to commercialize our product candidates, if approved, successfully will depend in part on the extent to which governmental authorities, private health insurers and other third-party payors establish appropriate coverage and reimbursement levels for our product candidates. As a threshold for coverage and reimbursement, third-party payors generally require that drug products have been approved for marketing by the FDA. A primary trend in the U.S. healthcare industry is cost containment. Third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular products and procedures. Increasingly, third-party payors are requiring that companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot assure you that coverage and reimbursement will be available for any product that we commercialize and, if coverage is available, what the level of reimbursement will be. Coverage and reimbursement may impact the demand for, or the price of, any product for which we obtain marketing approval. If coverage and reimbursement are not available or are available only to limited levels, we may not be able to successfully commercialize any product candidate that we successfully develop.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong><em>Healthcare reform measures could hinder or prevent our products candidates&#8217; commercial success, if approved.</em></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">In the United States, there have been, and we anticipate there will continue to be, a number of legislative and regulatory changes to the healthcare system that could impact our ability to sell any of our products profitably if approved. In the United States, the Federal government passed the Patient Protection and Affordable Care Act in 2010, as amended by the Health Care and Education Reconciliation Act (collectively, the &#8220;ACA&#8221;) which substantially changed the way healthcare is financed by both governmental and private insurers. The ACA contains a number of provisions, including those governing enrollment in federal healthcare programs, reimbursement changes and fraud and abuse, which impact existing government healthcare programs and will result in the development of new programs, including Medicare payment for performance initiatives and improvements to the physician quality reporting system and feedback program. Additionally, the ACA:</p> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="width:4%;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">increases the minimum level of Medicaid rebates payable by manufacturers of brand-name drugs from 15.1% to 23.1%&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">requires collection of rebates for drugs paid by Medicaid managed care organizations&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">requires manufacturers to participate in a coverage gap discount program, under which they must agree to offer 50 percent point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D&#894; and</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">imposes a non-deductible annual fee on pharmaceutical manufacturers or importers who sell &#8220;branded prescription drugs&#8221; to specified federal government programs.</td></tr></table> <p style="MARGIN: 0px">&#160;&#160;</p> <p style="MARGIN: 0px">The Trump administration and the U.S. Congress have made numerous efforts to modify, repeal, or otherwise invalidate all, or certain provisions of, the ACA. In May 2017, the U.S. House of Representatives voted to pass the American Health Care Act (the &#8220;AHCA&#8221;) which would repeal numerous provisions of the ACA. The U.S. Senate considered, but did not vote to pass, the AHCA, leaving the ACA largely in place. The Tax Cuts and Jobs Act signed into law in December 2017 repealed the ACA&#8217;s individual health insurance mandate, which is considered a significant component of the ACA. Uncertainty remains with respect to the impact the Trump administration and the U.S. Congress may have, if any, on the future stability of the ACA and its resulting impact on our business. We expect efforts to modify or repeal the ACA to continue, and the potential impact of such efforts are unclear. Any future changes will likely take time to unfold and could have a significant impact on coverage and reimbursement for healthcare items and services covered by plans that were authorized by the ACA. Increasing emphasis on managed care in the U.S. will continue to put downward pressure on the pricing of products, and cost-control initiatives could have the effect of decreasing the price that we or any of our collaborators may receive for our future products. We expect that the ACA and other healthcare reform initiatives adopted in the future may result in more rigorous coverage criteria and additional downward pressure on the price we may receive for any approved product. We cannot predict with certainty the effect the ACA or other healthcare reform initiatives that may be adopted in the future will have on our business. Our results of operations may be adversely affected by the ACA, changes to the ACA, and by other healthcare reform initiatives adopted in the future.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">In addition to the ACA, other legislative changes have been proposed and adopted since the ACA was enacted. On August 2, 2011, the Budget Control Act of 2011 was signed into law, which, among other things, created the Joint Select Committee on Deficit Reduction to recommend to Congress proposals in spending reductions. The Joint Select Committee did not achieve a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, triggering the legislation&#8217;s automatic reduction to several government programs. This includes reductions to Medicare payments to providers of 2% per fiscal year, which went into effect on April 1, 2013, and, due to subsequent legislative amendments, will remain in effect through 2025 unless Congressional action is taken. On January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. In addition, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed bills designed to, among other things, reform government program reimbursement methodologies.</p> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"> <p style="MARGIN: 0px; text-align:center;">29</p></td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc1">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates if approved, or additional pricing pressure. The implementation of cost containment measures or other healthcare reform initiatives may prevent us from being able to generate revenue, attain profitability, or commercialize any products for which we may obtain regulatory approval. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to make and implement healthcare reforms may adversely affect:</p> <p style="MARGIN: 0px">&#160; </p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="width:4%;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">our ability to set a price we believe is fair for our products&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">our ability to generate revenues and achieve or maintain profitability&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">the availability of capital&#894; and</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">our ability to obtain timely approval of our products.</td></tr></table>&#160;&#160;&#160;&#160;&#160; <p style="MARGIN: 0px"><strong><em>We may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, and health information privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</em></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">If we obtain FDA approval for any of our product candidates and begin commercializing those products in the United States, our operations may be directly, or indirectly through our customers, subject to various federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute, the federal False Claims Act, and physician sunshine laws and regulations. These laws may impact, among other things, our proposed sales, marketing, and education programs. In addition, we may be subject to patient privacy regulation by both the federal government and the states in which we conduct our business. The laws that may affect our ability to operate include:</p> <p style="MARGIN: 0px">&#160; </p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="width:4%;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce, or in return for, the purchase or recommendation of an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">HIPAA, which created federal criminal statutes that prohibit executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">HIPAA, as amended by the Health Information Technology and Clinical Health Act and its implementing regulations, which imposes certain requirements relating to the privacy, security, and transmission of individually identifiable health information&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">the federal physician sunshine requirements under the ACA, which require manufacturers of drugs, devices, biologics, and medical supplies to report annually to the U.S. Department of Health and Human Services information related to payments and other transfers of value to physicians, other healthcare providers, and teaching hospitals, and ownership and investment interests held by physicians and other healthcare providers and their immediate family members&#894; and</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws that may apply to items or services reimbursed by any third-party payor, including commercial insurers&#894; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources&#894; state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</td></tr></table> <p style="MARGIN: 0px">&#160;&#160;&#160;&#160;&#160; </p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">30</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc1">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160; &#160;</p> <p style="MARGIN: 0px">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. In addition, recent health care reform legislation has strengthened these laws. For example, the ACA, among other things, amends the intent requirement of the federal Anti-Kickback and criminal healthcare fraud statutes. A person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it. Moreover, the ACA provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from participation in government health care programs, such as Medicare and Medicaid, imprisonment, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong><em>We may be subject to requests for access to our product candidates. Demand for compassionate use of our unapproved therapies could strain our resources, delay our drug development activities, negatively impact our regulatory approval or commercial activities, and result in losses.</em></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">We are developing product candidates to treat life-threatening illnesses for which there are currently limited therapeutic options. If we experience requests for access to unapproved drugs, we may experience significant disruption to our business which could result in losses. We are a small company with limited resources, and any unanticipated trials or access programs resulting from requests for access could deplete our drug supply, increase our capital expenditures, and otherwise divert our resources from our primary goals.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">In addition, legislation referred to as &#8220;Right to Try&#8221; laws have been introduced at the local and national levels, which are intended to give patients access to unapproved therapies. New and emerging legislation regarding expanded access to unapproved drugs for life-threatening illnesses could negatively impact our business in the future. Either activism or legislation related to requests for access may require us to initiate an unanticipated expanded access program or to make our product candidates more widely available sooner than anticipated.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">Patients who receive access to unapproved drugs through compassionate use or expanded access programs have life-threatening illnesses and generally have exhausted all other available therapies. The risk for serious adverse events, including those which may be unrelated to our product candidates, in this patient population is high and could have a negative impact on the safety profile of our product candidate, which could cause significant delays or an inability to successfully commercialize our product candidate and could materially harm our business. In addition, in order to perform the controlled clinical trials required for regulatory approval and successful commercialization of our product candidates, we may also need to restructure or pause any ongoing compassionate use and/or expanded access programs, which could prompt adverse publicity or other disruptions related to current or potential participants in such programs.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong>Risks Related to our Common Stock</strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong><em>We are subject to the reporting requirements of federal securities laws, which is expensive.</em></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">We are a public reporting company in the United States and, accordingly, subject to the information and reporting requirements of the Exchange Act and other federal securities laws, and the compliance obligations of the Sarbanes-Oxley Act. The costs of preparing and filing annual and quarterly reports, proxy statements and other information with the SEC and furnishing audited reports to stockholders causes our expenses to be higher than they would be if we remained a privately-held company.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong><em>Our compliance with the Sarbanes-Oxley Act and SEC rules concerning internal controls is time consuming, difficult and costly.</em></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">We are a reporting company with the SEC and therefore must comply with Sarbanes-Oxley Act and SEC rules concerning internal controls. It is time consuming, difficult and costly for us to develop and implement the internal controls and reporting procedures required by the Sarbanes-Oxley Act. In order to expand our operations, we will need to hire additional financial reporting, internal control, and other finance staff in order to develop and implement appropriate internal controls and reporting procedures.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong><em>Our stock price may be volatile, which may result in losses to our stockholders.</em></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">The stock markets have experienced significant price and trading volume fluctuations, and the market prices of companies quoted on the OTCQB, where our shares of common stock will be quoted, generally have been very volatile and have experienced sharp share-price and trading-volume changes. The trading price of our common stock is likely to be volatile and could fluctuate widely in response to many of the following factors, some of which are beyond our control:</p> <p style="MARGIN: 0px">&#160; </p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">31</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc1">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160; </p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="width:4%;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">variations in our operating results&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">changes in expectations of our future financial performance, including financial estimates by securities analysts and investors&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">changes in operating and stock price performance of other companies in our industry&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">additions or departures of key personnel&#894; and</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">future sales of our common stock.</td></tr></table> <p style="MARGIN: 0px">&#160;&#160;&#160; </p> <p style="MARGIN: 0px">Domestic and international stock markets often experience significant price and volume fluctuations. These fluctuations, as well as general economic and political conditions unrelated to our performance, may adversely affect the price of our common stock. In particular, following initial public offerings, the market prices for stocks of companies often reach levels that bear no established relationship to the operating performance of these companies. These market prices are generally not sustainable and could vary widely. In the past, following periods of volatility in the market price of a public company&#8217;s securities, securities class action litigation has often been initiated.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong><em>Our common shares are thinly-traded, and in the future, may continue to be thinly-traded, and you may be unable to sell at or near ask prices or at all if you need to sell your shares to raise money or otherwise desire to liquidate such shares.</em></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">We cannot predict the extent to which an active public market for our common stock will develop or be sustained due to a number of factors, including the fact that we are a small company that is relatively unknown to stock analysts, stock brokers, institutional investors, and others in the investment community that generate or influence sales volume, and that even if we came to the attention of such persons, they tend to be risk-averse and would be reluctant to follow an unproven company such as ours or purchase or recommend the purchase of our shares until such time as we became more seasoned and viable. As a consequence, there may be periods of several days or more when trading activity in our shares is minimal or non-existent, as compared to a seasoned issuer which has a large and steady volume of trading activity that will generally support continuous sales without an adverse effect on share price. We cannot give you any assurance that a broader or more active public trading market for our common stock will develop or be sustained, or that current trading levels will be sustained.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">The market price for our common stock may be particularly volatile given our status as a relatively small company and lack of revenues that could lead to wide fluctuations in our share price. You may be unable to sell your common stock at or above your purchase price if at all, which may result in substantial losses to you.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">The market for our common shares may be characterized by significant price volatility when compared to seasoned issuers, and we expect that our share price will be more volatile than a seasoned issuer for the indefinite future. The potential volatility in our share price is attributable to a number of factors. First, as noted above, our common shares may be sporadically and/or thinly traded. As a consequence of this lack of liquidity, the trading of relatively small quantities of shares by our stockholders may disproportionately influence the price of those shares in either direction. The price for our shares could, for example, decline precipitously in the event that a large number of our common shares are sold on the market without commensurate demand, as compared to a seasoned issuer that could better absorb those sales without adverse impact on its share price. Secondly, an investment in us is a speculative or &#8220;risky&#8221; investment due to our lack of revenues or profits to date. As a consequence of this enhanced risk, more risk-averse investors may, under the fear of losing all or most of their investment in the event of negative news or lack of progress, be more inclined to sell their shares on the market more quickly and at greater discounts than would be the case with the stock of a seasoned issuer.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong><em>Because we became public by means of a &#8220;reverse merger,&#8221; we may not be able to attract the attention of major brokerage firms or investors in general. </em></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">Additional risks may exist because we became a public company through a &#8220;reverse merger.&#8221; Securities analysts of major brokerage firms may not provide coverage of us since there is little incentive to brokerage firms to recommend the purchase of our common stock. No assurance can be given that brokerage firms will want to conduct any secondary offerings on behalf of our company in the future. In addition, the SEC has recently issued an investor bulletin warning to investors about the risks of investing in companies that enter the U.S. capital markets through a &#8220;reverse merger.&#8221; The release of such information from the SEC may have the effect of reducing investor interest in companies, such as us, that enter the U.S. capital markets through a &#8220;reverse merger.&#8221;</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong><em>We cannot assure you that our common stock will become eligible for listing or quotation on any exchange and the failure to do so may adversely affect your ability to dispose of our common stock in a timely fashion.</em></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">In order for our common stock to become eligible for listing or quotation on any exchange, reverse merger companies must have had their securities traded on an over-the-counter market for at least one year, maintained a certain minimum closing price for not less than 30 of the most recent 60 days prior to the filing of an initial listing application and prior to listing, and timely filed with the SEC all required reports since the consummation of the reverse merger, including one annual report containing audited consolidated financial statements for a full fiscal year commencing after the date of filing of the Current Report on Form 8-K which discloses the reverse merger. We may not be able to meet all of the filing requirements above and may not be able to satisfy the initial standards for listing or quotation on any exchange in the foreseeable future or at all. Even if we are able to become listed or quoted on an exchange, we may not be able to maintain a listing of the common stock on such stock exchange.</p> <p style="MARGIN: 0px">&#160;&#160;</p> <p style="MARGIN: 0px"><strong><em>We do not anticipate paying any cash dividends.</em></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">We presently do not anticipate that we will pay any dividends on any of our capital stock in the foreseeable future. The payment of dividends, if any, would be contingent upon our revenues and earnings, if any, capital requirements, and general financial condition. The payment of any dividends will be within the discretion of our Board. We presently intend to retain all earnings, if any, to implement our business plan&#894; accordingly, we do not anticipate the declaration of any dividends in the foreseeable future.</p> <p style="MARGIN: 0px">&#160; </p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">32</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc1">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160; </p> <p style="MARGIN: 0px"><strong><em>Our common stock may be subject to penny stock rules, which may make it more difficult for our stockholders to sell their common stock.</em></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">Broker-dealer practices in connection with transactions in &#8220;penny stocks&#8221; are regulated by certain penny stock rules adopted by the SEC. Penny stocks generally are equity securities with a price of less than $5.00 per share. The penny stock rules require a broker-dealer, prior to a purchase or sale of a penny stock not otherwise exempt from the rules, to deliver to the customer a standardized risk disclosure document that provides information about penny stocks and the risks in the penny stock market. The broker-dealer also must provide the customer with current bid and offer quotations for the penny stock, the compensation of the broker-dealer and its salesperson in the transaction, and monthly account statements showing the market value of each penny stock held in the customer&#8217;s account. In addition, the penny stock rules generally require that prior to a transaction in a penny stock the broker-dealer make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser&#8217;s written agreement to the transaction. These disclosure requirements may have the effect of reducing the level of trading activity in the secondary market for a stock that becomes subject to the penny stock rules.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong><em>Volatility in our common stock price may subject us to securities litigation.</em></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">The market for our common stock is characterized by significant price volatility when compared to seasoned issuers, and we expect that our share price will continue to be more volatile than a seasoned issuer for the indefinite future. In the past, plaintiffs have often initiated securities class action litigation against a company following periods of volatility in the market price of its securities. We may, in the future, be the target of similar litigation. Securities litigation could result in substantial costs and liabilities and could divert management&#8217;s attention and resources.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong><em><em><strong>We will need additional capital, and the sale of additional shares or other equity securities could result in additional dilution to our stockholders.</strong></em></em></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">We expect our existing cash will be sufficient to fund our capital requirements for at least the next month. We require additional capital for the development and commercialization of our product candidates and may require additional cash resources due to changed business conditions or other future developments, including any investments or acquisitions we may decide to pursue. If our resources are insufficient to satisfy our cash requirements, we will seek to sell additional equity or debt securities or obtain a credit facility. The sale of additional equity securities could result in additional dilution to our stockholders. The incurrence of additional indebtedness would result in increased debt service obligations and could result in operating and financing covenants that would restrict our operations. We cannot assure you that financing will be available in amounts or on terms acceptable to us, if at all.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong><em>Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval. </em></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">Certain of our executive officers, directors and large stockholders own a significant percentage of our outstanding capital stock. As of March 16, 2020, our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates owned approximately 63% of our outstanding shares of common stock. As of March 16, 2020, Emerald Health Sciences, our majority stockholder, owned approximately 62% of our outstanding shares of common stock. Our Board is controlled by the directors and principal executive officer of Emerald Health Sciences. Accordingly, our directors and executive officers have significant influence over our affairs due to their substantial ownership coupled with their positions on our management team and have substantial voting power to approve matters requiring the approval of our stockholders. For example, these stockholders may be able to control elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This concentration of ownership may prevent or discourage unsolicited acquisition proposals or offers for our common stock that some of our stockholders may believe is in their best interest.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px"><strong><em>We have a substantial number of authorized common shares available for future issuance that could cause dilution of our stockholders&#8217; interest and adversely impact the rights of holders of our common stock.</em></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">We have a total of 500,000,000 shares of common stock authorized for issuance and up to 20,000,000 shares of preferred stock with the rights, preferences and privileges that our Board may determine from time to time. As of March 16, 2020, we have reserved 4,512,715 shares for issuance upon the exercise of outstanding options, and 24,830,750 shares for issuance upon the exercise of outstanding warrants. As of March 16, 2020, we had no outstanding preferred stock. As of March 16, 2020, we had 316,792,253 shares of common stock available for issuance. We may seek financing that could result in the issuance of additional shares of our capital stock and/or rights to acquire additional shares of our capital stock. We may also make acquisitions that result in issuances of additional shares of our capital stock. Those additional issuances of capital stock would result in a significant reduction of your percentage interest in us. Furthermore, the book value per share of our common stock may be reduced. This reduction would occur if the exercise price of any issued warrants, the conversion price of any convertible notes is lower than the book value per share of our common stock at the time of such exercise or conversion.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">The addition of a substantial number of shares of our common stock into the market or by the registration of any of our other securities under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), may significantly and negatively affect the prevailing market price for our common stock. The future sales of shares of our common stock issuable upon the exercise of outstanding warrants may have a depressive effect on the market price of our common stock, as such warrants would be more likely to be exercised at a time when the price of our common stock is greater than the exercise price.</p> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">33</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc1">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong><em>There is not now, and there may never be, an active, liquid and orderly trading market for our common stock, which may make it difficult for you to sell your shares of our common stock.</em></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">There is not now, nor has there been since our inception, any significant trading activity in our common stock or a market for shares of our common stock, and an active trading market for our shares may never develop or be sustained. As a result, investors in our common stock must bear the economic risk of holding those shares for an indefinite period of time. Although our common stock is quoted on the OTCQB, an over-the-counter quotation system, trading of our common stock is extremely limited and sporadic and at very low volumes. We do not now, and may not in the future, meet the initial listing standards of any national securities exchange. We presently anticipate that our common stock will continue to be quoted on the OTCQB or another over-the-counter quotation system in the foreseeable future. In those venues, our stockholders may find it difficult to obtain accurate quotations as to the market value of their shares of our common stock and may find few buyers to purchase their stock and few market makers to support its price. As a result of these and other factors, you may be unable to resell your shares of our common stock at or above the price for which you purchased them, or at all. Further, an inactive market may also impair our ability to raise capital by selling additional equity in the future and may impair our ability to enter into strategic partnerships or acquire companies or products by using our shares of common stock as consideration.</p> <p style="MARGIN: 0px">&#160;&#160; </p> <p style="MARGIN: 0px"><strong><em>If we are unable to implement and maintain effective internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our reported financial information and the market price of our common stock may be negatively affected.</em></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">As a public company, we are required to maintain internal control over financial reporting and to report any material weaknesses in such internal control. Section 404 of the Sarbanes-Oxley Act requires that we evaluate and determine the effectiveness of our internal control over financial reporting and provide a management report on the internal control over financial reporting. If we have a material weakness in our internal control over financial reporting, we may not detect errors on a timely basis and our consolidated financial statements may be materially misstated. We may not be able to complete our evaluation, testing and any required remediation in a timely fashion. During the evaluation and testing process, if we identify one or more material weaknesses in our internal control over financial reporting, our management will be unable to conclude that our internal control over financial reporting is effective. Moreover, when we are no longer a smaller reporting company, our independent registered public accounting firm will be required to issue an attestation report on the effectiveness of our internal control over financial reporting. Even if our management concludes that our internal control over financial reporting is effective, our independent registered public accounting firm may conclude that there are material weaknesses with respect to our internal controls or the level at which our internal controls are documented, designed, implemented or reviewed.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">If we are unable to conclude that our internal control over financial reporting is effective, or when we are no longer a smaller reporting company, if our auditors were to express an adverse opinion on the effectiveness of our internal control over financial reporting because we had one or more material weaknesses, investors could lose confidence in the accuracy and completeness of our financial disclosures, which could cause the price of our common stock to decline. Internal control deficiencies could also result in a restatement of our financial results in the future.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong><em>If securities or industry analysts do not publish research or reports about our business, or if they change their recommendations regarding our stock adversely, our stock price and trading volume could decline.</em></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">The trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about us or our business. We are currently covered by one research analyst. If no more analysts commence coverage of us, the trading price of our stock would likely decrease. Even if we do obtain more analyst coverage, if one or more of the analysts who cover us downgrade our stock, our stock price would likely decline. If one or more of these analysts cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong><em>The issuance of shares upon exercise of outstanding warrants and options may cause immediate and substantial dilution to our existing stockholders. </em></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">If the price per share of our common stock at the time of exercise of any warrants, options, or any other convertible securities is in excess of the various conversion or exercise prices of these convertible securities, conversion or exercise of these convertible securities would have a dilutive effect on our common stock. As of March 16, 2020, we had outstanding (i) warrants to purchase up to 24,830,750 shares of our common stock at exercise prices ranging from $0.00 to $5.00 per share, and (ii) options to purchase up to 4,512,715 shares of our common stock at exercise prices ranging from $0.245 to $0.42 per share. Further, any additional financing that we secure may require the granting of rights, preferences or privileges senior to those of our common stock and which result in additional dilution of the existing ownership interests of our common stockholders.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong><em>Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.</em></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">Under Section 382 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an &#8220;ownership change,&#8221; the corporation&#8217;s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes to offset its post-change income may be limited. In general, an &#8220;ownership change&#8221; occurs if the aggregate stock ownership of one or more stockholders or groups of stockholders who own at least 5% of a corporation&#8217;s stock increase their ownership by more than 50 percentage points over their lowest ownership percentage within a rolling three-year period. Similar rules may apply under state tax laws. If it is determined that we have in the past experienced any ownership changes, or if we experience ownership changes as a result of future transactions in our stock, our ability to use our net operating loss carryforwards and other tax attributes to offset U.S. federal taxable income may be subject to limitations, which could potentially result in increased future tax liability to us.</p> <p style="MARGIN: 0px">&#160; &#160;</p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">34</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc1">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160; &#160;</p> <p style="MARGIN: 0px"><u><strong><a name="item1b">Item 1B. Unresolved Staff Comments.</a></strong></u></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">Not applicable.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong><u><a name="item2">Item 2. Properties.</a></u></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">Our principal executive offices and corporate offices are located at 130 North Marina Drive, Long Beach, CA 90803.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">Our laboratory and office space previously consisted of approximately 3,415 square feet located at the Innovation Hub, Insight Park on the UM campus. Our lease expired on December 31, 2017 and our annual rent was approximately $111,000, payable in equal monthly installments with annual escalations. Upon expiration, we did not renew the laboratory lease. We have retained office space in Long Beach, California under a lease agreement at the rate of $2,609 per month and in Oxford, Mississippi, at the rate of $300 per month.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><u><strong><a name="item3">Item</a> 3. Legal Proceedings.</strong></u></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">Not applicable.</p> <p style="MARGIN: 0px">&#160;&#160;</p> <p style="MARGIN: 0px"><strong><u><a name="item4">Item</a> 4. Mine Safety Disclosures.</u></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">Not applicable.</p> <p style="MARGIN: 0px">&#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160; </p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">35</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc1">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160; </p> <p style="MARGIN: 0px; text-align:center;"><strong><a name="part2">PART</a> II</strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong><u><a name="item5">Item</a></u></strong><strong><u> </u></strong><strong><u>5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</u></strong><strong>. </strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong>Market Information.</strong></p> <p style="MARGIN: 0px; text-align:justify;">&#160; </p> <p style="MARGIN: 0px">Our common stock has been quoted on the OTCQB, under the symbol &#8220;EMBI&#8221;. Previously, it traded under the symbol &#8220;NMUS&#8221; until March 25, 2019. There can be infrequent trading volume, which precipitates wide spreads in the &#8220;bid&#8221; and &#8220;ask&#8221; quotes of our common stock, on any given day. On March 16, 2020, the last reported sale price of our common stock on the OTCQB was $0.08 per share.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px">The following table sets forth, for the quarters indicated, the high and low bid prices per share of our common stock on the OTCQB, reported by the Financial Industry Regulatory Authority Composite Feed or other qualified interdealer quotation medium. Such quotations reflect inter-dealer prices, without retail mark-up, mark-down or commission, and may not represent actual transactions.</p> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"> <tr> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"> <p style="MARGIN: 0px"><strong>Quarter Ended</strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px"><strong>High</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px"><strong>Low</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px">December 31, 2019</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.49</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.13</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px">September 30, 2019</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.45</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.25</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px">June 30, 2019</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.17</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.28</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px">March 31, 2019</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.90</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.30</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px">December 31, 2018</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.60</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.05</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px">September 30, 2018</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.39</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.18</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px">June 30, 2018</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.34</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.22</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px">March 31, 2018</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.48</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.14</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px">December 31, 2017</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.30</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.10</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px">September 30, 2017</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.32</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.23</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px">June 30, 2017</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.38</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.25</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px">March 31, 2017</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.50</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.24</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr></table> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong>Holders. </strong>As of March 16, 2020, there were approximately 60 stockholders of record. The number of stockholders of record does not include beneficial owners of our common stock, whose shares are held in the names of various dealers, clearing agencies, banks, brokers and other fiduciaries.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong>Dividends</strong>. We have never declared or paid a cash dividend on our common stock. We do not expect to pay cash dividends on our common stock in the foreseeable future. We currently intend to retain our earnings, if any, for use in our business. Any dividends declared in the future will be at the discretion of our Board and subject to any restrictions that may be imposed by our lenders.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong>Recent Sales of Unregistered Securities. </strong>None.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong>Issuer Purchases of Equity Securities. </strong>None during the fiscal year ended December 31, 2019 covered by this Annual Report.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong>Penny Stock Regulation. </strong>Shares of our common stock will probably be subject to rules adopted by the SEC that regulate broker-dealer practices in connection with transactions in &#8220;penny stocks.&#8221; Penny stocks are generally equity securities with a price of less than $5.00 (other than securities registered on certain national securities exchanges or quoted on the NASDAQ system, provided that current price and volume information with respect to transactions in those securities is provided by the exchange or system). The penny stock rules require a broker-dealer, prior to a transaction in a penny stock not otherwise exempt from those rules, deliver a standardized risk disclosure document prepared by the SEC, which contains the following:</p> <p style="MARGIN: 0px">&#160; </p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="width:4%;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">a description of the nature and level of risk in the market for penny stocks in both public offerings and secondary trading&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">a description of the broker&#8217;s or dealer&#8217;s duties to the customer and of the rights and remedies available to the customer with respect to violation to such duties or other requirements of securities&#8217; laws&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">a brief, clear, narrative description of a dealer market, including &#8220;bid&#8221; and &#8220;ask&#8221; prices for penny stocks and the significance of the spread between the &#8220;bid&#8221; and &#8220;ask&#8221; price&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">a toll-free telephone number for inquiries on disciplinary actions&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">definitions of significant terms in the disclosure document or in the conduct of trading in penny stocks&#894; and</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">such other information and is in such form (including language, type, size and format), as the SEC shall require by rule or regulation.</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Prior to effecting any transaction in penny stock, the broker-dealer also must provide the customer the following:</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">the bid and offer quotations for the penny stock&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">the compensation of the broker-dealer and its salesperson in the transaction&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">the number of shares to which such bid and ask prices apply, or other comparable information relating to the depth and liquidity of the market for such stock&#894; and</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">monthly account statements showing the market value of each penny stock held in the customer&#8217;s account.</td></tr></table> <p style="MARGIN: 0px">&#160;&#160;&#160; </p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">36</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc1">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">In addition, the penny stock rules require that prior to a transaction in a penny stock not otherwise exempt from those rules, the broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser&#8217;s written acknowledgment of the receipt of a risk disclosure statement, a written agreement to transactions involving penny stocks, and a signed and dated copy of a written suitability statement. These disclosure requirements may have the effect of reducing the trading activity in the secondary market for a stock that becomes subject to the penny stock rules. Holders of shares of our common stock may have difficulty selling those shares because our common stock will probably be subject to the penny stock rules.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong><u><a name="item6">Item</a> 6. Selected Financial Data</u></strong><strong>.</strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">Not applicable.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong><u><a name="item7">Item</a> 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operation</u></strong><strong>.</strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><em>The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements for the years ended December 31, 2019 and 2018 together with notes thereto. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of certain factors, including, but not limited, to those set forth under &#8220;Risk Factors&#8221; and elsewhere in this Annual Report on Form 10-K.</em></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><em>Unless otherwise provided in this Annual Report, references to &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and &#8220;Emerald Bioscience&#8221; in this discussion and analysis refer to Emerald Bioscience, Inc., a Nevada corporation formerly known as Nemus Bioscience, Inc. and Load Guard Logistics, Inc., together with its wholly-owned subsidiaries, Nemus, a California corporation, and EMBI Australia Pty Ltd., an Australian proprietary limited company.</em></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong>Overview</strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">We are a biopharmaceutical company targeting the discovery, development, and commercialization of cannabinoid-based therapeutics, through a number of license agreements with the University of Mississippi (&#8220;UM&#8221;). UM holds the only contract to cultivate cannabis for research purposes on behalf of the Federal Government of the United States and has held that federal license since 1968, and it has significant expertise in cannabis cultivation and the extraction, separation, processing and manufacture of cannabis extracts as well as the chemistry and physiology of cannabinoid molecules. We strive to serve as UM&#8217;s partner for the development and commercialization of cannabinoid-based therapeutics, and the realization of this partnership will depend on the successful development of these compounds through the regulatory requirements of drug approval agencies, like the FDA in the United States and the EMA in the European Union.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">Effective March 25, 2019, we changed our name from Nemus Bioscience, Inc. to Emerald Bioscience, Inc.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">In August 2019, we formed a new subsidiary in Australia, EMBI Australia Pty Ltd, in order to qualify for the Australian government&#8217;s research and development tax credit for research and development dollars spent in Australia. The primary purpose of EMBI Australia is to conduct clinical trials for our product candidates.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong>Recent Events and Significant Contracts</strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><em>Expansion of UM 5050 and UM 8930 Licenses from Ocular Delivery Only to All Fields of Use</em></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">On May 24, 2019, we executed two restated and amended license agreements with UM which expanded our use of UM 5050, a pro-drug of tetrahydrocannabinol (&#8220;THC&#8221;), and UM 8930, an analog of cannabidiol (&#8220;CBD&#8221;), from ocular delivery only to all fields of use. Pursuant to these license agreements, we have exclusive, perpetual, worldwide licenses related to UM 5050 and UM 8930. Additionally, with the prior written consent of UM, we have the right to sublicense the licensed intellectual property.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">The all fields use for tetrahydrocannabinol-valine-hemisuccinate (&#8220;THCVHS&#8221;), the proprietary prodrug of THC, is expected to allow us to explore related uses for the active moiety of the prodrug, namely THC. Independent in vitro and in vivo studies have demonstrated the potential use of THC in a variety of potential indications based on the ability of the cannabinoid to act as an anti-inflammatory, anti-fibrotic, and/or inhibitor of neovascularization. The Company has generated data related to these effects using an <em>ex vivo</em> human tissue model of the eye. The prodrug technology employed in THCVHS is designed to enhance the bioavailability and pharmacokinetic predictability of the active part of the molecule, once introduced into the body through routes of administration currently being considered by the development team. Given the positive data accumulated to date in studies of the eye, we could explore additional central nervous system applications for THCVHS. We expect to develop strategic collaborations to identify and advance these applications.</p> <p style="MARGIN: 0px">&#160; &#160;</p> <p style="MARGIN: 0px">The all fields use of cannabidiol-valine-hemisuccinate (&#8220;CBDVHS&#8221;), the analog of CBD, is expected to permit us to expand research and development into organ systems outside of the current ocular space. Potential disease targets over time could involve the central nervous system, the gastrointestinal tract, the endocrine/metabolic system, reproductive system diseases, or as yet unrecognized opportunities. This bioengineered version of CBD is expected to enlarge the disease target pool by virtue of new routes of administration into the body, thereby enhancing bioavailability. The determination by the DEA that CBDVHS is not a controlled substance permits us to enlarge the potential pool of clinical test sites and a more diverse patient pool in the study of disease. We expect to develop strategic collaborations to identify and advance these applications.</p> <p style="MARGIN: 0px">&#160;&#160; </p> <p style="MARGIN: 0px"><em>NB1111</em></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">The manufacturing of the active pharmaceutical ingredient of NB1111 is conducted in the United States. Formulation of the eye drop for testing is also performed in the United States but can rely on regulatory-accepted excipients that can be sourced from countries outside the United States, such as China. In lieu of the recent pandemic of COVID-19 there could possibly be an impact on sourcing materials that are part of the eye drop formulation, as well as impacting volunteer and/or patient recruitment in Australia for clinical studies. Therefore, we anticipate shifting our first-in-human studies of the lead drug candidate, NB1111, from the second-half of 2020, to the 2021 timeframe, The first-in-human studies are expected to be conducted in both normal controls and patients with glaucoma or ocular hypertension in Australia (the &#8220;Clinical Trial&#8221;). During 2019, we achieved various milestones related to the research and development of NB1111, including the following</p> <p style="MARGIN: 0px; text-align:justify;">&#160;&#160;&#160;&#160;</p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">37</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc1">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160; </p> <p style="MARGIN: 0px">UM completed experiments showing that NB1111 was statistically superior in lowering intraocular pressure (&#8220;IOP&#8221;) compared to the prostaglandin-based therapy, latanoprost, the current standard-of-care for treating glaucoma. Significance was reached across multiple timepoints during a seven-day course of dosing using a validated rabbit normotensive ocular model and NB1111 exerted pharmacologic activity consistent with twice-daily dosing.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">Glauconix Biosciences Inc. (&#8220;Glauconix&#8221;) completed their pilot study to research the mechanism of action and IOP-lowering ability of THC when administered into an <em>ex vivo</em> model of a 3D-human trabecular meshwork using both healthy and glaucomatous-derived tissues. The Glauconix study validated the mechanism of action of NB1111 in lowering IOP, a defining disease process of hypertensive glaucoma. Additionally, biomarkers associated with inflammation and fibrosis in both normal and tissues affected by glaucoma were significantly decreased, pointing to anti-inflammatory and anti-fibrotic activities that are often associated with the cannabinoid class of molecules in other disease-states; and data revealed that biomarkers associated with neovascularization, a disease process of new blood vessel formation that can damage the retina in a variety of ocular diseases, was also inhibited by THC, prompting further study for the utility of this drug in diseases of the retina.</p> <p style="MARGIN: 0px">&#160; &#160;</p> <p style="MARGIN: 0px">In August 2019, EMBI Australia Pty Ltd entered into a start-up agreement with Novotech (Australia) Pty Limited (&#8220;Novotech&#8221;). The start-up agreement is being entered into in connection with the launch of the Clinical Trial. We expect to pay approximately $45,000 in professional fees and pass through costs in connection with the services provided for in the start-up agreement. Additionally, on September 26, 2019, EMBI Australia Pty Ltd and Novotech executed a Master Services Agreement and anticipate entering into project agreements covering all anticipated services to be provided by Novotech to us in connection with the Clinical Trial.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">In August 2019, EMBI Australia entered into a master service agreement and initial statement of work with Agilex Biolabs Pty Ltd (&#8220;Agilex&#8221;), pursuant to which Agilex would assist with the assay set up for the anticipated Clinical Trial.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">In August 2019, we executed an agreement with Bioscience Laboratories, Inc. to complete Draize testing in advance of the anticipated Clinical Trial.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">AMRI worked toward closing the synthesis validation pathway to manufacture cGMP API of THCVHS with validation of drug product purity. In turn, on April 30, 2019, we entered into an additional agreement with AMRI related to non-GMP synthesis of a demonstration batch of our pro-drug of THC. In August 2019, our manufacturing agreement with AMRI for THCVHS that was executed in July 2018 was replaced by the agreement with Noramco discussed below.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">On August 7, 2019, we entered into a first amendment to our agreement with Noramco to manufacture THCVHS (the &#8220;Noramco Agreement,&#8221; as amended from time to time). CBDVHS was being manufactured pursuant to the Noramco Agreement prior to the amendment. We paid $257,800 upfront to add the manufacture of THCVHS to the Noramco Agreement and additional payments will be made upon Noramco&#8217;s shipping of the GMP active pharmaceutical ingredient to us. All other material terms of the Noramco Agreement remain the same.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px">In January 2019, we engaged RRD International, LLC (&#8220;RRD&#8221;) to provide strategic ophthalmic 505(b)(2) regulatory planning, prepare a Pre- IND meeting briefing book, and schedule and represent us at the Pre-IND meeting with the FDA. In May 2019, we executed a change order to extend our work with RRD as we continue to progress toward our Pre-IND meeting. In August 2019, we executed an additional work order with RRD to assist us in preparing an investigator&#8217;s brochure to support the Clinical Trial.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">In January 2019, we executed an agreement with Pharmaceuticals International, Inc. (&#8220;PII&#8221;) to conduct studies to determine options for producing a sterile dosage form which can be dosed in humans in a clinical study. PII will conduct appropriate formulation studies to determine storage and processing options. Pursuant to the terms of the agreement, we paid $72,500 to initiate the project. After the initial evaluation, we have agreed to pay additional fees and expenses upon completion of certain milestones.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><em>NB2222</em></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">NB2222 is the ocular formulation of our proprietary CBD analog. We have embarked on studies with UM exploring the utility of our drug candidate NB2222 as an eye drop nanoemulsion for the potential treatment and management of several eye diseases, including but not limited to, uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">In July 2019, we engaged Glauconix to conduct research as to whether CBD or CBDVHS is associated with an increase in IOP and, if so, what the potential mechanism of action would be by exposing the 3D-human trabecular meshwork tissue constructs to these molecules. In December 2019, we announced that data generated by Glauconix Biosciences, Inc. showed significant anti-inflammatory and anti-fibrotic activity in ocular tissue with CBDVHS when compared to CBD, indicating therapeutic potential as a neuroprotectant, especially in diseases of the retina. Additionally, CBD was associated with biomarkers related to the elevation of IOP while CBDVHS was not associated with elevating IOP at anti-fibrotic concentrations. </p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">In the second quarter of 2019, UM also completed pre-clinical experiments showing that NB2222 exhibited an ability to penetrate multiple chambers of the eye and reach the optic nerve. These findings support the therapeutic potential to provide ocular neuroprotection of retinal ganglion cells, an important goal in treating diseases that lead to vision loss. The data were published in the peer-reviewed Journal of Ocular Pharmacology and Therapeutics in a paper titled, &#8220;Analog Derivatization of Cannabidiol for Improved Ocular Permeation&#8221; (2019&#894; volume 35 (5): 1-10).</p> <p style="MARGIN: 0px">&#160;&#160;</p> <p style="MARGIN: 0px">In February 2019, we entered into the Noramco Agreement to provide manufacturing and product development services for our analog formulation of CBD. We paid $146,386 upfront and additional payments will be made upon Noramco&#8217;s shipping of the active pharmaceutical ingredient to us.&#160;&#160;&#160;</p> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">38</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc1">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><em>NB3111</em></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">NB3111 is a proprietary cannabinoid cocktail currently undergoing testing as an anti-infective agent against multiple strains of antibiotic resistant bacteria, particularly methicillin-resistant Staphylococcus aureus (&#8220;MRSA&#8221;). These studies look to examine the utility of cannabinoid-based therapies against a variety of MRSA strains and other gram-positive bacterial infections. We plan to continue to present data from these studies at an upcoming peer-reviewed scientific meeting focused on infectious diseases.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><em>Other Development Programs</em></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">We plan to continue to work with UM to explore other potential indications and associated routes of administration based on the expanded UM5050 and UM 8930 licenses. Our decision to advance a potential therapeutic candidate will be influenced by a number of criteria, including but not limited to, pre-clinical data, synthesis and formulation capability as well as prevailing market conditions.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">In July 2019, we engaged StemoniX to evaluate CBD and CBDVHS (and possibly additional CBD-derivatives) in a human in vitro neural model with an application to epilepsy. The series of experiments are designed to provide insight into how these cannabinoids stabilize neuronal cells. In November and December 2019, we also executed additional pre-clinical research agreements with StemoniX related to CBDVHS. </p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">In December 2019, we announced data generated by StemoniX, that CBDVHS was both pharmacologically and therapeutically distinct from CBD when studied in an in vitro human neural tissue model mimicking chemically-induced seizure-like hyperactivity. Additionally, CBDVHS was observed to gain potency in anti-seizure-like activity over the seven-day observation period whereas the suppressive effect afforded by CBD dissipated by day 3. In assessing safety parameters of CBDVHS, the molecule was not found to be toxic to the neurologic cells tested in multiple assays, both in acute and longer-term exposure. </p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong>Critical Accounting Policies and Estimates</strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">Our Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations section discusses our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of income and expenses during the reporting period. On an on-going basis, management evaluates its estimates and judgments, including those related to accrued expenses, financing operations, and contingencies and litigation. Management bases its estimates and judgments on historical experience and on various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. The most significant accounting estimates inherent in the preparation of our consolidated financial statements include estimates as to the appropriate carrying value of certain assets and liabilities which are not readily apparent from other sources. These accounting policies are described at relevant sections in this discussion and analysis and in the notes to the consolidated financial statements included in this Annual Report on Form 10-K. We believe that the following accounting policies are the most critical to aid you in fully understanding and evaluating our reported financial results and affect the more significant judgments and estimates that we use in the preparation of our consolidated financial statements.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><em>Fair Value Measurements</em></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">Certain assets and liabilities are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last is considered unobservable, is used to measure fair value:</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px 0px 0px 45px">Level 1: Valuations for assets and liabilities traded in active markets from readily available pricing sources such as quoted prices in active markets for identical assets or liabilities.</p> <p style="MARGIN: 0px 0px 0px 45px">&#160;</p> <p style="MARGIN: 0px 0px 0px 45px">Level 2: Observable inputs (other than Level 1 quoted prices) such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</p> <p style="MARGIN: 0px 0px 0px 45px">&#160;</p> <p style="MARGIN: 0px 0px 0px 45px">Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">The carrying values of our financial instruments, with the exception of the Credit Agreement (as defined below) and derivative liabilities, including, cash, prepaid expenses, accounts payable, and other current liabilities approximate their fair value due to the short maturities of these financial instruments. The derivative liabilities were valued on a recurring basis utilizing Level 3 inputs.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">Advances under the Credit Agreement are not recorded at fair value. However, fair value can be approximated and disclosed utilizing Level 3 inputs and independent third-party valuation techniques. </p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><em>Convertible Instruments</em></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">We account for hybrid contracts with embedded conversion features in accordance with GAAP. ASC 815, <em>Derivatives and Hedging Activities </em>(&#8220;ASC 815&#8221;) requires companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria includes circumstances in which the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.</p> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">39</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc1">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160; </p> <p style="MARGIN: 0px">We account for convertible debt instruments with embedded conversion features in accordance with ASC 470-20, <em>Debt with Conversion and Other Options </em>(&#8220;ASC 470-20&#8221;) if it&#8217;s determined that the conversion feature should not be bifurcated from their host instruments. Under ASC 470-20, we record, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the difference between the fair value of the underlying common stock at the commitment date and the embedded effective conversion price. When we determine that the embedded conversion option should be bifurcated from its host instrument, the embedded feature is accounted for in accordance with ASC 815. Under ASC 815, a portion of the proceeds received upon the issuance of the hybrid contract is allocated to the fair value of the derivative. The derivative is subsequently marked to market at each reporting date based on current fair value, with the changes in fair value reported in results of operations.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">We also follow ASC 480-10, <em>Distinguishing Liabilities from Equity </em>(&#8220;ASC 480-10&#8221;) when evaluating the accounting for its hybrid instruments. A financial instrument that embodies an unconditional obligation, or a financial instrument other than an outstanding share that embodies a conditional obligation, that the issuer must or may settle by issuing a variable number of its equity shares shall be classified as a liability (or an asset in some circumstances) if, at inception, the monetary value of the obligation is based solely or predominantly on any one of the following: (a) a fixed monetary amount known at inception (for example, a payable settled with a variable number of the issuer&#8217;s equity shares)&#894; (b) variations in something other than the fair value of the issuer&#8217;s equity shares (for example, a financial instrument indexed to the Standard and Poor&#8217;s S&amp;P 500 Index and settled with a variable number of the issuer&#8217;s equity shares)&#894; or (c) variations inversely related to changes in the fair value of the issuer&#8217;s equity shares (for example, a written put option that could be net share settled). Hybrid instruments meeting these criteria are not further evaluated for any embedded derivatives and are carried as a liability at fair value at each balance sheet date with a re-measurement reported other (income) expense in the accompanying Consolidated Statements of Comprehensive Income (Loss).</p> <p style="MARGIN: 0px">&#160;&#160;</p> <p style="MARGIN: 0px; text-align:justify;">When determining short-term vs. long-term classification of derivative liabilities, we first evaluate the instruments&#8217; exercise provisions. Generally, if a derivative is a liability and exercisable within one year, it will be classified as short-term. However, because of the unique provisions and circumstances that may impact the accounting for derivative instruments, we carefully evaluate all factors that could potentially restrict the instrument from being exercised or create a situation where exercise would be considered remote. We re-evaluate our derivative liabilities at each reporting period end and make updates for any changes in facts and circumstances that may impact classification.</p> <p style="MARGIN: 0px">&#160;&#160;</p> <p style="MARGIN: 0px"><em>Warrants Issued in Connection with Financings</em></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">We generally account for warrants issued in connection with debt and equity financings as a component of equity, unless the warrants include a conditional obligation to issue a variable number of shares or there is a deemed possibility that we may need to settle the warrants in cash. For warrants issued with a conditional obligation to issue a variable number of shares or the deemed possibility of a cash settlement, we record the fair value of the warrants as a liability at each balance sheet date and records changes in fair value in other (income) expense in the Consolidated Statements of Comprehensive Income (Loss).</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><em>Stock-Based Compensation Expense&#160;</em></p> <p style="MARGIN: 0px">&#160;&#160; &#160;</p> <p style="MARGIN: 0px; text-align:justify;">Stock-based compensation expense is estimated at the grant date based on the fair value of the award, and the cost is recognized as expense ratably over the vesting period with forfeitures accounted for as they occur. We use the Black-Scholes Merton option pricing model for estimating the grant date fair value of stock options using the following assumptions:</p> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="width:4%;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Volatility - Stock price volatility is estimated over the expected term based on a blended rate of industry peers and our actual stock volatility adjusted for periods in which significant financial variability was identified.</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Expected term - The expected term is based on a simplified method which defines the life as the weighted average of the contractual term of the options and the vesting period for each award.</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px">Risk-free rate - The risk-free interest rate for the expected term of the option is based on the average market rate on U.S. Treasury securities in effect during the period in which the awards were granted.</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Dividends - The dividend yield assumption is based on our history and expectation of paying no dividends in the foreseeable future.</td></tr></table> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><em>Net Income (Loss) Per Share of Common Stock</em></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">We apply FASB ASC No. 260, <em>Earnings per Share</em>. Basic net income (loss) per share of common stock is computed by dividing income (loss) available to common stockholders by the weighted-average number of shares of common stock outstanding for the period. The diluted net income (loss) per share of common stock is computed by giving effect to all potential common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, options to purchase common stock, restricted stock subject to vesting, warrants to purchase common stock and common shares underlying convertible debt instruments are considered to be common stock equivalents. In periods with a reported net loss, such common stock equivalents are excluded from the calculation of diluted net loss per share of common stock if their effect is anti-dilutive.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><em>Recently Issued and Adopted Accounting Pronouncements</em></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">See Note 2 to the accompanying Consolidated Financial Statements included in Part IV, Item 15 of this Annual Report on Form 10- K for information on recently issued accounting pronouncements and recently adopted accounting pronouncements. While we expect certain recently adopted accounting pronouncements to impact our estimates in future periods, the impact upon adoption was not significant to our current estimates and operations.</p> <p style="MARGIN: 0px">&#160; </p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">40</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc1">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160;&#160; </p> <p style="MARGIN: 0px"><strong>Results of Operations</strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong><em>For the years ended December 31, 2019 and 2018</em></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong>Revenues. </strong>To date, we have not generated any revenues, and do not expect to generate any revenue from the sale of products in the near future.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong>Operating expenses. </strong>For the year ended December 31, 2019, our total operating expenses were $6,632,578 as compared to $4,692,523 for the year ended December 31, 2018.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><u>Research </u><u>and development</u>. Research and development expenses for the year ended December 31, 2019 were $2,237,956, which consisted of upfront payments for the all fields of use licenses for UM 5050 and UM 8930, the annual license maintenance fee for UM 5070, salaries and benefits and consulting fees for the staff involved in our preclinical and clinical drug development activities, contract research and development fees paid to UM, Glauconix, StemoniX and Bioscience Laboratories, regulatory consulting fees paid to RRD, fees related to contract manufacturing paid to AMRI, Noramco and ElSohly Laboratories, fees related to contract formulation work paid to PII and fees paid to Novotech and Agilex in preparation of the Clinical Trial expected to launch in 2021. </p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">Research and development expenses for the year ended December 31, 2018 were $329,966, which consisted of the annual license maintenance fees for UM 5070, annual license maintenance fees for UM 5050 related to ocular delivery, annual license maintenance fees for UM 8930 related to ocular delivery, contract research and development fees and fees related to our contract with AMRI to manufacture our prodrug of THC.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">For the year ended December 31, 2019, research and development expenses increased by $1,907,990, as compared to the year ended December 31, 2018. The increase is primarily due to upfront payments for the all fields of use licenses for UM 5050 and UM 8930, contract manufacturing expenses, contract formulation expenses, regulatory fees, salaries and benefits and consulting fees for the staff involved in our preclinical and clinical drug development activities and contract research and development expenses, as the procurement of the Credit Agreement (as defined below) and funds raised through our November 2019 Common Stock Offering (as defined below) have allowed us to continue to focus on ramping up our research and development efforts.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><u>General and administrative</u>. General and administrative expenses for the year ended December 31, 2019 were $4,394,622, which primarily consisted of salaries, consulting fees, stock-based compensation expense and professional fees associated with our costs of being a public company. General and administrative expenses for the year ended December 31, 2018 were $4,362,557, which primarily consisted of the same components. General and administrative expenses remained relatively constant year over year.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong>Other expense (income). </strong>For the year ended December 31, 2019, we had non-operating income of $7,686,003, which was comprised primarily of the following:</p> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="width:4%;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">$9,734,759 of other income from the change in fair value of derivative liabilities which represents an overall decrease in the fair value of our derivative liabilities. The derivatives marked-to-market include the Series B and Emerald Health Sciences warrant liabilities and the compound derivative bifurcated from the Credit Agreement (as defined below). Several assumptions go into the third-party valuations for each of these instruments however the decrease in our stock price and valuation assumptions were all contributing factors to the decrease in the value of these instruments during the year ended December 31, 2019;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">$322,644 of other expense was related to drawdowns initiated under the Credit Agreement which required us to bifurcate compound embedded derivatives and record an additional charge for the fair value of such instruments in excess of proceeds;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">interest expense of $1,000,713 realized during the year ended December 31, 2019 due to the amortization of the debt discount and interest payments associated with the outstanding balance under the Credit Agreement which was entered into during the fourth quarter of 2018; and</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">$725,425 loss on extinguishment related to the prepayment of the Credit Agreement.</td></tr></table> <p style="MARGIN: 0px">&#160;&#160;&#160; </p> <p style="MARGIN: 0px; text-align:justify;">For the year ended December 31, 2018, we had non-operating expense of $14,500,071, which was comprised primarily of the following:</p> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="width:4%;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">$6,503,174 of other expense from the change in fair value of derivative liabilities which represents an overall increase in the fair value of our derivative liabilities. The derivatives marked-to-market include the conversion liabilities related to the Series B Preferred Stock and Secured Convertible Promissory Note - related party, the Series B and Emerald Health Sciences warrant liabilities and the compound derivative bifurcated from the Credit Agreement (defined below). A number of assumptions go into the third-party valuations for each of these instruments however the increase in our stock price, update to our volatility assumption and valuation assumptions were all contributing factors to the increase in the value of these instruments during the year ended December 31, 2018;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">$7,174,634 represented a loss from the excess of the fair value of the warrants on the date of issuance over the proceeds received in the Emerald Health Sciences Financing (defined below);</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">$137,192 in financing costs related to the Emerald Health Sciences Financing;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">$590,392 from a loss on extinguishment related to the Secured Convertible Promissory Note (as defined below); and</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">$94,763 from interest expense which includes non-cash interest expense from the amortization of the debt discounts and cash interest paid to debt holders.</td></tr></table> <p style="MARGIN: 0px">&#160;&#160;&#160; </p> <p style="MARGIN: 0px"><strong>Net income (loss). </strong>For the year ended December 31, 2019, we had net income of $1,051,825 as compared to a net loss of $19,194,236 for the year ended December 31, 2018. The net income generated during 2019 was driven by other income primarily related to a non-cash adjustment in derivative liabilities from the decrease in our stock price. We expect to incur net losses for the foreseeable future.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong>Liquidity and Capital Resources</strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px 0px 0px 0.35pt; text-align:justify;">We have incurred operating losses and negative cash flows from operations since inception. As of December 31, 2019, we had an accumulated deficit of $32,173,282. We anticipate that we will continue to incur operating losses into the foreseeable future in order to advance and develop a number of our potential drug candidates into preclinical and clinical development activities and support its corporate infrastructure which includes the costs associated with being a public company. As of December 31, 2019 and filing date of our 2019 Annual Report on Form 10K, we had cash in the amount of $1,829,977 and approximately $667,000, respectively.</p> <p style="MARGIN: 0px">&#160; &#160;&#160;</p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">41</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc1">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160;&#160; </p> <p style="MARGIN: 0px 0px 0px 0.35pt; text-align:justify;">On October 5, 2018, we secured a Credit Agreement with Emerald Health Sciences (the &#8220;Credit Agreement&#8221;), providing us with a credit facility of up to $20,000,000. Under the Credit Agreement, we may draw a remaining amount of up to $14,000,000 in advances from Emerald Health Sciences from time to time, each in a principal amount of at least $250,000. The advances are subject to approval by our Board, which is controlled by the directors of Emerald Health Sciences. As such, we do not consider the facility available until advance requests are approved, drawn down and funded. As of December 31, 2019, we have effected three drawdowns under the Credit Agreement, each in the amount of $2,000,000, for an aggregate principal amount of $6,000,000 in advances, and have issued to Emerald Health Sciences warrants to purchase an aggregate of 7,500,000 shares of common stock at an exercise price of $0.50 per share. On December 20, 2019, we entered into a Warrant Exercise Agreement with Emerald Health Sciences, pursuant to which Emerald Health Sciences has exercised 40,800,000 of such warrants and paid the aggregate exercise price of approximately $4,080,000 for the related warrant shares in the form of a reduction of the corresponding amount of obligations outstanding under the Credit Agreement. Upon consummation of the transactions under the Warrant Exercise Agreement, the total outstanding principal amount excluding discounts under the Credit Agreement was $2,014,500. </p> <p style="MARGIN: 0px 0px 0px 0.35pt; text-align:justify;">&#160;&#160;&#160;&#160;</p> <p style="MARGIN: 0px">On October 23, 2019, we filed a registration statement on Form S-1/A, which has been declared effective as of October 28, 2019, and on November 13, 2019, we filed a related registration statement on a Form S-1MEF that became effective under Rule 462(b). On November 21, 2019, we sold 8.0 million shares of common stock at $0.25 per share and 8.0 million warrants to purchase shares of common stock at an exercise price of $0.35 per share for aggregate gross proceeds of approximately $2.0 million, which were registered under the foregoing registration statements under a securities purchase agreement, as reported in the current report on the Form 8-K filed with the SEC on November 21, 2019. On December 9, 2019, December 24, 2019, January 22, 2020, February 11, 2020 and February 13, 2020, we filed post-effective amendments for the foregoing registration statements which became effective on February 13, 2020. We engaged H.C. Wainwright &amp; Co., LLC as our exclusive placement agent to use its reasonable best efforts to solicit offers to purchase the securities in this offering. The offering has been terminated and the Company has deregistered the shares associated with these registration statements. </p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">We intend to continue working toward identifying and obtaining new sources of financing. No assurances can be given that we will be successful in obtaining additional financing in the future. Any future financing that we may obtain may cause significant dilution to existing stockholders. Any debt financing or other financing of securities senior to common stock that we can obtain will likely include financial and other covenants that will restrict our flexibility. Any failure to comply with these covenants would have a negative impact on our business, prospects, financial condition, results of operations and cash flows.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">If adequate funds are not available, we may be required to delay, scale back or eliminate portions of our operations, cease operations or obtain funds through arrangements with strategic partners or others that may require us to relinquish rights to certain of our assets. Accordingly, the inability to obtain such financing could result in a significant loss of ownership and/or control of our assets and could also adversely affect our ability to fund our continued operations and our expansion efforts.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">During the next twelve months, we expect to incur significant research and development expenses with respect to our products. The majority of our research and development activity is focused on the development of potential drug candidates, preclinical studies and preparing for clinical trials.</p> <p style="MARGIN: 0px; text-align:justify;">&#160; &#160;</p> <p style="MARGIN: 0px">We also expect to incur significant legal and accounting costs in connection with being a public company. We expect those fees will be significant and will continue to impact our liquidity. Those fees will be higher as our business volume and activity increases.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">We also anticipate that we will need to hire additional employees or independent contractors as we prepare to enter clinical studies.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><em>Going Concern</em></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">Our independent registered public accounting firm has issued a report on our audited financial statements for the fiscal year ended December 31, 2019, that includes an explanatory paragraph referring to our recurring operating losses and expressing substantial doubt in our ability to continue as a going concern. Our consolidated financial statements have been prepared on a going concern basis, which assumes the realization of assets and settlement of liabilities in the normal course of business. Our ability to continue as a going concern is dependent upon our ability to generate profitable operations in the future and/or to obtain the necessary financing to meet our obligations and repay our liabilities arising from normal business operations when they become due. The outcome of these matters cannot be predicted with any certainty at this time and raise substantial doubt that we will be able to continue as a going concern. Our consolidated financial statements do not include any adjustments to the amount and classification of assets and liabilities that may be necessary should we be unable to continue as a going concern.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px"><strong>Off-Balance Sheet Arrangements</strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">There are no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong><u><a name="item7a">Item</a> 7A. Quantitative and Qualitative Disclosures About Market Risk</u></strong><strong>.</strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">Not applicable.</p> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">42</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc1">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160;&#160; </p> <p style="MARGIN: 0px"><strong><u><a name="item8">Item</a> 8. Financial Statements and Supplementary Data</u></strong><strong>.</strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">Our consolidated financial statements and the report of our independent registered public accounting firm are included in this report on pages F-1 through F-24.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><a name="item9"><strong><u>I</u></strong></a><strong><u>tem</u></strong><strong><u> 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</u>.</strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">Not applicable.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong><u><a name="item9a">Item</a> 9A. Controls and Procedures</u></strong><strong>.</strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong>Evaluation of Disclosure Controls and Procedures</strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">We maintain controls and procedures that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive and principal financial officers, as appropriate, to allow timely decisions regarding required disclosures. Based upon their evaluation of those controls and procedures performed as of the end of the period covered by this report, our principal executive officer and our principal financial officer concluded that our disclosure controls and procedures were effective.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong>Management&#8217;s Annual Report on Internal Control over Financial Reporting</strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting as defined in Rule 13a-15(f) and 15d-15(f) promulgated under the Exchange Act as a process designed by, or under the supervision of, a company&#8217;s principal executive and principal financial officers and effected by our board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:</p> <p style="MARGIN: 0px">&#160;&#160; </p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="width:4%;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-size:14pt">&#8226;</font></p></td> <td style="vertical-align:top;">pertain to the maintenance of records that in reasonable detail accurately and fairly reflect our transactions and dispositions of the company&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-size:14pt">&#8226;</font></p></td> <td style="vertical-align:top;">provide reasonable assurance that transactions are recorded as necessary to permit preparation of consolidated financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company&#894; and</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-size:14pt">&#8226;</font></p></td> <td style="vertical-align:top;">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</td></tr></table> <p style="MARGIN: 0px">&#160;&#160;&#160;&#160;&#160; </p> <p style="MARGIN: 0px">Because of its inherent limitations, our internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">Our management, with the supervision and participation of our Chief Executive Officer and Chief Financial Officer, assessed the effectiveness of our internal control over financial reporting as of December 31, 2019, based on criteria for effective internal control over financial reporting set forth by the Committee of Sponsoring Organizations of the Treadway Commission in <em>Internal Control-Integrated Framework - 2013 (COSO 2013 Framework).</em></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">Based on their assessment, our management concluded that, as of December 31, 2019, our internal control over financial reporting was effective.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">As we are a smaller reporting company, our independent registered public accounting firm is not required to attest to the effectiveness of our internal control over financial reporting.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong>Changes in internal control over financial reporting</strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">There was no change in our internal control over financial reporting during the fourth quarter ended December 31, 2019 that materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong><u><a name="item9b">Item</a> 9B. Other Information</u></strong><strong>.</strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">Effective March 23, 2020, some members of senior management will defer 50% of their compensation from the Company until further notice of the Board. Such deferral was approved by the Board on March 16, 2020. The aggregate deferred compensation, together with a retention bonus of 10% of the amount being deferred, will be payable to the senior management upon the Board&#8217;s further determination of the financial conditions of the Company.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;&#160;&#160;&#160; </p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">43</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc1">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><a name="part3">PART</a> III</strong></p> <p style="MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong><u><a name="item10">Item</a> 10. Directors, Executive Officers and Corporate Governance</u></strong><strong>.</strong></p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">The following table sets forth certain information as of the date of this Annual Report, with respect to our directors, executive officers and significant employees.</p> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="BORDER-BOTTOM: 1px solid;width:35%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;"><strong>Name</strong></p></td> <td style="width:2%;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:12%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;"><strong>Age</strong></p></td> <td style="width:2%;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:35%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;"><strong>Position</strong></p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;">Dr. Brian S. Murphy</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;">62</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;">Chief Executive Officer, Director</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;">Douglas Cesario</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;">44</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;">Chief Financial Officer</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;">Dr. Dennis Kim</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;">50</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;">Chief Medical Officer</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;">Punit Dhillon</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;">39</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;">Chairman, Director</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;">Jim Heppell</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;">63</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;">Director</p></td></tr></table> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong>Biographies of Directors, Executive Officers and Significant Employees</strong></p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong>Dr. Brian S. Murphy. </strong>Dr. Murphy was appointed as our Chief Executive Officer and as a director in August 2015. Dr. Murphy was appointed as our Chief Medical Officer in October 2014, and relinquished Chief Medical Officer responsibilities when Dr. Kim was hired in August 2019. Dr. Murphy was the Chief Medical Officer of Nemus Sub from August 2014 to October 2014. From 2009 to August 2014, Dr. Murphy served as the Chief Medical Officer of Eiger Biopharmaceuticals. From 2003 to 2006, Dr. Murphy was Chief Medical Officer at Epiphany Biosciences. From 2003 to 2006, Dr. Murphy was Chief Medical Officer at Valeant Pharmaceuticals International (VRX) where his responsibilities also included oversight of Global Medical Affairs and Pharmacovigilance. Dr. Murphy also served as Medical Director, then Vice President of Marketing and Commercial Strategy of Hepatology for InterMune, Inc. (ITMN). From 2000 to 2002, Dr. Murphy was Medical Director of North America for Antivirals/Interferons/Transplant at Hoffmann-LaRoche. Prior to joining industry, Dr. Murphy was Assistant Professor of Medicine at New York Medical College and was Director of the Clinical Strategies Program at St. Vincent&#8217;s Hospital in New York City, the lead hospital of the Catholic Healthcare Network of New York. Dr. Murphy is board-certified in internal medicine and completed his residency in internal medicine at Tufts-New England Medical Center and served as Chief Medical Resident in the Boston University program. Dr. Murphy completed parallel fellowship tracts at Harvard Medical School, one in internal medicine/clinical Epidemiology at the Massachusetts General Hospital and the other in Medical Ethics addressing issues of distributive justice and access to care at Brigham &amp; Women&#8217;s Hospital. Dr. Murphy earned his MD, MPH (general public health), and MS (pharmacology) degrees from New York Medical College and is a graduate of the Harvard School of Public Health (MPH in Health Policy and Management). He earned his MBA at the Columbia University Graduate School of Business. In making the decision to appoint Dr. Murphy to serve as a director, the Board considered, in addition to the criteria referred to above, his experience in the healthcare industry, current service as our Chief Executive Officer and his comprehensive knowledge of the Company, our business and operations.</p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160; &#160;</p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Douglas Cesario</strong>. Mr. Cesario was appointed as our Chief Financial Officer in May 2018. Prior to his appointment, Mr. Cesario served as Chief Financial Officer, Orange County Service Area, of Kaiser Foundation Hospitals &amp; Health Plan since April 2016, and prior to that as Director of Finance and as a Senior Management Consultant from November 2013. From 2007 to 2012, Mr. Cesario was the founder of a real estate investment and advisory company. Mr. Cesario previously served in private equity, investment banking and commercial real estate roles from 1997 through 2006. He earned his MBA from the UCLA Anderson School of Management. Based on his cumulative and diverse financial background, our Board believes Mr. Cesario has the requisite knowledge and expertise to serve as our Chief Financial Officer.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><strong>Dr. Dennis Kim</strong></strong>. Dr. Kim was appointed Chief Medical Officer in August 2019. He is a physician biotechnology executive with specialty training in endocrinology/metabolism spanning approximately 20 years of drug/product development and corporate strategy experience in the biotech and medical technology industries. Dr. Kim is an independent Board Member of Inversago Pharma. Dr. Kim previously served as Chief Medical Officer of Emerald Health Sciences, Inc. Prior to that, he was Chief Medical Officer at Zafgen, Inc. for over seven years where he oversaw all aspects of clinical and medical affairs in the field of diabetes, obesity, and rare metabolic/genetic disorders. Prior to joining Zafgen, Dr. Kim held multiple senior-level positions at Orexigen Therapeutics (Sr. VP of Medical and Clinical Affairs), EnteroMedics (Chief Medical Officer) and Amylin Pharmaceuticals (Exec Director of Corporate Strategy). He holds an MD from the University of Health Sciences, The Chicago Medical School, an MBA from UCSD Rady School of Management and a B.S. in biology from the University of California at Los Angeles. His endocrinology/metabolism specialty fellowship training was completed at UCSD School of Medicine.</p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p> <p style="MARGIN: 0px"><strong>Punit Dhillon. </strong>Mr. Dhillon was appointed as a member of our Board in connection with the consummation of the investment in us by Emerald Health Sciences in 2018. On December 17, 2019, Mr. Dhillon was appointed as Chairman of our Board. Mr. Dhillon is currently a board member of Emerald Health Pharmaceuticals, Inc., Emerald Health Therapeutics, Inc. (EMH), a TSX Venture Exchange listed company, and Arch Therapeutics Inc. (OTCQB: ARTH). Mr. Dhillon is a Co-founder and Director of OncoSec Medical Incorporated (NASDAQ: ONCS) and was formerly the CEO through March 2018. Prior to OncoSec, Mr. Dhillon was the Vice President of Finance and Operations at Inovio Pharmaceuticals, Inc. (NASDAQ: INO) from September 2003 until March 2011. Mr. Dhillon has also previously been a consultant and board member for several TSX Venture Exchange listed early-stage life science companies, which matured through advances in their development pipelines and subsequent M&amp;A transactions. Prior to joining Inovio, Mr. Dhillon worked for a corporate finance law firm as a law clerk and worked with MDS Capital Corp. (now Lumira Capital Corp.). Mr. Dhillon is an active member in his community and places great value on helping future leaders overcome challenges through mentorship and education and is a co-founder and board member of Young Entrepreneurship Leadership Launchpad (YELL), a not-for-profit and charity organization based in Canada. Mr. Dhillon has a Bachelor of Arts with honors in Political Science and a minor in Business Administration from Simon Fraser University. Mr. Dhillon&#8217;s experience in the biotechnology and pharmaceutical industry, and his experience with publicly traded companies were the primary qualifications that the Board considered in appointing him as a director of the Company.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">44</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc1">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Jim Heppell. </strong>Mr. Heppell was the founder, CEO and director of BC Advantage Life Sciences I Fund, which won the Canadian Venture Capital Deal of the Year Award in 2006 for having the highest realized return (23.4x its investment in Aspreva Pharmaceuticals) of any venture capital fund in Canada. Mr. Heppell has a Bachelor of Science degree in Microbiology and a law degree from the University of British Columbia. After being called to the Bar, he worked for six years with Fasken Martineau DuMoulin, during which time he was seconded to the BC Securities Commission for six months. Mr. Heppell then became President and Chief Executive Officer of Catalyst Corporate Finance Lawyers, a boutique corporate finance law firm that focused on assisting life science and technology companies. He is a past member of the Securities Policy Advisory Committee to the BCSC and is a Past-Chairman of the Securities Section of the Canadian Bar Association (B.C. Branch). Mr. Heppell is currently a director of a number of public and private life science companies, including Emerald Health Sciences. The Board considered Mr. Heppell&#8217;s significant experience with life science and technology companies in making the decision to appoint him as a director of the Company.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong>Section 16(a) Beneficial Ownership Reporting Compliance</strong></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>S</strong>ection 16(a) of the Exchange Act requires our directors, executive officers, and any persons who own more than 10% of a registered class of our equity securities, to file reports of ownership and changes in ownership with the SEC. SEC regulation requires executive officers, directors and greater than 10% stockholders to furnish us with copies of all Section 16(a) forms they file. Based solely on our review of the copies of such forms received by us, or written representations from certain reporting persons, we believe that during the year ended December 31, 2019, our executive officers, directors, and greater than 10% stockholders complied with all applicable filing requirements, except for one Form 4 for Emerald Health Sciences, which reported one transaction and was due on December 24, 2019 but was filed on January 28, 2020. </p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong>Family Relationships</strong></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">There are no family relationships among our directors or executive officers.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong>Term of Office of Directors</strong></p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">Our directors are elected at each annual meeting of stockholders and serve until the next annual meeting of stockholders or until their successor has been duly elected and qualified, or until their earlier death, resignation or removal.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong>Directors and Officers Involvement in Certain Legal Proceedings</strong></p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">During the past ten years, our directors and executive officers have not been involved in any of the legal proceedings set forth in Item 401(f) of Regulation S-K promulgated by the SEC.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong>Board and Committee Meetings</strong></p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">During 2019, our Board met four times (including telephonic meetings) and took action by written consent 16 times. Each director attended at least 75% of the meetings held by the Board and by each committee on which he served while he was a director, either in person or by teleconference, during the year. </p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong>Director Attendance at Annual Meetings</strong></p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">Although we do not have a formal policy regarding attendance by members of our Board at each annual meeting of stockholders, we encourage all of our directors to attend.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong>Audit Committee and Financial Expert</strong></p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p> <p style="MARGIN: 0px">On February 23, 2015, our Board established an audit committee that operates under a written charter that has been approved by our Board. The members of our audit committee are Mr. Punit Dhillon and Mr. Jim Heppell. Mr. Dhillon serves as chairman of the audit committee and our Board has determined that he is an &#8220;audit committee financial expert&#8221; as defined by applicable SEC rules. The Board has determined that Mr. Dhillon and Mr. Heppell are independent directors as that term is defined in Rule 5605(a)(2) of the Nasdaq Listing Rules, and we have determined that both Mr. Dhillon and Mr. Heppell as audit committee members meet the more stringent requirements under Rule 5605(c)(2) of the Nasdaq Listing Rules. Our audit committee met four times (including telephonic meetings) and took action by written consent one time in 2019.</p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">Our audit committee is responsible for: (1) selection and oversight of our independent accountant&#894; (2) establishing procedures for the receipt, retention and treatment of complaints regarding accounting, internal controls and auditing matters&#894; (3) establishing procedures for the confidential, anonymous submission by our employees of concerns regarding accounting and auditing matters&#894; (4) engaging outside advisors&#894; and, (5) approving fees for the independent auditor and any outside advisors engaged by the audit committee. The Audit Committee Charter is filed as Exhibit 99.1 to our Report on Form 8-K filed on February 27, 2015.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong>Compensation Committee</strong></p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">On May 31, 2015, our Board established a compensation and compliance committee which operated under a written charter that was approved by the Board. In 2018, the Board dissolved the former compensation and compliance committee and established a new compensation committee which operates under a written charter approved by the Board. The members of our compensation committee are Mr. Punit Dhillon and Mr. Jim Heppell. Mr. Heppell serves as chairman of the compensation committee. Our compensation committee did not meet during 2019 (including telephonic meetings) and took action by written consent one time.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">45</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc1">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160;&#160;</p> <p style="MARGIN: 0px; text-align:justify;">Our compensation committee is responsible for the oversight of, and the annual and ongoing review of, the Chief Executive Officer, the compensation of the senior management team, and the bonus programs in place for employees, which includes: (1) reviewing the performance of the Chief Executive Officer and such other senior officers as the Board may request, and determining the bonus entitlement for such officer or officers on an annual basis and recommending the same to the Board for approval&#894; (2) determining the proposed annual compensation of our executive officers for each fiscal year and recommending the same to the Board for approval&#894; (3) reviewing and discussing the bonus plan proposed for our senior management team with the Chief Executive Officer&#894; (4) reviewing and discussing the terms and conditions of proposed grants of stock options to directors, employees, consultants and advisors with the Chief Executive Officer&#894; (5) reviewing and recommending to the Board the compensation of the Board and committee members&#894; (6) reviewing and discussing with the Chief Executive Officer the standard forms of employment and consulting contracts used by us&#894; (7) reviewing and discussing with the Chief Executive Officer the general benefit plans in place for employees&#894; (8) engaging and setting the compensation for independent counsel and other advisors and consultants&#894; and (9) reviewing and assessing the adequacy of its Charter and submitting any recommended changes to our Board for its consideration and approval.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong>Nomination and Corporate Governance Committee</strong></p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p> <p style="MARGIN: 0px">In 2018, our Board established a nominating and corporate governance committee that operates under a written charter approved by the Board. The members of our nominating and corporate governance committee are Mr. Punit Dhillon and Mr. Jim Heppell. Mr. Heppell serves as chairman of the nominating and corporate governance committee. Our nominating and corporate governance committee did not meet or take action by written consent in 2019.</p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">Our nominating and corporate governance committee is responsible for assisting the Board in (1) identifying qualified individuals to become Board members, consistent with criteria approved by the Board, (2) determining the composition of the Board and its committees, (3) selecting the director nominees for the next annual meeting of shareholders, (4) monitoring a process to assess Board, committee and management effectiveness, (5) aiding and monitoring management succession planning and (6) developing, recommending to the Board, implementing and monitoring policies and processes related to our corporate governance guidelines.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong>Finance and Business Development Committee</strong></p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">In 2018, our Board established a finance and business development committee which operates under a written charter approved by the Board. The members of our finance and business development committee are Mr. Punit Dhillon and Mr. Jim Heppell. Mr. Punit Dhillon serves as chairman of the finance and business development committee. Our finance and business development committee did not meet and took action by written consent three times in 2019.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">Our finance and business development committee is responsible for assisting the Board in (1) matters affecting our balance sheet, including capital structure strategies, debt and equity financings and working capital (2) analysis and assessment of financial and strategic aspects of major acquisitions and divestitures, collaborations and joint ventures, (3) formulating and recommending for approval to the Board our financial policies, including management of the financial affairs of the Company, (4) developing and maintaining relationships with investment banks, financial institutions and other investors and monitor developments in the capital markets and financing trends, and (5) evaluating and making recommendations to the Board concerning business development opportunities.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong>Nominations to the Board of Directors</strong></p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">We do not have any defined policy or procedural requirements for shareholders to submit recommendations or nominations for directors. Our Board believes that, given the stage of our development, a specific nominating policy would be premature and of little assistance until our business operations develop to a more advanced level. We do not currently have any specific or minimum criteria for the election of nominees to the Board. The Board, with the help of its nomination and corporate governance committee, will assess all candidates, whether submitted by management or shareholders and make recommendations for election or appointment.</p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160; &#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong>Stockholder Communications</strong></p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">We do not have a formal policy regarding stockholder communications with our Board. A shareholder who wishes to communicate with our Board may do so by directing a written request addressed to our Chief Executive Officer, at the address appearing on the first page of this filing.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong>Code of Ethics</strong></p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">On October 31, 2014, we adopted a formal code of ethics that applies to our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions, as well as our other officers, directors and employees. A copy of our code of ethics is available on our website at <u>http://www.emeraldbio.life</u>. We intend to disclose any future amendments to provisions of our code of ethics, or waivers of provisions required to be disclosed under the rules of the SEC, on a current report on Form 8-K or at the same location on our website identified in the preceding sentence. Any amendment or waiver disclosed on our website will remain available on our website for at least 12 months after the initial disclosure.</p> <p style="MARGIN: 0px 0px 0px 0in">&#160;</p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">46</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc1">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px 0px 0px 0in"><strong><u><a name="item11">Item</a> 11. </u></strong><strong><u>Executive </u></strong><strong><u>Compensation</u></strong><strong>. </strong></p> <p style="MARGIN: 0px 0px 0px 0in">&#160;</p> <p style="MARGIN: 0px 0px 0px 0in"><strong>Summary Compensation Table </strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">The following table sets forth information concerning the compensation earned for services rendered to us for the fiscal years ended December 31, 2019 and 2018 of our named executive officers as determined in accordance with SEC rules.</p> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;" colspan="32"> <p style="MARGIN: 0px; text-align:center;"><strong>SUMMARY COMPENSATION TABLE</strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Name and </strong></p> <p style="MARGIN: 0px; text-align:justify;"><strong>Principal </strong></p> <p style="MARGIN: 0px; text-align:justify;"><strong>Position</strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> <p style="MARGIN: 0px; text-align:center;"><strong>Year</strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Salary</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>($)</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Bonus</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>($)</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Stock </strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Awards</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>($) <sup>(1)</sup></strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Option </strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Awards</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>($) <sup>(1)</sup></strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"> <p style="MARGIN: 0px; text-align:center;"><strong>Non-Equity Incentive Plan Compensation</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>($)</strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Nonqualified Deferred Compensation Earnings</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>($)</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>All </strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Other Compensation</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>($)</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Total</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>($)</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" colspan="2" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" colspan="2" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" colspan="2" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" colspan="2" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" colspan="2" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" colspan="2" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" colspan="2" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Dr. Brian S. Murphy, </p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:7%;"> <p style="MARGIN: 0px; text-align:center;">2019</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:5%;vertical-align:bottom;text-align:right;">390,000</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:5%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:5%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:5%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:5%;"> <p style="MARGIN: 0px 0px 0px 0in; text-align:right;">-</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:5%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:5%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:5%;vertical-align:bottom;text-align:right;">390,000</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">CEO/CMO</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px; text-align:center;">2018</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">390,000</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">171,000</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px 0px 0px 0in; text-align:right;">-</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">561,000</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Doug Cesario,</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px; text-align:center;">2019</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">250,000</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px 0px 0px 0in; text-align:right;">-</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">250,000</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">CFO</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px; text-align:center;">2018</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">174,038</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">169,884</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">200,772</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px 0px 0px 0in; text-align:right;">-</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">544,694</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Dr. Dennis Kim,</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px; text-align:center;">2019</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">119,812</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">164,985</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px 0px 0px 0in; text-align:right;">-</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">284,797</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">CMO</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px; text-align:center;">2018</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px 0px 0px 0in; text-align:right;">-</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Elizabeth M. Berecz,</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px; text-align:center;">2019</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px 0px 0px 0in; text-align:right;">-</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Former CFO <sup>(2)</sup></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px; text-align:center;">2018</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">246,795</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">133,000</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px 0px 0px 0in; text-align:right;">-</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">19,277</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">399,072</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Avtar Dhillon, </p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px; text-align:center;">2019</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px 0px 0px 0in; text-align:right;">-</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">117,890</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">117,890</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Former Executive Chairman <sup>(3)</sup></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px; text-align:center;">2018</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">225,000</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px 0px 0px 0in; text-align:right;">-</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">67,885</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">292,885</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Cosmas N. Lykos, Former </p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px; text-align:center;">2019</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px 0px 0px 0in; text-align:right;">-</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Chairman <sup>(4)</sup></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px; text-align:center;">2018</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">171,000</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px 0px 0px 0in; text-align:right;">-</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">220,000</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">391,000</td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr></table> <p style="MARGIN: 0px">________&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="width:3%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(1)</p> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:75%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Amounts reflect the full grant date fair value of restricted stock awards and stock options, computed in accordance with ASC Topic 718, rather than the amounts paid to or realized by the named individual.</p> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(2)</p> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Ms. Berecz separated from us, effective May 25, 2018, pursuant to a Separation Agreement and Release between us and Ms. Berecz. </p> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(3)</p> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Dr. Dhillon resigned as Chairman and member of our Board of Directors, effective December 17, 2019. For the year 2018, option awards granted to Dr. Dhillon represent compensation for services rendered as a member of our Board and other compensation includes $45,000 earned under the Independent Contractor Agreement (defined below) and $22,885 in fees earned for services rendered as a member of our Board. See &#8220;Director Compensation&#8221; below. For the year 2019, other compensation represents fees earned for services rendered as a member of our Board of Directors.</p> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(4)</p> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">In June 2014, our subsidiary entered into an independent contractor agreement with K2C, Inc. (&#8220;K2C&#8221;), which is wholly owned by Mr. Lykos, pursuant to which we paid K2C a monthly fee for services performed by Mr. Lykos for us. The agreement expired on June 1, 2017 and was automatically renewed for one year pursuant to the terms of the agreement. The monthly fee under the agreement was $10,000 until April 1, 2017, at which time it increased to a monthly fee of $20,000. Under the agreement, Mr. Lykos was also eligible to participate in our health, death and disability insurance plans. In addition, beginning in 2015, Mr. Lykos was a participant in our change in control severance plan. Effective February 28, 2018, we terminated the independent contractor agreement. Mr. Lykos resigned from the Board, effective January 18, 2018, in connection with the consummation of the investment in us by Emerald Health Sciences.</p></td></tr></table> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">47</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc1">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong>Employment and Severance Arrangements</strong></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><em>Employment Agreements</em></p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">In May 2018, we entered into an Executive Employment Agreement with Doug Cesario, our Chief Financial Officer. The agreement provides for an annual base salary of $250,000 per year and an annual discretionary bonus based in part on Mr. Cesario&#8217;s achievement of milestones agreed to by the Board or the Compensation Committee of the Board. Pursuant to the agreement, Mr. Cesario is entitled to receive the normal benefits available to other similarly situated executives and will be entitled to severance pay under certain circumstances. Mr. Cesario&#8217;s employment with us is at-will. Except for termination of Mr. Cesario&#8217;s employment for &#8220;Cause,&#8221; &#8220;By Death&#8221; or &#8220;By Disability&#8221; (as such terms are defined in the agreement), Mr. Cesario will be entitled to payment of an amount equal to a minimum of six months of Mr. Cesario&#8217;s then-current base salary&#894; and after three years of employment, Mr. Cesario will be entitled to an additional two months of his then-current base salary for each year he is employed beyond the initial three years of employment by us, to a maximum of 12 months.</p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">Pursuant to Mr. Cesario&#8217;s Executive Employment Agreement, Mr. Cesario was granted a one-time sign-on restricted stock award of 643,501 shares of restricted stock pursuant to our 2014 Omnibus Incentive Plan on July 23, 2018, which is the date that was 90 days after Mr. Cesario&#8217;s start date as an employee with us. 100% of the restricted stock award will vest on April 23, 2020, or upon a trigger event, including the sale of the Company or a merger that results in a change of control.</p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">In August 2019, we entered into a letter agreement with Dr. Dennis Kim, our Chief Medical Officer. The agreement provides for an annual base salary of $330,000 per year and an annual discretionary bonus target of up to 35% of annual salary. Pursuant to the agreement, Dr. Kim is entitled to receive the normal benefits available to other similarly situated executives and will be entitled to severance pay under circumstances. Dr. Kim&#8217;s employment with us is at-will. Except for termination of Dr. Kim&#8217;s employment for &#8220;Cause,&#8221; by death or by &#8220;Disability&#8221; (as such terms are defined in the agreement), Dr. Kim will be entitled to payment of an amount equal to six months of his then-current base salary for the first full year of continuous employment with us or twelve months after the first full year. Dr. Kim may take on advisory and consulting roles for up to 20% of his time so long as such roles do not conflict with the performance of his duties and responsibilities with us.</p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">Pursuant to Dr. Kim&#8217;s agreement, Dr. Kim was granted a one-time sign-on award of options to purchase an aggregate of 736,541 shares of our common stock of pursuant to the Plan. Subject to continued employment with us, the stock options vested 25% 90 days after his employment commenced and the remaining 75% vests 1/33<sup>rd</sup> on each of the next 33 months thereafter.</p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">The foregoing description of the employment agreements does not purport to be complete and is qualified in its entirety by reference to the full text of the employment agreements attached hereto as an exhibit and incorporated by reference herein.</p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Severance Arrangements</em></p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">In February 2015, we adopted a change in control severance plan, in which our named executive officers participate, that provides for the payment of severance benefits if the executive&#8217;s service is terminated within twelve months following a change in control, either due to a termination without cause or upon resignation for a good reason (as each term is defined in the plan).</p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">In either such event, and provided the executive timely executes and does not revoke a general release of claims against us, he or she will be entitled to receive: (i) a lump sum cash payment equal to at least six months&#8217; of the executive&#8217;s monthly compensation, plus an additional month for each full year of service over six years, (ii) Company-paid premiums for continued health insurance for a period equal to the length of the cash severance period or, if earlier, when executive becomes covered under a subsequent employer&#8217;s healthcare plan, and (iii) full vesting of all then-outstanding unvested stock options and restricted stock awards.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">The restricted stock award and options granted to Mr. Cesario in July 2018, will vest in full on a change in control (as defined in our 2014 Omnibus Incentive Plan).</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">In January 2018, we entered into a restricted stock agreement (the &#8220;Restricted Stock Agreements&#8221;) with each of Dr. Murphy, Elizabeth Berecz and Cosmas N. Lykos granting 900,000, 700,000 and 900,000 shares of restricted Common Stock, respectively. Each Restricted Stock Agreement provides that if the executive&#8217;s employment or service is terminated by us without cause, or is terminated by the grantee for good reason, then the executive shall be entitled to receive a cash severance payment equal to six months of their base compensation, payable in substantially equal installments during the six-month period following the termination date.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">In February 2018, we entered into a separation and release agreement with K2C, which provided for a lump sum payment of $180,000 and the immediate vesting of 900,000 shares of restricted common stock granted pursuant to the Restricted Stock Agreement, 325,000 shares of restricted common stock granted on October 20, 2015, 125,000 options granted on November 21, 2014, in exchange for a release of claims and certain other agreements. In addition, K2C also holds 1,110,000 shares of fully vested common stock pursuant to the common stock purchase warrant agreement dated June 20, 2013.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">In April 2018, we entered into a Separation Agreement and Release with Elizabeth Berecz, our former Chief Financial Officer. Pursuant to the agreement, Ms. Berecz agreed to certain ongoing cooperation obligations during a transition period and agreed to provide certain releases and waivers as contained in the agreement. As consideration under the agreement, we agreed to provide Ms. Berecz compensation and benefits as follows: (i) through May 25, 2018, Ms. Berecz&#8217;s separation date, an annualized base salary at the rate in effect as of the date of the separation agreement&#894; (ii) a lump sum gross payment of $145,833, in consideration for the restrictive covenants contained in the separation agreement&#894; and (iii) reimbursement for payments made by Ms. Berecz for COBRA coverage for a period of six (6) months following her separation date. In addition, the terms of the separation agreement provided for the immediate vesting of 700,000 shares of restricted common stock granted pursuant to Ms. Berecz&#8217;s Restricted Stock Agreement, 350,000 shares of restricted common stock granted on October 20, 2015, and 250,000 options granted in October 2014 and November 2014.</p> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">48</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc1">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">The foregoing descriptions of the separation agreements do not purport to be complete and are qualified in their entirety by reference to the full text of such separation agreements attached hereto as exhibits and incorporated by reference herein.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong>Outstanding Equity Awards at Fiscal Year-end</strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px 0px 0px 0in">As of December 31, 2019, our named executive officers held the following outstanding Company equity awards. </p> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 1px solid;" colspan="15"> <p style="MARGIN: 0px; text-align:center;">&#160;<strong>Option</strong><strong> </strong><strong>Awards</strong></p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 1px solid;" colspan="6"> <p style="MARGIN: 0px; text-align:center;"><strong>Stock</strong><strong> </strong><strong>Awards</strong></p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;"> <p style="MARGIN: 0px; text-align:left;"><strong>Name</strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;"> <p style="MARGIN: 0px; text-align:center;"><strong>Grant</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Date</strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Number of</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Securities</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Underlying Unexercised</strong></p> <p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Options (#)</strong></p> <p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Exercisable</strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Number</strong><strong> </strong><strong>of</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Securities</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Underlying</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Unexercised</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Options</strong><strong>(#)</strong></p> <p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Un-</strong></p> <p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>exercisable</strong><strong>&#160;</strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Option</strong></p> <p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Exercise</strong></p> <p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Price</strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;"> <p style="MARGIN: 0px; text-align:center;"><strong>Option</strong></p> <p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Expiration</strong></p> <p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Date</strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Number </strong><strong>of</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Shares of</strong></p> <p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Stock Not</strong></p> <p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Vested</strong><strong> </strong><strong>(#)</strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Market</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Value of</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Shares Not</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Vested ($)<sup>(2</sup></strong><strong><sup>)</sup></strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px">Dr. Brian S. Murphy,</p></td> <td style="width:1%;vertical-align:bottom;"></td> <td> <p style="MARGIN: 0px"><sup>(1)</sup> 10/31/2014</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">480,000</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.42</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px 0px 0px 0in; text-align:center;">10/31/2024</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px">CEO/CMO</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px"><sup>(1)</sup> 11/21/2014</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">175,000</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.42</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px 0px 0px 0in; text-align:center;">11/21/2024</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px"><sup>(6)</sup> 1/1/2018</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">450,000</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">58,725</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px">Doug Cesario,</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px"><sup>(3)</sup> 5/25/2018</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">787,662</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">407,411</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.245</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px 0px 0px 0in; text-align:center;">5/25/2028</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px">CFO</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px"><sup>(4)</sup> 5/25/2018</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">643,501</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">83,977</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px">Dr. Dennis Kim, CMO</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px"><sup>(7)</sup> 8/21/2019</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">217,614</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">518,927</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.300</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px 0px 0px 0in; text-align:center;">8/21/2029</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px">Avtar Dhillon,</p> <p style="MARGIN: 0px">Former Chairman</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><sup>(5)</sup> 10/10/2018</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:top;text-align:right;">1,000,000</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:top;text-align:right;">-</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:top;">$</td> <td class="ffcell" style="width:9%;vertical-align:top;text-align:right;">0.305</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; text-align:center;">10/10/2028</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:top;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:top;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr></table> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:4%;vertical-align:top;">(1)</td> <td style="vertical-align:top;"> <p style="MARGIN: 0px">The options specified above vest as follows: 20% of total vests on each anniversary of the grant date over five years, subject to the grantee&#8217;s continued service. The options granted expire ten years after the date of grant.</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:4%;vertical-align:top;">(2)</td> <td style="vertical-align:top;">The market value of shares that have not vested is calculated based on the per share closing price of our common stock on December 31, 2019.</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:4%;vertical-align:top;">(3)</td> <td style="vertical-align:top;">The options specified above vest as follows: 25% of total vests on the grant date and 1/33 each month thereafter on the anniversary of the grant date.</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:4%;vertical-align:top;">(4)</td> <td style="vertical-align:top;">The restricted stock vests in full on the two-year anniversary of the grant date, subject to the grantee&#8217;s continued service.</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:4%;vertical-align:top;">(5)</td> <td style="vertical-align:top;">The options specified above vest in twelve equal monthly installments following the grant date.</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:4%;vertical-align:top;">(6)</td> <td style="vertical-align:top;">The restricted stock vests 1/2 each year on the anniversary of the grant date and is subject to acceleration upon termination.</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:4%;vertical-align:top;">(7)</td> <td style="vertical-align:top;">The options specified above vest as follows: 25% of the total vests 90 days after his employment commenced and the remaining 75% vests 1/33 each of the next 33 months thereafter.</td></tr></table> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><em>Non-Equity Incentive Plan Awards</em></p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">In May 2018, in connection with the appointment of Mr. Cesario as our Chief Financial Officer and pursuant to the terms of the Executive Employment Agreement between Mr. Cesario and us, we entered into a stock option award agreement with Mr. Cesario pursuant to which Mr. Cesario was granted non-qualified stock options to purchase an aggregate of 1,195,073 shares of our common stock at an exercise price of $0.245 per share on July 23, 2018. 25% of the options vested on the date of grant and the remaining 75% of the options vest 1/33 on each of the next 33 months thereafter. The options will fully vest upon a trigger event, including the sale of the Company or a merger that results in a change of control.</p> <p style="MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><em>Exercises of Options</em></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">There were no exercises of stock options by our named executive officers during the year ended December 31, 2019.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px"><strong>Director Compensation</strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">On October 10, 2018, we amended our policy for the compensation of our non-employee directors as follows:</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">Each non-employee director will receive a cash retainer of $40,000 on an annual basis, and the executive chair of the Board, if a non-employee director, will receive an additional $40,000 retainer annually.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">Upon election to the Board, non-employee directors will receive a one-time award of 200,000 stock options which will vest in twelve equal monthly installments. In subsequent annual periods, each non-employee director will receive a grant of 100,000 common stock options which will vest in twelve equal monthly installments.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">49</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc1">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">Non-employee directors who serve as members of special committees of the Board will receive additional compensation as follows:</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="width:4%;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Audit Committee: $5,000 per year ($20,000 for the chair)</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Compensation Committee: $2,500 per year ($10,000 for the chair)</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Nominating and Corporate Governance Committee: $1,000 per year ($5,000 for the chair)</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Finance and Business Development Special Committee: $40,000 per year for the chair (no compensation for other members)</td></tr></table> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">Our directors received the following compensation for their service as our directors during the fiscal year ended December 31, 2019. </p> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="BORDER-BOTTOM: 1px solid;vertical-align:top;" colspan="29"> <p style="MARGIN: 0px; text-align:center;"><strong>DIRECTOR COMPENSATION <sup>(1)</sup> </strong></p></td></tr> <tr> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Name</strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:7%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Fees</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Earned</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>or Paid</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>in Cash</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:7%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Stock </strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Awards</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>$ <sup>(2)</sup> </strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:7%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Option </strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Awards</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>$<sup> (2)</sup></strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:7%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Non-Equity</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Incentive Plan Compensation</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>$</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:7%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Non-Qualified</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Deferred Compensation Earnings</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>$</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:7%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>All </strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Other Compensation</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>$</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:7%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Total</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>$</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Punit Dhillon</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:7%;vertical-align:bottom;text-align:right;">65,005</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:7%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:7%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:7%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:7%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:7%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:7%;vertical-align:bottom;text-align:right;">65,005</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Jim Heppell</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:7%;vertical-align:bottom;text-align:right;">60,000</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:7%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:7%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:7%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:7%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:7%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:7%;vertical-align:bottom;text-align:right;">60,000</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Avtar Dhillon</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:7%;vertical-align:bottom;text-align:right;">117,890</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:7%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:7%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:7%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:7%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:7%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:7%;vertical-align:bottom;text-align:right;">117,890</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr></table> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:4%;vertical-align:top;">(1)</td> <td style="vertical-align:top;">Does not include compensation received for services provided as executive officers.</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:4%;vertical-align:top;">(2)</td> <td style="vertical-align:top;"> <p style="MARGIN: 0px">Each non-employee director is entitled to an annual grant of 100,000 common stock options that vest in twelve equal monthly installments. However, no option grants were approved by the Board of Directors in 2019. Amounts reflect the full grant date fair value of restricted stock awards and stock options, computed in accordance with ASC Topic 718, rather than the amounts paid to or realized by the named individual. We provide information regarding the assumptions used to calculate the value of restricted stock awards and options granted to our directors in Note 2 and 6 to our Consolidated Financial Statements included elsewhere in this Annual Report on Form 10-K.</p></td></tr></table> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong><u><a name="item12">Item</a> 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</u></strong></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px"><strong>Securities Authorized for Issuance under Equity Compensation Plans</strong> </p> <p style="MARGIN: 0px">&#160; &#160; </p> <p style="MARGIN: 0px; text-align:justify;">The table below includes the following information as of December 31, 2019 for the Emerald Bioscience, Inc. 2014 Omnibus Incentive Plan. Shares available for issuance under the 2014 Omnibus Incentive Plan can be granted pursuant to stock options, stock appreciation rights, restricted stock, restricted stock unit awards, performance awards and other stock-based or cash-based awards, as selected by the plan administrator. For additional information about the 2014 Omnibus Incentive Plan, refer to Note 6 to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K. </p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="BORDER-BOTTOM: black 1px solid;vertical-align:top;" colspan="13"> <p style="MARGIN: 0px; text-align:center;"><strong>Equity Compensation Plan Information</strong></p></td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong>Plan category</strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Number of</strong> </p> <p style="MARGIN: 0px; text-align:center;"><strong>shares of</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>common</strong></p> <p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>stock to be issued upon exercise of outstanding options, warrants and rights</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>(a)</strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Weighted-</strong></p> <p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>average exercise price of outstanding options, warrants and rights</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>(b)</strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Number of shares of common stock remaining available for future</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>issuance</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>under equity</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>compensation</strong></p> <p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>plans (excluding shares of common stock reflected in column (a))</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>(c)</strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px">Equity compensation plans approved by security holders</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,317,642</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.33</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,128,381</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="BORDER-BOTTOM: black 1px solid;vertical-align:top;"> <p style="MARGIN: 0px">Equity compensation plans not approved by security holders <sup>(1)</sup></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,195,073</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">0.25</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">--</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><strong>Total</strong></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>4,512,715</strong></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"><strong>$</strong></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong><strong>0.31</strong></strong></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>13,128,381</strong></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr></table> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:4%;vertical-align:top;">(1)</td> <td style="vertical-align:top;">Reflects 1,195,073 shares of common stock issuable upon exercise of stock options granted to Mr. Cesario with an exercise price equal to $0.245 pursuant to a Stock Option Agreement.</td></tr></table> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">50</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc1">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong>Security Ownership of Certain Beneficial Owners and Management</strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">The following table sets forth certain information with respect to beneficial ownership of our common stock, by:</p> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="width:4%;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Each person known to be the beneficial owner of 5% or more of our outstanding common stock&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Each executive officer&#894;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Each director&#894; and</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">All of the executive officers and directors as a group.</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr></table> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">Beneficial ownership has been determined in accordance with Rule 13d-3 under the Exchange Act. Under this rule, certain shares may be deemed to be beneficially owned by more than one person (if, for example, persons share the power to vote or the power to dispose of the shares). In addition, shares are deemed to be beneficially owned by a person if the person has the right to acquire shares (for example, upon exercise of an option or warrant) within 60 days of the date as of which the information is provided. In computing the percentage ownership of any person, the amount of shares is deemed to include the amount of shares beneficially owned by such person by reason of such acquisition rights. As a result, the percentage of outstanding shares of any person as shown in the following table does not necessarily reflect the person&#8217;s actual voting power at any particular date.</p> <p style="MARGIN: 0px; text-align:justify;">The information set forth in the table below is based on 183,207,747 shares of our common stock issued and outstanding on March 16, 2020.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">To our knowledge, except as indicated in the footnotes to this table and pursuant to applicable community property laws, the persons named in the table have sole voting and investment power with respect to all shares of common stock shown as beneficially owned by them. Unless otherwise indicated, the address of each beneficial owner listed below is 130 North Marina Drive, Long Beach, CA 90803. </p> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"> <p style="MARGIN: 0px"><strong>Name and Address of Beneficial Owner</strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px"><strong>Beneficial</strong></p> <p style="MARGIN: 0px"><strong>Ownership</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px"><strong>Percent</strong></p> <p style="MARGIN: 0px"><strong>of Class</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px">Emerald Health Sciences Inc. <sup>(1)</sup></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">126,564,590</td> <td style="width:1%;vertical-align:bottom;"><sup>(2)</sup></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">64.6</td> <td style="width:1%;vertical-align:bottom;">%</td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px">Dr. Brian S. Murphy</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,930,000</td> <td style="width:1%;vertical-align:bottom;"><sup>(3)</sup></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.0</td> <td style="width:1%;vertical-align:bottom;">%</td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px">Doug Cesario</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,512,645</td> <td style="width:1%;vertical-align:bottom;"><sup>(4)</sup></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td></td> <td> <p style="MARGIN: 0px; text-align:right;">*%</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px">Dr. Dennis Kim</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">267,833</td> <td style="width:1%;vertical-align:bottom;"><sup>(5)</sup></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td></td> <td> <p style="MARGIN: 0px; text-align:right;">*%</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px">Punit Dhillon</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">200,000</td> <td style="width:1%;vertical-align:bottom;"><sup>(6)</sup></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td></td> <td> <p style="MARGIN: 0px; text-align:right;">*%</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px">Jim Heppell</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">200,000</td> <td style="width:1%;vertical-align:bottom;"><sup>(7)</sup></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td></td> <td> <p style="MARGIN: 0px; text-align:right;">*%</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px">All executive officers and directors as a group (6 persons)</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,110,478</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.2</td> <td style="width:1%;vertical-align:bottom;">%</td></tr></table> <p style="MARGIN: 0px">_________</p> <p style="MARGIN: 0px">*Denotes less than 1% of our outstanding shares of common stock.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:4%;vertical-align:top;">(1)</td> <td style="vertical-align:top;">The address of this entity is Office 8262, The Landing, 200 - 375 Water St., Vancouver, British Columbia, Canada V6B 0M9.</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:4%;vertical-align:top;">(2)</td> <td style="vertical-align:top;">Includes (i) 113,953,917 shares of common stock, (ii) 7,500,000 shares issuable on exercise of warrants and (iii) 5,110,673 shares issuable upon the conversion of outstanding principal and accrued interest associated with the Credit Agreement.</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:4%;vertical-align:top;">(3)</td> <td style="vertical-align:top;">Includes (i) 655,000 shares of common stock underlying options that may be exercised within 60 days of March 16, 2020, (ii) 1,275,000 shares of fully vested restricted stock.</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:4%;vertical-align:top;">(4)</td> <td style="vertical-align:top;">Includes (i) 869,144 shares of common stock underlying options that may be exercised within 60 days of March 16, 2020, and (ii) 643,501 shares of restricted stock subject to vesting.</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:4%;vertical-align:top;">(5)</td> <td style="vertical-align:top;">Includes 267,833 shares of common stock underlying options that may be exercised within 60 days of March 16, 2020.</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:4%;vertical-align:top;">(6)</td> <td style="vertical-align:top;">Includes 200,000 shares of common stock underlying options that may be exercised within 60 days of March 16, 2020.</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:4%;vertical-align:top;">(7)</td> <td style="vertical-align:top;">Includes 200,000 shares of common stock underlying options that may be exercised within 60 days of March 16, 2020.</td></tr></table> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong>Changes in Control</strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">Our management is not aware of any arrangements which may result in &#8220;changes in control&#8221; as that term is defined by the provisions of Item 403(c) of Regulation S-K.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong><u><a name="item13">Item</a></u></strong><strong><u> </u></strong><strong><u>13. Certain Relationships and Related Transactions, and Director Independence</u></strong><strong>. </strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong>Transactions with Related Persons</strong></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">Except as specified below, there have been no other transactions with related persons in the last two fiscal years, or any currently proposed transaction, in which we were or are to be a participant and the amount involved exceeds the lesser of $120,000 or 1% of the average of our total assets as of December 31, 2018 and 2019, and in which any related person had or will have a direct or indirect material interest.</p> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">51</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc1">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><em>K2C</em></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">In June 2014, our subsidiary entered into an independent contractor agreement with K2C, which is wholly owned by Mr. Lykos, who served as the Chairman of our Board until January 16, 2018, pursuant to which we paid K2C a monthly fee for services performed by Mr. Lykos for us. The agreement expired on June 1, 2017 and was automatically renewed for one year pursuant to the terms of the agreement. The monthly fee under the agreement was $10,000 and increased to $20,000 effective April 1, 2017. In 2017 and 2018, we paid K2C $210,000 and $220,000 respectively. Under the agreement, Mr. Lykos was also eligible to participate in our health, death and disability insurance plans. The independent contractor agreement with K2C was terminated as of February 28, 2018.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">In January 19, 2018, we entered into a Restricted Stock Agreement with K2C granting 900,000 Restricted Stock to K2C.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">In February 28, 2018, we entered into a separation and release agreement with K2C, which provided for a lump sum payment of $180,000 and the immediate vesting of 900,000 shares of restricted common stock granted pursuant to the Restricted Stock Agreement, 325,000 shares of restricted common stock granted on October 20, 2015, 125,000 options granted on November 21, 2014, in exchange for a release of claims and certain other agreements. In addition, K2C also holds 1,110,000 shares of fully vested common stock pursuant to the common stock purchase warrant agreement dated June 20, 2013.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><em>Elizabeth Berecz</em></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">In April 2018, we entered into a Separation Agreement and Release with Elizabeth Berecz, our former Chief Financial Officer. Pursuant to the agreement, we agreed to provide Ms. Berecz compensation and benefits as follows: (i) through May 25, 2018, Ms. Berecz&#8217;s separation date, an annualized base salary at the rate in effect as of the date of the separation agreement&#894; (ii) a lump sum gross payment of $145,833, in consideration for the restrictive covenants contained in the separation agreement&#894; and (iii) reimbursement for payments made by Ms. Berecz for COBRA coverage for a period of six (6) months following her separation date. In addition, the terms of the separation agreement provided for the immediate vesting of 700,000 shares of restricted common stock granted pursuant to Ms. Berecz&#8217;s Restricted Stock Agreement, 350,000 shares of restricted common stock granted on October 20, 2015, and 250,000 options granted in October 2014 and November 2014.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><em>Emerald Health Sciences</em></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">On December 28, 2017, we entered into a Secured Promissory Note and Security Agreement for a convertible loan (the &#8220;Convertible Promissory Note&#8221;) with Emerald Health Sciences. The Convertible Promissory Note provided for aggregate gross proceeds to us of up to $900,000 and was secured by all of our assets.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">On January 19, 2018, $900,000 funded under the Convertible Promissory Note converted into 9,000,000 shares of our common stock and the Convertible Promissory Note was terminated. Simultaneously, we entered into a Securities Purchase Agreement (the &#8220;Emerald Health Sciences Financing&#8221;) in which we sold to Emerald Health Sciences 15,000,000 shares of common stock and a warrant to purchase 20,400,000 shares of common stock at an exercise price of $0.10 for aggregate gross proceeds of $1,500,000. The second closing under the Emerald Health Sciences Financing occurred on February 16, 2018, pursuant to which we issued and sold to Emerald Health Sciences 15,000,000 shares of our Common Stock, and a warrant to purchase 20,400,000 shares of Common Stock at an exercise price of $0.10 per share for a term of five years, for aggregate gross proceeds of $1,500,000.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">On February 1, 2018, we entered into an Independent Contractor Agreement (the &#8220;Independent Contractor Agreement&#8221;) with Emerald Health Sciences, pursuant to which Emerald Health Sciences agreed to provide such services as were mutually agreed between Emerald Health Sciences and us, including reimbursements for reasonable expenses incurred in the performance of the Independent Contractor Agreement. These services included, but were not limited to, corporate advisory services and technical expertise in the areas of business development, marketing, investor relations, information technology and product development. The Independent Contractor Agreement had an initial term of ten years and specified compensation which was agreed upon between our chief executive officer and Emerald Health Sciences&#8217; Chairman, CEO and President on a month-to-month basis. Under this agreement, we incurred expenses of $542,000 and $550,000 during the years ended December 31, 2019 and 2018, respectively. At December 31, 2019, the Company has accrued $10.000 in expenses under this agreement. The Independent Contractor Agreement was terminated effective December 31, 2019.</p> <p style="MARGIN: 0px">&#160;&#160; </p> <p style="MARGIN: 0px; text-align:justify;">On February 6, 2018, we entered into a Consulting Agreement with Dr. Avtar Dhillon, the Chairman, Chief Executive Officer and President of Emerald Health Sciences. The services under the Consulting Agreement included, corporate finance and strategic business advisory. The Consulting Agreement had an initial term of one year and was renewable automatically unless terminated by either party. The agreement specified an annual fee of $60,000 payable semi-monthly in installments and included reimbursement for reasonable expenses incurred in the performance of the services. The contractor was also entitled to an annual discretionary bonus, payable 120 days after each fiscal year-end, to be determined by the Board upon its annual review. Under this agreement, we incurred expenses in the amount of $45,000 during the fiscal year ended December 31, 2018. This Consulting Agreement was canceled on October 5, 2018 in connection with our entry into the Credit Agreement with Emerald Health Sciences and Dr. Dhillon&#8217;s appointment as the Executive Chairman of our Board.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;&#160;</p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"> <p style="MARGIN: 0px; text-align:center;">52</p></td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc1">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px 0px 0px 0.35pt; text-align:justify;">On October 5, 2018, we entered into the Credit Agreement with Emerald Health Sciences. The Credit Agreement provides for a credit facility to us of up to $20,000,000 and is unsecured. Advances under the Credit Agreement bear interest at an annual rate of 7% (payable quarterly in arrears) and mature on October 5, 2022. At Emerald Health Sciences&#8217; election, advances and unpaid interest may be converted into Common Stock at a fixed conversion price of $0.40, subject to customary adjustments for stock splits, stock dividends, recapitalizations, etc. In connection with each advance under the Credit Agreement, we agreed to issue Emerald Health Sciences warrants to purchase shares of common stock in an amount equal to 50% of the number of shares of common stock that each advance may be converted into. The warrants have an exercise price of $0.50 per share, a term of five years and will be immediately exercisable upon issuance. The exercise price is subject to adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events or upon any distributions of assets, including cash, stock or other property to our shareholders. On November 1, 2018, we affected an initial draw under the Credit Agreement in the amount of $2,000,000 and issued Emerald Health Sciences a warrant to purchase 2,500,000 shares of common stock at an exercise price of $0.50 per share, in accordance with the terms of the Credit Agreement. On February 1, 2019, we affected the second draw under the Credit Agreement in the amount of $2,000,000 and issued Emerald Health Sciences a warrant to purchase 2,500,000 shares of common stock at an exercise price of $0.50 per share, in accordance with the terms of the Credit Agreement. On March 29, 2019, we affected the third draw under the Credit Agreement in the amount of $2,000,000 and issued Emerald Health Sciences a warrant to purchase 2,500,000 shares of common stock at an exercise price of $0.50 per share, in accordance with the terms of the Credit Agreement. On December 20, 2019, we entered into a Warrant Exchange Agreement, pursuant to which Emerald Health Sciences has exercised 40.80 million of such warrants and paid the aggregate exercise price of approximately $4.08 million for the related warrant shares in the form of a reduction of the corresponding amount of obligations outstanding under the Credit Agreement. Upon consummation of the transaction under the Warrant Exchange Agreement, the total outstanding principal amount excluding discounts under the Credit Agreement was $2,014,500. The Credit Agreement is still in place, however there is no guarantee of continued funding. A portion of the proceeds raised in this offering may be used to pay, in whole or in part, the principal and accrued interest on our Credit Agreement. See &#8220;Use of Proceeds.&#8221; The net proceeds of each advance shall be used for general corporate purposes and are subject to approval by our Board, which is controlled by the directors and principal executive officer of Emerald Health Sciences.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;&#160; </p> <p style="MARGIN: 0px; text-align:justify;">On December 19, 2019, we entered into an Independent Contractor Services Agreement with Dr. Avtar Dhillon, pursuant to which Dr. Dhillon will provide ongoing corporate finance and strategic business advisory services to us. In exchange for his services, Dr. Dhillon will receive a monthly fee of $10,000, with (i) $5,000 paid each month and (ii) $5,000 accruing from the effective date and payable upon the Company&#8217;s completion of a material financing. The Board will review the monthly rate paid to Dr. Dhillon within 90 days of the end of each fiscal year. The Independent Contractor Services Agreement has an initial term of one year and will renew automatically thereafter unless terminated earlier by either party. The Independent Contractor Services Agreement may be terminated by either party for cause upon written notice to the other party if the other party defaults in the performance of the agreement in any material respect or materially breaches the terms of the agreement, or without cause upon 30 days&#8217; prior written notice to the other party.</p> <p style="MARGIN: 0px">&#160;&#160;</p> <p style="MARGIN: 0px; text-align:justify;">On December 19, 2019, we entered into a Board Observer Agreement with Emerald Health Sciences. The Board Observer Agreement gives a right to Emerald Health Sciences to designate one observer to our Board for so long as Emerald Health Sciences maintains ownership of any securities in the Company. Under the Board Observer Agreement, the board observer will be permitted to attend all meetings (whether in person, telephonically or otherwise) of the Board in a non-voting, observer capacity. Emerald Health Sciences appointed Dr. Avtar Dhillon as an initial board observer. The Board Observer Agreement may be terminated by either party for cause upon written notice to the other party if the other party defaults in the performance of the agreement in any material respect or materially breaches the terms of the agreement, or without cause upon 30 days&#8217; prior written notice to the other party.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong>Review, Approval and Ratification of Related Party Transactions</strong></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">Given our small size and limited financial resources, we have not adopted formal policies and procedures for the review, approval or ratification of transactions, such as those described above, with our executive officers, directors and significant stockholders. However, all of the transactions described above were approved and ratified by our Board. In connection with the approval of the transactions described above, our Board took into account several factors, including their fiduciary duties to the Company, the relationships of the related parties described above to the Company, the material facts underlying each transaction, the anticipated benefits to the Company and related costs associated with such benefits, whether comparable products or services were available, and the terms we could receive from an unrelated third party.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">53</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc1">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160;&#160; </p> <p style="MARGIN: 0px; text-align:justify;">We intend to establish formal policies and procedures in the future, once we have sufficient resources and have appointed additional directors so that such transactions will be subject to the review, approval or ratification of our Board, or an appropriate committee thereof. On a moving forward basis, our Board will continue to approve any related party transaction based on the criteria set forth above.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong>Conflicts Related to Other Business Activities</strong></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">The persons serving as our officers and directors have existing responsibilities and, in the future, may have additional responsibilities, to provide management and services to other entities in addition to us. As a result, conflicts of interest between us and the other activities of those persons may occur from time to time.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px">We will attempt to resolve any such conflicts of interest in our favor. Our officers and directors are accountable to our shareholders and us as fiduciaries, which requires that such officers and directors exercise good faith and integrity in handling our affairs. A shareholder may be able to institute legal action on our behalf or on behalf of that shareholder and all other similarly situated shareholders to recover damages or for other relief in cases of the resolution of conflicts in any manner prejudicial to us.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong>Director Independence</strong></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">We have determined that Punit Dhillon and Jim Heppell are independent members of our Board, as that term is defined in Rule 5605(a)(2) of the Nasdaq Listing Rules.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong>Insider Trading Policy</strong></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">On October 31, 2014, our Board adopted an Insider Trading Policy applicable to all directors and officers. Insider trading generally refers to the buying or selling of a security in breach of a fiduciary duty or other relationship of trust and confidence while in possession of material, non-public information about the security. Insider trading violations may also include &#8216;tipping&#8217; such information, securities trading by the person &#8216;tipped,&#8217; and securities trading by those who misappropriate such information. The scope of insider trading violations can be wide reaching. As such, our Board has adopted an Insider Trading Policy that outlines the definitions of insider trading, the penalties and sanctions determined, and what constitutes material, non-public information. Illegal insider trading is against our policy as such trading can cause significant harm to the reputation for integrity and ethical conduct of our company. Individuals who fail to comply with the requirements of the policy are subject to disciplinary action, at our sole discretion, including dismissal for cause. All members of our Board and all executive officers are required to ratify the terms of this policy on an annual basis. Our Insider Trading Policy is available on our website at <u>http://www.emeraldbio.life</u>.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong><u><a name="item14">Item</a> 14. Principal Accounting Fees and Services</u></strong><strong>. </strong></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong>Audit Fees</strong></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">The aggregate fees billed in each of the fiscal years ended December 31, 2019 and 2018, for professional services rendered by Mayer Hoffman McCann P.C. for the audit of our annual consolidated financial statements included in our Annual Report on Form 10-K and quarterly reviews of the unaudited interim condensed consolidated financial statements included in our Quarterly Reports on Form 10-Q or services that are normally provided by the accountant in connection with statutory and regulatory filings or engagements for those fiscal years were $328,514 and $260,550, respectively. Substantially all MHM&#8217;s personnel, who work under the control of MHM shareholders, are employees of wholly-owned subsidiaries of CBIZ, Inc., which provides personnel and various services to MHM in an alternative practice structure.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong>Audit-Related Fees</strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">None. </p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong>Tax Fees </strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">None.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong>All Other Fees</strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">None.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong>Pre-Approval Policies and Procedures</strong></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">Prior to engaging Mayer Hoffman McCann P.C. to perform a particular service, our Board obtains an estimate for the service to be performed. All of the services described above were approved by the members of the Audit Committee of the Board in accordance with its procedures.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:center;"><strong><a name="part4">PART</a> IV</strong></p> <p style="MARGIN: 0px; text-align:center;">&#160;</p> <p style="MARGIN: 0px"><strong><u><a name="item15">Item</a> 15. Exhibits, Financial Statement Schedules</u></strong><strong>.</strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px 0px 0px 0.35pt; text-align:justify;">Financial Statements. The following consolidated financial statements of Emerald Bioscience, Inc., together with the report thereon of Mayer Hoffman McCann P.C., an independent registered public accounting firm, are included in this Annual Report on Form 10-K:</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">54</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc1">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:center;"><strong><a name="toc2">EMERALD</a> </strong><strong>BIOSCIENCE, </strong><strong>INC. </strong><strong>AND </strong><strong>SUBSIDIARIES </strong><strong>INDEX</strong><strong> </strong><strong>TO</strong><strong> </strong><strong>CONSOLIDATED</strong><strong> </strong><strong>FINANCIAL</strong><strong> </strong><strong>STATEMENTS</strong></p> <p style="MARGIN: 0px; text-align:left;">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:9%;"> <p style="MARGIN: 0px; text-align:center;"><strong>Page No.</strong></p></td> <td style="width:1%;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td> <p style="MARGIN: 0px"><a href="#REPORT">Report of Independent Registered Public Accounting Firm </a></p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px; text-align:right;">F-2</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td> <p style="MARGIN: 0px"><a href="#bs">Consolidated Balance Sheets as of December 31, 2019 and 2018 </a></p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px; text-align:right;">F-3</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td> <p style="MARGIN: 0px"><a href="#soc">Consolidated Statements of Comprehensive Income (Loss) for the years ended December 31, 2019 and 2018</a></p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px; text-align:right;">F-4</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td> <p style="MARGIN: 0px"><a href="#cf">Consolidated Statements of Cash Flows for the years ended December 31, 2019 and 2018 </a></p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px; text-align:right;">F-5</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td> <p style="MARGIN: 0px"><a href="#ssc">Consolidated Statements of Stockholders&#8217; Equity (Deficit) for the years ended December 31, 2019 and 2018 </a></p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px; text-align:right;">F-6</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td> <p style="MARGIN: 0px"><a href="#note">Notes to the Consolidated Financial Statements </a></p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px; text-align:right;">F-7</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr></table> <p style="MARGIN: 0px">&#160; </p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-1</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc2">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:center;"><strong><a name="REPORT">REPORT</a> OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</strong></p> <p style="MARGIN: 0px; text-align:left;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">To the Board of Directors and </p> <p style="MARGIN: 0px; text-align:justify;">Stockholders of Emerald Bioscience, Inc. and Subsidiaries:</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong>Opinion on the Financial Statements</strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">We have audited the accompanying consolidated balance sheets of Emerald Bioscience, Inc. and Subsidiaries (&#8220;Company&#8221;) as of December 31, 2019 and 2018, and the related consolidated statements of comprehensive income (loss), stockholders&#8217; equity (deficit), and cash flows for each of the two years in the period ended December 31, 2019, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2019 and 2018, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2019, in conformity with accounting principles generally accepted in the United States of America.</p> <p style="MARGIN: 0px">&#160;&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong>Going Concern Uncertainty</strong></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has incurred recurring operating losses and is dependent on additional financing to fund operations. These conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern. Management&#8217;s plans in regard to these matters are described in Note 1 to the financial statements. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty.</p> <p style="MARGIN: 0px; text-align:justify;">&#160; &#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong>Basis for Opinion</strong></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">/s/ Mayer Hoffman McCann P.C.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">We have served as the Company's auditor since 2014.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">Irvine, California</p> <p style="MARGIN: 0px; text-align:justify;">March 20, 2020</p> <p style="MARGIN: 0px">&#160;&#160;&#160;</p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-2</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc2">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td colspan="12"> <p style="MARGIN: 0px; text-align:center;"><strong>EMERALD BIOSCIENCE, INC. AND SUBSIDIARIES</strong></p></td></tr> <tr> <td colspan="12"> <p style="MARGIN: 0px; text-align:center;"><strong><a name="bs">CONSOLIDATED</a> BALANCE SHEETS</strong></p></td></tr></table> <p style="MARGIN: 0px">&#160; </p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"> <p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>December 31,</strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px 0px 0px 0in"><strong>ASSETS</strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2019</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2018</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in"><strong>Current assets</strong></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 15px">Cash </p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,829,977</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,853,373</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 15px">Restricted cash </p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,538</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,512</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 15px">Prepaid expenses </p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">152,695</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">93,193</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 15px">Other current assets </p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,550</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,609</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 30px">Total current assets </p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-TOP: 1px solid; BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-TOP: 1px solid; BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,994,760</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-TOP: 1px solid; BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-TOP: 1px solid; BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,953,687</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in">Property and equipment, net </p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,983</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,445</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 30px">Total assets </p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,996,743</td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,957,132</td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in"><strong>LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) </strong></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in"><strong>Current liabilities </strong></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 15px">Accounts payable </p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">129,809</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,597</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 15px">Accounts payable to related party </p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,000</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 15px">Other current liabilities </p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">420,406</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">184,461</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 15px">Derivative liabilities </p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">410,603</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">15,738,913</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 30px">Total current liabilities </p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">970,818</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,938,971</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in"><strong>Noncurrent liabilities </strong></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 15px">Convertible multi-draw credit agreement - related party, net of discount </p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">387,070</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,360,960</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 15px">Derivative liabilities, non-current </p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">90,797</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">219,453</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 30px">Total liabilities </p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,448,685</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">17,519,384</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in"><strong>Commitments and contingencies (Note 10) </strong></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in"><strong>Stockholders&#8217; equity (deficit) </strong></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 15px">Preferred stock, $0.001 par value; 20,000,000 shares authorized; no shares issued and outstanding at December 31, 2019 and December 31, 2018 </p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 15px; text-align:left;">Common stock, $0.001 par value; 500,000,000 shares authorized; 182,895,247 and 133,907,747 shares issued and outstanding at December 31, 2019 and December 31, 2018, respectively </p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">182,895</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">133,908</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 15px">Additional paid-in-capital </p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">32,538,445</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">17,528,947</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 15px">Accumulated deficit </p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(32,173,282</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(33,225,107</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 30px">Total stockholders&#8217; equity (deficit) </p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">548,058</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(15,562,252</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 30px">Total liabilities and stockholders&#8217; equity (deficit) </p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,996,743</td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,957,132</td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td colspan="11" style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; text-align:center;">See accompanying notes to the consolidated financial statements. </p></td></tr></table> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-3</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc2">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>EMERALD BIOSCIENCE, INC. AND SUBSIDIARIES</strong></p> <p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><a name="soc">CONSOLIDATED </a>STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</strong></p> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"> <p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Year Ended December 31, </strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2019</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2018</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in"><strong>Operating expenses</strong></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 15px">Research and development</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,237,956</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">329,966</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 15px">General and administrative</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,394,622</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,362,557</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 30px">Total operating expenses</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">6,632,578</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,692,523</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in"><strong>Operating loss</strong></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(6,632,578</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(4,692,523</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td></tr> <tr style="background-color:#ffffff;"> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in"><strong>Other expense (income)</strong></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 15px">Change in fair value of derivative liabilities</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(9,734,759</td> <td style="width:1%;vertical-align:bottom;">)</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,503,174</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 15px">Fair value of derivative liabilities in excess of proceeds</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">322,644</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,174,634</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 15px">Financing transaction costs</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">137,192</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 15px">Loss on extinguishment of debt - related party</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">725,425</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">590,392</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 15px">Interest expense </p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,000,713</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">94,763</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 15px">Interest income</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(26</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(84</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 30px">Total other expense (income), net</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(7,686,003</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">14,500,071</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in"><strong>Income (loss) before income taxes</strong></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,053,425</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(19,192,594</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td></tr> <tr style="background-color:#cceeff;"> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 15px">Provision for income taxes</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,600</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,642</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in"><strong>Net income (loss) and comprehensive income (loss)</strong></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-TOP: 1px solid; BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="BORDER-TOP: 1px solid; BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,051,825</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-TOP: 1px solid; BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="BORDER-TOP: 1px solid; BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(19,194,236</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td></tr> <tr style="background-color:#cceeff;"> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in"><strong>Earnings (loss) per common share:</strong></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 15px">Basic</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">0.01</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(0.16</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 15px">Diluted</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(0.05</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(0.16</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td></tr> <tr style="background-color:#cceeff;"> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in"><strong>Weighted average shares of common stock outstanding used to compute earnings (loss) per share:</strong></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 15px">Basic</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">135,154,931</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">121,154,334</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 15px">Diluted</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">169,560,265</p></td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">121,154,334</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td colspan="10"> <p style="MARGIN: 0px">&#160; </p></td></tr> <tr style="background-color:#ffffff;"> <td colspan="10" style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; text-align:center;">See accompanying notes to the consolidated financial statements.</p></td></tr></table> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-4</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc2">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:center;"><strong>EMERALD BIOSCIENCE, INC. AND SUBSIDIARIES</strong>&#160;</p> <p style="MARGIN: 0px; text-align:center;">&#160;<strong><a name="cf">CONSOLIDATED</a> STATEMENTS OF CASH FLOWS</strong>&#160;</p> <p style="MARGIN: 0px; text-align:left;">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"> <p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Year Ended December 31,</strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2019</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2018</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in"><strong>Cash flows from operating activities:</strong></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 15px">Net income (loss)</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,051,825</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(19,194,236</td> <td style="width:1%;vertical-align:bottom;">)</td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 15px">Adjustments to reconcile net income (loss) to net cash used in operating activities:</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px">Depreciation</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,462</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,544</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px">Loss on disposal of assets</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">803</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px">Stock-based compensation expense</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">680,455</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">674,961</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px">Change in fair value of derivative liabilities</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(9,734,759</td> <td style="width:1%;vertical-align:bottom;">)</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,503,174</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px">Fair value of derivative liabilities in excess of proceeds</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">322,644</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,174,634</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px">Financing transaction costs</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">137,192</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px">Loss on extinguishment of debt - related party</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">725,425</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">590,392</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px">Loss on common stock issuance from conversion of accrued interest</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,794</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px">Amortization of debt discount</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">629,293</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">58,536</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px">Changes in assets and liabilities:</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 60px">Prepaid expenses</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(59,502</td> <td style="width:1%;vertical-align:bottom;">)</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">198,235</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 60px">Other current assets</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(4,941</td> <td style="width:1%;vertical-align:bottom;">)</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(2,609</td> <td style="width:1%;vertical-align:bottom;">)</td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 60px">Accounts payable</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">124,212</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(85,324</td> <td style="width:1%;vertical-align:bottom;">)</td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 60px">Accounts payable to related party</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,000</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 60px">Other current liabilities</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">225,945</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(10,110</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 75px">Net cash used in operating activities</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(6,027,941</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(3,943,014</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td></tr> <tr style="background-color:#cceeff;"> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in"><strong>Cash flows from investing activities:</strong></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 15px">Purchases of property and equipment</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(4,385</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 60px">Net cash used in investing activities</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(4,385</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td></tr> <tr style="background-color:#cceeff;"> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in"><strong>Cash flows from financing activities:</strong></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 15px">Proceeds from the issuance of Common stock and warrants, net of $80,628 and $154,092 of issuance costs in 2019 and 2018, respectively</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,919,372</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,095,908</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 15px">Proceeds from warrant exercises</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,080,000</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">98,700</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 15px">Proceeds from secured convertible promissory note - related party</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">400,000</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 15px">Proceeds from convertible multi-draw credit agreement - related party, net of issuance costs</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,990,699</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,946,293</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 15px">Prepayment of convertible multi-draw credit agreement - related party</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(3,985,500</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 15px">Net cash provided by financing activities</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">6,004,571</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">5,540,901</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in"><strong>Net (decrease) increase in cash and restricted cash</strong></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(23,370</td> <td style="width:1%;vertical-align:bottom;">)</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,593,502</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in"><strong>Cash and restricted cash</strong>,<strong> beginning of year</strong></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,857,885</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">264,383</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in"><strong>Cash and restricted cash, end of year</strong></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,834,515</td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,857,885</td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in"><em>Supplemental disclosures of cash-flow information:</em></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in">Reconciliation of cash and restricted cash:</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 15px">Cash</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,829,977</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,853,373</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 15px">Restricted cash</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,538</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,512</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 40px">Total cash and restricted cash shown in the consolidated statements of cash flows</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,834,515</td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,857,885</td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in">Cash paid during the year for:</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 15px">Interest</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">371,420</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">23,334</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 15px">Income taxes</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,600</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,642</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in"><em>Supplemental disclosures of non-cash financing activities:</em></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 30px">Beneficial conversion feature on convertible multi-draw credit agreement</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,584,850</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">90,080</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 30px">Proceeds allocated to equity classified warrants issued with convertible multi-draw credit agreement</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">716,110</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">315,080</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 30px">Fair value of compound derivative liability bifurcated from convertible multi-draw credit agreement</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">193,414</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">204,102</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 30px">Reclassification of warrant liabilities to equity from exercise of warrants</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,077,698</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,539,866</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 30px">Fair value of warrants issued in connection with financings</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,424,634</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 30px">Conversion of outstanding preferred stock into common stock</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,947,228</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 30px">Fair value of common stock issued in extinguishment of convertible debt and accrued interest</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,713,766</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 30px">Conversion of outstanding preferred stock subject to redemption into common stock</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">828,915</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td colspan="11" style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; text-align:center;">See accompanying notes to the consolidated financial statements. </p></td></tr></table> <p style="MARGIN: 0px">&#160;&#160;&#160; </p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-5</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc2">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>EMERALD BIOSCIENCE, INC. AND SUBSIDIARIES</strong></p> <p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><a name="ssc">CONSOLIDATED</a> STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)</strong></p> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="hdcell" colspan="6" style="vertical-align:bottom;text-align:center;"></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><strong><font style="font-size:8pt">&#160;</font></strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><strong><font style="font-size:8pt">&#160;</font></strong></p></td> <td class="hdcell" colspan="6" style="vertical-align:bottom;text-align:center;"><font style="font-size:8pt"></font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><strong><font style="font-size:8pt">&#160;</font></strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><strong><font style="font-size:8pt">&#160;</font></strong></p></td> <td class="hdcell" colspan="6" style="vertical-align:bottom;text-align:center;"><font style="font-size:8pt"><strong>Redeemable </strong></font></td> <td style="vertical-align:bottom;"><font style="font-size:8pt"><strong>&#160;</strong></font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><strong><font style="font-size:8pt">&#160;</font></strong></p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="18"> <p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><font style="font-size:8pt">Stockholders' Equity (Deficit)</font></strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><strong><font style="font-size:8pt">&#160;</font></strong></p></td></tr> <tr> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><strong><font style="font-size:8pt">&#160;</font></strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><strong><font style="font-size:8pt">&#160;</font></strong></p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="6"><font style="font-size:8pt"><strong>Convertible</strong> </font> <p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><font style="font-size:8pt">Series F</font></strong></p><strong>Preferred Stock</strong> </td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><strong><font style="font-size:8pt">&#160;</font></strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><strong><font style="font-size:8pt">&#160;</font></strong></p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="6"><font style="font-size:8pt"><strong>Convertible</strong> </font> <p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><font style="font-size:8pt">Series D</font></strong></p><strong>Preferred Stock</strong> </td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><strong><font style="font-size:8pt">&#160;</font></strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><strong><font style="font-size:8pt">&#160;</font></strong></p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="6"><font style="font-size:8pt"><strong>Convertible</strong> </font> <p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><font style="font-size:8pt">Series B</font></strong></p><strong>Preferred Stock</strong> </td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><strong><font style="font-size:8pt">&#160;</font></strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><strong><font style="font-size:8pt">&#160;</font></strong></p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="6"> <p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><font style="font-size:8pt">Common Stock</font></strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><strong><font style="font-size:8pt">&#160;</font></strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><strong><font style="font-size:8pt">&#160;</font></strong></p></td> <td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><font style="font-size:8pt"><strong>Additional</strong> <p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><font style="font-size:8pt"><strong>Paid-In </strong></font></p></font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><strong><font style="font-size:8pt">&#160;</font></strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><strong><font style="font-size:8pt">&#160;</font></strong></p></td> <td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><font style="font-size:8pt"><strong>Accumulated</strong></font></td> <td style="vertical-align:bottom;"><font style="font-size:8pt"><strong>&#160;</strong></font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><strong><font style="font-size:8pt">&#160;</font></strong></p></td> <td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"> <p><font style="font-size:8pt"><strong>Total </strong></font><font style="font-size:8pt"><strong>Stockholders' </strong><strong>Equity </strong></font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><strong><font style="font-size:8pt">&#160;</font></strong></p></td></tr> <tr> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><strong><font style="font-size:8pt">&#160;</font></strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><strong><font style="font-size:8pt">&#160;</font></strong></p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><font style="font-size:8pt">Shares</font></strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px"><strong><font style="font-size:8pt">&#160;</font></strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><strong><font style="font-size:8pt">&#160;</font></strong></p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><font style="font-size:8pt">Amounts</font></strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px"><strong><font style="font-size:8pt">&#160;</font></strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><strong><font style="font-size:8pt">&#160;</font></strong></p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><font style="font-size:8pt">Shares</font></strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px"><strong><font style="font-size:8pt">&#160;</font></strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><strong><font style="font-size:8pt">&#160;</font></strong></p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><font style="font-size:8pt">Amounts</font></strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px"><strong><font style="font-size:8pt">&#160;</font></strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><strong><font style="font-size:8pt">&#160;</font></strong></p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><font style="font-size:8pt">Shares</font></strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px"><strong><font style="font-size:8pt">&#160;</font></strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><strong><font style="font-size:8pt">&#160;</font></strong></p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><font style="font-size:8pt">Amounts</font></strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px"><strong><font style="font-size:8pt">&#160;</font></strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><strong><font style="font-size:8pt">&#160;</font></strong></p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><font style="font-size:8pt">Shares</font></strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px"><strong><font style="font-size:8pt">&#160;</font></strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><strong><font style="font-size:8pt">&#160;</font></strong></p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><font style="font-size:8pt">Amounts</font></strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px"><strong><font style="font-size:8pt">&#160;</font></strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><strong><font style="font-size:8pt">&#160;</font></strong></p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"> <p><font style="font-size:8pt"><strong>Capital&#160;</strong><strong> </strong></font></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px"><strong><font style="font-size:8pt">&#160;</font></strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><strong><font style="font-size:8pt">&#160;</font></strong></p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><font style="font-size:8pt">Deficit</font></strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px"><strong><font style="font-size:8pt">&#160;</font></strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><strong><font style="font-size:8pt">&#160;</font></strong></p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><font style="font-size:8pt"><strong>(Deficit</strong>)</font></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160; </p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in"><font style="font-size:8pt"><strong>Balance, December 31, 2017</strong></font></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:4%;vertical-align:bottom;text-align:right;"><font style="font-size:8pt"><strong>2,000</strong></font></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt"><strong>&#160;</strong></font></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt"><strong>&#160;</strong></font></p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;"><font style="font-size:8pt"><strong>$</strong></font></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:4%;vertical-align:bottom;text-align:right;"><font style="font-size:8pt"><strong>1,777,781</strong></font></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt"><strong>&#160;</strong></font></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt"><strong>&#160;</strong></font></p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt"><strong>&#160;</strong></font></p></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:4%;vertical-align:bottom;text-align:right;"><font style="font-size:8pt"><strong>200</strong></font></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt"><strong>&#160;</strong></font></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt"><strong>&#160;</strong></font></p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;"><font style="font-size:8pt"><strong>$</strong></font></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:4%;vertical-align:bottom;text-align:right;"><font style="font-size:8pt"><strong>169,447</strong></font></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt"><strong>&#160;</strong></font></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt"><strong>&#160;</strong></font></p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt"><strong>&#160;</strong></font></p></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:4%;vertical-align:bottom;text-align:right;"><font style="font-size:8pt"><strong>2,834</strong></font></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt"><strong>&#160;</strong></font></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt"><strong>&#160;</strong></font></p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;"><font style="font-size:8pt"><strong>$</strong></font></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:4%;vertical-align:bottom;text-align:right;"><font style="font-size:8pt"><strong>822,201</strong></font></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt"><strong>&#160;</strong></font></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt"><strong>&#160;</strong></font></p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt"><strong>&#160;</strong></font></p></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:4%;vertical-align:bottom;text-align:right;"><font style="font-size:8pt"><strong>33,622,829</strong></font></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt"><strong>&#160;</strong></font></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt"><strong>&#160;</strong></font></p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;"><font style="font-size:8pt"><strong>$</strong></font></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:4%;vertical-align:bottom;text-align:right;"><font style="font-size:8pt"><strong>33,623</strong></font></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt"><strong>&#160;</strong></font></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt"><strong>&#160;</strong></font></p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;"><font style="font-size:8pt"><strong>$</strong></font></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:4%;vertical-align:bottom;text-align:right;"><font style="font-size:8pt"><strong>10,427,742</strong></font></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt"><strong>&#160;</strong></font></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt"><strong>&#160;</strong></font></p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;"><font style="font-size:8pt"><strong>$</strong></font></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:4%;vertical-align:bottom;text-align:right;"><font style="font-size:8pt"><strong>(14,030,871</strong></font></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"><font style="font-size:8pt"><strong>)</strong></font></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt"><strong>&#160;</strong></font></p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;"><font style="font-size:8pt"><strong>$</strong></font></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:4%;vertical-align:bottom;text-align:right;"><font style="font-size:8pt"><strong>(3,569,506</strong></font></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"><font style="font-size:8pt"><strong>)</strong></font></td></tr> <tr style="background-color:#ffffff;"> <td> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-size:8pt">Stock-based compensation expense</font>&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">674,961</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">674,961</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td></tr> <tr style="background-color:#ffffff;"> <td> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in"><font style="font-size:8pt">Common stock issued for services</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">3,143,501</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">3,143</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">(3,143</font></td> <td style="vertical-align:bottom;"><font style="font-size:8pt">)</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td></tr> <tr style="background-color:#ffffff;"> <td> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; text-align:left;"><font style="font-size:8pt">Issuance of common stock net of issuance costs of $16,900</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">32,500,000</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">32,500</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">(49,400</font></td> <td style="vertical-align:bottom;"><font style="font-size:8pt">)</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">(16,900</font></td> <td style="vertical-align:bottom;"><font style="font-size:8pt">)</font></td></tr> <tr style="background-color:#ffffff;"> <td> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td></tr> <tr style="background-color:#cceeff;"> <td> <p style="MARGIN: 0px; text-align:left;"><font style="font-size:8pt;margin:0px"><font style="font-size:8pt">Conversion of Series B Preferred Stock and conversion liability into common stock at $0.10 and $0.001 per share</font></font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">(2,834</font></td> <td style="vertical-align:bottom;"><font style="font-size:8pt">)</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">(822,201</font></td> <td style="vertical-align:bottom;"><font style="font-size:8pt">)</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">28,385,000</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">28,385</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">800,530</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">828,915</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td></tr> <tr style="background-color:#ffffff;"> <td> <p style="MARGIN: 0px; text-align:left;"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td></tr> <tr style="background-color:#cceeff;"> <td> <p style="MARGIN: 0px; text-align:left;"><font style="font-size:8pt;margin:0px"><font style="font-size:8pt">Conversion of Series D Preferred Stock to common stock at $0.10 per share</font></font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">(200</font></td> <td style="vertical-align:bottom;"><font style="font-size:8pt">)</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">(169,447</font></td> <td style="vertical-align:bottom;"><font style="font-size:8pt">)</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">2,000,000</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">2,000</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">167,447</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">169,447</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td></tr> <tr style="background-color:#ffffff;"> <td> <p style="MARGIN: 0px; text-align:left;"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td></tr> <tr style="background-color:#cceeff;"> <td> <p style="MARGIN: 0px; text-align:left;"><font style="font-size:8pt;margin:0px"><font style="font-size:8pt">Conversion of Series F Preferred Stock to common stock at $0.10 per share</font></font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">(2,000</font></td> <td style="vertical-align:bottom;"><font style="font-size:8pt">)</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">(1,777,781</font></td> <td style="vertical-align:bottom;"><font style="font-size:8pt">)</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">20,000,000</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">20,000</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">1,757,781</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">1,777,781</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td></tr> <tr style="background-color:#ffffff;"> <td> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; text-align:left;"><font style="font-size:8pt">Conversion of secured convertible promissory note - related party and accrued interest</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">9,037,667</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">9,038</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">1,714,522</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">1,723,560</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td></tr> <tr style="background-color:#ffffff;"> <td> <p style="MARGIN: 0px; text-align:left;"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; text-align:left;"><font style="font-size:8pt">Series B warrant exercises</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">5,218,750</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">5,219</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">1,633,347</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">1,638,566</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td></tr> <tr style="background-color:#ffffff;"> <td> <p style="MARGIN: 0px; text-align:left;"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; text-align:left;"><font style="font-size:8pt">Warrants issued in connection with convertible multi-draw credit agreement, related party</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">315,080</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">315,080</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td></tr> <tr style="background-color:#ffffff;"> <td> <p style="MARGIN: 0px; text-align:left;"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; text-align:left;"><font style="font-size:8pt">Beneficial conversion feature in connection with convertible multi-draw credit agreement - related party</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">90,080</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">90,080</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td></tr> <tr style="background-color:#ffffff;"> <td> <p style="MARGIN: 0px; text-align:left;"><font style="font-size:8pt">&#160; </font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; text-align:left;"><font style="font-size:8pt">Net loss for the year ended December 31, 2018</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;"><font style="font-size:8pt">(19,194,236</font></td> <td style="vertical-align:bottom;"><font style="font-size:8pt">)</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;"><font style="font-size:8pt">(19,194,236</font></td> <td style="vertical-align:bottom;"><font style="font-size:8pt">)</font></td></tr> <tr style="background-color:#ffffff;"> <td> <p style="MARGIN: 0px; text-align:left;"><font style="font-size:8pt">&#160; </font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; text-align:left;"><font style="font-size:8pt"><strong>Balance, December 31, 2018</strong></font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><font style="font-size:8pt"><strong>-</strong></font></td> <td style="PADDING-BOTTOM: 3px;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt"><strong>&#160;</strong></font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt"><strong>&#160;</strong></font></p></td> <td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;"><font style="font-size:8pt"><strong>$</strong></font></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><font style="font-size:8pt"><strong>-</strong></font></td> <td style="PADDING-BOTTOM: 3px;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt"><strong>&#160;</strong></font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt"><strong>&#160;</strong></font></p></td> <td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt"><strong>&#160;</strong></font></p></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><font style="font-size:8pt"><strong>-</strong></font></td> <td style="PADDING-BOTTOM: 3px;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt"><strong>&#160;</strong></font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt"><strong>&#160;</strong></font></p></td> <td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;"><font style="font-size:8pt"><strong>$</strong></font></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><font style="font-size:8pt"><strong>-</strong></font></td> <td style="PADDING-BOTTOM: 3px;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt"><strong>&#160;</strong></font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt"><strong>&#160;</strong></font></p></td> <td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt"><strong>&#160;</strong></font></p></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><font style="font-size:8pt"><strong>-</strong></font></td> <td style="PADDING-BOTTOM: 3px;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt"><strong>&#160;</strong></font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt"><strong>&#160;</strong></font></p></td> <td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;"><font style="font-size:8pt"><strong>$</strong></font></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><font style="font-size:8pt"><strong>-</strong></font></td> <td style="PADDING-BOTTOM: 3px;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt"><strong>&#160;</strong></font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt"><strong>&#160;</strong></font></p></td> <td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt"><strong>&#160;</strong></font></p></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><font style="font-size:8pt"><strong>133,907,747</strong></font></td> <td style="PADDING-BOTTOM: 3px;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt"><strong>&#160;</strong></font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt"><strong>&#160;</strong></font></p></td> <td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;"><font style="font-size:8pt"><strong>$</strong></font></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><font style="font-size:8pt"><strong>133,908</strong></font></td> <td style="PADDING-BOTTOM: 3px;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt"><strong>&#160;</strong></font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt"><strong>&#160;</strong></font></p></td> <td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;"><font style="font-size:8pt"><strong>$</strong></font></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><font style="font-size:8pt"><strong>17,528,947</strong></font></td> <td style="PADDING-BOTTOM: 3px;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt"><strong>&#160;</strong></font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt"><strong>&#160;</strong></font></p></td> <td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;"><font style="font-size:8pt"><strong>$</strong></font></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><font style="font-size:8pt"><strong>(33,225,107</strong></font></td> <td style="PADDING-BOTTOM: 3px;vertical-align:bottom;"><font style="font-size:8pt"><strong>)</strong></font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt"><strong>&#160;</strong></font></p></td> <td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;"><font style="font-size:8pt"><strong>$</strong></font></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><font style="font-size:8pt"><strong>(15,562,252</strong></font></td> <td style="PADDING-BOTTOM: 3px;vertical-align:bottom;"><font style="font-size:8pt"><strong>)</strong></font></td></tr> <tr style="background-color:#ffffff;"> <td> <p style="MARGIN: 0px; text-align:left;"><font style="font-size:8pt"><strong>&#160;&#160; </strong></font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-size:8pt">Stock-based compensation expense</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">680,455</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">680,455</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td></tr> <tr style="background-color:#ffffff;"> <td> <p style="MARGIN: 0px; text-align:left;"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in"><font style="font-size:8pt">Issuance of common stock and warrants, net of issuance costs of $80,628</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">8,000,000</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">8,000</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">1,911,372</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">1,919,372</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td></tr> <tr style="background-color:#ffffff;"> <td> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-size:8pt">Warrants issued in connection with convertible multi-draw credit agreement, related party</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">716,110</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">716,110</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td></tr> <tr style="background-color:#ffffff;"> <td> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in; text-align:left;"><font style="font-size:8pt">Beneficial conversion feature in connection with convertible multi-draw credit agreement - related party</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">1,584,850</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">1,584,850</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td></tr> <tr style="background-color:#ffffff;"> <td> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in"><font style="font-size:8pt">Series B warrant exercises</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">187,500</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">187</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">144,188</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">144,375</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td></tr> <tr style="background-color:#ffffff;"> <td> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in"><font style="font-size:8pt">Exercise of Emerald financing warrants</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">40,800,000</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">40,800</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">9,972,523</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"><font style="font-size:8pt">10,013,323</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td></tr> <tr style="background-color:#ffffff;"> <td> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in"><font style="font-size:8pt">Net income for the year ended December 31, 2019</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;"><font style="font-size:8pt">-</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;"><font style="font-size:8pt">1,051,825</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;"><font style="font-size:8pt">1,051,825</font></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td></tr> <tr style="background-color:#ffffff;"> <td> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160; </font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 0in"><strong><font style="font-size:8pt">Balance, December 31, 2019</font></strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><font style="font-size:8pt"><strong>-</strong></font></td> <td style="PADDING-BOTTOM: 3px;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt"><strong>&#160;</strong></font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt"><strong>&#160;</strong></font></p></td> <td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;"><font style="font-size:8pt"><strong>$</strong></font></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><font style="font-size:8pt"><strong>-</strong></font></td> <td style="PADDING-BOTTOM: 3px;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt"><strong>&#160;</strong></font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt"><strong>&#160;</strong></font></p></td> <td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt"><strong>&#160;</strong></font></p></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><font style="font-size:8pt"><strong>-</strong></font></td> <td style="PADDING-BOTTOM: 3px;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt"><strong>&#160;</strong></font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt"><strong>&#160;</strong></font></p></td> <td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;"><font style="font-size:8pt"><strong>$</strong></font></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><font style="font-size:8pt"><strong>-</strong></font></td> <td style="PADDING-BOTTOM: 3px;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt"><strong>&#160;</strong></font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt"><strong>&#160;</strong></font></p></td> <td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt"><strong>&#160;</strong></font></p></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><font style="font-size:8pt"><strong>-</strong></font></td> <td style="PADDING-BOTTOM: 3px;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt"><strong>&#160;</strong></font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt"><strong>&#160;</strong></font></p></td> <td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;"><font style="font-size:8pt"><strong>$</strong></font></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><font style="font-size:8pt"><strong>-</strong></font></td> <td style="PADDING-BOTTOM: 3px;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt"><strong>&#160;</strong></font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt"><strong>&#160;</strong></font></p></td> <td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><strong><font style="font-size:8pt">182,895,247</font></strong></td> <td style="PADDING-BOTTOM: 3px;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;"><strong><font style="font-size:8pt">$</font></strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><strong><font style="font-size:8pt">182,895</font></strong></td> <td style="PADDING-BOTTOM: 3px;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;"><strong><font style="font-size:8pt">$</font></strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><strong><font style="font-size:8pt">32,538,445</font></strong></td> <td style="PADDING-BOTTOM: 3px;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;"><strong><font style="font-size:8pt">$</font></strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><strong><font style="font-size:8pt">(32,173,282</font></strong></td> <td style="PADDING-BOTTOM: 3px;vertical-align:bottom;"><strong><font style="font-size:8pt">)</font></strong></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td> <td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;"><strong><font style="font-size:8pt">$</font></strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><strong><font style="font-size:8pt">548,058</font></strong></td> <td style="PADDING-BOTTOM: 3px;vertical-align:bottom;"> <p style="MARGIN: 0px"><font style="font-size:8pt">&#160;</font></p></td></tr></table> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:center;">See accompanying notes to the consolidated financial statements.</p> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-6</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc2">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px; text-align:center;">&#160;</p> <p style="MARGIN: 0px; text-align:center;"><strong><a name="note">EMERALD BIOSCIENCE, INC. AND SUBSIDIARIES</a></strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</strong> </p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong>1. Nature of Operations and Business Activities</strong></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong><em>Nature of Operations</em></strong></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">Emerald Bioscience, Inc. (the &#8220;Company&#8221;) was initially incorporated in Nevada on March 16, 2011 as Load Guard Logistics, Inc. On October 31, 2014, the Company closed a reverse merger transaction (the &#8220;Merger&#8221;) pursuant to which Nemus, a California corporation (&#8220;Nemus Sub&#8221;), became the Company&#8217;s wholly-owned subsidiary, and the Company assumed the operations of Nemus Sub. Nemus Sub was incorporated in the State of California on July 17, 2012. On November 3, 2014, the Company changed its name to Nemus Bioscience, Inc. by merging with Nemus Sub. </p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">In January 2018, the Company entered into a securities purchase agreement with Emerald Health Sciences, Inc. (&#8220;Emerald Health Sciences&#8221;) discussed in Note 5, pursuant to which Emerald Health Sciences purchased a majority of the equity interest in the Company, resulting in a change in control. As part of the transaction, the Company&#8217;s Board members, with the exception of Dr. Brian Murphy, the Company&#8217;s CEO/CMO, tendered their resignation and Emerald Health Sciences appointed two new nominees to the Board. Later, in October 2018, the Board appointed Dr. Avtar Dhillon, the Chairman, Chief Executive Officer and President of Emerald Health Sciences, as the Executive Chairman of the Company&#8217;s Board. </p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">On February 11, 2019, the Company&#8217;s Board of Directors (the &#8220;Board&#8221;) and majority stockholder unanimously approved an amendment to the Company&#8217;s articles of incorporation to change the name of the Company to Emerald Bioscience, Inc. Effective March 25, 2019, the Company filed a Certificate of Amendment with the Nevada Secretary of State changing the Company&#8217;s name to Emerald Bioscience, Inc. </p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">In August 2019, the Company formed a new subsidiary in Australia, EMBI Australia Pty Ltd., an Australian proprietary limited company (&#8220;EMBI Australia&#8221;), in order to qualify for the Australian government&#8217;s research and development tax credit for research and development dollars spent in Australia. The primary purpose of EMBI Australia is to conduct clinical trials for the Company&#8217;s product candidates.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">On December 17, 2019, Dr. Avtar Dhillon resigned as the Chairman of the Company&#8217;s Board and the Company entered into a Board Observer Agreement with Emerald Health Sciences. Refer to Note 11 - Related Party Matters for additional information. </p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px">The Company is a biopharmaceutical company located in Long Beach, California that plans to research, develop and commercialize therapeutics derived from cannabinoids through several license agreements with the University of Mississippi (&#8220;UM&#8221;). UM is the only entity federally permitted and licensed to cultivate cannabis for research purposes in the United States.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">As of December 31, 2019, the Company has devoted substantially all its efforts to securing product licenses, carrying out research and development, building infrastructure and raising capital. The Company has not yet realized revenue from its planned principal operations and is a number of years from potentially being able to do so. </p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong><em>Liquidity and Going Concern</em></strong></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px">The Company has incurred operating losses and negative cash flows from operations since inception and as of December 31, 2019, had an accumulated deficit of $32,173,282. The Company anticipates that it will continue to incur operating losses into the foreseeable future in order to advance and develop a number of potential drug candidates into preclinical and clinical development activities and support its corporate infrastructure which includes the costs associated with being a public company. As of December 31, 2019 and filing date of our 2019 Annual Report on Form 10K, the Company had cash in the amount of $1,829,977 and approximately $667,000, respectively.</p> <p style="MARGIN: 0px 0px 0px 0.35pt; text-align:justify;">&#160;&#160; </p> <p style="MARGIN: 0px 0px 0px 1.05pt; text-align:justify;">During the year ended December 31, 2019, the Company received net cash proceeds of $3,990,699 from the Credit Agreement (defined below) with Emerald Health Sciences and raised $1,919,372 in net proceeds pursuant to the sale of common stock and warrants under a registered direct offering. However, the Company&#8217;s cash flows from its financing efforts have been offset by cash used in operating activities of $6,027,941 for the year ended December 31, 2019. As the Company approaches its first clinical trial, it expects to ramp up research and development spending and projects to increase cash used in operating activities. However, based on the Company&#8217;s current cash position and expected cash requirements, without obtaining additional funding in the second quarter of 2020, management believes that the Company will not have enough funds to meet its obligations. These conditions give rise to substantial doubt as to the Company&#8217;s ability to continue as a going concern. The accompanying Consolidated Financial Statements do not include any adjustments that might result from the outcome of this uncertainty.</p> <p style="MARGIN: 0px 0px 0px 0.35pt; text-align:justify;">&#160;&#160;</p> <p style="MARGIN: 0px 0px 0px 0.35pt; text-align:justify;">The Company&#8217;s continued existence is dependent on its ability to raise sufficient additional funding to cover operating expenses and to invest in research and development activities. On October 5, 2018, the Company entered into a Multi-Draw Credit Agreement (the &#8220;Credit Agreement&#8221;) with Emerald Health Sciences (See Note 4). As of December 31, 2019, under the Credit Agreement, the Company may draw down up to the remaining amount under the Credit Agreement of $14,000,000 from time to time in principal amounts of at least $250,000. The drawdowns are subject to approval by the Company&#8217;s Board, which is controlled by the directors of Emerald Health Sciences. We do not consider the facility available until advance requests are approved, drawn down and funded. The Credit Agreement is still in place, however, there is no guarantee of continued funding.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;&#160;&#160;</p> <p style="MARGIN: 0px; text-align:justify;">The Company plans to continue to pursue funding through public or private equity or debt financings, licensing arrangements, asset sales, government grants or other arrangements. However, the Company cannot provide any assurances that such additional funds will be available on reasonable terms, or at all. If the Company raises additional funds by issuing equity securities, substantial dilution to existing stockholders would result.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;&#160; </p> <p style="MARGIN: 0px 0px 0px 0.35pt; text-align:justify;">Effective March 23, 2020, the Company approved a plan to defer 50% of senior management&#8217;s compensation indefinitely. If the members of senior management accept the plan, the aggregate deferred compensation, together with a retention bonus of 10% of the amount being deferred will be payable to senior management when decided by the Board. This measure, in conjunction with management&#8217;s plan to negotiate extended payment terms with its vendors and service providers, is intended to slow cash burn. The Company&#8217;s Board plans on further assessing the financial condition of the Company to determine what additional measures, if any, will be implemented. If the Company is unable to secure adequate additional funding, the Company may be forced to reduce spending further, liquidate assets where possible, suspend or curtail planned programs or cease operations.</p> <p style="MARGIN: 0px 0px 0px 0.35pt; text-align:justify;">&#160;&#160;&#160;</p> <p style="MARGIN: 0px 0px 0px 0.7pt; text-align:justify;">On March 11, 2020, the World Health Organization declared the outbreak of a respiratory disease caused by a new COVID-19 as a &#8220;pandemic&#8221;. Notably, the Company relies on third-party manufacturers to produce its product candidates. The manufacturing of the active pharmaceutical ingredient of NB1111 is conducted in the United States. Formulation of the eye drop for testing is also performed in the United States but can rely on regulatory-accepted excipients that can be sourced from countries outside the United States, such as China. In lieu of the recent pandemic of a COVID-19, there could possibly be an impact on sourcing materials that are part of the eye drop formulation, as well as impacting volunteer and/or patient recruitment in Australia for clinical studies. Therefore, the Company anticipates shifting its first-in-human studies of the lead drug candidate, NB1111, from the second half of 2020, to the 2021 timeframe. Additionally, COVID-19 has caused significant disruptions to the global financial markets which could impact the Company&#8217;s ability to raise additional capital.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">After considering the plans to alleviate substantial doubt, management has concluded that there is substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued.</p> <p style="MARGIN: 0px 0px 0px 0.7pt; text-align:justify;">&#160; &#160;&#160;&#160;&#160;&#160;&#160;</p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-7</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc2">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong>2. Summary of Significant Accounting Policies</strong></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong><em>Basis of Presentation</em></strong></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px">The preparation of financial statements in conformity with U.S. Generally Accepted Accounting Principles (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the amounts reported in the Consolidated Financial Statements and the accompanying notes. Actual results could differ from those estimates. Certain reclassifications have been made to prior year amounts to conform to the current year&#8217;s presentation. Such reclassifications had no net effect on the prior year&#8217;s total assets, total liabilities, total stockholders&#8217; deficit, net loss, and cash flows.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong><em>Use of Estimates</em></strong></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px">The preparation of the Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Consolidated Financial Statements and the reported amounts of income and expense during the reporting period. Actual results could differ from those estimates. The most significant accounting estimates inherent in the preparation of the Company&#8217;s financial statements include estimates as to the appropriate carrying value of certain assets and liabilities, which are not readily apparent from other sources. Such estimates and judgments are utilized for stock-based compensation expense, equity securities, derivative liabilities, and debt with embedded features.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong><em>Risks and Uncertainties</em></strong></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px 0px 0px 0.35pt; text-align:justify;">The Company&#8217;s operations are subject to a number of risks and uncertainties, including but not limited to, changes in the general economy, the size and growth of the potential markets for any of the Company&#8217;s product candidates, results of research and development activities, uncertainties surrounding regulatory developments in the United States and Australia, and the Company&#8217;s ability to attract new funding. </p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong><em>Cash and Cash Equivalents</em></strong></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px">The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The carrying values of those investments approximate their fair value due to their short maturity and liquidity. Cash includes cash on hand and amounts on deposit with financial institutions, which amounts may at times exceed federally insured limits. The Company has not experienced any losses on such accounts and does not believe it is exposed to any significant credit risk. As of December 31, 2019, the Company has no cash equivalents.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong><em>Restricted Cash</em></strong></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px">A deposit of $4,538 and $4,512 as of December 31, 2019 and 2018, respectively, was restricted from withdrawal and held by a bank in the form of a certificate of deposit. This certificate serves as collateral for payment of the Company&#8217;s credit cards.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong><em>Fair Value Measurements</em></strong></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px 0px 0px 0.35pt; text-align:justify;">Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (the &#8220;exit price&#8221;) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A fair value hierarchy based on three levels of inputs, of which the first two are considered observable, and the last is considered unobservable, is used to measure fair value:</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="width:6%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Level 1:</p></td> <td style="width:72%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Valuations for assets and liabilities traded in active markets from readily available pricing sources such as quoted prices in active markets for identical assets or liabilities.</p></td></tr> <tr> <td style="width:6%;vertical-align:top;"></td> <td style="width:72%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">&#160;</p></td></tr> <tr> <td style="width:6%;vertical-align:top;"> <p style="MARGIN: 0px">Level 2:</p></td> <td style="width:72%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Observable inputs (other than Level 1 quoted prices) such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</p></td></tr> <tr> <td style="width:6%;vertical-align:top;"></td> <td style="width:72%;vertical-align:top;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="width:6%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Level 3:</p></td> <td style="width:72%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</p></td></tr></table> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">The carrying values of the Company&#8217;s financial instruments, with the exception of the Credit Agreement and derivative liabilities, including, cash, prepaid expenses, accounts payable, and other current liabilities approximate their fair value due to the short maturities of these financial instruments. The derivative liabilities are valued on a recurring basis utilizing Level 3 inputs.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px">Advances under the Credit Agreement are not recorded at fair value. However, fair value can be approximated and disclosed utilizing Level 3 inputs and independent third-party valuation techniques (See Note 3). As of December 31, 2019 and 2018, the fair value of the advances under the Credit Agreement was $1,877,938 and $3,176,824, respectively. The carrying amount of the liability at December 31, 2019 and 2018, was $387,070 and $1,360,960, respectively, and is included in Convertible multi-draw credit agreement - related party, net of discount in the Company&#8217;s Consolidated Balance Sheets.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"> <p style="MARGIN: 0px; text-align:center;">F-8</p></td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc1">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong><em>Property and Equipment, Net</em></strong></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">Property and equipment, net, consist primarily of computers and equipment. Expenditures for additions, renewals and improvements are capitalized at cost. Depreciation is computed on a straight-line method based on the estimated useful life of the related asset currently ranging from two to three years. Maintenance and repairs that do not extend the life of assets are charged to expense when incurred. When properties are disposed of, the related costs and accumulated depreciation are removed from the accounts and any gain or loss is reported in the period the transaction takes place.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted cash flows expected to be generated by the asset. If the carrying amount exceeds its estimated future undiscounted cash flows, an impairment charge is recognized by the amount by which the carrying amount exceeds the fair value of the asset.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong><em>Income Taxes</em></strong></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px 0px 0px 0.35pt; text-align:justify;">The Company accounts for deferred income tax assets and liabilities based on differences between the financial reporting and tax bases of assets and liabilities, net operating loss carryforwards (the &#8220;NOLs&#8221;) and other tax credit carryforwards. These items are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the period that includes the enactment date. Any interest or penalties would be recorded in the Company&#8217;s Consolidated Statements of Comprehensive Income (Loss) in the period incurred. When necessary, the Company recognizes interest and penalties related to income tax matters in income tax expense.</p> <p style="MARGIN: 0px 0px 0px 0.35pt; text-align:justify;">&#160; &#160;</p> <p style="MARGIN: 0px 0px 0px 0.35pt; text-align:justify;">The Company records a valuation allowance against deferred tax assets to the extent that it is more likely than not that some portion or all of the deferred tax assets will not be realized. In making such determinations, management considers all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and recent financial operations. Due to the substantial doubt related to the Company&#8217;s ability to utilize its deferred tax assets, a valuation allowance for the full amount of the deferred tax assets has been established at December 31, 2019 and 2018. As a result of this valuation allowance, there are no income tax benefits reflected in the accompanying Consolidated Statements of Comprehensive Income (Loss) to offset pre-tax losses.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">The Company recognizes a tax benefit from uncertain tax positions when it is more likely than not (50%) that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits of the position. </p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong><em>Convertible Instruments</em></strong></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px">The Company accounts for hybrid contracts with embedded conversion features in accordance with GAAP. ASC 815, <em>Derivatives and Hedging Activities</em> (&#8220;ASC 815&#8221;) requires companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria includes circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. </p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px">The Company accounts for convertible debt instruments with embedded conversion features in accordance with ASC 470-20, <em>Debt with Conversion and Other Options</em> (&#8220;ASC 470-20&#8221;) if it is determined that the conversion feature should not be bifurcated from their host instruments. Under ASC 470-20, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the difference between the fair value of the underlying common stock at the commitment date and the embedded effective conversion price. When the Company determines that the embedded conversion option should be bifurcated from its host instrument, the embedded feature is accounted for in accordance with ASC 815. Under ASC 815, a portion of the proceeds received upon the issuance of the hybrid contract is allocated to the fair value of the derivative. The derivative is subsequently marked to market at each reporting date based on current fair value, with the changes in fair value reported in the results of operations.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">The Company also follows ASC 480-10, <em>Distinguishing Liabilities from Equity</em> (&#8220;ASC 480-10&#8221;) when evaluating the accounting for its hybrid instruments. A financial instrument that embodies an unconditional obligation, or a financial instrument other than an outstanding share that embodies a conditional obligation, that the issuer must or may settle by issuing a variable number of its equity shares shall be classified as a liability (or an asset in some circumstances) if, at inception, the monetary value of the obligation is based solely or predominantly on any one of the following: (a) a fixed monetary amount known at inception (for example, a payable settled with a variable number of the issuer&#8217;s equity shares); (b) variations in something other than the fair value of the issuer&#8217;s equity shares (for example, a financial instrument indexed to the Standard and Poor&#8217;s S&amp;P 500 Index and settled with a variable number of the issuer&#8217;s equity shares); or (c) variations inversely related to changes in the fair value of the issuer&#8217;s equity shares (for example, a written put option that could be net share settled). Hybrid instruments meeting these criteria are not further evaluated for any embedded derivatives and are carried as a liability at fair value at each balance sheet date with a re-measurement reported in other (income) expense in the accompanying Consolidated Statements of Comprehensive Income (Loss).</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-9</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc2">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">When determining short-term vs. long-term classification of derivative liabilities, the Company first evaluates the instruments&#8217; exercise provisions. Generally, if a derivative is a liability and exercisable within one year, it will be classified as short-term. However, because of the unique provisions and circumstances that may impact the accounting for derivative instruments, the Company carefully evaluates all factors that could potentially restrict the instrument from being exercised or create a situation where exercise would be considered remote. The Company re-evaluates its derivative liabilities at each reporting period end and make updates for any changes in facts and circumstances that may impact classification.</p> <p style="MARGIN: 0px">&#160;&#160; &#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong><em>Warrants Issued in Connection with Financings</em></strong></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">The Company generally accounts for warrants issued in connection with debt and equity financings as a component of equity, unless the warrants include a conditional obligation to issue a variable number of shares or there is a deemed possibility that the Company may need to settle the warrants in cash. For warrants issued with a conditional obligation to issue a variable number of shares or the deemed possibility of a cash settlement, the Company records the fair value of the warrants as a liability at each balance sheet date and records changes in fair value in other (income) expense in the Consolidated Statements of Comprehensive Income (Loss).</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong><em>Debt Issuance Costs and Interest</em></strong></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px 0px 0px 0.35pt; text-align:justify;">Discounts related to bifurcated derivatives, freestanding instruments issued in bundled transactions, and issuance costs are recorded as a reduction to the carrying value of the debt and amortized over the life of the debt using the effective interest method. The Company makes changes to the effective interest rate, as necessary, on a prospective basis. For debt facilities that provide for multiple advances, the Company initially defers any issuance costs until the first advance is made and then amortizes the costs over the life of the facility. </p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong><em>Research and Development Expenses and Licensed Technology</em></strong></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">Research and development costs are expensed when incurred. These costs may consist of external research and development expenses incurred under agreements with third-party contract research organizations and investigative sites, third-party manufacturing organizations and consultants; license fees; employee-related expenses, which include salaries and benefits for the personnel involved in the Company&#8217;s preclinical and clinical drug development activities; facilities expense, depreciation and other allocated expenses; and equipment and laboratory supplies.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">Costs incurred for the rights to use licensed technologies in the research and development process, including licensing fees and milestone payments, are charged to research and development expense as incurred in situations where the Company has not identified an alternative future use for the acquired rights, and are capitalized in situations where there is an identified alternative future use. No cost associated with the use of licensed technologies has been capitalized to date.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px"><strong><em>Stock-Based Compensation Expense </em></strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px 0px 0px 0.35pt; text-align:justify;">Stock-based compensation expense is estimated at the grant date based on the fair value of the award, and the cost is recognized as expense ratably over the vesting period with forfeitures accounted for as they occur. The Company uses the Black-Scholes Merton option pricing model for estimating the grant date fair value of stock options using the following assumptions:</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="width:4%;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Volatility - Stock price volatility is estimated over the expected term based on a blended rate of industry peers and the Company&#8217;s actual stock volatility adjusted for periods in which significant financial variability was identified.</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Expected term - The expected term is based on a simplified method which defines the life as the weighted average of the contractual term of the options and the vesting period for each award.</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px">Risk-free rate - The risk-free interest rate for the expected term of the option is based on the average market rate on U.S. Treasury securities in effect during the period in which the awards were granted.</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Dividends - The dividend yield assumption is based on the Company&#8217;s history and expectation of paying no dividends in the foreseeable future.</td></tr></table>&#160;&#160; <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-10</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc2">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong><em>Comprehensive Income (Loss)</em></strong></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. ASC 220 <em>Comprehensive Income</em> requires that an entity records all components of comprehensive income (loss), net of their related tax effects, in its financial statements in the period in which they are recognized. For the years ended December 31, 2019 and 2018, the comprehensive income (loss) was equal to net income (loss).</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong><em>Net Income (Loss) Per Share of Common Stock</em></strong></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px 0px 0px 0.35pt; text-align:justify;">The Company applies FASB ASC No. 260, <em>Earnings per Share</em> in calculating its basic and diluted net income (loss) per share. Basic net income (loss) per share of common stock is computed by dividing net income (loss) available to common stockholders by the weighted-average number of shares of common stock outstanding for the period. The diluted net loss per share of common stock is computed by giving effect to all potential common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, options to purchase common stock, restricted stock subject to vesting, warrants to purchase common stock and common shares underlying convertible debt instruments were considered to be common stock equivalents. In periods with a reported net loss, such common stock equivalents are excluded from the calculation of diluted net loss per share of common stock if their effect is anti-dilutive. For additional information regarding the net income (loss) per share, see Note 7 &#8220;Net Income (Loss) per Share of Common Stock.&#8221; </p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong><em>Recent Accounting Pronouncements</em></strong></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px">In December 2019, the FASB issued ASU No. 2019-12 <em>Income Taxes </em>(Topic 740) Simplifying the Accounting for Income Taxes. The Board issued this Update as part of its Simplification Initiative to improve areas of GAAP and reduce cost and complexity while maintaining usefulness. The main provisions remove certain exceptions, including the exception to the general methodology for calculating income taxes in an interim period when a year-to-date loss exceeds the anticipated loss for the year. In addition, the amendments simplify income tax accounting in the areas such as income-based franchise taxes, eliminating the requirements to allocate consolidated current and deferred tax expense in certain instances and a requirement that an entity reflects the effect of enacted changes in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date. For public companies, the standard is effective for fiscal years beginning after December 15, 2019, and interim periods therein. The Company plans to adopt this ASU on the effective date of January 1, 2020. The amendments in the update related to foreign subsidiaries will be applied on a modified retrospective basis, the amendments to franchise taxes will be applied on either a retrospective or modified retrospective basis and all other amendments will be applied on a prospective basis. The Company is still evaluating the impact from adopting this standard. However, because the Company&#8217;s deferred tax assets and liabilities are fully reserved, it does not expect a material impact from the adoption of this standard.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px">In November 2018, the FASB issued ASU No. 2018-08 <em>Collaborative Arrangements</em> (Topic 808) intended to improve financial reporting around collaborative arrangements and align the current guidance under ASC 808 with ASC 606 <em>Revenue from Contracts with Customers</em>. The ASU affects all companies that enter into collaborative arrangements. The ASU clarifies when certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606 and changes certain presentation requirements for transactions with collaborative arrangement participants that are not directly related to sales to third parties. For public companies, the standard is effective for fiscal years beginning after December 15, 2019, and interim periods therein. Earlier adoption is permitted for any annual or interim period for which consolidated financial statements have not yet been issued. The Company has not entered into any collaborative arrangements and therefore does not currently expect the adoption of this standard to have a material effect on its Consolidated Financial Statements. The Company plans to adopt this ASU on the effective date of January 1, 2020. Upon adoption, the Company will utilize the retrospective transition approach, as prescribed within this ASU.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong><em>Recently Adopted Accounting Standards </em></strong></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px">In July 2017, the FASB issued ASU 2017-11,<em> Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception</em> (&#8220;ASU 2017-11&#8221;). Part I of this update addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of the pricing of future equity offerings. Current accounting guidance creates cost and complexity for entities that issue financial instruments (such as warrants and convertible instruments) with down round features that require fair value measurement of the entire instrument or conversion option. Part II of this update addresses the difficulty of navigating<em> Topic 480, Distinguishing Liabilities from Equity</em>, because of the existence of extensive pending content in the FASB Accounting Standards Codification. This pending content is the result of the indefinite deferral of accounting requirements about mandatorily redeemable financial instruments of certain nonpublic entities and certain mandatorily redeemable non-controlling interests. The amendments in Part II of this update do not have an accounting effect. The Company adopted this ASU on the effective date of January 1, 2019. The adoption of this standard using a retrospective cumulative-effect adjustment approach had no impact on the Company&#8217;s accumulated deficit. The outstanding warrants issued in the Emerald Financing contain a down-round provision. However, in the absence of the down-round provision, these warrants would still require liability accounting and be considered derivatives (See Note 3). As such, the adoption of ASU 2017-11 on January 1, 2019, did not have an impact on the Company&#8217;s Consolidated Financial Statements and Notes thereto.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-11</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc2">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px">In February 2016, the FASB issued ASU No. 2016-02 <em>Leases</em> (Topic 842). In January, July and December 2018, and in March 2019, the FASB issued additional amendments to the new lease guidance relating to transition and clarification. This ASU requires most lessees to recognize right-of-use assets and lease liabilities and recognize expenses in a manner similar to current accounting standards. For public companies, the standard is effective for fiscal years beginning after December 15, 2018 and interim periods therein. The Company adopted this ASU on the effective date of January 1, 2019. Pursuant to ASU 2018-11, issued in July 2018, the Company elected to use the effective date as of the date of application for transition. Upon adoption, there was no cumulative effect recorded to the accumulated deficit, as the Company has no lease terms in excess of one year. The Company has elected the short-term lease practical expedient under the ASU, which resulted in no change to the current recognition accounting under ASC 840.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong>3. Warrants and Derivative Liabilities</strong></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong><em>Warrants</em></strong></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px 0px 0px 0.35pt; text-align:justify;">There are significant judgments and estimates inherent in the determination of the fair value of the Company&#8217;s warrants. These judgments and estimates include assumptions regarding the Company&#8217;s future operating performance, the time to completing a liquidity event and the determination of the appropriate valuation methods. If the Company had made different assumptions, the fair value of the warrants could have been significantly different (See Note 2).</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">Warrants vested and outstanding as of December 31, 2019 are summarized as follows:</p> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"> <p style="MARGIN: 0px; text-align:center;"><strong><strong>Number of</strong></strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Warrants</strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"> <p style="MARGIN: 0px; text-align:center;"><strong>Exercise</strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"> <p style="MARGIN: 0px; text-align:center;"><strong>Term</strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"> <p style="MARGIN: 0px; text-align:center;"><strong>Vested and</strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Source</strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Price</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>(Years)</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Outstanding</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Pre 2015 Common Stock Warrants</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.00</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td colspan="2"> <p style="MARGIN: 0px; text-align:right;">6-10</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,000,000</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">2015 Common Stock Warrants</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td>$</td> <td> <p style="MARGIN: 0px; text-align:right;">1.15-5.00</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td colspan="2"> <p style="MARGIN: 0px; text-align:right;">5-10</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">442,000</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Common Stock Warrants to Series B Stockholders</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,031,250</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">2016 Common Stock Warrants to Service Providers</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.15</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">40,000</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">2016 Series C Common Stock Warrants to Placement Agent </p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.40</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">125,000</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">2017 Series D Common Stock Warrants to Placement Agent </p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.25</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">480,000</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">2017 Common Stock Warrants to Service Provider</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.41</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">125,000</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">2018 Emerald Financing Warrants </p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.10</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,400,000</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px">Emerald Multi-Draw Credit Agreement Warrants</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.50</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,500,000</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">2019 Common Stock Warrants</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">0.35</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">5</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">8,000,000</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Total warrants vested and outstanding as of December 31, 2019</strong></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>25,143,250</strong></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr></table> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><em>2019 Common Stock Warrants</em></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">During the year ended December 31, 2019, the Company issued 8,000,000 fully vested common stock warrants to investors, in conjunction with the November 2019 Common Stock Offering discussed below (See Note 5). The warrants are equity classified at issuance and the Company allocated an aggregate of $722,208 of the gross proceeds to the warrants on a relative fair value basis. The warrants vested immediately and had an estimated aggregate fair value of $1,130,400 utilizing the Black-Scholes option pricing model with the following assumptions: </p> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>At Issuance</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Dividend yield</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px; text-align:left;">%</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Volatility factor</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">93.08</td> <td style="width:1%;vertical-align:bottom;">%</td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Risk-free interest rate</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.62</td> <td style="width:1%;vertical-align:bottom;">%</td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Expected term (years)</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.0</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Underlying common stock price</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.22</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr></table> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-12</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc2">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><em>Emerald Multi-Draw Credit Agreement Warrants </em></p> <p style="MARGIN: 0px">&#160;&#160;</p> <p style="MARGIN: 0px; text-align:justify;">During the year ended December 31, 2019, the Company issued 5,000,000 fully vested common stock warrants to Emerald Health Sciences, in conjunction with advances under the Credit Agreement discussed below (See Note 4). The warrants are equity classified at issuance and the Company allocated an aggregate of $716,110 of the gross proceeds to the warrants on a relative fair value basis. The proceeds allocated to the warrants were recorded as discounts to each advance and are being amortized over the term of the debt. The warrants vested immediately and had an estimated aggregate fair value of $1,830,573 utilizing the Black-Scholes option pricing model with the following assumptions: </p> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>At Issuance</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Dividend yield</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td> <td style="width:1%;vertical-align:bottom;">%</td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Volatility factor</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td></td> <td> <p style="MARGIN: 0px; text-align:right;">91.6-92.1</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">%</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Risk-free interest rate</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td></td> <td> <p style="MARGIN: 0px; text-align:right;">2.23-2.51</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">%</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Expected term (years)</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.0</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Underlying common stock price</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td>$</td> <td> <p style="MARGIN: 0px; text-align:right;">0.33-0.69</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr></table> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">On November 1, 2018, the Company issued 2,500,000 fully vested common stock warrants to Emerald Health Sciences, in conjunction with the first advance on the Credit Agreement discussed below (See Note 4). The warrants are equity classified at issuance and the Company allocated $315,080 of the gross proceeds to the warrants on a relative fair value basis. The proceeds allocated to the warrants was recorded as a discount to the November 1, 2018 advance and are being amortized over the term of the debt. The warrants vested immediately and had an estimated fair value of $593,629 utilizing the Black-Scholes option pricing model with the following assumptions:</p> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>At Issuance</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Dividend yield</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">%</td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Volatility factor</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">92.5</td> <td style="width:1%;vertical-align:bottom;">%</td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Risk-free interest rate</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.96</td> <td style="width:1%;vertical-align:bottom;">%</td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Expected term (years)</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.0</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Underlying common stock price</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.36</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr></table> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><em>2018 Emerald Financing Warrants </em></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">In January and February 2018, the Company issued an aggregate of 40,800,000 and 3,400,000 fully vested common stock warrants to Emerald Health Sciences and an accredited investor, respectively, in conjunction with the Emerald Financing discussed below (See Note 5). The Company reviewed the warrants for liability or equity classification under the guidance of ASC 480-10, <em>Distinguishing Liabilities from Equity</em>, and concluded that these warrants should be classified as liabilities. See the additional discussion below, <em>Derivative Liabilities- Emerald Financing Warrant Liability</em>. On December 20, 2019, Emerald Health Sciences paid the aggregate exercise price of $4,080,000 in the form of a reduction of the corresponding amount of obligations outstanding under the Credit Agreement to exercise 40,800,000 Emerald Financing Warrants. </p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong><em>Derivative Liabilities</em></strong></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">The following tables summarize the activity of derivative liabilities for the periods indicated: </p> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="18"> <p style="MARGIN: 0px; text-align:center;"><strong>Year Ended December 31, 2019</strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>December 31, 2018, Fair</strong> <strong>Value of</strong> <strong>Derivative Liabilities</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Fair Value of Derivative Liabilities Issued</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Change in</strong> </p> <p style="MARGIN: 0px; text-align:center;"><strong>Fair value of </strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Liabilities</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Reclassification</strong> <strong>of Derivatives</strong> <strong>to Equity or Extinguishment</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>December 31, 2019, Fair</strong> <strong>Value of</strong> <strong>Derivative Liabilities</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px">Emerald Multi-Draw Credit Agreement - compound derivative liability <sup>(1)</sup></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">219,453</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">516,058</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(484,147</td> <td style="width:1%;vertical-align:bottom;">)</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(160,567)</td> <td style="width:1%;vertical-align:bottom;">*</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">90,797</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:left;">Emerald Financing - warrant liability <sup>(2)</sup></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,251,413</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(9,042,066</td> <td style="width:1%;vertical-align:bottom;">)</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(5,933,323</td> <td style="width:1%;vertical-align:bottom;">)</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">276,024</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Series B - warrant liability <sup>(3)</sup></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">487,500</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(208,546</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(144,375</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">134,579</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Total derivative liabilities</strong></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>15,958,366</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>516,058</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>(9,734,759</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"><strong>)</strong></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>(6,238,265</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"><strong>)</strong></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>501,400</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Less, noncurrent portion of derivative liabilities</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(219,453</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(90,797</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:left;"><strong>Current balance of derivative liabilities</strong></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>15,738,913</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>410,603</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr></table> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><em>*This amount has been included in the calculation of the extinguishment loss recorded in connection with the prepayment of the Emerald Credit Agreement as described in Note 4 below.</em></p> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-13</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc2">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160;&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="18"> <p style="MARGIN: 0px; text-align:center;"><strong>Year Ended December 31, 2018</strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>December 31, 2017, Fair Value of Derivative Liabilities</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Fair Value of Derivative Liabilities Issued</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Change in </strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Fair value of Derivative Liabilities**</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Reclassification</strong> <strong>of Derivatives</strong> <strong>to Equity</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>December 31, 2018, Fair Value of</strong> <strong>Derivative Liabilities</strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px">Emerald Multi-Draw Credit Agreement - compound derivative liability <sup>(1)</sup></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">204,102</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,351</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">219,453</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Emerald Financing - warrant liability <sup>(2)</sup></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,424,634</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,826,779</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,251,413</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Series B - warrant liability <sup>(3)</sup></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">551,322</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,476,044</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,539,866</td> <td style="width:1%;vertical-align:bottom;">)</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">487,500</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Emerald Convertible Promissory Note - conversion liability <sup>(4)</sup></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">265,000</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">360,000</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">185,000</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(810,000</td> <td style="width:1%;vertical-align:bottom;">)</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Series B Preferred Stock - conversion liability <sup>(5)</sup></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">6,715</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(6,715</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Total derivative liabilities</strong></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>823,037</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>10,988,736</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>6,503,174</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>(2,356,581</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"><strong>)</strong></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>15,958,366</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Less, noncurrent portion of derivative liabilities</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(551,322</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(219,453</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Current balance of derivative liabilities</strong></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>271,715</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>15,738,913</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr></table> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px"><em>**The change in fair value of derivative liabilities for the year ended December 31, 2018, relate partially to the Company determining it had sufficient trading activity to utilize the actual volatility of the trading of the Company&#8217;s common stock as an input to the volatility assumption when computing the fair value of derivative liabilities. The volatility assumption was updated as of October 1, 2018 to incorporate the Company&#8217;s own volatility with six similar companies to develop a blended average. The Company had previously estimated the volatility assumption by averaging the volatility of six similar entities which had resulted in a lower volatility. The increase in value of the volatility assumption has led to a higher valuation of the derivative liabilities as disclosed below.</em></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><em><em>Emerald Multi-Draw Credit Agreement Compound Derivative Liability (1)</em></em> </p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">In connection with the advances under the Credit Agreement (See Note 4), the Company bifurcated a compound derivative liability related to a contingent interest feature and acceleration upon default provision (contingent put option) provided to Emerald Health Sciences. The Company&#8217;s estimate of fair value of the compound derivative liability was determined by using a differential cash flows valuation model, wherein the fair value of the underlying debt facility and its conversion right are estimated both with and without the presence of the contingent interest feature, holding all other assumptions constant. The resulting difference between the estimated fair values in both scenarios is the estimated fair value of the compound derivative. The fair value of the underlying debt facility is estimated by calculating the expected cash flows with consideration of the estimated probability of a change in control transaction, defined as an event of default by the agreement, and applying the expected default interest rate from the date of such default through maturity. The expected cash flows are then discounted back to the reporting date using a benchmark market yield. The conversion right component of the compound derivative is measured using a standard Black-Scholes model for each payment period. Because Emerald Health Sciences would forgo the contingent interest if the contingent put option was exercised upon an event of default, the value ascribed to the contingent put option within the compound derivative is de minimis. </p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><em>Emerald Financing Warrant Liability (2)</em></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">In January and February 2018, the Company issued 44,200,000 warrants to purchase common stock in conjunction with the Emerald Financing discussed above. The warrants vest immediately and have an exercise price of $0.10 per share with a term of five years and are exercisable in cash or through a cashless exercise provision. The warrants contain an anti-dilution protection feature provided to the investors if the Company subsequently issues or sells any shares of common stock, stock options, or convertible securities at a price less than the exercise price of $0.10. The exercise price is automatically adjusted down to the price of the instrument being issued. In addition, the warrants contain a contingent put option if the Company undergoes a subsequent financing that results in a change in control. The warrant holders also have the right to participate in subsequent financing transactions on an as-if converted basis. </p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px 0px 0px 0.35pt; text-align:justify;">In December 2019, Emerald Health Sciences paid the aggregate exercise price of $4,080,000 in the form of a reduction of the corresponding amount of obligations outstanding under the Credit Agreement to exercise 40,800,000 Emerald Financing Warrants. Under the Warrant Exercise Agreement between the Company and Emerald Health Sciences, the proceeds from the warrants were first applied directly to the accrued interest balance at the exercise date with the remainder applied to the oldest outstanding principal balances under the Credit Agreement. Immediately prior to exercise, the warrants were adjusted to fair value which considered the closing trading price on the exercise date (See Note 4).</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr"></td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-14</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc2">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">The Company reviewed the warrants for liability or equity classification under the guidance of ASC 480-10, <em>Distinguishing Liabilities from Equity</em>, and concluded that the warrants should be classified as a liability and re-measured to fair value at the end of each reporting period. The Company also reviewed the warrants under ASC 815, <em>Derivatives and Hedging/Contracts in Entity&#8217;s Own Equity</em>, and determined that the warrants also meet the definition of a derivative. With the assistance of a third-party valuation specialist, the Company valued the warrant liabilities utilizing the Monte Carlo valuation method pursuant to the accounting guidance of ASC 820-10, <em>Fair Value Measurement</em>s. On the closing dates, the Company estimated that the fair value of the warrants issued on January 19, 2018 and February 16, 2018 was $4,717,211 and $5,707,423, respectively. </p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">The warrant liabilities were valued using Monte Carlo simulations conducted at the closing dates of January 19, 2018 and February 16, 2018 and at the balance sheet dates using the following assumptions:</p> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>December 31, </strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>2019</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>December 31, </strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>2018</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>At</strong> <strong>Issuance</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Dividend yield</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td> <td style="width:1%;vertical-align:bottom;">%</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td> <td style="width:1%;vertical-align:bottom;">%</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td> <td style="width:1%;vertical-align:bottom;">%</td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Volatility factor</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">79.5</td> <td style="width:1%;vertical-align:bottom;">%</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td></td> <td> <p style="MARGIN: 0px; text-align:right;">92.1-92.4</p></td> <td>%</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">70.0</td> <td style="width:1%;vertical-align:bottom;">%</td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Risk-free interest rate</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.62</td> <td style="width:1%;vertical-align:bottom;">%</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.49</td> <td style="width:1%;vertical-align:bottom;">%</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td></td> <td> <p style="MARGIN: 0px; text-align:right;">2.45-2.60</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">%</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Expected term (years)</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.13</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td></td> <td> <p style="MARGIN: 0px; text-align:right;">4.05-4.13</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.0</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Underlying common stock price</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.13</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.40</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td>$</td> <td> <p style="MARGIN: 0px; text-align:right;">0.29-0.30</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr></table> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">Because fair value assigned to the warrants exceeded the proceeds received in the Emerald Financing, none of the consideration was allocated to common stock and the Company recorded an adjustment for the difference between the fair value of the warrant liabilities and the total proceeds received to other expense in the Consolidated Statements Comprehensive Income (Loss) for the year ended December 31, 2018 as follows: </p> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"> <p style="MARGIN: 0px; text-align:center;"><strong>Closing</strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>January </strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>2018</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>February</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>2018</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Total</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px">Initial fair value of Emerald Financing Warrant Liability</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,717,211</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,707,423</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,424,634</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px">Less: proceeds from the Emerald Financing</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,500,000</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,750,000</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,250,000</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Excess over proceeds adjustment</strong></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;"></td> <td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>3,217,211</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>3,957,423</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>7,174,634</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr></table> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">In addition, because the aggregate proceeds were allocated to the fair value of the Emerald Financing warrant liability, issuance costs totaling $137,192 were charged to other expense during the year ended December 31, 2018. </p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><em>Series B Warrant Liability (3)</em></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">In conjunction with the Redeemable Convertible Series B Preferred Stock financing, the Company issued the 2015 Series B Financing Warrants originally exercisable at a price of $1.15 per share. The warrants are exercisable in cash or through a cashless exercise provision and contain certain cash redemption rights. The Series B warrants also had a &#8220;down-round&#8221; protection feature if the Company subsequently issued or sold any shares of common stock, stock options, or convertible securities at a price less than the current exercise price. The down round provision was triggered and automatically adjusted down to $0.10 on December 28, 2017, after the Company entered into the Convertible Promissory Note (See Note 4) and again to $0.00 on January 19, 2018, as a result of the Emerald Financing (See Note 5). The strike price for these warrants is now permanently reset. However, because the remaining warrant holders still have certain cash redemption rights upon the occurrence of certain fundamental transactions, as defined in the Series B warrant agreements, the warrants continue to require liability classification. Subsequent to the repricing that occurred as a result of the Emerald Financing, the warrants have been valued using a Black Scholes Merton Option Pricing Model. </p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">To compute the fair value of the warrants, the Company utilized the following assumptions in the Black Scholes Merton Option Pricing Model for the periods indicated:</p> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"> <p style="MARGIN: 0px; text-align:center;"><strong>As of </strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>December 31,</strong> </p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2019</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2018</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Dividend yield</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td> <td style="width:1%;vertical-align:bottom;">%</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td> <td style="width:1%;vertical-align:bottom;">%</td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Volatility factor</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">79.2</td> <td style="width:1%;vertical-align:bottom;">%</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">93.0</td> <td style="width:1%;vertical-align:bottom;">%</td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Risk-free interest rate</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.60</td> <td style="width:1%;vertical-align:bottom;">%</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.79</td> <td style="width:1%;vertical-align:bottom;">%</td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Expected term (years)</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.64</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td></td> <td> <p style="MARGIN: 0px; text-align:right;">1.64-1.65</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Underlying common stock price</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.13</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.40</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr></table> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">In January 2018, 987,000 Series B warrants were exercised at a price of $0.10 resulting in cash proceeds to the Company of $98,700. Prior to exercise, these Series B Warrants were adjusted to fair value using a Black Scholes Merton Option Pricing Model which considered the closing trading price on the exercise dates. For the year ended December 31, 2019 and for the period from January 19, 2018 through December 31, 2018, 187,500 and 4,231,750 Series B warrants were exercised for no consideration. Prior to exercise, these Series B Warrants were adjusted to fair value using a Black Scholes Merton Option Pricing Model which considered the closing trading price on the exercise dates. Because the exercise price of these options had been reset to $0.00, the fair value derived from the valuation model approximated the market value of the Company&#8217;s common stock on the exercise dates.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><em>Emerald Convertible Promissory Note Conversion Liability (4)</em></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">In connection with the Convertible Promissory Note (See Note 4), the Company bifurcated a conversion liability related to an embedded conversion feature with a down-round protection provision. The Company valued the conversion liability pursuant to the accounting guidance of ASC 820-10, <em>Fair Value Measurement</em>s, as of the financing date of each closing utilizing the Black Scholes valuation model and the following assumptions: </p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-15</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc2">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>January 19,</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>2018</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Dividend yield</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">%</td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Volatility factor</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">70.0</td> <td style="width:1%;vertical-align:bottom;">%</td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Risk-free interest rate</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.29</td> <td style="width:1%;vertical-align:bottom;">%</td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Expected term (years)</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.003</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Underlying common stock price</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.19</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr></table> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">The fair value of the conversion liability on January 19, 2018 was $360,000. In connection with the Emerald Financing discussed in Note 5 below, the Convertible Promissory Note was converted, and the conversion liability was extinguished with the debt. </p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><em>Series B Preferred Stock Conversion Liability (5)</em></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px 0px 0px 0.35pt; text-align:justify;">On August 20, 2015, in connection with the Redeemable Convertible Series B Preferred Stock financing, the Company bifurcated a conversion liability related to the down-round protection provided to the Series B investors. The value of this embedded derivative was determined utilizing a &#8220;with and without&#8221; method by valuing the Series B Preferred Stock with and without the down-round protection. During the first fiscal quarter of 2018, all the remaining Series B Preferred Stock was converted to common stock and as a result, the Series B conversion liability was reduced to zero. The reduction of this liability totaling $6,715 was recorded to equity during the year ended December 31, 2018. </p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong>4. Convertible Debt - Related Party</strong></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">The Company&#8217;s Convertible Debt with Emerald Health Sciences consists of the following: </p> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"> <p style="MARGIN: 0px; text-align:center;"><strong>As of December 31, </strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2019</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2018</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Total principal value</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,014,500</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,000,000</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Unamortized debt discount</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,622,344</td> <td style="width:1%;vertical-align:bottom;">)</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(587,617</td> <td style="width:1%;vertical-align:bottom;">)</td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Unamortized debt issuance costs</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(5,086</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(51,423</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Carrying value of total convertible debt - related party</strong></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>387,070</strong></td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>1,360,960</strong></td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Less, noncurrent portion</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(387,070</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,360,960</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Current convertible debt - related party</strong></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>-</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>-</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr></table> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">The Company&#8217;s interest expense consists of the following:</p> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"> <p style="MARGIN: 0px"><strong>Year Ended</strong></p> <p style="MARGIN: 0px"><strong><strong>December 31,</strong></strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2019</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2018</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Interest expense - stated rate</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">371,420</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">26,433</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Non-cash interest expense:</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Amortization of debt discount</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">616,383</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">56,253</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Amortization of transaction costs</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12,910</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,283</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Other interest expense</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">9,794</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>1,000,713</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>94,763</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr></table> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><em>Multi-Draw Credit Agreement</em></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px 0px 0px 0.35pt; text-align:justify;">On October 5, 2018, the Company entered into the Credit Agreement with Emerald Health Sciences, a related party (See Note 11). The Credit Agreement provides for a credit facility to the Company of up to $20,000,000 and is unsecured. Advances under the Credit Agreement bear interest at an annual rate of 7% (payable quarterly in arrears) and mature on October 5, 2022. At Emerald Health Sciences&#8217; election, advances and unpaid interest may be converted into common stock at a fixed conversion price of $0.40, subject to customary adjustments for stock splits, stock dividends, recapitalizations, etc. As of December 31, 2019, the unused portion of the credit facility is $14,000,000. The drawdowns are subject to approval by the Company&#8217;s Board, which is controlled by the directors of Emerald Health Sciences. As such, we do not consider the facility available until advance requests are approved, drawn down and funded. The Credit Agreement is still in place, however, there is no guarantee of continued funding.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">The Credit Agreement provides for customary events of default which may result in the acceleration of the maturity of the advances in addition to, but not limited to, cross acceleration to certain other indebtedness of the Company or a change in control. In the case of an event of default arising from specified events of bankruptcy or insolvency or reorganization, all outstanding advances will become due and payable immediately without further action or notice. If any other event of default under the Credit Agreement occurs or is continuing, Emerald Health Sciences may, by written notice, terminate its commitment to make any advances and/or declare all the advances with any other amounts payable due immediately. If any amount under the Credit Agreement is not paid when due, such overdue amount shall bear interest at an annual default interest rate of the applicable rate plus 10%, until such amount is paid in full. </p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">In connection with each advance under the Credit Agreement, the Company agreed to issue to Emerald Health Sciences warrants to purchase shares of common stock in an amount equal to 50% of the number of shares of common stock that each advance may be converted into. The warrants have an exercise price of $0.50 per share, a term of five years and are immediately exercisable upon issuance. The exercise price is subject to adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events or upon any distributions of assets, including cash, stock or other property to the Company&#8217;s stockholders (See Note 3).</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-16</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc2">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">In accounting for each convertible advance and the warrants issued under the Credit Agreement, the Company allocates the proceeds between the debt host and the freestanding warrants on a relative fair value basis for each advance. On the date of each advance, if the effective conversion rate of the debt is less than the market value of the Company&#8217;s common stock, the Company records a beneficial conversion feature as a discount to the debt and an increase to additional paid-in capital. The debt discounts related to the warrants, beneficial conversion features and compound derivatives, if any, are being amortized over the term of the Credit Agreement using the effective interest rate method. Amortization of the debt discount is recognized as non-cash interest expense and the compound derivatives related to the contingent interest feature and acceleration upon default provision are remeasured at fair value in subsequent periods in the Company&#8217;s Consolidated Balance Sheets.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px">On November 1, 2018, the initial advance under Credit Agreement was made for $2,000,000 and the Company issued 2,500,000 warrants (See Note 3). In accounting for the convertible advances and warrants under the Credit Agreement, $1,684,920 of the proceeds was allocated to the debt and $315,080 was allocated to equity classified warrants. A beneficial conversion feature of $90,080 and a compound derivative liability of $204,102 were also recorded.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px 0px 0px 0.35pt; text-align:justify;">During the year ended December 31, 2019, the Company initiated two advances under Credit Agreement, each in the amount of $2,000,000, for an aggregate principal amount of $4,000,000, and the Company issued an aggregate of 5,000,000 warrants to Emerald Health Sciences (See Note 3). In accounting for the convertible advances and warrants issued under the Credit Agreement, an aggregate amount of $3,283,890 was allocated to the debt and $716,110 was allocated to equity classified warrants. A beneficial conversion feature of $1,584,850 and compound derivative liabilities of an aggregate of $516,058 have been recorded (See Note 3). Of the $516,058 in compound derivatives, $322,644 was recorded as other expense in the Consolidated Statements of Comprehensive Income (Loss) for the year ended December 31, 2019, as the value of the beneficial conversion feature exceeded the proceeds allocated to the third draw.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">Aggregate financing costs of $63,007 incurred in connection with the Credit Agreement have been recorded as a discount to the debt host and are being amortized using the effective interest rate method and recognized as non-cash interest expense over the term of the Credit Agreement. </p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px 0px 0px 0.35pt; text-align:justify;">During the year ended December 31, 2019, the Company used $3,985,500 in proceeds from the exercise of the 2018 Emerald Financing Warrants (Note 3) to prepay a portion of the principal balance on the Credit Agreement. In connection with the prepayment, the Company recorded an extinguishment loss of $725,425. The extinguishment loss was calculated as the difference between the fair value of the consideration paid to extinguish the debt and carrying value of the debt host plus the related compound derivative liability.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">For the years ended December 31, 2019 and 2018, the effective interest rate related to the Credit Agreement was 32.05% and 10.57%, respectively. As of December 31, 2019, the unamortized debt discount will be amortized over a remaining period of 2.76 years. The fair value of the underlying shares of the Credit Agreement was $657,231 at December 31, 2019. As of December 31, 2019, the if-converted value did not exceed the principal balance. </p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><em>Secured Convertible Promissory Note</em></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px 0px 0px 0.35pt; text-align:justify;">On December 28, 2017, the Company entered into a convertible Secured Promissory Note and Security Agreement with Emerald Health Sciences (the &#8220;Convertible Promissory Note&#8221;). The Convertible Promissory Note provided for aggregate gross proceeds to the Company of up to $900,000 and was secured by all the Company&#8217;s assets. Drawdowns on the Convertible Promissory Note were interest-bearing at an annual rate of 12% (compounding semi-annually), payable at maturity. The Convertible Promissory Note matured upon the earlier of June 30, 2018 or upon a default event, as defined, and elected by Emerald Health Sciences. At Emerald Health Sciences&#8217; election, drawdowns and unpaid interest were convertible into common stock at a conversion price of $0.10, subject to a full-ratchet antidilution right. The Convertible Promissory Note was automatically converted upon the occurrence of the private placement transaction with Emerald Health Sciences (the Emerald Financing) in January 2018. </p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">The Company received proceeds of $500,000 on December 28, 2017, and on January 19, 2018 the Company received the remaining $400,000 in funding as it had satisfied the conditions required. These conditions required receipt of conversion notices from all the existing Series B stockholders to convert their preferred shares to common stock. Such conversions occurred in January and February of 2018. On each financing date, the Company bifurcated a conversion liability from the Convertible Promissory Note related to the embedded conversion feature with a down-round protection provision (See Note 3). This resulted in a conversion liability of $265,000 at the first financing date which was one trading day prior to December 31, 2017. The second funding in January 2018 resulted in an additional conversion liability of $360,000. The conversion liabilities were recorded as a discount to the debt at each draw down date and were being amortized to interest expense. </p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px">On January 19, 2018, in conjunction with the Emerald Financing (See Note 5), the Convertible Promissory Note was automatically converted into common stock at a conversion price of $0.10 per share for 9,000,000 shares of common stock. Upon conversion, the debt and associated conversion liability were extinguished, resulting in a loss on extinguishment of $590,392 which was recorded to other expense for the year ended December 31, 2018. For the year ended December 31, 2018, the effective interest rate related to the Convertible Promissory Note was 13.94%.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong>5. Stockholders&#8217; Equity (Deficit) and Capitalization</strong></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong><em>Common Stock</em></strong></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">On November 14, 2018, the Company amended its articles of incorporation to increase the number of authorized shares of common stock available for issuance to 500,000,000.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-17</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc2">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><em>November 2019 Common Stock Offering</em></p> <p style="MARGIN: 0px; text-align:justify;"><em>&#160;&#160; </em></p> <p style="MARGIN: 0px; text-align:justify;">In November 2019, the Company sold in a registered direct offering an aggregate of 8,000,000 shares of its common stock, par value $0.001 per share, and warrants to purchase 8,000,000 shares of common stock (Note 3). The aggregate net proceeds of the transaction were $1,919,372.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><em>Warrant Exercises</em></p> <p style="MARGIN: 0px; text-align:justify;"><em>&#160;&#160; </em></p> <p style="MARGIN: 0px 0px 0px 0.35pt; text-align:justify;">During the year ended December 31, 2019, Emerald Health Sciences exercised 40,800,000 2018 Emerald Financing Warrants with an intrinsic value of $4,284,000, which resulted in the issuance of 40,800,000 shares of common stock.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px 0px 0px 0.35pt; text-align:justify;">During the year ended December 31, 2018, the Series B warrant holders exercised warrants with an intrinsic value of $144,375, which resulted in the issuance of 187,500 shares of common stock.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><em>Emerald Financing</em></p> <p style="MARGIN: 0px; text-align:justify;"><em>&#160;&#160; </em></p> <p style="MARGIN: 0px; text-align:justify;">On January 19, 2018, the Company entered into a Securities Purchase Agreement pursuant to which the Company sold to Emerald Health Sciences 15,000,000 shares of common stock and a warrant to purchase 20,400,000 shares of common stock at an exercise price of $0.10 for aggregate gross proceeds of $1,500,000 (the &#8220;Emerald Financing&#8221;). This transaction also resulted in the conversion of the $900,000 Convertible Promissory Note (Note 4). As part of the transaction, the Company&#8217;s Board members, with the exception of Dr. Brian Murphy, the Company&#8217;s CEO/CMO, tendered their resignation and Emerald Health Sciences appointed two new nominees to the Board. The Securities Purchase Agreement also provides that in the case of a subsequent financing in which the purchase price is less than $0.10 per share, Emerald Health Sciences shall be issued additional shares in order to protect against anti-dilution.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px">The second closing under the Emerald Financing occurred on February 16, 2018, pursuant to which the Company issued and sold to Emerald Health Sciences 15,000,000 shares of the Company&#8217;s common stock, and a warrant to purchase 20,400,000 shares of common stock at an exercise price of $0.10 per share for a term of five years. In addition, an accredited investor purchased 2,500,000 shares of common stock and a warrant to purchase 3,400,000 shares of common stock at an exercise price of $0.10 per share for a term of five years. The Company received aggregate gross proceeds of $1,750,000 from the second closing. In connection with the private placement, the Company incurred issuance costs of $154,092, of which $137,192 was allocated to the warrant liability and expensed during the period and $16,900 was recorded as a reduction to additional paid-in capital from the issuance of common stock.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><em>Conversion of Preferred Stock</em></p> <p style="MARGIN: 0px; text-align:justify;"><em>&#160;&#160; </em></p> <p style="MARGIN: 0px 0px 0px 0.35pt; text-align:justify;">During the year ended December 31, 2018, all remaining Preferred Series B, D, and F shares were converted to common stock as follows:</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="width:4%;"> <p style="MARGIN: 0px; text-align:justify;">&#160;</p></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><font style="font-family:symbol;display:inline">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px">For the year ended December 31, 2018, 2,833.55 shares of Series B Preferred stock were converted, resulting in the issuance of 28,385,000 shares of common stock.</p></td></tr> <tr> <td></td> <td></td> <td></td></tr> <tr> <td> <p style="MARGIN: 0px; text-align:justify;">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><font style="font-family:symbol;display:inline">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px">For the year ended December 31, 2018, 200 shares of Series D Preferred stock were converted, resulting in the issuance of 2,000,000 shares of common stock.</p></td></tr> <tr> <td></td> <td></td> <td></td></tr> <tr> <td> <p style="MARGIN: 0px; text-align:justify;">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><font style="font-family:symbol;display:inline">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px">For the year ended December 31, 2018, 2,000 shares of Series F Preferred stock were converted, resulting in the issuance of 20,000,000 shares of common stock.</p></td></tr></table> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong><em>Preferred Stock</em></strong></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">The Company has 20,000,000 authorized shares of preferred stock, with a par value of $0.001 per share. As of December 31, 2019, there were no shares of preferred stock issued and outstanding. </p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">During the year ended December 31, 2018, all remaining Preferred Series B, D, and F shares that were previously issued and outstanding were converted to common stock.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong>6. Stock-Based Compensation </strong></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong><em>Stock Incentive Plan</em></strong></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px">On October 31, 2014, after the closing of the Merger, the Board approved the Company&#8217;s 2014 Omnibus Incentive Plan (the &#8220;2014 Plan&#8221;). The 2014 Plan initially reserved 3,200,000 shares for future grants. In October 2018, the Company increased the share reserve under the 2014 Plan to equal 10% of the number of issued and outstanding shares of common stock of the Company. The 2014 Plan authorizes the issuance of awards including stock options, stock appreciation rights, restricted stock, stock units and performance units to employees, directors, and consultants of the Company. As of December 31, 2019, the shares available for future grant under the 2014 Plan are as follows:</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"> <tr> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Shares Available for Grant</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Available as of December 31, 2018</strong></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>9,142,273</strong></td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Share pool increase </p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,898,750</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Forfeited</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">153,125</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Cancelled</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">196,875</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Granted </p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,262,642</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Available as of December 31, 2019</strong></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>13,128,381</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr></table> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-18</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc2">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><em>Stock Options </em></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px">Options granted under the 2014 Plan expire no later than ten years from the date of grant. Options granted under the 2014 Plan may be either incentive or non-qualified stock options. For incentive and non-qualified stock option grants, the option price shall be at least 100% of the fair value on the date of grants, as determined by the Company&#8217;s Board of Directors. If at any time the Company grants an option, and the optionee directly or by attribution owns stock possessing more than 10% of the total combined voting power of all classes of stock of the Company, the option price shall be at least 110% of the fair value and shall not be exercisable more than five years after the date of grant.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">Options granted under the 2014 Plan may be immediately exercisable if permitted in the specific grant approved by the Board of Directors and, if exercised early may be subject to repurchase provisions. The shares issued generally vest over a period of one to five years from the date of grant.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">The following is a summary of option activities under the Company&#8217;s 2014 Plan for the year ended December 31, 2019: </p> <p style="MARGIN: 0px; text-align:justify;">&#160; </p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Number of</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Shares</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Weighted</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Average</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Exercise Price</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Weighted</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Average Remaining</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Contractual</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Term (Years)</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Aggregate</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Intrinsic</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Value*</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Outstanding, December 31, 2018</strong></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>2,405,000</strong></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"><strong>$</strong></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>0.33</strong></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>8.71</strong></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Granted</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,262,642</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.30</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Cancelled</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(196,875</td> <td style="width:1%;vertical-align:bottom;">)</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.26</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Forfeited</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(153,125</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">0.26</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;" colspan="2"> <p style="MARGIN: 0px">&#160;</p></td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Outstanding, December 31, 2019</strong></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>3,317,642</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>0.33</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>8.34</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>-</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Exercisable, December 31, 2019</strong></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>2,399,356</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>0.34</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>7.84</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>-</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Vested and expected to vest, December 31, 2019</strong></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>3,317,642</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>0.33</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>8.34</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>-</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr></table> <p style="MARGIN: 0px">&#160;&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><em>*The aggregate intrinsic value is the sum of the amounts by which the quoted market price of the Company&#8217;s stock exceeded the exercise price of the stock options at December 31, 2019 for those stock options for which the quoted market price was in excess of the exercise price (&#8220;in-the-money options&#8221;). </em></p> <p style="MARGIN: 0px; text-align:justify;">&#160;&#160; </p> <p style="MARGIN: 0px">The weighted-average grant-date fair value of stock options granted for the years ended December 31, 2019 and 2018 was $0.22 and $0.30, respectively. The total fair value of the stock options that vested during the years ended December 31, 2019 and 2018 was $473,030 and $418,688, respectively.</p> <p style="MARGIN: 0px 0px 0px 0.35pt; text-align:justify;">&#160;&#160;&#160;</p> <p style="MARGIN: 0px">The fair value of each stock option grant was estimated on the date of grant using the Black-Scholes option-pricing model under the following assumptions:</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"> <p style="MARGIN: 0px; text-align:center;"><strong>Year Ended December 31,</strong> </p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2019</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2018</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Dividend yield</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td> <td style="width:1%;vertical-align:bottom;">%</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px; text-align:left;">%</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Risk-free interest rate</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.49</td> <td style="width:1%;vertical-align:bottom;">%</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td></td> <td> <p style="MARGIN: 0px; text-align:right;">3.06-3.10</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">%</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Expected term (years)</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.65</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td></td> <td> <p style="MARGIN: 0px; text-align:right;">5.27-5.58</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Volatility</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">93.72</td> <td style="width:1%;vertical-align:bottom;">%</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td></td> <td> <p style="MARGIN: 0px; text-align:right;">70.00-93.60</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">%</p></td></tr></table> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><em>Restricted Stock Awards </em></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">There was no restricted stock award (&#8220;RSA&#8221;) activity under the Company&#8217;s 2014 Plan during the year ended December 31, 2019.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">On February 28, 2018, in conjunction with the signing of the K2C separation agreement discussed in Note 11 below, Mr. Lykos&#8217; RSAs amounting to 325,000 shares vested immediately resulting in a Type III award modification and a credit to stock compensation of $98,042 for the year ended December 31, 2018 due to a lower fair value of those shares as of the modification date.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">On May 25, 2018, in conjunction with the signing of her separation agreement, the former Nemus CFO, Ms. Elizabeth Berecz&#8217;s RSA&#8217;s amounting to 350,000 shares vested immediately resulting in a Type III award modification and a credit to stock compensation of $97,183 for the year ended December 31, 2018 due to a lower fair value of those shares as of the modification date as compared to the fair value immediately prior to acceleration.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong><em>Awards Granted Outside the 2014 Plan</em></strong> </p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><em>Options</em></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">There was no option activity outside of the 2014 Plan during the year ended December 31, 2019. </p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-19</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc2">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px">On May 25, 2018, the Company entered into Stock Option Agreement with Douglas Cesario, CFO, granting 1,195,073 stock options with an exercise price equal to $0.245 and a grant date fair value of $200,772 or $0.26 per share based on the following assumptions estimated on the date of grant using the Black-Scholes option-pricing model:</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>At Issuance</strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Dividend Yield</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px; text-align:left;">%</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Risk-free interest rate</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.79</td> <td style="width:1%;vertical-align:bottom;">%</td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Expected term (in years)</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.54</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Volatility</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">70</td> <td style="width:1%;vertical-align:bottom;">%</td></tr></table> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px 0px 0px 0.35pt; text-align:justify;">The options vested 25% on July 23, 2018, and the remaining 75% will vest 1/33 on each of the next 33 months thereafter. Options will fully vest upon a triggering event, including a sale of the Company or a merger that results in a change of control. At December 31, 2019, these options have a remaining contractual life of 8.57 years. At December 31, 2019, 760,501 options are exercisable and have no intrinsic value. At December 31, 2019, 1,195,073 options are vested and are expected to vest and have no intrinsic value.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">The total fair value of stock options that vested during the years ended December 31, 2019 and 2018 were $54,756 and $73,008, respectively.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><em>Restricted Stock Awards</em></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">On January 18, 2018, the Company entered into Restricted Stock Agreements with each of Dr. Murphy, Elizabeth Berecz, CFO, and Cosmas N. Lykos, the Company&#8217;s Founder granting 900,000, 700,000, and 900,000 shares of restricted common stock, respectively, with a fair value of $475,000. These agreements were issued outside of the 2014 Omnibus Incentive Plan. The restricted stock vests in equal 50% installments on the first and second anniversaries of the grant date, subject to continued employment with the Company through the applicable vesting date. Each Restricted Stock Agreement provides that if an executive&#8217;s employment or service is terminated by the Company without cause, or is terminated by the grantee for good reason, then the executive shall be entitled to receive a cash severance payment equal to six months of their base compensation, payable in substantially equal installments during the six-month period following the separation along with accelerated vesting of all outstanding stock awards.&#160;&#160;</p> <p style="MARGIN: 0px; text-align:justify;">&#160; </p> <p style="MARGIN: 0px">On February 28, 2018, in conjunction with the signing of the K2C separation agreement discussed in Note 8 below, Mr. Lykos&#8217; Restricted stock awards amounting to 900,000 shares became immediately vested resulting in a Type III award modification and stock compensation expense of $216,000 for the year ended December 31, 2018, due to an increase in the fair value of the award immediately before and after the modification date.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">On May 25, 2018, in conjunction with the signing of her separation agreement discussed above, the Company&#8217;s former CFO, Ms. Elizabeth Berecz&#8217;s Restricted stock awards amounting to 700,000 shares became immediately vested resulting in the recording of compensation expense of $184,800 for the year ended December 31, 2018, due to an increase in the fair value of the award immediately before and after the modification date.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">The following is a summary of RSA activity outside of the Company&#8217;s 2014 Plan during the year ended December 31, 2019: </p> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Number of</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Shares</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Weighted </strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Average Grant </strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Date Fair Value</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Unvested, December 31, 2018</strong></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>900,000</strong></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"><strong>$</strong></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>0.19</strong></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px"><strong>&#160;</strong></p></td></tr> <tr style="background-color:#ffffff;"> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Granted</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Released</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(450,000</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">0.19</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Unvested, December 31, 2019</strong></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>450,000</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>0.19</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px"><strong>&#160;</strong></p></td></tr></table> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong><em>Stock-Based Compensation Expense</em></strong></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px">The Company recognizes stock-based compensation expense using the straight-line method over the requisite service period. For the years ended December 31, 2019 and 2018, the Company recognized stock-based compensation expense of $680,455 and $674,961, respectively (including compensation expense for RSAs discussed above), which was recorded as a general and administrative expense in the Consolidated Statements of Comprehensive Income (Loss). The total amount of unrecognized compensation cost was $312,405 as of December 31, 2019. This amount will be recognized over a weighted-average period of 2.07 years.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;&#160;</p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-20</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc2">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong>7. Net Income (Loss) Per Share of Common Stock</strong></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">The following tables are a reconciliation of the numerators and denominators used in the calculation of basic and diluted net income (loss) per share computations:</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="10"> <p style="MARGIN: 0px; text-align:center;"><strong>For the Year Ended</strong> <strong>December 31, 2019</strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Income</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>(Numerator)</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Shares</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>(Denominator)</strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Per-Share</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Amount</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Net income</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,051,825</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Basic EPS</strong></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Income available to common stockholders</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">1,051,825</td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">135,154,931</td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>0.01</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Effect of Dilutive Securities</strong></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Unvested restricted stock</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">858,856</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Options</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">392,784</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Warrants</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">447,431</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Warrants &#8211; liability classified</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(9,250,612</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">32,706,263</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Diluted EPS</strong></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px">Loss available to common stockholders + assumed conversions</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(8,198,787</td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;">)</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">169,560,265</td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>(0.05</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"><strong>)</strong></td></tr></table> <p style="MARGIN: 0px">&#160;&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="10"> <p style="MARGIN: 0px; text-align:center;"><strong>For the Year Ended</strong> <strong>December 31, 2018</strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Income</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>(Numerator)</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Shares</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>(Denominator)</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Per-Share</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Amount</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Net loss</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(19,194,236</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Basic and Diluted EPS</strong></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Loss available to common stockholders</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">$&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">(19,194,236</td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;">)</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">121,154,334</td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>(0.16</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"><strong>)</strong></td></tr></table> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px 0px 0px 0.35pt; text-align:justify;">The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been anti-dilutive:</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"> <p style="MARGIN: 0px; text-align:center;"><strong>Year Ended</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>December 31,</strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2019</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2018</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Stock options </p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,119,931</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,600,073</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Unvested restricted stock</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">234,645</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,543,501</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Common shares underlying convertible debt</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,036,250</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,000,000</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Warrants</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20,712,000</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">53,130,750</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr></table> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong>8. Income Taxes </strong></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">The components of income (loss) before the income tax provision (benefit) consist of the following:</p> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"> <p style="MARGIN: 0px; text-align:center;"><strong>Year Ended </strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>December 31,</strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2019</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2018</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">US</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,120,521</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(19,192,594</td> <td style="width:1%;vertical-align:bottom;">)</td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Foreign</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(67,096</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Pre-tax income (loss) from operations </strong></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>1,053,425</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>(19,192,594</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"><strong>)</strong></td></tr></table> <p style="MARGIN: 0px">&#160;&#160; </p> <p style="MARGIN: 0px">Under the FASB&#8217;s accounting guidance related to income tax positions, among other things, the impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. Additionally, the guidance provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">The Company had no accrual for interest or penalties on the Company&#8217;s Balance Sheets at December 31, 2019 and 2018, and has not recognized interest and/or penalties in the Consolidated Statements of Comprehensive Income (Loss) for the years ended December 31, 2019 or 2018. </p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">The Company is subject to taxation in the United States and California. The Company&#8217;s tax years for 2016 (federal) and 2015 (California) and 2019 (Australia) and forward are subject to examination by the United States, California and Australia tax authorities.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px">At December 31, 2019, the Company had federal and California NOLs aggregating $13,213,037 and $24,481,423, respectively, which, if not used, it will begin to expire from 2033 and the Company had federal NOLs that do not expire but utilization is limited to 80% of taxable income for any given tax year in the amount of $11,275,349. At December 31, 2019, the Company had Australia NOLs aggregating $67,096 which do not expire.</p> <p style="MARGIN: 0px 0px 0px 0.35pt; text-align:justify;">&#160;</p> <p style="MARGIN: 0px 0px 0px 0.35pt; text-align:justify;">Utilization of the domestic NOL will be subject to a substantial annual limitation due to ownership change limitations that may have occurred, or that could occur in the future, as required by Section 382 of the Internal Revenue Code of 1986, as amended (the Code), as well as similar state provisions. These ownership changes may limit the amount of NOLs that can be utilized annually to offset future taxable income and tax, respectively. In general, an &#8220;ownership change&#8221; as defined by Section 382 of the Code results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percentage points of the outstanding stock of a company by certain stockholders.</p> <p style="MARGIN: 0px 0px 0px 0.35pt; text-align:justify;">&#160;&#160;&#160;</p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-21</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc2">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px 0px 0px 0.35pt; text-align:justify;">Upon the occurrence of an ownership change under Section 382 as outlined above, utilization of the NOLs are subject to an annual limitation under Section 382 of the Code, which is determined by first multiplying the value of the Company&#8217;s stock at the time of the ownership change by the applicable long-term, tax-exempt rate, and then could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the NOL before utilization. The multiple ownership changes may have already occurred as the Company raised capital through the issuance of stock. However, due to the existence of the valuation allowance for deferred tax assets, any potential change in ownership will not impact the Company&#8217;s effective tax rate.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">The tax effects of temporary differences and carryforwards that give rise to significant portions of the deferred income tax assets are as follows:</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"> <p style="MARGIN: 0px; text-align:center;"><strong>As of December 31,</strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Current deferred tax assets/(liabilities): </strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2019</strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2018</strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 11.25pt; text-align:justify;">State taxes</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">336</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">345</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 11.25pt; text-align:justify;">Capitalized research and development costs</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,327</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 11.25pt; text-align:justify;">Other</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">112,222</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">187,377</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 11.25pt; text-align:justify;">Net operating loss</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">6,434,544</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">5,104,432</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Gross deferred tax assets</strong></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>6,547,102</strong></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>5,302,481</strong></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Valuation allowance</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(6,206,450</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(5,302,481</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Net deferred tax assets </strong></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>340,652</strong></td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>-</strong></td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Deferred tax liabilities</strong></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 11.25pt; text-align:justify;">Note discount</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(340,652</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>-</strong></td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Total deferred tax liabilities</strong></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>(340,652</strong></td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"><strong>)</strong></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>-</strong></td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Net deferred tax assets</strong></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>-</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>-</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr></table> <p style="MARGIN: 0px">&#160; &#160;</p> <p style="MARGIN: 0px; text-align:justify;">The provision for income taxes on earnings subject to income taxes differs from the statutory Federal rate at December 31, 2019 and 2018, due to the following:</p> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"> <p style="MARGIN: 0px; text-align:center;"><strong>As of December 31,</strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2019</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2018</strong></p></td> <td style="PADDING-BOTTOM: 1px;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Expected income tax benefit at federal statutory tax rate </p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">221,219</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(4,030,454</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">State income taxes, net of federal benefit</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(434,881</td> <td style="width:1%;vertical-align:bottom;">)</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(319,816</td> <td style="width:1%;vertical-align:bottom;">)</td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Change in fair value of warrants </p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,874,873</td> <td style="width:1%;vertical-align:bottom;">)</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,869,116</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Change in valuation allowance</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,469,187</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,286,995</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Uncertain tax positions</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">436,145</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Change in compound derivative</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(101,671</td> <td style="width:1%;vertical-align:bottom;">)</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,224</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Loss on extinguishment of debt</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">117,198</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">123,982</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Stock compensation</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">121,289</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">67,966</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Rate adjustment</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">49,338</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Other permanent difference</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,351</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;">)</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">629</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Provision for Income Taxes</strong></p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>1,600</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>1,642</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr></table> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">The Company records a valuation allowance against deferred tax assets to the extent that it is more likely than not that some portion, or all of, the deferred tax assets will not be realized. Due to the substantial doubt related to the Company&#8217;s ability to utilize its deferred tax assets, a valuation allowance for the full amount of the deferred tax assets has been established at December 31, 2019. As a result of this valuation allowance, there are no income tax benefits reflected in the accompanying statement of operations to offset pre-tax losses.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">The Tax Cuts and Jobs Act of 2017 subjects a U.S. shareholder to tax on global intangible low-taxed income (&#8220;GILTI&#8221;) earned by certain foreign subsidiaries. The FASB Staff Q&amp;A, Topic 740, No. 5, Accounting for Global Intangible Low-Taxed Income, states that an entity can make an accounting policy election to recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only. The Company elects to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only.</p> <p style="MARGIN: 0px">&#160; &#160;</p> <p style="MARGIN: 0px; text-align:justify;">A reconciliation of the beginning and ending amounts of unrecognized tax positions are as follows:</p> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"> <p style="MARGIN: 0px; text-align:center;"><strong>As of December 31,</strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2019</strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="hdcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2018</strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Unrecognized tax positions, beginning of the year </p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Gross increase - current period tax positions</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">552,082</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Unrecognized tax positions, end of year</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>552,082</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;">$</td> <td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;"> <p style="MARGIN: 0px">&#160;</p></td></tr></table> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">If recognized, none of the unrecognized tax positions would impact the Company&#8217;s income tax benefit or effective tax rate as long as the Company&#8217;s net deferred tax assets remain subject to a full valuation allowance. The Company does not expect any significant increases or decreases to the Company&#8217;s unrecognized tax positions within the next twelve months.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong>9. Significant Contracts - University of Mississippi</strong></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong><em>UM 5050 Pro-Drug and UM 8930 Analog Agreements</em></strong></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">In July 2018, the Company renewed its ocular licenses for UM 5050, related to the pro-drug formulation of tetrahydrocannabinol (&#8220;THC&#8221;), and UM 8930, related to an analog formulation of cannabidiol (&#8220;CBD&#8221;). On May 24, 2019, the ocular delivery licenses were replaced by &#8220;all fields of use&#8221; licenses for both UM 5050 and UM 8930 (collectively, the &#8220;License Agreements&#8221;). Pursuant to the License Agreements, UM granted the Company an exclusive, perpetual license, including, with the prior written consent of UM, the right to sublicense, to intellectual property related to UM 5050 and UM 8930 for all fields of use.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;&#160;</p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-22</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc2">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">The License Agreements contain certain milestone payments, royalty and sublicensing fees payable by the Company, as defined therein. Each License Agreement provides for an annual maintenance fee of $75,000 payable on the anniversary of the effective date. The upfront payment for UM 5050 is $100,000 and the upfront payment for UM 8930 is $200,000. Additionally, there is also a $200,000 fee due within 30 days upon receipt of the first United States Patent and Trademark Office Notice of Allowance for UM 8930. The milestone payments payable for each license are as follows:</p> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="width:3%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">i)</p></td> <td style="width:76%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">$100,000 paid within 30 days following the submission of the first Investigational New Drug Application to the Food and Drug Administration or an equivalent application to a regulatory agency anywhere in the world, for a product;</p></td></tr> <tr> <td style="width:3%;"></td> <td style="width:76%;"> <p style="MARGIN: 0px; text-align:justify;">&#160;</p></td></tr> <tr> <td style="width:3%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">ii)</p></td> <td style="width:76%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">$200,000 paid within 30 days following the first submission of an NDA, or an equivalent application to a regulatory agency anywhere in the world, for each product that is administered in a different route of administration from that of the early submitted product(s); and</p></td></tr> <tr> <td style="width:3%;"></td> <td style="width:76%;"> <p style="MARGIN: 0px; text-align:justify;">&#160;</p></td></tr> <tr> <td style="width:3%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">iii)</p></td> <td style="width:76%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">$400,000 paid within 30 days following the approval of an NDA, or an equivalent application to a regulatory agency anywhere in the world, for each product that is administered in a different route of administration from that of the early approved product(s).</p></td></tr></table> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px 0px 0px 0.35pt; text-align:justify;">The royalty percentage due on net sales under each License Agreement is in the mid-single digits. The Company must also pay to UM a portion of all licensing fees received from any sublicensees, subject to a minimum royalty on net sales, and the Company is required to reimburse patent costs incurred by UM related to the licensed products. The royalty obligations apply by country and by licensed product, and end upon the later of the date that no valid claim of a licensed patent covers a licensed product in a given country, or ten years after the first commercial sale of such licensed product in such country.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">Each License Agreement continues, unless terminated, until the later of the expiration of the last to expire of the patents or patent applications within the licensed technology or the expiration of the Company&#8217;s payment obligations under such License Agreement. UM may terminate each License Agreement, by giving written notice of termination, upon the Company&#8217;s material breach of such License Agreement, including failure to make payments or satisfy covenants, representations or warranties without cure, noncompliance, a bankruptcy event, the Company&#8217;s dissolution or cessation of operations, the Company&#8217;s failure to make reasonable efforts to commercialize at least one product or failure to keep at least one product on the market after the first commercial sale for a continuous period of one year, other than for reasons outside the Company&#8217;s control, or the Company&#8217;s failure to meet certain pre-established development milestones. The Company may terminate each License Agreement upon 60 days&#8217; written notice to UM.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">As of December 31, 2019, none of the milestones under the license agreements have been met.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong><em>UM 5070 License Agreement</em></strong></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">In January 2017, the Company entered into a license agreement with UM pursuant to which UM granted us an exclusive, perpetual license, including the right to sublicense, to intellectual property related to a platform of cannabinoid-based molecules (&#8220;UM 5070&#8221;), to research, develop and commercialize products for the treatment of infectious diseases. The license agreement culminates roughly one year of screening and target molecule identification studies especially focused on therapy-resistant infectious organisms like Methicillin-resistant Staphylococcus aureus (&#8220;MRSA&#8221;). </p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">The Company paid UM an upfront license fee under the license agreement. Under the license agreement, the Company is also responsible for annual maintenance fees that will be credited against royalties in the current fiscal year, contingent milestone payments upon achievement of development and regulatory milestones, and royalties on net sales of licensed products sold for commercial use. The aggregate milestone payments due under the license agreement if all the milestones are achieved is $700,000 and the royalty percentage due on net sales is in the mid-single digits. The Company must also pay to UM a percentage of all licensing fees we receive from any sublicensees, subject to a minimum royalty on net sales by such sublicensees. The Company&#8217;s royalty obligations apply on a country by country and licensed product by licensed product basis, and end upon the later of the date that no valid claim of a licensed patent covers a licensed product in a given country, or ten years after first commercial sale of such licensed product in such country.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">The license agreement continues, unless terminated, until the later of the expiration of the last to expire of the patents or patent applications within the licensed technology or expiration of the Company&#8217;s payment obligations under the license. UM may terminate the license agreement, effective with the giving of notice, if: (a) the Company fails to pay any material amount payable to UM under the license agreement and do not cure such failure within 60 days after UM notifies us of such failure, (b) the Company materially breaches any covenant, representation or warranty in the license agreement and do not cure such breach within 60 days after UM notifies the Company of such breach, (c) the Company fails to comply in any material respect with the terms of the license and do not cure such noncompliance within 60 days after UM notifies us of such failure, (d) the Company is subject to a bankruptcy event, (e) the Company dissolves or ceases operations or (f) if after the first commercial sale of a product during the term of the license agreement, the Company materially fails to make reasonable efforts to commercialize at least one product or fail to keep at least one product on the market after the first commercial sale for a continuous period of one year, other than for reasons outside of the Company&#8217;s control. The Company may terminate the license agreement upon 60 days&#8217; written notice to UM.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">As of December 31, 2019, none of the milestones under this license agreement have been met.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong>10. Commitments and Contingencies</strong></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong><em>Legal Matters</em></strong></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><em>General Litigation and Disputes</em></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">From time to time, in the normal course of our operations, we may be a party to litigation and other dispute matters and claims. Litigation can be expensive and disruptive to normal business operations. Moreover, the results of complex legal proceedings are difficult to predict. An unfavorable outcome to any legal matter, if material, could have a materially adverse effect on our operations or our financial position, liquidity or results of operations. As of December 31, 2019, there were no pending or threatened lawsuits or claims that could reasonably be expected to have a material effect on the Company&#8217;s financial position or results of operations. </p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><em>Government Proceedings</em></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">Like other companies in the pharmaceutical industry, we are subject to extensive regulation by national, state and local government agencies in the United States. As a result, interaction with government agencies occurs in the normal course of our operations. It is possible that criminal charges and substantial fines and/or civil penalties or damages could result from any government investigation or proceeding. As of December 31, 2019, the Company had no proceedings or inquiries.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-23</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc2">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong><em>Change in Control Severance Plan</em></strong></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px 0px 0px 0.35pt; text-align:justify;">In February 2015, we adopted a change in control severance plan, in which our named executive officers participate, that provides for the payment of severance benefits if the executive&#8217;s service is terminated within twelve months following a change in control, either due to a termination without cause or upon resignation for a good reason (as each term is defined in the plan).</p> <p style="MARGIN: 0px 0px 0px 0.35pt; text-align:justify;">&#160;</p> <p style="MARGIN: 0px 0px 0px 0.35pt; text-align:justify;">In either such event, and provided the executive timely executes and does not revoke a general release of claims against the Company, he or she will be entitled to receive: (i) a lump sum cash payment equal to at least six months of the executive&#8217;s monthly compensation, plus an additional month for each full year of service over six years, (ii) Company-paid premiums for continued health insurance for a period equal to the length of the cash severance period or, if earlier, when executive becomes covered under a subsequent employer&#8217;s healthcare plan, and (iii) full vesting of all then-outstanding unvested stock options and restricted stock awards.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong>11. Related Party Matters</strong></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong><em>K2C, Inc.</em></strong></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px">In June 2014, the Company&#8217;s U.S. subsidiary entered into an independent contractor agreement with K2C, Inc. (&#8220;K2C&#8221;), which is wholly owned by the Company&#8217;s former Executive Chairman and Co-Founder, Mr. Cosmas N. Lykos, pursuant to which the Company paid K2C a monthly fee for services performed by Mr. Lykos for the Company. The agreement expired on June 1, 2017, and was automatically renewed for one year pursuant to the terms of the agreement. The monthly fee under the agreement was $10,000 and increased to $20,000 effective April 1, 2017.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">In February 2018, the Company entered into a separation and release agreement with K2C, which provided for a lump sum payment of $180,000 and the immediate vesting of 900,000 shares of restricted common stock granted on January 18, 2018, 325,000 shares of restricted common stock granted on October 20, 2015, and 125,000 options granted on November 21, 2014, in exchange for a release of claims and certain other agreements. During the year ended December 31, 2018, the Company recognized additional stock-based compensation expense of $112,270 for these restricted stock and option awards. </p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">For the year ended December 31, 2019, no expense was incurred under this agreement. For the year ended December 31, 2018, total expense incurred under this agreement was $220,000 (including the previously discussed lump sum payment). Under the separation agreement, Mr. Lykos was allowed to participate in the Company&#8217;s health, death and disability insurance plans for six months subsequent to K2C&#8217;s separation. </p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;"><strong><em>Emerald Health Sciences</em></strong></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">On February 1, 2018, the Company entered into an Independent Contractor Agreement with Emerald Health Sciences, pursuant to which Emerald Health Sciences agreed to provide such services as are mutually agreed between the Company and Emerald Health Sciences, including reimbursement for reasonable expenses incurred in the performance of the Independent Contractor Agreement. These services included, but were not limited to, corporate advisory services and technical expertise in the areas of business development, marketing, investor relations, information technology and product development. The Independent Contractor Agreement had an initial term of 10 years and specified compensation which was agreed upon between the Company&#8217;s Chief Executive Officer and Emerald Health Sciences&#8217; Chairman, CEO and President on a month-to-month basis. The fee due under this agreement was payable on a monthly basis. Under this agreement, for the years ended December 31, 2019 and 2018, the Company incurred expenses of $542,000 and $550,000, respectively. At December 31, 2019, the Company has accrued $10,000 in expense under this agreement. Effective December 31, 2019, the Independent Contractor Agreement has been terminated. </p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px">On February 6, 2018, the Company entered into a Consulting Agreement with Dr. Avtar Dhillon, the Chairman, Chief Executive Officer and President of Emerald Health Sciences. The services under the Consulting Agreement included corporate finance and strategic business advisory services. The Consulting Agreement had an initial term of one year and was renewable automatically unless terminated by either party. The agreement specified an annual fee of $60,000, payable semi-monthly in installments, and included reimbursement for reasonable expenses incurred in the performance of the services. Under the agreement, Dr. Avtar Dhillon was also entitled to a discretionary annual bonus, payable 120 days after each fiscal year-end, to be determined by the Board upon its annual review. Under this agreement, for the year ended December 31, 2018, the Company incurred $45,000. The Consulting Agreement was canceled on October 5, 2018 in connection with the Company&#8217;s entry into the Credit Agreement with Emerald Health Sciences (See Note 4) and Dr. Avtar Dhillon&#8217;s appointment as the Executive Chairman of the Company&#8217;s Board. </p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">On December 17, 2019, Dr. Avtar Dhillon resigned as the Chairman of the Board and the position of Chairman of the Finance and Business Development Committee of the Board. Concurrently, the Company entered into a Board Observer Agreement with Emerald Health Sciences to allow Dr. Dhillon to continue as a representative of Emerald Health Sciences as a non-voting observer in future meetings of the Board.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px 0px 0px 0.35pt; text-align:justify;">On December 19, 2019, the Company entered into an Independent Contractor Services Agreement with Dr. Avtar Dhillon, pursuant to which Dr. Dhillon will provide ongoing corporate finance and strategic business advisory services to the Company. In exchange for his services, Dr. Dhillon will receive a monthly fee of $10,000, with (i) $5,000 paid each month and (ii) $5,000 accruing from the effective date and payable upon the Company&#8217;s completion of a material financing. The Board will review the monthly rate paid to Dr. Dhillon within 90 days of the end of each fiscal year. The Independent Contractor Services Agreement has an initial term of one year and will renew automatically thereafter unless terminated earlier by either party. The Independent Contractor Services Agreement may be terminated by either party for cause upon written notice to the other party if the other party defaults in the performance of the agreement in any material respect or materially breaches the terms of the agreement, or without cause upon 30 days&#8217; prior written notice to the other party. </p> <p style="MARGIN: 0px; text-align:justify;">&#160; </p> <p style="MARGIN: 0px; text-align:justify;"><strong>12. Subsequent Events</strong></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px">In March 2020, the Company was notified by the United States Patent and Trademark Office, that a notice of allowance has been issued for the proprietary analog of cannabidiol, CBDVHS, under the UM 8930 License Agreement. As a result, the Company is required to pay UM a fee of $200,000 within 30 days from when the notice was received (Note 9).</p> <p style="MARGIN: 0px 0px 0px 0.35pt; text-align:justify;">&#160;&#160; &#160;</p> <p style="MARGIN: 0px 0px 0px 0.35pt; text-align:justify;">Refer to Note 1 for disclosure of the salary deferral program that was put in place during March 2020.</p> <p style="MARGIN: 0px 0px 0px 0.35pt; text-align:justify;">&#160; </p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-24</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc1">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong>The following exhibits are filed with this Annual Report on Form 10-K.</strong></p> <p style="MARGIN: 0px"><strong>&#160;&#160; </strong></p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="BORDER-BOTTOM: black 1px solid;width:9%;"> <p style="MARGIN: 0px"><strong>Exhibit</strong></p> <p style="MARGIN: 0px"><strong>Number </strong></p></td> <td style="width:2%;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;"> <p style="MARGIN: 0px"><strong>Description </strong><strong>of Exhibit</strong></p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724013000010/lgl_articles.htm">3.1 </a></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724013000010/lgl_articles.htm">Articles of Incorporation of Registrant, as amended <sup>(27)</sup></a></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724013000010/lgl_articles.htm">3.2</a></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724013000010/lgl_articles.htm">Amendment to the Articles of Incorporation of the Registrant <sup>(28)</sup></a></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724013000010/lgl_bylaws.htm">3.3</a></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724013000010/lgl_bylaws.htm">Bylaws of Registrant <sup>(1)</sup></a></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033415000053/ex-3_1.htm">3.8 </a></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033415000053/ex-3_1.htm">Certificate of Designation of the Relative Rights and Preferences of the Series B Preferred Stock filed with the Secretary of State of Nevada on August 19, 2015 <sup>(4)</sup></a></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724014000640/ex_4-1.htm">4.1</a></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724014000640/ex_4-1.htm">Form of Warrants issued by Nemus to certain security holders to purchase an aggregate of 3,000,000 shares of commons stock <sup>(2)</sup></a></p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724014000640/ex_4-2.htm">4.2</a></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724014000640/ex_4-2.htm">Form of Warrants issued by Nemus to certain security holders to purchase an aggregate of 1,000,000 shares of commons stock <sup>(2)</sup></a></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724015000237/ex_4-1.htm">4.3</a></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724015000237/ex_4-1.htm">Form of Common Stock Purchase Warrant to certain security holders to purchase shares of common stock <sup>(3)</sup></a></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724015000300/ex_4-3.htm">4.4</a></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724015000300/ex_4-3.htm">Form of Warrant dated April 25, 2015 issued by Nemus Bioscience, Inc. to holder to purchase 100,000 shares of common stock <sup>(4)</sup></a></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724015000300/ex_4-4.htm">4.5</a></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724015000300/ex_4-4.htm">Form of Warrant dated April 29, 2015 issued by Nemus Bioscience, Inc. to holder to purchase 90,000 shares of common stock <sup>(5)</sup></a></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724015000300/ex_4-5.htm">4.6</a></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724015000300/ex_4-5.htm">Form of Warrant dated April 26, 2015 issued by Nemus Bioscience, Inc. to holder to purchase 6,000 shares of common stock <sup>(5)</sup></a></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033415000037/ex4-6.htm">4.7</a></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033415000037/ex4-6.htm">Form of Warrant dated June 8, 2015 issued by Nemus Bioscience, Inc. to holder to purchase 10,000 shares of common stock <sup>(6)</sup></a></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033415000053/ex-4_1.htm">4.8</a></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033415000053/ex-4_1.htm">Form of Warrant to certain security holders to purchase shares of common stock <sup>(4)</sup></a></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724015000002/ex_10-2.htm">4.9</a></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724015000002/ex_10-2.htm">Registration Rights Agreement, dated January 7, 2015, by and between Nemus Bioscience, Inc. and certain investors <sup>(7)</sup></a></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033419000379/nemus_ex410.htm">4.10</a></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033419000379/nemus_ex410.htm">Form of Warrant<sup>(36)</sup></a></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033419002436/embi_ex41.htm">4.11</a></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033419002436/embi_ex41.htm">Form of Warrant <sup>(34)</sup></a></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724014000640/ex_10-1.htm">10.1&#8224; </a></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724014000640/ex_10-1.htm">Nemus Bioscience, Inc. 2014 Omnibus Incentive Plan <sup>(2)</sup></a></td></tr> <tr style="background-color:#cceeff;"> <td> <p style="MARGIN: 0px"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724014000640/ex_10-2.htm">10.2<u>&#8224;</u></a></p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724014000640/ex_10-2.htm">Form of Stock Option Agreement under 2014 Omnibus Incentive Plan <sup>(2)</sup></a></p></td></tr> <tr style="background-color:#ffffff;"> <td> <p style="MARGIN: 0px"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724014000640/ex_10-3.htm">10.3</a></p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724014000640/ex_10-3.htm">Memorandum of Understanding, dated July 31, 2013, between Nemus and University of Mississippi, National Center for Natural Products Research <sup>(2)</sup></a></p></td></tr></table> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr style="background-color:#cceeff;"> <td style="width:9%;vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724014000640/ex_10-9.htm">10.9 **</a></td> <td style="width:2%;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724014000640/ex_10-9.htm">License Agreement, dated September 29, 2014, between Nemus and the University of Mississippi, School of Pharmacy <sup>(2)</sup></a></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724014000640/ex_10-10.htm">10.10 **</a></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724014000640/ex_10-10.htm">License Agreement, dated September 29, 2014, between Nemus and the University of Mississippi, School of Pharmacy <sup>(2)</sup></a></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724014000640/ex_10-11.htm">10.11 **</a></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724014000640/ex_10-11.htm">License Agreement, dated September 29, 2014, between Nemus and the University of Mississippi, School of Pharmacy <sup>(2)</sup></a></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724014000640/ex_10-12.htm">10.12</a></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724014000640/ex_10-12.htm">Lease Agreement dated September 1, 2014 between University of Mississippi Research Foundation, Inc. and Nemus <sup>(2)</sup></a></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724014000640/ex_10-13.htm">10.13 </a></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724014000640/ex_10-13.htm">Center Tower Lease dated October 13, 2014, by and between Nemus and Center Tower Associates LLC. <sup>(2)</sup></a></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724015000002/ex_10-1.htm">10.17</a></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724015000002/ex_10-1.htm">Common Stock Purchase Agreement, dated January 7, 2015, by and between Nemus Bioscience, Inc. and certain investors <sup>(7)</sup></a></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724015000010/ex_10-1.htm">10.19 &#8224;</a></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724015000010/ex_10-1.htm">Form of Indemnification Agreement <sup>(8)</sup></a></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724015000113/ex10_1.htm">10.20 &#8224;</a></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724015000113/ex10_1.htm">Nemus Bioscience, Inc. Officer Change in Control Severance Plan <sup>(9)</sup></a></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033415000053/ex-10_2.htm">10.21</a></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033415000053/ex-10_2.htm">Form of Registration Rights Agreement between Nemus Bioscience, Inc. and certain investors (4) 10.22&#8224; Form of Restricted Stock Award Agreement under 2014 Omnibus Incentive Plan <sup>(10)</sup></a></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033415000467/ex-10_1.htm">10.23 **</a></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033415000467/ex-10_1.htm">License Agreement, dated December 14, 2015, between Nemus and the University of Mississippi, School of Pharmacy <sup>(11)</sup></a></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033415000467/ex-10_2.htm">10.24 **</a></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033415000467/ex-10_2.htm">License Agreement, dated December 14, 2015, between Nemus and the University of Mississippi, School of Pharmacy <sup>(11)</sup></a></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033416000847/ex-10_25.htm">10.25 ** </a></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033416000847/ex-10_25.htm">Letter Agreement with Albany Molecular Research Inc. dated February 5, 2016 <sup>(12)</sup></a></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033416001849/nmus_ex101.htm">10.26</a></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033416001849/nmus_ex101.htm">Form of Securities Purchase Agreement between Nemus Bioscience, Inc. and certain investors <sup>(13)</sup></a></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033416001849/nmus_ex102.htm">10.27 </a></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033416001849/nmus_ex102.htm">Form of Registration Rights Agreement between Nemus Bioscience, Inc. and certain investors <sup>(13)</sup></a></td></tr></table> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr style="background-color:#cceeff;"> <td style="width:9%;vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033416001861/nmus_ex101.htm">10.28 </a></td> <td style="width:2%;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033416001861/nmus_ex101.htm">Form of Lock-up Agreement between Nemus Bioscience, Inc. and certain shareholders <sup>(14)</sup></a></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033416002299/nmus_ex101.htm">10.29</a></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033416002299/nmus_ex101.htm">Form of Securities Purchase Agreement between Nemus Bioscience, Inc. and certain investors <sup>(15)</sup></a></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033416002299/nmus_ex102.htm">10.30 </a></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033416002299/nmus_ex102.htm">Form of Registration Rights Agreement between Nemus Bioscience, Inc. and certain investors <sup>(15)</sup></a></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033417000043/nmus_ex101.htm">10.31</a></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033417000043/nmus_ex101.htm">Form of Lock-up Agreement between Nemus Bioscience, Inc. and certain shareholders <sup>(16)</sup></a></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033417000139/nmus_ex101.htm">10.32 **</a></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033417000139/nmus_ex101.htm">License Agreement, dated January 10, 2017, between Nemus and the University of Mississippi, School of Pharmacy <sup>(17)</sup></a></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033417000851/nemus_ex101.htm">10.33</a></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033417000851/nemus_ex101.htm">Securities Purchase Agreement, dated May 3, 2017, between Nemus Bioscience, Inc. and Schneider Finance LLC <sup>(18)</sup></a></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033417001379/nemus_ex991.htm">10.34</a></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033417001379/nemus_ex991.htm">Financial Guarantee dated May 3, 2017 <sup>(19)</sup></a></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033417002280/nemus_ex101.htm">10.35</a></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033417002280/nemus_ex101.htm">Form of Securities Purchase Agreement <sup>(20)</sup></a></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033417002280/nemus_ex102.htm">10.36</a></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033417002280/nemus_ex102.htm">Form of Registration Rights Agreement (20) 10.37&#8224; Form of Restricted Stock Agreement <sup>(21)</sup></a></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033418000161/nemus_ex101.htm">10.38</a></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033418000161/nemus_ex101.htm">Securities Purchase Agreement <sup>(21)</sup></a></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033418000036/nemus_ex101.htm">10.39</a></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033418000036/nemus_ex101.htm">Convertible Bridge Promissory Note <sup>(22)</sup></a></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033418000482/nmus_ex1040.htm">10.40</a></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033418000482/nmus_ex1040.htm">Independent Contractor Termination Agreement and Release (23) 10.41* Independent Contractor Agreement <sup>(23)</sup></a></td></tr></table> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">55</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc1">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr style="background-color:#cceeff;"> <td style="width:9%;vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033418001127/nmus_ex101.htm">10.42&#8224;</a></td> <td style="width:2%;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033418001127/nmus_ex101.htm">Employment Agreement, dated May 25, 2018, between Nemus Bioscience, Inc. and Douglas Cesario (24) 10.43&#8224; Stock Option Agreement, dated May 25, 2018, between Nemus Bioscience, Inc. and Douglas Cesario <sup>(24)</sup></a></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033418001486/nemus_101.htm">10.44 ** </a></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033418001486/nemus_101.htm">Letter Agreement, dated July 31, 2018, by and between Nemus Bioscience, Inc. and Albany Molecular Research Inc. <sup>(25)</sup></a></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033418001906/nemus_ex101.htm">10.45</a></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033418001906/nemus_ex101.htm">Multi-Draw Credit Agreement, dated October 5, 2018, by and between Nemus Bioscience, Inc. and Emerald Health Sciences, Inc. <sup>(26)</sup></a></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033418001906/nemus_ex102.htm">10.46</a></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033418001906/nemus_ex102.htm">Registration Rights Agreement, dated October 5, 2018, by and between Nemus Bioscience, Inc. and Emerald Health Sciences, Inc. <sup>(26)</sup></a></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033418001906/nemus_ex103.htm">10.47 &#8224;</a></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033418001906/nemus_ex103.htm">Amendment No. 1 to 2014 Omnibus Incentive Plan <sup>(26)</sup></a></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033419000347/nemus_ex101.htm">10.48 **</a></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033419000347/nemus_ex101.htm">Master Development and Clinical Supply Agreement, dated February 26, 2019, by and between Nemus Bioscience, Inc. and Noramco, Inc. <sup>(29)</sup></a></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033419001000/embi_ex101.htm">10.49</a></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033419001000/embi_ex101.htm">Restated and Amended License Agreement, dated as of May 24, 2019, by and between the Company and University of Mississippi, School of Pharmacy <sup>(30)</sup></a></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033419001000/embi_ex102.htm">10.50</a></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033419001000/embi_ex102.htm">Restated and Amended License Agreement, dated as of May 24, 2019, by and between the Company and University of Mississippi, School of Pharmacy <sup>(30)</sup></a></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033419001557/embi_ex101.htm">10.51</a></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033419001557/embi_ex101.htm">First Amendment to Master Development and Clinical Supply Agreement, dated as of August 7, 2019, by and between the Company and Noramco, Inc. <sup>(31)</sup></a></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033419001760/embi_ex101.htm">10.52</a></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033419001760/embi_ex101.htm">Start-Up Agreement, dated as of August 23, 2019, by and between the Company and Novotech <sup>(32)</sup></a></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033419001760/embi_ex101.htm">10.53</a></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033419001760/embi_ex101.htm">Master Services Agreement, dated as of September 20, 2019, by and between EMBI Australia and Novotech (Australia) Pty Limited <sup>(33)</sup></a></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033419002436/embi_ex101.htm">10.54 </a></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033419002436/embi_ex101.htm">Form of Securities Purchase Agreement, dated as of November 20, 2019, between the Company and certain purchasers set forth in the signature page thereto <sup>(34)</sup></a></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033419002436/embi_ex41.htm">10.55 </a></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033419002436/embi_ex41.htm">Warrant Exercise Agreement, dated as of December 20, 2019, between the Company and Emerald Health Sciences <sup>(35)</sup></a></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033419002436/embi_ex101.htm">10.56 </a></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033419002436/embi_ex101.htm">Independent Contractor Services Agreement, dated as of December 19, 2019, between the Company and Dr. Avtar Dhillon. <sup>(35)</sup></a></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724014000640/ex_21-1.htm">21.1 </a></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000155724014000640/ex_21-1.htm">Subsidiaries of the Registrant <sup>(2)</sup></a></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"><a href="embi_ex231.htm">23.1*</a></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"><a href="embi_ex231.htm">Consent of Independent Registered Public Accounting Firm</a></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;"><a href="embi_ex311.htm">31.1*</a></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"><a href="embi_ex311.htm">Certification of Principal Executive Officer, pursuant to Rule 13a-14 and 15d-14 of the Securities Exchange Act of 1934</a></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"><a href="embi_ex312.htm">31.2*</a></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"><a href="embi_ex312.htm">Certification of Principal Financial Officer, pursuant to Rule 13a-14 and 15d-14 of the Securities Exchange Act of 1934 </a></td></tr> <tr style="background-color:#cceeff;"> <td> <p style="MARGIN: 0px"><a href="embi_ex321.htm">32.1***</a></p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px"><a href="embi_ex321.htm">Certification of Principal Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></p></td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;"><a href="embi_ex322.htm">32.2***</a></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"><a href="embi_ex322.htm">Certification of Principal Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;">101.ins&#8224;&#8224;</td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;">Instance Document</td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;">101.sch&#8224;&#8224; </td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;">XBRL Taxonomy Schema Document</td></tr> <tr style="background-color:#cceeff;"> <td style="vertical-align:top;">101.cal&#8224;&#8224;</td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;">XBRL Taxonomy Calculation Linkbase Document 101.def&#8224;&#8224; XBRL Taxonomy Definition Linkbase Document 101.lab&#8224;&#8224; XBRL Taxonomy Label Linkbase Document</td></tr> <tr style="background-color:#ffffff;"> <td style="vertical-align:top;">101.pre&#8224;&#8224;</td> <td></td> <td style="vertical-align:top;">XBRL Taxonomy Presentation Linkbase Document</td></tr></table>&#160; <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"> <p style="MARGIN: 0px; text-align:center;">56</p></td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc1">Table of Contents</a></em></td></tr></table><font style="font-size:12pt;display:inline">____________</font> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="width:4%;vertical-align:top;">(1)</td> <td style="vertical-align:top;">Included as exhibit to our Registration Statement on Form S-1 filed on January 30, 2013</td></tr> <tr> <td style="width:4%;vertical-align:top;">(2)</td> <td style="vertical-align:top;">Included as exhibit to our Current Report on Form 8-K filed on November 3, 2014.</td></tr> <tr> <td style="width:4%;vertical-align:top;">(3)</td> <td style="vertical-align:top;">Included as exhibit to our Current Report on Form 8-K filed April 7, 2015.</td></tr> <tr> <td style="width:4%;vertical-align:top;">(4)</td> <td style="vertical-align:top;">Included as exhibit to our Current Report on Form 8-K filed August 20, 2015.</td></tr> <tr> <td style="width:4%;vertical-align:top;">(5)</td> <td style="vertical-align:top;">Included as exhibit to our Quarterly Report on Form 10-Q filed May 13, 2015</td></tr> <tr> <td style="width:4%;vertical-align:top;">(6)</td> <td style="vertical-align:top;">Included as exhibit to our Quarterly Report on Form 10-Q filed August 14, 2015</td></tr> <tr> <td style="width:4%;vertical-align:top;">(7)</td> <td style="vertical-align:top;">Included as exhibit to our Current Report on Form 8-K filed on January 9, 2015.</td></tr> <tr> <td style="width:4%;vertical-align:top;">(8)</td> <td style="vertical-align:top;">Included as exhibit to our Current Report on Form 8-K filed on January 12, 2015.</td></tr> <tr> <td style="width:4%;vertical-align:top;">(9)</td> <td style="vertical-align:top;">Included as exhibit to our Current Report on Form 8-K filed on February 27, 2015.</td></tr> <tr> <td style="width:4%;vertical-align:top;">(10)</td> <td style="vertical-align:top;">Included as exhibit to our Current Report on Form 8-K filed on October 22, 2015.</td></tr> <tr> <td style="width:4%;vertical-align:top;">(11)</td> <td style="vertical-align:top;">Included as exhibit to our Current Report on Form 8-K filed on December 18, 2015.</td></tr> <tr> <td style="width:4%;vertical-align:top;">(12)</td> <td style="vertical-align:top;">Included as exhibit to our Annual Report on Form 10-K filed on March 21, 2016.</td></tr> <tr> <td style="width:4%;vertical-align:top;">(13)</td> <td style="vertical-align:top;">Included as exhibit to our Current Report on Form 8-K filed on October 26, 2016</td></tr> <tr> <td style="width:4%;vertical-align:top;">(14)</td> <td style="vertical-align:top;">Included as exhibit to our Current Report on Form 8-K filed on October 27, 2016.</td></tr> <tr> <td style="width:4%;vertical-align:top;">(15)</td> <td style="vertical-align:top;">Included as exhibit to our Current Report on Form 8-K filed on December 29, 2016.</td></tr> <tr> <td style="width:4%;vertical-align:top;">(16)</td> <td style="vertical-align:top;">Included as exhibit to our Current Report on Form 8-K filed on January 10, 2017.</td></tr> <tr> <td style="width:4%;vertical-align:top;">(17)</td> <td style="vertical-align:top;">Included as exhibit to our Current Report on Form 8-K/A filed on January 20, 2017.</td></tr> <tr> <td style="width:4%;vertical-align:top;">(18)</td> <td style="vertical-align:top;">Included as exhibit to our Current Report on Form 8-K filed on May 4, 2017.</td></tr> <tr> <td style="width:4%;vertical-align:top;">(19)</td> <td style="vertical-align:top;">Included as exhibit to our Current Report on Form 8-K filed on July 11, 2017.</td></tr> <tr> <td style="width:4%;vertical-align:top;">(20)</td> <td style="vertical-align:top;">Included as exhibit to our Current Report on Form 8-K filed on November 2, 2017.</td></tr> <tr> <td style="width:4%;vertical-align:top;">(21)</td> <td style="vertical-align:top;">Included as exhibit to our Current Report on Form 8-K filed on January 22, 2018.</td></tr> <tr> <td style="width:4%;vertical-align:top;">(22)</td> <td style="vertical-align:top;">Included as exhibit to our Current Report on Form 8-K filed on January 3, 2018.</td></tr> <tr> <td style="width:4%;vertical-align:top;">(23)</td> <td style="vertical-align:top;">Included as exhibit to our Annual Report on Form 10-K filed on March 19, 2018.</td></tr> <tr> <td style="width:4%;vertical-align:top;">(24)</td> <td style="vertical-align:top;">Included as exhibit to our Current Report on Form 8-K filed on June 1, 2018.</td></tr> <tr> <td style="width:4%;vertical-align:top;">(25)</td> <td style="vertical-align:top;">Included as exhibit to our Current Report on Form 8-K filed on August 1, 2018.</td></tr> <tr> <td style="width:4%;vertical-align:top;">(26)</td> <td style="vertical-align:top;">Included as exhibit to our Current Report on Form 8-K filed on October 12, 2018.</td></tr> <tr> <td style="width:4%;vertical-align:top;">(27)</td> <td style="vertical-align:top;">Included as exhibit to our Quarterly Report on Form 10-Q filed on November 14, 2018.</td></tr> <tr> <td style="width:4%;vertical-align:top;">(28)</td> <td style="vertical-align:top;">Included as exhibit to our Current Report on Form 8-K filed on November 16, 2018.</td></tr> <tr> <td style="width:4%;vertical-align:top;">(29)</td> <td style="vertical-align:top;">Included as exhibit to our Current Report on Form 8-K filed on March 4, 2019.</td></tr> <tr> <td style="width:4%;vertical-align:top;">(30)</td> <td style="vertical-align:top;">Included as exhibit to our Current Report on Form 8-K filed on May 29, 2019.</td></tr> <tr> <td style="width:4%;vertical-align:top;">(31)</td> <td style="vertical-align:top;">Included as exhibit to our Current Report on Form 8-K filed on August 8, 2019.</td></tr> <tr> <td style="width:4%;vertical-align:top;">(32)</td> <td style="vertical-align:top;">Included as exhibit to our Current Report on Form 8-K filed on August 27, 2019.</td></tr> <tr> <td style="width:4%;vertical-align:top;">(33)</td> <td style="vertical-align:top;">Included as exhibit to our Quarterly Report on Form 10-Q filed on September 30, 2019.</td></tr> <tr> <td style="width:4%;vertical-align:top;">(34)</td> <td style="vertical-align:top;">Included as exhibit to our Current Report on Form 8-K filed on November 21, 2019.</td></tr> <tr> <td style="width:4%;vertical-align:top;">(35)</td> <td style="vertical-align:top;">Included as exhibit to our Current Report on Form 8-K filed on December 20, 2019.</td></tr> <tr> <td> <p style="MARGIN: 0px">(36)</p></td> <td> <p style="MARGIN: 0px">Included as exhibit to our Annual Report on Form 10-K filed on March 14, 2019.</p></td></tr></table> <p style="MARGIN: 0px; text-align:justify;">* Filed Herewith</p> <p style="MARGIN: 0px; text-align:justify;">** Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934.</p> <p style="MARGIN: 0px; text-align:justify;">*** Furnished Herewith</p> <p style="MARGIN: 0px; text-align:justify;">&#8224; Management contract or compensatory plan or arrangement.</p> <p style="MARGIN: 0px; text-align:justify;">&#8224;&#8224; In accordance with Regulation S-T, XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, and is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not otherwise subject to liability under these sections.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong><u><a name="item16">Item</a> 16. Form 10-K Summary</u></strong><strong>.</strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">None. </p> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">57</td></tr> <tr> <td> <p style="PAGE-BREAK-AFTER: always; MARGIN: 0px">&#160;</p></td></tr> <tr> <td><em><a href="#toc1">Table of Contents</a></em></td></tr></table> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:center;"><strong>SIGNATURES</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>&#160;&#160;&#160;&#160; </strong></p> <p style="MARGIN: 0px"><strong>Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td colspan="2"> <p style="MARGIN: 0px"><strong>Emerald Bioscience, Inc. </strong></p> <p style="MARGIN: 0px"><strong>a Nevada corporation</strong></p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="width:50%;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:3%;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:35%;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:12%;"> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="vertical-align:top;"> <p style="MARGIN: 0px">March 20, 2020</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:left;">By:</p></td> <td style="BORDER-BOTTOM: 1px solid;vertical-align:top;"> <p style="MARGIN: 0px">/s/ <em>Brian S. Murphy</em></p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="vertical-align:top;"></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px">Brian S. Murphy</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="vertical-align:top;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:left;">Its:</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px">Chief Executive Officer, Director</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="vertical-align:top;"></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:left;">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px">(Principal Executive Officer)</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="vertical-align:top;"> <p style="MARGIN: 0px">March 20, 2020</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:left;">By:</p></td> <td style="BORDER-BOTTOM: 1px solid;vertical-align:top;"> <p style="MARGIN: 0px"><em>/s/ Doug Cesario</em></p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="vertical-align:top;"></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:left;">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px">Doug Cesario</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="vertical-align:top;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:left;">Its:</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px">Chief Financial Officer</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="vertical-align:top;"></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px">(Principal Financial and Accounting Officer)</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr></table> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px"><strong>Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</strong></p> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="width:3%;"> <p style="MARGIN: 0px">By: </p></td> <td style="BORDER-BOTTOM: black 1px solid;width:35%;"> <p style="MARGIN: 0px"><em>/s/ Brian S. Murphy </em></p></td> <td style="width:12%;"> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">March 20, 2020</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">Brian S. Murphy</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">Its:</p></td> <td> <p style="MARGIN: 0px">Chief Executive Officer, Director</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="vertical-align:top;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px">(Principal Executive Officer)</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="vertical-align:top;"> <p style="MARGIN: 0px">By:</p></td> <td style="BORDER-BOTTOM: black 1px solid;vertical-align:top;"> <p style="MARGIN: 0px"><em>/s/ Doug Cesario</em></p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px">March 20, 2020</p></td></tr> <tr> <td style="vertical-align:top;"> <p style="MARGIN: 0px">Its:</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px">Doug Cesario</p> <p style="MARGIN: 0px">Chief Financial Officer</p> <p style="MARGIN: 0px">(Principal Financial and Accounting Officer)</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="vertical-align:top;"> <p style="MARGIN: 0px">By:</p></td> <td style="BORDER-BOTTOM: black 1px solid;vertical-align:top;"> <p style="MARGIN: 0px"><em>/s/ Punit Dhillon</em></p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px">March 20, 2020</p></td></tr> <tr> <td style="vertical-align:top;"> <p style="MARGIN: 0px">Its:</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px">Punit Dhillon </p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">Chairman</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="vertical-align:top;"> <p style="MARGIN: 0px">By:</p></td> <td style="BORDER-BOTTOM: black 1px solid;vertical-align:top;"> <p style="MARGIN: 0px"><em>/s/ Jim Heppell</em></p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px">March 20, 2020</p></td></tr> <tr> <td style="vertical-align:top;"> <p style="MARGIN: 0px">Its:</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px">Jim Heppell </p> <p style="MARGIN: 0px">Director</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px">&#160;</p></td></tr></table> <p style="MARGIN: 0px">&#160;&#160;</p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td class="hpbhr">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"> <p style="MARGIN: 0px; text-align:center;">58</p></td></tr></table> <p style="MARGIN: 0px">&#160;</p></body></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>embi_ex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html><head><title>embi_ex231.htm</title><!--Document Created by EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN; MARGIN: 0px 7%"><body style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN; MARGIN: 0px 7%" scroll="yes"><p style="MARGIN: 0px; text-align:right;"><strong>EXHIBIT 23.1</strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:center;"><strong><u>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</u></strong></p> <p style="MARGIN: 0px; text-align:left;">&#160;</p> <p style="MARGIN: 0px">As independent registered public accountants, we hereby consent to the incorporation by reference in Registration Statement Nos. 333-227860, 333-231951&#160;and 333-234673 of our report dated March 20, 2020, relating to the consolidated financial statements of Emerald Bioscience, Inc. and Subsidiaries, which report includes an explanatory paragraph relating to the uncertainty of the Company&#8217;s ability to continue as a going concern, for the years ended December 31, 2019 and 2018.</p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">/s/ Mayer Hoffman McCann P.C.</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">Irvine, California</p> <p style="MARGIN: 0px">March 20, 2020</p> <p style="MARGIN: 0px">&#160;</p></body></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>embi_ex311.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<html><head><title>embi_ex311.htm</title><!--Document Created by EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN; MARGIN: 0px 7%"><body style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN; MARGIN: 0px 7%" scroll="yes"><p style="MARGIN: 0px; text-align:right;"><strong>EXHIBIT 31.1</strong></p> <p style="MARGIN: 0px; text-align:center;">&#160;</p> <p style="MARGIN: 0px; text-align:center;"><strong>Certification </strong><strong>of Principal Executive Officer</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Required </strong><strong>By </strong><strong>Rule 13a-14(A) of the Securities Exchange Act of 1934, As Amended,</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>As Adopted Pursuant To Section 302 of the Sarbanes--Oxley Act of 2002</strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">I, Brian S. Murphy, certify that:</p> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="width:4%;vertical-align:top;">1.</td> <td style="vertical-align:top;">I have reviewed this annual report on Form 10-K of Emerald Bioscience, Inc.;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="vertical-align:top;">2.</td> <td style="vertical-align:top;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="vertical-align:top;">3.</td> <td style="vertical-align:top;">Based on my knowledge, the consolidated financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="vertical-align:top;">4.</td> <td style="vertical-align:top;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Ru1es 13a-15(e) and 15d-15(e )) and internal control over financial reporting (as defined in Exchange Act Ru1es 13a-15(f) and 15d-15(f)) for the registrant and have:</td></tr></table> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:4%;vertical-align:top;">(a)</td> <td style="vertical-align:top;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particu1arly during the period in which this report is being prepared;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:4%;vertical-align:top;">(b)</td> <td style="vertical-align:top;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with generally accepted accounting principles;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:4%;vertical-align:top;">(c)</td> <td style="vertical-align:top;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:4%;vertical-align:top;">(d)</td> <td style="vertical-align:top;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.</td></tr></table> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="width:4%;vertical-align:top;">5.</td> <td style="vertical-align:top;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</td></tr></table> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:4%;vertical-align:top;">(a)</td> <td style="vertical-align:top;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:4%;vertical-align:top;">(b)</td> <td style="vertical-align:top;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</td></tr></table>&#160; &#160; <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td style="width:35%;"> <p style="MARGIN: 0px">Date: March 20, 2020</p></td> <td style="width:65%;"></td></tr> <tr> <td>&#160;</td> <td>&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid;"> <p style="MARGIN: 0px"><em>/s/ Brian </em>S. <em>Murphy</em></p></td> <td></td></tr> <tr> <td> <p style="MARGIN: 0px">Brian S. Murphy, Chief Executive Officer</p></td> <td>&#160;</td></tr> <tr> <td> <p style="MARGIN: 0px">(Principal Executive Officer)</p></td> <td>&#160;</td></tr></table></body></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>embi_ex312.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<html><head><title>embi_ex312.htm</title><!--Document Created by EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN; MARGIN: 0px 7%"><body style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN; MARGIN: 0px 7%" scroll="yes"><p style="MARGIN: 0px; text-align:right;"><strong>EXHIBIT 31.2</strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:center;"><strong>Certification </strong><strong>of Principal Financial Officer</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Required </strong><strong>By </strong><strong>Rule 13a-14(A) of the Securities Exchange Act of 1934, As Amended,</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>As Adopted Pursuant To Section 302 of the Sarbanes--Oxley Act of 2002</strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">I, Doug Cesario, certify that:</p> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="width:4%;vertical-align:top;">1.</td> <td style="vertical-align:top;">I have reviewed this annual report on Form 10-K of Emerald Bioscience, Inc.;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="width:4%;vertical-align:top;">2.</td> <td style="vertical-align:top;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="width:4%;vertical-align:top;">3.</td> <td style="vertical-align:top;">Based on my knowledge, the consolidated financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="width:4%;vertical-align:top;">4.</td> <td style="vertical-align:top;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Ru1es 13a-15(e) and 15d-15(e )) and internal control over financial reporting (as defined in Exchange Act Ru1es 13a-15(f) and 15d-15(f)) for the registrant and have:</td></tr></table> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:4%;vertical-align:top;">(a)</td> <td style="vertical-align:top;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particu1arly during the period in which this report is being prepared;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:4%;vertical-align:top;">(b)</td> <td style="vertical-align:top;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with generally accepted accounting principles;</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:4%;vertical-align:top;">(c)</td> <td style="vertical-align:top;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:4%;vertical-align:top;">(d)</td> <td style="vertical-align:top;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.</td></tr></table> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="width:4%;vertical-align:top;">5.</td> <td style="vertical-align:top;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</td></tr></table> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="width:4%;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px">(a)</p></td> <td> <p style="MARGIN: 0px">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</p></td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="vertical-align:top;"> <p style="MARGIN: 0px">&#160;</p></td> <td style="vertical-align:top;">(b)</td> <td style="vertical-align:top;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</td></tr></table>&#160;&#160; <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td style="width:35%;">Date: March 20, 2020</td> <td style="width:65%;"></td></tr> <tr> <td>&#160;</td> <td>&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid;"> <p style="MARGIN: 0px"><em>/s/ Doug Cesario</em></p></td> <td></td></tr> <tr> <td> <p style="MARGIN: 0px">Doug Cesario, Chief Financial Officer</p></td> <td>&#160;</td></tr> <tr> <td> <p style="MARGIN: 0px">(Principal Financial Officer)</p></td> <td>&#160;</td></tr></table> <p style="MARGIN: 0px">&#160;</p></body></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>embi_ex321.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<html><head><title>embi_ex321.htm</title><!--Document Created by EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN; MARGIN: 0px 7%"><body style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN; MARGIN: 0px 7%" scroll="yes"><p style="MARGIN: 0px; text-align:right;"><strong>EXHIBIT 32.1</strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:center;"><strong>Certification of Chief Executive Officer</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Section 906 of the Sarbanes-Oxley Act of 2002</strong></p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">In connection with the Annual Report of Emerald Bioscience, Inc., a Nevada corporation (the &#8220;Company&#8221;) on Form 10-K for the year ending December 31, 2019, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Brian S. Murphy, Chief Executive Officer of the Company, hereby certify, that, to my knowledge, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to&#167; 906 of the Sarbanes-Oxley Act of 2002:</p> <p style="MARGIN: 0px">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="width:4%;vertical-align:top;">(1)</td> <td style="vertical-align:top;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="vertical-align:top;">(2)</td> <td style="vertical-align:top;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</td></tr></table> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">A signed original of this written statement required by Section 906 has been provided to Emerald Bioscience, Inc., and will be retained by Emerald Bioscience, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</p> <p style="MARGIN: 0px">&#160; </p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td style="width:30%;">&#160;&#160;</td> <td style="width:15%;">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid;"> <p style="MARGIN: 0px; text-align:justify;"><em>/s/ Brian </em>S. <em>Murphy</em></p></td> <td></td></tr> <tr> <td> <p style="MARGIN: 0px">Brian S. Murphy</p></td> <td>&#160;</td></tr> <tr> <td> <p style="MARGIN: 0px">Chief Executive Officer</p> <p style="MARGIN: 0px">(Principal Executive Officer) </p></td> <td>&#160;</td></tr> <tr> <td> <p style="MARGIN: 0px">March 20, 2020</p></td> <td>&#160;</td></tr></table></body></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>embi_ex322.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<html><head><title>embi_ex322.htm</title><!--Document Created by EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN; MARGIN: 0px 7%"><body style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN; MARGIN: 0px 7%" scroll="yes"><p style="MARGIN: 0px; text-align:right;"><strong>EXHIBIT 32.2</strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:center;"><strong>Certification of Chief Financial Officer</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Section 906 of the Sarbanes-Oxley Act of 2002</strong></p> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px; text-align:justify;">In connection with the Annual Report of Emerald Bioscience, Inc., a Nevada corporation (the &#8220;Company&#8221;) on Form 10-K for the year ending December 31, 2019, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Doug Cesario, Chief Financial Officer of the Company, hereby certify, that, to my knowledge, pursuant to 18 U .S.C. &#167; 1350, as adopted pursuant to&#167; 906 of the Sarbanes-Oxley Act of 2002:</p> <p style="MARGIN: 0px; text-align:justify;">&#160;</p> <table style="border-collapse:collapse;text-align:justify;font:10pt times new roman;width:100%"> <tr> <td style="width:4%;vertical-align:top;">(1)</td> <td style="vertical-align:top;">The Report fully complies with the requirements of Section 13(a) or 15( d) of the Securities Exchange Act of 1934, as amended; and</td></tr> <tr> <td> <p style="MARGIN: 0px">&#160;</p></td> <td> <p style="MARGIN: 0px">&#160;</p></td></tr> <tr> <td style="vertical-align:top;">(2)</td> <td style="vertical-align:top;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</td></tr></table> <p style="MARGIN: 0px">&#160;</p> <p style="MARGIN: 0px">A signed original of this written statement required by Section 906 has been provided to&#160;Emerald&#160;Bioscience, Inc., and will be retained by Emerald Bioscience, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</p> <p style="MARGIN: 0px">&#160; </p> <table style="border-collapse:collapse;font:10pt times new roman;width:100%"> <tr> <td style="width:35%;">&#160;&#160;</td> <td style="width:65%;">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid;"><em>/s/ Doug Cesario</em></td> <td></td></tr> <tr> <td> <p style="MARGIN: 0px">Doug Cesario</p></td> <td>&#160;</td></tr> <tr> <td> <p style="MARGIN: 0px">Chief Financial Officer</p> <p style="MARGIN: 0px">(Principal Financial Officer)</p></td> <td>&#160;</td></tr> <tr> <td> <p style="MARGIN: 0px">March 20, 2020</p></td> <td>&#160;</td></tr></table></body></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>7
<FILENAME>embi-20191231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--INTEGIX by Ez-XBRL-->

<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:embi="http://www.emeraldbio.life/20191231" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































  <link:schemaRef xlink:href="embi-20191231.xsd" xlink:type="simple"></link:schemaRef>
  <context id="Context_As_Of_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_DerivativeInstrumentRiskAxis_SeriesBPreferredStockConversionLiabilityMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">embi:SeriesBPreferredStockConversionLiabilityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="Context_As_Of_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="Context_As_Of_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="Context_As_Of_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="Context_As_Of_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_AwardTypeAxis_RestrictedStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="Context_As_Of_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_DerivativeInstrumentRiskAxis_SeriesBPreferredStockConversionLiabilityMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">embi:SeriesBPreferredStockConversionLiabilityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="Context_As_Of_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">embi:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="Context_As_Of_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="Context_As_Of_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementEquityComponentsAxis_CommonStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="Context_As_Of_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="Context_As_Of_01_Nov_2018T00_00_00_TO_01_Nov_2018T00_00_00_TypeOfArrangementAxis_MultiDrawCreditAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:MultiDrawCreditAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-11-01</instant>
    </period>
  </context>
  <context id="Context_As_Of_05_Oct_2018T00_00_00_TO_05_Oct_2018T00_00_00_LegalEntityAxis_EmeraldFinancingMember_TypeOfArrangementAxis_MultiDrawCreditAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:MultiDrawCreditAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-10-05</instant>
    </period>
  </context>
  <context id="Context_As_Of_16-Feb-2018T00_00_00_RangeAxis_MaximumMember_LegalEntityAxis_EmeraldFinancingMember_PricingModelAxis_MonteCarloSimulationsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:MonteCarloSimulationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-02-16</instant>
    </period>
  </context>
  <context id="Context_As_Of_16-Feb-2018T00_00_00_RangeAxis_MinimumMember_LegalEntityAxis_EmeraldFinancingMember_PricingModelAxis_MonteCarloSimulationsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:MonteCarloSimulationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-02-16</instant>
    </period>
  </context>
  <context id="Context_As_Of_16_Feb_2018T00_00_00_TO_16_Feb_2018T00_00_00_MeasurementInputTypeAxis_MeasurementInputExpectedDividendRateMember_PricingModelAxis_MonteCarloSimulationsMember_LegalEntityAxis_EmeraldFinancingMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:MonteCarloSimulationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-02-16</instant>
    </period>
  </context>
  <context id="Context_As_Of_16_Feb_2018T00_00_00_TO_16_Feb_2018T00_00_00_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember_PricingModelAxis_MonteCarloSimulationsMember_LegalEntityAxis_EmeraldFinancingMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:MonteCarloSimulationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-02-16</instant>
    </period>
  </context>
  <context id="Context_As_Of_16_Feb_2018T00_00_00_TO_16_Feb_2018T00_00_00_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember_PricingModelAxis_MonteCarloSimulationsMember_LegalEntityAxis_EmeraldFinancingMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:MonteCarloSimulationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-02-16</instant>
    </period>
  </context>
  <context id="Context_As_Of_16_Feb_2018T00_00_00_TO_16_Feb_2018T00_00_00_RangeAxis_MaximumMember_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember_PricingModelAxis_MonteCarloSimulationsMember_LegalEntityAxis_EmeraldFinancingMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>





                    <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:MonteCarloSimulationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-02-16</instant>
    </period>
  </context>
  <context id="Context_As_Of_16_Feb_2018T00_00_00_TO_16_Feb_2018T00_00_00_RangeAxis_MinimumMember_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember_PricingModelAxis_MonteCarloSimulationsMember_LegalEntityAxis_EmeraldFinancingMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>





                    <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:MonteCarloSimulationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-02-16</instant>
    </period>
  </context>
  <context id="Context_As_Of_16_Feb_2018T00_00_00_TO_16_Feb_2018T00_00_00_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldHealthSciencesIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-02-16</instant>
    </period>
  </context>
  <context id="Context_As_Of_16_Feb_2018T00_00_00_TO_16_Feb_2018T00_00_00_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember_RelatedPartyTransactionsByRelatedPartyAxis_InvestorMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldHealthSciencesIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-02-16</instant>
    </period>
  </context>
  <context id="Context_As_Of_19-Jan-2018T00_00_00_RangeAxis_MaximumMember_LegalEntityAxis_EmeraldFinancingMember_PricingModelAxis_MonteCarloSimulationsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:MonteCarloSimulationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-01-19</instant>
    </period>
  </context>
  <context id="Context_As_Of_19-Jan-2018T00_00_00_RangeAxis_MinimumMember_LegalEntityAxis_EmeraldFinancingMember_PricingModelAxis_MonteCarloSimulationsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:MonteCarloSimulationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-01-19</instant>
    </period>
  </context>
  <context id="Context_As_Of_19_Jan_2018T00_00_00_TO_19_Jan_2018T00_00_00_MeasurementInputTypeAxis_MeasurementInputExpectedDividendRateMember_PricingModelAxis_MonteCarloSimulationsMember_LegalEntityAxis_EmeraldFinancingMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:MonteCarloSimulationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-01-19</instant>
    </period>
  </context>
  <context id="Context_As_Of_19_Jan_2018T00_00_00_TO_19_Jan_2018T00_00_00_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember_PricingModelAxis_MonteCarloSimulationsMember_LegalEntityAxis_EmeraldFinancingMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:MonteCarloSimulationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-01-19</instant>
    </period>
  </context>
  <context id="Context_As_Of_19_Jan_2018T00_00_00_TO_19_Jan_2018T00_00_00_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember_PricingModelAxis_MonteCarloSimulationsMember_LegalEntityAxis_EmeraldFinancingMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:MonteCarloSimulationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-01-19</instant>
    </period>
  </context>
  <context id="Context_As_Of_19_Jan_2018T00_00_00_TO_19_Jan_2018T00_00_00_RangeAxis_MaximumMember_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember_PricingModelAxis_MonteCarloSimulationsMember_LegalEntityAxis_EmeraldFinancingMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>





                    <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:MonteCarloSimulationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-01-19</instant>
    </period>
  </context>
  <context id="Context_As_Of_19_Jan_2018T00_00_00_TO_19_Jan_2018T00_00_00_RangeAxis_MinimumMember_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember_PricingModelAxis_MonteCarloSimulationsMember_LegalEntityAxis_EmeraldFinancingMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>





                    <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:MonteCarloSimulationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-01-19</instant>
    </period>
  </context>
  <context id="Context_As_Of_19_Jan_2018T00_00_00_TO_19_Jan_2018T00_00_00_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldHealthSciencesIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-01-19</instant>
    </period>
  </context>
  <context id="Context_As_Of_28_Dec_2017T00_00_00_TO_28_Dec_2017T00_00_00_ShortTermDebtTypeAxis_BridgeLoanMember_TypeOfArrangementAxis_SecuredPromissoryNoteAndSecurityAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:SecuredPromissoryNoteAndSecurityAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldHealthSciencesIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2017-12-28</instant>
    </period>
  </context>
  <context id="Context_As_Of_31-Dec-2018T00_00_00_LegalEntityAxis_EmeraldHealthSciencesIncMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldHealthSciencesIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00">



        <entity>


              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
    </entity>
    <period>


              <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_deiLegalEntityAxis_embiEmeraldFinancingMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_usgaapClassOfWarrantOrRightAxis_embiEmeraldConvertiblePromissoryNoteConversionLiabilityMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:EmeraldConvertiblePromissoryNoteConversionLiabilityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_usgaapClassOfWarrantOrRightAxis_embiSeriesBWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:SeriesBWarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_usgaapStatementClassOfStockAxis_usgaapSeriesDPreferredStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_usgaapStatementClassOfStockAxis_usgaapSeriesFPreferredStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00">



        <entity>


              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
    </entity>
    <period>


              <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00_deiLegalEntityAxis_embiEmeraldFinancingMember_embiPricingModelAxis_embiMonteCarloSimulationsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:MonteCarloSimulationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00_LegalEntityAxis_EmeraldFinancingMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00_MeasurementInputTypeAxis_MeasurementInputExpectedDividendRateMember_PricingModelAxis_PricingModelMember_StatementClassOfStockAxis_SeriesBWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:SeriesBWarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember_PricingModelAxis_PricingModelMember_StatementClassOfStockAxis_SeriesBWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:SeriesBWarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">embi:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtMember_LegalEntityAxis_EmeraldHealthSciencesIncMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldHealthSciencesIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00_usgaapClassOfWarrantOrRightAxis_embiEmeraldConvertiblePromissoryNoteConversionLiabilityMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:EmeraldConvertiblePromissoryNoteConversionLiabilityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00_usgaapClassOfWarrantOrRightAxis_embiSeriesBWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:SeriesBWarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00_usgaapClassOfWarrantOrRightAxis_embiSeriesBWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:SeriesBWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00_usgaapIncomeTaxAuthorityAxis_usgaapForeignCountryMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember_embiPricingModelAxis_embiMonteCarloSimulationsMember_deiLegalEntityAxis_embiEmeraldFinancingMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:MonteCarloSimulationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedTermMember_embiPricingModelAxis_embiMonteCarloSimulationsMember_deiLegalEntityAxis_embiEmeraldFinancingMember_srtRangeAxis_srtMaximumMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>





                    <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:MonteCarloSimulationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedTermMember_embiPricingModelAxis_embiMonteCarloSimulationsMember_deiLegalEntityAxis_embiEmeraldFinancingMember_srtRangeAxis_srtMinimumMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>





                    <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:MonteCarloSimulationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedTermMember_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember_srtRangeAxis_srtMaximumMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>





                    <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:SeriesBWarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedTermMember_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember_srtRangeAxis_srtMinimumMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>





                    <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:SeriesBWarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember_embiPricingModelAxis_embiMonteCarloSimulationsMember_deiLegalEntityAxis_embiEmeraldFinancingMember_srtRangeAxis_srtMaximumMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>





                    <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:MonteCarloSimulationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember_embiPricingModelAxis_embiMonteCarloSimulationsMember_deiLegalEntityAxis_embiEmeraldFinancingMember_srtRangeAxis_srtMinimumMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>





                    <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:MonteCarloSimulationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember_embiPricingModelAxis_embiMonteCarloSimulationsMember_deiLegalEntityAxis_embiEmeraldFinancingMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:MonteCarloSimulationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:MultiDrawCreditAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="Context_As_Of_31_Oct_2014T00_00_00_TO_31_Oct_2014T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">embi:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2014-10-31</instant>
    </period>
  </context>
  <context id="Context_Custom_01_Dec_2017T00_00_00_TO_28_Dec_2017T00_00_00_ShortTermDebtTypeAxis_BridgeLoanMember_TypeOfArrangementAxis_SecuredPromissoryNoteAndSecurityAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:SecuredPromissoryNoteAndSecurityAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldHealthSciencesIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2017-12-01</startDate>
      <endDate>2017-12-28</endDate>
    </period>
  </context>
  <context id="Context_Custom_01_Feb_2018T00_00_00_TO_06_Feb_2018T00_00_00_LegalEntityAxis_EmeraldHealthSciencesIncMember_TypeOfArrangementAxis_ConsultingAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:ConsultingAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldHealthSciencesIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-02-01</startDate>
      <endDate>2018-02-06</endDate>
    </period>
  </context>
  <context id="Context_Custom_01_Feb_2018T00_00_00_TO_16_Feb_2018T00_00_00_LegalEntityAxis_EmeraldFinancingMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-02-01</startDate>
      <endDate>2018-02-16</endDate>
    </period>
  </context>
  <context id="Context_Custom_01_Feb_2018T00_00_00_TO_16_Feb_2018T00_00_00_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldHealthSciencesIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-02-01</startDate>
      <endDate>2018-02-16</endDate>
    </period>
  </context>
  <context id="Context_Custom_01_Feb_2018T00_00_00_TO_16_Feb_2018T00_00_00_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember_RelatedPartyTransactionsByRelatedPartyAxis_InvestorMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldHealthSciencesIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-02-01</startDate>
      <endDate>2018-02-16</endDate>
    </period>
  </context>
  <context id="Context_Custom_01_Feb_2018T00_00_00_TO_28_Feb_2018T00_00_00_AwardTypeAxis_RestrictedStockMember_LegalEntityAxis_K2CIncMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:K2CIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-02-01</startDate>
      <endDate>2018-02-28</endDate>
    </period>
  </context>
  <context id="Context_Custom_01_Feb_2018T00_00_00_TO_28_Feb_2018T00_00_00_TypeOfArrangementAxis_RestrictedStockAgreementsMember_LegalEntityAxis_K2CIncMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:RestrictedStockAgreementsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:K2CIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-02-01</startDate>
      <endDate>2018-02-28</endDate>
    </period>
  </context>
  <context id="Context_Custom_01_Feb_2018T00_00_00_TO_28_Feb_2018T00_00_00_TypeOfArrangementAxis_SeparationAndReleaseAgreementMember_LegalEntityAxis_K2CIncMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:SeparationAndReleaseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:K2CIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-02-01</startDate>
      <endDate>2018-02-28</endDate>
    </period>
  </context>
  <context id="Context_Custom_01_Feb_2018T00_00_00_TO_28_Feb_2018T00_00_00_TypeOfArrangementAxis_SeparationAndReleaseAgreementMember_LegalEntityAxis_K2CIncMember_VestingAxis_ShareBasedCompensationAwardTrancheOneMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:SeparationAndReleaseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:K2CIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-02-01</startDate>
      <endDate>2018-02-28</endDate>
    </period>
  </context>
  <context id="Context_Custom_01_Feb_2018T00_00_00_TO_28_Feb_2018T00_00_00_TypeOfArrangementAxis_SeparationAndReleaseAgreementMember_LegalEntityAxis_K2CIncMember_VestingAxis_ShareBasedCompensationAwardTrancheThreeMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:SeparationAndReleaseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:K2CIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-02-01</startDate>
      <endDate>2018-02-28</endDate>
    </period>
  </context>
  <context id="Context_Custom_01_Feb_2018T00_00_00_TO_28_Feb_2018T00_00_00_TypeOfArrangementAxis_SeparationAndReleaseAgreementMember_LegalEntityAxis_K2CIncMember_VestingAxis_ShareBasedCompensationAwardTrancheTwoMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:SeparationAndReleaseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:K2CIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-02-01</startDate>
      <endDate>2018-02-28</endDate>
    </period>
  </context>
  <context id="Context_Custom_01_Jan_2018T00_00_00_TO_18_Jan_2018T00_00_00_AwardTypeAxis_RestrictedStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-01-01</startDate>
      <endDate>2018-01-18</endDate>
    </period>
  </context>
  <context id="Context_Custom_01_Jan_2018T00_00_00_TO_18_Jan_2018T00_00_00_AwardTypeAxis_RestrictedStockMember_TitleOfIndividualAxis_BoardOfDirectorsChairmanMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-01-01</startDate>
      <endDate>2018-01-18</endDate>
    </period>
  </context>
  <context id="Context_Custom_01_Jan_2018T00_00_00_TO_18_Jan_2018T00_00_00_AwardTypeAxis_RestrictedStockMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-01-01</startDate>
      <endDate>2018-01-18</endDate>
    </period>
  </context>
  <context id="Context_Custom_01_Jan_2018T00_00_00_TO_18_Jan_2018T00_00_00_AwardTypeAxis_RestrictedStockMember_TitleOfIndividualAxis_ChiefFinancialOfficerMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-01-01</startDate>
      <endDate>2018-01-18</endDate>
    </period>
  </context>
  <context id="Context_Custom_01_Jan_2018T00_00_00_TO_19_Jan_2018T00_00_00_LegalEntityAxis_EmeraldFinancingMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-01-01</startDate>
      <endDate>2018-01-19</endDate>
    </period>
  </context>
  <context id="Context_Custom_01_Jan_2018T00_00_00_TO_19_Jan_2018T00_00_00_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldHealthSciencesIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-01-01</startDate>
      <endDate>2018-01-19</endDate>
    </period>
  </context>
  <context id="Context_Custom_01_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_LegalEntityAxis_K2CIncMember_TypeOfArrangementAxis_IndependentContractorAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:IndependentContractorAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:K2CIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2014-06-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="Context_Custom_01_May_2018T00_00_00_TO_25_May_2018T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_usgaapPlanNameAxis_embiAwardsGrantedOutsideThe2014PlanMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">embi:AwardsGrantedOutsideThe2014PlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-05-01</startDate>
      <endDate>2018-05-25</endDate>
    </period>
  </context>
  <context id="Context_Custom_01_May_2018T00_00_00_TO_25_May_2018T00_00_00_AwardTypeAxis_RestrictedStockMember_TitleOfIndividualAxis_ChiefFinancialOfficerMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-05-01</startDate>
      <endDate>2018-05-25</endDate>
    </period>
  </context>
  <context id="Context_Custom_01_May_2018T00_00_00_TO_25_May_2018T00_00_00_TitleOfIndividualAxis_DouglasCesarioMember_TypeOfArrangementAxis_RestrictedStockAgreementsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">embi:DouglasCesarioMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:RestrictedStockAgreementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-05-01</startDate>
      <endDate>2018-05-25</endDate>
    </period>
  </context>
  <context id="Context_Custom_01_Oct_2018T00_00_00_TO_05_Oct_2018T00_00_00_LegalEntityAxis_EmeraldFinancingMember_TypeOfArrangementAxis_MultiDrawCreditAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:MultiDrawCreditAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-10-01</startDate>
      <endDate>2018-10-05</endDate>
    </period>
  </context>
  <context id="Context_Custom_25_Mar_2017T00_00_00_TO_01_Apr_2017T00_00_00_LegalEntityAxis_K2CIncMember_TypeOfArrangementAxis_IndependentContractorAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:IndependentContractorAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:K2CIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2017-03-25</startDate>
      <endDate>2017-04-01</endDate>
    </period>
  </context>
  <context id="Context_Custom_31_Oct_2018T00_00_00_TO_01_Nov_2018T00_00_00_TypeOfArrangementAxis_MultiDrawCreditAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:MultiDrawCreditAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-10-31</startDate>
      <endDate>2018-11-01</endDate>
    </period>
  </context>
  <context id="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00">



        <entity>


              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
    </entity>
    <period>



              <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertibleDebtSecuritiesMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_deiLegalEntityAxis_embiEmeraldFinancingMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember_usgaapTypeOfArrangementAxis_embiConsultingAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:ConsultingAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldHealthSciencesIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember_usgaapTypeOfArrangementAxis_embiIndependentContractorAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:IndependentContractorAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldHealthSciencesIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_deiLegalEntityAxis_embiK2CIncMember_usgaapTypeOfArrangementAxis_embiRestrictedStockAgreementsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:RestrictedStockAgreementsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:K2CIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_DerivativeInstrumentRiskAxis_SeriesBPreferredStockConversionLiabilityMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">embi:SeriesBPreferredStockConversionLiabilityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_LegalEntityAxis_K2CIncMember_TypeOfArrangementAxis_IndependentContractorAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:IndependentContractorAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:K2CIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">embi:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_srtTitleOfIndividualAxis_embiDouglasCesarioMember_usgaapTypeOfArrangementAxis_embiRestrictedStockAgreementsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">embi:DouglasCesarioMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:RestrictedStockAgreementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementClassOfStockAxis_SeriesDPreferredStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementClassOfStockAxis_SeriesFPreferredStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementEquityComponentsAxis_CommonStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_usgaapClassOfWarrantOrRightAxis_embiEmeraldConvertiblePromissoryNoteConversionLiabilityMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:EmeraldConvertiblePromissoryNoteConversionLiabilityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_usgaapClassOfWarrantOrRightAxis_embiSeriesBWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:SeriesBWarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_usgaapClassOfWarrantOrRightAxis_embiSeriesBWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:SeriesBWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_srtRangeAxis_srtMaximumMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">embi:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_srtRangeAxis_srtMinimumMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">embi:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_usgaapTypeOfArrangementAxis_embiSeparationAndReleaseAgreementMember_deiLegalEntityAxis_embiK2CIncMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:SeparationAndReleaseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:K2CIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="C_20170101to20170110_usgaapTypeOfArrangementAxis_embiUm5070LicenseAgreementMember_deiLegalEntityAxis_embiUniversityOfMississippiMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapIntellectualPropertyMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:Um5070LicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:UniversityOfMississippiMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2017-01-01</startDate>
      <endDate>2017-01-10</endDate>
    </period>
  </context>
  <context id="C_20171228_usgaapClassOfWarrantOrRightAxis_embiSeriesBWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:SeriesBWarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2017-12-28</instant>
    </period>
  </context>
  <context id="C_20171231_usgaapClassOfWarrantOrRightAxis_embiEmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_20180101to20180119_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldHealthSciencesIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-01-01</startDate>
      <endDate>2018-01-19</endDate>
    </period>
  </context>
  <context id="C_20180101to20180119_usgaapClassOfWarrantOrRightAxis_embiEmeraldConvertiblePromissoryNoteConversionLiabilityMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:EmeraldConvertiblePromissoryNoteConversionLiabilityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-01-01</startDate>
      <endDate>2018-01-19</endDate>
    </period>
  </context>
  <context id="C_20180101to20180119_usgaapShortTermDebtTypeAxis_usgaapBridgeLoanMember_usgaapTypeOfArrangementAxis_embiSecuredPromissoryNoteAndSecurityAgreementMember_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:SecuredPromissoryNoteAndSecurityAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldHealthSciencesIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-01-01</startDate>
      <endDate>2018-01-19</endDate>
    </period>
  </context>
  <context id="C_20180101to20180131_usgaapClassOfWarrantOrRightAxis_embiSeriesBWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:SeriesBWarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-01-01</startDate>
      <endDate>2018-01-31</endDate>
    </period>
  </context>
  <context id="C_20180101to20181231_srtTitleOfIndividualAxis_srtChiefFinancialOfficerMember_usgaapTypeOfArrangementAxis_embiRestrictedStockAgreementsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:RestrictedStockAgreementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="C_20180101to20181231_usgaapAwardTypeAxis_usgaapRestrictedStockMember_deiLegalEntityAxis_embiK2CIncMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:K2CIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="C_20180101to20181231_usgaapAwardTypeAxis_usgaapRestrictedStockMember_usgaapTitleOfIndividualAxis_usgaapChiefFinancialOfficerMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="C_20180101to20181231_usgaapClassOfWarrantOrRightAxis_embiEmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="C_20180119_deiLegalEntityAxis_embiEmeraldFinancingMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-01-19</instant>
    </period>
  </context>
  <context id="C_20180119_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldHealthSciencesIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-01-19</instant>
    </period>
  </context>
  <context id="C_20180119_embiPricingModelAxis_embiPricingModelMember_usgaapClassOfWarrantOrRightAxis_embiEmeraldConvertiblePromissoryNoteConversionLiabilityMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:EmeraldConvertiblePromissoryNoteConversionLiabilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-01-19</instant>
    </period>
  </context>
  <context id="C_20180119_usgaapClassOfWarrantOrRightAxis_embiSeriesBWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:SeriesBWarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-01-19</instant>
    </period>
  </context>
  <context id="C_20180119_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldFinancingWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandEighteenEmeraldFinancingWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-01-19</instant>
    </period>
  </context>
  <context id="C_20180119_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember_embiPricingModelAxis_embiPricingModelMember_usgaapClassOfWarrantOrRightAxis_embiEmeraldConvertiblePromissoryNoteConversionLiabilityMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:EmeraldConvertiblePromissoryNoteConversionLiabilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-01-19</instant>
    </period>
  </context>
  <context id="C_20180119_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedTermMember_embiPricingModelAxis_embiPricingModelMember_usgaapClassOfWarrantOrRightAxis_embiEmeraldConvertiblePromissoryNoteConversionLiabilityMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:EmeraldConvertiblePromissoryNoteConversionLiabilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-01-19</instant>
    </period>
  </context>
  <context id="C_20180119_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember_embiPricingModelAxis_embiPricingModelMember_usgaapClassOfWarrantOrRightAxis_embiEmeraldConvertiblePromissoryNoteConversionLiabilityMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:EmeraldConvertiblePromissoryNoteConversionLiabilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-01-19</instant>
    </period>
  </context>
  <context id="C_20180119_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember_embiPricingModelAxis_embiPricingModelMember_usgaapClassOfWarrantOrRightAxis_embiEmeraldConvertiblePromissoryNoteConversionLiabilityMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:EmeraldConvertiblePromissoryNoteConversionLiabilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-01-19</instant>
    </period>
  </context>
  <context id="C_20180120to20181231_usgaapClassOfWarrantOrRightAxis_embiSeriesBWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:SeriesBWarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-01-20</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="C_20180131_usgaapClassOfWarrantOrRightAxis_embiSeriesBWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:SeriesBWarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-01-31</instant>
    </period>
  </context>
  <context id="C_20180216_deiLegalEntityAxis_embiEmeraldFinancingMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-02-16</instant>
    </period>
  </context>
  <context id="C_20180216_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldFinancingWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandEighteenEmeraldFinancingWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-02-16</instant>
    </period>
  </context>
  <context id="C_20180501to20180525_srtTitleOfIndividualAxis_srtChiefFinancialOfficerMember_usgaapTypeOfArrangementAxis_embiRestrictedStockAgreementsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:RestrictedStockAgreementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-05-01</startDate>
      <endDate>2018-05-25</endDate>
    </period>
  </context>
  <context id="C_20180701to20180731_usgaapTypeOfArrangementAxis_embiLicenseAgreementMember_deiLegalEntityAxis_embiUniversityOfMississippiMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapIntellectualPropertyMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:LicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:UniversityOfMississippiMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-07-01</startDate>
      <endDate>2018-07-31</endDate>
    </period>
  </context>
  <context id="C_20180701to20180731_usgaapTypeOfArrangementAxis_embiOptionAgreementMember_deiLegalEntityAxis_embiUniversityOfMississippiMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapIntellectualPropertyMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:OptionAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:UniversityOfMississippiMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-07-01</startDate>
      <endDate>2018-07-31</endDate>
    </period>
  </context>
  <context id="C_20180701to20180731_usgaapTypeOfArrangementAxis_embiUm5050ProdrugAndUm8930AnalogAgreementsMember_deiLegalEntityAxis_embiUniversityOfMississippiMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapIntellectualPropertyMember_embiMilestonePaymentsPayableAxis_embiMilestone1Member">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>





                    <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:Um5050ProdrugAndUm8930AnalogAgreementsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:MilestonePaymentsPayableAxis">embi:Milestone1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:UniversityOfMississippiMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-07-01</startDate>
      <endDate>2018-07-31</endDate>
    </period>
  </context>
  <context id="C_20180701to20180731_usgaapTypeOfArrangementAxis_embiUm5050ProdrugAndUm8930AnalogAgreementsMember_deiLegalEntityAxis_embiUniversityOfMississippiMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapIntellectualPropertyMember_embiMilestonePaymentsPayableAxis_embiMilestone2Member">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>





                    <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:Um5050ProdrugAndUm8930AnalogAgreementsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:MilestonePaymentsPayableAxis">embi:Milestone2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:UniversityOfMississippiMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-07-01</startDate>
      <endDate>2018-07-31</endDate>
    </period>
  </context>
  <context id="C_20180701to20180731_usgaapTypeOfArrangementAxis_embiUm5050ProdrugAndUm8930AnalogAgreementsMember_deiLegalEntityAxis_embiUniversityOfMississippiMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapIntellectualPropertyMember_embiMilestonePaymentsPayableAxis_embiMilestone3Member">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>





                    <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:Um5050ProdrugAndUm8930AnalogAgreementsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:MilestonePaymentsPayableAxis">embi:Milestone3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:UniversityOfMississippiMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-07-01</startDate>
      <endDate>2018-07-31</endDate>
    </period>
  </context>
  <context id="C_20181024to20181101_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-10-24</startDate>
      <endDate>2018-11-01</endDate>
    </period>
  </context>
  <context id="C_20181101_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-11-01</instant>
    </period>
  </context>
  <context id="C_20181101_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_embiPricingModelAxis_embiPricingModelMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-11-01</instant>
    </period>
  </context>
  <context id="C_20181101_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_embiPricingModelAxis_embiPricingModelMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedTermMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-11-01</instant>
    </period>
  </context>
  <context id="C_20181101_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_embiPricingModelAxis_embiPricingModelMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-11-01</instant>
    </period>
  </context>
  <context id="C_20181101_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember_embiPricingModelAxis_embiPricingModelMember_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-11-01</instant>
    </period>
  </context>
  <context id="C_20181101_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember_embiPricingModelAxis_embiPricingModelMember_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-11-01</instant>
    </period>
  </context>
  <context id="C_20181115">



        <entity>


              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
    </entity>
    <period>


              <instant>2018-11-15</instant>
    </period>
  </context>
  <context id="C_20181231_usgaapClassOfWarrantOrRightAxis_embiEmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="C_20181231_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember_embiPricingModelAxis_embiPricingModelMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:SeriesBWarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="C_20181231_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember_embiPricingModelAxis_embiPricingModelMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:SeriesBWarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="C_20190101to20191231">



        <entity>


              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20190101to20191231_deiLegalEntityAxis_embiEmeraldFinancingMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20190101to20191231_deiLegalEntityAxis_embiEmeraldFinancingMember_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:MultiDrawCreditAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20190101to20191231_embiDilutedSecuritiesAxis_embiOptionsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="embi:DilutedSecuritiesAxis">embi:OptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20190101to20191231_embiDilutedSecuritiesAxis_embiUnvestedRestrictedStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="embi:DilutedSecuritiesAxis">embi:UnvestedRestrictedStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20190101to20191231_embiDilutedSecuritiesAxis_embiWarrantsLiabilityClassifiedMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="embi:DilutedSecuritiesAxis">embi:WarrantsLiabilityClassifiedMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20190101to20191231_embiDilutedSecuritiesAxis_embiWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="embi:DilutedSecuritiesAxis">embi:WarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20190101to20191231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapConvertibleDebtSecuritiesMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20190101to20191231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapEmployeeStockOptionMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20190101to20191231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapRestrictedStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20190101to20191231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20190101to20191231_usgaapAwardTypeAxis_usgaapRestrictedStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_embiCommonStockWarrantsToSeriesBStockholdersMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:CommonStockWarrantsToSeriesBStockholdersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_embiEmeraldConvertiblePromissoryNoteConversionLiabilityMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:EmeraldConvertiblePromissoryNoteConversionLiabilityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_embiEmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_embiPre2015CommonStockWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:Pre2015CommonStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_embiPre2015CommonStockWarrantsMember_srtRangeAxis_srtMaximumMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:Pre2015CommonStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_embiPre2015CommonStockWarrantsMember_srtRangeAxis_srtMinimumMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:Pre2015CommonStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_embiSeriesBWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:SeriesBWarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldFinancingWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandEighteenEmeraldFinancingWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_embiTwoThousandFifteenCommonStockWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandFifteenCommonStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_embiTwoThousandFifteenCommonStockWarrantsMember_srtRangeAxis_srtMaximumMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandFifteenCommonStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_embiTwoThousandFifteenCommonStockWarrantsMember_srtRangeAxis_srtMinimumMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandFifteenCommonStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_embiTwoThousandNineteenCommonStockWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandNineteenCommonStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_embiTwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_embiTwoThousandSeventeenSeriesDPlacementAgentWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_embiTwoThousandSixteenCommonStockWarrantsToServiceProvidersMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_embiTwoThousandSixteenSeriesCPlacementAgentWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandSixteenSeriesCPlacementAgentWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20190101to20191231_usgaapPlanNameAxis_embiAwardsGrantedOutside2014PlanMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">embi:AwardsGrantedOutside2014PlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20190101to20191231_usgaapPlanNameAxis_embiAwardsGrantedOutside2014PlanMember_usgaapAwardTypeAxis_usgaapRestrictedStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">embi:AwardsGrantedOutside2014PlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20190101to20191231_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">embi:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20190101to20191231_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">embi:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20190101to20191231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20190101to20191231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20190101to20191231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20190101to20191231_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20190101to20191231_usgaapTitleOfIndividualAxis_embiDouglasCesarioMember_usgaapTypeOfArrangementAxis_embiRestrictedStockAgreementsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">embi:DouglasCesarioMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:RestrictedStockAgreementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20190101to20191231_usgaapTypeOfArrangementAxis_embiIndependentContractorAgreementMember_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:IndependentContractorAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldHealthSciencesIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20190101to20191231_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:MultiDrawCreditAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20190628">



        <entity>


              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
    </entity>
    <period>


              <instant>2019-06-28</instant>
    </period>
  </context>
  <context id="C_20191101to20191130_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-11-01</startDate>
      <endDate>2019-11-30</endDate>
    </period>
  </context>
  <context id="C_20191130_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-11-30</instant>
    </period>
  </context>
  <context id="C_20191201to20191219_usgaapTypeOfArrangementAxis_embiIndependentContractorAgreementMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_embiAvtarDhillonMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">embi:AvtarDhillonMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:IndependentContractorAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-12-01</startDate>
      <endDate>2019-12-19</endDate>
    </period>
  </context>
  <context id="C_20191201to20191220_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldFinancingWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandEighteenEmeraldFinancingWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-12-01</startDate>
      <endDate>2019-12-20</endDate>
    </period>
  </context>
  <context id="C_20191231">



        <entity>


              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_deiLegalEntityAxis_embiEmeraldFinancingMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_deiLegalEntityAxis_embiEmeraldFinancingMember_embiPricingModelAxis_embiMonteCarloSimulationsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:MonteCarloSimulationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:SeriesBWarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_srtRangeAxis_srtMaximumMember_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_embiPricingModelAxis_embiPricingModelMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_srtRangeAxis_srtMaximumMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_embiPricingModelAxis_embiPricingModelMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>





                    <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_srtRangeAxis_srtMaximumMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_embiPricingModelAxis_embiPricingModelMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>





                    <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_srtRangeAxis_srtMinimumMember_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_embiPricingModelAxis_embiPricingModelMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_srtRangeAxis_srtMinimumMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_embiPricingModelAxis_embiPricingModelMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>





                    <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_srtRangeAxis_srtMinimumMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_embiPricingModelAxis_embiPricingModelMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>





                    <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapAwardTypeAxis_usgaapRestrictedStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapClassOfWarrantOrRightAxis_embiCommonStockWarrantsToSeriesBStockholdersMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:CommonStockWarrantsToSeriesBStockholdersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapClassOfWarrantOrRightAxis_embiEmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapClassOfWarrantOrRightAxis_embiPre2015CommonStockWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:Pre2015CommonStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapClassOfWarrantOrRightAxis_embiSeriesBWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:SeriesBWarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldFinancingWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandEighteenEmeraldFinancingWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapClassOfWarrantOrRightAxis_embiTwoThousandFifteenCommonStockWarrantsMember_srtRangeAxis_srtMaximumMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandFifteenCommonStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapClassOfWarrantOrRightAxis_embiTwoThousandFifteenCommonStockWarrantsMember_srtRangeAxis_srtMinimumMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandFifteenCommonStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapClassOfWarrantOrRightAxis_embiTwoThousandNineteenCommonStockWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandNineteenCommonStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapClassOfWarrantOrRightAxis_embiTwoThousandNineteenCommonStockWarrantsMember_embiPricingModelAxis_embiPricingModelMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandNineteenCommonStockWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapClassOfWarrantOrRightAxis_embiTwoThousandNineteenCommonStockWarrantsMember_embiPricingModelAxis_embiPricingModelMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandNineteenCommonStockWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapClassOfWarrantOrRightAxis_embiTwoThousandNineteenCommonStockWarrantsMember_embiPricingModelAxis_embiPricingModelMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedTermMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandNineteenCommonStockWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapClassOfWarrantOrRightAxis_embiTwoThousandNineteenCommonStockWarrantsMember_embiPricingModelAxis_embiPricingModelMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandNineteenCommonStockWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapClassOfWarrantOrRightAxis_embiTwoThousandNineteenCommonStockWarrantsMember_embiPricingModelAxis_embiPricingModelMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandNineteenCommonStockWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapClassOfWarrantOrRightAxis_embiTwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapClassOfWarrantOrRightAxis_embiTwoThousandSeventeenSeriesDPlacementAgentWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapClassOfWarrantOrRightAxis_embiTwoThousandSixteenCommonStockWarrantsToServiceProvidersMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapClassOfWarrantOrRightAxis_embiTwoThousandSixteenSeriesCPlacementAgentWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandSixteenSeriesCPlacementAgentWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapIncomeTaxAuthorityAxis_usgaapForeignCountryMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember_embiPricingModelAxis_embiMonteCarloSimulationsMember_deiLegalEntityAxis_embiEmeraldFinancingMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:MonteCarloSimulationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember_embiPricingModelAxis_embiPricingModelMember_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:SeriesBWarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedTermMember_embiPricingModelAxis_embiMonteCarloSimulationsMember_deiLegalEntityAxis_embiEmeraldFinancingMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:MonteCarloSimulationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedTermMember_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:SeriesBWarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedTermMember_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_embiPricingModelAxis_embiPricingModelMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember_embiPricingModelAxis_embiMonteCarloSimulationsMember_deiLegalEntityAxis_embiEmeraldFinancingMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:MonteCarloSimulationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:SeriesBWarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember_embiPricingModelAxis_embiMonteCarloSimulationsMember_deiLegalEntityAxis_embiEmeraldFinancingMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:MonteCarloSimulationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:SeriesBWarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">embi:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">embi:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapShortTermDebtTypeAxis_usgaapConvertibleDebtMember_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldHealthSciencesIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapTypeOfArrangementAxis_embiIndependentContractorAgreementMember_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:IndependentContractorAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldHealthSciencesIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:MultiDrawCreditAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20200301to20200331_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-03-01</startDate>
      <endDate>2020-03-31</endDate>
    </period>
  </context>
  <context id="C_20200316">



        <entity>


              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
    </entity>
    <period>


              <instant>2020-03-16</instant>
    </period>
  </context>
  <context id="C_20200331">



        <entity>


              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
    </entity>
    <period>


              <instant>2020-03-31</instant>
    </period>
  </context>
  <unit id="USD">


        <measure>iso4217:USD</measure>
  </unit>
  <unit id="USD_per_Share">


        <divide>



              <unitNumerator>


                    <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>


                    <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="USD_per_warrants">


        <measure>embi:USD_per_warrants</measure>
  </unit>
  <unit id="pure">


        <measure>pure</measure>
  </unit>
  <unit id="shares">


        <measure>shares</measure>
  </unit>
  <dei:EntityCentralIndexKey contextRef="C_20190101to20191231" id="Fdei_EntityCentralIndexKey_Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00">0001516551</dei:EntityCentralIndexKey>
  <dei:EntityCurrentReportingStatus contextRef="C_20190101to20191231" id="Fdei_EntityCurrentReportingStatus_Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityVoluntaryFilers contextRef="C_20190101to20191231" id="Fdei_EntityVoluntaryFilers_Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00">No</dei:EntityVoluntaryFilers>
  <dei:CurrentFiscalYearEndDate contextRef="C_20190101to20191231" id="Fdei_CurrentFiscalYearEndDate_Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:EntityFilerCategory contextRef="C_20190101to20191231" id="Fdei_EntityFilerCategory_Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00">Non-accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityWellKnownSeasonedIssuer contextRef="C_20190101to20191231" id="Fdei_EntityWellKnownSeasonedIssuer_Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00">No</dei:EntityWellKnownSeasonedIssuer>
  <dei:AmendmentFlag contextRef="C_20190101to20191231" id="Fdei_AmendmentFlag_Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00">false</dei:AmendmentFlag>
  <dei:DocumentFiscalYearFocus contextRef="C_20190101to20191231" id="Fdei_DocumentFiscalYearFocus_Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00">2019</dei:DocumentFiscalYearFocus>
  <dei:DocumentFiscalPeriodFocus contextRef="C_20190101to20191231" id="Fdei_DocumentFiscalPeriodFocus_Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00">FY</dei:DocumentFiscalPeriodFocus>
  <dei:EntitySmallBusiness contextRef="C_20190101to20191231" id="Fdei_EntitySmallBusiness_Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00">true</dei:EntitySmallBusiness>
  <dei:EntityEmergingGrowthCompany contextRef="C_20190101to20191231" id="Fdei_EntityEmergingGrowthCompany_Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00">false</dei:EntityEmergingGrowthCompany>
  <dei:EntityShellCompany contextRef="C_20190101to20191231" id="Fdei_EntityShellCompany_Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00">false</dei:EntityShellCompany>
  <dei:DocumentType contextRef="C_20190101to20191231" id="F22_10K">10-K</dei:DocumentType>
  <dei:DocumentPeriodEndDate contextRef="C_20190101to20191231" id="F31_December31">2019-12-31</dei:DocumentPeriodEndDate>
  <dei:EntityRegistrantName contextRef="C_20190101to20191231" id="F49_NemusBiosc">Emerald Bioscience, Inc.</dei:EntityRegistrantName>
  <dei:EntityInteractiveDataCurrent contextRef="C_20190101to20191231" id="Fxbrl_20200312193409162">Yes</dei:EntityInteractiveDataCurrent>
  <dei:EntityPublicFloat contextRef="C_20190628" decimals="0" id="F200_16326892" unitRef="USD">17116620</dei:EntityPublicFloat>
  <dei:EntityCommonStockSharesOutstanding contextRef="C_20200316" decimals="INF" id="F202_133907747" unitRef="shares">183207747</dei:EntityCommonStockSharesOutstanding>
  <us-gaap:Cash contextRef="C_20191231" decimals="0" id="F7313" unitRef="USD">1829977</us-gaap:Cash>
  <us-gaap:Cash contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="F7319" unitRef="USD">1853373</us-gaap:Cash>
  <us-gaap:Cash contextRef="C_20200331" decimals="0" id="Fxbrl_20200319123750932" unitRef="USD">667000</us-gaap:Cash>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="C_20191231" decimals="0" id="F7329" unitRef="USD">4538</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="F7336" unitRef="USD">4512</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:PrepaidExpenseCurrent contextRef="C_20191231" decimals="0" id="F7346" unitRef="USD">152695</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:PrepaidExpenseCurrent contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="F7353" unitRef="USD">93193</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:OtherAssetsCurrent contextRef="C_20191231" decimals="0" id="F7363" unitRef="USD">7550</us-gaap:OtherAssetsCurrent>
  <us-gaap:OtherAssetsCurrent contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="Fxbrl_20200312110300768" unitRef="USD">2609</us-gaap:OtherAssetsCurrent>
  <us-gaap:AssetsCurrent contextRef="C_20191231" decimals="0" id="F7380" unitRef="USD">1994760</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="F7387" unitRef="USD">1953687</us-gaap:AssetsCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="C_20191231" decimals="0" id="F7416" unitRef="USD">1983</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="F7423" unitRef="USD">3445</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:Assets contextRef="C_20191231" decimals="0" id="F7451" unitRef="USD">1996743</us-gaap:Assets>
  <us-gaap:Assets contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="F7457" unitRef="USD">1957132</us-gaap:Assets>
  <us-gaap:AccountsPayableCurrent contextRef="C_20191231" decimals="0" id="F7545" unitRef="USD">129809</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="F7551" unitRef="USD">15597</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableRelatedPartiesCurrent contextRef="C_20191231" decimals="0" id="F7561" unitRef="USD">10000</us-gaap:AccountsPayableRelatedPartiesCurrent>
  <us-gaap:OtherLiabilitiesCurrent contextRef="C_20191231" decimals="0" id="F7578" unitRef="USD">420406</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:OtherLiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="F7585" unitRef="USD">184461</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:DerivativeLiabilitiesCurrent contextRef="C_20191231" decimals="0" id="F7595" unitRef="USD">410603</us-gaap:DerivativeLiabilitiesCurrent>
  <us-gaap:DerivativeLiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="F7602" unitRef="USD">15738913</us-gaap:DerivativeLiabilitiesCurrent>
  <us-gaap:DerivativeLiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" decimals="0" id="Fxbrl_20200312132138067" unitRef="USD">271715</us-gaap:DerivativeLiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent contextRef="C_20191231" decimals="0" id="F7629" unitRef="USD">970818</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="F7636" unitRef="USD">15938971</us-gaap:LiabilitiesCurrent>
  <us-gaap:ConvertibleDebtNoncurrent contextRef="C_20191231" decimals="0" id="F7685" unitRef="USD">387070</us-gaap:ConvertibleDebtNoncurrent>
  <us-gaap:ConvertibleDebtNoncurrent contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="Fxbrl_20200312110850425" unitRef="USD">1360960</us-gaap:ConvertibleDebtNoncurrent>
  <us-gaap:ConvertibleDebtNoncurrent contextRef="C_20191231_usgaapShortTermDebtTypeAxis_usgaapConvertibleDebtMember_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember" decimals="0" id="F19358_1360960" unitRef="USD">387070</us-gaap:ConvertibleDebtNoncurrent>
  <us-gaap:ConvertibleDebtNoncurrent contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtMember_LegalEntityAxis_EmeraldHealthSciencesIncMember" decimals="0" id="Fxbrl_20200312170430534" unitRef="USD">1360960</us-gaap:ConvertibleDebtNoncurrent>
  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="C_20191231" decimals="0" id="F7702" unitRef="USD">90797</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="F7709" unitRef="USD">219453</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" decimals="0" id="Fxbrl_20200312132120481" unitRef="USD">551322</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:Liabilities contextRef="C_20191231" decimals="0" id="F7738" unitRef="USD">1448685</us-gaap:Liabilities>
  <us-gaap:Liabilities contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="F7745" unitRef="USD">17519384</us-gaap:Liabilities>
  <us-gaap:CommitmentsAndContingencies contextRef="C_20191231" id="Fxbrl_20200312111922271" unitRef="USD" xsi:nil="true"></us-gaap:CommitmentsAndContingencies>
  <us-gaap:CommitmentsAndContingencies contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" id="Fxbrl_20200312111941206" unitRef="USD" xsi:nil="true"></us-gaap:CommitmentsAndContingencies>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="4" id="Fxbrl_202003121123093570" unitRef="USD_per_Share">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="C_20191231" decimals="4" id="Fxbrl_20200312112309357" unitRef="USD_per_Share">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="INF" id="Fxbrl_202003121123528860" unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized contextRef="C_20191231" decimals="INF" id="Fxbrl_20200312112352886" unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesOutstanding contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="Fxbrl_202003121127021822" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding contextRef="C_20191231" decimals="0" id="Fxbrl_202003121127021820" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="Fxbrl_202003121127021821" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued contextRef="C_20191231" decimals="0" id="Fxbrl_20200312112702182" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockValue contextRef="C_20191231" decimals="0" id="Fxbrl_20200312111830605" unitRef="USD">0</us-gaap:PreferredStockValue>
  <us-gaap:PreferredStockValue contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="Fxbrl_20200312111841544" unitRef="USD">0</us-gaap:PreferredStockValue>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="3" id="Fxbrl_202001201406380850" unitRef="USD_per_Share">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="C_20191231" decimals="3" id="Fxbrl_20200120140638085" unitRef="USD_per_Share">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="INF" id="F8010_5000000000" unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized contextRef="C_20191231" decimals="INF" id="F8010_500000000" unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized contextRef="C_20181115" decimals="INF" id="Fxbrl_20200312151530981" unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesOutstanding contextRef="C_20191231" decimals="INF" id="F8010_1339077470" unitRef="shares">182895247</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="INF" id="F8010_336228290" unitRef="shares">133907747</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesIssued contextRef="C_20191231" decimals="INF" id="F8010_133907747" unitRef="shares">182895247</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="INF" id="F8010_33622829" unitRef="shares">133907747</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockValue contextRef="C_20191231" decimals="0" id="F8016" unitRef="USD">182895</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="F8023" unitRef="USD">133908</us-gaap:CommonStockValue>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="C_20191231" decimals="0" id="F8033" unitRef="USD">32538445</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="F8040" unitRef="USD">17528947</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="C_20191231" decimals="0" id="F8067_33225107" unitRef="USD">-32173282</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="F8073_14030871" unitRef="USD">-33225107</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:StockholdersEquity contextRef="C_20191231" decimals="0" id="F8082_15562252" unitRef="USD">548058</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="F8088_3569506" unitRef="USD">-15562252</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_usgaapStatementClassOfStockAxis_usgaapSeriesFPreferredStockMember" decimals="0" id="Fxbrl_20200312161542767" unitRef="USD">1777781</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_usgaapStatementClassOfStockAxis_usgaapSeriesDPreferredStockMember" decimals="0" id="Fxbrl_20200312161643177" unitRef="USD">169447</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" decimals="0" id="Fxbrl_20200312161646514" unitRef="USD">822201</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="Context_As_Of_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember" decimals="0" id="Fxbrl_20200312161742993" unitRef="USD">33623</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="Context_As_Of_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" decimals="0" id="Fxbrl_20200312161749164" unitRef="USD">10427742</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="Context_As_Of_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" decimals="0" id="Fxbrl_20200312161752170" unitRef="USD">-14030871</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" decimals="0" id="Fxbrl_20200312161754666" unitRef="USD">-3569506</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="Context_As_Of_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementEquityComponentsAxis_CommonStockMember" decimals="0" id="Fxbrl_20200312161801810" unitRef="USD">133908</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="Context_As_Of_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" decimals="0" id="Fxbrl_20200312161806178" unitRef="USD">17528947</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="Context_As_Of_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" decimals="0" id="Fxbrl_20200312161812522" unitRef="USD">-33225107</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20191231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="0" id="Fxbrl_20200312161823886" unitRef="USD">182895</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20191231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" decimals="0" id="Fxbrl_20200312161832175" unitRef="USD">32538445</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20191231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" decimals="0" id="Fxbrl_20200312161835907" unitRef="USD">-32173282</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="C_20191231" decimals="0" id="F8096" unitRef="USD">1996743</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="F8102" unitRef="USD">1957132</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="C_20190101to20191231" decimals="0" id="F8185" unitRef="USD">2237956</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="F8191" unitRef="USD">329966</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="C_20190101to20191231" decimals="0" id="F8201" unitRef="USD">4394622</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="F8208" unitRef="USD">4362557</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:OperatingExpenses contextRef="C_20190101to20191231" decimals="0" id="F8237" unitRef="USD">6632578</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="F8244" unitRef="USD">4692523</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss contextRef="C_20190101to20191231" decimals="0" id="F8274_4692523" unitRef="USD">-6632578</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="F8280_3859229" unitRef="USD">-4692523</us-gaap:OperatingIncomeLoss>
  <embi:ChangeInFairValueOfDerivativeLiabilities contextRef="C_20190101to20191231" decimals="0" id="F8328" unitRef="USD">-9734759</embi:ChangeInFairValueOfDerivativeLiabilities>
  <embi:ChangeInFairValueOfDerivativeLiabilities contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="F8335_767198" unitRef="USD">6503174</embi:ChangeInFairValueOfDerivativeLiabilities>
  <embi:FairValueOfDerivativeLiabilityInExcessOfProceeds contextRef="C_20190101to20191231" decimals="0" id="F8344" unitRef="USD">-322644</embi:FairValueOfDerivativeLiabilityInExcessOfProceeds>
  <embi:FairValueOfDerivativeLiabilityInExcessOfProceeds contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="Fxbrl_20200312122701136" unitRef="USD">-7174634</embi:FairValueOfDerivativeLiabilityInExcessOfProceeds>
  <embi:FairValueOfDerivativeLiabilityInExcessOfProceeds contextRef="C_20190101to20191231_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20200312150724208" unitRef="USD">322644</embi:FairValueOfDerivativeLiabilityInExcessOfProceeds>
  <us-gaap:PaymentsOfDerivativeIssuanceCosts contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="Fxbrl_20200312123143515" unitRef="USD">-137192</us-gaap:PaymentsOfDerivativeIssuanceCosts>
  <us-gaap:PaymentsOfDerivativeIssuanceCosts contextRef="C_20190101to20191231_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember" decimals="0" id="F19591_137192" unitRef="USD">-137192</us-gaap:PaymentsOfDerivativeIssuanceCosts>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="C_20190101to20191231" decimals="0" id="F8378" unitRef="USD">-725425</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="Fxbrl_20200312123233029" unitRef="USD">-590392</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="C_20190101to20191231_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20200312151401293" unitRef="USD">-725425</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <us-gaap:InterestExpense contextRef="C_20190101to20191231" decimals="0" id="F8395" unitRef="USD">1000713</us-gaap:InterestExpense>
  <us-gaap:InterestExpense contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="F8402" unitRef="USD">94763</us-gaap:InterestExpense>
  <us-gaap:InvestmentIncomeInterest contextRef="C_20190101to20191231" decimals="0" id="F8412_84" unitRef="USD">26</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InvestmentIncomeInterest contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="Fxbrl_20200312124246651" unitRef="USD">84</us-gaap:InvestmentIncomeInterest>
  <us-gaap:NonoperatingIncomeExpense contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20200312124546756" unitRef="USD">7686003</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="Fxbrl_20200312124551934" unitRef="USD">-14500071</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="C_20190101to20191231" decimals="0" id="F8448_19192594" unitRef="USD">1053425</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="F8454_3092698" unitRef="USD">-19192594</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="C_20190101to20191231" decimals="0" id="F8482" unitRef="USD">1600</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="F8489" unitRef="USD">1642</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:NetIncomeLoss contextRef="C_20190101to20191231" decimals="0" id="F8518_19194236" unitRef="USD">1051825</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="F8523_3094298" unitRef="USD">-19194236</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" decimals="0" id="Fxbrl_20200312163232720" unitRef="USD">-19194236</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="C_20190101to20191231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" decimals="0" id="Fxbrl_20200312163243581" unitRef="USD">1051825</us-gaap:NetIncomeLoss>
  <us-gaap:EarningsPerShareBasic contextRef="C_20190101to20191231" decimals="2" id="Fxbrl_20200312124625825" unitRef="USD_per_Share">0.01</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareBasic contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="2" id="Fxbrl_20200312124631312" unitRef="USD_per_Share">-0.16</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareDiluted contextRef="C_20190101to20191231" decimals="2" id="Fxbrl_20200312124643696" unitRef="USD_per_Share">-0.05</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareDiluted contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="2" id="Fxbrl_20200312124648130" unitRef="USD_per_Share">-0.16</us-gaap:EarningsPerShareDiluted>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20200312124659683" unitRef="shares">135154931</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="Fxbrl_20200312124705756" unitRef="shares">121154334</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20200312124715242" unitRef="shares">169560265</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="Fxbrl_20200312124724475" unitRef="shares">121154334</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:Depreciation contextRef="C_20190101to20191231" decimals="0" id="F8738" unitRef="USD">1462</us-gaap:Depreciation>
  <us-gaap:Depreciation contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="F8745" unitRef="USD">1544</us-gaap:Depreciation>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="F8762" unitRef="USD">-803</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <us-gaap:ShareBasedCompensation contextRef="C_20190101to20191231" decimals="0" id="F8789" unitRef="USD">680455</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="F8796" unitRef="USD">674961</us-gaap:ShareBasedCompensation>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="C_20190101to20191231" decimals="0" id="F8823" unitRef="USD">-9734759</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="F8830_767198" unitRef="USD">6503174</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_embiTwoThousandNineteenCommonStockWarrantsMember" decimals="0" id="Fxbrl_20200312150638626" unitRef="USD">1130400</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" decimals="0" id="Fxbrl_20200312150855350" unitRef="USD">1830573</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="C_20181024to20181101_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" decimals="0" id="Fxbrl_20200312153214382" unitRef="USD">593629</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_embiEmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember" decimals="0" id="F18071" unitRef="USD">-484147</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="C_20190101to20191231_deiLegalEntityAxis_embiEmeraldFinancingMember" decimals="0" id="F18107" unitRef="USD">-9042066</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_embiSeriesBWarrantMember" decimals="0" id="F18145" unitRef="USD">-208546</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="C_20180101to20181231_usgaapClassOfWarrantOrRightAxis_embiEmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember" decimals="0" id="Fxbrl_20200312130236461" unitRef="USD">15351</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_deiLegalEntityAxis_embiEmeraldFinancingMember" decimals="0" id="Fxbrl_20200312131206726" unitRef="USD">4826779</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_usgaapClassOfWarrantOrRightAxis_embiSeriesBWarrantMember" decimals="0" id="F18469_560986" unitRef="USD">1476044</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_usgaapClassOfWarrantOrRightAxis_embiEmeraldConvertiblePromissoryNoteConversionLiabilityMember" decimals="0" id="Fxbrl_20200312131807532" unitRef="USD">185000</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_DerivativeInstrumentRiskAxis_SeriesBPreferredStockConversionLiabilityMember" decimals="0" id="F18542_102848" unitRef="USD">0</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="C_20180101to20180119_usgaapClassOfWarrantOrRightAxis_embiEmeraldConvertiblePromissoryNoteConversionLiabilityMember" decimals="0" id="F19222_360000" unitRef="USD">360000</us-gaap:FairValueAdjustmentOfWarrants>
  <embi:FairValueOfDerivativeLiabilityExcessOfProceeds contextRef="C_20190101to20191231" decimals="0" id="F8839" unitRef="USD">322644</embi:FairValueOfDerivativeLiabilityExcessOfProceeds>
  <embi:FairValueOfDerivativeLiabilityExcessOfProceeds contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="Fxbrl_20200312143650887" unitRef="USD">7174634</embi:FairValueOfDerivativeLiabilityExcessOfProceeds>
  <embi:LossOnCommonStockIssuanceFromConversionOfAccruedInterest contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="Fxbrl_20200312143835626" unitRef="USD">9794</embi:LossOnCommonStockIssuanceFromConversionOfAccruedInterest>
  <us-gaap:AmortizationOfDebtDiscountPremium contextRef="C_20190101to20191231" decimals="0" id="F8907" unitRef="USD">629293</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:AmortizationOfDebtDiscountPremium contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="Fxbrl_20200312143953353" unitRef="USD">58536</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="C_20190101to20191231" decimals="0" id="F8960" unitRef="USD">59502</us-gaap:IncreaseDecreaseInPrepaidExpense>
  <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="F8967_121273" unitRef="USD">-198235</us-gaap:IncreaseDecreaseInPrepaidExpense>
  <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="C_20190101to20191231" decimals="0" id="F8993_2609" unitRef="USD">4941</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
  <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="F8999" unitRef="USD">2609</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="C_20190101to20191231" decimals="0" id="F9009_85324" unitRef="USD">124212</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="F9015_173729" unitRef="USD">-85324</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="C_20190101to20191231" decimals="0" id="F9024" unitRef="USD">10000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
  <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20200312144240789" unitRef="USD">225945</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
  <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="Fxbrl_20200312144242946" unitRef="USD">-10110</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="C_20190101to20191231" decimals="0" id="F9056_3943014" unitRef="USD">-6027941</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="F9062_3331285" unitRef="USD">-3943014</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="F9097_19654" unitRef="USD">4385</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="F9112_19654" unitRef="USD">-4385</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20200312150605814" unitRef="USD">80628</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="Fxbrl_20200312150611129" unitRef="USD">154092</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20200312144510319" unitRef="USD">1919372</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="Fxbrl_20200312144515614" unitRef="USD">3095908</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="C_20190101to20191231_deiLegalEntityAxis_embiEmeraldFinancingMember_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20200312164654139" unitRef="USD">1919372</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_Custom_01_Jan_2018T00_00_00_TO_19_Jan_2018T00_00_00_LegalEntityAxis_EmeraldFinancingMember" decimals="0" id="F18935" unitRef="USD">-1500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_Custom_01_Feb_2018T00_00_00_TO_16_Feb_2018T00_00_00_LegalEntityAxis_EmeraldFinancingMember" decimals="0" id="F18942" unitRef="USD">-1750000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_deiLegalEntityAxis_embiEmeraldFinancingMember" decimals="0" id="F18949" unitRef="USD">-3250000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_Custom_01_Jan_2018T00_00_00_TO_19_Jan_2018T00_00_00_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember" decimals="0" id="F19589_1500000" unitRef="USD">1500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_Custom_01_Feb_2018T00_00_00_TO_16_Feb_2018T00_00_00_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember_RelatedPartyTransactionsByRelatedPartyAxis_InvestorMember" decimals="0" id="F19591_1750000" unitRef="USD">1750000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20200312144456974" unitRef="USD">4080000</us-gaap:ProceedsFromIssuanceOfWarrants>
  <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="Fxbrl_20200312144754042" unitRef="USD">98700</us-gaap:ProceedsFromIssuanceOfWarrants>
  <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_embiTwoThousandNineteenCommonStockWarrantsMember" decimals="0" id="Fxbrl_20200312150629565" unitRef="USD">722208</us-gaap:ProceedsFromIssuanceOfWarrants>
  <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" decimals="0" id="Fxbrl_20200312150841585" unitRef="USD">716110</us-gaap:ProceedsFromIssuanceOfWarrants>
  <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="C_20181024to20181101_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" decimals="0" id="Fxbrl_20200312153203110" unitRef="USD">315080</us-gaap:ProceedsFromIssuanceOfWarrants>
  <us-gaap:ProceedsFromConvertibleDebt contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="F9216" unitRef="USD">400000</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:ProceedsFromConvertibleDebt contextRef="Context_Custom_01_Dec_2017T00_00_00_TO_28_Dec_2017T00_00_00_ShortTermDebtTypeAxis_BridgeLoanMember_TypeOfArrangementAxis_SecuredPromissoryNoteAndSecurityAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember" decimals="0" id="F19560_500000" unitRef="USD">500000</us-gaap:ProceedsFromConvertibleDebt>
  <embi:ProceedsFromConvertibleMultiDrawCreditAgreement contextRef="C_20190101to20191231" decimals="0" id="F9226" unitRef="USD">3990699</embi:ProceedsFromConvertibleMultiDrawCreditAgreement>
  <embi:ProceedsFromConvertibleMultiDrawCreditAgreement contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="Fxbrl_20200312144833676" unitRef="USD">1946293</embi:ProceedsFromConvertibleMultiDrawCreditAgreement>
  <embi:ProceedsFromConvertibleMultiDrawCreditAgreement contextRef="C_20190101to20191231_deiLegalEntityAxis_embiEmeraldFinancingMember_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20200312164629654" unitRef="USD">3990699</embi:ProceedsFromConvertibleMultiDrawCreditAgreement>
  <embi:RepaymentOfConvertibleMultiDrawCreditAgreement contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20200312144908661" unitRef="USD">3985500</embi:RepaymentOfConvertibleMultiDrawCreditAgreement>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="C_20190101to20191231" decimals="0" id="F9243" unitRef="USD">6004571</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="F9250" unitRef="USD">5540901</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="C_20190101to20191231" decimals="0" id="F9280" unitRef="USD">-23370</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="F9287" unitRef="USD">1593502</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="F9317" unitRef="USD">1857885</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" decimals="0" id="F9323" unitRef="USD">264383</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="C_20191231" decimals="0" id="F9352" unitRef="USD">1834515</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:InterestPaidNet contextRef="C_20190101to20191231" decimals="0" id="F9528" unitRef="USD">371420</us-gaap:InterestPaidNet>
  <us-gaap:InterestPaidNet contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="Fxbrl_20200312145202788" unitRef="USD">23334</us-gaap:InterestPaidNet>
  <us-gaap:IncomeTaxesPaid contextRef="C_20190101to20191231" decimals="0" id="F9562" unitRef="USD">1600</us-gaap:IncomeTaxesPaid>
  <us-gaap:IncomeTaxesPaid contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="F9568" unitRef="USD">1642</us-gaap:IncomeTaxesPaid>
  <us-gaap:ConversionOfStockAmountConverted1 contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="F9622" unitRef="USD">1947228</us-gaap:ConversionOfStockAmountConverted1>
  <embi:ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="F9639" unitRef="USD">828915</embi:ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock>
  <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="Fxbrl_20200312145323373" unitRef="USD">1713766</us-gaap:DebtConversionConvertedInstrumentAmount1>
  <embi:FairValueOfWarrantsIssuedInConnectionWithFinancings contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="Fxbrl_20200312145327785" unitRef="USD">10424634</embi:FairValueOfWarrantsIssuedInConnectionWithFinancings>
  <embi:ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement contextRef="C_20190101to20191231" decimals="0" id="F9683" unitRef="USD">716110</embi:ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement>
  <embi:ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="Fxbrl_20200312145331970" unitRef="USD">315080</embi:ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement>
  <embi:ExerciseOfWarrants contextRef="C_20190101to20191231" decimals="0" id="F9700" unitRef="USD">6077698</embi:ExerciseOfWarrants>
  <embi:ExerciseOfWarrants contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="Fxbrl_20200312145337033" unitRef="USD">1539866</embi:ExerciseOfWarrants>
  <embi:FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement contextRef="C_20190101to20191231" decimals="0" id="F9717" unitRef="USD">193414</embi:FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement>
  <embi:FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="Fxbrl_20200312145341985" unitRef="USD">204102</embi:FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement>
  <embi:BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement contextRef="C_20190101to20191231" decimals="0" id="F9734" unitRef="USD">1584850</embi:BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement>
  <embi:BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="Fxbrl_20200312145244988" unitRef="USD">90080</embi:BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement>
  <us-gaap:SharesIssued contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_usgaapStatementClassOfStockAxis_usgaapSeriesFPreferredStockMember" decimals="INF" id="Fxbrl_20200312161553156" unitRef="shares">2000</us-gaap:SharesIssued>
  <us-gaap:SharesIssued contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_usgaapStatementClassOfStockAxis_usgaapSeriesDPreferredStockMember" decimals="INF" id="Fxbrl_20200312161621717" unitRef="shares">200</us-gaap:SharesIssued>
  <us-gaap:SharesIssued contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" decimals="INF" id="Fxbrl_20200312161625234" unitRef="shares">2834</us-gaap:SharesIssued>
  <us-gaap:SharesIssued contextRef="Context_As_Of_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember" decimals="INF" id="Fxbrl_20200312161931349" unitRef="shares">33622829</us-gaap:SharesIssued>
  <us-gaap:SharesIssued contextRef="Context_As_Of_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementEquityComponentsAxis_CommonStockMember" decimals="INF" id="Fxbrl_20200312161939058" unitRef="shares">133907747</us-gaap:SharesIssued>
  <us-gaap:SharesIssued contextRef="C_20191231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="INF" id="Fxbrl_20200312161947818" unitRef="shares">182895247</us-gaap:SharesIssued>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" decimals="0" id="Fxbrl_20200312162230109" unitRef="USD">674961</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="Fxbrl_20200312162238192" unitRef="USD">674961</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="C_20190101to20191231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" decimals="0" id="Fxbrl_20200312162244430" unitRef="USD">680455</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20200312162248678" unitRef="USD">680455</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementEquityComponentsAxis_CommonStockMember" decimals="INF" id="Fxbrl_20200312162341054" unitRef="shares">3143501</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementEquityComponentsAxis_CommonStockMember" decimals="0" id="Fxbrl_20200312162312397" unitRef="USD">3143</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" decimals="0" id="Fxbrl_20200312162319141" unitRef="USD">-3143</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <embi:ShareIssuanceCosts contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="Fxbrl_20200312170952888" unitRef="USD">16900</embi:ShareIssuanceCosts>
  <embi:StockIssuedDuringPeriodSharesNetOfIssuanceCosts contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementEquityComponentsAxis_CommonStockMember" decimals="INF" id="Fxbrl_20200312162415839" unitRef="shares">32500000</embi:StockIssuedDuringPeriodSharesNetOfIssuanceCosts>
  <embi:StockIssuedDuringPeriodValueNetOfIssuanceCosts contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementEquityComponentsAxis_CommonStockMember" decimals="0" id="Fxbrl_20200312162426039" unitRef="USD">32500</embi:StockIssuedDuringPeriodValueNetOfIssuanceCosts>
  <embi:StockIssuedDuringPeriodValueNetOfIssuanceCosts contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" decimals="0" id="Fxbrl_20200312162431567" unitRef="USD">-49400</embi:StockIssuedDuringPeriodValueNetOfIssuanceCosts>
  <embi:StockIssuedDuringPeriodValueNetOfIssuanceCosts contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="Fxbrl_20200312162434541" unitRef="USD">-16900</embi:StockIssuedDuringPeriodValueNetOfIssuanceCosts>
  <embi:ConversionPricePerShare contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" decimals="2" id="Fxbrl_20200312170859558" unitRef="USD_per_Share">0.10</embi:ConversionPricePerShare>
  <embi:ConversionPricePerShare contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementClassOfStockAxis_SeriesDPreferredStockMember" decimals="3" id="Fxbrl_20200312170930519" unitRef="USD_per_Share">0.10</embi:ConversionPricePerShare>
  <embi:ConversionPricePerShare contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementClassOfStockAxis_SeriesFPreferredStockMember" decimals="2" id="Fxbrl_20200312170939001" unitRef="USD_per_Share">0.10</embi:ConversionPricePerShare>
  <embi:ConversionLiabilityIntoCommonStockPerShare contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" decimals="4" id="Fxbrl_20200312170912804" unitRef="USD_per_Share">0.001</embi:ConversionLiabilityIntoCommonStockPerShare>
  <embi:ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" decimals="INF" id="Fxbrl_20200312162514346" unitRef="shares">-2834</embi:ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares>
  <embi:ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementEquityComponentsAxis_CommonStockMember" decimals="INF" id="Fxbrl_20200312162532953" unitRef="shares">28385000</embi:ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares>
  <embi:ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" decimals="0" id="Fxbrl_20200312162604743" unitRef="USD">-822201</embi:ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue>
  <embi:ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementEquityComponentsAxis_CommonStockMember" decimals="0" id="Fxbrl_20200312162610154" unitRef="USD">28385</embi:ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue>
  <embi:ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" decimals="0" id="Fxbrl_20200312162612824" unitRef="USD">800530</embi:ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue>
  <embi:ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="Fxbrl_20200312162615400" unitRef="USD">828915</embi:ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue>
  <embi:ConversionOfSeriesDPreferredStockToCommonStockShares contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementClassOfStockAxis_SeriesDPreferredStockMember" decimals="INF" id="Fxbrl_20200312162633618" unitRef="shares">-200</embi:ConversionOfSeriesDPreferredStockToCommonStockShares>
  <embi:ConversionOfSeriesDPreferredStockToCommonStockShares contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementEquityComponentsAxis_CommonStockMember" decimals="INF" id="Fxbrl_20200312162640019" unitRef="shares">2000000</embi:ConversionOfSeriesDPreferredStockToCommonStockShares>
  <embi:ConversionOfSeriesDPreferredStockToCommonStock contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementClassOfStockAxis_SeriesDPreferredStockMember" decimals="0" id="Fxbrl_20200312162651577" unitRef="USD">-169447</embi:ConversionOfSeriesDPreferredStockToCommonStock>
  <embi:ConversionOfSeriesDPreferredStockToCommonStock contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementEquityComponentsAxis_CommonStockMember" decimals="0" id="Fxbrl_20200312162657227" unitRef="USD">2000</embi:ConversionOfSeriesDPreferredStockToCommonStock>
  <embi:ConversionOfSeriesDPreferredStockToCommonStock contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" decimals="0" id="Fxbrl_20200312162659667" unitRef="USD">167447</embi:ConversionOfSeriesDPreferredStockToCommonStock>
  <embi:ConversionOfSeriesDPreferredStockToCommonStock contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="Fxbrl_20200312162702555" unitRef="USD">169447</embi:ConversionOfSeriesDPreferredStockToCommonStock>
  <embi:ConversionOfSeriesFPreferredStockToCommonStockShares contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementClassOfStockAxis_SeriesFPreferredStockMember" decimals="INF" id="Fxbrl_20200312162714921" unitRef="shares">-2000</embi:ConversionOfSeriesFPreferredStockToCommonStockShares>
  <embi:ConversionOfSeriesFPreferredStockToCommonStockShares contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementEquityComponentsAxis_CommonStockMember" decimals="INF" id="Fxbrl_20200312162720090" unitRef="shares">20000000</embi:ConversionOfSeriesFPreferredStockToCommonStockShares>
  <embi:ConversionOfSeriesFPreferredStockToCommonStockValue contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementClassOfStockAxis_SeriesFPreferredStockMember" decimals="0" id="Fxbrl_20200312162731949" unitRef="USD">-1777781</embi:ConversionOfSeriesFPreferredStockToCommonStockValue>
  <embi:ConversionOfSeriesFPreferredStockToCommonStockValue contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementEquityComponentsAxis_CommonStockMember" decimals="0" id="Fxbrl_20200312162737878" unitRef="USD">20000</embi:ConversionOfSeriesFPreferredStockToCommonStockValue>
  <embi:ConversionOfSeriesFPreferredStockToCommonStockValue contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" decimals="0" id="Fxbrl_20200312162740662" unitRef="USD">1757781</embi:ConversionOfSeriesFPreferredStockToCommonStockValue>
  <embi:ConversionOfSeriesFPreferredStockToCommonStockValue contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="Fxbrl_20200312162743806" unitRef="USD">1777781</embi:ConversionOfSeriesFPreferredStockToCommonStockValue>
  <embi:ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterestShares contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementEquityComponentsAxis_CommonStockMember" decimals="INF" id="Fxbrl_20200312162818493" unitRef="shares">9037667</embi:ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterestShares>
  <embi:ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementEquityComponentsAxis_CommonStockMember" decimals="0" id="Fxbrl_20200312162843336" unitRef="USD">9038</embi:ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest>
  <embi:ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" decimals="0" id="Fxbrl_20200312162848554" unitRef="USD">1714522</embi:ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest>
  <embi:ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="Fxbrl_20200312162851122" unitRef="USD">1723560</embi:ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest>
  <embi:StockIssuedDuringPeriodSharesSeriesBWarrantExercises contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementEquityComponentsAxis_CommonStockMember" decimals="INF" id="Fxbrl_20200312162931312" unitRef="shares">5218750</embi:StockIssuedDuringPeriodSharesSeriesBWarrantExercises>
  <embi:StockIssuedDuringPeriodSharesSeriesBWarrantExercises contextRef="C_20190101to20191231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="INF" id="Fxbrl_20200312162944005" unitRef="shares">187500</embi:StockIssuedDuringPeriodSharesSeriesBWarrantExercises>
  <embi:StockIssuedDuringPeriodValueSeriesBWarrantExercises contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementEquityComponentsAxis_CommonStockMember" decimals="0" id="Fxbrl_20200312163030508" unitRef="USD">5219</embi:StockIssuedDuringPeriodValueSeriesBWarrantExercises>
  <embi:StockIssuedDuringPeriodValueSeriesBWarrantExercises contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" decimals="0" id="Fxbrl_20200312163026772" unitRef="USD">1633347</embi:StockIssuedDuringPeriodValueSeriesBWarrantExercises>
  <embi:StockIssuedDuringPeriodValueSeriesBWarrantExercises contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="Fxbrl_20200312163020868" unitRef="USD">1638566</embi:StockIssuedDuringPeriodValueSeriesBWarrantExercises>
  <embi:StockIssuedDuringPeriodValueSeriesBWarrantExercises contextRef="C_20190101to20191231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="0" id="Fxbrl_20200312163036011" unitRef="USD">187</embi:StockIssuedDuringPeriodValueSeriesBWarrantExercises>
  <embi:StockIssuedDuringPeriodValueSeriesBWarrantExercises contextRef="C_20190101to20191231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" decimals="0" id="Fxbrl_20200312163038883" unitRef="USD">144188</embi:StockIssuedDuringPeriodValueSeriesBWarrantExercises>
  <embi:StockIssuedDuringPeriodValueSeriesBWarrantExercises contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20200312163042203" unitRef="USD">144375</embi:StockIssuedDuringPeriodValueSeriesBWarrantExercises>
  <embi:WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" decimals="0" id="Fxbrl_20200312163104560" unitRef="USD">315080</embi:WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue>
  <embi:WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="Fxbrl_20200312163109714" unitRef="USD">315080</embi:WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue>
  <embi:WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue contextRef="C_20190101to20191231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" decimals="0" id="Fxbrl_20200312163114674" unitRef="USD">716110</embi:WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue>
  <embi:WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20200312163118850" unitRef="USD">716110</embi:WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue>
  <embi:BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" decimals="0" id="Fxbrl_20200312163204409" unitRef="USD">90080</embi:BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue>
  <embi:BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="Fxbrl_20200312163209834" unitRef="USD">90080</embi:BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue>
  <embi:BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue contextRef="C_20190101to20191231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" decimals="0" id="Fxbrl_20200312163216275" unitRef="USD">1584850</embi:BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue>
  <embi:BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20200312163219087" unitRef="USD">1584850</embi:BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue>
  <embi:ShareAndWarrantsIssuanceCosts contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20200312171819888" unitRef="USD">80628</embi:ShareAndWarrantsIssuanceCosts>
  <embi:StockIssuedDuringPeriodSharesNetOfIssuanceCostsAndWarrants contextRef="C_20190101to20191231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="INF" id="Fxbrl_20200312163356100" unitRef="shares">8000000</embi:StockIssuedDuringPeriodSharesNetOfIssuanceCostsAndWarrants>
  <embi:StockIssuedDuringPeriodValueNetOfIssuanceCostsAndWarrants contextRef="C_20190101to20191231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="0" id="Fxbrl_20200312163415182" unitRef="USD">8000</embi:StockIssuedDuringPeriodValueNetOfIssuanceCostsAndWarrants>
  <embi:StockIssuedDuringPeriodValueNetOfIssuanceCostsAndWarrants contextRef="C_20190101to20191231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" decimals="0" id="Fxbrl_20200312163437310" unitRef="USD">1911372</embi:StockIssuedDuringPeriodValueNetOfIssuanceCostsAndWarrants>
  <embi:StockIssuedDuringPeriodValueNetOfIssuanceCostsAndWarrants contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20200312163440816" unitRef="USD">1919372</embi:StockIssuedDuringPeriodValueNetOfIssuanceCostsAndWarrants>
  <embi:FinancingSharesWarrantExercise contextRef="C_20190101to20191231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="INF" id="Fxbrl_20200312163500102" unitRef="shares">40800000</embi:FinancingSharesWarrantExercise>
  <embi:FinancingValueWarrantExercise contextRef="C_20190101to20191231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="0" id="Fxbrl_20200312163511285" unitRef="USD">40800</embi:FinancingValueWarrantExercise>
  <embi:FinancingValueWarrantExercise contextRef="C_20190101to20191231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" decimals="0" id="Fxbrl_20200312163516335" unitRef="USD">9972523</embi:FinancingValueWarrantExercise>
  <embi:FinancingValueWarrantExercise contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20200312163519807" unitRef="USD">10013323</embi:FinancingValueWarrantExercise>
  <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock contextRef="C_20190101to20191231" id="F89bda070-2de8-11ea-add8-41ed81237e2f">&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;1. Nature of Operations and Business Activities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Nature of Operations&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Emerald Bioscience, Inc. (the &amp;#x201c;Company&amp;#x201d;) was initially incorporated in Nevada on March 16, 2011 as Load Guard Logistics, Inc. On October 31, 2014, the Company closed a reverse merger transaction (the &amp;#x201c;Merger&amp;#x201d;) pursuant to which Nemus, a California corporation (&amp;#x201c;Nemus Sub&amp;#x201d;), became the Company&amp;#x2019;s wholly-owned subsidiary, and the Company assumed the operations of Nemus Sub. Nemus Sub was incorporated in the State of California on July 17, 2012. On November 3, 2014, the Company changed its name to Nemus Bioscience, Inc. by merging with Nemus Sub.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;In January 2018, the Company entered into a securities purchase agreement with Emerald Health Sciences, Inc. (&amp;#x201c;Emerald Health Sciences&amp;#x201d;) discussed in Note 5, pursuant to which Emerald Health Sciences purchased a majority of the equity interest in the Company, resulting in a change in control. As part of the transaction, the Company&amp;#x2019;s Board members, with the exception of Dr. Brian Murphy, the Company&amp;#x2019;s CEO/CMO, tendered their resignation and Emerald Health Sciences appointed two new nominees to the Board. Later, in October 2018, the Board appointed Dr. Avtar Dhillon, the Chairman, Chief Executive Officer and President of Emerald Health Sciences, as the Executive Chairman of the Company&amp;#x2019;s Board.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;On February 11, 2019, the Company&amp;#x2019;s Board of Directors (the &amp;#x201c;Board&amp;#x201d;) and majority stockholder unanimously approved an amendment to the Company&amp;#x2019;s articles of incorporation to change the name of the Company to Emerald Bioscience, Inc. Effective March 25, 2019, the Company filed a Certificate of Amendment with the Nevada Secretary of State changing the Company&amp;#x2019;s name to Emerald Bioscience, Inc.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;In August 2019, the Company formed a new subsidiary in Australia, EMBI Australia Pty Ltd., an Australian proprietary limited company (&amp;#x201c;EMBI Australia&amp;#x201d;), in order to qualify for the Australian government&amp;#x2019;s research and development tax credit for research and development dollars spent in Australia. The primary purpose of EMBI Australia is to conduct clinical trials for the Company&amp;#x2019;s product candidates.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;On December 17, 2019, Dr. Avtar Dhillon resigned as the Chairman of the Company&amp;#x2019;s Board and the Company entered into a Board Observer Agreement with Emerald Health Sciences. Refer to Note 11 - Related Party Matters for additional information.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;The Company, is a biopharmaceutical company located in Long Beach, California that plans to research, develop and commercialize therapeutics derived from cannabinoids through several license agreements with the University of Mississippi (&amp;#x201c;UM&amp;#x201d;). UM is the only entity federally permitted and licensed to cultivate cannabis for research purposes in the United States.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;As of December 31, 2019, the Company has devoted substantially all its efforts to securing product licenses, carrying out research and development, building infrastructure and raising capital. The Company has not yet realized revenue from its planned principal operations and is a number of years from potentially being able to do so.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Liquidity and Going Concern&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;The Company has incurred operating losses and negative cash flows from operations since inception and as of December 31, 2019, had an accumulated deficit of&lt;span&gt;&lt;span&gt; $32,173,282.&amp;#160;&lt;/span&gt;&lt;/span&gt;The Company anticipates that it will continue to incur operating losses into the foreseeable future in order to advance and develop a number of potential drug candidates into preclinical and clinical development activities and support its corporate infrastructure which includes the costs associated with being a public company. &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;As of December 31, 2019 and filing date of our 2019 Annual Report on Form 10K, the Company had cash in the amount of&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt; $1,829,977&amp;#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;and approximately $667,000, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;During the year ended December 31, 2019, the Company received net cash proceeds of $3,990,699 from the Credit Agreement (defined below) with Emerald Health Sciences and raised $1,919,372 in net proceeds pursuant to the sale of common stock and warrants under a registered direct offering. However, the Company&amp;#x2019;s cash flows from its financing efforts have been offset by cash used in operating activities of $6,027,941 for the year ended December 31, 2019. &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;As the Company approaches its first clinical trial, it expects to ramp up research and development spending and projects to increase cash used in operating activities. However, based on the Company&amp;#x2019;s current cash position and expected cash requirements, without obtaining additional funding in the second quarter of 2020, management believes that the Company will not have enough funds to meet its obligations. These conditions give rise to substantial doubt as to the Company&amp;#x2019;s ability to continue as a going concern. The accompanying Consolidated Financial Statements do not include any adjustments that might result from the outcome of this uncertainty.&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;The Company&amp;#x2019;s continued existence is dependent on its ability to raise sufficient additional funding to cover operating expenses and to invest in research and development activities. On October 5, 2018, the Company entered into a Multi-Draw Credit Agreement (the &amp;#x201c;Credit Agreement&amp;#x201d;) with Emerald Health Sciences (See Note 4). As of December 31, 2019, under the Credit Agreement, the Company may&amp;#160;draw down up to the remaining amount under the Credit Agreement of&amp;#160;&lt;span&gt;&lt;span&gt;$14,000,000 &lt;/span&gt;&lt;/span&gt;from time to time in principal amounts of at least&lt;span&gt;&lt;span&gt; $250,000. &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The drawdowns are subject to approval by the Company&amp;#x2019;s Board, which is controlled by the directors of Emerald Health Sciences. We do not consider the facility available until advance requests are approved, drawn down and funded. The Credit Agreement is still in place, however, there is no guarantee of continued funding.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;The Company plans to continue to pursue funding through public or private equity or debt financings, licensing arrangements, asset sales, government grants or other arrangements. However, the Company cannot provide any assurances that such additional funds will be available on reasonable terms, or at all. If the Company raises additional funds by issuing equity securities, substantial dilution to existing stockholders would result.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Effective March 23, 2020, the Company approved a plan to defer 50% of senior management&amp;#x2019;s compensation indefinitely. If the members of senior management accept the plan, the aggregate deferred compensation, together with a retention bonus of 10% of the amount being deferred will be payable to senior management when decided by the Board. This measure, in conjunction with management&amp;#x2019;s plan to negotiate extended payment terms with its vendors and service providers, is intended to slow cash burn. The Company&amp;#x2019;s Board plans on further assessing the financial condition of the Company to determine what additional measures, if any, will be implemented. If the Company is unable to secure adequate additional funding, the Company may be forced to reduce spending further, liquidate assets where possible, suspend or curtail planned programs or cease operations.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;On March 11, 2020, the World Health Organization declared the outbreak of a respiratory disease caused by a new COVID-19 as a &amp;#x201c;pandemic&amp;#x201d;. Notably, the Company relies on third-party manufacturers to produce its product candidates. The manufacturing of the active pharmaceutical ingredient of NB1111 is conducted in the United States. Formulation of the eye drop for testing is also performed in the United States but can rely on regulatory-accepted excipients that can be sourced from countries outside the United States, such as China. In lieu of the recent pandemic of a COVID-19, there could possibly be an impact on sourcing materials that are part of the eye drop formulation, as well as impacting volunteer and/or patient recruitment in Australia for clinical studies. Therefore, the Company anticipates shifting its first-in-human studies of the lead drug candidate, NB1111, from the second half of 2020, to the 2021 timeframe. Additionally, COVID-19 has caused significant disruptions to the global financial markets which could impact the Company&amp;#x2019;s ability to raise additional capital.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;After considering the plans to alleviate substantial doubt, management has concluded that there is substantial doubt about the Company's ability to continue as a going concern within one year after the date that the financial statements are issued.&lt;/p&gt;</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
  <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="Context_As_Of_05_Oct_2018T00_00_00_TO_05_Oct_2018T00_00_00_LegalEntityAxis_EmeraldFinancingMember_TypeOfArrangementAxis_MultiDrawCreditAgreementMember" decimals="0" id="F17126_20000000" unitRef="USD">14000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
  <us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity contextRef="Context_As_Of_05_Oct_2018T00_00_00_TO_05_Oct_2018T00_00_00_LegalEntityAxis_EmeraldFinancingMember_TypeOfArrangementAxis_MultiDrawCreditAgreementMember" decimals="0" id="F17126_250000" unitRef="USD">250000</us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="C_20190101to20191231" id="F89bda071-2de8-11ea-add8-41ed81237e2f">&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;2. Summary of Significant Accounting Policies&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;div&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;The preparation of financial statements in conformity with U.S. Generally Accepted Accounting Principles (&amp;#x201c;GAAP&amp;#x201d;) requires management to make estimates and assumptions that affect the amounts reported in the Consolidated Financial Statements and the accompanying notes. Actual results could differ from those estimates. Certain reclassifications have been made to prior year amounts to conform to the current year&amp;#x2019;s presentation. Such reclassifications had no net effect on the prior year&amp;#x2019;s total assets, total liabilities, total stockholders&amp;#x2019; deficit, net loss and cash flows.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;div&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;The preparation of the Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Consolidated Financial Statements and the reported amounts of income and expense during the reporting period. Actual results could differ from those estimates. The most significant accounting estimates inherent in the preparation of the Company&amp;#x2019;s financial statements include estimates as to the appropriate carrying value of certain assets and liabilities which are not readily apparent from other sources. Such estimates and judgments are utilized for stock-based compensation expense, equity securities, derivative liabilities and debt with embedded features.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;div&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Risks and Uncertainties&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;The Company&amp;#x2019;s operations are subject to a number of risks and uncertainties, including but not limited to, changes in the general economy, the size and growth of the potential markets for any of the Company&amp;#x2019;s product candidates, results of research and development activities, uncertainties surrounding regulatory developments in the United States and Australia and the Company&amp;#x2019;s ability to attract new funding.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;div&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The carrying values of those investments approximate&amp;#160;their fair value due to their short maturity and liquidity. Cash includes cash on hand and amounts on deposit with financial institutions, which amounts may at times exceed federally insured limits. The Company has not experienced any losses on such accounts and does not believe it is exposed to any significant credit risk. As of December 31, 2019, the Company has no cash equivalents.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;div&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Restricted Cash&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;A deposit of $4,538 and $4,512 &lt;/span&gt;&lt;/span&gt;as of December 31, 2019 and&amp;#160;2018, respectively, was restricted from withdrawal and held by a bank in the form of a certificate of deposit. This certificate serves as collateral for payment of the Company&amp;#x2019;s credit cards.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;div&gt;&lt;p style="text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Fair Value Measurements&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (the &amp;#x201c;exit price&amp;#x201d;) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last is considered unobservable, is used to measure fair value:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN" width="100%"&gt;&lt;tbody&gt;&lt;tr style="height:15"&gt;&lt;td style="width:7%" valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Level 1:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:93%" valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Valuations for assets and liabilities traded in active markets from readily available pricing sources such as quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15"&gt;&lt;td valign="top"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="top"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Level 2:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Observable inputs (other than Level 1 quoted prices) such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15"&gt;&lt;td valign="top"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="top"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Level 3:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;The carrying values of the Company&amp;#x2019;s financial instruments, with the exception of the Credit Agreement and derivative liabilities, including, cash, prepaid expenses, accounts payable, and other current liabilities approximate their fair value due to the short maturities of these financial instruments. The derivative liabilities are valued on a recurring basis utilizing Level 3 inputs.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Advances under the Credit Agreement are not recorded at fair value. However, fair value can be approximated and disclosed utilizing Level 3 inputs and independent third-party valuation techniques (See Note 3). As of December 31, 2019 and 2018, the fair value of the advances under the Credit Agreement was $1,877,938 and $3,176,824, respectively. The carrying amount of the liability at December 31, 2019 and 2018, was $387,070 and $1,360,960, respectively, and is included in Convertible multi-draw credit agreement - related party, net of discount in the Company&amp;#x2019;s Consolidated Balance Sheets.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;div&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Property and Equipment, Net&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Property and equipment, net, consist primarily of computers and equipment. Expenditures for additions, renewals and improvements are capitalized at cost. Depreciation is computed on a&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt; straight-line method based on &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;the estimated useful life of the related asset currently ranging from two to three years. Maintenance and repairs that do not extend the life of assets are charged to expense when incurred. When properties are disposed of, the related costs and accumulated depreciation are removed from the accounts and any gain or loss is reported in the period the transaction takes place.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted cash flows expected to be generated by the asset. If the carrying amount exceeds its estimated future undiscounted cash flows, an impairment charge is recognized by the amount by which the carrying amount exceeds the fair value of the asset.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;div&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;The Company accounts for deferred income tax assets and liabilities based on differences between the financial reporting and tax bases of assets and liabilities, net operating loss carryforwards (the &amp;#x201c;NOLs&amp;#x201d;) and other tax credit carryforwards. These items are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the period that includes the enactment date. Any interest or penalties would be recorded in the Company&amp;#x2019;s Consolidated Statements of Comprehensive Income (Loss) in the period incurred. When necessary, the Company recognizes interest and penalties related to income tax matters in income tax expense.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;The Company records a valuation allowance against deferred tax assets to the extent that it is more likely than not that some portion or all of the deferred tax assets will not be realized. In making such determinations, management considers all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and recent financial operations. Due to the substantial doubt related to the Company&amp;#x2019;s ability to utilize its deferred tax assets, a valuation allowance for the full amount of the deferred tax assets has been established at December 31, 2019 and 2018. As a result of this valuation allowance, there are no income tax benefits reflected in the accompanying Consolidated Statements of Comprehensive Income (Loss) to offset pre-tax losses.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;The Company recognizes a tax benefit from uncertain tax positions when it is more likely than not (50%) that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits of the position.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;div&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Convertible Instruments&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;The Company accounts for hybrid contracts with embedded conversion features in accordance with GAAP. ASC 815, &lt;em&gt;Derivatives and Hedging Activities&lt;/em&gt; (&amp;#x201c;ASC 815&amp;#x201d;) requires companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria includes circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;The Company accounts for convertible debt instruments with embedded conversion features in accordance with ASC 470-20, Debt with Conversion and Other Options (&amp;#x201c;ASC 470-20&amp;#x201d;) if it is determined that the conversion feature should not be bifurcated from their host instruments. Under ASC 470-20, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the difference between the fair value of the underlying common stock at the commitment date and the embedded effective conversion price. When the Company determines that the embedded conversion option should be bifurcated from its host instrument, the embedded feature is accounted for in accordance with ASC 815. Under ASC 815, a portion of the proceeds received upon the issuance of the hybrid contract is allocated to the fair value of the derivative. The derivative is subsequently marked to market at each reporting date based on current fair value, with the changes in fair value reported in the results of operations.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;The Company also follows ASC 480-10, &lt;em&gt;Distinguishing Liabilities from Equity&lt;/em&gt; (&amp;#x201c;ASC 480-10&amp;#x201d;) when evaluating the accounting for its hybrid instruments. A financial instrument that embodies an unconditional obligation, or a financial instrument other than an outstanding share that embodies a conditional obligation, that the issuer must or may settle by issuing a variable number of its equity shares shall be classified as a liability (or an asset in some circumstances) if, at inception, the monetary value of the obligation is based solely or predominantly on any one of the following: (a) a fixed monetary amount known at inception (for example, a payable settled with a variable number of the issuer&amp;#x2019;s equity shares); (b) variations in something other than the fair value of the issuer&amp;#x2019;s equity shares (for example, a financial instrument indexed to the Standard and Poor&amp;#x2019;s S&amp;amp;P 500 Index and settled with a variable number of the issuer&amp;#x2019;s equity shares); or (c) variations inversely related to changes in the fair value of the issuer&amp;#x2019;s equity shares (for example, a written put option that could be net share settled). Hybrid instruments meeting these criteria are not further evaluated for any embedded derivatives and are carried as a liability at fair value at each balance sheet date with a re-measurement reported in other (income) expense in the accompanying Consolidated Statements of Comprehensive Income (Loss).&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;When determining short-term vs. long-term classification of derivative liabilities, the Company first evaluates the instruments&amp;#x2019; exercise provisions. Generally, if a derivative is a liability and exercisable within one year, it will be classified as short-term. However, because of the unique provisions and circumstances that may impact the accounting for derivative instruments, the Company carefully evaluates all factors that could potentially restrict the instrument from being exercised or create a situation where exercise would be considered remote. The Company re-evaluates its derivative liabilities at each reporting period end and make&amp;#160;updates for any changes in facts and circumstances that may impact classification.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;div&gt;&lt;p style="margin:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Warrants Issued in Connection with Financings&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;The Company generally accounts for warrants issued in connection with debt and equity financings as a component of equity, unless the warrants include a conditional obligation to issue a variable number of shares or there is a deemed possibility that the Company may need to settle the warrants in cash. For warrants issued with a conditional obligation to issue a variable number of shares or the deemed possibility of a cash settlement, the Company records the fair value of the warrants as a liability at each balance sheet date and records changes in fair value in other (income) expense in the Consolidated Statements of Comprehensive Income (Loss).&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;div&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Debt Issuance Costs and Interest&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Discounts related to bifurcated derivatives, freestanding instruments issued in bundled transactions and issuance costs are recorded as a reduction to the carrying value of the debt and amortized over the life of the debt using the effective interest method. The Company makes changes to the effective interest rate, as necessary, on a prospective basis. For debt facilities that provide for multiple advances, the Company initially defers any issuance costs until the first advance is made and then amortizes the costs over the life of the facility.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;div&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Research and Development Expenses and Licensed Technology&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Research and development costs are expensed when incurred. These costs may consist of external research and development expenses incurred under agreements with third-party contract research organizations and investigative sites, third-party manufacturing organizations and consultants; license fees; employee-related expenses, which include salaries and benefits for the personnel involved in the Company&amp;#x2019;s preclinical and clinical drug development activities; facilities expense, depreciation and other allocated expenses; and equipment and laboratory supplies.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Costs incurred for the rights to use licensed technologies in the research and development process, including licensing fees and milestone payments, are charged to research and development expense as incurred in situations where the Company has not identified an alternative future use for the acquired rights, and are capitalized in situations where there is an identified alternative future use. No cost associated with the use of licensed technologies has been capitalized to date.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;div&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Stock-Based Compensation&amp;#160;&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;em&gt;&lt;strong&gt;Expense&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Stock-based compensation expense is estimated at the grant date based on the fair value of the award, and the cost is recognized as expense ratably over the vesting period with forfeitures accounted for as they occur. The Company uses the Black-Scholes Merton option pricing model for estimating the grant date fair value of stock options using the following assumptions:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN" width="100%"&gt;&lt;tbody&gt;&lt;tr style="height:15"&gt;&lt;td style="width:4%"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:4%" valign="top"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&amp;#x2022;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Volatility - Stock price volatility is estimated over the expected term based on a blended rate of industry peers and the Company&amp;#x2019;s actual stock volatility adjusted for periods in which significant financial variability was identified.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15"&gt;&lt;td&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&amp;#x2022;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Expected term - The expected term is based on a simplified method which defines the life as the weighted average of the contractual term of the options and the vesting period for each award.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15"&gt;&lt;td&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&amp;#x2022;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Risk-free rate - The risk-free interest rate for the expected term of the option is based on the average market rate on U.S. Treasury securities in effect during the period in which the awards were granted.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15"&gt;&lt;td&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&amp;#x2022;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Dividends - &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;The dividend yield assumption is based on the Company&amp;#x2019;s history and expectation of paying no dividends in the foreseeable future.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="MARGIN:0px 0px 0px 0in"&gt;&amp;#160;&lt;/p&gt;&lt;div&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;em&gt;Comprehensive Income (Loss)&lt;/em&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. ASC 220 &lt;em&gt;Comprehensive Income&lt;/em&gt; requires that an entity records all components of comprehensive income (loss), net of their related tax effects, in its financial statements in the period in which they are recognized. For the years ended December 31, 2019 and 2018, the comprehensive income (loss) was equal to net income (loss).&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;div&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;em&gt;Net Income (Loss) Per Share of Common Stock&lt;/em&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;The Company applies FASB ASC No. 260, &lt;em&gt;Earnings per Share&lt;/em&gt; in calculating its basic and diluted net income (loss) per share. Basic net income (loss) per share of common stock is computed by dividing net income (loss) available to common stockholders by the weighted-average number of shares of common stock outstanding for the period. The diluted net loss per share of common stock is computed by giving effect to all potential common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, options to purchase common stock, restricted stock subject to vesting, warrants to purchase common stock and common shares underlying convertible debt instruments were considered to be common stock equivalents. In periods with a reported net loss, such common stock equivalents are excluded from the calculation of diluted net loss per share of common stock if their effect is anti-dilutive. For additional information regarding the net income (loss) per share, see Note 7 &amp;#x201c;Net Income (Loss) per Share of Common Stock.&amp;#x201d;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;div&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;In December 2019, the FASB issued ASU No. 2019-12 Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes. The Board issued this Update as part of its Simplification Initiative to improve areas of GAAP and reduce cost and complexity while maintaining usefulness. The main provisions remove certain exceptions, including the exception to the general methodology for calculating income taxes in an interim period when a year-to-date loss exceeds the anticipated loss for the year. In addition, the amendments simplify income tax accounting in the areas such as income-based franchise taxes, eliminating the requirements to allocate consolidated current and deferred tax expense in certain instances and a requirement that an entity reflects the effect of enacted changes in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date. For public companies, the standard is effective for fiscal years beginning after December 15, 2019, and interim periods therein. The Company plans to adopt this ASU on the effective date of January 1, 2020. The amendments in the update related to foreign subsidiaries will be applied on a modified retrospective basis, the amendments to franchise taxes will be applied on either a retrospective or modified retrospective basis and all other amendments will be applied on a prospective basis. The Company is still evaluating the impact from adopting this standard. However, because the Company&amp;#x2019;s deferred tax assets and liabilities are fully reserved, it does not expect a material impact from the adoption of this standard.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;In November 2018, the FASB issued ASU No. 2018-08 &lt;em&gt;Collaborative Arrangements&lt;/em&gt; (Topic 808) intended to improve financial reporting around collaborative arrangements and align the current guidance under ASC 808 with ASC 606 &lt;em&gt;Revenue from Contracts with Customers&lt;/em&gt;. The ASU affects all companies that enter into collaborative arrangements. The ASU clarifies when certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606 and changes certain presentation requirements for transactions with collaborative arrangement participants that are not directly related to sales to third parties. For public companies, the standard is effective for fiscal years beginning after December 15, 2019 and interim periods therein. Earlier adoption is permitted for any annual or interim period for which consolidated financial statements have not yet been issued. The Company has not entered into any collaborative arrangements and therefore does not currently expect the adoption of this standard to have a material effect on its Consolidated Financial Statements. The Company plans to adopt this ASU on the effective date of January 1, 2020. Upon adoption, the Company will utilize the retrospective transition approach, as prescribed within this ASU.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px 0px 0px 0in;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Recently Adopted Accounting Standards &lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception (&amp;#x201c;ASU 2017-11&amp;#x201d;). Part I of this update addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of the pricing of future equity offerings. Current accounting guidance creates cost and complexity for entities that issue financial instruments (such as warrants and convertible instruments) with down round features that require fair value measurement of the entire instrument or conversion option. Part II of this update addresses the difficulty of navigating Topic 480, Distinguishing Liabilities from Equity, because of the existence of extensive pending content in the FASB Accounting Standards Codification. This pending content is the result of the indefinite deferral of accounting requirements about mandatorily redeemable financial instruments of certain nonpublic entities and certain mandatorily redeemable non-controlling interests. The amendments in Part II of this update do not have an accounting effect. The Company adopted this ASU on the effective date of January 1, 2019. The adoption of this standard using a retrospective cumulative-effect adjustment approach had no impact on the Company&amp;#x2019;s accumulated deficit. The outstanding warrants issued in the Emerald Financing contain a down-round provision. However, in the absence of the down-round provision, these warrants would still require liability accounting and be considered derivatives (See Note 3). As such, the adoption of ASU 2017-11 on January 1, 2019, did not have an impact on the Company&amp;#x2019;s Consolidated Financial Statements and Notes thereto.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;In February 2016, the FASB issued ASU No. 2016-02 &lt;em&gt;Leases&lt;/em&gt; (Topic 842). In January, July and December 2018, and in March 2019, the FASB issued additional amendments to the new lease guidance relating to transition and clarification. This ASU requires most lessees to recognize right of use assets and lease liabilities and recognize expenses in a manner similar to current accounting standards. For public companies, the standard is effective for fiscal years beginning after December 15, 2018 and interim periods therein. The Company adopted this ASU on the effective date of January 1, 2019. Pursuant to ASU 2018-11, issued in July 2018, the Company elected to use the effective date as of the date of application for transition. Upon adoption there was no cumulative effect recorded to the accumulated deficit, as the Company has no lease terms in excess of one year. The Company has elected the short-term lease practical expedient under the ASU which resulted in no change to the current recognition accounting under ASC 840.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="C_20190101to20191231" id="Fxbrl_20200312172222083">&lt;div&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;The preparation of financial statements in conformity with U.S. Generally Accepted Accounting Principles (&amp;#x201c;GAAP&amp;#x201d;) requires management to make estimates and assumptions that affect the amounts reported in the Consolidated Financial Statements and the accompanying notes. Actual results could differ from those estimates. Certain reclassifications have been made to prior year amounts to conform to the current year&amp;#x2019;s presentation. Such reclassifications had no net effect on the prior year&amp;#x2019;s total assets, total liabilities, total stockholders&amp;#x2019; deficit, net loss and cash flows.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:UseOfEstimates contextRef="C_20190101to20191231" id="Fxbrl_20200312172232079">&lt;div&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;The preparation of the Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Consolidated Financial Statements and the reported amounts of income and expense during the reporting period. Actual results could differ from those estimates. The most significant accounting estimates inherent in the preparation of the Company&amp;#x2019;s financial statements include estimates as to the appropriate carrying value of certain assets and liabilities which are not readily apparent from other sources. Such estimates and judgments are utilized for stock-based compensation expense, equity securities, derivative liabilities and debt with embedded features.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
  <embi:RisksAndUncertaintiesPolicyTextBlock contextRef="C_20190101to20191231" id="Fxbrl_20200312172236390">&lt;div&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Risks and Uncertainties&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;The Company&amp;#x2019;s operations are subject to a number of risks and uncertainties, including but not limited to, changes in the general economy, the size and growth of the potential markets for any of the Company&amp;#x2019;s product candidates, results of research and development activities, uncertainties surrounding regulatory developments in the United States and Australia and the Company&amp;#x2019;s ability to attract new funding.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</embi:RisksAndUncertaintiesPolicyTextBlock>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="C_20190101to20191231" id="Fxbrl_20200312172242668">&lt;div&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The carrying values of those investments approximate&amp;#160;their fair value due to their short maturity and liquidity. Cash includes cash on hand and amounts on deposit with financial institutions, which amounts may at times exceed federally insured limits. The Company has not experienced any losses on such accounts and does not believe it is exposed to any significant credit risk. As of December 31, 2019, the Company has no cash equivalents.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="C_20190101to20191231" id="Fxbrl_20200312172247864">&lt;div&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Restricted Cash&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;A deposit of $4,538 and $4,512 &lt;/span&gt;&lt;/span&gt;as of December 31, 2019 and&amp;#160;2018, respectively, was restricted from withdrawal and held by a bank in the form of a certificate of deposit. This certificate serves as collateral for payment of the Company&amp;#x2019;s credit cards.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
  <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="C_20190101to20191231" id="Fxbrl_20200312172259843">&lt;div&gt;&lt;p style="text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Fair Value Measurements&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (the &amp;#x201c;exit price&amp;#x201d;) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last is considered unobservable, is used to measure fair value:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN" width="100%"&gt;&lt;tbody&gt;&lt;tr style="height:15"&gt;&lt;td style="width:7%" valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Level 1:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:93%" valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Valuations for assets and liabilities traded in active markets from readily available pricing sources such as quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15"&gt;&lt;td valign="top"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="top"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Level 2:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Observable inputs (other than Level 1 quoted prices) such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15"&gt;&lt;td valign="top"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="top"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Level 3:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;The carrying values of the Company&amp;#x2019;s financial instruments, with the exception of the Credit Agreement and derivative liabilities, including, cash, prepaid expenses, accounts payable, and other current liabilities approximate their fair value due to the short maturities of these financial instruments. The derivative liabilities are valued on a recurring basis utilizing Level 3 inputs.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Advances under the Credit Agreement are not recorded at fair value. However, fair value can be approximated and disclosed utilizing Level 3 inputs and independent third-party valuation techniques (See Note 3). As of December 31, 2019 and 2018, the fair value of the advances under the Credit Agreement was $1,877,938 and $3,176,824, respectively. The carrying amount of the liability at December 31, 2019 and 2018, was $387,070 and $1,360,960, respectively, and is included in Convertible multi-draw credit agreement - related party, net of discount in the Company&amp;#x2019;s Consolidated Balance Sheets.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
  <us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding contextRef="C_20191231" decimals="0" id="Fxbrl_20200312162659544" unitRef="USD">1877938</us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding>
  <us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="Fxbrl_20200312162708541" unitRef="USD">3176824</us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="C_20190101to20191231" id="Fxbrl_20200312172305552">&lt;div&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Property and Equipment, Net&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Property and equipment, net, consist primarily of computers and equipment. Expenditures for additions, renewals and improvements are capitalized at cost. Depreciation is computed on a&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt; straight-line method based on &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;the estimated useful life of the related asset currently ranging from two to three years. Maintenance and repairs that do not extend the life of assets are charged to expense when incurred. When properties are disposed of, the related costs and accumulated depreciation are removed from the accounts and any gain or loss is reported in the period the transaction takes place.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted cash flows expected to be generated by the asset. If the carrying amount exceeds its estimated future undiscounted cash flows, an impairment charge is recognized by the amount by which the carrying amount exceeds the fair value of the asset.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <us-gaap:PropertyPlantAndEquipmentDepreciationMethods contextRef="C_20190101to20191231" id="F17228_straightli">straight-line method</us-gaap:PropertyPlantAndEquipmentDepreciationMethods>
  <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="C_20190101to20191231" id="Fxbrl_20200312171638055">two to three years</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
  <us-gaap:IncomeTaxPolicyTextBlock contextRef="C_20190101to20191231" id="Fxbrl_20200312172311249">&lt;div&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;The Company accounts for deferred income tax assets and liabilities based on differences between the financial reporting and tax bases of assets and liabilities, net operating loss carryforwards (the &amp;#x201c;NOLs&amp;#x201d;) and other tax credit carryforwards. These items are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the period that includes the enactment date. Any interest or penalties would be recorded in the Company&amp;#x2019;s Consolidated Statements of Comprehensive Income (Loss) in the period incurred. When necessary, the Company recognizes interest and penalties related to income tax matters in income tax expense.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;The Company records a valuation allowance against deferred tax assets to the extent that it is more likely than not that some portion or all of the deferred tax assets will not be realized. In making such determinations, management considers all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and recent financial operations. Due to the substantial doubt related to the Company&amp;#x2019;s ability to utilize its deferred tax assets, a valuation allowance for the full amount of the deferred tax assets has been established at December 31, 2019 and 2018. As a result of this valuation allowance, there are no income tax benefits reflected in the accompanying Consolidated Statements of Comprehensive Income (Loss) to offset pre-tax losses.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;The Company recognizes a tax benefit from uncertain tax positions when it is more likely than not (50%) that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits of the position.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:DerivativesPolicyTextBlock contextRef="C_20190101to20191231" id="Fxbrl_20200312172318650">&lt;div&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Convertible Instruments&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;The Company accounts for hybrid contracts with embedded conversion features in accordance with GAAP. ASC 815, &lt;em&gt;Derivatives and Hedging Activities&lt;/em&gt; (&amp;#x201c;ASC 815&amp;#x201d;) requires companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria includes circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;The Company accounts for convertible debt instruments with embedded conversion features in accordance with ASC 470-20, Debt with Conversion and Other Options (&amp;#x201c;ASC 470-20&amp;#x201d;) if it is determined that the conversion feature should not be bifurcated from their host instruments. Under ASC 470-20, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the difference between the fair value of the underlying common stock at the commitment date and the embedded effective conversion price. When the Company determines that the embedded conversion option should be bifurcated from its host instrument, the embedded feature is accounted for in accordance with ASC 815. Under ASC 815, a portion of the proceeds received upon the issuance of the hybrid contract is allocated to the fair value of the derivative. The derivative is subsequently marked to market at each reporting date based on current fair value, with the changes in fair value reported in the results of operations.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;The Company also follows ASC 480-10, &lt;em&gt;Distinguishing Liabilities from Equity&lt;/em&gt; (&amp;#x201c;ASC 480-10&amp;#x201d;) when evaluating the accounting for its hybrid instruments. A financial instrument that embodies an unconditional obligation, or a financial instrument other than an outstanding share that embodies a conditional obligation, that the issuer must or may settle by issuing a variable number of its equity shares shall be classified as a liability (or an asset in some circumstances) if, at inception, the monetary value of the obligation is based solely or predominantly on any one of the following: (a) a fixed monetary amount known at inception (for example, a payable settled with a variable number of the issuer&amp;#x2019;s equity shares); (b) variations in something other than the fair value of the issuer&amp;#x2019;s equity shares (for example, a financial instrument indexed to the Standard and Poor&amp;#x2019;s S&amp;amp;P 500 Index and settled with a variable number of the issuer&amp;#x2019;s equity shares); or (c) variations inversely related to changes in the fair value of the issuer&amp;#x2019;s equity shares (for example, a written put option that could be net share settled). Hybrid instruments meeting these criteria are not further evaluated for any embedded derivatives and are carried as a liability at fair value at each balance sheet date with a re-measurement reported in other (income) expense in the accompanying Consolidated Statements of Comprehensive Income (Loss).&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;When determining short-term vs. long-term classification of derivative liabilities, the Company first evaluates the instruments&amp;#x2019; exercise provisions. Generally, if a derivative is a liability and exercisable within one year, it will be classified as short-term. However, because of the unique provisions and circumstances that may impact the accounting for derivative instruments, the Company carefully evaluates all factors that could potentially restrict the instrument from being exercised or create a situation where exercise would be considered remote. The Company re-evaluates its derivative liabilities at each reporting period end and make&amp;#160;updates for any changes in facts and circumstances that may impact classification.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
  <embi:WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock contextRef="C_20190101to20191231" id="Fxbrl_20200312172323957">&lt;div&gt;&lt;p style="margin:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Warrants Issued in Connection with Financings&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;The Company generally accounts for warrants issued in connection with debt and equity financings as a component of equity, unless the warrants include a conditional obligation to issue a variable number of shares or there is a deemed possibility that the Company may need to settle the warrants in cash. For warrants issued with a conditional obligation to issue a variable number of shares or the deemed possibility of a cash settlement, the Company records the fair value of the warrants as a liability at each balance sheet date and records changes in fair value in other (income) expense in the Consolidated Statements of Comprehensive Income (Loss).&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</embi:WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock>
  <us-gaap:DebtPolicyTextBlock contextRef="C_20190101to20191231" id="Fxbrl_20200312172327653">&lt;div&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Debt Issuance Costs and Interest&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Discounts related to bifurcated derivatives, freestanding instruments issued in bundled transactions and issuance costs are recorded as a reduction to the carrying value of the debt and amortized over the life of the debt using the effective interest method. The Company makes changes to the effective interest rate, as necessary, on a prospective basis. For debt facilities that provide for multiple advances, the Company initially defers any issuance costs until the first advance is made and then amortizes the costs over the life of the facility.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:DebtPolicyTextBlock>
  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="C_20190101to20191231" id="Fxbrl_20200312172333574">&lt;div&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Research and Development Expenses and Licensed Technology&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Research and development costs are expensed when incurred. These costs may consist of external research and development expenses incurred under agreements with third-party contract research organizations and investigative sites, third-party manufacturing organizations and consultants; license fees; employee-related expenses, which include salaries and benefits for the personnel involved in the Company&amp;#x2019;s preclinical and clinical drug development activities; facilities expense, depreciation and other allocated expenses; and equipment and laboratory supplies.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Costs incurred for the rights to use licensed technologies in the research and development process, including licensing fees and milestone payments, are charged to research and development expense as incurred in situations where the Company has not identified an alternative future use for the acquired rights, and are capitalized in situations where there is an identified alternative future use. No cost associated with the use of licensed technologies has been capitalized to date.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="C_20190101to20191231" id="Fxbrl_20200312172343509">&lt;div&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Stock-Based Compensation&amp;#160;&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;em&gt;&lt;strong&gt;Expense&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Stock-based compensation expense is estimated at the grant date based on the fair value of the award, and the cost is recognized as expense ratably over the vesting period with forfeitures accounted for as they occur. The Company uses the Black-Scholes Merton option pricing model for estimating the grant date fair value of stock options using the following assumptions:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN" width="100%"&gt;&lt;tbody&gt;&lt;tr style="height:15"&gt;&lt;td style="width:4%"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:4%" valign="top"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&amp;#x2022;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Volatility - Stock price volatility is estimated over the expected term based on a blended rate of industry peers and the Company&amp;#x2019;s actual stock volatility adjusted for periods in which significant financial variability was identified.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15"&gt;&lt;td&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&amp;#x2022;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Expected term - The expected term is based on a simplified method which defines the life as the weighted average of the contractual term of the options and the vesting period for each award.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15"&gt;&lt;td&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&amp;#x2022;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Risk-free rate - The risk-free interest rate for the expected term of the option is based on the average market rate on U.S. Treasury securities in effect during the period in which the awards were granted.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15"&gt;&lt;td&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&amp;#x2022;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Dividends - &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;The dividend yield assumption is based on the Company&amp;#x2019;s history and expectation of paying no dividends in the foreseeable future.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="C_20190101to20191231" id="Fxbrl_20200312172350180">&lt;div&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;em&gt;Comprehensive Income (Loss)&lt;/em&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. ASC 220 &lt;em&gt;Comprehensive Income&lt;/em&gt; requires that an entity records all components of comprehensive income (loss), net of their related tax effects, in its financial statements in the period in which they are recognized. For the years ended December 31, 2019 and 2018, the comprehensive income (loss) was equal to net income (loss).&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="C_20190101to20191231" id="Fxbrl_20200312172355667">&lt;div&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;em&gt;Net Income (Loss) Per Share of Common Stock&lt;/em&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;The Company applies FASB ASC No. 260, &lt;em&gt;Earnings per Share&lt;/em&gt; in calculating its basic and diluted net income (loss) per share. Basic net income (loss) per share of common stock is computed by dividing net income (loss) available to common stockholders by the weighted-average number of shares of common stock outstanding for the period. The diluted net loss per share of common stock is computed by giving effect to all potential common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, options to purchase common stock, restricted stock subject to vesting, warrants to purchase common stock and common shares underlying convertible debt instruments were considered to be common stock equivalents. In periods with a reported net loss, such common stock equivalents are excluded from the calculation of diluted net loss per share of common stock if their effect is anti-dilutive. For additional information regarding the net income (loss) per share, see Note 7 &amp;#x201c;Net Income (Loss) per Share of Common Stock.&amp;#x201d;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="C_20190101to20191231" id="Fxbrl_20200312172415604">&lt;div&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;In December 2019, the FASB issued ASU No. 2019-12 Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes. The Board issued this Update as part of its Simplification Initiative to improve areas of GAAP and reduce cost and complexity while maintaining usefulness. The main provisions remove certain exceptions, including the exception to the general methodology for calculating income taxes in an interim period when a year-to-date loss exceeds the anticipated loss for the year. In addition, the amendments simplify income tax accounting in the areas such as income-based franchise taxes, eliminating the requirements to allocate consolidated current and deferred tax expense in certain instances and a requirement that an entity reflects the effect of enacted changes in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date. For public companies, the standard is effective for fiscal years beginning after December 15, 2019, and interim periods therein. The Company plans to adopt this ASU on the effective date of January 1, 2020. The amendments in the update related to foreign subsidiaries will be applied on a modified retrospective basis, the amendments to franchise taxes will be applied on either a retrospective or modified retrospective basis and all other amendments will be applied on a prospective basis. The Company is still evaluating the impact from adopting this standard. However, because the Company&amp;#x2019;s deferred tax assets and liabilities are fully reserved, it does not expect a material impact from the adoption of this standard.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;In November 2018, the FASB issued ASU No. 2018-08 &lt;em&gt;Collaborative Arrangements&lt;/em&gt; (Topic 808) intended to improve financial reporting around collaborative arrangements and align the current guidance under ASC 808 with ASC 606 &lt;em&gt;Revenue from Contracts with Customers&lt;/em&gt;. The ASU affects all companies that enter into collaborative arrangements. The ASU clarifies when certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606 and changes certain presentation requirements for transactions with collaborative arrangement participants that are not directly related to sales to third parties. For public companies, the standard is effective for fiscal years beginning after December 15, 2019 and interim periods therein. Earlier adoption is permitted for any annual or interim period for which consolidated financial statements have not yet been issued. The Company has not entered into any collaborative arrangements and therefore does not currently expect the adoption of this standard to have a material effect on its Consolidated Financial Statements. The Company plans to adopt this ASU on the effective date of January 1, 2020. Upon adoption, the Company will utilize the retrospective transition approach, as prescribed within this ASU.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px 0px 0px 0in;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Recently Adopted Accounting Standards &lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception (&amp;#x201c;ASU 2017-11&amp;#x201d;). Part I of this update addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of the pricing of future equity offerings. Current accounting guidance creates cost and complexity for entities that issue financial instruments (such as warrants and convertible instruments) with down round features that require fair value measurement of the entire instrument or conversion option. Part II of this update addresses the difficulty of navigating Topic 480, Distinguishing Liabilities from Equity, because of the existence of extensive pending content in the FASB Accounting Standards Codification. This pending content is the result of the indefinite deferral of accounting requirements about mandatorily redeemable financial instruments of certain nonpublic entities and certain mandatorily redeemable non-controlling interests. The amendments in Part II of this update do not have an accounting effect. The Company adopted this ASU on the effective date of January 1, 2019. The adoption of this standard using a retrospective cumulative-effect adjustment approach had no impact on the Company&amp;#x2019;s accumulated deficit. The outstanding warrants issued in the Emerald Financing contain a down-round provision. However, in the absence of the down-round provision, these warrants would still require liability accounting and be considered derivatives (See Note 3). As such, the adoption of ASU 2017-11 on January 1, 2019, did not have an impact on the Company&amp;#x2019;s Consolidated Financial Statements and Notes thereto.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;In February 2016, the FASB issued ASU No. 2016-02 &lt;em&gt;Leases&lt;/em&gt; (Topic 842). In January, July and December 2018, and in March 2019, the FASB issued additional amendments to the new lease guidance relating to transition and clarification. This ASU requires most lessees to recognize right of use assets and lease liabilities and recognize expenses in a manner similar to current accounting standards. For public companies, the standard is effective for fiscal years beginning after December 15, 2018 and interim periods therein. The Company adopted this ASU on the effective date of January 1, 2019. Pursuant to ASU 2018-11, issued in July 2018, the Company elected to use the effective date as of the date of application for transition. Upon adoption there was no cumulative effect recorded to the accumulated deficit, as the Company has no lease terms in excess of one year. The Company has elected the short-term lease practical expedient under the ASU which resulted in no change to the current recognition accounting under ASC 840.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <embi:WarrantsAndDerivativeLiabilitiesTextBlock contextRef="C_20190101to20191231" id="F89bf9c40-2de8-11ea-add8-41ed81237e2f">&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;3. Warrants and Derivative Liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;There are significant judgments and estimates inherent in the determination of the fair value of the Company&amp;#x2019;s warrants. These judgments and estimates include assumptions regarding the Company&amp;#x2019;s future operating performance, the time to completing a liquidity event and the determination of the appropriate valuation methods. If the Company had made different assumptions, the fair value of the warrants could have been significantly different (See Note 2).&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Warrants vested and outstanding as of December 31, 2019 are summarized as follows:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="WIDTH:100%;TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN" width="100%"&gt;&lt;tbody&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;width:85px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:8px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong&gt;&lt;strong&gt;Number of&lt;/strong&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong&gt;Warrantsv&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Exercise&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;width:85px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Term&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:8px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;strong&gt;Vested&lt;/strong&gt; and&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="border:1pt none;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Source&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1px solid black;text-align:center;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Price&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1px solid black;text-align:center;width:85px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;(Years)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:8px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1px solid black;text-align:center;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Outstanding&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="background-color:rgb(204, 238, 255)" valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Pre 2015 Common Stock Warrants&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;1.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:85px;background-color:rgb(204, 238, 255)"&gt;&lt;p style="MARGIN:0px;text-align:right"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;6&amp;#x2014;10&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:8px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;4,000,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;2015 Common Stock Warrants&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)"&gt;&lt;p style="MARGIN:0px;text-align:right"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;1.15&amp;#x2014;5.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:85px;background-color:rgb(255, 255, 255)"&gt;&lt;p style="MARGIN:0px;text-align:right"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;5&amp;#x2014;10&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:8px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;442,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="background-color:rgb(204, 238, 255)" valign="top"&gt;&lt;p style="margin-top:0px;margin-right:0px;margin-bottom:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Common Stock Warrants to Series B Stockholders&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:77px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:8px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;1,031,250&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;2016 Common Stock Warrants to Service Providers&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;1.15&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:77px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:8px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;40,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="background-color:rgb(204, 238, 255)" valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;2016 Series C Common Stock Warrants to Placement Agent&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;0.40&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:77px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:8px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;125,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;2017 Series D Common Stock Warrants to Placement Agent&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;0.25&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:77px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:8px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;480,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="background-color:rgb(204, 238, 255)" valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;2017 Common Stock Warrants to Service Provider&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;0.41&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:77px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:8px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;125,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;2018 Emerald Financing Warrants&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;0.10&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:77px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:8px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;3,400,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="border:1pt none;background-color:rgb(204, 238, 255)" valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Emerald Multi Draw Credit Agreement Warrants&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border:1pt none;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border:1pt none;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border:1pt none;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;0.50&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;width:1%;border:1pt none;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border:1pt none;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border:1pt none;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border:1pt none;text-align:right;width:77px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;width:8px;border:1pt none;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border:1pt none;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border:1pt none;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border:1pt none;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;7,500,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;width:1%;border:1pt none;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="top"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;2019 Common Stock Warrants&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255);border-bottom:1pt solid black" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255);border-bottom:1pt solid black" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;0.35&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;width:77px;background-color:rgb(255, 255, 255);border-bottom:1pt solid black" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:8px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom:1pt solid black;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom:1pt solid black;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;8,000,000&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="background-color:rgb(204, 238, 255)" valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Total warrants vested and outstanding as of December 31, 2019&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:77px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:8px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;25,143,250&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;em&gt;2019 Common Stock Warrants&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;During the year ended December 31, 2019, the Company issued 8,000,000 fully vested common stock warrants to investors, in conjunction with the November 2019 Common Stock Offering discussed below (See Note 5). The warrants are equity classified at issuance and the Company allocated an aggregate of $722,208 of the gross proceeds to the warrants on a relative fair value basis. The warrants vested immediately and had an estimated aggregate fair value of $1,130,400 utilizing the Black-Scholes option pricing model with the following assumptions:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&amp;#160;&lt;/p&gt;&lt;div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="border:0px" width="100%"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;At Issuance&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="top"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="top"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Volatility factor&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;93.08&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="top"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;1.62&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="top"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Expected term (years)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;5.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="top"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Underlying common stock price&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;0.22&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;i&gt;Emerald Multi-Draw Credit Agreement Warrants&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br/&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;During the year ended December 31, 2019, the Company issued 5,000,000 fully vested common stock warrants to Emerald Health Sciences, in conjunction with advances under the Credit Agreement discussed below (See Note 4). The warrants are equity classified at issuance and the Company allocated an aggregate of $716,110 of the gross proceeds to the warrants on a relative fair value basis. The proceeds allocated to the warrants were recorded as discounts to each advance and are being amortized over the term of the debt. The warrants vested immediately and had an estimated aggregate fair value of $1,830,573 utilizing the Black-Scholes option pricing model with the following assumptions:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&amp;#160;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="border:0px" width="100%"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;At Issuance&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="top"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="top"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Volatility factor&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;91.6&amp;#x2014;92.1&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="top"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;2.23&amp;#x2014;2.51&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="top"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Expected term (years)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;5.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="top"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Underlying common stock price&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;$0.33&amp;#x2014;0.69&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;br/&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;On November 1, 2018, the Company issued 2,500,000 &lt;/span&gt;&lt;/span&gt;fully vested common stock warrants to Emerald Health Sciences, in conjunction with the first advance on the Credit Agreement discussed below (See Note 4). The warrants are equity classified at issuance and the Company allocated&lt;span&gt;&lt;span&gt; $315,080 &lt;/span&gt;&lt;/span&gt;of the gross proceeds to the warrants on a relative fair value basis. The proceeds allocated to the warrants was recorded as a discount to the November 1, 2018 advance and are being amortized over the term of the debt. The warrants vested immediately and had an estimated fair value of&lt;span&gt;&lt;span&gt; $593,629 &lt;/span&gt;&lt;/span&gt;utilizing the Black-Scholes option pricing model with the following assumptions:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font:10pt Times New Roman;margin:auto;text-align:justify;width:100%" width="85%"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;strong&gt;At&lt;/strong&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;strong&gt;Issuance&lt;/strong&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Volatility factor&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;92.5&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;2.96&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Expected term (years)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;5.0&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Underlying common stock price&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;0.36&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;i&gt;2018 Emerald Financing Warrants &lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;In January and February 2018, the Company issued an aggregate of 40,800,000 and 3,400,000 &lt;/span&gt;&lt;/span&gt;&lt;span&gt;&lt;span&gt;fully vested common stock warrants to Emerald Health Sciences and an accredited investor, respectively, in conjunction with the Emerald Financing discussed below (See Note 5). The Company reviewed the warrants for liability or equity classification under the guidance of ASC 480-10, &lt;em&gt;Distinguishing Liabilities from Equity&lt;/em&gt;, and concluded that these warrants should be classified as liabilities. See the additional discussion below, &lt;em&gt;Derivative Liabilities- Emerald Financing Warrant Liability&lt;/em&gt;. On December 20, 2019, Emerald Health Sciences paid the aggregate exercise price of $4,080,000 in the form of a reduction of the corresponding amount of obligations outstanding under the Credit Agreement to exercise 40,800,000 Emerald Financing Warrants.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Derivative Liabilities&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;The following tables summarize the activity of derivative liabilities for the periods indicated:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="WIDTH:100%;TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN" width="100%"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="18" style="border:1pt none;text-align:center" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Year Ended December 31, 2019&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;2018, Fair&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Value of&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Derivative Liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Fair Value of Derivative Liabilities Issued&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1px solid black;text-align:center;width:80px" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Change in&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Fair value of&amp;#160;Liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:8px" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Reclassification&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;of Derivatives&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;to Equity&amp;#160;or Extinguishment&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;2019, Fair&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Value of&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Derivative Liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Emerald Multi Draw Credit Agreement - compound derivative liability (1)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9px" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:108px" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;219,453&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;516,058&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:72px" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;(484,147&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:8px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;(160,567&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;)*&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6px" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:73px" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;90,797&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Emerald Financing - warrant liability (2)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:108px" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;15,251,413&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:72px" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;(9,042,066&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:8px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;(5,933,323&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:73px" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;276,024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Series B - warrant liability (3)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9px;border-bottom:1pt solid black" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:108px;border-bottom:1pt solid black" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;487,500&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border-bottom:1pt solid black" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;border-bottom:1pt solid black" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border-bottom:1pt solid black" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:72px;border-bottom:1pt solid black" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;(208,546&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:8px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border-bottom:1pt solid black" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;border-bottom:1pt solid black" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;(144,375&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6px;border-bottom:1pt solid black" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:73px;border-bottom:1pt solid black" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;134,579&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Total derivative liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom:3px double black;width:9px" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3px double black;text-align:right;width:108px" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;15,958,366&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:black 3px double;width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:black 3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;516,058&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:black 3px double;width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3px double black;text-align:right;width:72px" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;(9,734,759&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom:3px;width:8px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:black 3px double;width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:black 3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;(6,238,265&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom:3px double black;width:6px" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3px double black;text-align:right;width:73px" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;501,400&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Less, noncurrent portion of derivative liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9px;border-bottom:1pt solid black" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:108px;border-bottom:1pt solid black" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;(219,453&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:72px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:8px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom:1px solid black;width:6px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom:1px solid black;text-align:right;width:73px" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;(90,797&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Current balance of derivative liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9px;border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:108px;border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;15,738,913&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:72px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:8px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border:1pt none" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border:1pt none" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;width:6px" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;text-align:right;width:73px" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;410,603&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;em&gt;*This amount has been included in the calculation of the extinguishment loss recorded in connection with the prepayment of the Emerald Credit Agreement as described in Note 4 below.&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&amp;#160;&lt;/p&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="WIDTH:100%;TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN" width="100%"&gt;&lt;tbody&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="18" style="border-bottom:1px solid black;text-align:center;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Year Ended December 31, 2018&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1px solid black;text-align:center;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;2017, Fair&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Value of&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Derivative Liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1px solid black;text-align:center;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Fair Value of Derivative Liabilities Issued&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1px solid black;text-align:center;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Change in&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Fair value of Derivative Liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;**&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1px solid black;text-align:center;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Reclassification&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;of Derivatives&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;to Equity&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);width:6px" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:12px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1px solid black;text-align:center;width:82px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;2018, Fair&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Value of&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Derivative Liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="background-color:rgb(204, 238, 255)" valign="top"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Emerald Multi Draw Credit Agreement - compound derivative liability (1)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;204,102&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;15,351&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:12px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:11px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;219,453&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="top"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Emerald Financing - warrant liability (2)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;10,424,634&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;4,826,779&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:12px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:11px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;15,251,413&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="background-color:rgb(204, 238, 255)" valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Series B - warrant liability (3)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;551,322&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;1,476,044&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;(1,539,866&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:12px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:11px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;487,500&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="top"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Emerald Convertible Promissory Note - conversion liability (4)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;265,000&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;360,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;185,000&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;(810,000&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:12px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:11px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="background-color:rgb(204, 238, 255)" valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Series B Preferred Stock - conversion liability (5)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;6,715&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;(6,715&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:6px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:12px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:11px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="top"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Total derivative liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom:2.5pt double black;width:1%;background-color:rgb(255, 255, 255);border-top:1pt solid black;border-right:none;border-left:none;border-image:initial" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2.5pt double black;text-align:right;width:9%;background-color:rgb(255, 255, 255);border-top:1pt solid black;border-right:none;border-left:none;border-image:initial" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;823,037&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom:3px;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom:2.5pt double black;width:1%;background-color:rgb(255, 255, 255);border-top:1pt solid black;border-right:none;border-left:none;border-image:initial" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2.5pt double black;text-align:right;width:9%;background-color:rgb(255, 255, 255);border-top:1pt solid black;border-right:none;border-left:none;border-image:initial" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;10,988,736&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom:3px;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom:2.5pt double black;width:1%;background-color:rgb(255, 255, 255);border-top:1pt solid black;border-right:none;border-left:none;border-image:initial" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2.5pt double black;text-align:right;width:9%;background-color:rgb(255, 255, 255);border-top:1pt solid black;border-right:none;border-left:none;border-image:initial" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;6,503,174&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom:3px;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom:2.5pt double black;width:1%;background-color:rgb(255, 255, 255);border-top:1pt solid black;border-right:none;border-left:none;border-image:initial" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2.5pt double black;text-align:right;width:9%;background-color:rgb(255, 255, 255);border-top:1pt solid black;border-right:none;border-left:none;border-image:initial" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;(2,356,581&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom:3px;width:6px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:12px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom:2.5pt double black;width:11px;background-color:rgb(255, 255, 255);border-top:1pt solid black;border-right:none;border-left:none;border-image:initial" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2.5pt double black;text-align:right;width:9%;background-color:rgb(255, 255, 255);border-top:1pt solid black;border-right:none;border-left:none;border-image:initial" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;15,958,366&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom:3px;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="background-color:rgb(204, 238, 255)" valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Less, noncurrent portion of derivative liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;(551,322&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:12px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border:1pt none;width:11px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border:1pt none;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;(219,453&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Current balance of derivative liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;border-bottom:2.5pt double black;background-color:rgb(255, 255, 255);border-top:1pt solid black;border-right:none;border-left:none;border-image:initial" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;border-bottom:2.5pt double black;background-color:rgb(255, 255, 255);border-top:1pt solid black;border-right:none;border-left:none;border-image:initial" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;271,715&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:12px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom:2.5pt double black;width:11px;background-color:rgb(255, 255, 255);border-top:1pt solid black;border-right:none;border-left:none;border-image:initial" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2.5pt double black;text-align:right;width:9%;background-color:rgb(255, 255, 255);border-top:1pt solid black;border-right:none;border-left:none;border-image:initial" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;15,738,913&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom:3px;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;em&gt;**The change in fair value of derivative liabilities for the year ended December 31, 2018, relate partially to the Company determining it had sufficient trading activity to utilize the actual volatility of the trading of the Company&amp;#x2019;s common stock as an input to the volatility assumption when computing the fair value of derivative liabilities. The volatility assumption was updated as of October 1, 2018 to incorporate the Company&amp;#x2019;s own volatility with six similar companies to develop a blended average. The Company had previously estimated the volatility assumption by averaging the volatility of six similar entities which had resulted in a lower volatility. The increase in value of the volatility assumption has led to a higher valuation of the derivative liabilities as disclosed below.&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&amp;#160;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;i&gt;Emerald Multi-Draw Credit Agreement Compound Derivative Liability (1)&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br/&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0in;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;In connection with the advances under the Credit Agreement (See Note 4), the Company bifurcated a compound derivative liability related to a contingent interest feature and acceleration upon default provision (contingent put option) provided to Emerald Health Sciences. The Company&amp;#x2019;s estimate of fair value of the compound derivative liability was determined by using a differential cash flows valuation model, wherein the fair value of the underlying debt facility and its conversion right are estimated both with and without the presence of the contingent interest feature, holding all other assumptions constant. The resulting difference between the estimated fair values in both scenarios is the estimated fair value of the compound derivative. The fair value of the underlying debt facility is estimated by calculating the expected cash flows with consideration of the estimated probability of a change in control transaction, defined as an event of default by the agreement, and applying the expected default interest rate from the date of such default through maturity. The expected cash flows are then discounted back to the reporting date using a benchmark market yield. The conversion right component of the compound derivative is measured using a standard Black-Scholes model for each payment period. Because Emerald Health Sciences would forgo the contingent interest if the contingent put option was exercised upon an event of default, the value ascribed to the contingent put option within the compound derivative is de minimis.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;i&gt;Emerald Financing Warrant Liability (2)&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br/&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;In January and February 2018, the Company issued 44,200,000 warrants to purchase common stock in conjunction with the Emerald Financing discussed above. The warrants vest immediately and have an exercise price of $0.10 per share with a term of five years and are exercisable in cash or through a cashless exercise provision. The warrants contain an anti-dilution protection feature provided to the investors if the Company subsequently issues or sells any shares of common stock, stock options, or convertible securities at a price less than the exercise price of $0.10. The exercise price is automatically adjusted down to the price of the instrument being issued. &lt;/span&gt;&lt;/span&gt;&lt;span&gt;&lt;span&gt;In addition, the warrants contain a contingent put option if the Company undergoes a subsequent financing that results in a change in control. The warrant holders also have the right to participate in subsequent financing transactions on an as-if converted basis.&lt;/span&gt;&lt;/span&gt;&lt;br/&gt;&lt;br/&gt;&lt;span&gt;&lt;span&gt;In December 2019, Emerald Health Sciences paid the aggregate exercise price of $4,080,000 in the form of a reduction of the corresponding amount of obligations outstanding under the Credit Agreement to exercise 40,800,000 Emerald Financing Warrants. Under the Warrant Exercise Agreement between the Company and Emerald Health Sciences, the proceeds from the warrants were first applied directly to the accrued interest balance at the exercise date with the remainder applied to the oldest outstanding principal balances under the Credit Agreement. Immediately prior to exercise, the warrants were adjusted to fair value which considered the closing trading price on the exercise date (See Note 4).&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;The Company reviewed the warrants for liability or equity classification under the guidance of ASC 480-10, &lt;i&gt;Distinguishing Liabilities from Equity&lt;/i&gt;, and concluded that the warrants should be classified as a liability and re-measured to fair value at the end of each reporting period. &lt;/span&gt;&lt;/span&gt;&lt;span&gt;&lt;span&gt;The Company also reviewed the warrants under ASC 815, &lt;em&gt;Derivatives and Hedging/Contracts in Entity&amp;#x2019;s Own Equity&lt;/em&gt;, and determined that the warrants also meet the definition of a derivative. With the assistance of a third-party valuation specialist, the Company valued the warrant liabilities utilizing the Monte Carlo valuation method pursuant to the accounting guidance of ASC 820-10, &lt;em&gt;Fair Value Measurement&lt;/em&gt;s. On the closing dates, the Company estimated that the fair value of the warrants issued on January 19, 2018 and February 16, 2018 was&lt;/span&gt;&lt;/span&gt;&lt;span&gt;&lt;span&gt; $4,717,211&amp;#160;and $5,707,423, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;The warrant liabilities were valued using Monte Carlo simulations conducted at the closing dates of January 19, 2018 and February 16, 2018 and at the balance sheet dates using the following assumptions:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="WIDTH:100%;TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN;margin:auto" width="100%"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style="width:null" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;2018&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom:1pt solid black;width:8%"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;At Issuance&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td style="width:null" valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:8%"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td style="width:null" valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Volatility factor&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="MARGIN:0px;text-align:right"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;79.5&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;92.1&amp;#x2014;92.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;width:8%"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;70.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td style="width:null" valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;1.62&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;2.49&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:8%"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;2.45&amp;#x2014;2.60&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td style="width:null" valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Expected term (years)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="MARGIN:0px;text-align:right"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;3.13&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;4.05&amp;#x2014;4.13&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;width:8%"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;5.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td style="width:null" valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Underlying common stock price&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;0.13&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;0.40&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:8%"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;0.29&amp;#x2014;0.30&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Because fair value assigned to the warrants exceeded the proceeds received in the Emerald Financing, none of the consideration was allocated to common stock and the Company recorded an adjustment for the difference between the fair value of the warrant liabilities and the total proceeds received to other expense in the Consolidated Statements Comprehensive Income (Loss) for the year ended December 31, 2018 as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="WIDTH:100%;TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN" width="100%"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="BORDER-BOTTOM:black 1px solid;text-align:center" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Closing&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align:center" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;January &lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;2018&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;February&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;2018&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Total&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;Initial fair value of Emerald Financing Warrant Liability&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;4,717,211&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;5,707,423&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;10,424,634&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;Less: proceeds from the Emerald Financing&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border:1pt none;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border:1pt none;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;1,500,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;width:1%;border:1pt none" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border:1pt none" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border:1pt none;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border:1pt none;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;1,750,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;width:1%;border:1pt none" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border:1pt none" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border:1pt none;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border:1pt none;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;3,250,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Excess over proceeds adjustment&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border:1pt none" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border:1pt none;width:1%" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border:1pt none;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;3,217,211&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom:3px;width:1%;border:1pt none" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border:1pt none" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border:1pt none;width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border:1pt none;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;3,957,423&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom:3px;width:1%;border:1pt none" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border:1pt none" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border:1pt none;width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border:1pt none;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;7,174,634&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom:3px;width:1%;border:1pt none" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;In addition, because the aggregate proceeds were allocated to the fair value of the Emerald Financing warrant liability, issuance costs totaling&lt;span&gt;&lt;span&gt; $137,192 &lt;/span&gt;&lt;/span&gt;were charged to other expense during the year ended December 31, 2018.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;i&gt;Series B Warrant Liability (3)&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br/&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;In conjunction with the Redeemable Convertible Series B Preferred Stock financing, the Company issued the 2015 Series B Financing Warrants originally exercisable at a price of $1.15 per share. The warrants are exercisable in cash or through a cashless exercise provision and contain certain cash redemption rights. The Series B warrants also had a &amp;#x201c;down-round&amp;#x201d; protection feature if the Company subsequently issued or sold any shares of common stock, stock options, or convertible securities at a price less than the current exercise price. The down round provision was triggered and automatically adjusted down to $0.10 on December 28, 2017, after the Company entered into the Convertible Promissory Note (See Note 4) and again to $0.00 on January 19, 2018, as a result of the Emerald Financing (See Note 5). The strike price for these warrants is now permanently reset. However, because the remaining warrant holders still have certain cash redemption rights upon the occurrence of certain fundamental transactions, as defined in the Series B warrant agreements, the warrants continue to require liability classification. Subsequent to the repricing that occurred as a result of the Emerald Financing, the warrants have been valued using a Black Scholes Merton Option Pricing Model.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;To compute the fair value of the warrants, the Company utilized the following assumptions in the Black Scholes Merton Option Pricing Model for the periods indicated:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN;margin:auto" width="85%"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center" valign="bottom"&gt;&lt;p style="MARGIN:0px 0px 0px 0in;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;As of &lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0in;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;2018&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Volatility factor&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;79.2&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;93.0&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="MARGIN:0px;text-align:right"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;1.60&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;2.79&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Expected term (years)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="MARGIN:0px;text-align:right"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;0.64&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;1.64&amp;#x2014;1.65&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Underlying common stock price&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;0.13&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;0.40&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&amp;#160;&amp;#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;In January 2018, 987,000 Series B warrants were exercised at a price of $0.10 resulting in cash proceeds to the Company of $98,700. &lt;/span&gt;&lt;/span&gt;Prior to exercise, these Series B Warrants were adjusted to fair value using a Black Scholes Merton Option Pricing Model which considered the closing trading price on the exercise dates.&lt;span&gt;&lt;span&gt; &lt;/span&gt;&lt;/span&gt;For the year ended December 31, 2019 and for the period from January 19, 2018 through December 31, 2018, 187,500 and&lt;span&gt;&lt;span&gt; 4,231,750 &lt;/span&gt;&lt;/span&gt;Series B warrants were exercised for no consideration. Prior to exercise, these Series B Warrants were adjusted to fair value using a Black Scholes Merton Option Pricing Model which considered the closing trading price on the exercise dates. Because the exercise price of these options had been reset to $0.00, the fair value derived from the valuation model approximated the market value of the Company&amp;#x2019;s common stock on the exercise dates.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;i&gt;Emerald Convertible Promissory Note Conversion Liability (4)&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br/&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;In connection with the Convertible Promissory Note (See Note 4), the Company bifurcated a conversion liability related to an embedded conversion feature with a down-round protection provision. The Company valued the conversion liability pursuant to the accounting guidance of ASC 820-10, &lt;em&gt;Fair Value Measurement&lt;/em&gt;s, as of the financing date of each closing utilizing the Black Scholes valuation model and the following assumptions:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="WIDTH:100%;TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN" width="100%"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;January 19,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;2018&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Volatility factor&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;70.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;1.29&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Expected term (years)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;0.003&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Underlying common stock price&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;0.19&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;The fair value of the conversion liability on January 19, 2018 was&lt;span&gt;&lt;span&gt; $360,000&lt;/span&gt;&lt;/span&gt;. In connection with the Emerald Financing discussed in Note 5 below, the Convertible Promissory Note was converted, and the conversion liability was extinguished with the debt.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;i&gt;Series B Preferred Stock Conversion Liability (5)&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br/&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;On August 20, 2015, in connection with the Redeemable Convertible Series B Preferred Stock financing, the Company bifurcated a conversion liability related to the down-round protection provided to the Series B investors. The value of this embedded derivative was determined utilizing a &amp;#x201c;with and without&amp;#x201d; method by valuing the Series B Preferred Stock with and without the down-round protection. During the first fiscal quarter of 2018, all the remaining Series B Preferred Stock was converted to common stock and as a result, the Series B conversion liability was reduced to zero. The reduction of this liability totaling&lt;span&gt;&lt;span&gt; $6,715 &lt;/span&gt;&lt;/span&gt;was recorded to equity during the year ended December 31, 2018.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;</embi:WarrantsAndDerivativeLiabilitiesTextBlock>
  <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="C_20190101to20191231" id="F89f6b1d0-2de8-11ea-add8-41ed81237e2f">&lt;table border="0" cellpadding="0" cellspacing="0" style="WIDTH:100%;TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN" width="100%"&gt;&lt;tbody&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;width:85px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:8px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong&gt;&lt;strong&gt;Number of&lt;/strong&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong&gt;Warrantsv&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Exercise&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;width:85px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Term&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:8px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;strong&gt;Vested&lt;/strong&gt; and&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="border:1pt none;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Source&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1px solid black;text-align:center;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Price&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1px solid black;text-align:center;width:85px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;(Years)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:8px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1px solid black;text-align:center;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Outstanding&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="background-color:rgb(204, 238, 255)" valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Pre 2015 Common Stock Warrants&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;1.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:85px;background-color:rgb(204, 238, 255)"&gt;&lt;p style="MARGIN:0px;text-align:right"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;6&amp;#x2014;10&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:8px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;4,000,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;2015 Common Stock Warrants&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)"&gt;&lt;p style="MARGIN:0px;text-align:right"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;1.15&amp;#x2014;5.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:85px;background-color:rgb(255, 255, 255)"&gt;&lt;p style="MARGIN:0px;text-align:right"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;5&amp;#x2014;10&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:8px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;442,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="background-color:rgb(204, 238, 255)" valign="top"&gt;&lt;p style="margin-top:0px;margin-right:0px;margin-bottom:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Common Stock Warrants to Series B Stockholders&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:77px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:8px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;1,031,250&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;2016 Common Stock Warrants to Service Providers&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;1.15&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:77px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:8px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;40,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="background-color:rgb(204, 238, 255)" valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;2016 Series C Common Stock Warrants to Placement Agent&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;0.40&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:77px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:8px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;125,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;2017 Series D Common Stock Warrants to Placement Agent&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;0.25&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:77px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:8px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;480,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="background-color:rgb(204, 238, 255)" valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;2017 Common Stock Warrants to Service Provider&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;0.41&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:77px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:8px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;125,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;2018 Emerald Financing Warrants&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;0.10&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:77px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:8px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;3,400,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="border:1pt none;background-color:rgb(204, 238, 255)" valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Emerald Multi Draw Credit Agreement Warrants&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border:1pt none;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border:1pt none;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border:1pt none;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;0.50&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;width:1%;border:1pt none;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border:1pt none;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border:1pt none;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border:1pt none;text-align:right;width:77px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;width:8px;border:1pt none;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border:1pt none;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border:1pt none;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border:1pt none;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;7,500,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;width:1%;border:1pt none;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="top"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;2019 Common Stock Warrants&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255);border-bottom:1pt solid black" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255);border-bottom:1pt solid black" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;0.35&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;width:77px;background-color:rgb(255, 255, 255);border-bottom:1pt solid black" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:8px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom:1pt solid black;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom:1pt solid black;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;8,000,000&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="background-color:rgb(204, 238, 255)" valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Total warrants vested and outstanding as of December 31, 2019&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:77px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:8px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;25,143,250&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20191231_usgaapClassOfWarrantOrRightAxis_embiPre2015CommonStockWarrantsMember" decimals="2" id="Fxbrl_20200205111038133" unitRef="USD_per_Share">1.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20191231_usgaapClassOfWarrantOrRightAxis_embiTwoThousandFifteenCommonStockWarrantsMember_srtRangeAxis_srtMinimumMember" decimals="2" id="F17631_115" unitRef="USD_per_Share">1.15</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20191231_usgaapClassOfWarrantOrRightAxis_embiTwoThousandFifteenCommonStockWarrantsMember_srtRangeAxis_srtMaximumMember" decimals="2" id="Fxbrl_20200203124218507" unitRef="USD_per_Share">5.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20191231_usgaapClassOfWarrantOrRightAxis_embiCommonStockWarrantsToSeriesBStockholdersMember" decimals="2" id="Fxbrl_20200205111035637" unitRef="USD_per_Share">0.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20191231_usgaapClassOfWarrantOrRightAxis_embiTwoThousandSixteenCommonStockWarrantsToServiceProvidersMember" decimals="2" id="F17725" unitRef="USD_per_Share">1.15</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20191231_usgaapClassOfWarrantOrRightAxis_embiTwoThousandSixteenSeriesCPlacementAgentWarrantsMember" decimals="2" id="F17748" unitRef="USD_per_Share">0.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20191231_usgaapClassOfWarrantOrRightAxis_embiTwoThousandSeventeenSeriesDPlacementAgentWarrantsMember" decimals="2" id="Fxbrl_20200313095317567" unitRef="USD_per_Share">0.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20191231_usgaapClassOfWarrantOrRightAxis_embiTwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember" decimals="2" id="F17794" unitRef="USD_per_Share">0.41</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20191231_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldFinancingWarrantsMember" decimals="2" id="F17817" unitRef="USD_per_Share">0.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20191231_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" decimals="2" id="F17840" unitRef="USD_per_Share">0.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20191231_usgaapClassOfWarrantOrRightAxis_embiTwoThousandNineteenCommonStockWarrantsMember" decimals="2" id="Fxbrl_20200312110805360" unitRef="USD_per_Share">0.35</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20180216_deiLegalEntityAxis_embiEmeraldFinancingMember" decimals="2" id="Fxbrl_202003121549111130" unitRef="USD_per_Share">0.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20180119_deiLegalEntityAxis_embiEmeraldFinancingMember" decimals="2" id="Fxbrl_20200312154911113" unitRef="USD_per_Share">0.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20191231_usgaapClassOfWarrantOrRightAxis_embiSeriesBWarrantMember" decimals="2" id="Fxbrl_20200312155748431" unitRef="USD_per_Share">1.15</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20171228_usgaapClassOfWarrantOrRightAxis_embiSeriesBWarrantMember" decimals="2" id="Fxbrl_20200312160006059" unitRef="USD_per_Share">0.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20180119_usgaapClassOfWarrantOrRightAxis_embiSeriesBWarrantMember" decimals="2" id="Fxbrl_20200312160259053" unitRef="USD_per_Share">0.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20180131_usgaapClassOfWarrantOrRightAxis_embiSeriesBWarrantMember" decimals="2" id="Fxbrl_20200217165853620" unitRef="USD_per_Share">0.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_05_Oct_2018T00_00_00_TO_05_Oct_2018T00_00_00_LegalEntityAxis_EmeraldFinancingMember_TypeOfArrangementAxis_MultiDrawCreditAgreementMember" decimals="2" id="F19534_050" unitRef="USD_per_Share">0.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_19_Jan_2018T00_00_00_TO_19_Jan_2018T00_00_00_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember" decimals="2" id="Fxbrl_20200206194554535" unitRef="USD_per_Share">0.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_16_Feb_2018T00_00_00_TO_16_Feb_2018T00_00_00_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember" decimals="2" id="Fxbrl_20200312161628630" unitRef="USD_per_Share">0.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_16_Feb_2018T00_00_00_TO_16_Feb_2018T00_00_00_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember_RelatedPartyTransactionsByRelatedPartyAxis_InvestorMember" decimals="2" id="Fxbrl_20200312161748281" unitRef="USD_per_Share">0.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <embi:TermOfWarrant contextRef="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_embiPre2015CommonStockWarrantsMember_srtRangeAxis_srtMinimumMember" id="Fxbrl_20200205112327914">P6Y</embi:TermOfWarrant>
  <embi:TermOfWarrant contextRef="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_embiPre2015CommonStockWarrantsMember_srtRangeAxis_srtMaximumMember" id="Fxbrl_20200205112331077">P10Y</embi:TermOfWarrant>
  <embi:TermOfWarrant contextRef="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_embiTwoThousandFifteenCommonStockWarrantsMember_srtRangeAxis_srtMinimumMember" id="Fxbrl_20200205112337829">P5Y</embi:TermOfWarrant>
  <embi:TermOfWarrant contextRef="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_embiTwoThousandFifteenCommonStockWarrantsMember_srtRangeAxis_srtMaximumMember" id="Fxbrl_20200205112341116">P10Y</embi:TermOfWarrant>
  <embi:TermOfWarrant contextRef="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_embiCommonStockWarrantsToSeriesBStockholdersMember" id="Fxbrl_20200205112346953">P5Y</embi:TermOfWarrant>
  <embi:TermOfWarrant contextRef="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_embiTwoThousandSixteenCommonStockWarrantsToServiceProvidersMember" id="Fxbrl_20200205112358947">P10Y</embi:TermOfWarrant>
  <embi:TermOfWarrant contextRef="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_embiTwoThousandSixteenSeriesCPlacementAgentWarrantsMember" id="Fxbrl_20200205112405010">P5Y</embi:TermOfWarrant>
  <embi:TermOfWarrant contextRef="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_embiTwoThousandSeventeenSeriesDPlacementAgentWarrantsMember" id="Fxbrl_20200205112411178">P5Y</embi:TermOfWarrant>
  <embi:TermOfWarrant contextRef="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_embiTwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember" id="Fxbrl_20200205112418891">P5Y</embi:TermOfWarrant>
  <embi:TermOfWarrant contextRef="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldFinancingWarrantsMember" id="Fxbrl_20200205112433659">P5Y</embi:TermOfWarrant>
  <embi:TermOfWarrant contextRef="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" id="Fxbrl_20200205112438783">P5Y</embi:TermOfWarrant>
  <embi:TermOfWarrant contextRef="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_embiTwoThousandNineteenCommonStockWarrantsMember" id="Fxbrl_20200312110842970">P5Y</embi:TermOfWarrant>
  <embi:WarrantsVestedAndOutstanding contextRef="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_embiPre2015CommonStockWarrantsMember" decimals="INF" id="F17622" unitRef="shares">4000000</embi:WarrantsVestedAndOutstanding>
  <embi:WarrantsVestedAndOutstanding contextRef="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_embiTwoThousandFifteenCommonStockWarrantsMember" decimals="INF" id="F17645" unitRef="shares">442000</embi:WarrantsVestedAndOutstanding>
  <embi:WarrantsVestedAndOutstanding contextRef="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_embiCommonStockWarrantsToSeriesBStockholdersMember" decimals="INF" id="F17693" unitRef="shares">1031250</embi:WarrantsVestedAndOutstanding>
  <embi:WarrantsVestedAndOutstanding contextRef="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_embiTwoThousandSixteenCommonStockWarrantsToServiceProvidersMember" decimals="INF" id="F17739" unitRef="shares">40000</embi:WarrantsVestedAndOutstanding>
  <embi:WarrantsVestedAndOutstanding contextRef="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_embiTwoThousandSixteenSeriesCPlacementAgentWarrantsMember" decimals="INF" id="F17762" unitRef="shares">125000</embi:WarrantsVestedAndOutstanding>
  <embi:WarrantsVestedAndOutstanding contextRef="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_embiTwoThousandSeventeenSeriesDPlacementAgentWarrantsMember" decimals="INF" id="F17785" unitRef="shares">480000</embi:WarrantsVestedAndOutstanding>
  <embi:WarrantsVestedAndOutstanding contextRef="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_embiTwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember" decimals="INF" id="F17808" unitRef="shares">125000</embi:WarrantsVestedAndOutstanding>
  <embi:WarrantsVestedAndOutstanding contextRef="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldFinancingWarrantsMember" decimals="INF" id="Fxbrl_20200217112604451" unitRef="shares">3400000</embi:WarrantsVestedAndOutstanding>
  <embi:WarrantsVestedAndOutstanding contextRef="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" decimals="INF" id="F17854" unitRef="shares">7500000</embi:WarrantsVestedAndOutstanding>
  <embi:WarrantsVestedAndOutstanding contextRef="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_embiTwoThousandNineteenCommonStockWarrantsMember" decimals="INF" id="Fxbrl_20200312110908199" unitRef="shares">8000000</embi:WarrantsVestedAndOutstanding>
  <embi:WarrantsVestedAndOutstanding contextRef="C_20190101to20191231" decimals="INF" id="F17882_53130750" unitRef="shares">25143250</embi:WarrantsVestedAndOutstanding>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="C_20191231_usgaapClassOfWarrantOrRightAxis_embiTwoThousandNineteenCommonStockWarrantsMember" decimals="INF" id="Fxbrl_20200312150604803" unitRef="shares">8000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="C_20191231_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" decimals="0" id="Fxbrl_20200312150807618" unitRef="shares">5000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="C_20181101_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" decimals="INF" id="F17890_2500000" unitRef="shares">2500000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="C_20180119_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldFinancingWarrantsMember" decimals="INF" id="Fxbrl_20200206151100379" unitRef="shares">40800000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="C_20180216_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldFinancingWarrantsMember" decimals="INF" id="F17968_3400000" unitRef="shares">3400000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="C_20180216_deiLegalEntityAxis_embiEmeraldFinancingMember" decimals="INF" id="F18737_442000000" unitRef="shares">44200000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="C_20180119_deiLegalEntityAxis_embiEmeraldFinancingMember" decimals="INF" id="F18737_44200000" unitRef="shares">44200000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_embiTwoThousandNineteenCommonStockWarrantsMember" id="Fxbrl_20200312115051828">&lt;div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="border:0px" width="100%"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;At Issuance&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="top"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="top"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Volatility factor&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;93.08&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="top"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;1.62&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="top"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Expected term (years)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;5.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="top"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Underlying common stock price&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;0.22&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
  <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="C_20190101to20191231_deiLegalEntityAxis_embiEmeraldFinancingMember" id="F89f79c30-2de8-11ea-add8-41ed81237e2f">&lt;table border="0" cellpadding="0" cellspacing="0" style="WIDTH:100%;TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN;margin:auto" width="100%"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style="width:null" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;2018&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom:1pt solid black;width:8%"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;At Issuance&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td style="width:null" valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:8%"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td style="width:null" valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Volatility factor&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="MARGIN:0px;text-align:right"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;79.5&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;92.1&amp;#x2014;92.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;width:8%"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;70.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td style="width:null" valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;1.62&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;2.49&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:8%"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;2.45&amp;#x2014;2.60&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td style="width:null" valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Expected term (years)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="MARGIN:0px;text-align:right"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;3.13&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;4.05&amp;#x2014;4.13&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;width:8%"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;5.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td style="width:null" valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Underlying common stock price&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;0.13&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;0.40&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:8%"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;0.29&amp;#x2014;0.30&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
  <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_embiSeriesBWarrantMember" id="F89f77520-2de8-11ea-add8-41ed81237e2f">&lt;table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN;margin:auto" width="85%"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center" valign="bottom"&gt;&lt;p style="MARGIN:0px 0px 0px 0in;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;As of &lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0in;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;2018&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Volatility factor&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;79.2&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;93.0&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="MARGIN:0px;text-align:right"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;1.60&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;2.79&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Expected term (years)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="MARGIN:0px;text-align:right"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;0.64&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;1.64&amp;#x2014;1.65&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Underlying common stock price&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;0.13&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;0.40&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
  <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_embiEmeraldConvertiblePromissoryNoteConversionLiabilityMember" id="F89f9e620-2de8-11ea-add8-41ed81237e2f">&lt;table border="0" cellpadding="0" cellspacing="0" style="WIDTH:100%;TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN" width="100%"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;January 19,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;2018&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Volatility factor&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;70.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;1.29&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Expected term (years)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;0.003&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Underlying common stock price&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;0.19&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
  <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" id="Fxbrl_20200312173229139">&lt;div&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&amp;#160;&lt;/p&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="border:0px" width="100%"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom"&gt;&lt;strong&gt;At Issuance&lt;/strong&gt;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="top"&gt;Dividend yield&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right;width:9%" valign="bottom"&gt;0.00&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="top"&gt;Volatility factor&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;91.6-92.1%&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="top"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;2.23-2.51%&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="top"&gt;Expected term (years)&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right;width:1%" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right;width:9%" valign="bottom"&gt;5.0&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="top"&gt;Underlying common stock price&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"&gt;$0.33-0.69&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&amp;#160;&lt;/p&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="border:0px" width="100%"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom"&gt;&lt;strong&gt;At Issuance&lt;/strong&gt;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="top"&gt;Dividend yield&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right;width:9%" valign="bottom"&gt;0.00&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="top"&gt;Volatility factor&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right;width:9%" valign="bottom"&gt;92.5&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="top"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right;width:9%" valign="bottom"&gt;2.96&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="top"&gt;Expected term (years)&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right;width:9%" valign="bottom"&gt;5.0&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="top"&gt;Underlying common stock price&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;$&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right;width:9%" valign="bottom"&gt;0.36&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20191231_usgaapClassOfWarrantOrRightAxis_embiTwoThousandNineteenCommonStockWarrantsMember_embiPricingModelAxis_embiPricingModelMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember" decimals="2" id="Fxbrl_20200312113524158" unitRef="pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20191231_usgaapClassOfWarrantOrRightAxis_embiTwoThousandNineteenCommonStockWarrantsMember_embiPricingModelAxis_embiPricingModelMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember" decimals="2" id="Fxbrl_20200312113538882" unitRef="pure">93.08</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20191231_usgaapClassOfWarrantOrRightAxis_embiTwoThousandNineteenCommonStockWarrantsMember_embiPricingModelAxis_embiPricingModelMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember" decimals="2" id="Fxbrl_20200312113606294" unitRef="pure">1.62</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20191231_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember_embiPricingModelAxis_embiPricingModelMember_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" decimals="4" id="Fxbrl_20200312121601931" unitRef="pure">0.0000</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20191231_srtRangeAxis_srtMinimumMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_embiPricingModelAxis_embiPricingModelMember" decimals="1" id="Fxbrl_20200312121857396" unitRef="pure">91.6</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20191231_srtRangeAxis_srtMaximumMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_embiPricingModelAxis_embiPricingModelMember" decimals="3" id="Fxbrl_20200312122000203" unitRef="pure">0.921</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20191231_srtRangeAxis_srtMinimumMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_embiPricingModelAxis_embiPricingModelMember" decimals="4" id="Fxbrl_20200312122106001" unitRef="pure">0.0223</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20191231_srtRangeAxis_srtMaximumMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_embiPricingModelAxis_embiPricingModelMember" decimals="4" id="Fxbrl_20200312122155266" unitRef="pure">0.0251</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20181101_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember_embiPricingModelAxis_embiPricingModelMember_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" decimals="2" id="Fxbrl_20200205113343551" unitRef="pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20181101_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_embiPricingModelAxis_embiPricingModelMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember" decimals="1" id="F17921" unitRef="pure">92.5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20181101_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember_embiPricingModelAxis_embiPricingModelMember_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" decimals="2" id="F17930" unitRef="pure">2.96</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20191231_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember_embiPricingModelAxis_embiMonteCarloSimulationsMember_deiLegalEntityAxis_embiEmeraldFinancingMember" decimals="2" id="Fxbrl_20200205152028421" unitRef="pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember_embiPricingModelAxis_embiMonteCarloSimulationsMember_deiLegalEntityAxis_embiEmeraldFinancingMember" decimals="2" id="Fxbrl_20200205152034541" unitRef="pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="Context_As_Of_16_Feb_2018T00_00_00_TO_16_Feb_2018T00_00_00_MeasurementInputTypeAxis_MeasurementInputExpectedDividendRateMember_PricingModelAxis_MonteCarloSimulationsMember_LegalEntityAxis_EmeraldFinancingMember" decimals="2" id="Fxbrl_202003121349083840" unitRef="pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="Context_As_Of_19_Jan_2018T00_00_00_TO_19_Jan_2018T00_00_00_MeasurementInputTypeAxis_MeasurementInputExpectedDividendRateMember_PricingModelAxis_MonteCarloSimulationsMember_LegalEntityAxis_EmeraldFinancingMember" decimals="2" id="Fxbrl_20200312134908384" unitRef="pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20191231_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember_embiPricingModelAxis_embiMonteCarloSimulationsMember_deiLegalEntityAxis_embiEmeraldFinancingMember" decimals="1" id="Fxbrl_20200206120303222" unitRef="pure">79.5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember_embiPricingModelAxis_embiMonteCarloSimulationsMember_deiLegalEntityAxis_embiEmeraldFinancingMember_srtRangeAxis_srtMinimumMember" decimals="1" id="Fxbrl_20200312140555674" unitRef="pure">92.1</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember_embiPricingModelAxis_embiMonteCarloSimulationsMember_deiLegalEntityAxis_embiEmeraldFinancingMember_srtRangeAxis_srtMaximumMember" decimals="1" id="Fxbrl_20200312140723171" unitRef="pure">92.4</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="Context_As_Of_19_Jan_2018T00_00_00_TO_19_Jan_2018T00_00_00_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember_PricingModelAxis_MonteCarloSimulationsMember_LegalEntityAxis_EmeraldFinancingMember" decimals="1" id="Fxbrl_202003121349357290" unitRef="pure">70.0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="Context_As_Of_16_Feb_2018T00_00_00_TO_16_Feb_2018T00_00_00_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember_PricingModelAxis_MonteCarloSimulationsMember_LegalEntityAxis_EmeraldFinancingMember" decimals="1" id="Fxbrl_20200312134935729" unitRef="pure">70.0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20191231_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember_embiPricingModelAxis_embiMonteCarloSimulationsMember_deiLegalEntityAxis_embiEmeraldFinancingMember" decimals="2" id="F18819" unitRef="pure">1.62</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember_embiPricingModelAxis_embiMonteCarloSimulationsMember_deiLegalEntityAxis_embiEmeraldFinancingMember" decimals="2" id="Fxbrl_20200312140829797" unitRef="pure">2.49</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="Context_As_Of_16_Feb_2018T00_00_00_TO_16_Feb_2018T00_00_00_RangeAxis_MinimumMember_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember_PricingModelAxis_MonteCarloSimulationsMember_LegalEntityAxis_EmeraldFinancingMember" decimals="2" id="Fxbrl_202003121349443800" unitRef="USD_per_warrants">2.45</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="Context_As_Of_19_Jan_2018T00_00_00_TO_19_Jan_2018T00_00_00_RangeAxis_MinimumMember_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember_PricingModelAxis_MonteCarloSimulationsMember_LegalEntityAxis_EmeraldFinancingMember" decimals="2" id="Fxbrl_20200312134944380" unitRef="pure">2.45</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="Context_As_Of_16_Feb_2018T00_00_00_TO_16_Feb_2018T00_00_00_RangeAxis_MaximumMember_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember_PricingModelAxis_MonteCarloSimulationsMember_LegalEntityAxis_EmeraldFinancingMember" decimals="2" id="Fxbrl_202003121349522680" unitRef="USD_per_warrants">2.60</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="Context_As_Of_19_Jan_2018T00_00_00_TO_19_Jan_2018T00_00_00_RangeAxis_MaximumMember_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember_PricingModelAxis_MonteCarloSimulationsMember_LegalEntityAxis_EmeraldFinancingMember" decimals="2" id="Fxbrl_20200312134952268" unitRef="pure">2.60</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20191231_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember" decimals="2" id="Fxbrl_20200205152042188" unitRef="pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00_MeasurementInputTypeAxis_MeasurementInputExpectedDividendRateMember_PricingModelAxis_PricingModelMember_StatementClassOfStockAxis_SeriesBWarrantMember" decimals="2" id="Fxbrl_20200205152044389" unitRef="pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20191231_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember" decimals="1" id="Fxbrl_20200206121614358" unitRef="pure">79.2</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember_PricingModelAxis_PricingModelMember_StatementClassOfStockAxis_SeriesBWarrantMember" decimals="1" id="Fxbrl_20200206121621182" unitRef="pure">93.0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20191231_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember" decimals="2" id="Fxbrl_20200205150631448" unitRef="pure">1.60</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20181231_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember_embiPricingModelAxis_embiPricingModelMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember" decimals="2" id="F19066" unitRef="pure">2.79</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20180119_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember_embiPricingModelAxis_embiPricingModelMember_usgaapClassOfWarrantOrRightAxis_embiEmeraldConvertiblePromissoryNoteConversionLiabilityMember" decimals="2" id="Fxbrl_20200205152053236" unitRef="pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20180119_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember_embiPricingModelAxis_embiPricingModelMember_usgaapClassOfWarrantOrRightAxis_embiEmeraldConvertiblePromissoryNoteConversionLiabilityMember" decimals="2" id="Fxbrl_20200206145741923" unitRef="pure">70</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20180119_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember_embiPricingModelAxis_embiPricingModelMember_usgaapClassOfWarrantOrRightAxis_embiEmeraldConvertiblePromissoryNoteConversionLiabilityMember" decimals="2" id="F19181" unitRef="pure">1.29</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="C_20191231_usgaapClassOfWarrantOrRightAxis_embiTwoThousandNineteenCommonStockWarrantsMember_embiPricingModelAxis_embiPricingModelMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedTermMember" id="Fxbrl_20200312113952907">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
  <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="C_20191231_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedTermMember_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_embiPricingModelAxis_embiPricingModelMember" id="Fxbrl_20200312122231490">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
  <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="C_20181101_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_embiPricingModelAxis_embiPricingModelMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedTermMember" id="Fxbrl_20200205113341064">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
  <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="C_20180119_deiLegalEntityAxis_embiEmeraldFinancingMember" id="Fxbrl_202002171251155780">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
  <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="C_20180216_deiLegalEntityAxis_embiEmeraldFinancingMember" id="Fxbrl_20200217125115578">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
  <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="C_20191231_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedTermMember_embiPricingModelAxis_embiMonteCarloSimulationsMember_deiLegalEntityAxis_embiEmeraldFinancingMember" id="Fxbrl_20200206112333402">P3Y1M17D</us-gaap:WarrantsAndRightsOutstandingTerm>
  <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedTermMember_embiPricingModelAxis_embiMonteCarloSimulationsMember_deiLegalEntityAxis_embiEmeraldFinancingMember_srtRangeAxis_srtMinimumMember" id="Fxbrl_20200312140910563">P4Y18D</us-gaap:WarrantsAndRightsOutstandingTerm>
  <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedTermMember_embiPricingModelAxis_embiMonteCarloSimulationsMember_deiLegalEntityAxis_embiEmeraldFinancingMember_srtRangeAxis_srtMaximumMember" id="Fxbrl_20200312140942622">P4Y1M17D</us-gaap:WarrantsAndRightsOutstandingTerm>
  <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="Context_As_Of_19_Jan_2018T00_00_00_TO_19_Jan_2018T00_00_00_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember_PricingModelAxis_MonteCarloSimulationsMember_LegalEntityAxis_EmeraldFinancingMember" id="Fxbrl_202003121350309550">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
  <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="Context_As_Of_16_Feb_2018T00_00_00_TO_16_Feb_2018T00_00_00_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember_PricingModelAxis_MonteCarloSimulationsMember_LegalEntityAxis_EmeraldFinancingMember" id="Fxbrl_20200312135030955">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
  <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="C_20191231_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedTermMember_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember" id="Fxbrl_20200206130320828">P0Y7M20D</us-gaap:WarrantsAndRightsOutstandingTerm>
  <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedTermMember_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember_srtRangeAxis_srtMinimumMember" id="Fxbrl_20200312141831709">P1Y7M20D</us-gaap:WarrantsAndRightsOutstandingTerm>
  <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedTermMember_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember_srtRangeAxis_srtMaximumMember" id="Fxbrl_20200312141937790">P1Y7M24D</us-gaap:WarrantsAndRightsOutstandingTerm>
  <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="C_20180119_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedTermMember_embiPricingModelAxis_embiPricingModelMember_usgaapClassOfWarrantOrRightAxis_embiEmeraldConvertiblePromissoryNoteConversionLiabilityMember" id="Fxbrl_20200206150107194">P0Y1D</us-gaap:WarrantsAndRightsOutstandingTerm>
  <us-gaap:SharesIssuedPricePerShare contextRef="C_20191231_usgaapClassOfWarrantOrRightAxis_embiTwoThousandNineteenCommonStockWarrantsMember_embiPricingModelAxis_embiPricingModelMember" decimals="2" id="Fxbrl_20200312114041071" unitRef="USD_per_Share">0.22</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare contextRef="C_20191231_srtRangeAxis_srtMinimumMember_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_embiPricingModelAxis_embiPricingModelMember" decimals="2" id="Fxbrl_20200312122308200" unitRef="USD_per_Share">0.33</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare contextRef="C_20191231_srtRangeAxis_srtMaximumMember_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_embiPricingModelAxis_embiPricingModelMember" decimals="2" id="Fxbrl_20200312122338076" unitRef="USD_per_Share">0.69</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare contextRef="C_20181101_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_embiPricingModelAxis_embiPricingModelMember" decimals="2" id="F17948" unitRef="USD_per_Share">0.36</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare contextRef="C_20191231_deiLegalEntityAxis_embiEmeraldFinancingMember_embiPricingModelAxis_embiMonteCarloSimulationsMember" decimals="2" id="F18849" unitRef="USD_per_Share">0.13</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00_deiLegalEntityAxis_embiEmeraldFinancingMember_embiPricingModelAxis_embiMonteCarloSimulationsMember" decimals="2" id="Fxbrl_20200312140457738" unitRef="USD_per_Share">0.40</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare contextRef="Context_As_Of_16-Feb-2018T00_00_00_RangeAxis_MinimumMember_LegalEntityAxis_EmeraldFinancingMember_PricingModelAxis_MonteCarloSimulationsMember" decimals="2" id="Fxbrl_202003121357181540" unitRef="USD_per_Share">0.29</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare contextRef="Context_As_Of_19-Jan-2018T00_00_00_RangeAxis_MinimumMember_LegalEntityAxis_EmeraldFinancingMember_PricingModelAxis_MonteCarloSimulationsMember" decimals="2" id="Fxbrl_20200312135718154" unitRef="USD_per_Share">0.29</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare contextRef="Context_As_Of_16-Feb-2018T00_00_00_RangeAxis_MaximumMember_LegalEntityAxis_EmeraldFinancingMember_PricingModelAxis_MonteCarloSimulationsMember" decimals="2" id="Fxbrl_202003121358110020" unitRef="USD_per_Share">0.30</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare contextRef="Context_As_Of_19-Jan-2018T00_00_00_RangeAxis_MaximumMember_LegalEntityAxis_EmeraldFinancingMember_PricingModelAxis_MonteCarloSimulationsMember" decimals="2" id="Fxbrl_20200312135811002" unitRef="USD_per_Share">0.30</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare contextRef="C_20191231_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember" decimals="2" id="F19091" unitRef="USD_per_Share">0.13</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare contextRef="C_20181231_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember_embiPricingModelAxis_embiPricingModelMember" decimals="2" id="F19097" unitRef="USD_per_Share">0.40</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare contextRef="C_20180119_embiPricingModelAxis_embiPricingModelMember_usgaapClassOfWarrantOrRightAxis_embiEmeraldConvertiblePromissoryNoteConversionLiabilityMember" decimals="2" id="F19212" unitRef="USD_per_Share">0.19</us-gaap:SharesIssuedPricePerShare>
  <embi:ClassOfWarrantOrRightWarrantsAggregateExercisePrice contextRef="C_20191201to20191220_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldFinancingWarrantsMember" decimals="0" id="Fxbrl_20200312153530419" unitRef="USD">4080000</embi:ClassOfWarrantOrRightWarrantsAggregateExercisePrice>
  <embi:ClassOfWarrantOrRightWarrantsAggregateExercisePrice contextRef="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldFinancingWarrantsMember" decimals="0" id="Fxbrl_20200313101352984" unitRef="USD">4080000</embi:ClassOfWarrantOrRightWarrantsAggregateExercisePrice>
  <embi:ClassOfWarrantOrRightWarrantsExercise contextRef="C_20191201to20191220_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldFinancingWarrantsMember" decimals="0" id="Fxbrl_20200312153537405" unitRef="shares">40800000</embi:ClassOfWarrantOrRightWarrantsExercise>
  <embi:ClassOfWarrantOrRightWarrantsExercise contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_usgaapClassOfWarrantOrRightAxis_embiSeriesBWarrantMember" decimals="INF" id="Fxbrl_20200206174925546" unitRef="shares">987000</embi:ClassOfWarrantOrRightWarrantsExercise>
  <embi:ClassOfWarrantOrRightWarrantsExercise contextRef="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_embiSeriesBWarrantMember" decimals="INF" id="Fxbrl_20200312160609028" unitRef="shares">187500</embi:ClassOfWarrantOrRightWarrantsExercise>
  <embi:ClassOfWarrantOrRightWarrantsExercise contextRef="C_20180120to20181231_usgaapClassOfWarrantOrRightAxis_embiSeriesBWarrantMember" decimals="INF" id="Fxbrl_20200206175515582" unitRef="shares">4231750</embi:ClassOfWarrantOrRightWarrantsExercise>
  <embi:ClassOfWarrantOrRightWarrantsExercise contextRef="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldFinancingWarrantsMember" decimals="INF" id="Fxbrl_20200312154250875" unitRef="shares">40800000</embi:ClassOfWarrantOrRightWarrantsExercise>
  <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock contextRef="C_20190101to20191231" id="Fxbrl_20200205114021131">&lt;div&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="WIDTH:100%;TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN" width="100%"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="18" style="border:1pt none;text-align:center" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Year Ended December 31, 2019&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;2018, Fair&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Value of&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Derivative Liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Fair Value of Derivative Liabilities Issued&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1px solid black;text-align:center;width:80px" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Change in&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Fair value of&amp;#160;Liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:8px" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Reclassification&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;of Derivatives&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;to Equity&amp;#160;or Extinguishment&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;2019, Fair&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Value of&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Derivative Liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Emerald Multi Draw Credit Agreement - compound derivative liability (1)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9px" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:108px" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;219,453&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;516,058&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:72px" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;(484,147&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:8px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;(160,567&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;)*&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6px" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:73px" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;90,797&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Emerald Financing - warrant liability (2)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:108px" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;15,251,413&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:72px" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;(9,042,066&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:8px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;(5,933,323&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:73px" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;276,024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Series B - warrant liability (3)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9px;border-bottom:1pt solid black" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:108px;border-bottom:1pt solid black" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;487,500&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border-bottom:1pt solid black" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;border-bottom:1pt solid black" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border-bottom:1pt solid black" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:72px;border-bottom:1pt solid black" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;(208,546&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:8px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border-bottom:1pt solid black" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;border-bottom:1pt solid black" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;(144,375&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6px;border-bottom:1pt solid black" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:73px;border-bottom:1pt solid black" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;134,579&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Total derivative liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom:3px double black;width:9px" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3px double black;text-align:right;width:108px" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;15,958,366&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:black 3px double;width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:black 3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;516,058&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:black 3px double;width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3px double black;text-align:right;width:72px" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;(9,734,759&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom:3px;width:8px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:black 3px double;width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:black 3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;(6,238,265&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom:3px double black;width:6px" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3px double black;text-align:right;width:73px" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;501,400&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Less, noncurrent portion of derivative liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9px;border-bottom:1pt solid black" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:108px;border-bottom:1pt solid black" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;(219,453&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:72px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:8px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom:1px solid black;width:6px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom:1px solid black;text-align:right;width:73px" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;(90,797&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Current balance of derivative liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9px;border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:108px;border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;15,738,913&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:72px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:8px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border:1pt none" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border:1pt none" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;width:6px" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;text-align:right;width:73px" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;410,603&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;em&gt;*This amount has been included in the calculation of the extinguishment loss recorded in connection with the prepayment of the Emerald Credit Agreement as described in Note 4 below.&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&amp;#160;&lt;/p&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="WIDTH:100%;TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN" width="100%"&gt;&lt;tbody&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="18" style="border-bottom:1px solid black;text-align:center;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Year Ended December 31, 2018&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1px solid black;text-align:center;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;2017, Fair&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Value of&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Derivative Liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1px solid black;text-align:center;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Fair Value of Derivative Liabilities Issued&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1px solid black;text-align:center;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Change in&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Fair value of Derivative Liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;**&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1px solid black;text-align:center;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Reclassification&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;of Derivatives&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;to Equity&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);width:6px" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:12px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1px solid black;text-align:center;width:82px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;2018, Fair&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Value of&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Derivative Liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="background-color:rgb(204, 238, 255)" valign="top"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Emerald Multi Draw Credit Agreement - compound derivative liability (1)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;204,102&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;15,351&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:12px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:11px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;219,453&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="top"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Emerald Financing - warrant liability (2)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;10,424,634&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;4,826,779&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:12px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:11px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;15,251,413&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="background-color:rgb(204, 238, 255)" valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Series B - warrant liability (3)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;551,322&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;1,476,044&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;(1,539,866&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:12px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:11px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;487,500&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="top"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Emerald Convertible Promissory Note - conversion liability (4)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;265,000&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;360,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;185,000&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;(810,000&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:12px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:11px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="background-color:rgb(204, 238, 255)" valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Series B Preferred Stock - conversion liability (5)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;6,715&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;(6,715&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:6px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:12px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:11px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="top"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Total derivative liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom:2.5pt double black;width:1%;background-color:rgb(255, 255, 255);border-top:1pt solid black;border-right:none;border-left:none;border-image:initial" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2.5pt double black;text-align:right;width:9%;background-color:rgb(255, 255, 255);border-top:1pt solid black;border-right:none;border-left:none;border-image:initial" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;823,037&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom:3px;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom:2.5pt double black;width:1%;background-color:rgb(255, 255, 255);border-top:1pt solid black;border-right:none;border-left:none;border-image:initial" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2.5pt double black;text-align:right;width:9%;background-color:rgb(255, 255, 255);border-top:1pt solid black;border-right:none;border-left:none;border-image:initial" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;10,988,736&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom:3px;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom:2.5pt double black;width:1%;background-color:rgb(255, 255, 255);border-top:1pt solid black;border-right:none;border-left:none;border-image:initial" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2.5pt double black;text-align:right;width:9%;background-color:rgb(255, 255, 255);border-top:1pt solid black;border-right:none;border-left:none;border-image:initial" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;6,503,174&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom:3px;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom:2.5pt double black;width:1%;background-color:rgb(255, 255, 255);border-top:1pt solid black;border-right:none;border-left:none;border-image:initial" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2.5pt double black;text-align:right;width:9%;background-color:rgb(255, 255, 255);border-top:1pt solid black;border-right:none;border-left:none;border-image:initial" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;(2,356,581&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom:3px;width:6px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:12px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom:2.5pt double black;width:11px;background-color:rgb(255, 255, 255);border-top:1pt solid black;border-right:none;border-left:none;border-image:initial" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2.5pt double black;text-align:right;width:9%;background-color:rgb(255, 255, 255);border-top:1pt solid black;border-right:none;border-left:none;border-image:initial" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;15,958,366&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom:3px;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="background-color:rgb(204, 238, 255)" valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Less, noncurrent portion of derivative liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;(551,322&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:12px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border:1pt none;width:11px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border:1pt none;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;(219,453&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Current balance of derivative liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;border-bottom:2.5pt double black;background-color:rgb(255, 255, 255);border-top:1pt solid black;border-right:none;border-left:none;border-image:initial" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;border-bottom:2.5pt double black;background-color:rgb(255, 255, 255);border-top:1pt solid black;border-right:none;border-left:none;border-image:initial" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;271,715&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:12px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom:2.5pt double black;width:11px;background-color:rgb(255, 255, 255);border-top:1pt solid black;border-right:none;border-left:none;border-image:initial" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2.5pt double black;text-align:right;width:9%;background-color:rgb(255, 255, 255);border-top:1pt solid black;border-right:none;border-left:none;border-image:initial" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;15,738,913&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom:3px;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;em&gt;**The change in fair value of derivative liabilities for the year ended December 31, 2018, relate partially to the Company determining it had sufficient trading activity to utilize the actual volatility of the trading of the Company&amp;#x2019;s common stock as an input to the volatility assumption when computing the fair value of derivative liabilities. The volatility assumption was updated as of October 1, 2018 to incorporate the Company&amp;#x2019;s own volatility with six similar companies to develop a blended average. The Company had previously estimated the volatility assumption by averaging the volatility of six similar entities which had resulted in a lower volatility. The increase in value of the volatility assumption has led to a higher valuation of the derivative liabilities as disclosed below.&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
  <us-gaap:DerivativeLiabilities contextRef="C_20181231_usgaapClassOfWarrantOrRightAxis_embiEmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember" decimals="0" id="Fxbrl_20200312123900292" unitRef="USD">219453</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="C_20191231_usgaapClassOfWarrantOrRightAxis_embiEmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember" decimals="0" id="Fxbrl_20200205123115583" unitRef="USD">90797</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00_LegalEntityAxis_EmeraldFinancingMember" decimals="0" id="Fxbrl_20200312124755719" unitRef="USD">15251413</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="C_20191231_deiLegalEntityAxis_embiEmeraldFinancingMember" decimals="0" id="F18121" unitRef="USD">276024</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00_usgaapClassOfWarrantOrRightAxis_embiSeriesBWarrantMember" decimals="0" id="Fxbrl_20200205115917956" unitRef="USD">487500</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="C_20191231_usgaapClassOfWarrantOrRightAxis_embiSeriesBWarrantMember" decimals="0" id="F18158" unitRef="USD">134579</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="F18243_823037" unitRef="USD">15958366</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="C_20191231" decimals="0" id="F18278_15958366" unitRef="USD">501400</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="C_20171231_usgaapClassOfWarrantOrRightAxis_embiEmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember" decimals="0" id="Fxbrl_20200312130113709" unitRef="USD">0</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_deiLegalEntityAxis_embiEmeraldFinancingMember" decimals="0" id="Fxbrl_20200312131100918" unitRef="USD">0</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_usgaapClassOfWarrantOrRightAxis_embiSeriesBWarrantMember" decimals="0" id="F18457" unitRef="USD">551322</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_usgaapClassOfWarrantOrRightAxis_embiEmeraldConvertiblePromissoryNoteConversionLiabilityMember" decimals="0" id="Fxbrl_20200312131714749" unitRef="USD">265000</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00_usgaapClassOfWarrantOrRightAxis_embiEmeraldConvertiblePromissoryNoteConversionLiabilityMember" decimals="0" id="Fxbrl_20200205120321545" unitRef="USD">0</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="Context_As_Of_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_DerivativeInstrumentRiskAxis_SeriesBPreferredStockConversionLiabilityMember" decimals="0" id="F18528" unitRef="USD">6715</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="Context_As_Of_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_DerivativeInstrumentRiskAxis_SeriesBPreferredStockConversionLiabilityMember" decimals="0" id="Fxbrl_20200205120532859" unitRef="USD">0</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" decimals="0" id="Fxbrl_20200313121301002" unitRef="USD">823037</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="Context_As_Of_01_Nov_2018T00_00_00_TO_01_Nov_2018T00_00_00_TypeOfArrangementAxis_MultiDrawCreditAgreementMember" decimals="0" id="F19550_204102" unitRef="USD">204102</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="C_20191231_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20200312144054063" unitRef="USD">516058</us-gaap:DerivativeLiabilities>
  <embi:FairValueOfWarrantsIssued contextRef="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_embiEmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember" decimals="0" id="F18065" unitRef="USD">516058</embi:FairValueOfWarrantsIssued>
  <embi:FairValueOfWarrantsIssued contextRef="C_20190101to20191231_deiLegalEntityAxis_embiEmeraldFinancingMember" decimals="0" id="F18100" unitRef="USD">0</embi:FairValueOfWarrantsIssued>
  <embi:FairValueOfWarrantsIssued contextRef="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_embiSeriesBWarrantMember" decimals="0" id="Fxbrl_20200312125306379" unitRef="USD">0</embi:FairValueOfWarrantsIssued>
  <embi:FairValueOfWarrantsIssued contextRef="C_20190101to20191231" decimals="0" id="F18252_10988736" unitRef="USD">516058</embi:FairValueOfWarrantsIssued>
  <embi:FairValueOfWarrantsIssued contextRef="C_20180101to20181231_usgaapClassOfWarrantOrRightAxis_embiEmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember" decimals="0" id="Fxbrl_20200312130206655" unitRef="USD">204102</embi:FairValueOfWarrantsIssued>
  <embi:FairValueOfWarrantsIssued contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_deiLegalEntityAxis_embiEmeraldFinancingMember" decimals="0" id="Fxbrl_20200312131159445" unitRef="USD">10424634</embi:FairValueOfWarrantsIssued>
  <embi:FairValueOfWarrantsIssued contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_usgaapClassOfWarrantOrRightAxis_embiSeriesBWarrantMember" decimals="0" id="Fxbrl_20200312131454660" unitRef="USD">0</embi:FairValueOfWarrantsIssued>
  <embi:FairValueOfWarrantsIssued contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_usgaapClassOfWarrantOrRightAxis_embiEmeraldConvertiblePromissoryNoteConversionLiabilityMember" decimals="0" id="F18497" unitRef="USD">360000</embi:FairValueOfWarrantsIssued>
  <embi:FairValueOfWarrantsIssued contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_DerivativeInstrumentRiskAxis_SeriesBPreferredStockConversionLiabilityMember" decimals="0" id="Fxbrl_20200312131936306" unitRef="USD">0</embi:FairValueOfWarrantsIssued>
  <embi:FairValueOfWarrantsIssued contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="Fxbrl_20200313121321459" unitRef="USD">10988736</embi:FairValueOfWarrantsIssued>
  <embi:FairValueOfWarrantsIssued contextRef="Context_Custom_01_Jan_2018T00_00_00_TO_19_Jan_2018T00_00_00_LegalEntityAxis_EmeraldFinancingMember" decimals="0" id="F18913" unitRef="USD">4717211</embi:FairValueOfWarrantsIssued>
  <embi:FairValueOfWarrantsIssued contextRef="Context_Custom_01_Feb_2018T00_00_00_TO_16_Feb_2018T00_00_00_LegalEntityAxis_EmeraldFinancingMember" decimals="0" id="F18919" unitRef="USD">5707423</embi:FairValueOfWarrantsIssued>
  <embi:ReclassificationOfDerivativesToEquity contextRef="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_embiEmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember" decimals="0" id="Fxbrl_20200312124640128" unitRef="USD">-160567</embi:ReclassificationOfDerivativesToEquity>
  <embi:ReclassificationOfDerivativesToEquity contextRef="C_20190101to20191231_deiLegalEntityAxis_embiEmeraldFinancingMember" decimals="0" id="Fxbrl_20200312124841860" unitRef="USD">-5933323</embi:ReclassificationOfDerivativesToEquity>
  <embi:ReclassificationOfDerivativesToEquity contextRef="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_embiSeriesBWarrantMember" decimals="0" id="F18152_1539866" unitRef="USD">-144375</embi:ReclassificationOfDerivativesToEquity>
  <embi:ReclassificationOfDerivativesToEquity contextRef="C_20190101to20191231" decimals="0" id="F18270_2356581" unitRef="USD">-6238265</embi:ReclassificationOfDerivativesToEquity>
  <embi:ReclassificationOfDerivativesToEquity contextRef="C_20180101to20181231_usgaapClassOfWarrantOrRightAxis_embiEmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember" decimals="0" id="Fxbrl_20200312130251056" unitRef="USD">0</embi:ReclassificationOfDerivativesToEquity>
  <embi:ReclassificationOfDerivativesToEquity contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_deiLegalEntityAxis_embiEmeraldFinancingMember" decimals="0" id="Fxbrl_20200312131221999" unitRef="USD">0</embi:ReclassificationOfDerivativesToEquity>
  <embi:ReclassificationOfDerivativesToEquity contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_usgaapClassOfWarrantOrRightAxis_embiSeriesBWarrantMember" decimals="0" id="Fxbrl_20200312131551332" unitRef="USD">-1539866</embi:ReclassificationOfDerivativesToEquity>
  <embi:ReclassificationOfDerivativesToEquity contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_usgaapClassOfWarrantOrRightAxis_embiEmeraldConvertiblePromissoryNoteConversionLiabilityMember" decimals="0" id="Fxbrl_20200312131827870" unitRef="USD">-810000</embi:ReclassificationOfDerivativesToEquity>
  <embi:ReclassificationOfDerivativesToEquity contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_DerivativeInstrumentRiskAxis_SeriesBPreferredStockConversionLiabilityMember" decimals="0" id="F18548_9258" unitRef="USD">-6715</embi:ReclassificationOfDerivativesToEquity>
  <embi:ReclassificationOfDerivativesToEquity contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="Fxbrl_20200313121406001" unitRef="USD">-2356581</embi:ReclassificationOfDerivativesToEquity>
  <embi:FairValueOfCommonStockWarrantsIssued contextRef="C_20180119_deiLegalEntityAxis_embiEmeraldFinancingMember" decimals="0" id="F18739_47" unitRef="USD">4717211</embi:FairValueOfCommonStockWarrantsIssued>
  <embi:FairValueOfCommonStockWarrantsIssued contextRef="C_20180216_deiLegalEntityAxis_embiEmeraldFinancingMember" decimals="0" id="F18739_57" unitRef="USD">5707423</embi:FairValueOfCommonStockWarrantsIssued>
  <embi:ScheduleOfAdjustmentForDifferenceBetweenFairValueOfWarrantLiabilitiesAndTotalProceedsReceivedTableTextBlock contextRef="C_20190101to20191231" id="F8a0027b0-2de8-11ea-add8-41ed81237e2f">&lt;table border="0" cellpadding="0" cellspacing="0" style="WIDTH:100%;TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN" width="100%"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="BORDER-BOTTOM:black 1px solid;text-align:center" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Closing&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align:center" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;January &lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;2018&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;February&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;2018&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Total&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;Initial fair value of Emerald Financing Warrant Liability&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;4,717,211&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;5,707,423&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;10,424,634&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;Less: proceeds from the Emerald Financing&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border:1pt none;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border:1pt none;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;1,500,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;width:1%;border:1pt none" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border:1pt none" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border:1pt none;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border:1pt none;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;1,750,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;width:1%;border:1pt none" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border:1pt none" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border:1pt none;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border:1pt none;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;3,250,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Excess over proceeds adjustment&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border:1pt none" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border:1pt none;width:1%" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border:1pt none;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;3,217,211&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom:3px;width:1%;border:1pt none" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border:1pt none" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border:1pt none;width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border:1pt none;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;3,957,423&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom:3px;width:1%;border:1pt none" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border:1pt none" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border:1pt none;width:1%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border:1pt none;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;7,174,634&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom:3px;width:1%;border:1pt none" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</embi:ScheduleOfAdjustmentForDifferenceBetweenFairValueOfWarrantLiabilitiesAndTotalProceedsReceivedTableTextBlock>
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="Context_Custom_01_Jan_2018T00_00_00_TO_19_Jan_2018T00_00_00_LegalEntityAxis_EmeraldFinancingMember" decimals="0" id="F18960_3217211" unitRef="USD">3217211</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="Context_Custom_01_Feb_2018T00_00_00_TO_16_Feb_2018T00_00_00_LegalEntityAxis_EmeraldFinancingMember" decimals="0" id="F18969_3957423" unitRef="USD">3957423</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_deiLegalEntityAxis_embiEmeraldFinancingMember" decimals="0" id="F18978_7174634" unitRef="USD">7174634</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
  <us-gaap:ProceedsFromWarrantExercises contextRef="C_20180101to20180131_usgaapClassOfWarrantOrRightAxis_embiSeriesBWarrantMember" decimals="0" id="F19115_98700" unitRef="USD">98700</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:ProceedsFromWarrantExercises contextRef="C_20190101to20191231_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20200312151144810" unitRef="USD">3985500</us-gaap:ProceedsFromWarrantExercises>
  <embi:ConvertibleDebtRelatedPartyTextBlock contextRef="C_20190101to20191231" id="F89bf9c41-2de8-11ea-add8-41ed81237e2f">&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;4. Convertible Debt &amp;#x2013; Related Party&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0in"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company&amp;#x2019;s Convertible Debt with Emerald Health Sciences consists of the following:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN;margin:auto" width="85%"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="BORDER-BOTTOM:black 1px solid;text-align:center" valign="bottom"&gt;&lt;p style="MARGIN:0px 0px 0px 12pt;TEXT-INDENT:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;As of December 31, &lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px 0px 0px 12pt;TEXT-INDENT:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px 0px 0px 12pt;TEXT-INDENT:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2018&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Total principal value&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,014,500&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6px" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:62px" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,000,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Unamortized debt discount&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(1,622,344&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:62px" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(587,617&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:black 1px solid;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:black 1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(5,086&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom:1px solid black;width:6px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom:1px solid black;text-align:right;width:62px" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(51,423&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Carrying value of total convertible debt -&amp;#160;related party&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:black 1px solid;width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:black 1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;387,070&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom:1px solid black;width:6px" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1px solid black;text-align:right;width:62px" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;1,360,960&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Less, noncurrent portion&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:black 1px solid;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:black 1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(387,070&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom:1px solid black;width:6px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom:1px solid black;text-align:right;width:62px" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(1,360,960&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Current convertible debt &amp;#x2013; related party&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom:2.5pt double black;width:1%;border-top:none;border-right:none;border-left:none;border-image:initial" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2.5pt double black;text-align:right;width:9%;border-top:none;border-right:none;border-left:none;border-image:initial" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&amp;#x2014;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom:2.5pt double black;width:6px;border-top:none;border-right:none;border-left:none;border-image:initial" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2.5pt double black;text-align:right;width:62px;border-top:none;border-right:none;border-left:none;border-image:initial" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&amp;#x2014;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="MARGIN:0px 0px 0px 0in;TEXT-INDENT:0.5in"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company&amp;#x2019;s interest expense consists of the following:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN;margin:auto" width="85%"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="BORDER-BOTTOM:black 1px solid;text-align:center" valign="bottom"&gt;&lt;p style="MARGIN:0px 0px 0px 12pt;TEXT-INDENT:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Year&amp;#160;Ended December 31,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px 0px 0px 12pt;TEXT-INDENT:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border:1pt none" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-width:1pt;border-style:none none solid;border-top-color:initial;border-right-color:initial;border-bottom-color:black;border-left-color:initial;border-image:initial;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px 0px 0px 12pt;TEXT-INDENT:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2018&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="margin-top:0px;margin-right:0px;margin-bottom:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Interest expense - stated rate&amp;#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;371,420&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;26,433&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Non-cash interest expense:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="margin-top:0px;margin-right:0px;margin-bottom:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Amortization of debt discount&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;616,383&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;56,253&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="margin-top:0px;margin-right:0px;margin-bottom:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Amortization of transaction costs&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;12,910&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,283&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="margin-top:0px;margin-right:0px;margin-bottom:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Other interest expense&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border:1pt none;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border:1pt none;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border:1pt none;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border:1pt none;text-align:right;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;9,794&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid black;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid black;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;1,000,713&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid black;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid black;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;94,763&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;i&gt;Multi-Draw Credit Agreement&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On October 5, 2018, the Company entered into the Credit Agreement with Emerald Health Sciences, a related party (See Note 11). The Credit Agreement provides for a credit facility to the Company of up to $20,000,000 and is unsecured. Advances under the Credit Agreement bear interest at an annual rate of 7% (payable quarterly in arrears) and mature on October 5, 2022. At Emerald Health Sciences&amp;#x2019; election, advances and unpaid interest may be converted into common stock at a fixed conversion price of $0.40, subject to customary adjustments for stock splits, stock dividends, recapitalizations, etc. As of December 31, 2019, the unused portion of the credit facility is $14,000,000.&amp;#160;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;The drawdowns are subject to approval by the Company&amp;#x2019;s Board, which is controlled by the directors of Emerald Health Sciences. As such, we do not consider the facility available until advance requests are approved, drawn down and funded. The Credit Agreement is still in place, however, there is no guarantee of continued funding.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Credit Agreement provides for customary events of default which may result in the acceleration of the maturity of the advances in addition to, but not limited to, cross acceleration to certain other indebtedness of the Company or a change in control. In the case of an event of default arising from specified events of bankruptcy or insolvency or reorganization, all outstanding advances will become due and payable immediately without further action or notice. If any other event of default under the Credit Agreement occurs or is continuing, Emerald Health Sciences may, by written notice, terminate its commitment to make any advances and/or declare all the advances with any other amounts payable due immediately. If any amount under the Credit Agreement is not paid when due, such overdue amount shall bear interest at an annual default interest rate of the applicable rate plus 10%, until such amount is paid in full.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In connection with each advance under the Credit Agreement, the Company agreed to issue to Emerald Health Sciences warrants to purchase shares of common stock in an amount equal to 50% of the number of shares of common stock that each advance may be converted into. The warrants have an exercise price of $0.50 per share, a term of five years and are immediately exercisable upon issuance. The exercise price is subject to adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events or upon any distributions of assets, including cash, stock or other property to the Company&amp;#x2019;s stockholders (See Note 3).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In accounting for each convertible advance and the warrants issued under the Credit Agreement, the Company allocates the proceeds between the debt host and the freestanding warrants on a relative fair value basis for each advance. On the date of each advance, if the effective conversion rate of the debt is less than the market value of the Company&amp;#x2019;s common stock, the Company records a beneficial conversion feature as a discount to the debt and an increase to additional paid-in capital. The debt discounts related to the warrants, beneficial conversion features and compound derivatives, if any, are being amortized over the term of the Credit Agreement using the effective interest rate method. Amortization of the debt discount is recognized as non-cash interest expense and the compound derivatives related to the contingent interest feature and acceleration upon default provision are remeasured at fair value in subsequent periods in the Company&amp;#x2019;s Consolidated Balance Sheets.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 1.4pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;On November 1, 2018, the&amp;#160;initial advance under Credit Agreement was made for $2,000,000 and the Company issued 2,500,000 warrants (See Note 3). &lt;/span&gt;&lt;/span&gt;In accounting for the convertible advances and warrants under the Credit Agreement, $&lt;span&gt;&lt;span&gt;1,684,920 &lt;/span&gt;&lt;/span&gt;of the proceeds was allocated to the debt and&lt;span&gt;&lt;span&gt; $315,080 &lt;/span&gt;&lt;/span&gt;was allocated to equity classified warrants. A beneficial conversion feature of&lt;span&gt;&lt;span&gt; $90,080 &lt;/span&gt;&lt;/span&gt;and a compound derivative liability of&lt;span&gt;&lt;span&gt; $204,102 &lt;/span&gt;&lt;/span&gt;were also recorded.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;During the year ended December 31, 2019, the Company initiated two advances under Credit Agreement, each in the amount of $2,000,000, for an aggregate principal amount of $4,000,000, and the Company issued an aggregate of 5,000,000 warrants to Emerald Health Sciences (See Note 3). In accounting for the convertible advances and warrants issued under the Credit Agreement, an aggregate amount of $3,283,890 was allocated to the debt and $716,110 was allocated to equity classified warrants. A beneficial conversion feature of $1,584,850 and compound derivative liabilities of an aggregate of $516,058 have been recorded (See Note 3). Of the $516,058 in compound derivatives, $322,644 was recorded as other expense in the Consolidated Statements of Comprehensive Income (Loss) for the year ended December 31, 2019, as the value of the beneficial conversion feature exceeded the proceeds allocated to the third draw.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px 0px 0px 0in;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Aggregate financing costs of $63,007 incurred in connection with the Credit Agreement have been recorded as a discount to the debt host and are being amortized using the effective interest rate method and recognized as non-cash interest expense over the term of the Credit Agreement.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0in"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;During the year ended December 31, 2019, the Company used $3,985,500 in proceeds from the exercise of the 2018 Emerald Financing Warrants (Note 3) to prepay a portion of the principal balance on the Credit Agreement. In connection with the prepayment, the Company recorded an extinguishment loss of $725,425.&amp;#160;&lt;/span&gt;&lt;/span&gt;The extinguishment loss was calculated as the difference between the fair value of the consideration paid to extinguish the debt and carrying value of the debt host plus the related compound derivative liability.&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;For the years ended December 31, 2019 and 2018, the effective interest rate related to the Credit Agreement was 32.05% and 10.57%, respectively. As of December 31, 2019, the unamortized debt discount will be amortized over a remaining period of 2.76 years. The fair value of the underlying shares of the Credit Agreement was $657,231 at December 31, 2019. As of December 31, 2019, the if-converted value did not exceed the principal balance.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;i&gt;Secured Convertible Promissory Note&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0in;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On December 28, 2017, the Company entered into a convertible Secured Promissory Note and Security Agreement with Emerald Health Sciences (the &amp;#x201c;Convertible Promissory Note&amp;#x201d;). The Convertible Promissory Note provided for aggregate gross proceeds to the Company of up to $900,000 and was secured by all the Company&amp;#x2019;s assets. Drawdowns on the Convertible Promissory Note were interest-bearing at an annual rate of 12% (compounding semi-annually), payable at maturity. The Convertible Promissory Note matured upon the earlier of June 30, 2018 or upon a default event, as defined, and elected by Emerald Health Sciences. At Emerald Health Sciences&amp;#x2019; election, drawdowns and unpaid interest were convertible into common stock at a conversion price of $0.10, subject to a full-ratchet antidilution right. The Convertible Promissory Note was automatically converted upon the occurrence of the private placement transaction with Emerald Health Sciences (the Emerald Financing) in January 2018.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company received proceeds of $500,000 on December 28, 2017, and on January 19, 2018 the Company received the remaining $400,000 in funding as it had satisfied the conditions required. These conditions required receipt of conversion notices from all the existing Series B stockholders to convert their preferred shares to common stock. Such conversions occurred in January and February of 2018. On each financing date, the Company bifurcated a conversion liability from the Convertible Promissory Note related to the embedded conversion feature with a down-round protection provision (See Note 3). This resulted in a conversion liability of $265,000 at the first financing date which was one trading day prior to December 31, 2017. The second funding in January 2018 resulted in an additional conversion liability of $360,000. The conversion liabilities were recorded as a discount to the debt at each draw down date and were being amortized to interest expense.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On January 19, 2018, in conjunction with the Emerald Financing (See Note 5), the Convertible Promissory Note was automatically converted into common stock at a conversion price of $0.10 per share for 9,000,000 shares of common stock. Upon conversion, the debt and associated conversion liability were extinguished, resulting in a loss on extinguishment of $590,392 which was recorded to&amp;#160;other expense for the year ended December 31, 2018. For the year ended December 31, 2018, the effective interest rate related to the Convertible Promissory Note was 13.94%.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0in"&gt;&amp;#160;&lt;/p&gt;</embi:ConvertibleDebtRelatedPartyTextBlock>
  <us-gaap:ConvertibleDebtTableTextBlock contextRef="C_20190101to20191231" id="F8a03aa20-2de8-11ea-add8-41ed81237e2f">&lt;table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN;margin:auto" width="85%"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="BORDER-BOTTOM:black 1px solid;text-align:center" valign="bottom"&gt;&lt;p style="MARGIN:0px 0px 0px 12pt;TEXT-INDENT:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;As of December 31, &lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px 0px 0px 12pt;TEXT-INDENT:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px 0px 0px 12pt;TEXT-INDENT:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2018&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Total principal value&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,014,500&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6px" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:62px" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,000,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Unamortized debt discount&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(1,622,344&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:62px" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(587,617&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:black 1px solid;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:black 1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(5,086&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom:1px solid black;width:6px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom:1px solid black;text-align:right;width:62px" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(51,423&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Carrying value of total convertible debt -&amp;#160;related party&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:black 1px solid;width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:black 1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;387,070&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom:1px solid black;width:6px" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1px solid black;text-align:right;width:62px" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;1,360,960&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Less, noncurrent portion&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:black 1px solid;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:black 1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(387,070&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom:1px solid black;width:6px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom:1px solid black;text-align:right;width:62px" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(1,360,960&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Current convertible debt &amp;#x2013; related party&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom:2.5pt double black;width:1%;border-top:none;border-right:none;border-left:none;border-image:initial" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2.5pt double black;text-align:right;width:9%;border-top:none;border-right:none;border-left:none;border-image:initial" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&amp;#x2014;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom:2.5pt double black;width:6px;border-top:none;border-right:none;border-left:none;border-image:initial" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2.5pt double black;text-align:right;width:62px;border-top:none;border-right:none;border-left:none;border-image:initial" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&amp;#x2014;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ConvertibleDebtTableTextBlock>
  <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent contextRef="C_20191231_usgaapShortTermDebtTypeAxis_usgaapConvertibleDebtMember_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember" decimals="0" id="F19289" unitRef="USD">2014500</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
  <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtMember_LegalEntityAxis_EmeraldHealthSciencesIncMember" decimals="0" id="F19295" unitRef="USD">2000000</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
  <us-gaap:DebtInstrumentUnamortizedDiscountCurrent contextRef="C_20191231_usgaapShortTermDebtTypeAxis_usgaapConvertibleDebtMember_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember" decimals="0" id="F19305_587617" unitRef="USD">1622344</us-gaap:DebtInstrumentUnamortizedDiscountCurrent>
  <us-gaap:DebtInstrumentUnamortizedDiscountCurrent contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtMember_LegalEntityAxis_EmeraldHealthSciencesIncMember" decimals="0" id="F19311_265000" unitRef="USD">587617</us-gaap:DebtInstrumentUnamortizedDiscountCurrent>
  <us-gaap:DeferredFinanceCostsCurrentGross contextRef="C_20191231_usgaapShortTermDebtTypeAxis_usgaapConvertibleDebtMember_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember" decimals="0" id="F19320_51423" unitRef="USD">5086</us-gaap:DeferredFinanceCostsCurrentGross>
  <us-gaap:DeferredFinanceCostsCurrentGross contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtMember_LegalEntityAxis_EmeraldHealthSciencesIncMember" decimals="0" id="Fxbrl_20200312123520246" unitRef="USD">51423</us-gaap:DeferredFinanceCostsCurrentGross>
  <us-gaap:ConvertibleDebt contextRef="C_20191231_usgaapShortTermDebtTypeAxis_usgaapConvertibleDebtMember_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember" decimals="0" id="F19337_1360960" unitRef="USD">387070</us-gaap:ConvertibleDebt>
  <us-gaap:ConvertibleDebt contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtMember_LegalEntityAxis_EmeraldHealthSciencesIncMember" decimals="0" id="F19346_235000" unitRef="USD">1360960</us-gaap:ConvertibleDebt>
  <us-gaap:ConvertibleDebtCurrent contextRef="C_20191231_usgaapShortTermDebtTypeAxis_usgaapConvertibleDebtMember_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember" decimals="0" id="Fxbrl_20200312124408060" unitRef="USD">0</us-gaap:ConvertibleDebtCurrent>
  <us-gaap:ConvertibleDebtCurrent contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtMember_LegalEntityAxis_EmeraldHealthSciencesIncMember" decimals="0" id="F19384_235000" unitRef="USD">0</us-gaap:ConvertibleDebtCurrent>
  <us-gaap:ConvertibleDebtCurrent contextRef="Context_As_Of_28_Dec_2017T00_00_00_TO_28_Dec_2017T00_00_00_ShortTermDebtTypeAxis_BridgeLoanMember_TypeOfArrangementAxis_SecuredPromissoryNoteAndSecurityAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember" decimals="0" id="F19560_265000" unitRef="USD">265000</us-gaap:ConvertibleDebtCurrent>
  <embi:ScheduleOfInterestExpenseTableTextBlock contextRef="C_20190101to20191231" id="F8a03d130-2de8-11ea-add8-41ed81237e2f">&lt;table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN;margin:auto" width="85%"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="BORDER-BOTTOM:black 1px solid;text-align:center" valign="bottom"&gt;&lt;p style="MARGIN:0px 0px 0px 12pt;TEXT-INDENT:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Year&amp;#160;Ended December 31,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px 0px 0px 12pt;TEXT-INDENT:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border:1pt none" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-width:1pt;border-style:none none solid;border-top-color:initial;border-right-color:initial;border-bottom-color:black;border-left-color:initial;border-image:initial;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px 0px 0px 12pt;TEXT-INDENT:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2018&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="margin-top:0px;margin-right:0px;margin-bottom:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Interest expense - stated rate&amp;#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;371,420&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;26,433&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Non-cash interest expense:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="margin-top:0px;margin-right:0px;margin-bottom:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Amortization of debt discount&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;616,383&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;56,253&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="margin-top:0px;margin-right:0px;margin-bottom:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Amortization of transaction costs&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;12,910&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,283&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="margin-top:0px;margin-right:0px;margin-bottom:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Other interest expense&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border:1pt none;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border:1pt none;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border:1pt none;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border:1pt none;text-align:right;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;9,794&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid black;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid black;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;1,000,713&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid black;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid black;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;94,763&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</embi:ScheduleOfInterestExpenseTableTextBlock>
  <embi:CouponInterestExpense contextRef="C_20190101to20191231" decimals="0" id="F19426" unitRef="USD">371420</embi:CouponInterestExpense>
  <embi:CouponInterestExpense contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="Fxbrl_20200312181105488" unitRef="USD">26433</embi:CouponInterestExpense>
  <embi:AmortizationOfDebtDiscount contextRef="C_20190101to20191231" decimals="0" id="F19461" unitRef="USD">616383</embi:AmortizationOfDebtDiscount>
  <embi:AmortizationOfDebtDiscount contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="Fxbrl_20200312125431046" unitRef="USD">56253</embi:AmortizationOfDebtDiscount>
  <embi:AmortizationOfTransactionCosts contextRef="C_20190101to20191231" decimals="0" id="F19478" unitRef="USD">12910</embi:AmortizationOfTransactionCosts>
  <embi:AmortizationOfTransactionCosts contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="Fxbrl_20200312125559228" unitRef="USD">2283</embi:AmortizationOfTransactionCosts>
  <us-gaap:InterestExpenseOther contextRef="C_20190101to20191231" decimals="0" id="F19495" unitRef="USD">0</us-gaap:InterestExpenseOther>
  <us-gaap:InterestExpenseOther contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="Fxbrl_20200312125733702" unitRef="USD">9794</us-gaap:InterestExpenseOther>
  <us-gaap:LineOfCreditFacilityAverageOutstandingAmount contextRef="Context_Custom_01_Oct_2018T00_00_00_TO_05_Oct_2018T00_00_00_LegalEntityAxis_EmeraldFinancingMember_TypeOfArrangementAxis_MultiDrawCreditAgreementMember" decimals="0" id="F19530_20000000" unitRef="USD">20000000</us-gaap:LineOfCreditFacilityAverageOutstandingAmount>
  <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd contextRef="Context_As_Of_05_Oct_2018T00_00_00_TO_05_Oct_2018T00_00_00_LegalEntityAxis_EmeraldFinancingMember_TypeOfArrangementAxis_MultiDrawCreditAgreementMember" decimals="2" id="F19530_7" unitRef="pure">0.07</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
  <us-gaap:DebtInstrumentMaturityDate contextRef="Context_Custom_01_Oct_2018T00_00_00_TO_05_Oct_2018T00_00_00_LegalEntityAxis_EmeraldFinancingMember_TypeOfArrangementAxis_MultiDrawCreditAgreementMember" id="F19530_October520">2022-10-05</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="Context_As_Of_05_Oct_2018T00_00_00_TO_05_Oct_2018T00_00_00_LegalEntityAxis_EmeraldFinancingMember_TypeOfArrangementAxis_MultiDrawCreditAgreementMember" decimals="2" id="F19530_040" unitRef="USD_per_Share">0.40</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="Context_As_Of_28_Dec_2017T00_00_00_TO_28_Dec_2017T00_00_00_ShortTermDebtTypeAxis_BridgeLoanMember_TypeOfArrangementAxis_SecuredPromissoryNoteAndSecurityAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember" decimals="2" id="F19558_010" unitRef="USD_per_Share">0.10</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="C_20180119_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember" decimals="2" id="Fxbrl_20200312154910102" unitRef="USD_per_Share">0.10</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:LineOfCreditFacilityCommitmentFeeAmount contextRef="Context_Custom_01_Oct_2018T00_00_00_TO_05_Oct_2018T00_00_00_LegalEntityAxis_EmeraldFinancingMember_TypeOfArrangementAxis_MultiDrawCreditAgreementMember" decimals="0" id="F19530_18000000" unitRef="USD">14000000</us-gaap:LineOfCreditFacilityCommitmentFeeAmount>
  <embi:PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase contextRef="Context_Custom_01_Oct_2018T00_00_00_TO_05_Oct_2018T00_00_00_LegalEntityAxis_EmeraldFinancingMember_TypeOfArrangementAxis_MultiDrawCreditAgreementMember" decimals="2" id="Fxbrl_20200206193406229" unitRef="pure">0.50</embi:PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase>
  <us-gaap:ProceedsFromRelatedPartyDebt contextRef="Context_Custom_31_Oct_2018T00_00_00_TO_01_Nov_2018T00_00_00_TypeOfArrangementAxis_MultiDrawCreditAgreementMember" decimals="0" id="F19550_2000000" unitRef="USD">2000000</us-gaap:ProceedsFromRelatedPartyDebt>
  <us-gaap:ProceedsFromRelatedPartyDebt contextRef="C_20190101to20191231_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20200312145046377" unitRef="USD">4000000</us-gaap:ProceedsFromRelatedPartyDebt>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="Context_As_Of_01_Nov_2018T00_00_00_TO_01_Nov_2018T00_00_00_TypeOfArrangementAxis_MultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20200206193608683" unitRef="shares">2500000</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="C_20191231_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember" decimals="INF" id="Fxbrl_20200312143941518" unitRef="shares">5000000</us-gaap:ClassOfWarrantOrRightOutstanding>
  <embi:AllocationOfDebtOnBasisOfRelativeFairValue contextRef="Context_As_Of_01_Nov_2018T00_00_00_TO_01_Nov_2018T00_00_00_TypeOfArrangementAxis_MultiDrawCreditAgreementMember" decimals="0" id="F19550_1684920" unitRef="USD">1684920</embi:AllocationOfDebtOnBasisOfRelativeFairValue>
  <embi:AllocationOfDebtOnBasisOfRelativeFairValue contextRef="C_20191231_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20200312143645287" unitRef="USD">3283890</embi:AllocationOfDebtOnBasisOfRelativeFairValue>
  <embi:AllocationOfWarrantOnBasisOfRelativeFairValue contextRef="Context_As_Of_01_Nov_2018T00_00_00_TO_01_Nov_2018T00_00_00_TypeOfArrangementAxis_MultiDrawCreditAgreementMember" decimals="0" id="F19550_315080" unitRef="USD">315080</embi:AllocationOfWarrantOnBasisOfRelativeFairValue>
  <embi:AllocationOfWarrantOnBasisOfRelativeFairValue contextRef="C_20191231_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20200312143548908" unitRef="USD">716110</embi:AllocationOfWarrantOnBasisOfRelativeFairValue>
  <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="Context_Custom_31_Oct_2018T00_00_00_TO_01_Nov_2018T00_00_00_TypeOfArrangementAxis_MultiDrawCreditAgreementMember" decimals="0" id="F19550_90080" unitRef="USD">90080</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
  <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="C_20190101to20191231_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20200312144021620" unitRef="USD">1584850</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
  <embi:AmountOfEachWarrantOutstanding contextRef="C_20191231_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20200312150208179" unitRef="USD">2000000</embi:AmountOfEachWarrantOutstanding>
  <embi:ConvertibleMultiDrawCreditAgreementIssuanceCosts contextRef="C_20190101to20191231_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember" decimals="0" id="F19552_53707" unitRef="USD">63007</embi:ConvertibleMultiDrawCreditAgreementIssuanceCosts>
  <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="C_20191231_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember" decimals="4" id="Fxbrl_20200312153140699" unitRef="pure">0.3205</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
  <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember" decimals="4" id="Fxbrl_20200312153232619" unitRef="pure">0.1057</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
  <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="Context_As_Of_31-Dec-2018T00_00_00_LegalEntityAxis_EmeraldHealthSciencesIncMember" decimals="4" id="F19562_1394" unitRef="pure">0.1394</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
  <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1 contextRef="C_20190101to20191231_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember" id="Fxbrl_20200312153324934">P2Y9M3D</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
  <embi:FairValueOfUnderlyingShares contextRef="C_20191231_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20200312152916661" unitRef="USD">657231</embi:FairValueOfUnderlyingShares>
  <us-gaap:BridgeLoan contextRef="Context_As_Of_28_Dec_2017T00_00_00_TO_28_Dec_2017T00_00_00_ShortTermDebtTypeAxis_BridgeLoanMember_TypeOfArrangementAxis_SecuredPromissoryNoteAndSecurityAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember" decimals="0" id="F19558_900000" unitRef="USD">900000</us-gaap:BridgeLoan>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="Context_As_Of_28_Dec_2017T00_00_00_TO_28_Dec_2017T00_00_00_ShortTermDebtTypeAxis_BridgeLoanMember_TypeOfArrangementAxis_SecuredPromissoryNoteAndSecurityAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember" decimals="2" id="F19558_12" unitRef="pure">0.12</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:RepaymentsOfConvertibleDebt contextRef="C_20180101to20180119_usgaapShortTermDebtTypeAxis_usgaapBridgeLoanMember_usgaapTypeOfArrangementAxis_embiSecuredPromissoryNoteAndSecurityAgreementMember_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember" decimals="0" id="F19560_400000" unitRef="USD">400000</us-gaap:RepaymentsOfConvertibleDebt>
  <embi:AdditionalConversionLiability contextRef="Context_As_Of_28_Dec_2017T00_00_00_TO_28_Dec_2017T00_00_00_ShortTermDebtTypeAxis_BridgeLoanMember_TypeOfArrangementAxis_SecuredPromissoryNoteAndSecurityAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember" decimals="0" id="F19560_360000" unitRef="USD">360000</embi:AdditionalConversionLiability>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits contextRef="C_20180101to20180119_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember" decimals="INF" id="F19562_9000000" unitRef="shares">9000000</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="C_20190101to20191231" id="F89bfc350-2de8-11ea-add8-41ed81237e2f">&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;5. Stockholders&amp;#x2019; Equity (Deficit) and Capitalization&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;&lt;em&gt;Common Stock&lt;/em&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;On November 14, 2018, the Company amended its articles of incorporation to increase the number of authorized shares of common stock available for issuance to 500,000,000.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;em&gt;November 2019 Common Stock Offering&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;In November 2019, the Company sold in a registered direct offering an aggregate of 8,000,000 shares of its common stock, par value $0.001 per share, and warrants to purchase 8,000,000 shares of common stock (Note 3). The aggregate net proceeds of the transaction were $1,919,372.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;em&gt;Warrant Exercises&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;During the year ended December 31, 2019, Emerald Health Sciences exercised 40,800,000 2018 Emerald Financing Warrants with an intrinsic value of $4,284,000, which resulted in the issuance of 40,800,000 shares of common stock.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;During the year ended December 31, 2018, the Series B warrant holders exercised warrants with an intrinsic value of $144,375, which resulted in the issuance of 187,500 shares of common stock.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&amp;#160;&amp;#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;i&gt;Emerald Financing&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;On January 19, 2018, the Company entered into a Securities Purchase Agreement pursuant to which the Company sold to Emerald Health Sciences 15,000,000 shares of common stock and a warrant to purchase 20,400,000 shares of common stock at an exercise price of $0.10 for aggregate gross proceeds of $1,500,000 (the &amp;#x201c;Emerald Financing&amp;#x201d;). This transaction also resulted in the conversion of the $900,000&amp;#160;Convertible Promissory Note (Note 4). As part of the transaction, the Company&amp;#x2019;s Board members, with the exception of Dr. Brian Murphy, the Company&amp;#x2019;s CEO/CMO, tendered their resignation and Emerald Health Sciences appointed two new nominees to the Board.&amp;#160;The Securities Purchase Agreement also provides that in the case of a subsequent financing in which the purchase price is less than $0.10 per share, Emerald Health Sciences shall be issued additional shares in order to protect against anti-dilution.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;The second closing under the Emerald Financing occurred on February 16, 2018, pursuant to which the Company issued and sold to Emerald Health Sciences 15,000,000 shares of the Company&amp;#x2019;s common stock, and a warrant to purchase 20,400,000 shares of common stock at an exercise price of $0.10 per share for a term of five years. In addition, an accredited investor purchased 2,500,000 shares of common stock and a warrant to purchase 3,400,000 shares of common stock at an exercise price of&amp;#160;$0.10 per share for a term of five years. The Company received aggregate gross proceeds of $1,750,000 from the second closing. In connection with the private placement, the Company incurred issuance costs of $154,092, of which $137,192 was allocated to the warrant liability and expensed during the period and $16,900 was recorded as a reduction to additional paid-in capital from the issuance of common stock.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;i&gt;Conversion of Preferred Stock&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;During the year ended December 31, 2018 all remaining Preferred Series B, D, and F shares were converted to common stock as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN" width="100%"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style="width:31px"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:33px" valign="top"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;For the year ended December 31, 2018,&amp;#160;2,833.55&lt;span&gt;&amp;#160;shares of Series B Preferred stock were converted, resulting in the issuance of &lt;/span&gt;28,385,000&lt;span&gt;&amp;#160;shares of common stock.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:31px"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:33px;text-align:center" valign="top"&gt;&amp;#x2022;&lt;/td&gt;&lt;td valign="top"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;For the year ended December 31, 2018, 200&amp;#160;shares of Series D Preferred stock were converted, resulting in the issuance of 2,000,000&amp;#160;shares of common stock.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:31px"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:33px;text-align:center" valign="top"&gt;&amp;#x2022;&lt;/td&gt;&lt;td valign="top"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;For the year ended December 31, 2018, 2,000&amp;#160;shares of Series F Preferred stock were converted, resulting in the issuance of 20,000,000&amp;#160;shares of common stock.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p&gt;&lt;br/&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;&lt;em&gt;Preferred Stock&lt;/em&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;The Company has 20,000,000 authorized shares of preferred stock, with a par value of $0.001 per share. As of December 31, 2019, there were no shares of preferred stock issued and outstanding.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;During the year ended December 31, 2018, all remaining Preferred Series B, D, and F shares that were previously issued and outstanding were converted to common stock.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="C_20191101to20191130_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember" decimals="INF" id="Fxbrl_20200312151658410" unitRef="shares">8000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
  <us-gaap:SaleOfStockPricePerShare contextRef="C_20191130_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember" decimals="3" id="Fxbrl_20200312151838053" unitRef="USD_per_Share">0.001</us-gaap:SaleOfStockPricePerShare>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="C_20191130_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember" decimals="INF" id="Fxbrl_20200312151856612" unitRef="shares">8000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="C_20191231_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldFinancingWarrantsMember" decimals="INF" id="Fxbrl_20200312154432742" unitRef="shares">40800000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00_usgaapClassOfWarrantOrRightAxis_embiSeriesBWarrantsMember" decimals="INF" id="Fxbrl_20200312155326912" unitRef="shares">187500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_19_Jan_2018T00_00_00_TO_19_Jan_2018T00_00_00_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember" decimals="INF" id="F19589_20400000" unitRef="shares">20400000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_16_Feb_2018T00_00_00_TO_16_Feb_2018T00_00_00_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember" decimals="INF" id="Fxbrl_20200312161545156" unitRef="shares">20400000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_16_Feb_2018T00_00_00_TO_16_Feb_2018T00_00_00_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember_RelatedPartyTransactionsByRelatedPartyAxis_InvestorMember" decimals="INF" id="F19591_3400000" unitRef="shares">3400000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="C_20191101to20191130_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember" decimals="0" id="Fxbrl_20200312151938092" unitRef="USD">1919372</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
  <embi:IntrinsicValueOfWarrantExercises contextRef="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldFinancingWarrantsMember" decimals="0" id="Fxbrl_20200312154321711" unitRef="USD">4284000</embi:IntrinsicValueOfWarrantExercises>
  <embi:IntrinsicValueOfWarrantExercises contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_usgaapClassOfWarrantOrRightAxis_embiSeriesBWarrantsMember" decimals="0" id="Fxbrl_20200312155110602" unitRef="USD">144375</embi:IntrinsicValueOfWarrantExercises>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_Custom_01_Feb_2018T00_00_00_TO_16_Feb_2018T00_00_00_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember" decimals="INF" id="F19589_150000000" unitRef="shares">15000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_Custom_01_Jan_2018T00_00_00_TO_19_Jan_2018T00_00_00_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember" decimals="INF" id="F19589_15000000" unitRef="shares">15000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_Custom_01_Feb_2018T00_00_00_TO_16_Feb_2018T00_00_00_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember_RelatedPartyTransactionsByRelatedPartyAxis_InvestorMember" decimals="INF" id="F19591_2500000" unitRef="shares">2500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <embi:SubsequentFinancingPurchasePriceDescription contextRef="Context_Custom_01_Jan_2018T00_00_00_TO_19_Jan_2018T00_00_00_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember" id="Fxbrl_20200312170324167">The Securities Purchase Agreement also provides that in the case of a subsequent financing in which the purchase price is less than $0.10 per share, Emerald Health Sciences shall be issued additional shares in order to protect against anti-dilution.</embi:SubsequentFinancingPurchasePriceDescription>
  <embi:TermOfWarrants contextRef="Context_Custom_01_Feb_2018T00_00_00_TO_16_Feb_2018T00_00_00_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember" id="Fxbrl_20200312161906914">P5Y</embi:TermOfWarrants>
  <embi:TermOfWarrants contextRef="Context_Custom_01_Feb_2018T00_00_00_TO_16_Feb_2018T00_00_00_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember_LegalEntityAxis_EmeraldHealthSciencesIncMember_RelatedPartyTransactionsByRelatedPartyAxis_InvestorMember" id="Fxbrl_20200312161951690">P5Y</embi:TermOfWarrants>
  <embi:EmeraldFinancingIssuanceCosts contextRef="C_20190101to20191231_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember" decimals="0" id="F19591_154092" unitRef="USD">154092</embi:EmeraldFinancingIssuanceCosts>
  <embi:ReductionToAdditionalPaidInCapitalFromTheIssuanceOfCommonStock contextRef="C_20190101to20191231_usgaapSubsidiarySaleOfStockAxis_usgaapPrivatePlacementMember" decimals="0" id="F19591_16900" unitRef="USD">16900</embi:ReductionToAdditionalPaidInCapitalFromTheIssuanceOfCommonStock>
  <us-gaap:ConversionOfStockSharesConverted1 contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" decimals="INF" id="Fxbrl_20200214165856607" unitRef="shares">2833.55</us-gaap:ConversionOfStockSharesConverted1>
  <us-gaap:ConversionOfStockSharesConverted1 contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementClassOfStockAxis_SeriesDPreferredStockMember" decimals="INF" id="Fxbrl_20200214171355474" unitRef="shares">200</us-gaap:ConversionOfStockSharesConverted1>
  <us-gaap:ConversionOfStockSharesConverted1 contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementClassOfStockAxis_SeriesFPreferredStockMember" decimals="INF" id="Fxbrl_20200214171823227" unitRef="shares">2000</us-gaap:ConversionOfStockSharesConverted1>
  <us-gaap:ConversionOfStockSharesIssued1 contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" decimals="INF" id="Fxbrl_20200214170210246" unitRef="shares">28385000</us-gaap:ConversionOfStockSharesIssued1>
  <us-gaap:ConversionOfStockSharesIssued1 contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementClassOfStockAxis_SeriesDPreferredStockMember" decimals="INF" id="Fxbrl_20200214171220603" unitRef="shares">2000000</us-gaap:ConversionOfStockSharesIssued1>
  <us-gaap:ConversionOfStockSharesIssued1 contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementClassOfStockAxis_SeriesFPreferredStockMember" decimals="INF" id="Fxbrl_20200214171825278" unitRef="shares">20000000</us-gaap:ConversionOfStockSharesIssued1>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="C_20190101to20191231" id="F89bfc351-2de8-11ea-add8-41ed81237e2f">&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;6. Stock-Based Compensation&lt;/strong&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Stock Incentive Plan&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br/&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;On October 31, 2014, after the closing of the Merger, the Board approved the Company&amp;#x2019;s 2014 Omnibus Incentive Plan (the &amp;#x201c;2014 Plan&amp;#x201d;). The 2014 Plan initially reserved 3,200,000 shares for future grants. In October 2018, the Company increased the share reserve under the 2014 Plan to equal 10% of the number of issued and outstanding shares of common stock of the Company. The 2014 Plan authorizes the issuance of awards including stock options, stock appreciation rights, restricted stock, stock units and performance units to employees, directors, and consultants of the Company. As of December 31, 2019, the shares available for future grant under the 2014 Plan are as follows:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN;margin:auto" width="85%"&gt;&lt;tbody&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1px solid black;text-align:center;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Shares Available for Grant&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="top"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Available as of December 31, 2018&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;9,142,273&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="background-color:rgb(204, 238, 255)" valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Share pool increase&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;4,898,750&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Forfeited&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;153,125&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="background-color:rgb(204, 238, 255)" valign="top"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Cancelled&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;196,875&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Granted&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom:1px solid black;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom:1px solid black;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;(1,262,642&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="background-color:rgb(204, 238, 255)" valign="top"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Available as of December 31, 2019&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom:2.5pt double black;width:1%;background-color:rgb(204, 238, 255);border-top:none;border-right:none;border-left:none;border-image:initial" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom:2.5pt double black;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-top:none;border-right:none;border-left:none;border-image:initial" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;13,128,381&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom:3px;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&amp;#160;&amp;#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;i&gt;Stock Options&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br/&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Options granted under the 2014 Plan expire no later than ten&amp;#160;years from the date of grant. Options granted under the 2014 Plan may be either incentive or non-qualified stock options. For incentive and non-qualified stock option grants, the option price shall be at least 100% of the fair value on the date of grants, as determined by the Company&amp;#x2019;s Board of Directors. If at any time the Company grants an option, and the optionee directly or by attribution owns stock possessing more than 10% of the total combined voting power of all classes of stock of the Company, the option price shall be at least 110% of the fair value and shall not be exercisable more than five years after the date of grant.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Options granted under the 2014 Plan may be immediately exercisable if permitted in the specific grant approved by the Board of Directors and, if exercised early may be subject to repurchase provisions. The shares issued generally vest over a period of one to five years from the date of grant.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;The following is a summary of option activities under the Company&amp;#x2019;s 2014 Plan for the year ended December 31, 2019:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&amp;#160;&amp;#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font:10pt Times New Roman;margin:auto;text-align:justify;width:100%" width="85%"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1px solid black;text-align:center;width:76px" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Number of&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Shares&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Weighted&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Average&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Exercise Price&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Weighted&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Average Remaining&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Contractual&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Term&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;(Years)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Aggregate Intrinsic Value*&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Outstanding, December 31, 2018&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:5px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;2,405,000&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;0.33&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:72px" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;8.71&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align:right;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:5px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:72px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align:right;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Granted&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:5px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;1,262,642&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;0.30&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:72px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align:right;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Cancelled&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:5px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;(196,875&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;0.26&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:72px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align:right;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Forfeited&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom:1px solid black;width:5px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:black 1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;(153,125&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:black 1px solid;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:black 1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;0.26&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom:1px solid black;width:6px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom:1px solid black;text-align:right;width:72px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:black 1px solid;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Outstanding, December 31, 2019&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom:3px double black;width:5px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:black 3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;3,317,642&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:black 3px double;width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:black 3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;0.33&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom:3px double black;width:6px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom:3px double black;text-align:right;width:72px" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;8.34&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:black 3px double;width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:black 3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Exercisable, December 31, 2019&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom:1px solid black;width:5px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:black 1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2,399,356&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:black 1px solid;width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:black 1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;0.34&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom:1px solid black;width:6px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom:1px solid black;text-align:right;width:72px" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;7.84&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:black 1px solid;width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:black 1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Vested and expected to vest, December 31, 2019&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;width:5px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;3,317,642&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;width:1%;border:1pt none" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border:1pt none" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;0.33&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;width:1%;border:1pt none" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border:1pt none" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;width:6px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;text-align:right;width:72px" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;8.34&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;width:1%;border:1pt none" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border:1pt none" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;width:1%;border:1pt none" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;i&gt;*The aggregate intrinsic value is the sum of the amounts by which the quoted market price of the Company&amp;#x2019;s stock exceeded the exercise price of the stock options at December 31, 2019&amp;#160;for those stock options for which the quoted market price was in excess of the exercise price (&amp;#x201c;in-the-money options&amp;#x201d;).&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;The weighted-average grant-date fair value of stock options granted for the years ended December 31, 2019 and 2018 was $0.22 and $0.30, respectively. The total fair value of the stock options that vested during the years ended December 31, 2019 and 2018 was $473,030 and $418,688, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px 0px 0px 0in;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;The fair value of each stock option grant was estimated on the date of grant using the Black-Scholes option-pricing model under the following assumptions:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;div&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font:10pt Times New Roman;margin:auto;text-align:justify;width:100%" width="85%"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Year&amp;#160;Ended December 31,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2018&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1.49&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&lt;p style="MARGIN:0px;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3.06&amp;#x2014;3.10&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Expected term (years)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5.65&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&lt;p style="MARGIN:0px;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5.27&amp;#x2014;5.58&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Volatility&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;93.72&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&lt;p style="MARGIN:0px;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;70.00&amp;#x2014;93.60&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;i&gt;Restricted Stock Awards&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br/&gt;&amp;#160;&lt;/p&gt;&lt;/div&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;There was no restricted stock award (&amp;#x201c;RSA&amp;#x201d;) activity under the Company&amp;#x2019;s 2014 Plan during the year ended December 31, 2019.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;br/&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;On February 28, 2018, in conjunction with the signing of the K2C separation agreement discussed in Note 11 below, Mr. Lykos&amp;#x2019; RSAs amounting to &lt;/span&gt;325,000&lt;span&gt; shares vested immediately resulting in a Type III award modification and a credit to stock compensation of $&lt;/span&gt;98,042&lt;span&gt; for the year ended December 31, 2018 due to a lower fair value of those shares as of the modification date.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;On May 25, 2018, in conjunction with the signing of her separation agreement, the former Nemus CFO, Ms. Elizabeth Berecz&amp;#x2019;s RSA&amp;#x2019;s amounting to 350,000 shares vested immediately resulting in a Type III award modification and a credit to stock compensation of $97,183 for the year ended December 31, 2018 due to a lower fair value of those shares as of the modification date as compared to the fair value immediately prior to acceleration.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Awards Granted Outside the 2014 Plan&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;i&gt;Options&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;br/&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;There was no option activity outside of the 2014 Plan during the year ended December 31, 2019.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br/&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;On May 25, 2018, the Company entered into Stock Option Agreement with Douglas Cesario, CFO, granting 1,195,073 stock options with an exercise price equal to $0.245 and a grant date fair value of $200,772 or $0.26 per share based on the following assumptions estimated on the date of grant using the Black-Scholes option-pricing model:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font:10pt Times New Roman;margin:auto;text-align:justify;width:100%" width="85%"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;At Issuance&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Dividend Yield&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2.79&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Expected term (in years)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;5.54&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Volatility&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;70&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;The options vested 25% on July 23, 2018, and the remaining 75% will vest 1/33 on each of the next 33 months thereafter. Options will fully vest upon a triggering event, including a sale of the Company or a merger that results in a change of control. At December 31, 2019, these options have a remaining contractual life of 8.57 years. At December 31, 2019, 760,501 options are exercisable and have no intrinsic value. At December 31, 2019, 1,195,073 options are vested and are expected to vest and have no intrinsic value.&lt;br/&gt;&lt;br/&gt;The total fair value of stock options that vested during the years ended December 31, 2019 and 2018 were $54,756 and $73,008, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;i&gt;Restricted Stock Awards&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br/&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;On January 18, 2018, the Company entered into Restricted Stock Agreements with each of Dr. Murphy, Elizabeth Berecz, CFO, and Cosmas N. Lykos, the Company&amp;#x2019;s Founder granting 900,000, 700,000, and 900,000 shares of restricted common stock, respectively, with a fair value of $475,000. These agreements were issued outside of the 2014 Omnibus Incentive Plan. The restricted stock vests in equal 50% installments on the first and second anniversaries of the grant date, subject to continued employment with the Company through the applicable vesting date. Each Restricted Stock Agreement provides that if an executive&amp;#x2019;s employment or service is terminated by the Company without cause, or is terminated by the grantee for good reason, then the executive shall be entitled to receive a cash severance payment equal to six months of their base compensation, payable in substantially equal installments during the six-month period following the separation along with accelerated vesting of all outstanding stock awards.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;On February 28, 2018, in conjunction with the signing of the K2C separation agreement discussed in Note 8 below, Mr. Lykos&amp;#x2019; Restricted stock awards amounting to 900,000 shares became immediately vested resulting in a Type III award modification and stock compensation expense of $216,000 for the year ended December 31, 2018, due to an increase in the fair value of the award immediately before and after the modification date.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;On May 25, 2018, in conjunction with the signing of her separation agreement discussed above, the Company&amp;#x2019;s former CFO, Ms. Elizabeth Berecz&amp;#x2019;s Restricted stock awards amounting to 700,000 shares became immediately vested resulting in the recording of compensation expense of&lt;span&gt;&lt;span&gt; $184,800 for the year ended December 31, 2018, due to an increase in the fair value of the award immediately before and after the modification date.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px 0px 0px 0in;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;The following is a summary of RSA activity outside of the Company&amp;#x2019;s 2014 Plan during the year ended December 31, 2019:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font:10pt Times New Roman;margin:auto;text-align:justify;width:100%" width="85%"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Number of&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Shares&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Weighted &lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Average Grant &lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Date Fair Value&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Unvested, December 31, 2018&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;900,000&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:7px" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:72px" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;0.19&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:7px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:72px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Granted&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:7px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:72px" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Released&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border:1pt none;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border:1pt none;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;(450,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;width:1%;border:1pt none" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;border:1pt none" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border:1pt none;width:7px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border:1pt none;text-align:right;width:72px" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;0.19&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;width:1%;border:1pt none" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Unvested, December 31, 2019&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid black;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid black;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;450,000&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom:3px;width:1%;border:1pt none" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border:1pt none" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid black;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;width:7px" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid black;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;text-align:right;width:72px" valign="bottom"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;0.19&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/td&gt;&lt;td style="padding-bottom:3px;width:1%;border:1pt none" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Stock-Based Compensation Expense&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br/&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px 0px 0px 0in;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;The Company recognizes stock-based compensation expense using the straight-line method over the requisite service period. For the years ended December 31, 2019 and 2018, the Company recognized stock-based compensation expense of&lt;span&gt;&lt;span&gt; $680,455 and $674,961, &lt;/span&gt;&lt;/span&gt;respectively (including compensation expense for RSAs discussed above), which was recorded as a general and administrative expense in the Consolidated Statements of Comprehensive Income (Loss). The total amount of unrecognized compensation cost was&lt;span&gt;&lt;span&gt; $312,405 &lt;/span&gt;&lt;/span&gt;as of December 31, 2019. This amount will be recognized over a weighted-average period of 2.07 years.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="Context_As_Of_31_Oct_2014T00_00_00_TO_31_Oct_2014T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" decimals="INF" id="F19992_3200000" unitRef="shares">3200000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="C_20190101to20191231_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" id="F8a09ebb0-2de8-11ea-add8-41ed81237e2f">&lt;table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN;margin:auto" width="85%"&gt;&lt;tbody&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1px solid black;text-align:center;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Shares Available for Grant&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="top"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Available as of December 31, 2018&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;9,142,273&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="background-color:rgb(204, 238, 255)" valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Share pool increase&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;4,898,750&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Forfeited&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;153,125&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="background-color:rgb(204, 238, 255)" valign="top"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Cancelled&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;196,875&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Granted&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom:1px solid black;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom:1px solid black;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;(1,262,642&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="background-color:rgb(204, 238, 255)" valign="top"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Available as of December 31, 2019&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom:2.5pt double black;width:1%;background-color:rgb(204, 238, 255);border-top:none;border-right:none;border-left:none;border-image:initial" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom:2.5pt double black;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-top:none;border-right:none;border-left:none;border-image:initial" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;13,128,381&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom:3px;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member" decimals="INF" id="F20014_870000" unitRef="shares">9142273</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="C_20191231_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member" decimals="INF" id="F20067_9142273" unitRef="shares">13128381</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" decimals="INF" id="F20150_1130000" unitRef="shares">2405000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="C_20191231_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" decimals="INF" id="F20313_2405000" unitRef="shares">3317642</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease contextRef="C_20190101to20191231_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member" decimals="INF" id="F20026" unitRef="shares">4898750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="C_20190101to20191231_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member" decimals="INF" id="F20036" unitRef="shares">153125</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="C_20190101to20191231_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" decimals="INF" id="F20281_427000" unitRef="shares">153125</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="C_20190101to20191231_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member" decimals="INF" id="F20046" unitRef="shares">196875</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="C_20190101to20191231_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" decimals="INF" id="F20251_48000" unitRef="shares">196875</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="C_20190101to20191231_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member" decimals="INF" id="F20056_2393501" unitRef="shares">1262642</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="C_20190101to20191231_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" decimals="INF" id="F20220" unitRef="shares">1262642</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_Custom_01_May_2018T00_00_00_TO_25_May_2018T00_00_00_TitleOfIndividualAxis_DouglasCesarioMember_TypeOfArrangementAxis_RestrictedStockAgreementsMember" decimals="INF" id="F20640_1195073" unitRef="shares">1195073</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="C_20190101to20191231_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" id="Fxbrl_20200313125351664">&lt;div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font:10pt Times New Roman;margin:auto;text-align:justify;width:100%" width="85%"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1px solid black;text-align:center;width:76px" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Number of&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Shares&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Weighted&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Average&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Exercise Price&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Weighted&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Average Remaining&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Contractual&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Term&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;(Years)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Aggregate Intrinsic Value*&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Outstanding, December 31, 2018&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:5px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;2,405,000&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;0.33&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:72px" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;8.71&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align:right;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:5px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:72px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align:right;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Granted&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:5px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;1,262,642&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;0.30&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:72px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align:right;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Cancelled&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:5px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;(196,875&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;0.26&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:72px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align:right;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Forfeited&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom:1px solid black;width:5px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:black 1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;(153,125&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:black 1px solid;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:black 1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;0.26&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom:1px solid black;width:6px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom:1px solid black;text-align:right;width:72px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:black 1px solid;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Outstanding, December 31, 2019&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom:3px double black;width:5px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:black 3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;3,317,642&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:black 3px double;width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:black 3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;0.33&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom:3px double black;width:6px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom:3px double black;text-align:right;width:72px" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;8.34&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:black 3px double;width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:black 3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Exercisable, December 31, 2019&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom:1px solid black;width:5px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:black 1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2,399,356&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:black 1px solid;width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:black 1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;0.34&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom:1px solid black;width:6px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom:1px solid black;text-align:right;width:72px" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;7.84&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:black 1px solid;width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:black 1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Vested and expected to vest, December 31, 2019&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;width:5px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;3,317,642&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;width:1%;border:1pt none" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border:1pt none" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;0.33&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;width:1%;border:1pt none" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border:1pt none" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;width:6px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;text-align:right;width:72px" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;8.34&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;width:1%;border:1pt none" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border:1pt none" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;width:1%;border:1pt none" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;i&gt;*The aggregate intrinsic value is the sum of the amounts by which the quoted market price of the Company&amp;#x2019;s stock exceeded the exercise price of the stock options at December 31, 2019&amp;#160;for those stock options for which the quoted market price was in excess of the exercise price (&amp;#x201c;in-the-money options&amp;#x201d;).&lt;/i&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" decimals="2" id="F20159_060" unitRef="USD_per_Share">0.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="C_20191231_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" decimals="2" id="F20322_033" unitRef="USD_per_Share">0.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" id="Fxbrl_20200312110611626">P8Y8M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="C_20190101to20191231_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" id="Fxbrl_20200312110624774">P8Y4M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="C_20190101to20191231_usgaapTitleOfIndividualAxis_embiDouglasCesarioMember_usgaapTypeOfArrangementAxis_embiRestrictedStockAgreementsMember" id="Fxbrl_20200312115141081">P8Y6M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="C_20190101to20191231_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" decimals="2" id="F20227" unitRef="USD_per_Share">0.30</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_Custom_01_May_2018T00_00_00_TO_25_May_2018T00_00_00_TitleOfIndividualAxis_DouglasCesarioMember_TypeOfArrangementAxis_RestrictedStockAgreementsMember" decimals="3" id="F20640_0245" unitRef="USD_per_Share">0.245</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="C_20190101to20191231_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" decimals="2" id="F20257" unitRef="USD_per_Share">0.26</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="C_20190101to20191231_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" decimals="2" id="F20287" unitRef="USD_per_Share">0.26</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="C_20191231_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" decimals="0" id="F20341_182000" unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="C_20191231_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" decimals="INF" id="F20355_859417" unitRef="shares">2399356</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="C_20191231_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" decimals="2" id="F20364_037" unitRef="USD_per_Share">0.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="C_20190101to20191231_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" id="Fxbrl_20200312110807381">P7Y10M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="C_20191231_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" decimals="0" id="F20383_36458" unitRef="USD">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="C_20191231_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" decimals="INF" id="F20397_2405000" unitRef="shares">3317642</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="C_20191231_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" decimals="2" id="F20406_033" unitRef="USD_per_Share">0.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="C_20190101to20191231_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" id="Fxbrl_20200312110800045">P8Y4M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="C_20191231_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" decimals="0" id="F20425_182000" unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="C_20190101to20191231_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" decimals="3" id="Fxbrl_20200312101835309" unitRef="USD_per_Share">0.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" decimals="2" id="Fxbrl_20200312110908864" unitRef="USD_per_Share">0.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="C_20190101to20191231_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" decimals="0" id="Fxbrl_20200312121607438" unitRef="USD">473030</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" decimals="0" id="Fxbrl_20200312121620696" unitRef="USD">418688</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="C_20190101to20191231_usgaapTitleOfIndividualAxis_embiDouglasCesarioMember_usgaapTypeOfArrangementAxis_embiRestrictedStockAgreementsMember" decimals="0" id="Fxbrl_20200312120145466" unitRef="USD">54756</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_srtTitleOfIndividualAxis_embiDouglasCesarioMember_usgaapTypeOfArrangementAxis_embiRestrictedStockAgreementsMember" decimals="0" id="Fxbrl_20200312120208824" unitRef="USD">73008</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="C_20190101to20191231_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" id="Fxbrl_20200312113614218">&lt;div&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font:10pt Times New Roman;margin:auto;text-align:justify;width:100%" width="85%"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Year&amp;#160;Ended December 31,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2018&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1.49&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&lt;p style="MARGIN:0px;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3.06&amp;#x2014;3.10&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Expected term (years)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5.65&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&lt;p style="MARGIN:0px;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5.27&amp;#x2014;5.58&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Volatility&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;93.72&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&lt;p style="MARGIN:0px;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;70.00&amp;#x2014;93.60&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="C_20190101to20191231_usgaapPlanNameAxis_embiAwardsGrantedOutside2014PlanMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" id="F8a0cf8f0-2de8-11ea-add8-41ed81237e2f">&lt;table border="0" cellpadding="0" cellspacing="0" style="font:10pt Times New Roman;margin:auto;text-align:justify;width:100%" width="85%"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;At Issuance&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Dividend Yield&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;2.79&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Expected term (in years)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;5.54&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Volatility&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;70&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="C_20190101to20191231_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" decimals="4" id="Fxbrl_20200312112447768" unitRef="pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" decimals="4" id="Fxbrl_20200312113028285" unitRef="pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Context_Custom_01_May_2018T00_00_00_TO_25_May_2018T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_usgaapPlanNameAxis_embiAwardsGrantedOutsideThe2014PlanMember" decimals="4" id="Fxbrl_20200312105126481" unitRef="pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="C_20190101to20191231_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" decimals="4" id="Fxbrl_20200312112425628" unitRef="pure">0.0149</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_srtRangeAxis_srtMinimumMember" decimals="4" id="Fxbrl_20200312113057480" unitRef="pure">0.0306</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_srtRangeAxis_srtMaximumMember" decimals="4" id="Fxbrl_20200312113106545" unitRef="pure">0.0310</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Context_Custom_01_May_2018T00_00_00_TO_25_May_2018T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_usgaapPlanNameAxis_embiAwardsGrantedOutsideThe2014PlanMember" decimals="4" id="F20671" unitRef="pure">0.0279</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="C_20190101to20191231_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" id="Fxbrl_20200312112757668">P5Y7M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_srtRangeAxis_srtMinimumMember" id="Fxbrl_20200312113356167">P5Y3M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_srtRangeAxis_srtMaximumMember" id="Fxbrl_20200312113400667">P5Y6M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Context_Custom_01_May_2018T00_00_00_TO_25_May_2018T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_usgaapPlanNameAxis_embiAwardsGrantedOutsideThe2014PlanMember" id="Fxbrl_20200312105206710">P5Y6M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="C_20190101to20191231_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" decimals="4" id="Fxbrl_20200312112436857" unitRef="pure">0.9372</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_srtRangeAxis_srtMinimumMember" decimals="4" id="Fxbrl_20200312113244396" unitRef="pure">0.7000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_srtRangeAxis_srtMaximumMember" decimals="4" id="Fxbrl_20200312113321995" unitRef="pure">0.9360</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Context_Custom_01_May_2018T00_00_00_TO_25_May_2018T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_usgaapPlanNameAxis_embiAwardsGrantedOutsideThe2014PlanMember" decimals="2" id="F20690" unitRef="pure">0.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="Context_Custom_01_Feb_2018T00_00_00_TO_28_Feb_2018T00_00_00_TypeOfArrangementAxis_RestrictedStockAgreementsMember_LegalEntityAxis_K2CIncMember" decimals="INF" id="F20630_325000" unitRef="shares">325000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="C_20180501to20180525_srtTitleOfIndividualAxis_srtChiefFinancialOfficerMember_usgaapTypeOfArrangementAxis_embiRestrictedStockAgreementsMember" decimals="INF" id="F20632_350000" unitRef="shares">350000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="C_20190101to20191231_usgaapAwardTypeAxis_usgaapRestrictedStockMember" decimals="INF" id="F20809_1600000" unitRef="shares">450000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="Context_Custom_01_Feb_2018T00_00_00_TO_28_Feb_2018T00_00_00_TypeOfArrangementAxis_SeparationAndReleaseAgreementMember_LegalEntityAxis_K2CIncMember_VestingAxis_ShareBasedCompensationAwardTrancheOneMember" decimals="INF" id="F21568_900000" unitRef="shares">900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="Context_Custom_01_Feb_2018T00_00_00_TO_28_Feb_2018T00_00_00_TypeOfArrangementAxis_SeparationAndReleaseAgreementMember_LegalEntityAxis_K2CIncMember_VestingAxis_ShareBasedCompensationAwardTrancheTwoMember" decimals="0" id="F21568_325000" unitRef="shares">325000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="Context_Custom_01_Feb_2018T00_00_00_TO_28_Feb_2018T00_00_00_TypeOfArrangementAxis_SeparationAndReleaseAgreementMember_LegalEntityAxis_K2CIncMember_VestingAxis_ShareBasedCompensationAwardTrancheThreeMember" decimals="0" id="F21568_125000" unitRef="shares">125000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
  <us-gaap:RestrictedStockExpense contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_deiLegalEntityAxis_embiK2CIncMember_usgaapTypeOfArrangementAxis_embiRestrictedStockAgreementsMember" decimals="0" id="F20630_98042" unitRef="USD">98042</us-gaap:RestrictedStockExpense>
  <us-gaap:RestrictedStockExpense contextRef="C_20180101to20181231_srtTitleOfIndividualAxis_srtChiefFinancialOfficerMember_usgaapTypeOfArrangementAxis_embiRestrictedStockAgreementsMember" decimals="0" id="F20632_97183" unitRef="USD">97183</us-gaap:RestrictedStockExpense>
  <us-gaap:RestrictedStockExpense contextRef="C_20180101to20181231_usgaapAwardTypeAxis_usgaapRestrictedStockMember_deiLegalEntityAxis_embiK2CIncMember" decimals="0" id="F20699_216000" unitRef="USD">216000</us-gaap:RestrictedStockExpense>
  <us-gaap:RestrictedStockExpense contextRef="C_20180101to20181231_usgaapAwardTypeAxis_usgaapRestrictedStockMember_usgaapTitleOfIndividualAxis_usgaapChiefFinancialOfficerMember" decimals="0" id="F20715_184800" unitRef="USD">184800</us-gaap:RestrictedStockExpense>
  <embi:FairMarketValueOfStockOptions contextRef="Context_Custom_01_May_2018T00_00_00_TO_25_May_2018T00_00_00_TitleOfIndividualAxis_DouglasCesarioMember_TypeOfArrangementAxis_RestrictedStockAgreementsMember" decimals="0" id="F20640_200772" unitRef="USD">200772</embi:FairMarketValueOfStockOptions>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="C_20190101to20191231_usgaapTitleOfIndividualAxis_embiDouglasCesarioMember_usgaapTypeOfArrangementAxis_embiRestrictedStockAgreementsMember" id="Fxbrl_20200312115005747">The options vested 25% on July 23, 2018, and the remaining 75% will vest 1/33 on each of the next 33 months thereafter.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="Context_Custom_01_May_2018T00_00_00_TO_25_May_2018T00_00_00_TitleOfIndividualAxis_DouglasCesarioMember_TypeOfArrangementAxis_RestrictedStockAgreementsMember" decimals="2" id="F20693_25" unitRef="pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="Context_Custom_01_Jan_2018T00_00_00_TO_18_Jan_2018T00_00_00_AwardTypeAxis_RestrictedStockMember" decimals="2" id="F20697_50" unitRef="pure">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="C_20190101to20191231_usgaapTitleOfIndividualAxis_embiDouglasCesarioMember_usgaapTypeOfArrangementAxis_embiRestrictedStockAgreementsMember" decimals="0" id="Fxbrl_20200312115257552" unitRef="shares">760501</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="C_20190101to20191231_usgaapTitleOfIndividualAxis_embiDouglasCesarioMember_usgaapTypeOfArrangementAxis_embiRestrictedStockAgreementsMember" decimals="0" id="Fxbrl_20200312115359926" unitRef="shares">1195073</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="Context_Custom_01_Jan_2018T00_00_00_TO_18_Jan_2018T00_00_00_AwardTypeAxis_RestrictedStockMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember" decimals="INF" id="Fxbrl_20200214151412074" unitRef="shares">900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="Context_Custom_01_Jan_2018T00_00_00_TO_18_Jan_2018T00_00_00_AwardTypeAxis_RestrictedStockMember_TitleOfIndividualAxis_ChiefFinancialOfficerMember" decimals="INF" id="F20697_700000" unitRef="shares">700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="Context_Custom_01_Jan_2018T00_00_00_TO_18_Jan_2018T00_00_00_AwardTypeAxis_RestrictedStockMember_TitleOfIndividualAxis_BoardOfDirectorsChairmanMember" decimals="INF" id="Fxbrl_20200214152158111" unitRef="shares">900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="Context_Custom_01_Feb_2018T00_00_00_TO_28_Feb_2018T00_00_00_AwardTypeAxis_RestrictedStockMember_LegalEntityAxis_K2CIncMember" decimals="0" id="Fxbrl_20200312114139929" unitRef="shares">900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="Context_Custom_01_May_2018T00_00_00_TO_25_May_2018T00_00_00_AwardTypeAxis_RestrictedStockMember_TitleOfIndividualAxis_ChiefFinancialOfficerMember" decimals="0" id="Fxbrl_20200312114311476" unitRef="shares">700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="C_20190101to20191231_usgaapAwardTypeAxis_usgaapRestrictedStockMember" decimals="INF" id="F20792" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <embi:FairMarketValueOfSharesGranted contextRef="Context_Custom_01_Jan_2018T00_00_00_TO_18_Jan_2018T00_00_00_AwardTypeAxis_RestrictedStockMember" decimals="0" id="F20697_475000" unitRef="USD">475000</embi:FairMarketValueOfSharesGranted>
  <us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock contextRef="C_20190101to20191231_usgaapPlanNameAxis_embiAwardsGrantedOutside2014PlanMember_usgaapAwardTypeAxis_usgaapRestrictedStockMember" id="F8a125020-2de8-11ea-add8-41ed81237e2f">&lt;table border="0" cellpadding="0" cellspacing="0" style="font:10pt Times New Roman;margin:auto;text-align:justify;width:100%" width="85%"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Number of&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Shares&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Weighted &lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Average Grant &lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Date Fair Value&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Unvested, December 31, 2018&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;strong&gt;900,000&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:7px" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:72px" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;0.19&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:7px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:72px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Granted&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:7px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:72px" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Released&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border:1pt none;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border:1pt none;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;(450,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;width:1%;border:1pt none" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;border:1pt none" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border:1pt none;width:7px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border:1pt none;text-align:right;width:72px" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;0.19&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;width:1%;border:1pt none" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Unvested, December 31, 2019&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid black;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid black;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;450,000&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom:3px;width:1%;border:1pt none" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border:1pt none" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid black;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;width:7px" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid black;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;text-align:right;width:72px" valign="bottom"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;0.19&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/td&gt;&lt;td style="padding-bottom:3px;width:1%;border:1pt none" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="Context_As_Of_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_AwardTypeAxis_RestrictedStockMember" decimals="INF" id="Fxbrl_20200312104751322" unitRef="shares">900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="C_20191231_usgaapAwardTypeAxis_usgaapRestrictedStockMember" decimals="INF" id="F20827_900000" unitRef="shares">450000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="Context_As_Of_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_AwardTypeAxis_RestrictedStockMember" decimals="2" id="Fxbrl_20200312104716108" unitRef="USD_per_Share">0.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="C_20191231_usgaapAwardTypeAxis_usgaapRestrictedStockMember" decimals="2" id="F20836_019" unitRef="USD_per_Share">0.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="C_20190101to20191231_usgaapAwardTypeAxis_usgaapRestrictedStockMember" decimals="0" id="F20799" unitRef="USD_per_Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="C_20190101to20191231_usgaapAwardTypeAxis_usgaapRestrictedStockMember" decimals="2" id="F20815" unitRef="USD_per_Share">0.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="C_20191231" decimals="0" id="F20845_748616" unitRef="USD">312405</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="C_20190101to20191231" id="Fxbrl_20200312113821221">P2Y25D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:EarningsPerShareTextBlock contextRef="C_20190101to20191231" id="F89bfc352-2de8-11ea-add8-41ed81237e2f">&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;7. &lt;/strong&gt;&lt;strong&gt;Net Income (Loss) Per Share of Common Stock&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0in"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;The following tables are a reconciliation of the numerators and denominators used in the calculation of basic and diluted net income (loss) per share computations:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;div&gt;&lt;table style="font:10pt/normal times new roman;width:100%;text-align:justify;border-collapse:collapse;font-size-adjust:none;font-stretch:normal"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="10" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:black;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;For the Year Ended&lt;/strong&gt; &lt;strong&gt;December 31, 2019&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Income&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;(Numerator)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:black;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Shares&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;(Denominator)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Per-Share&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Amount&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Net income&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:black;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:black;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;1,051,825&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Basic EPS&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Income available to common stockholders&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:black;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:black;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;1,051,825&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:black;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:black;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;135,154,931&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:black;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:black;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;0.01&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Effect of Dilutive Securities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Unvested restricted stock&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;858,856&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Options&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;392,784&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Warrants&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;447,431&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Warrants &amp;#x2013; liability classified&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;(9,250,612&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;vertical-align:bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;32,706,263&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Diluted EPS&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Loss available to common stockholders + assumed conversions&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;(8,198,787&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;vertical-align:bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;169,560,265&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;(0.05&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;vertical-align:bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="margin:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&amp;#160;&amp;#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;table style="font:10pt/normal times new roman;width:100%;text-align:justify;border-collapse:collapse;font-size-adjust:none;font-stretch:normal"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="10" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:black;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;For the Year Ended&lt;/strong&gt; &lt;strong&gt;December 31, 2018&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Income&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;(Numerator)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:black;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Shares&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;(Denominator)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Per-Share&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Amount&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Net loss&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;(19,194,236&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;vertical-align:bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Basic and Diluted EPS&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Loss available to common stockholders&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:black;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:black;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;(19,194,236&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;vertical-align:bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:black;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:black;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;121,154,334&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:black;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:black;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;(0.16&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;vertical-align:bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been anti-dilutive:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font:10pt Times New Roman;margin:auto;text-align:justify;width:100%" width="85%"&gt;&lt;tbody&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom:1px solid black;text-align:center;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Year Ended&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1px solid black;text-align:center;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1px solid black;text-align:center;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;2018&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="background-color:rgb(204, 238, 255)" valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Stock options&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;4,119,931&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;3,600,073&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Unvested restricted stock&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;234,645&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;1,543,501&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="background-color:rgb(204, 238, 255)" valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Common shares underlying convertible debt&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;5,036,250&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;5,000,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Warrants&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;20,712,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;53,130,750&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="C_20190101to20191231" id="Fxbrl_20200318174619197">&lt;div&gt;&lt;table style="font:10pt/normal times new roman;width:100%;text-align:justify;border-collapse:collapse;font-size-adjust:none;font-stretch:normal"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="10" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:black;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;For the Year Ended&lt;/strong&gt; &lt;strong&gt;December 31, 2019&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Income&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;(Numerator)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:black;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Shares&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;(Denominator)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Per-Share&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Amount&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Net income&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:black;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:black;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;1,051,825&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Basic EPS&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Income available to common stockholders&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:black;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:black;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;1,051,825&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:black;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:black;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;135,154,931&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:black;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:black;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;0.01&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Effect of Dilutive Securities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Unvested restricted stock&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;858,856&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Options&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;392,784&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Warrants&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;447,431&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Warrants &amp;#x2013; liability classified&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;(9,250,612&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;vertical-align:bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;32,706,263&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Diluted EPS&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Loss available to common stockholders + assumed conversions&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;(8,198,787&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;vertical-align:bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;169,560,265&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;(0.05&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;vertical-align:bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="margin:0px"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&amp;#160;&amp;#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;table style="font:10pt/normal times new roman;width:100%;text-align:justify;border-collapse:collapse;font-size-adjust:none;font-stretch:normal"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="10" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:black;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;For the Year Ended&lt;/strong&gt; &lt;strong&gt;December 31, 2018&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Income&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;(Numerator)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:black;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Shares&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;(Denominator)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Per-Share&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Amount&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Net loss&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;(19,194,236&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;vertical-align:bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;Basic and Diluted EPS&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Loss available to common stockholders&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:black;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:black;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;(19,194,236&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;vertical-align:bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:black;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:black;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;121,154,334&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:black;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:black;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;(0.16&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;vertical-align:bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20200318164303884" unitRef="USD">1051825</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="Fxbrl_20200318164402399" unitRef="USD">-19194236</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <embi:DilutiveSecuritiesEffectOnBasicEarningsPerShareShares contextRef="C_20190101to20191231_embiDilutedSecuritiesAxis_embiUnvestedRestrictedStockMember" decimals="0" id="Fxbrl_20200318174237346" unitRef="shares">858856</embi:DilutiveSecuritiesEffectOnBasicEarningsPerShareShares>
  <embi:DilutiveSecuritiesEffectOnBasicEarningsPerShareShares contextRef="C_20190101to20191231_embiDilutedSecuritiesAxis_embiOptionsMember" decimals="0" id="Fxbrl_20200318174243663" unitRef="shares">392784</embi:DilutiveSecuritiesEffectOnBasicEarningsPerShareShares>
  <embi:DilutiveSecuritiesEffectOnBasicEarningsPerShareShares contextRef="C_20190101to20191231_embiDilutedSecuritiesAxis_embiWarrantsMember" decimals="0" id="Fxbrl_20200318174245845" unitRef="shares">447431</embi:DilutiveSecuritiesEffectOnBasicEarningsPerShareShares>
  <embi:DilutiveSecuritiesEffectOnBasicEarningsPerShareShares contextRef="C_20190101to20191231_embiDilutedSecuritiesAxis_embiWarrantsLiabilityClassifiedMember" decimals="0" id="Fxbrl_20200318174247813" unitRef="shares">32706263</embi:DilutiveSecuritiesEffectOnBasicEarningsPerShareShares>
  <us-gaap:DilutiveSecurities contextRef="C_20190101to20191231_embiDilutedSecuritiesAxis_embiWarrantsLiabilityClassifiedMember" decimals="0" id="Fxbrl_20200318174353457" unitRef="USD">-9250612</us-gaap:DilutiveSecurities>
  <embi:NetLossAdjustedBalance contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20200318165704226" unitRef="USD">-8198787</embi:NetLossAdjustedBalance>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="C_20190101to20191231" id="F8a219260-2de8-11ea-add8-41ed81237e2f">&lt;table border="0" cellpadding="0" cellspacing="0" style="font:10pt Times New Roman;margin:auto;text-align:justify;width:100%" width="85%"&gt;&lt;tbody&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom:1px solid black;text-align:center;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;Year Ended&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1px solid black;text-align:center;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1px solid black;text-align:center;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;2018&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="background-color:rgb(204, 238, 255)" valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Stock options&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;4,119,931&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;3,600,073&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Unvested restricted stock&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;234,645&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;1,543,501&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="background-color:rgb(204, 238, 255)" valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Common shares underlying convertible debt&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;5,036,250&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;5,000,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Warrants&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;20,712,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;53,130,750&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="C_20190101to20191231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapEmployeeStockOptionMember" decimals="0" id="F20972" unitRef="shares">4119931</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember" decimals="0" id="F20979" unitRef="shares">3600073</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="C_20190101to20191231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapRestrictedStockMember" decimals="0" id="F20989" unitRef="shares">234645</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockMember" decimals="0" id="F20996" unitRef="shares">1543501</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="C_20190101to20191231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapConvertibleDebtSecuritiesMember" decimals="0" id="F21006" unitRef="shares">5036250</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertibleDebtSecuritiesMember" decimals="0" id="F21013" unitRef="shares">5000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="C_20190101to20191231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapWarrantMember" decimals="0" id="F21040" unitRef="shares">20712000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" decimals="0" id="F21047" unitRef="shares">53130750</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="C_20190101to20191231" id="F89bfea60-2de8-11ea-add8-41ed81237e2f">&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;8. Income Taxes &lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The components of income (loss) before the income tax provision (benefit) consist of the following:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;div&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN" width="100%"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Year Ended &lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2018&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;US&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,120,521&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(19,192,594&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Foreign&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(67,096&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;Pre-tax income (loss) from operations&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid black;border-bottom:2.5pt double black;border-right:none;border-left:none;border-image:initial;width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid black;border-bottom:2.5pt double black;border-right:none;border-left:none;border-image:initial;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;1,053,425&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid black;border-bottom:2.5pt double black;border-right:none;border-left:none;border-image:initial;width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid black;border-bottom:2.5pt double black;border-right:none;border-left:none;border-image:initial;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;(19,192,594&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;width:1%" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0in;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Under the FASB&amp;#x2019;s accounting guidance related to income tax positions, among other things, the impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. Additionally, the guidance provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0in;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;The Company had no accrual for interest or penalties on the Company&amp;#x2019;s Balance Sheets at December 31, 2019 and 2018, and has not recognized interest and/or penalties in the Consolidated Statements of Comprehensive Income (Loss) for the years ended December 31, 2019 or 2018.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0in;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0in;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;The Company is subject to taxation in the United States and California. The Company&amp;#x2019;s tax years for 2016 (federal) and 2015 (California) and 2019 (Australia) and forward are subject to examination by the United States, California and Australia tax authorities.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0in;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;At December 31, 2019, the Company had federal and California NOLs aggregating $13,213,037 and $24,481,423, respectively, which, if not used, it will begin to expire from 2033 and the Company had federal NOLs that do not expire but utilization is limited to 80% of taxable income for any given tax year in the amount of $11,275,349. At December 31, 2019, the Company had Australia NOLs aggregating $67,096 which do not expire.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Utilization of the domestic NOL will be subject to a substantial annual limitation due to ownership change limitations that may have occurred, or that could occur in the future, as required by Section 382 of the Internal Revenue Code of 1986, as amended (the Code), as well as similar state provisions. These ownership changes may limit the amount of NOLs that can be utilized annually to offset future taxable income and tax, respectively.&amp;#160;In general, an &amp;#x201c;ownership change&amp;#x201d; as defined by Section 382 of the Code&amp;#160;results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percentage points of the outstanding stock of a company by certain stockholders.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Upon the occurrence of an ownership change under Section 382 as outlined above, utilization of the NOLs are subject to an annual limitation under Section 382 of the Code, which is determined by first multiplying the value of the Company&amp;#x2019;s stock at the time of the ownership change by the applicable long-term, tax-exempt rate, and then could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the NOL before utilization. The multiple ownership changes may have already occurred as the Company raised capital through the issuance of stock. However, due to the existence of the valuation allowance for deferred tax assets, any potential change in ownership will not impact the Company&amp;#x2019;s effective tax rate.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The tax effects of temporary differences and carryforwards that give rise to significant portions of the deferred income tax assets are as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="WIDTH:100%;TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN" width="100%"&gt;&lt;tbody&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);width:6px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom:1px solid;text-align:center;background-color:rgb(255, 255, 255);width:159px" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;As of December 31,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px 0px 0px 0in;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Current deferred tax assets/(liabilities):&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);width:6px" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1px solid;text-align:center;width:80px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1px solid;text-align:center;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2018&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="background-color:rgb(204, 238, 255)" valign="top"&gt;&lt;p style="MARGIN:0px 0px 0px 15px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;State taxes&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;336&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:6px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:73px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;345&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="top"&gt;&lt;p style="MARGIN:0px 0px 0px 15px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Capitalized research and development costs&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:6px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:73px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;10,327&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="background-color:rgb(204, 238, 255)" valign="top"&gt;&lt;p style="MARGIN:0px 0px 0px 15px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Other&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;112,222&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:6px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:73px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;187,377&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="top"&gt;&lt;p style="MARGIN:0px 0px 0px 15px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Net operating loss&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom:1px solid;width:9px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom:1px solid;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;6,434,544&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom:1px solid;width:6px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom:1px solid;text-align:right;width:73px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5,104,432&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="background-color:rgb(204, 238, 255)" valign="top"&gt;&lt;p style="MARGIN:0px 0px 0px 0in;text-align:justify"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;6,547,102&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:6px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:73px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;5,302,481&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="top"&gt;&lt;p style="MARGIN:0px 0px 0px 0in;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Valuation allowance&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom:1px solid;width:9px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom:1px solid;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(6,206,450&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom:1px solid;width:6px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom:1px solid;text-align:right;width:73px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(5,302,481&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="background-color:rgb(204, 238, 255)" valign="top"&gt;&lt;p style="MARGIN:0px 0px 0px 0in;text-align:justify"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Net&amp;#160;deferred tax assets&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border:1pt none;width:9px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border:1pt none;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;340,652&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border:1pt none;width:6px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border:1pt none;text-align:right;width:73px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&amp;#x2014;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom:3px;width:1%;background-color:rgb(204, 238, 255);border:1pt none" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="top"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:6px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-width:1pt;border-style:none none solid;border-top-color:initial;border-right-color:initial;border-bottom-color:black;border-left-color:initial;border-image:initial;width:9px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-width:1pt;border-style:none none solid;border-top-color:initial;border-right-color:initial;border-bottom-color:black;border-left-color:initial;border-image:initial;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;border:1pt none;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;border:1pt none;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-width:1pt;border-style:none none solid;border-top-color:initial;border-right-color:initial;border-bottom-color:black;border-left-color:initial;border-image:initial;width:6px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-width:1pt;border-style:none none solid;border-top-color:initial;border-right-color:initial;border-bottom-color:black;border-left-color:initial;border-image:initial;text-align:right;width:73px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom:3px;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="background-color:rgb(204, 238, 255)" valign="top"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Deferred tax liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border:1pt none;width:9px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border:1pt none;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;border:1pt none;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;border:1pt none;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border:1pt none;width:6px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border:1pt none;text-align:right;width:73px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom:3px;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="top"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#160; &amp;#160;&amp;#160;Note discount&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom:1pt solid black;width:9px;background-color:rgb(255, 255, 255);border-top:1pt solid black" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid black;text-align:right;width:9%;background-color:rgb(255, 255, 255);border-top:1pt solid black" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(340,652&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border:1pt none;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border:1pt none;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom:1pt solid black;width:6px;background-color:rgb(255, 255, 255);border-top:1pt solid black" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid black;text-align:right;width:73px;background-color:rgb(255, 255, 255);border-top:1pt solid black" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:3px;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="background-color:rgb(204, 238, 255)" valign="top"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Total deferred tax liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom:1pt solid black;width:9px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom:1pt solid black;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;(340,652&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border:1pt none;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;border:1pt none;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom:1pt solid black;width:6px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom:1pt solid black;text-align:right;width:73px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:3px;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="top"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Net deferred tax assets&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom:2.5pt double black;width:9px;background-color:rgb(255, 255, 255);border-top:none;border-right:none;border-left:none;border-image:initial" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2.5pt double black;text-align:right;width:9%;background-color:rgb(255, 255, 255);border-top:none;border-right:none;border-left:none;border-image:initial" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border:1pt none;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;border:1pt none;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom:2.5pt double black;width:6px;background-color:rgb(255, 255, 255);border-top:none;border-right:none;border-left:none;border-image:initial" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2.5pt double black;text-align:right;width:73px;background-color:rgb(255, 255, 255);border-top:none;border-right:none;border-left:none;border-image:initial" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:3px;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The provision for income taxes on earnings subject to income taxes differs from the statutory Federal rate at December 31, 2019 and 2018, due to the following:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="WIDTH:100%;TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN" width="100%"&gt;&lt;tbody&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom:1px solid;text-align:center;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;As of December 31,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1px solid;text-align:center;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1px solid;text-align:center;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2018&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="background-color:rgb(204, 238, 255)" valign="top"&gt;&lt;p style="MARGIN:0px 0px 0px 0in;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Expected income tax benefit at federal statutory tax rate&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;221,219&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(4,030,454&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="top"&gt;&lt;p style="MARGIN:0px 0px 0px 0in;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(434,881&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(319,816&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="background-color:rgb(204, 238, 255)" valign="top"&gt;&lt;p style="MARGIN:0px 0px 0px 0in;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Change in fair value of warrants&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(1,874,873&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,869,116&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="top"&gt;&lt;p style="MARGIN:0px 0px 0px 0in;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Change in valuation allowance&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,469,187&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,286,995&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="background-color:rgb(204, 238, 255)" valign="top"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Uncertain tax positions&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;436,145&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="top"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Change in compound derivative&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(101,671&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,224&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="background-color:rgb(204, 238, 255)" valign="top"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Loss on extinguishment of debt&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;117,198&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;123,982&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="top"&gt;&lt;p style="MARGIN:0px 0px 0px 0in;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Stock compensation&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;121,289&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;67,966&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="background-color:rgb(204, 238, 255)" valign="top"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Rate adjustment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;49,338&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="top"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Other permanent difference&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(1,351&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255);border-bottom:1pt solid black" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255);border-bottom:1pt solid black" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;629&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="background-color:rgb(204, 238, 255)" valign="top"&gt;&lt;p style="MARGIN:0px 0px 0px 0in;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Provision for Income Taxes&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid black;border-right:none;border-bottom:2.5pt double black;border-left:none;width:1%;background-color:rgb(204, 238, 255);border-image:initial" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid black;border-right:none;border-bottom:2.5pt double black;border-left:none;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-image:initial" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;1,600&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom:3px;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;1,642&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom:3px;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company records a valuation allowance against deferred tax assets to the extent that it is more likely than not that some portion, or all of, the deferred tax assets will not be realized. Due to the substantial doubt related to the Company&amp;#x2019;s ability to utilize its deferred tax assets, a valuation allowance for the full amount of the deferred tax assets has been established at December 31, 2019. As a result of this valuation allowance, there are no income tax benefits reflected in the accompanying statement of operations to offset pre-tax losses.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Tax Cuts and Jobs Act of 2017 subjects a U.S. shareholder to tax on global intangible low-taxed income ("GILTI") earned by certain foreign subsidiaries. The FASB Staff Q&amp;amp;A, Topic 740, No. 5, Accounting for Global Intangible Low-Taxed Income, states that an entity can make an accounting policy election to recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only. The Company elects to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;A reconciliation of the beginning and ending amounts of unrecognized tax positions are as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&amp;#160;&lt;/p&gt;&lt;div&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN" width="100%"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;As of December 31,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2018&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Unrecognized tax positions, beginning of the year&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Gross increase - current period tax positions&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:black 1px solid;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:black 1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;552,082&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:black 1px solid;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:black 1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Unrecognized tax positions, end of year&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;552,082&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;If recognized, none of the unrecognized tax positions would impact the Company&amp;#x2019;s income tax benefit or effective tax rate as long as the Company&amp;#x2019;s net deferred tax assets remain subject to a full valuation allowance. The Company does not expect any significant increases or decreases to the Company&amp;#x2019;s unrecognized tax positions within the next twelve months.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="C_20190101to20191231" id="Fxbrl_20200312180511770">&lt;div&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN" width="100%"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Year Ended &lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2018&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;US&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,120,521&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(19,192,594&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Foreign&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(67,096&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;Pre-tax income (loss) from operations&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid black;border-bottom:2.5pt double black;border-right:none;border-left:none;border-image:initial;width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid black;border-bottom:2.5pt double black;border-right:none;border-left:none;border-image:initial;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;1,053,425&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid black;border-bottom:2.5pt double black;border-right:none;border-left:none;border-image:initial;width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid black;border-bottom:2.5pt double black;border-right:none;border-left:none;border-image:initial;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;(19,192,594&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;width:1%" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
  <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20200312142718097" unitRef="USD">1120521</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
  <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="Fxbrl_20200312142814097" unitRef="USD">-19192594</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
  <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20200312142741160" unitRef="USD">-67096</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
  <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="Fxbrl_20200312143007351" unitRef="USD">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
  <us-gaap:OperatingLossCarryforwards contextRef="C_20191231" decimals="0" id="Fxbrl_20200312145242432" unitRef="USD">13213037</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwards contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00_usgaapIncomeTaxAuthorityAxis_usgaapForeignCountryMember" decimals="0" id="Fxbrl_20200318184133382" unitRef="USD">11275349</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwards contextRef="C_20191231_usgaapIncomeTaxAuthorityAxis_usgaapForeignCountryMember" decimals="0" id="Fxbrl_20200312145421108" unitRef="USD">67096</us-gaap:OperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="C_20191231" decimals="0" id="Fxbrl_20200312145334442" unitRef="USD">24481423</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
  <us-gaap:TaxCreditCarryforwardLimitationsOnUse contextRef="C_20190101to20191231" id="Fxbrl_20200312183033777">In general, an &amp;#x201c;ownership change&amp;#x201d; as defined by Section 382 of the Code&amp;#160;results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percentage points of the outstanding stock of a company by certain stockholders.</us-gaap:TaxCreditCarryforwardLimitationsOnUse>
  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="C_20190101to20191231" id="F8a1b9ef0-2de8-11ea-add8-41ed81237e2f">&lt;table border="0" cellpadding="0" cellspacing="0" style="WIDTH:100%;TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN" width="100%"&gt;&lt;tbody&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);width:6px" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom:1px solid;text-align:center;background-color:rgb(255, 255, 255);width:159px" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;As of December 31,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px 0px 0px 0in;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Current deferred tax assets/(liabilities):&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);width:6px" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1px solid;text-align:center;width:80px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1px solid;text-align:center;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2018&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="background-color:rgb(204, 238, 255)" valign="top"&gt;&lt;p style="MARGIN:0px 0px 0px 15px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;State taxes&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;336&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:6px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:73px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;345&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="top"&gt;&lt;p style="MARGIN:0px 0px 0px 15px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Capitalized research and development costs&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:6px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:73px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;10,327&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="background-color:rgb(204, 238, 255)" valign="top"&gt;&lt;p style="MARGIN:0px 0px 0px 15px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Other&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;112,222&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:6px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:73px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;187,377&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="top"&gt;&lt;p style="MARGIN:0px 0px 0px 15px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Net operating loss&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom:1px solid;width:9px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom:1px solid;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;6,434,544&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom:1px solid;width:6px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom:1px solid;text-align:right;width:73px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5,104,432&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="background-color:rgb(204, 238, 255)" valign="top"&gt;&lt;p style="MARGIN:0px 0px 0px 0in;text-align:justify"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;6,547,102&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:6px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:73px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;5,302,481&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="top"&gt;&lt;p style="MARGIN:0px 0px 0px 0in;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Valuation allowance&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom:1px solid;width:9px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom:1px solid;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(6,206,450&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom:1px solid;width:6px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-bottom:1px solid;text-align:right;width:73px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(5,302,481&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="background-color:rgb(204, 238, 255)" valign="top"&gt;&lt;p style="MARGIN:0px 0px 0px 0in;text-align:justify"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Net&amp;#160;deferred tax assets&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border:1pt none;width:9px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border:1pt none;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;340,652&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border:1pt none;width:6px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border:1pt none;text-align:right;width:73px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&amp;#x2014;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom:3px;width:1%;background-color:rgb(204, 238, 255);border:1pt none" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="top"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:6px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-width:1pt;border-style:none none solid;border-top-color:initial;border-right-color:initial;border-bottom-color:black;border-left-color:initial;border-image:initial;width:9px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-width:1pt;border-style:none none solid;border-top-color:initial;border-right-color:initial;border-bottom-color:black;border-left-color:initial;border-image:initial;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;border:1pt none;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;border:1pt none;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-width:1pt;border-style:none none solid;border-top-color:initial;border-right-color:initial;border-bottom-color:black;border-left-color:initial;border-image:initial;width:6px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-width:1pt;border-style:none none solid;border-top-color:initial;border-right-color:initial;border-bottom-color:black;border-left-color:initial;border-image:initial;text-align:right;width:73px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom:3px;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="background-color:rgb(204, 238, 255)" valign="top"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Deferred tax liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border:1pt none;width:9px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border:1pt none;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;border:1pt none;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;border:1pt none;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border:1pt none;width:6px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border:1pt none;text-align:right;width:73px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom:3px;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="top"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#160; &amp;#160;&amp;#160;Note discount&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom:1pt solid black;width:9px;background-color:rgb(255, 255, 255);border-top:1pt solid black" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid black;text-align:right;width:9%;background-color:rgb(255, 255, 255);border-top:1pt solid black" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(340,652&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border:1pt none;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border:1pt none;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom:1pt solid black;width:6px;background-color:rgb(255, 255, 255);border-top:1pt solid black" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid black;text-align:right;width:73px;background-color:rgb(255, 255, 255);border-top:1pt solid black" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:3px;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="background-color:rgb(204, 238, 255)" valign="top"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Total deferred tax liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom:1pt solid black;width:9px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom:1pt solid black;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;(340,652&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border:1pt none;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;border:1pt none;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom:1pt solid black;width:6px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom:1pt solid black;text-align:right;width:73px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:3px;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="top"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Net deferred tax assets&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom:2.5pt double black;width:9px;background-color:rgb(255, 255, 255);border-top:none;border-right:none;border-left:none;border-image:initial" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2.5pt double black;text-align:right;width:9%;background-color:rgb(255, 255, 255);border-top:none;border-right:none;border-left:none;border-image:initial" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border:1pt none;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;border:1pt none;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom:2.5pt double black;width:6px;background-color:rgb(255, 255, 255);border-top:none;border-right:none;border-left:none;border-image:initial" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2.5pt double black;text-align:right;width:73px;background-color:rgb(255, 255, 255);border-top:none;border-right:none;border-left:none;border-image:initial" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:3px;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
  <us-gaap:DeferredTaxAssetsStateTaxes contextRef="C_20191231" decimals="0" id="F21134" unitRef="USD">336</us-gaap:DeferredTaxAssetsStateTaxes>
  <us-gaap:DeferredTaxAssetsStateTaxes contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="F21140" unitRef="USD">345</us-gaap:DeferredTaxAssetsStateTaxes>
  <embi:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts contextRef="C_20191231" decimals="0" id="F21150" unitRef="USD">0</embi:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts>
  <embi:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="F21157" unitRef="USD">10327</embi:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts>
  <us-gaap:DeferredTaxAssetsOther contextRef="C_20191231" decimals="0" id="F21167" unitRef="USD">112222</us-gaap:DeferredTaxAssetsOther>
  <us-gaap:DeferredTaxAssetsOther contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="F21174" unitRef="USD">187377</us-gaap:DeferredTaxAssetsOther>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="C_20191231" decimals="0" id="F21184" unitRef="USD">6434544</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="F21191" unitRef="USD">5104432</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsGross contextRef="C_20191231" decimals="0" id="F21201" unitRef="USD">6547102</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsGross contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="F21208" unitRef="USD">5302481</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="C_20191231" decimals="0" id="F21218_5302481" unitRef="USD">6206450</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="F21224_4015487" unitRef="USD">5302481</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsNet contextRef="C_20191231" decimals="0" id="Fxbrl_20200312151224507" unitRef="USD">340652</us-gaap:DeferredTaxAssetsNet>
  <us-gaap:DeferredTaxAssetsNet contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="Fxbrl_20200312151258630" unitRef="USD">0</us-gaap:DeferredTaxAssetsNet>
  <embi:DeferredTaxLiabilitiesNoteDiscount contextRef="C_20191231" decimals="0" id="Fxbrl_20200312161635596" unitRef="USD">340652</embi:DeferredTaxLiabilitiesNoteDiscount>
  <embi:DeferredTaxLiabilitiesNoteDiscount contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="Fxbrl_20200312162645121" unitRef="USD">0</embi:DeferredTaxLiabilitiesNoteDiscount>
  <us-gaap:DeferredTaxLiabilities contextRef="C_20191231" decimals="0" id="Fxbrl_20200312161638082" unitRef="USD">340652</us-gaap:DeferredTaxLiabilities>
  <us-gaap:DeferredTaxLiabilities contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="Fxbrl_20200312162823168" unitRef="USD">0</us-gaap:DeferredTaxLiabilities>
  <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="C_20191231" decimals="0" id="Fxbrl_20200312161643783" unitRef="USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
  <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="Fxbrl_20200312162846249" unitRef="USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
  <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="C_20190101to20191231" id="F8a2032d0-2de8-11ea-add8-41ed81237e2f">&lt;table border="0" cellpadding="0" cellspacing="0" style="WIDTH:100%;TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN" width="100%"&gt;&lt;tbody&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom:1px solid;text-align:center;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;As of December 31,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1px solid;text-align:center;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1px solid;text-align:center;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2018&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="background-color:rgb(204, 238, 255)" valign="top"&gt;&lt;p style="MARGIN:0px 0px 0px 0in;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Expected income tax benefit at federal statutory tax rate&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;221,219&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(4,030,454&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="top"&gt;&lt;p style="MARGIN:0px 0px 0px 0in;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(434,881&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(319,816&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="background-color:rgb(204, 238, 255)" valign="top"&gt;&lt;p style="MARGIN:0px 0px 0px 0in;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Change in fair value of warrants&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(1,874,873&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,869,116&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="top"&gt;&lt;p style="MARGIN:0px 0px 0px 0in;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Change in valuation allowance&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,469,187&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,286,995&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="background-color:rgb(204, 238, 255)" valign="top"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Uncertain tax positions&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;436,145&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="top"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Change in compound derivative&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(101,671&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,224&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="background-color:rgb(204, 238, 255)" valign="top"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Loss on extinguishment of debt&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;117,198&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;123,982&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="top"&gt;&lt;p style="MARGIN:0px 0px 0px 0in;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Stock compensation&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;121,289&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;67,966&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="background-color:rgb(204, 238, 255)" valign="top"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Rate adjustment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;49,338&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="background-color:rgb(255, 255, 255)" valign="top"&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Other permanent difference&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(1,351&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255);border-bottom:1pt solid black" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%;background-color:rgb(255, 255, 255);border-bottom:1pt solid black" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;629&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="background-color:rgb(204, 238, 255)" valign="top"&gt;&lt;p style="MARGIN:0px 0px 0px 0in;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;Provision for Income Taxes&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid black;border-right:none;border-bottom:2.5pt double black;border-left:none;width:1%;background-color:rgb(204, 238, 255);border-image:initial" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid black;border-right:none;border-bottom:2.5pt double black;border-left:none;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-image:initial" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;1,600&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom:3px;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;1,642&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom:3px;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
  <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="C_20190101to20191231" decimals="0" id="F21284_4030454" unitRef="USD">221219</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
  <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="F21289_1082444" unitRef="USD">-4030454</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
  <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="C_20190101to20191231" decimals="0" id="F21298_319816" unitRef="USD">-434881</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="F21304_208619" unitRef="USD">-319816</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
  <embi:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrant contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20200312174227248" unitRef="USD">-1874873</embi:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrant>
  <embi:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrant contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="F21320_268519" unitRef="USD">2869116</embi:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrant>
  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="C_20190101to20191231" decimals="0" id="F21329" unitRef="USD">1469187</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="F21336_344321" unitRef="USD">1286995</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <embi:IncomeTaxReconciliationUncertainTaxPositions contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20200312170814104" unitRef="USD">436145</embi:IncomeTaxReconciliationUncertainTaxPositions>
  <embi:IncomeTaxReconciliationUncertainTaxPositions contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="Fxbrl_20200312171349214" unitRef="USD">0</embi:IncomeTaxReconciliationUncertainTaxPositions>
  <embi:IncomeTaxReconciliationChangeInCompoundDerivative contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20200312170828004" unitRef="USD">-101671</embi:IncomeTaxReconciliationChangeInCompoundDerivative>
  <embi:IncomeTaxReconciliationChangeInCompoundDerivative contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="Fxbrl_20200312171547477" unitRef="USD">3224</embi:IncomeTaxReconciliationChangeInCompoundDerivative>
  <us-gaap:ExtinguishmentOfDebtGainLossIncomeTax contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20200312170918935" unitRef="USD">117198</us-gaap:ExtinguishmentOfDebtGainLossIncomeTax>
  <us-gaap:ExtinguishmentOfDebtGainLossIncomeTax contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="Fxbrl_20200312171600177" unitRef="USD">123982</us-gaap:ExtinguishmentOfDebtGainLossIncomeTax>
  <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="C_20190101to20191231" decimals="0" id="F21345" unitRef="USD">121289</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
  <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="F21352" unitRef="USD">67966</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
  <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20200312170954380" unitRef="USD">49338</us-gaap:IncomeTaxReconciliationOtherAdjustments>
  <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="Fxbrl_20200312171616781" unitRef="USD">0</us-gaap:IncomeTaxReconciliationOtherAdjustments>
  <us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20200312174353593" unitRef="USD">-1351</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
  <us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="F21369" unitRef="USD">629</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
  <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="C_20190101to20191231" id="Fxbrl_20200312180558013">&lt;div&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN" width="100%"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;As of December 31,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2018&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Unrecognized tax positions, beginning of the year&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Gross increase - current period tax positions&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:black 1px solid;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:black 1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;552,082&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:black 1px solid;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:black 1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Unrecognized tax positions, end of year&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;552,082&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;width:1%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%" valign="bottom"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
  <us-gaap:UnrecognizedTaxBenefits contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="Fxbrl_20200312173048837" unitRef="USD">0</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:UnrecognizedTaxBenefits contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" decimals="0" id="Fxbrl_20200312173142466" unitRef="USD">0</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:UnrecognizedTaxBenefits contextRef="C_20191231" decimals="0" id="Fxbrl_20200312173117546" unitRef="USD">552082</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="C_20190101to20191231" decimals="0" id="Fxbrl_20200312173104891" unitRef="USD">552082</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00" decimals="0" id="Fxbrl_20200312173216019" unitRef="USD">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
  <embi:SignificantContractsTextBlock contextRef="C_20190101to20191231" id="F89bfea61-2de8-11ea-add8-41ed81237e2f">&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;9. Significant Contracts - University of Mississippi&lt;/strong&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;em&gt;UM 5050 Pro-Drug and UM 8930 Analog Agreements&lt;/em&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;In July 2018, the Company renewed its ocular licenses for UM 5050, related to the pro-drug formulation of tetrahydrocannabinol (&amp;#x201c;THC&amp;#x201d;), and UM 8930, related to an analog formulation of cannabidiol (&amp;#x201c;CBD&amp;#x201d;). On May 24, 2019, the ocular delivery licenses were replaced by &amp;#x201c;all fields of use&amp;#x201d; licenses for both UM 5050 and UM 8930 (collectively, the &amp;#x201c;License Agreements&amp;#x201d;). Pursuant to the License Agreements, UM granted the Company an exclusive, perpetual license, including, with the prior written consent of UM, the right to sublicense, to intellectual property related to UM 5050 and UM 8930 for all fields of use.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;The License Agreements contain certain milestone payments, royalty and sublicensing fees payable by the Company, as defined therein. Each License Agreement provides for an annual maintenance fee of $75,000 payable on the anniversary of the effective date. The upfront payment for UM 5050 is $100,000 and the upfront payment for UM 8930 is $200,000. Additionally, there is also a $200,000 fee due within 30 days upon receipt of the first United States Patent and Trademark Office Notice of Allowance for UM 8930. The milestone payments payable for each license are as follows:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&amp;#160;&lt;/p&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="border:0px" width="100%"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:3%" valign="top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;i)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:76%" valign="top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$100,000 paid within 30 days following the submission of the first Investigational New Drug Application to the Food and Drug Administration or an equivalent application to a regulatory agency anywhere in the world, for a product;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:3%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:76%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:3%" valign="top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;ii)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:76%" valign="top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$200,000 paid within 30 days following the first submission of an NDA, or an equivalent application to a regulatory agency anywhere in the world, for each product that is administered in a different route of administration from that of the early submitted product(s); and&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:3%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:76%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:3%" valign="top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;iii)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:76%" valign="top"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$400,000 paid within 30 days following the approval of an NDA, or an equivalent application to a regulatory agency anywhere in the world, for each product that is administered in a different route of administration from that of the early approved product(s).&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;The royalty percentage due on net sales under each License Agreement is in the mid-single digits. The Company must also pay to UM a portion of all licensing fees received from any sublicensees, subject to a minimum royalty on net sales, and the Company is required to reimburse patent costs incurred by UM related to the licensed products. The royalty obligations apply by country and by licensed product, and end upon the later of the date that no valid claim of a licensed patent covers a licensed product in a given country, or ten&amp;#160;years after the first commercial sale of such licensed product in such country.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Each License Agreement continues, unless terminated, until the later of the expiration of the last to expire of the patents or patent applications within the licensed technology or the expiration of the Company&amp;#x2019;s payment obligations under such License Agreement. UM may terminate each License Agreement, by giving written notice of termination, upon the Company&amp;#x2019;s material breach of such License Agreement, including failure to make payments or satisfy covenants, representations or warranties without cure, noncompliance, a bankruptcy event, the Company&amp;#x2019;s dissolution or cessation of operations, the Company&amp;#x2019;s failure to make reasonable efforts to commercialize at least one product or failure to keep at least one product on the market after the first commercial sale for a continuous period of one year, other than for reasons outside the Company&amp;#x2019;s control, or the Company&amp;#x2019;s failure to meet certain pre-established development milestones. The Company may terminate each License Agreement upon 60 days&amp;#x2019; written notice to UM.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br/&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;As of December 31, 2019, none of the milestones under the license agreements have been met.&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;em&gt;UM 5070 License Agreement&lt;/em&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;In January 2017, the Company entered into a license agreement with UM pursuant to which UM granted us an exclusive, perpetual license, including the right to sublicense, to intellectual property related to a platform of cannabinoid-based molecules (&amp;#x201c;UM 5070&amp;#x201d;), to research, develop and commercialize products for the treatment of infectious diseases. The license agreement culminates roughly one year of screening and target molecule identification studies especially focused on therapy-resistant infectious organisms like Methicillin-resistant Staphylococcus aureus (&amp;#x201c;MRSA&amp;#x201d;).&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;The Company paid UM an upfront license fee under the license agreement. Under the license agreement, the Company is also responsible for annual maintenance fees that will be credited against royalties in the current fiscal year, contingent milestone payments upon achievement of development and regulatory milestones, and royalties on net sales of licensed products sold for commercial use. The aggregate milestone payments due under the license agreement if all the milestones are achieved is $700,000 and the royalty percentage due on net sales is in the mid-single digits. The Company must also pay to UM a percentage of all licensing fees we receive from any sublicensees, subject to a minimum royalty on net sales by such sublicensees. The Company&amp;#x2019;s royalty obligations apply on a country by country and licensed product by licensed product basis, and end upon the later of the date that no valid claim of a licensed patent covers a licensed product in a given country, or ten years after first commercial sale of such licensed product in such country.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;The license agreement continues, unless terminated, until the later of the expiration of the last to expire of the patents or patent applications within the licensed technology or expiration of the Company&amp;#x2019;s payment obligations under the license. UM may terminate the license agreement, effective with the giving of notice, if: (a) the Company fails to pay any material amount payable to UM under the license agreement and do not cure such failure within 60 days after UM notifies us of such failure, (b) the Company materially breaches any covenant, representation or warranty in the license agreement and do not cure such breach within 60 days after UM notifies the Company of such breach, (c) the Company fails to comply in any material respect with the terms of the license and do not cure such noncompliance within 60 days after UM notifies us of such failure, (d) the Company is subject to a bankruptcy event, (e) the Company dissolves or ceases operations or (f) if after the first commercial sale of a product during the term of the license agreement, the Company materially fails to make reasonable efforts to commercialize at least one product or fail to keep at least one product on the market after the first commercial sale for a continuous period of one year, other than for reasons outside of the Company&amp;#x2019;s control. The Company may terminate the license agreement upon 60 days&amp;#x2019; written notice to UM.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br/&gt;&lt;br/&gt;As of December 31, 2019, none of the milestones under this license agreement have been met.&lt;/p&gt;</embi:SignificantContractsTextBlock>
  <embi:AnnualMaintenanceFeePayable contextRef="C_20191231" decimals="0" id="Fxbrl_20200312142403636" unitRef="USD">75000</embi:AnnualMaintenanceFeePayable>
  <embi:PaymentForUpfrontFees contextRef="C_20180701to20180731_usgaapTypeOfArrangementAxis_embiOptionAgreementMember_deiLegalEntityAxis_embiUniversityOfMississippiMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapIntellectualPropertyMember" decimals="0" id="Fxbrl_20200312142536312" unitRef="USD">100000</embi:PaymentForUpfrontFees>
  <embi:PaymentForUpfrontFees contextRef="C_20180701to20180731_usgaapTypeOfArrangementAxis_embiLicenseAgreementMember_deiLegalEntityAxis_embiUniversityOfMississippiMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapIntellectualPropertyMember" decimals="0" id="Fxbrl_20200312142929311" unitRef="USD">200000</embi:PaymentForUpfrontFees>
  <embi:AnnualFeesForLicenseAgreement contextRef="C_20180701to20180731_usgaapTypeOfArrangementAxis_embiLicenseAgreementMember_deiLegalEntityAxis_embiUniversityOfMississippiMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapIntellectualPropertyMember" decimals="0" id="Fxbrl_20200312143017748" unitRef="USD">200000</embi:AnnualFeesForLicenseAgreement>
  <embi:AggregateMilestonePaymentsIfMilestonesAchieved contextRef="C_20180701to20180731_usgaapTypeOfArrangementAxis_embiUm5050ProdrugAndUm8930AnalogAgreementsMember_deiLegalEntityAxis_embiUniversityOfMississippiMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapIntellectualPropertyMember_embiMilestonePaymentsPayableAxis_embiMilestone1Member" decimals="0" id="Fxbrl_20200312141947731" unitRef="USD">100000</embi:AggregateMilestonePaymentsIfMilestonesAchieved>
  <embi:AggregateMilestonePaymentsIfMilestonesAchieved contextRef="C_20180701to20180731_usgaapTypeOfArrangementAxis_embiUm5050ProdrugAndUm8930AnalogAgreementsMember_deiLegalEntityAxis_embiUniversityOfMississippiMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapIntellectualPropertyMember_embiMilestonePaymentsPayableAxis_embiMilestone2Member" decimals="0" id="Fxbrl_20200312141958505" unitRef="USD">200000</embi:AggregateMilestonePaymentsIfMilestonesAchieved>
  <embi:AggregateMilestonePaymentsIfMilestonesAchieved contextRef="C_20180701to20180731_usgaapTypeOfArrangementAxis_embiUm5050ProdrugAndUm8930AnalogAgreementsMember_deiLegalEntityAxis_embiUniversityOfMississippiMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapIntellectualPropertyMember_embiMilestonePaymentsPayableAxis_embiMilestone3Member" decimals="0" id="Fxbrl_20200312142002979" unitRef="USD">400000</embi:AggregateMilestonePaymentsIfMilestonesAchieved>
  <embi:AggregateMilestonePaymentsIfMilestonesAchieved contextRef="C_20170101to20170110_usgaapTypeOfArrangementAxis_embiUm5070LicenseAgreementMember_deiLegalEntityAxis_embiUniversityOfMississippiMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapIntellectualPropertyMember" decimals="0" id="Fxbrl_20200312140730836" unitRef="USD">700000</embi:AggregateMilestonePaymentsIfMilestonesAchieved>
  <embi:TermOfAgreement contextRef="C_20180701to20180731_usgaapTypeOfArrangementAxis_embiUm5050ProdrugAndUm8930AnalogAgreementsMember_deiLegalEntityAxis_embiUniversityOfMississippiMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapIntellectualPropertyMember_embiMilestonePaymentsPayableAxis_embiMilestone1Member" id="Fxbrl_20200312142017438">P30D</embi:TermOfAgreement>
  <embi:TermOfAgreement contextRef="C_20180701to20180731_usgaapTypeOfArrangementAxis_embiUm5050ProdrugAndUm8930AnalogAgreementsMember_deiLegalEntityAxis_embiUniversityOfMississippiMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapIntellectualPropertyMember_embiMilestonePaymentsPayableAxis_embiMilestone2Member" id="Fxbrl_20200312142049659">P30D</embi:TermOfAgreement>
  <embi:TermOfAgreement contextRef="C_20180701to20180731_usgaapTypeOfArrangementAxis_embiUm5050ProdrugAndUm8930AnalogAgreementsMember_deiLegalEntityAxis_embiUniversityOfMississippiMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapIntellectualPropertyMember_embiMilestonePaymentsPayableAxis_embiMilestone3Member" id="Fxbrl_20200312142052915">P30D</embi:TermOfAgreement>
  <embi:TermOfAgreement contextRef="C_20170101to20170110_usgaapTypeOfArrangementAxis_embiUm5070LicenseAgreementMember_deiLegalEntityAxis_embiUniversityOfMississippiMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapIntellectualPropertyMember" id="Fxbrl_20200312140949659">P1Y</embi:TermOfAgreement>
  <embi:NoticePeriodForTermination contextRef="C_20170101to20170110_usgaapTypeOfArrangementAxis_embiUm5070LicenseAgreementMember_deiLegalEntityAxis_embiUniversityOfMississippiMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapIntellectualPropertyMember" id="Fxbrl_20200312141129527">P60D</embi:NoticePeriodForTermination>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="C_20190101to20191231" id="Fxbrl_20200312144119752">&lt;div&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;10. Commitments and Contingencies&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;em&gt;Legal Matters&lt;/em&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;em&gt;General Litigation and Disputes&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;From time to time, in the normal course of our operations, we may be a party to litigation and other dispute matters and claims. Litigation can be expensive and disruptive to normal business operations. Moreover, the results of complex legal proceedings are difficult to predict. An unfavorable outcome to any legal matter, if material, could have a materially adverse effect on our operations or our financial position, liquidity or results of operations. As of December 31, 2019, there were no pending or threatened lawsuits or claims that could reasonably be expected to have a material effect on the Company&amp;#x2019;s financial position or results of operations.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;em&gt;Government Proceedings&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;Like other companies in the pharmaceutical industry, we are subject to extensive regulation by national, state and local government agencies in the United States. As a result, interaction with government agencies occurs in the normal course of our operations. It is possible that criminal charges and substantial fines and/or civil penalties or damages could result from any government investigation or proceeding. As of December 31, 2019, the Company had no proceedings or inquiries.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;&lt;strong style="font-size:10pt"&gt;&lt;em&gt;Change in Control Severance Plan&lt;/em&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;In February 2015, we adopted a change in control severance plan, in which our named executive officers participate, that provides for the payment of severance benefits if the executive&amp;#x2019;s service is terminated within twelve months following a change in control, either due to a termination without cause or upon resignation for a good reason (as each term is defined in the plan).&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;In either such event, and provided the executive timely executes and does not revoke a general release of claims against the Company, he or she will be entitled to receive: (i) a lump sum cash payment equal to at least six months of the executive&amp;#x2019;s monthly compensation, plus an additional month for each full year of service over six years, (ii) Company-paid premiums for continued health insurance for a period equal to the length of the cash severance period or, if earlier, when executive becomes covered under a subsequent employer&amp;#x2019;s healthcare plan, and (iii) full vesting of all then-outstanding unvested stock options and restricted stock awards.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="C_20190101to20191231" id="F89c01171-2de8-11ea-add8-41ed81237e2f">&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;11. &lt;/strong&gt;&lt;strong&gt;Related Party Matters&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;K2C, Inc.&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;In June 2014, the Company&amp;#x2019;s U.S. subsidiary entered into an independent contractor agreement with K2C, Inc. (&amp;#x201c;K2C&amp;#x201d;), which is wholly owned by the Company&amp;#x2019;s former Executive Chairman and Co-Founder, Mr. Cosmas N. Lykos, pursuant to which the Company paid K2C a monthly fee for services performed by Mr. Lykos for the Company. The agreement expired on June 1, 2017, and was automatically renewed for one year pursuant to the terms of the agreement. The monthly fee under the agreement was $10,000 and increased to $20,000 effective April 1, 2017.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;In February 2018, the Company entered into a separation and release agreement with K2C, which provided for a lump sum payment of $180,000 and the immediate vesting of 900,000 shares of restricted common stock granted on January 18, 2018, 325,000 shares of restricted common stock granted on October 20, 2015, and 125,000 options granted on November 21, 2014, in exchange for a release of claims and certain other agreements. During the year ended December 31, 2018, the Company recognized additional stock-based compensation expense of $112,270 for these restricted stock and option awards.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;For the year ended December 31, 2019, no expense was incurred under this agreement. For the year ended December 31, 2018, total expense incurred under this agreement was $220,000 (including the previously discussed lump sum payment). Under the separation agreement, Mr. Lykos was allowed to participate in the Company&amp;#x2019;s health, death and disability insurance plans for six months subsequent to K2C&amp;#x2019;s separation.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Emerald Health Sciences&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;On February 1, 2018, the Company entered into an Independent Contractor Agreement with Emerald Health Sciences, pursuant to which Emerald Health Sciences agreed to provide such services as are mutually agreed between the Company and Emerald Health Sciences, including reimbursement for reasonable expenses incurred in the performance of the Independent Contractor Agreement. These services included, but were not limited to, corporate advisory services and technical expertise in the areas of business development, marketing, investor relations, information technology and product development. The Independent Contractor Agreement had an initial term of 10 years and specified compensation which was agreed upon between the Company&amp;#x2019;s Chief Executive Officer and Emerald Health Sciences&amp;#x2019; Chairman, CEO and President on a month-to-month basis. The fee due under this agreement was payable on a monthly basis. Under this agreement, for the years ended December 31, 2019 and 2018, the Company incurred expenses of $542,000 and $550,000, respectively. At December 31, 2019, the Company has accrued $10,000 in expense under this agreement. Effective December 31, 2019, the Independent Contractor Agreement has been terminated.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;On February 6, 2018, the Company entered into a Consulting Agreement with Dr. Avtar Dhillon, the Chairman, Chief Executive Officer and President of Emerald Health Sciences. The services under the Consulting Agreement included corporate finance and strategic business advisory services. The Consulting Agreement had an initial term of one year and was renewable automatically unless terminated by either party.&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt; &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;The agreement specified an annual fee of&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt; $60,000,&amp;#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;payable semi-monthly in installments, and included reimbursement for reasonable expenses incurred in the performance of the services. Under the agreement, Dr. Avtar Dhillon was also entitled to a discretionary annual bonus, payable&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt; 120 days &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;after each fiscal year-end, to be determined by the Board upon its annual review. Under this agreement, for the year ended December 31, 2018, the Company incurred&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt; $45,000. &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;The Consulting Agreement was canceled on October 5, 2018 in connection with the Company&amp;#x2019;s entry into the Credit Agreement with Emerald Health Sciences (See Note 4)&amp;#160;and Dr. Avtar Dhillon&amp;#x2019;s appointment as the Executive Chairman of the Company&amp;#x2019;s Board.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On December 17, 2019, Dr. Avtar Dhillon resigned as the Chairman of the Board and the position of Chairman of the Finance and Business Development Committee of the Board. Concurrently, the Company entered into a Board Observer Agreement with Emerald Health Sciences to allow Dr. Dhillon to continue as a representative of Emerald Health Sciences as a non-voting observer in future meetings of the Board.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On December 19, 2019, the Company entered into an Independent Contractor Services Agreement with Dr. Avtar Dhillon, pursuant to which Dr. Dhillon will provide ongoing corporate finance and strategic business advisory services to the Company. In exchange for his services, Dr. Dhillon will receive a monthly fee of $10,000, with (i) $5,000 paid each month and (ii) $5,000 accruing from the effective date and payable upon the Company&amp;#x2019;s completion of a material financing. The Board will review the monthly rate paid to Dr. Dhillon within 90 days of the end of each fiscal year. The Independent Contractor Services Agreement has an initial term of one year and will renew automatically thereafter unless terminated earlier by either party. The Independent Contractor Services Agreement may be terminated by either party for cause upon written notice to the other party if the other party defaults in the performance of the agreement in any material respect or materially breaches the terms of the agreement, or without cause upon 30 days&amp;#x2019; prior written notice to the other party.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <embi:MonthlyFee contextRef="Context_Custom_01_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_LegalEntityAxis_K2CIncMember_TypeOfArrangementAxis_IndependentContractorAgreementMember" decimals="0" id="F21566_10000" unitRef="USD">10000</embi:MonthlyFee>
  <embi:MonthlyFee contextRef="Context_Custom_25_Mar_2017T00_00_00_TO_01_Apr_2017T00_00_00_LegalEntityAxis_K2CIncMember_TypeOfArrangementAxis_IndependentContractorAgreementMember" decimals="0" id="F21566_20000" unitRef="USD">20000</embi:MonthlyFee>
  <embi:MonthlyFee contextRef="C_20191201to20191219_usgaapTypeOfArrangementAxis_embiIndependentContractorAgreementMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_embiAvtarDhillonMember" decimals="0" id="Fxbrl_20200312154042798" unitRef="USD">10000</embi:MonthlyFee>
  <embi:LumpSumPaymentInAgreement contextRef="Context_Custom_01_Feb_2018T00_00_00_TO_28_Feb_2018T00_00_00_TypeOfArrangementAxis_SeparationAndReleaseAgreementMember_LegalEntityAxis_K2CIncMember" decimals="0" id="F21568_180000" unitRef="USD">180000</embi:LumpSumPaymentInAgreement>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_usgaapTypeOfArrangementAxis_embiSeparationAndReleaseAgreementMember_deiLegalEntityAxis_embiK2CIncMember" decimals="0" id="F21568_112270" unitRef="USD">112270</us-gaap:AllocatedShareBasedCompensationExpense>
  <embi:TotalExpenseIncurredUnderAgreement contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_LegalEntityAxis_K2CIncMember_TypeOfArrangementAxis_IndependentContractorAgreementMember" decimals="0" id="F21570_220000" unitRef="USD">220000</embi:TotalExpenseIncurredUnderAgreement>
  <embi:TotalExpenseIncurredUnderAgreement contextRef="C_20190101to20191231_usgaapTypeOfArrangementAxis_embiIndependentContractorAgreementMember_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember" decimals="0" id="Fxbrl_20200312145356993" unitRef="USD">542000</embi:TotalExpenseIncurredUnderAgreement>
  <embi:TotalExpenseIncurredUnderAgreement contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember_usgaapTypeOfArrangementAxis_embiIndependentContractorAgreementMember" decimals="0" id="Fxbrl_20200312145401038" unitRef="USD">550000</embi:TotalExpenseIncurredUnderAgreement>
  <embi:TotalExpenseIncurredUnderAgreement contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember_usgaapTypeOfArrangementAxis_embiConsultingAgreementMember" decimals="0" id="F21578_45000" unitRef="USD">45000</embi:TotalExpenseIncurredUnderAgreement>
  <embi:InitialTermOfAgreement contextRef="C_20190101to20191231_usgaapTypeOfArrangementAxis_embiIndependentContractorAgreementMember_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember" id="Fxbrl_20200313142945442">P10Y</embi:InitialTermOfAgreement>
  <embi:InitialTermOfAgreement contextRef="Context_Custom_01_Feb_2018T00_00_00_TO_06_Feb_2018T00_00_00_LegalEntityAxis_EmeraldHealthSciencesIncMember_TypeOfArrangementAxis_ConsultingAgreementMember" id="Fxbrl_20200313144534236">P1Y</embi:InitialTermOfAgreement>
  <embi:AccruedExpenseUnderAgreement contextRef="C_20191231_usgaapTypeOfArrangementAxis_embiIndependentContractorAgreementMember_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember" decimals="0" id="Fxbrl_20200312151542523" unitRef="USD">10000</embi:AccruedExpenseUnderAgreement>
  <embi:AnnualFeeForAgreement contextRef="Context_Custom_01_Feb_2018T00_00_00_TO_06_Feb_2018T00_00_00_LegalEntityAxis_EmeraldHealthSciencesIncMember_TypeOfArrangementAxis_ConsultingAgreementMember" decimals="0" id="F21578_60000" unitRef="USD">60000</embi:AnnualFeeForAgreement>
  <embi:PeriodOfDiscretionaryAnnualBonusPayableToContractorAfterEachFiscalYearEnd contextRef="Context_Custom_01_Feb_2018T00_00_00_TO_06_Feb_2018T00_00_00_LegalEntityAxis_EmeraldHealthSciencesIncMember_TypeOfArrangementAxis_ConsultingAgreementMember" id="F21578_120days">P120D</embi:PeriodOfDiscretionaryAnnualBonusPayableToContractorAfterEachFiscalYearEnd>
  <embi:MonthlyFeePaidEachMonthInExchangeOfServices contextRef="C_20191201to20191219_usgaapTypeOfArrangementAxis_embiIndependentContractorAgreementMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_embiAvtarDhillonMember" decimals="0" id="Fxbrl_20200312154405489" unitRef="USD">5000</embi:MonthlyFeePaidEachMonthInExchangeOfServices>
  <embi:MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices contextRef="C_20191201to20191219_usgaapTypeOfArrangementAxis_embiIndependentContractorAgreementMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_embiAvtarDhillonMember" decimals="0" id="Fxbrl_20200312154410800" unitRef="USD">5000</embi:MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices>
  <us-gaap:SubsequentEventsTextBlock contextRef="C_20190101to20191231" id="F89c03880-2de8-11ea-add8-41ed81237e2f">&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;12. Subsequent Events&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In March 2020, the Company was notified by the United States Patent and Trademark Office, that a notice of allowance has been issued for the proprietary analog of cannabidiol, CBDVHS, under the UM 8930 License Agreement. As a result, the Company is required to pay UM a fee of $200,000 within 30 days from when the notice was received (Note 9).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Refer to Note 1 for disclosure of the salary deferral program that was put in place during March 2020.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
  <embi:PaymentOfUpfrontLicenseFee contextRef="C_20200301to20200331_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember" decimals="0" id="Fxbrl_20200318143947936" unitRef="USD">200000</embi:PaymentOfUpfrontLicenseFee>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>embi-20191231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<schema xmlns:embi="http://www.emeraldbio.life/20191231" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" targetNamespace="http://www.emeraldbio.life/20191231" elementFormDefault="qualified">
  <!-- INTEGIX by Ez-XBRL -->
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/currency/2019-01-31" schemaLocation="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/exch/2019-01-31" schemaLocation="https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd"/>
  <import namespace="http://fasb.org/us-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd"/>
  <import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd"/>
  <import namespace="http://fasb.org/srt-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd"/>
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.emeraldbio.life/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>0001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
        <link:definition>0002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/Consolidatedbalancesheetsparentheticals" id="Consolidatedbalancesheetsparentheticals">
        <link:definition>0003 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" id="CONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>0004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>0005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSParentheticals" id="CONSOLIDATEDSTATEMENTSOFCASHFLOWSParentheticals">
        <link:definition>0006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/ConsolidatedStatementsOfStockholdersEquityDeficit" id="ConsolidatedStatementsOfStockholdersEquityDeficit">
        <link:definition>0007 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/ConsolidatedStatementsOfStockholdersEquityDeficitParentheticals" id="ConsolidatedStatementsOfStockholdersEquityDeficitParentheticals">
        <link:definition>0008 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/NatureOfOperationsAndBusinessActivities" id="NatureOfOperationsAndBusinessActivities">
        <link:definition>0009 - Disclosure - Nature of Operations and Business Activities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
        <link:definition>0010 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilities" id="WarrantsAndDerivativeLiabilities">
        <link:definition>0011 - Disclosure - Warrants and Derivative Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/ConvertibleDebtRelatedParty" id="ConvertibleDebtRelatedParty">
        <link:definition>0012 - Disclosure - Convertible Debt - Related Party</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/StockholdersEquityDeficitAndCapitalization" id="StockholdersEquityDeficitAndCapitalization">
        <link:definition>0013 - Disclosure - Stockholders' Equity (Deficit) and Capitalization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/StockBasedCompensation" id="StockBasedCompensation">
        <link:definition>0014 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/NetIncomeLossPerShareOfCommonStock" id="NetIncomeLossPerShareOfCommonStock">
        <link:definition>0015 - Disclosure - Net Income (Loss) Per Share of Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/IncomeTaxes" id="IncomeTaxes">
        <link:definition>0016 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/SignificantContractsUniversityOfMississippi" id="SignificantContractsUniversityOfMississippi">
        <link:definition>0017 - Disclosure - Significant Contracts - University of Mississippi</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/COMMITMENTSANDCONTINGENCIES" id="COMMITMENTSANDCONTINGENCIES">
        <link:definition>0018 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/RelatedPartyMatters" id="RelatedPartyMatters">
        <link:definition>0019 - Disclosure - Related Party Matters</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/SubsequentEvents" id="SubsequentEvents">
        <link:definition>0020 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>0021 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesTables" id="WarrantsAndDerivativeLiabilitiesTables">
        <link:definition>0022 - Disclosure - Warrants and Derivative Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyTables" id="ConvertibleDebtRelatedPartyTables">
        <link:definition>0023 - Disclosure - Convertible Debt - Related Party (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/StockBasedCompensationTables" id="StockBasedCompensationTables">
        <link:definition>0024 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/NetIncomeLossPerShareOfCommonStockTables" id="NetIncomeLossPerShareOfCommonStockTables">
        <link:definition>0025 - Disclosure - Net Income (Loss) Per Share of Common Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/Incometaxestables" id="Incometaxestables">
        <link:definition>0026 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/NatureOfOperationsAndBusinessActivitiesDetailTextuals" id="NatureOfOperationsAndBusinessActivitiesDetailTextuals">
        <link:definition>0027 - Disclosure - Nature of Operations and Business Activities (Detail Textuals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPoliciesDetailTextuals" id="SummaryOfSignificantAccountingPoliciesDetailTextuals">
        <link:definition>0028 - Disclosure - Summary of Significant Accounting Policies (Detail Textuals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails" id="WarrantsAndDerivativeLiabilitiesDetails">
        <link:definition>0029 - Disclosure - Warrants and Derivative Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails1" id="WarrantsAndDerivativeLiabilitiesDetails1">
        <link:definition>0030 - Disclosure - Warrants and Derivative Liabilities (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails2" id="WarrantsAndDerivativeLiabilitiesDetails2">
        <link:definition>0031 - Disclosure - Warrants and Derivative Liabilities (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails6" id="WarrantsAndDerivativeLiabilitiesDetails6">
        <link:definition>0032 - Disclosure - Warrants and Derivative Liabilities (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails3" id="WarrantsAndDerivativeLiabilitiesDetails3">
        <link:definition>0033 - Disclosure - Warrants and Derivative Liabilities (Details 4)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails7" id="WarrantsAndDerivativeLiabilitiesDetails7">
        <link:definition>0034 - Disclosure - Warrants and Derivative Liabilities (Details 5)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails4" id="WarrantsAndDerivativeLiabilitiesDetails4">
        <link:definition>0035 - Disclosure - Warrants and Derivative Liabilities (Details 6)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails5" id="WarrantsAndDerivativeLiabilitiesDetails5">
        <link:definition>0036 - Disclosure - Warrants and Derivative Liabilities (Details 7)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetailsTextuals" id="WarrantsAndDerivativeLiabilitiesDetailsTextuals">
        <link:definition>0037 - Disclosure - Warrants and Derivative Liabilities (Details Textuals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetails" id="ConvertibleDebtRelatedPartyDetails">
        <link:definition>0038 - Disclosure - Convertible Debt - Related Party (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetails1" id="ConvertibleDebtRelatedPartyDetails1">
        <link:definition>0039 - Disclosure - Convertible Debt - Related Party (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetailTextuals" id="ConvertibleDebtRelatedPartyDetailTextuals">
        <link:definition>0040 - Disclosure - Convertible Debt - Related Party (Detail Textuals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetailTextuals1" id="ConvertibleDebtRelatedPartyDetailTextuals1">
        <link:definition>0041 - Disclosure - Convertible Debt - Related Party (Detail Textuals 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/StockholdersEquityDeficitAndCapitalizationDetailTextuals" id="StockholdersEquityDeficitAndCapitalizationDetailTextuals">
        <link:definition>0042 - Disclosure - Stockholders' Equity (Deficit) and Capitalization (Detail Textuals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/StockholdersEquityDeficitAndCapitalizationDetailTextuals1" id="StockholdersEquityDeficitAndCapitalizationDetailTextuals1">
        <link:definition>0043 - Disclosure - Stockholders' Equity (Deficit) and Capitalization (Detail Textuals 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetails" id="StockBasedCompensationDetails">
        <link:definition>0044 - Disclosure - Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetails1" id="StockBasedCompensationDetails1">
        <link:definition>0045 - Disclosure - Stock-Based Compensation (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetails2" id="StockBasedCompensationDetails2">
        <link:definition>0046 - Disclosure - Stock-Based Compensation (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetails3" id="StockBasedCompensationDetails3">
        <link:definition>0047 - Disclosure - Stock-Based Compensation (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetails4" id="StockBasedCompensationDetails4">
        <link:definition>0048 - Disclosure - Stock-Based Compensation (Details 4)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetailTextuals" id="StockBasedCompensationDetailTextuals">
        <link:definition>0049 - Disclosure - Stock-Based Compensation (Detail Textuals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetailTextuals1" id="StockBasedCompensationDetailTextuals1">
        <link:definition>0050 - Disclosure - Stock-Based Compensation (Detail Textuals 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetailTextuals2" id="StockBasedCompensationDetailTextuals2">
        <link:definition>0051 - Disclosure - Stock-Based Compensation (Detail Textuals 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/NetIncomeLossPerShareOfCommonStockDetails" id="NetIncomeLossPerShareOfCommonStockDetails">
        <link:definition>0052 - Disclosure - Net Income (Loss) Per Share of Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/NetIncomeLossPerShareOfCommonStockDetails1" id="NetIncomeLossPerShareOfCommonStockDetails1">
        <link:definition>0053 - Disclosure - Net Income (Loss) Per Share of Common Stock (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/IncomeTaxesDetails" id="IncomeTaxesDetails">
        <link:definition>0054 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/IncomeTaxesDetails1" id="IncomeTaxesDetails1">
        <link:definition>0055 - Disclosure - Income Taxes (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/IncomeTaxesDetails2" id="IncomeTaxesDetails2">
        <link:definition>0056 - Disclosure - Income Taxes (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/IncomeTaxesDetails3" id="IncomeTaxesDetails3">
        <link:definition>0057 - Disclosure - Income Taxes (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/IncomeTaxesDetailTextuals" id="IncomeTaxesDetailTextuals">
        <link:definition>0058 - Disclosure - Income Taxes (Detail Textuals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/SignificantContractsUniversityOfMississippiDetailTextuals" id="SignificantContractsUniversityOfMississippiDetailTextuals">
        <link:definition>0059 - Disclosure - Significant Contracts - University of Mississippi (Detail Textuals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/RelatedPartyMattersDetails" id="RelatedPartyMattersDetails">
        <link:definition>0061 - Disclosure - Related Party Matters (Detail Textuals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/SubsequentEventsDetailTextuals" id="SubsequentEventsDetailTextuals">
        <link:definition>0063 - Disclosure - Subsequent Events (Detail Textuals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="embi-20191231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="embi-20191231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="embi-20191231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="embi-20191231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
    </appinfo>
  </annotation>
  <element name="AccruedExpenseUnderAgreement" id="embi_AccruedExpenseUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AdditionalConversionLiability" id="embi_AdditionalConversionLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="AggregateMilestonePaymentsIfMilestonesAchieved" id="embi_AggregateMilestonePaymentsIfMilestonesAchieved" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AlbanyMolecularResearchIncMember" id="embi_AlbanyMolecularResearchIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AllocationOfDebtOnBasisOfRelativeFairValue" id="embi_AllocationOfDebtOnBasisOfRelativeFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AllocationOfWarrantOnBasisOfRelativeFairValue" id="embi_AllocationOfWarrantOnBasisOfRelativeFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AmortizationOfDebtDiscount" id="embi_AmortizationOfDebtDiscount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AmortizationOfTransactionCosts" id="embi_AmortizationOfTransactionCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AmountOfEachWarrantOutstanding" id="embi_AmountOfEachWarrantOutstanding" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="AmountOfPassThroughExpensesAndConsultingFees" id="embi_AmountOfPassThroughExpensesAndConsultingFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AnnualFeeForAgreement" id="embi_AnnualFeeForAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AnnualFeesForLicenseAgreement" id="embi_AnnualFeesForLicenseAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AnnualMaintenanceFeePayable" id="embi_AnnualMaintenanceFeePayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="AvtarDhillonMember" id="embi_AvtarDhillonMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AwardsGrantedOutside2014PlanMember" id="embi_AwardsGrantedOutside2014PlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AwardsGrantedOutsideThe2014PlanMember" id="embi_AwardsGrantedOutsideThe2014PlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue" id="embi_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement" id="embi_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="BeneficialConversionFeatureUponIssuanceofSeriesDPreferredStock" id="embi_BeneficialConversionFeatureUponIssuanceofSeriesDPreferredStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="BeneficialConversionFeatureUponIssuanceofSeriesFPreferredStock" id="embi_BeneficialConversionFeatureUponIssuanceofSeriesFPreferredStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="CashPaidDuringPeriodForAbstract" id="embi_CashPaidDuringPeriodForAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ChangeInFairValueOfDerivativeLiabilities" id="embi_ChangeInFairValueOfDerivativeLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ChangeInFairValueOfWarrantLiability" id="embi_ChangeInFairValueOfWarrantLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ClassOfWarrantOrRightWarrantsAggregateExercisePrice" id="embi_ClassOfWarrantOrRightWarrantsAggregateExercisePrice" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ClassOfWarrantOrRightWarrantsExercise" id="embi_ClassOfWarrantOrRightWarrantsExercise" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CommonSharesUnderlyingConvertiblePreferredStockMember" id="embi_CommonSharesUnderlyingConvertiblePreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CommonStockAggregatePurchasePrice" id="embi_CommonStockAggregatePurchasePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CommonStockIssuedForServices" id="embi_CommonStockIssuedForServices" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="CommonStockWarrantsToSeriesBStockholdersMember" id="embi_CommonStockWarrantsToSeriesBStockholdersMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ConsultingAgreementMember" id="embi_ConsultingAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ContractPayableDue" id="embi_ContractPayableDue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ConversionLiabilityIntoCommonStockPerShare" id="embi_ConversionLiabilityIntoCommonStockPerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock" id="embi_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares" id="embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue" id="embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest" id="embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterestShares" id="embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterestShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ConversionOfSeriesCPreferredStockToCommonStockShares" id="embi_ConversionOfSeriesCPreferredStockToCommonStockShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ConversionOfSeriesCPreferredStockToCommonStockSharesValue" id="embi_ConversionOfSeriesCPreferredStockToCommonStockSharesValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ConversionOfSeriesDPreferredStockToCommonStock" id="embi_ConversionOfSeriesDPreferredStockToCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ConversionOfSeriesDPreferredStockToCommonStockShares" id="embi_ConversionOfSeriesDPreferredStockToCommonStockShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ConversionOfSeriesFPreferredStockToCommonStockShares" id="embi_ConversionOfSeriesFPreferredStockToCommonStockShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ConversionOfSeriesFPreferredStockToCommonStockValue" id="embi_ConversionOfSeriesFPreferredStockToCommonStockValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ConversionPrice" id="embi_ConversionPrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ConversionPricePerShare" id="embi_ConversionPricePerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ConvertedRate10000001Member" id="embi_ConvertedRate10000001Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ConvertedRate100001Member" id="embi_ConvertedRate100001Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ConvertedRateAxis" id="embi_ConvertedRateAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" nillable="true"/>
  <element name="ConvertedRateDomain" id="embi_ConvertedRateDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ConvertibleDebtRelatedPartyTextBlock" id="embi_ConvertibleDebtRelatedPartyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ConvertibleMultiDrawCreditAgreementIssuanceCosts" id="embi_ConvertibleMultiDrawCreditAgreementIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="CouponInterestExpense" id="embi_CouponInterestExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="CurrentConvertibleDebtExcludingNoncurrentPortion" id="embi_CurrentConvertibleDebtExcludingNoncurrentPortion" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="December2015Member" id="embi_December2015Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DeemedDividendFromBeneficialConversionFeatureOfSeriesDPreferredStock" id="embi_DeemedDividendFromBeneficialConversionFeatureOfSeriesDPreferredStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="DeemedDividendFromBeneficialConversionFeatureOfSeriesFPreferredStock" id="embi_DeemedDividendFromBeneficialConversionFeatureOfSeriesFPreferredStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" id="embi_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="DeferredTaxLiabilitiesNoteDiscount" id="embi_DeferredTaxLiabilitiesNoteDiscount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="DerivativeLiabilitiesLineItems" id="embi_DerivativeLiabilitiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DerivativeLiabilitiesTable" id="embi_DerivativeLiabilitiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" nillable="true"/>
  <element name="DilutedSecuritiesAxis" id="embi_DilutedSecuritiesAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" nillable="true"/>
  <element name="DilutedSecuritiesDomain" id="embi_DilutedSecuritiesDomain" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DilutiveSecuritiesEffectOnBasicEarningsPerShareShares" id="embi_DilutiveSecuritiesEffectOnBasicEarningsPerShareShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DocumentAndEntityInformationAbstract" id="embi_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DouglasCesarioMember" id="embi_DouglasCesarioMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrant" id="embi_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrant" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="EmeraldConvertiblePromissoryNoteConversionLiabilityMember" id="embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EmeraldFinancingIssuanceCosts" id="embi_EmeraldFinancingIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="EmeraldFinancingMember" id="embi_EmeraldFinancingMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EmeraldHealthSciencesIncMember" id="embi_EmeraldHealthSciencesIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember" id="embi_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EmeraldWarrantLiabilityMember" id="embi_EmeraldWarrantLiabilityMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EquityLineItems" id="embi_EquityLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EquityTable" id="embi_EquityTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" nillable="true"/>
  <element name="EstimatedAgreementFeesAndExpenses" id="embi_EstimatedAgreementFeesAndExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="EstimatedInitialPaymentForContract" id="embi_EstimatedInitialPaymentForContract" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ExerciseOfWarrants" id="embi_ExerciseOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="FairMarketValueOfSharesGranted" id="embi_FairMarketValueOfSharesGranted" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="FairMarketValueOfStockOptions" id="embi_FairMarketValueOfStockOptions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="FairValueOfCommonStockWarrantsIssued" id="embi_FairValueOfCommonStockWarrantsIssued" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement" id="embi_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="FairValueOfDerivativeLiabilitiesRollForward" id="embi_FairValueOfDerivativeLiabilitiesRollForward" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FairValueOfDerivativeLiabilityExcessOfProceeds" id="embi_FairValueOfDerivativeLiabilityExcessOfProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="FairValueOfDerivativeLiabilityInExcessOfProceeds" id="embi_FairValueOfDerivativeLiabilityInExcessOfProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="FairValueOfUnderlyingShares" id="embi_FairValueOfUnderlyingShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="FairValueOfWarrantsIssued" id="embi_FairValueOfWarrantsIssued" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="FairValueOfWarrantsIssuedInConnectionWithFinancings" id="embi_FairValueOfWarrantsIssuedInConnectionWithFinancings" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="FeesAndExpensesForServicesProvided" id="embi_FeesAndExpensesForServicesProvided" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="FinancingSharesWarrantExercise" id="embi_FinancingSharesWarrantExercise" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FinancingValueWarrantExercise" id="embi_FinancingValueWarrantExercise" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="FixedAssetsProvidedToUniversityInLieuOfCash" id="embi_FixedAssetsProvidedToUniversityInLieuOfCash" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="GlauconixBiosciencesIncMember" id="embi_GlauconixBiosciencesIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="GuarantorFailedToPay" id="embi_GuarantorFailedToPay" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="IncomeTaxReconciliationChangeInCompoundDerivative" id="embi_IncomeTaxReconciliationChangeInCompoundDerivative" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="IncomeTaxReconciliationUncertainTaxPositions" id="embi_IncomeTaxReconciliationUncertainTaxPositions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="IncreaseChangeInFairValueOfWarrantLiability" id="embi_IncreaseChangeInFairValueOfWarrantLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="IncreaseDecreaseInDepositsAndOtherAssets" id="embi_IncreaseDecreaseInDepositsAndOtherAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="IncrementalAgreementFeesAndExpenses" id="embi_IncrementalAgreementFeesAndExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="IndependentContractorAgreementMember" id="embi_IndependentContractorAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="InitialTermOfAgreement" id="embi_InitialTermOfAgreement" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="IntrinsicValueOfWarrantExercises" id="embi_IntrinsicValueOfWarrantExercises" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="IssuanceOfPreferredStockNetOfIssuanceCosts" id="embi_IssuanceOfPreferredStockNetOfIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="IssuanceOfPreferredStockNetOfIssuanceCostsShares" id="embi_IssuanceOfPreferredStockNetOfIssuanceCostsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="IssuanceOfPreferredStockSeriesNetOfIssuanceCostsShares" id="embi_IssuanceOfPreferredStockSeriesNetOfIssuanceCostsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="IssuanceOfPreferredStockSeriesNetOfIssuanceCostsValue" id="embi_IssuanceOfPreferredStockSeriesNetOfIssuanceCostsValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="K2CIncMember" id="embi_K2CIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LeaseAgreementMember" id="embi_LeaseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LetterAgreementMember" id="embi_LetterAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LicenseAgreementMember" id="embi_LicenseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LiquidationProvisionCommonStockEquivalentShares" id="embi_LiquidationProvisionCommonStockEquivalentShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LiquidationProvisionCommonStockEquivalentValue" id="embi_LiquidationProvisionCommonStockEquivalentValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="LossOnCommonStockIssuanceFromConversionOfAccruedInterest" id="embi_LossOnCommonStockIssuanceFromConversionOfAccruedInterest" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="LumpSumPaymentInAgreement" id="embi_LumpSumPaymentInAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="MasterServiceAgreementMember" id="embi_MasterServiceAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="Milestone1Member" id="embi_Milestone1Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="Milestone2Member" id="embi_Milestone2Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="Milestone3Member" id="embi_Milestone3Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="MilestonePaymentsPayableAxis" id="embi_MilestonePaymentsPayableAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" nillable="true"/>
  <element name="MilestonePaymentsPayableDomain" id="embi_MilestonePaymentsPayableDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="MinimumLitigationJudgementAmount" id="embi_MinimumLitigationJudgementAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="MonteCarloSimulationsMember" id="embi_MonteCarloSimulationsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="MonthAndYearOfAgreementAxis" id="embi_MonthAndYearOfAgreementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" nillable="true"/>
  <element name="MonthAndYearOfAgreementDomain" id="embi_MonthAndYearOfAgreementDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="MonthlyFee" id="embi_MonthlyFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices" id="embi_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="MonthlyFeePaidEachMonthInExchangeOfServices" id="embi_MonthlyFeePaidEachMonthInExchangeOfServices" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="MultiDrawCreditAgreementMember" id="embi_MultiDrawCreditAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NatureOfOperationsAndBusinessActivitiesAbstract" id="embi_NatureOfOperationsAndBusinessActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NatureOfOperationsAndBusinessActivitiesLineItems" id="embi_NatureOfOperationsAndBusinessActivitiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NatureOfOperationsAndBusinessActivitiesTable" id="embi_NatureOfOperationsAndBusinessActivitiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" nillable="true"/>
  <element name="NetLossAdjustedBalance" id="embi_NetLossAdjustedBalance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="NonCashInterestExpenseAbstract" id="embi_NonCashInterestExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NoramcoAgreementMember" id="embi_NoramcoAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NoticePeriodForTermination" id="embi_NoticePeriodForTermination" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfCommonStockIssuedUponConversionOfPreferredStock" id="embi_NumberOfCommonStockIssuedUponConversionOfPreferredStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfInvestors" id="embi_NumberOfInvestors" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfLicenseAgreements" id="embi_NumberOfLicenseAgreements" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfWarrantsExercisable" id="embi_NumberOfWarrantsExercisable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OctoberTwoThousandFifteenMember" id="embi_OctoberTwoThousandFifteenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OmnibusIncentivePlan2014Member" id="embi_OmnibusIncentivePlan2014Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OneTimeUpfrontPayment" id="embi_OneTimeUpfrontPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="OptionAgreementMember" id="embi_OptionAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OptionsMember" id="embi_OptionsMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PaymentForUpfrontFees" id="embi_PaymentForUpfrontFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="PaymentOfUpfrontLicenseFee" id="embi_PaymentOfUpfrontLicenseFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="PercentageOfAccruedInterestOnOutstandingBalance" id="embi_PercentageOfAccruedInterestOnOutstandingBalance" type="num:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase" id="embi_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase" type="num:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfConversionAmount" id="embi_PercentageOfConversionAmount" type="num:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfSharesToBeRedeemed" id="embi_PercentageOfSharesToBeRedeemed" type="num:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PeriodOfDiscretionaryAnnualBonusPayableToContractorAfterEachFiscalYearEnd" id="embi_PeriodOfDiscretionaryAnnualBonusPayableToContractorAfterEachFiscalYearEnd" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PharmaceuticalsInternationalInc.AgreementMember" id="embi_PharmaceuticalsInternationalInc.AgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="Pre2015CommonStockWarrantsMember" id="embi_Pre2015CommonStockWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PreferredStockPutOptionLiability" id="embi_PreferredStockPutOptionLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="PricingModelAxis" id="embi_PricingModelAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" nillable="true"/>
  <element name="PricingModelDomain" id="embi_PricingModelDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PricingModelMember" id="embi_PricingModelMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement" id="embi_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ProceedsFromConvertibleMultiDrawCreditAgreement" id="embi_ProceedsFromConvertibleMultiDrawCreditAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ProceedsFromEmeraldFinancingNetOfIssuanceCosts" id="embi_ProceedsFromEmeraldFinancingNetOfIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ProceedsFromFinancingBetweenConversionLiabilityAndWarrants" id="embi_ProceedsFromFinancingBetweenConversionLiabilityAndWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ProvisionForConversionOfPreferredStock" id="embi_ProvisionForConversionOfPreferredStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ReclassificationOfDerivativesToEquity" id="embi_ReclassificationOfDerivativesToEquity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="RedemptionAmountPercentage" id="embi_RedemptionAmountPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ReductionToAdditionalPaidInCapitalFromTheIssuanceOfCommonStock" id="embi_ReductionToAdditionalPaidInCapitalFromTheIssuanceOfCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="RepaymentOfConvertibleMultiDrawCreditAgreement" id="embi_RepaymentOfConvertibleMultiDrawCreditAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ResearchAgreementMember" id="embi_ResearchAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RestrictedStockAgreementsMember" id="embi_RestrictedStockAgreementsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RisksAndUncertaintiesPolicyTextBlock" id="embi_RisksAndUncertaintiesPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RrdInternationalAgreementMember" id="embi_RrdInternationalAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ScheduleOfAdjustmentForDifferenceBetweenFairValueOfWarrantLiabilitiesAndTotalProceedsReceivedTableTextBlock" id="embi_ScheduleOfAdjustmentForDifferenceBetweenFairValueOfWarrantLiabilitiesAndTotalProceedsReceivedTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ScheduleOfAssumptionsUsedToComputeFairValueOfWarrantsTableTextBlock" id="embi_ScheduleOfAssumptionsUsedToComputeFairValueOfWarrantsTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ScheduleOfInterestExpenseTableTextBlock" id="embi_ScheduleOfInterestExpenseTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SecondDrawOnMultiDrawCreditFacilityMember" id="embi_SecondDrawOnMultiDrawCreditFacilityMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SecuredPromissoryNoteAndSecurityAgreementMember" id="embi_SecuredPromissoryNoteAndSecurityAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SecuritiesPurchaseAgreementMember" id="embi_SecuritiesPurchaseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SeparationAndReleaseAgreementMember" id="embi_SeparationAndReleaseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SeriesBPreferredStockConversionLiabilityMember" id="embi_SeriesBPreferredStockConversionLiabilityMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SeriesBWarrantMember" id="embi_SeriesBWarrantMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SeriesBWarrantsMember" id="embi_SeriesBWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SeriesFPreferredStockPutOptionLiabilityMember" id="embi_SeriesFPreferredStockPutOptionLiabilityMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareAndWarrantsIssuanceCosts" id="embi_ShareAndWarrantsIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ShareIssuanceCosts" id="embi_ShareIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="SignificantContractsAbstract" id="embi_SignificantContractsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SignificantContractsLineItems" id="embi_SignificantContractsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SignificantContractsTable" id="embi_SignificantContractsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" nillable="true"/>
  <element name="SignificantContractsTextBlock" id="embi_SignificantContractsTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants" id="embi_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockBasedCompensationForNonEmployeesPolicyTextBlock" id="embi_StockBasedCompensationForNonEmployeesPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockIssuanceCosts" id="embi_StockIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="StockIssuedDuringPeriodSharesIssuedForStockBasedCompensationExpense" id="embi_StockIssuedDuringPeriodSharesIssuedForStockBasedCompensationExpense" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockIssuedDuringPeriodSharesNetOfIssuanceCosts" id="embi_StockIssuedDuringPeriodSharesNetOfIssuanceCosts" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockIssuedDuringPeriodSharesNetOfIssuanceCostsAndWarrants" id="embi_StockIssuedDuringPeriodSharesNetOfIssuanceCostsAndWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockIssuedDuringPeriodSharesSeriesBWarrantExercises" id="embi_StockIssuedDuringPeriodSharesSeriesBWarrantExercises" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockIssuedDuringPeriodValueNetOfIssuanceCosts" id="embi_StockIssuedDuringPeriodValueNetOfIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="StockIssuedDuringPeriodValueNetOfIssuanceCostsAndWarrants" id="embi_StockIssuedDuringPeriodValueNetOfIssuanceCostsAndWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="StockIssuedDuringPeriodValueSeriesBWarrantExercises" id="embi_StockIssuedDuringPeriodValueSeriesBWarrantExercises" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="SubsequentFinancingPurchasePriceDescription" id="embi_SubsequentFinancingPurchasePriceDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TermOfAgreement" id="embi_TermOfAgreement" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TermOfWarrant" id="embi_TermOfWarrant" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TermOfWarrants" id="embi_TermOfWarrants" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TermsOfAgreementRenewed" id="embi_TermsOfAgreementRenewed" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TotalExpenseIncurredUnderAgreement" id="embi_TotalExpenseIncurredUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="TwoThousandEighteenEmeraldFinancingWarrantsMember" id="embi_TwoThousandEighteenEmeraldFinancingWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" id="embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwoThousandFifteenCommonStockWarrantsMember" id="embi_TwoThousandFifteenCommonStockWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember" id="embi_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember" id="embi_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwoThousandNineteenCommonStockWarrantsMember" id="embi_TwoThousandNineteenCommonStockWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember" id="embi_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember" id="embi_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember" id="embi_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwoThousandSixteenSeriesCPlacementAgentWarrantsMember" id="embi_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="Um5050ProdrugAndUm8930AnalogAgreementsMember" id="embi_Um5050ProdrugAndUm8930AnalogAgreementsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="Um5070LicenseAgreementMember" id="embi_Um5070LicenseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="UnamortizedDebtDiscountPeriod" id="embi_UnamortizedDebtDiscountPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="UniversityOfMississippiAgreementsLineItems" id="embi_UniversityOfMississippiAgreementsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="UniversityOfMississippiAgreementsTable" id="embi_UniversityOfMississippiAgreementsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" nillable="true"/>
  <element name="UniversityOfMississippiMember" id="embi_UniversityOfMississippiMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="UnvestedRestrictedStockMember" id="embi_UnvestedRestrictedStockMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="UpfrontPayment" id="embi_UpfrontPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ValueOfCommonStockCalledByWarrants" id="embi_ValueOfCommonStockCalledByWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WarrantsAndDerivativeLiabilitiesAbstract" id="embi_WarrantsAndDerivativeLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WarrantsAndDerivativeLiabilitiesTextBlock" id="embi_WarrantsAndDerivativeLiabilitiesTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue" id="embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock" id="embi_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WarrantsLiabilityClassifiedMember" id="embi_WarrantsLiabilityClassifiedMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WarrantsMember" id="embi_WarrantsMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WarrantsVestedAndOutstanding" id="embi_WarrantsVestedAndOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WorkingCapitalDeficit" id="embi_WorkingCapitalDeficit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>embi-20191231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#ConsolidatedBalanceSheets" roleURI="http://www.emeraldbio.life/role/ConsolidatedBalanceSheets"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.emeraldbio.life/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.emeraldbio.life/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#WarrantsAndDerivativeLiabilitiesDetails7" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails7"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#ConvertibleDebtRelatedPartyDetails" roleURI="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetails"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#IncomeTaxesDetails1" roleURI="http://www.emeraldbio.life/role/IncomeTaxesDetails1"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#IncomeTaxesDetails2" roleURI="http://www.emeraldbio.life/role/IncomeTaxesDetails2"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/ConsolidatedBalanceSheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_20"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0" xlink:to="loc_us-gaap_AssetsCurrent_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_Cash_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_OtherAssetsCurrent_4" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_7" xlink:to="loc_us-gaap_Liabilities_8" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8" xlink:to="loc_us-gaap_LiabilitiesCurrent_8" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_8" xlink:to="loc_us-gaap_AccountsPayableCurrent_8" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_8" xlink:to="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_9" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_8" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_10" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_8" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_11" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_13" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_14" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_7" xlink:to="loc_us-gaap_CommitmentsAndContingencies_16" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_7" xlink:to="loc_us-gaap_StockholdersEquity_17" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_17" xlink:to="loc_us-gaap_PreferredStockValue_17" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_17" xlink:to="loc_us-gaap_CommonStockValue_18" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_17" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_19" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_17" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_20" order="30" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_6"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ChangeInFairValueOfDerivativeLiabilities" xlink:label="loc_embi_ChangeInFairValueOfDerivativeLiabilities_6"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_FairValueOfDerivativeLiabilityInExcessOfProceeds" xlink:label="loc_embi_FairValueOfDerivativeLiabilityInExcessOfProceeds_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDerivativeIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDerivativeIssuanceCosts_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_11"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1" order="0" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2" xlink:to="loc_us-gaap_OperatingIncomeLoss_2" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_2" xlink:to="loc_us-gaap_OperatingExpenses_2" order="0" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_2" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_2" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_3" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_6" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_6" xlink:to="loc_embi_ChangeInFairValueOfDerivativeLiabilities_6" order="0" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_6" xlink:to="loc_embi_FairValueOfDerivativeLiabilityInExcessOfProceeds_7" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_6" xlink:to="loc_us-gaap_PaymentsOfDerivativeIssuanceCosts_8" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_6" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_6" xlink:to="loc_us-gaap_InterestExpense_10" order="40" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_6" xlink:to="loc_us-gaap_InvestmentIncomeInterest_11" order="50" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_5"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_FairValueOfDerivativeLiabilityExcessOfProceeds" xlink:label="loc_embi_FairValueOfDerivativeLiabilityExcessOfProceeds_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDerivativeIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDerivativeIssuanceCosts_7"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_LossOnCommonStockIssuanceFromConversionOfAccruedInterest" xlink:label="loc_embi_LossOnCommonStockIssuanceFromConversionOfAccruedInterest_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_10"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_CommonStockIssuedForServices" xlink:label="loc_embi_CommonStockIssuedForServices_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_12"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_IncreaseDecreaseInDepositsAndOtherAssets" xlink:label="loc_embi_IncreaseDecreaseInDepositsAndOtherAssets_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_22"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_23"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ProceedsFromConvertibleMultiDrawCreditAgreement" xlink:label="loc_embi_ProceedsFromConvertibleMultiDrawCreditAgreement_24"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_RepaymentOfConvertibleMultiDrawCreditAgreement" xlink:label="loc_embi_RepaymentOfConvertibleMultiDrawCreditAgreement_25"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_NetIncomeLoss_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_Depreciation_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_3" order="20" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_ShareBasedCompensation_4" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_5" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_embi_FairValueOfDerivativeLiabilityExcessOfProceeds_6" order="50" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_PaymentsOfDerivativeIssuanceCosts_7" order="60" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_embi_LossOnCommonStockIssuanceFromConversionOfAccruedInterest_8" order="70" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9" order="80" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_10" order="90" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_embi_CommonStockIssuedForServices_11" order="100" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_12" order="110" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_embi_IncreaseDecreaseInDepositsAndOtherAssets_13" order="120" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_14" order="130" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_15" order="140" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_16" order="150" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_17" order="160" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_19" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_19" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_19" order="0" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_21" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_21" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_21" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_21" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_22" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_21" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_23" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_21" xlink:to="loc_embi_ProceedsFromConvertibleMultiDrawCreditAgreement_24" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_21" xlink:to="loc_embi_RepaymentOfConvertibleMultiDrawCreditAgreement_25" order="40" use="optional" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails7">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_0"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_FairValueOfWarrantsIssued" xlink:label="loc_embi_FairValueOfWarrantsIssued_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_0" xlink:to="loc_embi_FairValueOfWarrantsIssued_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2" order="10" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaap_ConvertibleDebt_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_2"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ConvertibleDebt_0" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ConvertibleDebt_0" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_2" order="10" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/IncomeTaxesDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsStateTaxes" xlink:label="loc_us-gaap_DeferredTaxAssetsStateTaxes_1"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:label="loc_embi_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_8"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_DeferredTaxLiabilitiesNoteDiscount" xlink:label="loc_embi_DeferredTaxLiabilitiesNoteDiscount_8"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_0" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_1" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1" xlink:to="loc_us-gaap_DeferredTaxAssetsStateTaxes_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1" xlink:to="loc_embi_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_4" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_1" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_6" order="10" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_0" xlink:to="loc_us-gaap_DeferredTaxLiabilities_8" order="10" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_8" xlink:to="loc_embi_DeferredTaxLiabilitiesNoteDiscount_8" order="0" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/IncomeTaxesDetails2">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_2"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrant" xlink:label="loc_embi_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrant_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_4"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_IncomeTaxReconciliationUncertainTaxPositions" xlink:label="loc_embi_IncomeTaxReconciliationUncertainTaxPositions_5"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_IncomeTaxReconciliationChangeInCompoundDerivative" xlink:label="loc_embi_IncomeTaxReconciliationChangeInCompoundDerivative_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ExtinguishmentOfDebtGainLossIncomeTax" xlink:label="loc_us-gaap_ExtinguishmentOfDebtGainLossIncomeTax_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_10"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_0" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_0" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_0" xlink:to="loc_embi_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrant_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_0" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_4" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_0" xlink:to="loc_embi_IncomeTaxReconciliationUncertainTaxPositions_5" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_0" xlink:to="loc_embi_IncomeTaxReconciliationChangeInCompoundDerivative_6" order="50" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_0" xlink:to="loc_us-gaap_ExtinguishmentOfDebtGainLossIncomeTax_7" order="60" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_0" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_8" order="70" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_0" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_9" order="80" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_0" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_10" order="90" use="optional" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>embi-20191231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <!-- INTEGIX by Ez-XBRL -->
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#ConsolidatedBalanceSheets" roleURI="http://www.emeraldbio.life/role/ConsolidatedBalanceSheets"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#Consolidatedbalancesheetsparentheticals" roleURI="http://www.emeraldbio.life/role/Consolidatedbalancesheetsparentheticals"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.emeraldbio.life/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWSParentheticals" roleURI="http://www.emeraldbio.life/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSParentheticals"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#ConsolidatedStatementsOfStockholdersEquityDeficit" roleURI="http://www.emeraldbio.life/role/ConsolidatedStatementsOfStockholdersEquityDeficit"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#ConsolidatedStatementsOfStockholdersEquityDeficitParentheticals" roleURI="http://www.emeraldbio.life/role/ConsolidatedStatementsOfStockholdersEquityDeficitParentheticals"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#WarrantsAndDerivativeLiabilitiesTables" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesTables"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#StockBasedCompensationTables" roleURI="http://www.emeraldbio.life/role/StockBasedCompensationTables"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#NatureOfOperationsAndBusinessActivitiesDetailTextuals" roleURI="http://www.emeraldbio.life/role/NatureOfOperationsAndBusinessActivitiesDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#SummaryOfSignificantAccountingPoliciesDetailTextuals" roleURI="http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPoliciesDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#WarrantsAndDerivativeLiabilitiesDetails1" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails1"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#WarrantsAndDerivativeLiabilitiesDetails5" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails5"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#WarrantsAndDerivativeLiabilitiesDetails6" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails6"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#WarrantsAndDerivativeLiabilitiesDetails7" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails7"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#ConvertibleDebtRelatedPartyDetails" roleURI="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetails"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#ConvertibleDebtRelatedPartyDetailTextuals" roleURI="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#ConvertibleDebtRelatedPartyDetailTextuals1" roleURI="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetailTextuals1"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#StockholdersEquityDeficitAndCapitalizationDetailTextuals" roleURI="http://www.emeraldbio.life/role/StockholdersEquityDeficitAndCapitalizationDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#StockholdersEquityDeficitAndCapitalizationDetailTextuals1" roleURI="http://www.emeraldbio.life/role/StockholdersEquityDeficitAndCapitalizationDetailTextuals1"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#StockBasedCompensationDetails" roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetails"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#StockBasedCompensationDetails1" roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetails1"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#StockBasedCompensationDetails2" roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetails2"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#StockBasedCompensationDetails3" roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetails3"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#StockBasedCompensationDetails4" roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetails4"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#StockBasedCompensationDetailTextuals" roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#StockBasedCompensationDetailTextuals1" roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetailTextuals1"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#StockBasedCompensationDetailTextuals2" roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetailTextuals2"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#SignificantContractsUniversityOfMississippiDetailTextuals" roleURI="http://www.emeraldbio.life/role/SignificantContractsUniversityOfMississippiDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#RelatedPartyMattersDetails" roleURI="http://www.emeraldbio.life/role/RelatedPartyMattersDetails"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#IncomeTaxesDetailTextuals" roleURI="http://www.emeraldbio.life/role/IncomeTaxesDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#NetIncomeLossPerShareOfCommonStockDetails" roleURI="http://www.emeraldbio.life/role/NetIncomeLossPerShareOfCommonStockDetails"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#NetIncomeLossPerShareOfCommonStockDetails1" roleURI="http://www.emeraldbio.life/role/NetIncomeLossPerShareOfCommonStockDetails1"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#WarrantsAndDerivativeLiabilitiesDetails2" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails2"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#WarrantsAndDerivativeLiabilitiesDetails3" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails3"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#WarrantsAndDerivativeLiabilitiesDetails4" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails4"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#WarrantsAndDerivativeLiabilitiesDetails" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#WarrantsAndDerivativeLiabilitiesDetailsTextuals" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetailsTextuals"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#SubsequentEventsDetailTextuals" roleURI="http://www.emeraldbio.life/role/SubsequentEventsDetailTextuals"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/ConsolidatedBalanceSheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="loc_us-gaap_SeriesFPreferredStockMember_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaap_AccruedSalariesCurrent_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_22"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_25"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_27"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_28"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_29"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_29"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_30"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_31"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_32"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_33"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_35"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1" xlink:to="loc_us-gaap_ClassOfStockDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1" xlink:to="loc_us-gaap_SeriesDPreferredStockMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1" xlink:to="loc_us-gaap_SeriesFPreferredStockMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1" xlink:to="loc_us-gaap_ClassOfStockDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AssetsAbstract_8" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_8" xlink:to="loc_us-gaap_AssetsCurrentAbstract_8" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_9" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_10" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8" xlink:to="loc_us-gaap_OtherAssetsCurrent_11" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8" xlink:to="loc_us-gaap_AssetsCurrent_12" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_14" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_8" xlink:to="loc_us-gaap_Assets_15" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_17" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_17" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_17" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_17" xlink:to="loc_us-gaap_AccountsPayableCurrent_17" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_17" xlink:to="loc_us-gaap_AccruedSalariesCurrent_18" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_17" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_19" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_17" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_20" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_17" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_21" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_17" xlink:to="loc_us-gaap_LiabilitiesCurrent_22" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_17" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_24" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_24" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_24" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_24" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_25" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_17" xlink:to="loc_us-gaap_Liabilities_27" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_17" xlink:to="loc_us-gaap_CommitmentsAndContingencies_28" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_17" xlink:to="loc_us-gaap_StockholdersEquityAbstract_29" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29" xlink:to="loc_us-gaap_CommonStockValue_29" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_30" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_31" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_32" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29" xlink:to="loc_us-gaap_StockholdersEquity_33" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_17" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_35" order="50" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/Consolidatedbalancesheetsparentheticals">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="loc_us-gaap_SeriesFPreferredStockMember_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_11"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_StockIssuanceCosts" xlink:label="loc_embi_StockIssuanceCosts_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreference_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_17"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1" xlink:to="loc_us-gaap_ClassOfStockDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1" xlink:to="loc_us-gaap_SeriesDPreferredStockMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1" xlink:to="loc_us-gaap_SeriesFPreferredStockMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1" xlink:to="loc_us-gaap_ClassOfStockDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_8" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_9" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_10" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_11" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_embi_StockIssuanceCosts_12" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_TemporaryEquityLiquidationPreference_13" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_14" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_15" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesIssued_16" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_17" order="100" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_9"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_FixedAssetsProvidedToUniversityInLieuOfCash" xlink:label="loc_embi_FixedAssetsProvidedToUniversityInLieuOfCash_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_13"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_FairValueOfDerivativeLiabilityExcessOfProceeds" xlink:label="loc_embi_FairValueOfDerivativeLiabilityExcessOfProceeds_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDerivativeIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDerivativeIssuanceCosts_15"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_LossOnCommonStockIssuanceFromConversionOfAccruedInterest" xlink:label="loc_embi_LossOnCommonStockIssuanceFromConversionOfAccruedInterest_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_18"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_CommonStockIssuedForServices" xlink:label="loc_embi_CommonStockIssuedForServices_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_20"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_IncreaseDecreaseInDepositsAndOtherAssets" xlink:label="loc_embi_IncreaseDecreaseInDepositsAndOtherAssets_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_22"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_25"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_28"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_30"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_30"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_31"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_33"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_33"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ProceedsFromEmeraldFinancingNetOfIssuanceCosts" xlink:label="loc_embi_ProceedsFromEmeraldFinancingNetOfIssuanceCosts_34"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_35"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_36"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ProceedsFromConvertibleMultiDrawCreditAgreement" xlink:label="loc_embi_ProceedsFromConvertibleMultiDrawCreditAgreement_37"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_38"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_40"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_41"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_42"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_42"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_42"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_43"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_CashPaidDuringPeriodForAbstract" xlink:label="loc_embi_CashPaidDuringPeriodForAbstract_45"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_45"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_46"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_48"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_48"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock" xlink:label="loc_embi_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock_49"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_50"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_FairValueOfWarrantsIssuedInConnectionWithFinancings" xlink:label="loc_embi_FairValueOfWarrantsIssuedInConnectionWithFinancings_51"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement" xlink:label="loc_embi_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement_52"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ExerciseOfWarrants" xlink:label="loc_embi_ExerciseOfWarrants_53"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement" xlink:label="loc_embi_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement_54"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement" xlink:label="loc_embi_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement_55"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1" xlink:to="loc_us-gaap_ClassOfStockDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1" xlink:to="loc_us-gaap_SeriesDPreferredStockMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1" xlink:to="loc_us-gaap_ClassOfStockDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7" xlink:to="loc_us-gaap_NetIncomeLoss_7" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8" xlink:to="loc_us-gaap_Depreciation_8" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_9" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8" xlink:to="loc_embi_FixedAssetsProvidedToUniversityInLieuOfCash_10" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8" xlink:to="loc_us-gaap_ShareBasedCompensation_11" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_12" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_13" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8" xlink:to="loc_embi_FairValueOfDerivativeLiabilityExcessOfProceeds_14" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8" xlink:to="loc_us-gaap_PaymentsOfDerivativeIssuanceCosts_15" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8" xlink:to="loc_embi_LossOnCommonStockIssuanceFromConversionOfAccruedInterest_16" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_17" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_18" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8" xlink:to="loc_embi_CommonStockIssuedForServices_19" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_20" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_20" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_20" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_20" xlink:to="loc_embi_IncreaseDecreaseInDepositsAndOtherAssets_21" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_20" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_22" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_20" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_23" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_20" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_24" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_20" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_25" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_28" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_30" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_30" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_30" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_30" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_31" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_33" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_33" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_33" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_33" xlink:to="loc_embi_ProceedsFromEmeraldFinancingNetOfIssuanceCosts_34" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_33" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_35" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_33" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_36" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_33" xlink:to="loc_embi_ProceedsFromConvertibleMultiDrawCreditAgreement_37" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_33" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_38" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_40" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_41" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_SupplementalCashFlowElementsAbstract_42" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_42" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_42" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_42" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_42" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_42" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_43" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_42" xlink:to="loc_embi_CashPaidDuringPeriodForAbstract_45" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_CashPaidDuringPeriodForAbstract_45" xlink:to="loc_us-gaap_InterestPaidNet_45" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_CashPaidDuringPeriodForAbstract_45" xlink:to="loc_us-gaap_IncomeTaxesPaid_46" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_42" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_48" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_48" xlink:to="loc_us-gaap_ConversionOfStockAmountConverted1_48" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_48" xlink:to="loc_embi_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock_49" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_48" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_50" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_48" xlink:to="loc_embi_FairValueOfWarrantsIssuedInConnectionWithFinancings_51" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_48" xlink:to="loc_embi_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement_52" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_48" xlink:to="loc_embi_ExerciseOfWarrants_53" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_48" xlink:to="loc_embi_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement_54" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_48" xlink:to="loc_embi_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement_55" order="70" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSParentheticals">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_Default"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1" xlink:to="loc_us-gaap_ClassOfStockDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1" xlink:to="loc_us-gaap_SeriesDPreferredStockMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1" xlink:to="loc_us-gaap_ClassOfStockDomain_Default" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/ConsolidatedStatementsOfStockholdersEquityDeficit">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="loc_us-gaap_SeriesFPreferredStockMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_19"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_StockIssuedDuringPeriodSharesIssuedForStockBasedCompensationExpense" xlink:label="loc_embi_StockIssuedDuringPeriodSharesIssuedForStockBasedCompensationExpense_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_22"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_StockIssuedDuringPeriodValueNetOfIssuanceCosts" xlink:label="loc_embi_StockIssuedDuringPeriodValueNetOfIssuanceCosts_23"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_StockIssuedDuringPeriodSharesNetOfIssuanceCosts" xlink:label="loc_embi_StockIssuedDuringPeriodSharesNetOfIssuanceCosts_24"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_StockIssuedDuringPeriodValueNetOfIssuanceCostsAndWarrants" xlink:label="loc_embi_StockIssuedDuringPeriodValueNetOfIssuanceCostsAndWarrants_25"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_StockIssuedDuringPeriodSharesNetOfIssuanceCostsAndWarrants" xlink:label="loc_embi_StockIssuedDuringPeriodSharesNetOfIssuanceCostsAndWarrants_26"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue" xlink:label="loc_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue_27"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares" xlink:label="loc_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares_28"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ConversionOfSeriesDPreferredStockToCommonStock" xlink:label="loc_embi_ConversionOfSeriesDPreferredStockToCommonStock_29"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ConversionOfSeriesDPreferredStockToCommonStockShares" xlink:label="loc_embi_ConversionOfSeriesDPreferredStockToCommonStockShares_30"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ConversionOfSeriesFPreferredStockToCommonStockValue" xlink:label="loc_embi_ConversionOfSeriesFPreferredStockToCommonStockValue_31"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ConversionOfSeriesFPreferredStockToCommonStockShares" xlink:label="loc_embi_ConversionOfSeriesFPreferredStockToCommonStockShares_32"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest" xlink:label="loc_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest_33"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterestShares" xlink:label="loc_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterestShares_34"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue" xlink:label="loc_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_35"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue" xlink:label="loc_embi_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_36"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_StockIssuedDuringPeriodValueSeriesBWarrantExercises" xlink:label="loc_embi_StockIssuedDuringPeriodValueSeriesBWarrantExercises_37"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_StockIssuedDuringPeriodSharesSeriesBWarrantExercises" xlink:label="loc_embi_StockIssuedDuringPeriodSharesSeriesBWarrantExercises_38"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_FinancingValueWarrantExercise" xlink:label="loc_embi_FinancingValueWarrantExercise_39"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_FinancingSharesWarrantExercise" xlink:label="loc_embi_FinancingSharesWarrantExercise_40"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_41"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1" xlink:to="loc_us-gaap_ClassOfStockDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1" xlink:to="loc_us-gaap_SeriesFPreferredStockMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1" xlink:to="loc_us-gaap_SeriesDPreferredStockMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1" xlink:to="loc_us-gaap_ClassOfStockDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7" xlink:to="loc_us-gaap_EquityComponentDomain_7" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7" xlink:to="loc_us-gaap_CommonStockMember_7" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_8" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7" xlink:to="loc_us-gaap_WarrantMember_9" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7" xlink:to="loc_us-gaap_RetainedEarningsMember_10" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7" xlink:to="loc_us-gaap_EquityComponentDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_15" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_15" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_15" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_15" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_16" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_15" xlink:to="loc_us-gaap_StockholdersEquity_17" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_15" xlink:to="loc_us-gaap_SharesIssued_18" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_15" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_19" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_15" xlink:to="loc_embi_StockIssuedDuringPeriodSharesIssuedForStockBasedCompensationExpense_20" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_15" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_21" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_15" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_22" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_15" xlink:to="loc_embi_StockIssuedDuringPeriodValueNetOfIssuanceCosts_23" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_15" xlink:to="loc_embi_StockIssuedDuringPeriodSharesNetOfIssuanceCosts_24" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_15" xlink:to="loc_embi_StockIssuedDuringPeriodValueNetOfIssuanceCostsAndWarrants_25" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_15" xlink:to="loc_embi_StockIssuedDuringPeriodSharesNetOfIssuanceCostsAndWarrants_26" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_15" xlink:to="loc_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue_27" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_15" xlink:to="loc_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares_28" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_15" xlink:to="loc_embi_ConversionOfSeriesDPreferredStockToCommonStock_29" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_15" xlink:to="loc_embi_ConversionOfSeriesDPreferredStockToCommonStockShares_30" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_15" xlink:to="loc_embi_ConversionOfSeriesFPreferredStockToCommonStockValue_31" order="160" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_15" xlink:to="loc_embi_ConversionOfSeriesFPreferredStockToCommonStockShares_32" order="170" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_15" xlink:to="loc_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest_33" order="180" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_15" xlink:to="loc_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterestShares_34" order="190" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_15" xlink:to="loc_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_35" order="200" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_15" xlink:to="loc_embi_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_36" order="210" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_15" xlink:to="loc_embi_StockIssuedDuringPeriodValueSeriesBWarrantExercises_37" order="220" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_15" xlink:to="loc_embi_StockIssuedDuringPeriodSharesSeriesBWarrantExercises_38" order="230" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_15" xlink:to="loc_embi_FinancingValueWarrantExercise_39" order="240" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_15" xlink:to="loc_embi_FinancingSharesWarrantExercise_40" order="250" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_15" xlink:to="loc_us-gaap_NetIncomeLoss_41" order="260" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/ConsolidatedStatementsOfStockholdersEquityDeficitParentheticals">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="loc_us-gaap_SeriesFPreferredStockMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_Default"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ShareIssuanceCosts" xlink:label="loc_embi_ShareIssuanceCosts_8"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ShareAndWarrantsIssuanceCosts" xlink:label="loc_embi_ShareAndWarrantsIssuanceCosts_9"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ConversionPricePerShare" xlink:label="loc_embi_ConversionPricePerShare_10"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ConversionLiabilityIntoCommonStockPerShare" xlink:label="loc_embi_ConversionLiabilityIntoCommonStockPerShare_11"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1" xlink:to="loc_us-gaap_ClassOfStockDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1" xlink:to="loc_us-gaap_SeriesFPreferredStockMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1" xlink:to="loc_us-gaap_SeriesDPreferredStockMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1" xlink:to="loc_us-gaap_ClassOfStockDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_embi_ShareIssuanceCosts_8" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_embi_ShareAndWarrantsIssuanceCosts_9" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_embi_ConversionPricePerShare_10" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_embi_ConversionLiabilityIntoCommonStockPerShare_11" order="40" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesTables">
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_DerivativeLiabilitiesLineItems" xlink:label="loc_embi_DerivativeLiabilitiesLineItems_0"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_DerivativeLiabilitiesTable" xlink:label="loc_embi_DerivativeLiabilitiesTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_EmeraldFinancingMember" xlink:label="loc_embi_EmeraldFinancingMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_5"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_TwoThousandNineteenCommonStockWarrantsMember" xlink:label="loc_embi_TwoThousandNineteenCommonStockWarrantsMember_5"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_SeriesBWarrantMember" xlink:label="loc_embi_SeriesBWarrantMember_6"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" xlink:label="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_7"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember" xlink:label="loc_embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_15"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ScheduleOfAdjustmentForDifferenceBetweenFairValueOfWarrantLiabilitiesAndTotalProceedsReceivedTableTextBlock" xlink:label="loc_embi_ScheduleOfAdjustmentForDifferenceBetweenFairValueOfWarrantLiabilitiesAndTotalProceedsReceivedTableTextBlock_16"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ScheduleOfAssumptionsUsedToComputeFairValueOfWarrantsTableTextBlock" xlink:label="loc_embi_ScheduleOfAssumptionsUsedToComputeFairValueOfWarrantsTableTextBlock_17"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_0" xlink:to="loc_embi_DerivativeLiabilitiesTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_embi_DerivativeLiabilitiesTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_embi_EmeraldFinancingMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_embi_DerivativeLiabilitiesTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5" xlink:to="loc_embi_TwoThousandNineteenCommonStockWarrantsMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5" xlink:to="loc_embi_SeriesBWarrantMember_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5" xlink:to="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_7" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5" xlink:to="loc_embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_8" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_0" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_13" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_14" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_0" xlink:to="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_15" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_0" xlink:to="loc_embi_ScheduleOfAdjustmentForDifferenceBetweenFairValueOfWarrantLiabilitiesAndTotalProceedsReceivedTableTextBlock_16" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_0" xlink:to="loc_embi_ScheduleOfAssumptionsUsedToComputeFairValueOfWarrantsTableTextBlock_17" order="50" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockBasedCompensationTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_6"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_OmnibusIncentivePlan2014Member" xlink:label="loc_embi_OmnibusIncentivePlan2014Member_6"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_AwardsGrantedOutside2014PlanMember" xlink:label="loc_embi_AwardsGrantedOutside2014PlanMember_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_15"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:to="loc_us-gaap_RestrictedStockMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_PlanNameAxis_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_6" xlink:to="loc_us-gaap_PlanNameDomain_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_6" xlink:to="loc_embi_OmnibusIncentivePlan2014Member_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_6" xlink:to="loc_embi_AwardsGrantedOutside2014PlanMember_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_6" xlink:to="loc_us-gaap_PlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_12" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_13" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_14" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_15" order="40" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/NatureOfOperationsAndBusinessActivitiesDetailTextuals">
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_NatureOfOperationsAndBusinessActivitiesLineItems" xlink:label="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_0"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_NatureOfOperationsAndBusinessActivitiesTable" xlink:label="loc_embi_NatureOfOperationsAndBusinessActivitiesTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_EmeraldFinancingMember" xlink:label="loc_embi_EmeraldFinancingMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_MultiDrawCreditAgreementMember" xlink:label="loc_embi_MultiDrawCreditAgreementMember_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_15"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ProceedsFromConvertibleMultiDrawCreditAgreement" xlink:label="loc_embi_ProceedsFromConvertibleMultiDrawCreditAgreement_16"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_0" xlink:to="loc_embi_NatureOfOperationsAndBusinessActivitiesTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_embi_EmeraldFinancingMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5" xlink:to="loc_embi_MultiDrawCreditAgreementMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_0" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_10" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_0" xlink:to="loc_us-gaap_Cash_11" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_0" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_12" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_0" xlink:to="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_13" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_14" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_15" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_0" xlink:to="loc_embi_ProceedsFromConvertibleMultiDrawCreditAgreement_16" order="70" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPoliciesDetailTextuals">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:label="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDepreciationMethods" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDepreciationMethods_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_11"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_srt_RangeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1" xlink:to="loc_srt_RangeMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1" xlink:to="loc_srt_MinimumMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1" xlink:to="loc_srt_MaximumMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1" xlink:to="loc_srt_RangeMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_8" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_9" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDepreciationMethods_10" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_11" order="50" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_TwoThousandNineteenCommonStockWarrantsMember" xlink:label="loc_embi_TwoThousandNineteenCommonStockWarrantsMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_Default"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_PricingModelAxis" xlink:label="loc_embi_PricingModelAxis_5"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_PricingModelDomain" xlink:label="loc_embi_PricingModelDomain_5"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_PricingModelMember" xlink:label="loc_embi_PricingModelMember_5"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_PricingModelDomain" xlink:label="loc_embi_PricingModelDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputOfferedPriceMember" xlink:label="loc_us-gaap_MeasurementInputOfferedPriceMember_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_25"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandNineteenCommonStockWarrantsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_embi_PricingModelAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_embi_PricingModelAxis_5" xlink:to="loc_embi_PricingModelDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_PricingModelDomain_5" xlink:to="loc_embi_PricingModelMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_embi_PricingModelAxis_5" xlink:to="loc_embi_PricingModelDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_9" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_9" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_9" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_9" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_10" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_9" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_11" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_9" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_12" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_9" xlink:to="loc_us-gaap_MeasurementInputOfferedPriceMember_13" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_9" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_srt_RangeAxis_17" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_17" xlink:to="loc_srt_RangeMember_17" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_17" xlink:to="loc_srt_MinimumMember_17" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_17" xlink:to="loc_srt_MaximumMember_18" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_17" xlink:to="loc_srt_RangeMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_23" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_24" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_25" order="30" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails5">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_PricingModelAxis" xlink:label="loc_embi_PricingModelAxis_8"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_PricingModelDomain" xlink:label="loc_embi_PricingModelDomain_8"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_PricingModelMember" xlink:label="loc_embi_PricingModelMember_8"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_PricingModelDomain" xlink:label="loc_embi_PricingModelDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_12"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember" xlink:label="loc_embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_19"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_embi_PricingModelAxis_8" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_embi_PricingModelAxis_8" xlink:to="loc_embi_PricingModelDomain_8" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_PricingModelDomain_8" xlink:to="loc_embi_PricingModelMember_8" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_embi_PricingModelAxis_8" xlink:to="loc_embi_PricingModelDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_12" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_12" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_12" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_12" xlink:to="loc_embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_12" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_12" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_17" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_18" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_19" order="30" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails6">
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_DerivativeLiabilitiesLineItems" xlink:label="loc_embi_DerivativeLiabilitiesLineItems_0"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_DerivativeLiabilitiesTable" xlink:label="loc_embi_DerivativeLiabilitiesTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_EmeraldFinancingMember" xlink:label="loc_embi_EmeraldFinancingMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_5"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_SeriesBPreferredStockConversionLiabilityMember" xlink:label="loc_embi_SeriesBPreferredStockConversionLiabilityMember_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_9"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember" xlink:label="loc_embi_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_9"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_SeriesBWarrantMember" xlink:label="loc_embi_SeriesBWarrantMember_10"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember" xlink:label="loc_embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_Default"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_FairValueOfDerivativeLiabilitiesRollForward" xlink:label="loc_embi_FairValueOfDerivativeLiabilitiesRollForward_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_16"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_FairValueOfWarrantsIssued" xlink:label="loc_embi_FairValueOfWarrantsIssued_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_18"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ReclassificationOfDerivativesToEquity" xlink:label="loc_embi_ReclassificationOfDerivativesToEquity_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_21"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_0" xlink:to="loc_embi_DerivativeLiabilitiesTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_embi_DerivativeLiabilitiesTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_embi_EmeraldFinancingMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_embi_DerivativeLiabilitiesTable_1" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_5" xlink:to="loc_embi_SeriesBPreferredStockConversionLiabilityMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_embi_DerivativeLiabilitiesTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_9" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_9" xlink:to="loc_embi_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_9" xlink:to="loc_embi_SeriesBWarrantMember_10" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_9" xlink:to="loc_embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_11" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_0" xlink:to="loc_embi_FairValueOfDerivativeLiabilitiesRollForward_16" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_FairValueOfDerivativeLiabilitiesRollForward_16" xlink:to="loc_us-gaap_DerivativeLiabilities_16" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_FairValueOfDerivativeLiabilitiesRollForward_16" xlink:to="loc_embi_FairValueOfWarrantsIssued_17" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_FairValueOfDerivativeLiabilitiesRollForward_16" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_18" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_FairValueOfDerivativeLiabilitiesRollForward_16" xlink:to="loc_embi_ReclassificationOfDerivativesToEquity_19" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_FairValueOfDerivativeLiabilitiesRollForward_16" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_20" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_FairValueOfDerivativeLiabilitiesRollForward_16" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_21" order="50" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails7">
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_DerivativeLiabilitiesLineItems" xlink:label="loc_embi_DerivativeLiabilitiesLineItems_0"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_DerivativeLiabilitiesTable" xlink:label="loc_embi_DerivativeLiabilitiesTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_EmeraldFinancingMember" xlink:label="loc_embi_EmeraldFinancingMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_FairValueOfWarrantsIssued" xlink:label="loc_embi_FairValueOfWarrantsIssued_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_8"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_0" xlink:to="loc_embi_DerivativeLiabilitiesTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_embi_DerivativeLiabilitiesTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_embi_EmeraldFinancingMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_0" xlink:to="loc_embi_FairValueOfWarrantsIssued_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_7" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_8" order="30" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaap_ShortTermDebtLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_5"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_EmeraldHealthSciencesIncMember" xlink:label="loc_embi_EmeraldHealthSciencesIncMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsCurrentGross" xlink:label="loc_us-gaap_DeferredFinanceCostsCurrentGross_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaap_ConvertibleDebt_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_15"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_1" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_1" xlink:to="loc_us-gaap_ConvertibleDebtMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_1" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_dei_LegalEntityAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_5" xlink:to="loc_dei_EntityDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_5" xlink:to="loc_embi_EmeraldHealthSciencesIncMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_5" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_10" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_11" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_us-gaap_DeferredFinanceCostsCurrentGross_12" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_us-gaap_ConvertibleDebt_13" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_14" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_15" order="60" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetailTextuals">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_EmeraldFinancingMember" xlink:label="loc_embi_EmeraldFinancingMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_MultiDrawCreditAgreementMember" xlink:label="loc_embi_MultiDrawCreditAgreementMember_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityAverageOutstandingAmount" xlink:label="loc_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_14"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase" xlink:label="loc_embi_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_16"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_AmountOfEachWarrantOutstanding" xlink:label="loc_embi_AmountOfEachWarrantOutstanding_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_20"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_AllocationOfDebtOnBasisOfRelativeFairValue" xlink:label="loc_embi_AllocationOfDebtOnBasisOfRelativeFairValue_21"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_AllocationOfWarrantOnBasisOfRelativeFairValue" xlink:label="loc_embi_AllocationOfWarrantOnBasisOfRelativeFairValue_22"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_24"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_FairValueOfDerivativeLiabilityInExcessOfProceeds" xlink:label="loc_embi_FairValueOfDerivativeLiabilityInExcessOfProceeds_25"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_26"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_27"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_28"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ConvertibleMultiDrawCreditAgreementIssuanceCosts" xlink:label="loc_embi_ConvertibleMultiDrawCreditAgreementIssuanceCosts_29"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_30"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_FairValueOfUnderlyingShares" xlink:label="loc_embi_FairValueOfUnderlyingShares_31"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_32"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_embi_EmeraldFinancingMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5" xlink:to="loc_embi_MultiDrawCreditAgreementMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_10" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_11" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_12" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_13" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_14" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_embi_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase_15" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_16" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_embi_AmountOfEachWarrantOutstanding_17" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_18" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_19" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_20" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_embi_AllocationOfDebtOnBasisOfRelativeFairValue_21" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_embi_AllocationOfWarrantOnBasisOfRelativeFairValue_22" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_23" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_DerivativeLiabilities_24" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_embi_FairValueOfDerivativeLiabilityInExcessOfProceeds_25" order="160" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_26" order="170" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_27" order="180" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_28" order="190" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_embi_ConvertibleMultiDrawCreditAgreementIssuanceCosts_29" order="200" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_30" order="210" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_embi_FairValueOfUnderlyingShares_31" order="220" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_32" order="230" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetailTextuals1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaap_ShortTermDebtLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BridgeLoanMember" xlink:label="loc_us-gaap_BridgeLoanMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_SecuredPromissoryNoteAndSecurityAgreementMember" xlink:label="loc_embi_SecuredPromissoryNoteAndSecurityAgreementMember_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_9"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_EmeraldHealthSciencesIncMember" xlink:label="loc_embi_EmeraldHealthSciencesIncMember_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BridgeLoan" xlink:label="loc_us-gaap_BridgeLoan_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_22"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_23"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_AdditionalConversionLiability" xlink:label="loc_embi_AdditionalConversionLiability_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_25"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_26"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_27"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_28"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_1" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_1" xlink:to="loc_us-gaap_BridgeLoanMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_1" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5" xlink:to="loc_embi_SecuredPromissoryNoteAndSecurityAgreementMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_dei_LegalEntityAxis_9" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_9" xlink:to="loc_dei_EntityDomain_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_9" xlink:to="loc_embi_EmeraldHealthSciencesIncMember_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_9" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_13" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_13" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_13" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_13" xlink:to="loc_us-gaap_SubsequentEventMember_13" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_13" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_us-gaap_BridgeLoan_18" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_19" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_20" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_21" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_22" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_23" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_embi_AdditionalConversionLiability_24" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_25" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_26" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_27" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_28" order="110" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockholdersEquityDeficitAndCapitalizationDetailTextuals">
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_EquityLineItems" xlink:label="loc_embi_EquityLineItems_0"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_EquityTable" xlink:label="loc_embi_EquityTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_SecuritiesPurchaseAgreementMember" xlink:label="loc_embi_SecuritiesPurchaseAgreementMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_5"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_EmeraldHealthSciencesIncMember" xlink:label="loc_embi_EmeraldHealthSciencesIncMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaap_InvestorMember_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_18"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_TwoThousandEighteenEmeraldFinancingWarrantsMember" xlink:label="loc_embi_TwoThousandEighteenEmeraldFinancingWarrantsMember_18"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_SeriesBWarrantsMember" xlink:label="loc_embi_SeriesBWarrantsMember_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_25"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_26"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_27"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ClassOfWarrantOrRightWarrantsExercise" xlink:label="loc_embi_ClassOfWarrantOrRightWarrantsExercise_28"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_IntrinsicValueOfWarrantExercises" xlink:label="loc_embi_IntrinsicValueOfWarrantExercises_29"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_30"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_31"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_32"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_33"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BridgeLoan" xlink:label="loc_us-gaap_BridgeLoan_34"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_SubsequentFinancingPurchasePriceDescription" xlink:label="loc_embi_SubsequentFinancingPurchasePriceDescription_35"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_TermOfWarrants" xlink:label="loc_embi_TermOfWarrants_36"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_EmeraldFinancingIssuanceCosts" xlink:label="loc_embi_EmeraldFinancingIssuanceCosts_37"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDerivativeIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDerivativeIssuanceCosts_38"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ReductionToAdditionalPaidInCapitalFromTheIssuanceOfCommonStock" xlink:label="loc_embi_ReductionToAdditionalPaidInCapitalFromTheIssuanceOfCommonStock_39"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_embi_EquityLineItems_0" xlink:to="loc_embi_EquityTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_embi_EquityTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_embi_SecuritiesPurchaseAgreementMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_embi_EquityTable_1" xlink:to="loc_dei_LegalEntityAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_5" xlink:to="loc_dei_EntityDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_5" xlink:to="loc_embi_EmeraldHealthSciencesIncMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_5" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_embi_EquityTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9" xlink:to="loc_us-gaap_RelatedPartyDomain_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_9" xlink:to="loc_us-gaap_InvestorMember_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9" xlink:to="loc_us-gaap_RelatedPartyDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_embi_EquityTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_13" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_13" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_13" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_13" xlink:to="loc_us-gaap_IPOMember_13" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_13" xlink:to="loc_us-gaap_PrivatePlacementMember_14" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_13" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_embi_EquityTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_18" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_18" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_18" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_18" xlink:to="loc_embi_TwoThousandEighteenEmeraldFinancingWarrantsMember_18" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_18" xlink:to="loc_embi_SeriesBWarrantsMember_19" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_18" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_EquityLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_24" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_EquityLineItems_0" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_25" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_EquityLineItems_0" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_26" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_EquityLineItems_0" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_27" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_EquityLineItems_0" xlink:to="loc_embi_ClassOfWarrantOrRightWarrantsExercise_28" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_EquityLineItems_0" xlink:to="loc_embi_IntrinsicValueOfWarrantExercises_29" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_EquityLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_30" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_EquityLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_31" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_EquityLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_32" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_EquityLineItems_0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_33" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_EquityLineItems_0" xlink:to="loc_us-gaap_BridgeLoan_34" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_EquityLineItems_0" xlink:to="loc_embi_SubsequentFinancingPurchasePriceDescription_35" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_EquityLineItems_0" xlink:to="loc_embi_TermOfWarrants_36" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_EquityLineItems_0" xlink:to="loc_embi_EmeraldFinancingIssuanceCosts_37" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_EquityLineItems_0" xlink:to="loc_us-gaap_PaymentsOfDerivativeIssuanceCosts_38" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_EquityLineItems_0" xlink:to="loc_embi_ReductionToAdditionalPaidInCapitalFromTheIssuanceOfCommonStock_39" order="160" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockholdersEquityDeficitAndCapitalizationDetailTextuals1">
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_EquityLineItems" xlink:label="loc_embi_EquityLineItems_0"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_EquityTable" xlink:label="loc_embi_EquityTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="loc_us-gaap_SeriesFPreferredStockMember_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_13"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_embi_EquityLineItems_0" xlink:to="loc_embi_EquityTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_embi_EquityTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1" xlink:to="loc_us-gaap_ClassOfStockDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1" xlink:to="loc_us-gaap_SeriesDPreferredStockMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1" xlink:to="loc_us-gaap_SeriesFPreferredStockMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1" xlink:to="loc_us-gaap_ClassOfStockDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_EquityLineItems_0" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_8" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_EquityLineItems_0" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_9" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_EquityLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_10" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_EquityLineItems_0" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_11" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_EquityLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesIssued_12" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_EquityLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_13" order="60" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockBasedCompensationDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_OmnibusIncentivePlan2014Member" xlink:label="loc_embi_OmnibusIncentivePlan2014Member_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_10"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_PlanNameAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1" xlink:to="loc_us-gaap_PlanNameDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1" xlink:to="loc_embi_OmnibusIncentivePlan2014Member_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1" xlink:to="loc_us-gaap_PlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_8" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_9" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_10" order="40" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockBasedCompensationDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_OmnibusIncentivePlan2014Member" xlink:label="loc_embi_OmnibusIncentivePlan2014Member_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_22"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_25"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_26"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_27"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_28"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_29"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_PlanNameAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1" xlink:to="loc_us-gaap_PlanNameDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1" xlink:to="loc_embi_OmnibusIncentivePlan2014Member_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1" xlink:to="loc_us-gaap_PlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_10" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_11" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_12" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_13" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_14" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_15" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_17" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_17" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_18" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_19" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_20" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_21" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_22" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_24" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_24" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_24" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_24" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_25" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_24" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_26" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_24" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_27" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_24" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_28" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_24" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_29" order="50" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockBasedCompensationDetails2">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_10"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_OmnibusIncentivePlan2014Member" xlink:label="loc_embi_OmnibusIncentivePlan2014Member_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_18"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_srt_RangeAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5" xlink:to="loc_srt_RangeMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5" xlink:to="loc_srt_MinimumMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5" xlink:to="loc_srt_MaximumMember_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5" xlink:to="loc_srt_RangeMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_PlanNameAxis_10" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_10" xlink:to="loc_us-gaap_PlanNameDomain_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_10" xlink:to="loc_embi_OmnibusIncentivePlan2014Member_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_10" xlink:to="loc_us-gaap_PlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_15" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_16" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_17" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_18" order="40" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockBasedCompensationDetails3">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_5"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_AwardsGrantedOutsideThe2014PlanMember" xlink:label="loc_embi_AwardsGrantedOutsideThe2014PlanMember_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_13"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_PlanNameAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_5" xlink:to="loc_us-gaap_PlanNameDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_5" xlink:to="loc_embi_AwardsGrantedOutsideThe2014PlanMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_5" xlink:to="loc_us-gaap_PlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_10" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_11" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_12" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_13" order="40" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockBasedCompensationDetails4">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_12"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:to="loc_us-gaap_RestrictedStockMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_10" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_11" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_12" order="20" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockBasedCompensationDetailTextuals">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ChiefFinancialOfficerMember" xlink:label="loc_srt_ChiefFinancialOfficerMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_5"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_OmnibusIncentivePlan2014Member" xlink:label="loc_embi_OmnibusIncentivePlan2014Member_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_13"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_RestrictedStockAgreementsMember" xlink:label="loc_embi_RestrictedStockAgreementsMember_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_17"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_K2CIncMember" xlink:label="loc_embi_K2CIncMember_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_22"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_us-gaap_RestrictedStockExpense_25"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_26"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_27"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_srt_TitleOfIndividualAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_1" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:to="loc_srt_ChiefFinancialOfficerMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_1" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_PlanNameAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_5" xlink:to="loc_us-gaap_PlanNameDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_5" xlink:to="loc_embi_OmnibusIncentivePlan2014Member_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_5" xlink:to="loc_us-gaap_PlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_9" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9" xlink:to="loc_us-gaap_EmployeeStockOptionMember_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_13" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_13" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_13" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_13" xlink:to="loc_embi_RestrictedStockAgreementsMember_13" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_13" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_dei_LegalEntityAxis_17" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_17" xlink:to="loc_dei_EntityDomain_17" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_17" xlink:to="loc_embi_K2CIncMember_17" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_17" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_22" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_23" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_24" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_RestrictedStockExpense_25" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_26" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_27" order="60" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockBasedCompensationDetailTextuals1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_DouglasCesarioMember" xlink:label="loc_embi_DouglasCesarioMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_RestrictedStockAgreementsMember" xlink:label="loc_embi_RestrictedStockAgreementsMember_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_11"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_FairMarketValueOfStockOptions" xlink:label="loc_embi_FairMarketValueOfStockOptions_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_18"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_srt_TitleOfIndividualAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_1" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:to="loc_embi_DouglasCesarioMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_1" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5" xlink:to="loc_embi_RestrictedStockAgreementsMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_10" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_11" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_embi_FairMarketValueOfStockOptions_12" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_13" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_14" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_15" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_16" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_17" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_18" order="90" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockBasedCompensationDetailTextuals2">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srt_ChiefExecutiveOfficerMember_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ChiefFinancialOfficerMember" xlink:label="loc_srt_ChiefFinancialOfficerMember_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="loc_srt_BoardOfDirectorsChairmanMember_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_11"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_K2CIncMember" xlink:label="loc_embi_K2CIncMember_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_16"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_FairMarketValueOfSharesGranted" xlink:label="loc_embi_FairMarketValueOfSharesGranted_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_us-gaap_RestrictedStockExpense_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_22"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:to="loc_us-gaap_RestrictedStockMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_srt_TitleOfIndividualAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_5" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5" xlink:to="loc_srt_ChiefExecutiveOfficerMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5" xlink:to="loc_srt_ChiefFinancialOfficerMember_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5" xlink:to="loc_srt_BoardOfDirectorsChairmanMember_7" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_5" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_dei_LegalEntityAxis_11" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_11" xlink:to="loc_dei_EntityDomain_11" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_11" xlink:to="loc_embi_K2CIncMember_11" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_11" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_16" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_embi_FairMarketValueOfSharesGranted_17" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_18" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_RestrictedStockExpense_19" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensation_20" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_21" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_22" order="70" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/SignificantContractsUniversityOfMississippiDetailTextuals">
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_UniversityOfMississippiAgreementsLineItems" xlink:label="loc_embi_UniversityOfMississippiAgreementsLineItems_0"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_UniversityOfMississippiAgreementsTable" xlink:label="loc_embi_UniversityOfMississippiAgreementsTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_OptionAgreementMember" xlink:label="loc_embi_OptionAgreementMember_1"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_LicenseAgreementMember" xlink:label="loc_embi_LicenseAgreementMember_2"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_Um5070LicenseAgreementMember" xlink:label="loc_embi_Um5070LicenseAgreementMember_3"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_Um5050ProdrugAndUm8930AnalogAgreementsMember" xlink:label="loc_embi_Um5050ProdrugAndUm8930AnalogAgreementsMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_8"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_UniversityOfMississippiMember" xlink:label="loc_embi_UniversityOfMississippiMember_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_MonthAndYearOfAgreementAxis" xlink:label="loc_embi_MonthAndYearOfAgreementAxis_12"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_MonthAndYearOfAgreementDomain" xlink:label="loc_embi_MonthAndYearOfAgreementDomain_12"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_December2015Member" xlink:label="loc_embi_December2015Member_12"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_OctoberTwoThousandFifteenMember" xlink:label="loc_embi_OctoberTwoThousandFifteenMember_13"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_MonthAndYearOfAgreementDomain" xlink:label="loc_embi_MonthAndYearOfAgreementDomain_Default"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_MilestonePaymentsPayableAxis" xlink:label="loc_embi_MilestonePaymentsPayableAxis_17"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_MilestonePaymentsPayableDomain" xlink:label="loc_embi_MilestonePaymentsPayableDomain_17"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_Milestone1Member" xlink:label="loc_embi_Milestone1Member_17"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_Milestone2Member" xlink:label="loc_embi_Milestone2Member_18"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_Milestone3Member" xlink:label="loc_embi_Milestone3Member_19"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_MilestonePaymentsPayableDomain" xlink:label="loc_embi_MilestonePaymentsPayableDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:label="loc_us-gaap_IntellectualPropertyMember_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_AnnualMaintenanceFeePayable" xlink:label="loc_embi_AnnualMaintenanceFeePayable_28"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_TermOfAgreement" xlink:label="loc_embi_TermOfAgreement_29"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_PaymentForUpfrontFees" xlink:label="loc_embi_PaymentForUpfrontFees_30"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_NumberOfLicenseAgreements" xlink:label="loc_embi_NumberOfLicenseAgreements_31"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_NoticePeriodForTermination" xlink:label="loc_embi_NoticePeriodForTermination_32"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_AnnualFeesForLicenseAgreement" xlink:label="loc_embi_AnnualFeesForLicenseAgreement_33"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_AggregateMilestonePaymentsIfMilestonesAchieved" xlink:label="loc_embi_AggregateMilestonePaymentsIfMilestonesAchieved_34"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_embi_UniversityOfMississippiAgreementsLineItems_0" xlink:to="loc_embi_UniversityOfMississippiAgreementsTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_embi_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_embi_OptionAgreementMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_embi_LicenseAgreementMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_embi_Um5070LicenseAgreementMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_embi_Um5050ProdrugAndUm8930AnalogAgreementsMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_embi_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_dei_LegalEntityAxis_8" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_8" xlink:to="loc_dei_EntityDomain_8" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_8" xlink:to="loc_embi_UniversityOfMississippiMember_8" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_8" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_embi_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_embi_MonthAndYearOfAgreementAxis_12" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_embi_MonthAndYearOfAgreementAxis_12" xlink:to="loc_embi_MonthAndYearOfAgreementDomain_12" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_MonthAndYearOfAgreementDomain_12" xlink:to="loc_embi_December2015Member_12" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_MonthAndYearOfAgreementDomain_12" xlink:to="loc_embi_OctoberTwoThousandFifteenMember_13" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_embi_MonthAndYearOfAgreementAxis_12" xlink:to="loc_embi_MonthAndYearOfAgreementDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_embi_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_embi_MilestonePaymentsPayableAxis_17" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_embi_MilestonePaymentsPayableAxis_17" xlink:to="loc_embi_MilestonePaymentsPayableDomain_17" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_MilestonePaymentsPayableDomain_17" xlink:to="loc_embi_Milestone1Member_17" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_MilestonePaymentsPayableDomain_17" xlink:to="loc_embi_Milestone2Member_18" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_MilestonePaymentsPayableDomain_17" xlink:to="loc_embi_Milestone3Member_19" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_embi_MilestonePaymentsPayableAxis_17" xlink:to="loc_embi_MilestonePaymentsPayableDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_embi_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_23" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_23" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_23" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_23" xlink:to="loc_us-gaap_IntellectualPropertyMember_23" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_23" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_UniversityOfMississippiAgreementsLineItems_0" xlink:to="loc_embi_AnnualMaintenanceFeePayable_28" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_UniversityOfMississippiAgreementsLineItems_0" xlink:to="loc_embi_TermOfAgreement_29" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_UniversityOfMississippiAgreementsLineItems_0" xlink:to="loc_embi_PaymentForUpfrontFees_30" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_UniversityOfMississippiAgreementsLineItems_0" xlink:to="loc_embi_NumberOfLicenseAgreements_31" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_UniversityOfMississippiAgreementsLineItems_0" xlink:to="loc_embi_NoticePeriodForTermination_32" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_UniversityOfMississippiAgreementsLineItems_0" xlink:to="loc_embi_AnnualFeesForLicenseAgreement_33" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_UniversityOfMississippiAgreementsLineItems_0" xlink:to="loc_embi_AggregateMilestonePaymentsIfMilestonesAchieved_34" order="70" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/RelatedPartyMattersDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_IndependentContractorAgreementMember" xlink:label="loc_embi_IndependentContractorAgreementMember_1"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_SeparationAndReleaseAgreementMember" xlink:label="loc_embi_SeparationAndReleaseAgreementMember_2"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ConsultingAgreementMember" xlink:label="loc_embi_ConsultingAgreementMember_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_7"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_K2CIncMember" xlink:label="loc_embi_K2CIncMember_7"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_EmeraldHealthSciencesIncMember" xlink:label="loc_embi_EmeraldHealthSciencesIncMember_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_18"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_AvtarDhillonMember" xlink:label="loc_embi_AvtarDhillonMember_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_Default"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_MonthlyFee" xlink:label="loc_embi_MonthlyFee_23"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_LumpSumPaymentInAgreement" xlink:label="loc_embi_LumpSumPaymentInAgreement_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_25"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_26"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_InitialTermOfAgreement" xlink:label="loc_embi_InitialTermOfAgreement_27"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_TotalExpenseIncurredUnderAgreement" xlink:label="loc_embi_TotalExpenseIncurredUnderAgreement_28"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_AccruedExpenseUnderAgreement" xlink:label="loc_embi_AccruedExpenseUnderAgreement_29"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_PercentageOfAccruedInterestOnOutstandingBalance" xlink:label="loc_embi_PercentageOfAccruedInterestOnOutstandingBalance_30"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_AnnualFeeForAgreement" xlink:label="loc_embi_AnnualFeeForAgreement_31"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_PeriodOfDiscretionaryAnnualBonusPayableToContractorAfterEachFiscalYearEnd" xlink:label="loc_embi_PeriodOfDiscretionaryAnnualBonusPayableToContractorAfterEachFiscalYearEnd_32"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_MonthlyFeePaidEachMonthInExchangeOfServices" xlink:label="loc_embi_MonthlyFeePaidEachMonthInExchangeOfServices_33"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices" xlink:label="loc_embi_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices_34"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_embi_IndependentContractorAgreementMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_embi_SeparationAndReleaseAgreementMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_embi_ConsultingAgreementMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_dei_LegalEntityAxis_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_7" xlink:to="loc_dei_EntityDomain_7" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_7" xlink:to="loc_embi_K2CIncMember_7" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_7" xlink:to="loc_embi_EmeraldHealthSciencesIncMember_8" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_7" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_VestingAxis_12" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_12" xlink:to="loc_us-gaap_VestingDomain_12" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_12" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_12" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_12" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_13" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_12" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_14" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_12" xlink:to="loc_us-gaap_VestingDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_18" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_18" xlink:to="loc_us-gaap_RelatedPartyDomain_18" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_18" xlink:to="loc_embi_AvtarDhillonMember_18" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_18" xlink:to="loc_us-gaap_RelatedPartyDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_embi_MonthlyFee_23" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_embi_LumpSumPaymentInAgreement_24" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_25" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_26" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_embi_InitialTermOfAgreement_27" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_embi_TotalExpenseIncurredUnderAgreement_28" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_embi_AccruedExpenseUnderAgreement_29" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_embi_PercentageOfAccruedInterestOnOutstandingBalance_30" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_embi_AnnualFeeForAgreement_31" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_embi_PeriodOfDiscretionaryAnnualBonusPayableToContractorAfterEachFiscalYearEnd_32" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_embi_MonthlyFeePaidEachMonthInExchangeOfServices_33" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_embi_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices_34" order="120" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/IncomeTaxesDetailTextuals">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_6"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_0" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1" xlink:to="loc_us-gaap_ForeignCountryMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_0" xlink:to="loc_us-gaap_OperatingLossCarryforwards_6" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/NetIncomeLossPerShareOfCommonStockDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDilutedLineItems" xlink:label="loc_us-gaap_EarningsPerShareDilutedLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_1"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_DilutedSecuritiesAxis" xlink:label="loc_embi_DilutedSecuritiesAxis_1"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_DilutedSecuritiesDomain" xlink:label="loc_embi_DilutedSecuritiesDomain_1"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_UnvestedRestrictedStockMember" xlink:label="loc_embi_UnvestedRestrictedStockMember_1"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_OptionsMember" xlink:label="loc_embi_OptionsMember_2"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_WarrantsMember" xlink:label="loc_embi_WarrantsMember_3"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_WarrantsLiabilityClassifiedMember" xlink:label="loc_embi_WarrantsLiabilityClassifiedMember_4"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_DilutedSecuritiesDomain" xlink:label="loc_embi_DilutedSecuritiesDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DilutiveSecurities" xlink:label="loc_us-gaap_DilutiveSecurities_9"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_DilutiveSecuritiesEffectOnBasicEarningsPerShareShares" xlink:label="loc_embi_DilutiveSecuritiesEffectOnBasicEarningsPerShareShares_10"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_0" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_1" xlink:to="loc_embi_DilutedSecuritiesAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_embi_DilutedSecuritiesAxis_1" xlink:to="loc_embi_DilutedSecuritiesDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_DilutedSecuritiesDomain_1" xlink:to="loc_embi_UnvestedRestrictedStockMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_DilutedSecuritiesDomain_1" xlink:to="loc_embi_OptionsMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_DilutedSecuritiesDomain_1" xlink:to="loc_embi_WarrantsMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_DilutedSecuritiesDomain_1" xlink:to="loc_embi_WarrantsLiabilityClassifiedMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_embi_DilutedSecuritiesAxis_1" xlink:to="loc_embi_DilutedSecuritiesDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_0" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_9" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_9" xlink:to="loc_us-gaap_DilutiveSecurities_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_9" xlink:to="loc_embi_DilutiveSecuritiesEffectOnBasicEarningsPerShareShares_10" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/NetIncomeLossPerShareOfCommonStockDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_3"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_CommonSharesUnderlyingConvertiblePreferredStockMember" xlink:label="loc_embi_CommonSharesUnderlyingConvertiblePreferredStockMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_10"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:to="loc_us-gaap_RestrictedStockMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:to="loc_embi_CommonSharesUnderlyingConvertiblePreferredStockMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:to="loc_us-gaap_WarrantMember_5" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_10" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails2">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputOfferedPriceMember" xlink:label="loc_us-gaap_MeasurementInputOfferedPriceMember_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_14"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" xlink:label="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_Default"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_PricingModelAxis" xlink:label="loc_embi_PricingModelAxis_18"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_PricingModelDomain" xlink:label="loc_embi_PricingModelDomain_18"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_PricingModelMember" xlink:label="loc_embi_PricingModelMember_18"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_PricingModelDomain" xlink:label="loc_embi_PricingModelDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_25"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputOfferedPriceMember_5" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_srt_RangeAxis_9" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9" xlink:to="loc_srt_RangeMember_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9" xlink:to="loc_srt_MinimumMember_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9" xlink:to="loc_srt_MaximumMember_10" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9" xlink:to="loc_srt_RangeMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_14" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_14" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_14" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_14" xlink:to="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_14" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_14" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_embi_PricingModelAxis_18" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_embi_PricingModelAxis_18" xlink:to="loc_embi_PricingModelDomain_18" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_PricingModelDomain_18" xlink:to="loc_embi_PricingModelMember_18" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_embi_PricingModelAxis_18" xlink:to="loc_embi_PricingModelDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_23" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_24" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_25" order="30" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails3">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_PricingModelAxis" xlink:label="loc_embi_PricingModelAxis_8"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_PricingModelDomain" xlink:label="loc_embi_PricingModelDomain_8"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_MonteCarloSimulationsMember" xlink:label="loc_embi_MonteCarloSimulationsMember_8"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_PricingModelDomain" xlink:label="loc_embi_PricingModelDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_12"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_EmeraldFinancingMember" xlink:label="loc_embi_EmeraldFinancingMember_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_22"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_24"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_embi_PricingModelAxis_8" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_embi_PricingModelAxis_8" xlink:to="loc_embi_PricingModelDomain_8" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_PricingModelDomain_8" xlink:to="loc_embi_MonteCarloSimulationsMember_8" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_embi_PricingModelAxis_8" xlink:to="loc_embi_PricingModelDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_dei_LegalEntityAxis_12" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_12" xlink:to="loc_dei_EntityDomain_12" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_12" xlink:to="loc_embi_EmeraldFinancingMember_12" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_12" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_srt_RangeAxis_16" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_16" xlink:to="loc_srt_RangeMember_16" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_16" xlink:to="loc_srt_MinimumMember_16" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_16" xlink:to="loc_srt_MaximumMember_17" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_16" xlink:to="loc_srt_RangeMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_22" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_23" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_24" order="30" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails4">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputOfferedPriceMember" xlink:label="loc_us-gaap_MeasurementInputOfferedPriceMember_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_PricingModelAxis" xlink:label="loc_embi_PricingModelAxis_9"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_PricingModelDomain" xlink:label="loc_embi_PricingModelDomain_9"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_PricingModelMember" xlink:label="loc_embi_PricingModelMember_9"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_PricingModelDomain" xlink:label="loc_embi_PricingModelDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_13"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_SeriesBWarrantMember" xlink:label="loc_embi_SeriesBWarrantMember_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_25"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputOfferedPriceMember_5" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_embi_PricingModelAxis_9" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_embi_PricingModelAxis_9" xlink:to="loc_embi_PricingModelDomain_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_PricingModelDomain_9" xlink:to="loc_embi_PricingModelMember_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_embi_PricingModelAxis_9" xlink:to="loc_embi_PricingModelDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_13" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_13" xlink:to="loc_us-gaap_ClassOfStockDomain_13" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_13" xlink:to="loc_embi_SeriesBWarrantMember_13" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_13" xlink:to="loc_us-gaap_ClassOfStockDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_srt_RangeAxis_17" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_17" xlink:to="loc_srt_RangeMember_17" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_17" xlink:to="loc_srt_MinimumMember_17" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_17" xlink:to="loc_srt_MaximumMember_18" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_17" xlink:to="loc_srt_RangeMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_23" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_24" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_25" order="30" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_Pre2015CommonStockWarrantsMember" xlink:label="loc_embi_Pre2015CommonStockWarrantsMember_1"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_TwoThousandFifteenCommonStockWarrantsMember" xlink:label="loc_embi_TwoThousandFifteenCommonStockWarrantsMember_2"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_CommonStockWarrantsToSeriesBStockholdersMember" xlink:label="loc_embi_CommonStockWarrantsToSeriesBStockholdersMember_3"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember" xlink:label="loc_embi_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember_4"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember" xlink:label="loc_embi_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember_5"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember" xlink:label="loc_embi_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember_6"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember" xlink:label="loc_embi_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember_7"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_TwoThousandEighteenEmeraldFinancingWarrantsMember" xlink:label="loc_embi_TwoThousandEighteenEmeraldFinancingWarrantsMember_8"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" xlink:label="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_9"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_TwoThousandNineteenCommonStockWarrantsMember" xlink:label="loc_embi_TwoThousandNineteenCommonStockWarrantsMember_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_20"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_TermOfWarrant" xlink:label="loc_embi_TermOfWarrant_21"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_WarrantsVestedAndOutstanding" xlink:label="loc_embi_WarrantsVestedAndOutstanding_22"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_Pre2015CommonStockWarrantsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandFifteenCommonStockWarrantsMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_CommonStockWarrantsToSeriesBStockholdersMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember_5" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember_6" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember_7" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandEighteenEmeraldFinancingWarrantsMember_8" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_9" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandNineteenCommonStockWarrantsMember_10" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_srt_RangeAxis_14" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_14" xlink:to="loc_srt_RangeMember_14" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_14" xlink:to="loc_srt_MinimumMember_14" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_14" xlink:to="loc_srt_MaximumMember_15" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_14" xlink:to="loc_srt_RangeMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_20" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_embi_TermOfWarrant_21" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_embi_WarrantsVestedAndOutstanding_22" order="30" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetailsTextuals">
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_DerivativeLiabilitiesLineItems" xlink:label="loc_embi_DerivativeLiabilitiesLineItems_0"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_DerivativeLiabilitiesTable" xlink:label="loc_embi_DerivativeLiabilitiesTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_EmeraldFinancingMember" xlink:label="loc_embi_EmeraldFinancingMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_5"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_TwoThousandNineteenCommonStockWarrantsMember" xlink:label="loc_embi_TwoThousandNineteenCommonStockWarrantsMember_5"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" xlink:label="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_6"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_TwoThousandEighteenEmeraldFinancingWarrantsMember" xlink:label="loc_embi_TwoThousandEighteenEmeraldFinancingWarrantsMember_7"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_SeriesBWarrantMember" xlink:label="loc_embi_SeriesBWarrantMember_8"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember" xlink:label="loc_embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_13"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_SeriesBPreferredStockConversionLiabilityMember" xlink:label="loc_embi_SeriesBPreferredStockConversionLiabilityMember_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_20"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_NumberOfWarrantsExercisable" xlink:label="loc_embi_NumberOfWarrantsExercisable_21"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ClassOfWarrantOrRightWarrantsAggregateExercisePrice" xlink:label="loc_embi_ClassOfWarrantOrRightWarrantsAggregateExercisePrice_22"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ClassOfWarrantOrRightWarrantsExercise" xlink:label="loc_embi_ClassOfWarrantOrRightWarrantsExercise_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_25"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_FairValueOfCommonStockWarrantsIssued" xlink:label="loc_embi_FairValueOfCommonStockWarrantsIssued_26"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDerivativeIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDerivativeIssuanceCosts_27"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_28"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ReclassificationOfDerivativesToEquity" xlink:label="loc_embi_ReclassificationOfDerivativesToEquity_29"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_0" xlink:to="loc_embi_DerivativeLiabilitiesTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_embi_DerivativeLiabilitiesTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_embi_EmeraldFinancingMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_embi_DerivativeLiabilitiesTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5" xlink:to="loc_embi_TwoThousandNineteenCommonStockWarrantsMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5" xlink:to="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5" xlink:to="loc_embi_TwoThousandEighteenEmeraldFinancingWarrantsMember_7" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5" xlink:to="loc_embi_SeriesBWarrantMember_8" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5" xlink:to="loc_embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_9" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_embi_DerivativeLiabilitiesTable_1" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_13" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_13" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_13" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_13" xlink:to="loc_embi_SeriesBPreferredStockConversionLiabilityMember_13" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_13" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_18" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_19" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_0" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_20" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_0" xlink:to="loc_embi_NumberOfWarrantsExercisable_21" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_0" xlink:to="loc_embi_ClassOfWarrantOrRightWarrantsAggregateExercisePrice_22" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_0" xlink:to="loc_embi_ClassOfWarrantOrRightWarrantsExercise_23" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_24" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_0" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_25" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_0" xlink:to="loc_embi_FairValueOfCommonStockWarrantsIssued_26" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_0" xlink:to="loc_us-gaap_PaymentsOfDerivativeIssuanceCosts_27" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_0" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_28" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_0" xlink:to="loc_embi_ReclassificationOfDerivativesToEquity_29" order="120" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/SubsequentEventsDetailTextuals">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_PaymentOfUpfrontLicenseFee" xlink:label="loc_embi_PaymentOfUpfrontLicenseFee_6"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1" xlink:to="loc_us-gaap_SubsequentEventMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_embi_PaymentOfUpfrontLicenseFee_6" order="10" use="optional"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>embi-20191231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_23"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_AccruedExpenseUnderAgreement" xlink:label="loc_embi_AccruedExpenseUnderAgreement_24"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_AdditionalConversionLiability" xlink:label="loc_embi_AdditionalConversionLiability_25"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_AggregateMilestonePaymentsIfMilestonesAchieved" xlink:label="loc_embi_AggregateMilestonePaymentsIfMilestonesAchieved_26"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_AlbanyMolecularResearchIncMember" xlink:label="loc_embi_AlbanyMolecularResearchIncMember_27"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_AllocationOfDebtOnBasisOfRelativeFairValue" xlink:label="loc_embi_AllocationOfDebtOnBasisOfRelativeFairValue_28"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_AllocationOfWarrantOnBasisOfRelativeFairValue" xlink:label="loc_embi_AllocationOfWarrantOnBasisOfRelativeFairValue_29"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_AmortizationOfDebtDiscount" xlink:label="loc_embi_AmortizationOfDebtDiscount_30"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_AmortizationOfTransactionCosts" xlink:label="loc_embi_AmortizationOfTransactionCosts_31"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_AmountOfEachWarrantOutstanding" xlink:label="loc_embi_AmountOfEachWarrantOutstanding_32"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_AmountOfPassThroughExpensesAndConsultingFees" xlink:label="loc_embi_AmountOfPassThroughExpensesAndConsultingFees_33"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_AnnualFeeForAgreement" xlink:label="loc_embi_AnnualFeeForAgreement_34"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_AnnualFeesForLicenseAgreement" xlink:label="loc_embi_AnnualFeesForLicenseAgreement_35"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_AnnualMaintenanceFeePayable" xlink:label="loc_embi_AnnualMaintenanceFeePayable_36"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_AvtarDhillonMember" xlink:label="loc_embi_AvtarDhillonMember_37"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_AwardsGrantedOutside2014PlanMember" xlink:label="loc_embi_AwardsGrantedOutside2014PlanMember_38"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_AwardsGrantedOutsideThe2014PlanMember" xlink:label="loc_embi_AwardsGrantedOutsideThe2014PlanMember_39"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue" xlink:label="loc_embi_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_40"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement" xlink:label="loc_embi_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement_41"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_BeneficialConversionFeatureUponIssuanceofSeriesDPreferredStock" xlink:label="loc_embi_BeneficialConversionFeatureUponIssuanceofSeriesDPreferredStock_42"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_BeneficialConversionFeatureUponIssuanceofSeriesFPreferredStock" xlink:label="loc_embi_BeneficialConversionFeatureUponIssuanceofSeriesFPreferredStock_43"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_CashPaidDuringPeriodForAbstract" xlink:label="loc_embi_CashPaidDuringPeriodForAbstract_44"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ChangeInFairValueOfDerivativeLiabilities" xlink:label="loc_embi_ChangeInFairValueOfDerivativeLiabilities_45"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ChangeInFairValueOfWarrantLiability" xlink:label="loc_embi_ChangeInFairValueOfWarrantLiability_46"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ClassOfWarrantOrRightWarrantsAggregateExercisePrice" xlink:label="loc_embi_ClassOfWarrantOrRightWarrantsAggregateExercisePrice_47"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ClassOfWarrantOrRightWarrantsExercise" xlink:label="loc_embi_ClassOfWarrantOrRightWarrantsExercise_48"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_CommonSharesUnderlyingConvertiblePreferredStockMember" xlink:label="loc_embi_CommonSharesUnderlyingConvertiblePreferredStockMember_49"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_CommonStockAggregatePurchasePrice" xlink:label="loc_embi_CommonStockAggregatePurchasePrice_50"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_CommonStockIssuedForServices" xlink:label="loc_embi_CommonStockIssuedForServices_51"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_CommonStockWarrantsToSeriesBStockholdersMember" xlink:label="loc_embi_CommonStockWarrantsToSeriesBStockholdersMember_52"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ConsultingAgreementMember" xlink:label="loc_embi_ConsultingAgreementMember_53"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ContractPayableDue" xlink:label="loc_embi_ContractPayableDue_54"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ConversionLiabilityIntoCommonStockPerShare" xlink:label="loc_embi_ConversionLiabilityIntoCommonStockPerShare_55"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock" xlink:label="loc_embi_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock_56"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares" xlink:label="loc_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares_57"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue" xlink:label="loc_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue_58"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest" xlink:label="loc_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest_59"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterestShares" xlink:label="loc_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterestShares_60"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ConversionOfSeriesCPreferredStockToCommonStockShares" xlink:label="loc_embi_ConversionOfSeriesCPreferredStockToCommonStockShares_61"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ConversionOfSeriesCPreferredStockToCommonStockSharesValue" xlink:label="loc_embi_ConversionOfSeriesCPreferredStockToCommonStockSharesValue_62"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ConversionOfSeriesDPreferredStockToCommonStock" xlink:label="loc_embi_ConversionOfSeriesDPreferredStockToCommonStock_63"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ConversionOfSeriesDPreferredStockToCommonStockShares" xlink:label="loc_embi_ConversionOfSeriesDPreferredStockToCommonStockShares_64"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ConversionOfSeriesFPreferredStockToCommonStockShares" xlink:label="loc_embi_ConversionOfSeriesFPreferredStockToCommonStockShares_65"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ConversionOfSeriesFPreferredStockToCommonStockValue" xlink:label="loc_embi_ConversionOfSeriesFPreferredStockToCommonStockValue_66"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ConversionPrice" xlink:label="loc_embi_ConversionPrice_67"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ConversionPricePerShare" xlink:label="loc_embi_ConversionPricePerShare_68"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ConvertedRate10000001Member" xlink:label="loc_embi_ConvertedRate10000001Member_69"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ConvertedRate100001Member" xlink:label="loc_embi_ConvertedRate100001Member_70"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ConvertedRateAxis" xlink:label="loc_embi_ConvertedRateAxis_71"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ConvertedRateDomain" xlink:label="loc_embi_ConvertedRateDomain_72"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ConvertibleDebtRelatedPartyTextBlock" xlink:label="loc_embi_ConvertibleDebtRelatedPartyTextBlock_73"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ConvertibleMultiDrawCreditAgreementIssuanceCosts" xlink:label="loc_embi_ConvertibleMultiDrawCreditAgreementIssuanceCosts_74"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_CouponInterestExpense" xlink:label="loc_embi_CouponInterestExpense_75"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_CurrentConvertibleDebtExcludingNoncurrentPortion" xlink:label="loc_embi_CurrentConvertibleDebtExcludingNoncurrentPortion_76"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_December2015Member" xlink:label="loc_embi_December2015Member_77"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_DeemedDividendFromBeneficialConversionFeatureOfSeriesDPreferredStock" xlink:label="loc_embi_DeemedDividendFromBeneficialConversionFeatureOfSeriesDPreferredStock_78"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_DeemedDividendFromBeneficialConversionFeatureOfSeriesFPreferredStock" xlink:label="loc_embi_DeemedDividendFromBeneficialConversionFeatureOfSeriesFPreferredStock_79"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:label="loc_embi_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_80"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_DeferredTaxLiabilitiesNoteDiscount" xlink:label="loc_embi_DeferredTaxLiabilitiesNoteDiscount_81"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_DerivativeLiabilitiesLineItems" xlink:label="loc_embi_DerivativeLiabilitiesLineItems_82"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_DerivativeLiabilitiesTable" xlink:label="loc_embi_DerivativeLiabilitiesTable_83"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_DilutedSecuritiesAxis" xlink:label="loc_embi_DilutedSecuritiesAxis_84"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_DilutedSecuritiesDomain" xlink:label="loc_embi_DilutedSecuritiesDomain_85"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_DilutiveSecuritiesEffectOnBasicEarningsPerShareShares" xlink:label="loc_embi_DilutiveSecuritiesEffectOnBasicEarningsPerShareShares_86"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_DocumentAndEntityInformationAbstract" xlink:label="loc_embi_DocumentAndEntityInformationAbstract_87"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_DouglasCesarioMember" xlink:label="loc_embi_DouglasCesarioMember_88"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrant" xlink:label="loc_embi_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrant_89"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember" xlink:label="loc_embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_90"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_EmeraldFinancingIssuanceCosts" xlink:label="loc_embi_EmeraldFinancingIssuanceCosts_91"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_EmeraldFinancingMember" xlink:label="loc_embi_EmeraldFinancingMember_92"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_EmeraldHealthSciencesIncMember" xlink:label="loc_embi_EmeraldHealthSciencesIncMember_93"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember" xlink:label="loc_embi_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_94"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_EmeraldWarrantLiabilityMember" xlink:label="loc_embi_EmeraldWarrantLiabilityMember_95"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_EquityLineItems" xlink:label="loc_embi_EquityLineItems_96"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_EquityTable" xlink:label="loc_embi_EquityTable_97"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_EstimatedAgreementFeesAndExpenses" xlink:label="loc_embi_EstimatedAgreementFeesAndExpenses_98"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_EstimatedInitialPaymentForContract" xlink:label="loc_embi_EstimatedInitialPaymentForContract_99"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ExerciseOfWarrants" xlink:label="loc_embi_ExerciseOfWarrants_100"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_FairMarketValueOfSharesGranted" xlink:label="loc_embi_FairMarketValueOfSharesGranted_101"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_FairMarketValueOfStockOptions" xlink:label="loc_embi_FairMarketValueOfStockOptions_102"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_FairValueOfCommonStockWarrantsIssued" xlink:label="loc_embi_FairValueOfCommonStockWarrantsIssued_103"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement" xlink:label="loc_embi_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement_104"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_FairValueOfDerivativeLiabilitiesRollForward" xlink:label="loc_embi_FairValueOfDerivativeLiabilitiesRollForward_105"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_FairValueOfDerivativeLiabilityExcessOfProceeds" xlink:label="loc_embi_FairValueOfDerivativeLiabilityExcessOfProceeds_106"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_FairValueOfDerivativeLiabilityInExcessOfProceeds" xlink:label="loc_embi_FairValueOfDerivativeLiabilityInExcessOfProceeds_107"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_FairValueOfUnderlyingShares" xlink:label="loc_embi_FairValueOfUnderlyingShares_108"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_FairValueOfWarrantsIssued" xlink:label="loc_embi_FairValueOfWarrantsIssued_109"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_FairValueOfWarrantsIssuedInConnectionWithFinancings" xlink:label="loc_embi_FairValueOfWarrantsIssuedInConnectionWithFinancings_110"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_FeesAndExpensesForServicesProvided" xlink:label="loc_embi_FeesAndExpensesForServicesProvided_111"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_FinancingSharesWarrantExercise" xlink:label="loc_embi_FinancingSharesWarrantExercise_112"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_FinancingValueWarrantExercise" xlink:label="loc_embi_FinancingValueWarrantExercise_113"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_FixedAssetsProvidedToUniversityInLieuOfCash" xlink:label="loc_embi_FixedAssetsProvidedToUniversityInLieuOfCash_114"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_GlauconixBiosciencesIncMember" xlink:label="loc_embi_GlauconixBiosciencesIncMember_115"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_GuarantorFailedToPay" xlink:label="loc_embi_GuarantorFailedToPay_116"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_IncomeTaxReconciliationChangeInCompoundDerivative" xlink:label="loc_embi_IncomeTaxReconciliationChangeInCompoundDerivative_117"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_IncomeTaxReconciliationUncertainTaxPositions" xlink:label="loc_embi_IncomeTaxReconciliationUncertainTaxPositions_118"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_IncreaseChangeInFairValueOfWarrantLiability" xlink:label="loc_embi_IncreaseChangeInFairValueOfWarrantLiability_119"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_IncreaseDecreaseInDepositsAndOtherAssets" xlink:label="loc_embi_IncreaseDecreaseInDepositsAndOtherAssets_120"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_IncrementalAgreementFeesAndExpenses" xlink:label="loc_embi_IncrementalAgreementFeesAndExpenses_121"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_IndependentContractorAgreementMember" xlink:label="loc_embi_IndependentContractorAgreementMember_122"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_InitialTermOfAgreement" xlink:label="loc_embi_InitialTermOfAgreement_123"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_IntrinsicValueOfWarrantExercises" xlink:label="loc_embi_IntrinsicValueOfWarrantExercises_124"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_IssuanceOfPreferredStockNetOfIssuanceCosts" xlink:label="loc_embi_IssuanceOfPreferredStockNetOfIssuanceCosts_125"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_IssuanceOfPreferredStockNetOfIssuanceCostsShares" xlink:label="loc_embi_IssuanceOfPreferredStockNetOfIssuanceCostsShares_126"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_IssuanceOfPreferredStockSeriesNetOfIssuanceCostsShares" xlink:label="loc_embi_IssuanceOfPreferredStockSeriesNetOfIssuanceCostsShares_127"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_IssuanceOfPreferredStockSeriesNetOfIssuanceCostsValue" xlink:label="loc_embi_IssuanceOfPreferredStockSeriesNetOfIssuanceCostsValue_128"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_K2CIncMember" xlink:label="loc_embi_K2CIncMember_129"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_LeaseAgreementMember" xlink:label="loc_embi_LeaseAgreementMember_130"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_LetterAgreementMember" xlink:label="loc_embi_LetterAgreementMember_131"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_LicenseAgreementMember" xlink:label="loc_embi_LicenseAgreementMember_132"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_LiquidationProvisionCommonStockEquivalentShares" xlink:label="loc_embi_LiquidationProvisionCommonStockEquivalentShares_133"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_LiquidationProvisionCommonStockEquivalentValue" xlink:label="loc_embi_LiquidationProvisionCommonStockEquivalentValue_134"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_LossOnCommonStockIssuanceFromConversionOfAccruedInterest" xlink:label="loc_embi_LossOnCommonStockIssuanceFromConversionOfAccruedInterest_135"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_LumpSumPaymentInAgreement" xlink:label="loc_embi_LumpSumPaymentInAgreement_136"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_MasterServiceAgreementMember" xlink:label="loc_embi_MasterServiceAgreementMember_137"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_Milestone1Member" xlink:label="loc_embi_Milestone1Member_138"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_Milestone2Member" xlink:label="loc_embi_Milestone2Member_139"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_Milestone3Member" xlink:label="loc_embi_Milestone3Member_140"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_MilestonePaymentsPayableAxis" xlink:label="loc_embi_MilestonePaymentsPayableAxis_141"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_MilestonePaymentsPayableDomain" xlink:label="loc_embi_MilestonePaymentsPayableDomain_142"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_MinimumLitigationJudgementAmount" xlink:label="loc_embi_MinimumLitigationJudgementAmount_143"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_MonteCarloSimulationsMember" xlink:label="loc_embi_MonteCarloSimulationsMember_144"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_MonthAndYearOfAgreementAxis" xlink:label="loc_embi_MonthAndYearOfAgreementAxis_145"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_MonthAndYearOfAgreementDomain" xlink:label="loc_embi_MonthAndYearOfAgreementDomain_146"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_MonthlyFee" xlink:label="loc_embi_MonthlyFee_147"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices" xlink:label="loc_embi_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices_148"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_MonthlyFeePaidEachMonthInExchangeOfServices" xlink:label="loc_embi_MonthlyFeePaidEachMonthInExchangeOfServices_149"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_MultiDrawCreditAgreementMember" xlink:label="loc_embi_MultiDrawCreditAgreementMember_150"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_NatureOfOperationsAndBusinessActivitiesAbstract" xlink:label="loc_embi_NatureOfOperationsAndBusinessActivitiesAbstract_151"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_NatureOfOperationsAndBusinessActivitiesLineItems" xlink:label="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_152"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_NatureOfOperationsAndBusinessActivitiesTable" xlink:label="loc_embi_NatureOfOperationsAndBusinessActivitiesTable_153"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_NetLossAdjustedBalance" xlink:label="loc_embi_NetLossAdjustedBalance_154"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_NonCashInterestExpenseAbstract" xlink:label="loc_embi_NonCashInterestExpenseAbstract_155"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_NoramcoAgreementMember" xlink:label="loc_embi_NoramcoAgreementMember_156"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_NoticePeriodForTermination" xlink:label="loc_embi_NoticePeriodForTermination_157"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_NumberOfCommonStockIssuedUponConversionOfPreferredStock" xlink:label="loc_embi_NumberOfCommonStockIssuedUponConversionOfPreferredStock_158"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_NumberOfInvestors" xlink:label="loc_embi_NumberOfInvestors_159"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_NumberOfLicenseAgreements" xlink:label="loc_embi_NumberOfLicenseAgreements_160"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_NumberOfWarrantsExercisable" xlink:label="loc_embi_NumberOfWarrantsExercisable_161"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_OctoberTwoThousandFifteenMember" xlink:label="loc_embi_OctoberTwoThousandFifteenMember_162"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_OmnibusIncentivePlan2014Member" xlink:label="loc_embi_OmnibusIncentivePlan2014Member_163"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_OneTimeUpfrontPayment" xlink:label="loc_embi_OneTimeUpfrontPayment_164"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_OptionAgreementMember" xlink:label="loc_embi_OptionAgreementMember_165"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_OptionsMember" xlink:label="loc_embi_OptionsMember_166"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_PaymentForUpfrontFees" xlink:label="loc_embi_PaymentForUpfrontFees_167"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_PaymentOfUpfrontLicenseFee" xlink:label="loc_embi_PaymentOfUpfrontLicenseFee_168"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_PercentageOfAccruedInterestOnOutstandingBalance" xlink:label="loc_embi_PercentageOfAccruedInterestOnOutstandingBalance_169"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase" xlink:label="loc_embi_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase_170"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_PercentageOfConversionAmount" xlink:label="loc_embi_PercentageOfConversionAmount_171"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_PercentageOfSharesToBeRedeemed" xlink:label="loc_embi_PercentageOfSharesToBeRedeemed_172"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_PeriodOfDiscretionaryAnnualBonusPayableToContractorAfterEachFiscalYearEnd" xlink:label="loc_embi_PeriodOfDiscretionaryAnnualBonusPayableToContractorAfterEachFiscalYearEnd_173"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_PharmaceuticalsInternationalInc.AgreementMember" xlink:label="loc_embi_PharmaceuticalsInternationalInc.AgreementMember_174"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_Pre2015CommonStockWarrantsMember" xlink:label="loc_embi_Pre2015CommonStockWarrantsMember_175"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_PreferredStockPutOptionLiability" xlink:label="loc_embi_PreferredStockPutOptionLiability_176"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_PricingModelAxis" xlink:label="loc_embi_PricingModelAxis_177"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_PricingModelDomain" xlink:label="loc_embi_PricingModelDomain_178"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_PricingModelMember" xlink:label="loc_embi_PricingModelMember_179"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement" xlink:label="loc_embi_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement_180"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ProceedsFromConvertibleMultiDrawCreditAgreement" xlink:label="loc_embi_ProceedsFromConvertibleMultiDrawCreditAgreement_181"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ProceedsFromEmeraldFinancingNetOfIssuanceCosts" xlink:label="loc_embi_ProceedsFromEmeraldFinancingNetOfIssuanceCosts_182"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ProceedsFromFinancingBetweenConversionLiabilityAndWarrants" xlink:label="loc_embi_ProceedsFromFinancingBetweenConversionLiabilityAndWarrants_183"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ProvisionForConversionOfPreferredStock" xlink:label="loc_embi_ProvisionForConversionOfPreferredStock_184"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ReclassificationOfDerivativesToEquity" xlink:label="loc_embi_ReclassificationOfDerivativesToEquity_185"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_RedemptionAmountPercentage" xlink:label="loc_embi_RedemptionAmountPercentage_186"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ReductionToAdditionalPaidInCapitalFromTheIssuanceOfCommonStock" xlink:label="loc_embi_ReductionToAdditionalPaidInCapitalFromTheIssuanceOfCommonStock_187"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_RepaymentOfConvertibleMultiDrawCreditAgreement" xlink:label="loc_embi_RepaymentOfConvertibleMultiDrawCreditAgreement_188"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ResearchAgreementMember" xlink:label="loc_embi_ResearchAgreementMember_189"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_RestrictedStockAgreementsMember" xlink:label="loc_embi_RestrictedStockAgreementsMember_190"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_RisksAndUncertaintiesPolicyTextBlock" xlink:label="loc_embi_RisksAndUncertaintiesPolicyTextBlock_191"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_RrdInternationalAgreementMember" xlink:label="loc_embi_RrdInternationalAgreementMember_192"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ScheduleOfAdjustmentForDifferenceBetweenFairValueOfWarrantLiabilitiesAndTotalProceedsReceivedTableTextBlock" xlink:label="loc_embi_ScheduleOfAdjustmentForDifferenceBetweenFairValueOfWarrantLiabilitiesAndTotalProceedsReceivedTableTextBlock_193"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ScheduleOfAssumptionsUsedToComputeFairValueOfWarrantsTableTextBlock" xlink:label="loc_embi_ScheduleOfAssumptionsUsedToComputeFairValueOfWarrantsTableTextBlock_194"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ScheduleOfInterestExpenseTableTextBlock" xlink:label="loc_embi_ScheduleOfInterestExpenseTableTextBlock_195"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_SecondDrawOnMultiDrawCreditFacilityMember" xlink:label="loc_embi_SecondDrawOnMultiDrawCreditFacilityMember_196"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_SecuredPromissoryNoteAndSecurityAgreementMember" xlink:label="loc_embi_SecuredPromissoryNoteAndSecurityAgreementMember_197"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_SecuritiesPurchaseAgreementMember" xlink:label="loc_embi_SecuritiesPurchaseAgreementMember_198"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_SeparationAndReleaseAgreementMember" xlink:label="loc_embi_SeparationAndReleaseAgreementMember_199"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_SeriesBPreferredStockConversionLiabilityMember" xlink:label="loc_embi_SeriesBPreferredStockConversionLiabilityMember_200"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_SeriesBWarrantMember" xlink:label="loc_embi_SeriesBWarrantMember_201"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_SeriesBWarrantsMember" xlink:label="loc_embi_SeriesBWarrantsMember_202"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_SeriesFPreferredStockPutOptionLiabilityMember" xlink:label="loc_embi_SeriesFPreferredStockPutOptionLiabilityMember_203"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ShareAndWarrantsIssuanceCosts" xlink:label="loc_embi_ShareAndWarrantsIssuanceCosts_204"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ShareIssuanceCosts" xlink:label="loc_embi_ShareIssuanceCosts_205"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_SignificantContractsAbstract" xlink:label="loc_embi_SignificantContractsAbstract_206"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_SignificantContractsLineItems" xlink:label="loc_embi_SignificantContractsLineItems_207"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_SignificantContractsTable" xlink:label="loc_embi_SignificantContractsTable_208"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_SignificantContractsTextBlock" xlink:label="loc_embi_SignificantContractsTextBlock_209"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants" xlink:label="loc_embi_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants_210"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_StockBasedCompensationForNonEmployeesPolicyTextBlock" xlink:label="loc_embi_StockBasedCompensationForNonEmployeesPolicyTextBlock_211"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_StockIssuanceCosts" xlink:label="loc_embi_StockIssuanceCosts_212"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_StockIssuedDuringPeriodSharesIssuedForStockBasedCompensationExpense" xlink:label="loc_embi_StockIssuedDuringPeriodSharesIssuedForStockBasedCompensationExpense_213"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_StockIssuedDuringPeriodSharesNetOfIssuanceCosts" xlink:label="loc_embi_StockIssuedDuringPeriodSharesNetOfIssuanceCosts_214"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_StockIssuedDuringPeriodSharesNetOfIssuanceCostsAndWarrants" xlink:label="loc_embi_StockIssuedDuringPeriodSharesNetOfIssuanceCostsAndWarrants_215"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_StockIssuedDuringPeriodSharesSeriesBWarrantExercises" xlink:label="loc_embi_StockIssuedDuringPeriodSharesSeriesBWarrantExercises_216"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_StockIssuedDuringPeriodValueNetOfIssuanceCosts" xlink:label="loc_embi_StockIssuedDuringPeriodValueNetOfIssuanceCosts_217"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_StockIssuedDuringPeriodValueNetOfIssuanceCostsAndWarrants" xlink:label="loc_embi_StockIssuedDuringPeriodValueNetOfIssuanceCostsAndWarrants_218"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_StockIssuedDuringPeriodValueSeriesBWarrantExercises" xlink:label="loc_embi_StockIssuedDuringPeriodValueSeriesBWarrantExercises_219"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_SubsequentFinancingPurchasePriceDescription" xlink:label="loc_embi_SubsequentFinancingPurchasePriceDescription_220"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_TermOfAgreement" xlink:label="loc_embi_TermOfAgreement_221"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_TermOfWarrant" xlink:label="loc_embi_TermOfWarrant_222"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_TermOfWarrants" xlink:label="loc_embi_TermOfWarrants_223"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_TermsOfAgreementRenewed" xlink:label="loc_embi_TermsOfAgreementRenewed_224"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_TotalExpenseIncurredUnderAgreement" xlink:label="loc_embi_TotalExpenseIncurredUnderAgreement_225"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_TwoThousandEighteenEmeraldFinancingWarrantsMember" xlink:label="loc_embi_TwoThousandEighteenEmeraldFinancingWarrantsMember_226"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" xlink:label="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_227"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_TwoThousandFifteenCommonStockWarrantsMember" xlink:label="loc_embi_TwoThousandFifteenCommonStockWarrantsMember_228"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember" xlink:label="loc_embi_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember_229"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember" xlink:label="loc_embi_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember_230"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_TwoThousandNineteenCommonStockWarrantsMember" xlink:label="loc_embi_TwoThousandNineteenCommonStockWarrantsMember_231"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember" xlink:label="loc_embi_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember_232"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember" xlink:label="loc_embi_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember_233"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember" xlink:label="loc_embi_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember_234"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember" xlink:label="loc_embi_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember_235"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_Um5050ProdrugAndUm8930AnalogAgreementsMember" xlink:label="loc_embi_Um5050ProdrugAndUm8930AnalogAgreementsMember_236"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_Um5070LicenseAgreementMember" xlink:label="loc_embi_Um5070LicenseAgreementMember_237"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_UnamortizedDebtDiscountPeriod" xlink:label="loc_embi_UnamortizedDebtDiscountPeriod_238"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_UniversityOfMississippiAgreementsLineItems" xlink:label="loc_embi_UniversityOfMississippiAgreementsLineItems_239"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_UniversityOfMississippiAgreementsTable" xlink:label="loc_embi_UniversityOfMississippiAgreementsTable_240"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_UniversityOfMississippiMember" xlink:label="loc_embi_UniversityOfMississippiMember_241"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_UnvestedRestrictedStockMember" xlink:label="loc_embi_UnvestedRestrictedStockMember_242"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_UpfrontPayment" xlink:label="loc_embi_UpfrontPayment_243"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ValueOfCommonStockCalledByWarrants" xlink:label="loc_embi_ValueOfCommonStockCalledByWarrants_244"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_WarrantsAndDerivativeLiabilitiesAbstract" xlink:label="loc_embi_WarrantsAndDerivativeLiabilitiesAbstract_245"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_WarrantsAndDerivativeLiabilitiesTextBlock" xlink:label="loc_embi_WarrantsAndDerivativeLiabilitiesTextBlock_246"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue" xlink:label="loc_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_247"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock" xlink:label="loc_embi_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock_248"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_WarrantsLiabilityClassifiedMember" xlink:label="loc_embi_WarrantsLiabilityClassifiedMember_249"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_WarrantsMember" xlink:label="loc_embi_WarrantsMember_250"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_WarrantsVestedAndOutstanding" xlink:label="loc_embi_WarrantsVestedAndOutstanding_251"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_WorkingCapitalDeficit" xlink:label="loc_embi_WorkingCapitalDeficit_252"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="loc_srt_BoardOfDirectorsChairmanMember_253"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srt_ChiefExecutiveOfficerMember_254"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ChiefFinancialOfficerMember" xlink:label="loc_srt_ChiefFinancialOfficerMember_255"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_256"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_257"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_258"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_259"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_260"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_261"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_262"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_263"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_264"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_265"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaap_AccruedSalariesCurrent_266"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_267"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_268"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:label="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices_269"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_270"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_271"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_272"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_273"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_274"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_275"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_276"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_277"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_278"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_279"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_280"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaap_AreaOfLand_281"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_282"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_283"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_284"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_285"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_286"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_287"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_288"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BridgeLoan" xlink:label="loc_us-gaap_BridgeLoan_289"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BridgeLoanMember" xlink:label="loc_us-gaap_BridgeLoanMember_290"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_291"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_292"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_293"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_294"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_295"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_296"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_297"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_298"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_299"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_300"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_301"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_302"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_303"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_304"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_305"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_306"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_307"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_308"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_309"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_310"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_311"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_312"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_313"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_314"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_315"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_316"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_317"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_318"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_319"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_320"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_321"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaap_ConvertibleDebt_322"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_323"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_324"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_325"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_326"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock_327"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_328"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_329"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_330"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_331"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_332"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_333"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_334"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_335"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_336"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_337"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_338"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_339"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_340"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="loc_us-gaap_DebtPolicyTextBlock_341"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsCurrentGross" xlink:label="loc_us-gaap_DeferredFinanceCostsCurrentGross_342"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_343"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_344"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_345"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_346"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_347"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_348"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_349"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_350"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_351"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_352"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsStateTaxes" xlink:label="loc_us-gaap_DeferredTaxAssetsStateTaxes_353"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_354"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_355"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_356"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_357"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_358"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_359"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_360"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_361"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_362"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DilutiveSecurities" xlink:label="loc_us-gaap_DilutiveSecurities_363"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_364"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_365"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_366"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_367"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueFromRelatedParties" xlink:label="loc_us-gaap_DueFromRelatedParties_368"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_369"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_370"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_371"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_372"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_373"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_374"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_375"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDilutedLineItems" xlink:label="loc_us-gaap_EarningsPerShareDilutedLineItems_376"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_377"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_378"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_379"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_380"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_381"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_382"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_383"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_384"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ExtinguishmentOfDebtGainLossIncomeTax" xlink:label="loc_us-gaap_ExtinguishmentOfDebtGainLossIncomeTax_385"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_386"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_387"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_388"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_389"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_390"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_391"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_392"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_393"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_394"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_395"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_396"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_397"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_398"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_399"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_400"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_401"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_402"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_403"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_404"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_405"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_406"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_407"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_408"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_409"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_410"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_411"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_412"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_413"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_414"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_415"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_416"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_417"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_418"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_419"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_420"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_421"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:label="loc_us-gaap_IntellectualPropertyMember_422"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_423"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseOther" xlink:label="loc_us-gaap_InterestExpenseOther_424"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_425"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_426"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaap_InvestorMember_427"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_428"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_429"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_430"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_431"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_432"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_433"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_434"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_435"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityAverageOutstandingAmount" xlink:label="loc_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_436"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_437"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_438"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:label="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_439"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_440"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_441"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="loc_us-gaap_MeasurementInputExercisePriceMember_442"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_443"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_444"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputOfferedPriceMember" xlink:label="loc_us-gaap_MeasurementInputOfferedPriceMember_445"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_446"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_447"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_448"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_449"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_450"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_451"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_452"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_453"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_454"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_455"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_456"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_457"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_458"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_459"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_460"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseMember_461"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_462"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_463"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_464"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_465"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_466"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_467"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_468"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_469"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_470"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_471"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_472"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_473"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDerivativeIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDerivativeIssuanceCosts_474"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_475"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireFurnitureAndFixtures" xlink:label="loc_us-gaap_PaymentsToAcquireFurnitureAndFixtures_476"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_477"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_478"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_479"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockConversionBasis" xlink:label="loc_us-gaap_PreferredStockConversionBasis_480"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockConvertibleConversionPriceDecrease" xlink:label="loc_us-gaap_PreferredStockConvertibleConversionPriceDecrease_481"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="loc_us-gaap_PreferredStockLiquidationPreferenceValue_482"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_483"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_484"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_485"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_486"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_487"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_488"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_489"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_490"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_491"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_492"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_493"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_494"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_495"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_496"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromOtherDebt" xlink:label="loc_us-gaap_ProceedsFromOtherDebt_497"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_498"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_499"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDepreciationMethods" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDepreciationMethods_500"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_501"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_502"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_503"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_504"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_505"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RedeemablePreferredStockDividends" xlink:label="loc_us-gaap_RedeemablePreferredStockDividends_506"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_507"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_508"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_509"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_510"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_511"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_512"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_513"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_514"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_515"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_us-gaap_RestrictedStockExpense_516"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_517"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_518"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_519"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_520"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_521"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_522"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_523"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_524"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_525"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_526"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_527"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_528"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_529"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_530"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_531"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_532"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_533"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_534"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_535"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_536"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_537"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_538"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_539"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_540"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_541"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_542"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_543"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_544"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_545"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_546"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_547"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="loc_us-gaap_SeriesEPreferredStockMember_548"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="loc_us-gaap_SeriesFPreferredStockMember_549"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_550"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_551"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_552"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_553"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_554"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_555"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_556"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_557"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_558"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_559"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_560"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_561"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_562"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_563"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_564"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_565"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_566"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_567"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_568"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_569"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_570"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_571"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_572"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_573"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_574"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_575"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_576"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_577"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_578"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_579"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_580"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_581"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_582"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_583"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_584"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_585"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_586"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_587"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_588"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_589"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_590"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_591"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_592"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_593"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_594"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_595"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_596"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_597"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_598"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaap_ShortTermDebtLineItems_599"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_600"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_601"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_602"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_603"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_604"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_605"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_606"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_607"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_608"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_609"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="loc_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_610"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_611"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_612"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_613"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_614"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_615"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_616"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_617"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_618"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_619"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_620"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_621"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_622"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_623"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_624"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_625"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_626"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_627"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:label="loc_us-gaap_TaxCreditCarryforwardLimitationsOnUse_628"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_629"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreference_630"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_631"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_632"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_633"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_634"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_635"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_636"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_637"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_638"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_639"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_640"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_641"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_642"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_643"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_644"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_645"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_646"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_647"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_648"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_649"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag_0" xml:lang="en-US">Amendment Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_AmendmentFlag_1" xml:lang="en-US">Amendment Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate_0" xml:lang="en-US">Current Fiscal Year End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_CurrentFiscalYearEndDate_1" xml:lang="en-US">Current Fiscal Year End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus_0" xml:lang="en-US">Document Fiscal Period Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_DocumentFiscalPeriodFocus_1" xml:lang="en-US">Document Fiscal Period Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus_0" xml:lang="en-US">Document Fiscal Year Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_DocumentFiscalYearFocus_1" xml:lang="en-US">Document Fiscal Year Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate_0" xml:lang="en-US">Document Period End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_DocumentPeriodEndDate_1" xml:lang="en-US">Document Period End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType_0" xml:lang="en-US">Document Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_DocumentType_1" xml:lang="en-US">Document Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey_0" xml:lang="en-US">Entity Central Index Key</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_EntityCentralIndexKey_1" xml:lang="en-US">Entity Central Index Key</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_0" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_1" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCurrentReportingStatus_0" xml:lang="en-US">Entity Current Reporting Status</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityDomain_0" xml:lang="en-US">Entity [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany_0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityExTransitionPeriod_0" xml:lang="en-US">Entity Ex Transition Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory_0" xml:lang="en-US">Entity Filer Category</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_EntityFilerCategory_1" xml:lang="en-US">Entity Filer Category</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityInteractiveDataCurrent_0" xml:lang="en-US">Entity Interactive Data Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityPublicFloat_0" xml:lang="en-US">Entity Public Float</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName_0" xml:lang="en-US">Entity Registrant Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_EntityRegistrantName_1" xml:lang="en-US">Entity Registrant Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityShellCompany_0" xml:lang="en-US">Entity Shell Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntitySmallBusiness_0" xml:lang="en-US">Entity Small Business</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityVoluntaryFilers_0" xml:lang="en-US">Entity Voluntary Filers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_0" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LegalEntityAxis_0" xml:lang="en-US">Legal Entity [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_Security12bTitle_0" xml:lang="en-US">Title of 12(b) Security</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_TradingSymbol_0" xml:lang="en-US">Trading Symbol</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_TradingSymbol_1" xml:lang="en-US">Trading Symbol</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_AccruedExpenseUnderAgreement_0" xml:lang="en-US">Accrued expense Under Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_AccruedExpenseUnderAgreement_1" xml:lang="en-US">Represents total accrued expense under the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_AccruedExpenseUnderAgreement_2" xml:lang="en-US">Accrued expense under agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_AdditionalConversionLiability_0" xml:lang="en-US">Threshold number of specified trading days that common stock price to additional conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_AdditionalConversionLiability_1" xml:lang="en-US">Additional Conversion Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_AdditionalConversionLiability_2" xml:lang="en-US">Additional conversion liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_AggregateMilestonePaymentsIfMilestonesAchieved_0" xml:lang="en-US">This element represents amount of aggregate milestone payments under the license agreements if the milestones are achieved.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_AggregateMilestonePaymentsIfMilestonesAchieved_1" xml:lang="en-US">Aggregate Milestone Payments If Milestones Achieved</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_AggregateMilestonePaymentsIfMilestonesAchieved_2" xml:lang="en-US">Aggregate milestone payments if milestones achieved</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_AlbanyMolecularResearchIncMember_0" xml:lang="en-US">Albany Molecular Research Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_AlbanyMolecularResearchIncMember_1" xml:lang="en-US">AMRI</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_AllocationOfDebtOnBasisOfRelativeFairValue_0" xml:lang="en-US">Represents allocation of debt on the basis of relative fair value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_AllocationOfDebtOnBasisOfRelativeFairValue_1" xml:lang="en-US">Allocation Of Debt On Basis Of Relative Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_AllocationOfDebtOnBasisOfRelativeFairValue_2" xml:lang="en-US">Allocation of debt on the basis of relative fair value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_AllocationOfWarrantOnBasisOfRelativeFairValue_0" xml:lang="en-US">Represents allocation of warrant on the basis of relative fair value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_AllocationOfWarrantOnBasisOfRelativeFairValue_1" xml:lang="en-US">Allocation Of Warrant On Basis Of Relative Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_AllocationOfWarrantOnBasisOfRelativeFairValue_2" xml:lang="en-US">Allocation of warrant on the basis of relative fair value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_AmortizationOfDebtDiscount_0" xml:lang="en-US">Amount of amortization expense attributable to debt discount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_AmortizationOfDebtDiscount_1" xml:lang="en-US">Amortization Of Debt Discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_AmortizationOfDebtDiscount_2" xml:lang="en-US">Amortization of debt discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_AmortizationOfTransactionCosts_0" xml:lang="en-US">Amount of amortization of transaction costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_AmortizationOfTransactionCosts_1" xml:lang="en-US">Amortization Of Transaction Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_AmortizationOfTransactionCosts_2" xml:lang="en-US">Amortization of transaction costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_AmountOfEachWarrantOutstanding_0" xml:lang="en-US">Amount of each warrant outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_AmountOfEachWarrantOutstanding_1" xml:lang="en-US">Amount of each warrant outstanding.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_AmountOfEachWarrantOutstanding_2" xml:lang="en-US">Amount of each warrant outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_AmountOfPassThroughExpensesAndConsultingFees_0" xml:lang="en-US">Represent the amount of pass through expenses and consulting fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_AmountOfPassThroughExpensesAndConsultingFees_1" xml:lang="en-US">Amount Of Pass Through Expenses And Consulting Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_AmountOfPassThroughExpensesAndConsultingFees_2" xml:lang="en-US">Amount of pass through expenses and consulting fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_AnnualFeeForAgreement_0" xml:lang="en-US">Represents amount of annual fee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_AnnualFeeForAgreement_1" xml:lang="en-US">Annual Fee For Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_AnnualFeeForAgreement_2" xml:lang="en-US">Annual fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_AnnualFeesForLicenseAgreement_0" xml:lang="en-US">Represents annual fees for license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_AnnualFeesForLicenseAgreement_1" xml:lang="en-US">Annual Fees For License Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_AnnualFeesForLicenseAgreement_2" xml:lang="en-US">Annual fees for license agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_AnnualMaintenanceFeePayable_0" xml:lang="en-US">Annual Maintenance Fee Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_AnnualMaintenanceFeePayable_1" xml:lang="en-US">Represents the amount of annual maintenance fee payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_AvtarDhillonMember_0" xml:lang="en-US">Avtar Dhillon[Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_AvtarDhillonMember_1" xml:lang="en-US">Name of board member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_AvtarDhillonMember_2" xml:lang="en-US">Dr. Avtar Dhillon</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_AwardsGrantedOutside2014PlanMember_0" xml:lang="en-US">Represents awards Granted Outside the 2014 Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_AwardsGrantedOutside2014PlanMember_1" xml:lang="en-US">Awards Granted Outside 2014 Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_AwardsGrantedOutside2014PlanMember_2" xml:lang="en-US">Awards Granted Outside the 2014 Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_AwardsGrantedOutsideThe2014PlanMember_0" xml:lang="en-US">Awards Granted Outside the 2014 Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_AwardsGrantedOutsideThe2014PlanMember_1" xml:lang="en-US">Information about awards granted outside the 2014 Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_AwardsGrantedOutsideThe2014PlanMember_2" xml:lang="en-US">Awards Granted Outside the 2014 Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_0" xml:lang="en-US">Represents beneficial conversion feature in connection with convertible multi-draw credit agreement - related party value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_1" xml:lang="en-US">Beneficial Conversion Feature In Connection With Convertible Multi Draw Credit Agreement Related Party Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_2" xml:lang="en-US">Beneficial conversion feature in connection with convertible multi-draw credit agreement - related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement_0" xml:lang="en-US">Amount of beneficial conversion feature recorded on advances under the convertible multi-draw credit agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement_1" xml:lang="en-US">Beneficial Conversion Feature On Convertible Multi Draw Credit Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement_2" xml:lang="en-US">Beneficial conversion feature on convertible multi-draw credit agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_BeneficialConversionFeatureUponIssuanceofSeriesDPreferredStock_0" xml:lang="en-US">Amount of increase (decrease) resulting from beneficial conversion feature Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_BeneficialConversionFeatureUponIssuanceofSeriesDPreferredStock_1" xml:lang="en-US">Beneficial Conversion Feature Upon Issuance of Series D Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_BeneficialConversionFeatureUponIssuanceofSeriesDPreferredStock_2" xml:lang="en-US">Beneficial conversion feature upon issuance of Series D Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_BeneficialConversionFeatureUponIssuanceofSeriesFPreferredStock_0" xml:lang="en-US">Amount of increase (decrease) resulting from beneficial conversion feature series F Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_BeneficialConversionFeatureUponIssuanceofSeriesFPreferredStock_1" xml:lang="en-US">Beneficial Conversion Feature Upon Issuance of Series F Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_BeneficialConversionFeatureUponIssuanceofSeriesFPreferredStock_2" xml:lang="en-US">Beneficial conversion feature upon issuance of Series F Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_CashPaidDuringPeriodForAbstract_0" xml:lang="en-US">Cash Paid During Period For Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_CashPaidDuringPeriodForAbstract_1" xml:lang="en-US">Cash paid during the year for:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ChangeInFairValueOfDerivativeLiabilities_0" xml:lang="en-US">Amount of expense (income) related to adjustment to fair value of derivative liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ChangeInFairValueOfDerivativeLiabilities_1" xml:lang="en-US">Change In Fair Value Of Derivative Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_ChangeInFairValueOfDerivativeLiabilities_2" xml:lang="en-US">Change in fair value of derivative liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ChangeInFairValueOfWarrantLiability_0" xml:lang="en-US">Amount of expense (income) related to warrant liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ChangeInFairValueOfWarrantLiability_1" xml:lang="en-US">Change In Fair Value Of Warrant Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_ChangeInFairValueOfWarrantLiability_2" xml:lang="en-US">Change in fair value of warrant liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ClassOfWarrantOrRightWarrantsAggregateExercisePrice_0" xml:lang="en-US">Class Of Warrant Or Right, Warrants Aggregate Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ClassOfWarrantOrRightWarrantsAggregateExercisePrice_1" xml:lang="en-US">Represents amount of aggregate exercise price of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ClassOfWarrantOrRightWarrantsAggregateExercisePrice_2" xml:lang="en-US">Warrants aggregate exercise price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ClassOfWarrantOrRightWarrantsExercise_0" xml:lang="en-US">Class Of Warrant Or Right, Warrants Exercise</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ClassOfWarrantOrRightWarrantsExercise_1" xml:lang="en-US">Represents number of warrants exercise.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_ClassOfWarrantOrRightWarrantsExercise_2" xml:lang="en-US">Warrants exercise</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_CommonSharesUnderlyingConvertiblePreferredStockMember_0" xml:lang="en-US">Represents common shares underlying convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_CommonSharesUnderlyingConvertiblePreferredStockMember_1" xml:lang="en-US">Common Shares Underlying Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_CommonSharesUnderlyingConvertiblePreferredStockMember_2" xml:lang="en-US">Common shares underlying convertible preferred stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_CommonStockAggregatePurchasePrice_0" xml:lang="en-US">Represents common stock aggregate purchase price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_CommonStockAggregatePurchasePrice_1" xml:lang="en-US">Common Stock Aggregate Purchase Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_CommonStockAggregatePurchasePrice_2" xml:lang="en-US">Aggregate purchase price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_CommonStockIssuedForServices_0" xml:lang="en-US">Represents amount related to common stock issued for services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_CommonStockIssuedForServices_1" xml:lang="en-US">Common stock issued for services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_CommonStockWarrantsToSeriesBStockholdersMember_0" xml:lang="en-US">Common Stock Warrants to Series B Stockholders [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_CommonStockWarrantsToSeriesBStockholdersMember_1" xml:lang="en-US">Type of member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_CommonStockWarrantsToSeriesBStockholdersMember_2" xml:lang="en-US">Common Stock Warrants to Series B Stockholders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ConsultingAgreementMember_0" xml:lang="en-US">Consulting Agreement that involves two or more parties.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ConsultingAgreementMember_1" xml:lang="en-US">Consulting Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_ConsultingAgreementMember_2" xml:lang="en-US">Consulting Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ContractPayableDue_0" xml:lang="en-US">Represent information related amount payable under research agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ContractPayableDue_1" xml:lang="en-US">Contract Payable Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ContractPayableDue_2" xml:lang="en-US">Payments due for aggregate amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ConversionLiabilityIntoCommonStockPerShare_0" xml:lang="en-US">Represents conversion liability into common stock per share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ConversionLiabilityIntoCommonStockPerShare_1" xml:lang="en-US">Conversion Liability Into Common Stock Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ConversionLiabilityIntoCommonStockPerShare_2" xml:lang="en-US">Conversion liability into common stock per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock_0" xml:lang="en-US">Represents amount of conversion of outstanding preferred stock subject to redemption into common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock_1" xml:lang="en-US">Conversion Of Outstanding Preferred Stock Subject To Redemption Into Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock_2" xml:lang="en-US">Conversion of outstanding preferred stock subject to redemption into common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares_0" xml:lang="en-US">Represents conversion of Preferred Stock Series and conversion liability into common stock, shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares_1" xml:lang="en-US">Conversion of Series B Preferred Stock and conversion liability into common stock at $0.80 and $0.40 per share for December 31, 2016 and $0.25 and $0.15 per share for December 31, 2017 (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares_2" xml:lang="en-US">Conversion Of Preferred Stock Series And Conversion Liability Into Common Stock, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares_3" xml:lang="en-US">Conversion of Series B Preferred Stock and conversion liability into common stock at $0.10 and $0.001 per share (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue_0" xml:lang="en-US">Represents conversion of Preferred Stock Series and conversion liability into common stock, value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue_1" xml:lang="en-US">Conversion Of Preferred Stock Series And Conversion Liability Into Common Stock, Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue_2" xml:lang="en-US">Conversion of Series B Preferred Stock and conversion liability into common stock at $0.10 and $0.001 per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue_3" xml:lang="en-US">Conversion of Series A and Series B Preferred Stock and conversion liability into common stock at $0.80 per share and $0.80 and $0.40 per share for 2015 and 2016, respectively</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest_0" xml:lang="en-US">Represents value conversion of secured convertible promissory note related party and accrued interest.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest_1" xml:lang="en-US">Conversion Of Secured Convertible Promissory Note Related Party And Accrued Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest_2" xml:lang="en-US">Conversion of secured convertible promissory note - related party and accrued interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterestShares_0" xml:lang="en-US">Represents value conversion of secured convertible promissory note related party and accrued interest shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterestShares_1" xml:lang="en-US">Conversion Of Secured Convertible Promissory Note Related Party And Accrued Interest Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterestShares_2" xml:lang="en-US">Conversion of secured convertible promissory note - related party and accrued interest (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ConversionOfSeriesCPreferredStockToCommonStockShares_0" xml:lang="en-US">Represents conversion of Preferred Stock Series and conversion series D preferred stock common stock, shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ConversionOfSeriesCPreferredStockToCommonStockShares_1" xml:lang="en-US">Conversion Of Series C Preferred Stock To Common Stock Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_ConversionOfSeriesCPreferredStockToCommonStockShares_2" xml:lang="en-US">Conversion of Series C Preferred Stock to common stock at $0.25 per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ConversionOfSeriesCPreferredStockToCommonStockShares_3" xml:lang="en-US">Conversion of Series C Preferred Stock to common stock at $0.40 and $0.25 per share for December 31, 2016 and 2017 respectively (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ConversionOfSeriesCPreferredStockToCommonStockSharesValue_0" xml:lang="en-US">Represents conversion of Preferred Stock Series and conversion of series C preferred stock to common stock, value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ConversionOfSeriesCPreferredStockToCommonStockSharesValue_1" xml:lang="en-US">Conversion Of Series C Preferred Stock To Common Stock Shares Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ConversionOfSeriesCPreferredStockToCommonStockSharesValue_2" xml:lang="en-US">Conversion of Series C Preferred Stock to common stock at $0.25 per share for December 31, 2017</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ConversionOfSeriesDPreferredStockToCommonStock_0" xml:lang="en-US">Represents conversion of Preferred Stock Series and conversion of series D preferred stock to common stock, value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ConversionOfSeriesDPreferredStockToCommonStock_1" xml:lang="en-US">Conversion Of Series D Preferred Stock To Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_ConversionOfSeriesDPreferredStockToCommonStock_2" xml:lang="en-US">Conversion of Series D Preferred Stock to common stock at $0.10 per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ConversionOfSeriesDPreferredStockToCommonStock_3" xml:lang="en-US">Conversion of Series D Preferred Stock to common stock at $0.25 per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ConversionOfSeriesDPreferredStockToCommonStockShares_0" xml:lang="en-US">Represents conversion of Preferred Stock Series and conversion series D preferred stock common stock, shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ConversionOfSeriesDPreferredStockToCommonStockShares_1" xml:lang="en-US">Conversion Of Series D Preferred Stock To Common Stock,Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_ConversionOfSeriesDPreferredStockToCommonStockShares_2" xml:lang="en-US">Conversion of Series D Preferred Stock to common stock at $0.10 per share (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ConversionOfSeriesDPreferredStockToCommonStockShares_3" xml:lang="en-US">Conversion of Series D Preferred Stock to common stock at $0.25 per share (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ConversionOfSeriesFPreferredStockToCommonStockShares_0" xml:lang="en-US">Number of shares of series F preferred stock converted during the period into common stocks.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ConversionOfSeriesFPreferredStockToCommonStockShares_1" xml:lang="en-US">Conversion Of Series F Preferred Stock To Common Stock Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ConversionOfSeriesFPreferredStockToCommonStockShares_2" xml:lang="en-US">Conversion of Series F Preferred Stock to common stock at $0.10 per share (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ConversionOfSeriesFPreferredStockToCommonStockValue_0" xml:lang="en-US">Value of shares of series F preferred stock converted into common stocks during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ConversionOfSeriesFPreferredStockToCommonStockValue_1" xml:lang="en-US">Conversion Of Series F Preferred Stock To Common Stock Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ConversionOfSeriesFPreferredStockToCommonStockValue_2" xml:lang="en-US">Conversion of Series F Preferred Stock to common stock at $0.10 per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ConversionPrice_0" xml:lang="en-US">Represents conversion price per share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ConversionPrice_1" xml:lang="en-US">Conversion Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ConversionPrice_2" xml:lang="en-US">Conversion price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ConversionPricePerShare_0" xml:lang="en-US">Represents the value related to conversion of Series A Preferred Stock and conversion liability into common stock per share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ConversionPricePerShare_1" xml:lang="en-US">Conversion Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ConversionPricePerShare_2" xml:lang="en-US">Conversion of preferred stock price per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ConvertedRate10000001Member_0" xml:lang="en-US">Converted rate 1,000,000:1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ConvertedRate10000001Member_1" xml:lang="en-US">Converted Rate 1,000,0001 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ConvertedRate10000001Member_2" xml:lang="en-US">Converted rate of 1,000,000:1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ConvertedRate100001Member_0" xml:lang="en-US">Converted rate 10,000:1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ConvertedRate100001Member_1" xml:lang="en-US">Converted Rate 10,0001 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_ConvertedRate100001Member_2" xml:lang="en-US">Converted rate of 10,000:1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ConvertedRateAxis_0" xml:lang="en-US">Information by type of converted rate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ConvertedRateAxis_1" xml:lang="en-US">Converted Rate [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ConvertedRateDomain_0" xml:lang="en-US">Converted rate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ConvertedRateDomain_1" xml:lang="en-US">Converted Rate [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ConvertibleDebtRelatedPartyTextBlock_0" xml:lang="en-US">The entire disclosure for convertible debt - related party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ConvertibleDebtRelatedPartyTextBlock_1" xml:lang="en-US">Convertible Debt Related Party [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ConvertibleDebtRelatedPartyTextBlock_2" xml:lang="en-US">Convertible Debt - Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ConvertibleMultiDrawCreditAgreementIssuanceCosts_0" xml:lang="en-US">Amount of convertible multi-draw credit agreement issuance costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ConvertibleMultiDrawCreditAgreementIssuanceCosts_1" xml:lang="en-US">Convertible Multi Draw Credit Agreement Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_ConvertibleMultiDrawCreditAgreementIssuanceCosts_2" xml:lang="en-US">Convertible multi-draw credit agreement issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_CouponInterestExpense_0" xml:lang="en-US">Amount of interest expense classified as coupon interest expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_CouponInterestExpense_1" xml:lang="en-US">Coupon Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_CouponInterestExpense_2" xml:lang="en-US">Interest expense - stated rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_CurrentConvertibleDebtExcludingNoncurrentPortion_0" xml:lang="en-US">The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_CurrentConvertibleDebtExcludingNoncurrentPortion_1" xml:lang="en-US">Current Convertible Debt Excluding Noncurrent Portion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_CurrentConvertibleDebtExcludingNoncurrentPortion_2" xml:lang="en-US">Current convertible debt - related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_embi_CurrentConvertibleDebtExcludingNoncurrentPortion_3" xml:lang="en-US">Current convertible debt - related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_December2015Member_0" xml:lang="en-US">December 2015 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_December2015Member_1" xml:lang="en-US">Represents December 2015 as agreement month and year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_December2015Member_2" xml:lang="en-US">December 2015</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_DeemedDividendFromBeneficialConversionFeatureOfSeriesDPreferredStock_0" xml:lang="en-US">Amount of decrease in additional paid in capital (APIC) resulting from dividends conversion of series D preferred stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_embi_DeemedDividendFromBeneficialConversionFeatureOfSeriesDPreferredStock_1" xml:lang="en-US">Deemed dividend from beneficial conversion feature of Series D Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_DeemedDividendFromBeneficialConversionFeatureOfSeriesDPreferredStock_2" xml:lang="en-US">Deemed Dividend From Beneficial Conversion Feature Of Series D Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_DeemedDividendFromBeneficialConversionFeatureOfSeriesDPreferredStock_3" xml:lang="en-US">Deemed dividend from beneficial conversion feature of Series D Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_DeemedDividendFromBeneficialConversionFeatureOfSeriesFPreferredStock_0" xml:lang="en-US">Amount of decrease in additional paid in capital (APIC) resulting from dividends conversion of series F preferred stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_embi_DeemedDividendFromBeneficialConversionFeatureOfSeriesFPreferredStock_1" xml:lang="en-US">Deemed dividend from beneficial conversion feature of Series F Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_DeemedDividendFromBeneficialConversionFeatureOfSeriesFPreferredStock_2" xml:lang="en-US">Deemed Dividend From Beneficial Conversion Feature Of Series F Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_DeemedDividendFromBeneficialConversionFeatureOfSeriesFPreferredStock_3" xml:lang="en-US">Deemed dividend from beneficial conversion feature of Series F Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_0" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalized research and development costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_1" xml:lang="en-US">Deferred Tax Assets Capitalized Research And Development Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_2" xml:lang="en-US">Capitalized research and development costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_DeferredTaxLiabilitiesNoteDiscount_0" xml:lang="en-US">Deferred Tax Liabilities Note Discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_DeferredTaxLiabilitiesNoteDiscount_1" xml:lang="en-US">Represents amount of notes discount related to deferred tax liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_DeferredTaxLiabilitiesNoteDiscount_2" xml:lang="en-US">Note discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_DerivativeLiabilitiesLineItems_0" xml:lang="en-US">Line item represents derivative liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_DerivativeLiabilitiesLineItems_1" xml:lang="en-US">Derivative Liabilities [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_DerivativeLiabilitiesTable_0" xml:lang="en-US">A table or schedule providing information about derivative liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_DerivativeLiabilitiesTable_1" xml:lang="en-US">Derivative Liabilities [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_DilutedSecuritiesAxis_0" xml:lang="en-US">Diluted Securities [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_DilutedSecuritiesDomain_0" xml:lang="en-US">Diluted Securities [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_DilutedSecuritiesDomain_1" xml:lang="en-US">Information by type of diluted security.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_DilutiveSecuritiesEffectOnBasicEarningsPerShareShares_0" xml:lang="en-US">Dilutive Securities Effect on Basic Earnings Per Share shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_DilutiveSecuritiesEffectOnBasicEarningsPerShareShares_1" xml:lang="en-US">Number of shares for calculating diluted earnings per share (EPS), resulting from the assumed exercise stock options, restrictive stock units (RSUs), convertible preferred stock of an employee stock ownership plan (ESOP), and other dilutive convertible securities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_DilutiveSecuritiesEffectOnBasicEarningsPerShareShares_2" xml:lang="en-US">Shares (Denominator)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_DocumentAndEntityInformationAbstract_0" xml:lang="en-US">Document and Entity Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_DocumentAndEntityInformationAbstract_1" xml:lang="en-US">Document and Entity Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_DouglasCesarioMember_0" xml:lang="en-US">Represents the Douglas Cesario.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_DouglasCesarioMember_1" xml:lang="en-US">Douglas Cesario [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_DouglasCesarioMember_2" xml:lang="en-US">Douglas Cesario, CFO</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrant_0" xml:lang="en-US">Represents amount related to Change in fair value of warrant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_embi_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrant_1" xml:lang="en-US">Change in fair value of warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrant_2" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Change In Fair Value Of Warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrant_3" xml:lang="en-US">Change in fair value of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_0" xml:lang="en-US">Information about emerald convertible promissory note - conversion liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_1" xml:lang="en-US">Emerald Convertible Promissory Note Conversion Liability [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_2" xml:lang="en-US">Emerald Convertible Promissory Note Conversion Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_3" xml:lang="en-US">Emerald Convertible Promissory Note - conversion liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_EmeraldFinancingIssuanceCosts_0" xml:lang="en-US">Cost incurred for Emerald Financing, issuance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_EmeraldFinancingIssuanceCosts_1" xml:lang="en-US">Emerald Financing Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_EmeraldFinancingIssuanceCosts_2" xml:lang="en-US">Emerald financing issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_EmeraldFinancingMember_0" xml:lang="en-US">Represents Emerald financing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_EmeraldFinancingMember_1" xml:lang="en-US">Emerald Financing [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_EmeraldFinancingMember_2" xml:lang="en-US">Emerald Financing Warrant Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_EmeraldFinancingMember_3" xml:lang="en-US">Emerald Financing - Warrant Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_EmeraldHealthSciencesIncMember_0" xml:lang="en-US">Information by Emerald Health Sciences, Inc. ("Emerald").</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_EmeraldHealthSciencesIncMember_1" xml:lang="en-US">Emerald Health Sciences Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_EmeraldHealthSciencesIncMember_2" xml:lang="en-US">Emerald Health Sciences Inc</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_EmeraldHealthSciencesIncMember_3" xml:lang="en-US">Emerald Health Sciences Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_0" xml:lang="en-US">Emerald Multi Draw Credit Agreement Compound Derivative Liability [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_1" xml:lang="en-US">Represents information about Emerald Multi Draw Credit Agreement - compound derivative liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="lab_embi_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_2" xml:lang="en-US">Emerald Multi-Draw Credit Agreement - compound derivative liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_3" xml:lang="en-US">Emerald Multi-Draw Credit Agreement Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_4" xml:lang="en-US">Emerald Multi-Draw Credit Agreement Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_EmeraldWarrantLiabilityMember_0" xml:lang="en-US">Represents the information about Emerald Warrant Liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_EmeraldWarrantLiabilityMember_1" xml:lang="en-US">Emerald Warrant Liability [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_EmeraldWarrantLiabilityMember_2" xml:lang="en-US">Emerald Warrant Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_EmeraldWarrantLiabilityMember_3" xml:lang="en-US">Emerald Warrant Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_EquityLineItems_0" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_EquityLineItems_1" xml:lang="en-US">Equity [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_EquityTable_0" xml:lang="en-US">Represents tabular disclosure of Equity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_EquityTable_1" xml:lang="en-US">Equity [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_EstimatedAgreementFeesAndExpenses_0" xml:lang="en-US">Represent a estimated agreement fees and expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_EstimatedAgreementFeesAndExpenses_1" xml:lang="en-US">Estimated Agreement Fees And Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_EstimatedAgreementFeesAndExpenses_2" xml:lang="en-US">Estimated agreement fees and expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_EstimatedInitialPaymentForContract_0" xml:lang="en-US">Estimated Initial Payment For Contract.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_EstimatedInitialPaymentForContract_1" xml:lang="en-US">Estimated Initial Payment For Contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_EstimatedInitialPaymentForContract_2" xml:lang="en-US">Estimated initial payment for contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ExerciseOfWarrants_0" xml:lang="en-US">Represents the fair value of derivative liabilities reclassified to equity upon the exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ExerciseOfWarrants_1" xml:lang="en-US">Exercise Of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ExerciseOfWarrants_2" xml:lang="en-US">Reclassification of warrant liabilities to equity from exercise of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_FairMarketValueOfSharesGranted_0" xml:lang="en-US">Fair value of shares granted.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_FairMarketValueOfSharesGranted_1" xml:lang="en-US">Fair Market Value Of Shares Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_FairMarketValueOfSharesGranted_2" xml:lang="en-US">Fair market value of shares granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_FairMarketValueOfStockOptions_0" xml:lang="en-US">Represents the fair market value of stock options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_FairMarketValueOfStockOptions_1" xml:lang="en-US">Fair Market Value Of Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_FairMarketValueOfStockOptions_2" xml:lang="en-US">Fair market value of stock options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_FairValueOfCommonStockWarrantsIssued_0" xml:lang="en-US">Fair value of common stock warrants issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_FairValueOfCommonStockWarrantsIssued_1" xml:lang="en-US">Represents the fair value of the common stock warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_FairValueOfCommonStockWarrantsIssued_2" xml:lang="en-US">Fair value of common stock warrants issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement_0" xml:lang="en-US">Represents the initial fair value of the compound derivative liability that was bifurcated from advances under the convertible multi-draw credit agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement_1" xml:lang="en-US">Fair Value Of Compound Derivative Liability Issued With Convertible Multi Draw Credit Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement_2" xml:lang="en-US">Fair value of compound derivative liability bifurcated from convertible multi-draw credit agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_FairValueOfDerivativeLiabilitiesRollForward_0" xml:lang="en-US">Represents the amount of derivative liabilities at fair value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_FairValueOfDerivativeLiabilitiesRollForward_1" xml:lang="en-US">Fair Value Of Derivative Liabilities [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_FairValueOfDerivativeLiabilityExcessOfProceeds_0" xml:lang="en-US">Represents amount of fair value of derivative liability in excess of proceeds.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_embi_FairValueOfDerivativeLiabilityExcessOfProceeds_1" xml:lang="en-US">Fair value of warrant liability in excess of proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_FairValueOfDerivativeLiabilityExcessOfProceeds_2" xml:lang="en-US">Fair Value Of Derivative Liability Excess Of Proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_FairValueOfDerivativeLiabilityExcessOfProceeds_3" xml:lang="en-US">Fair value of warrant liability in excess of proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_FairValueOfDerivativeLiabilityExcessOfProceeds_4" xml:lang="en-US">Fair value of derivative liabilities in excess of proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_FairValueOfDerivativeLiabilityInExcessOfProceeds_0" xml:lang="en-US">Amount of expense (income) related to fair value of derivative liability in excess of proceeds.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_embi_FairValueOfDerivativeLiabilityInExcessOfProceeds_1" xml:lang="en-US">Fair value of derivative liabilities in excess of proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_FairValueOfDerivativeLiabilityInExcessOfProceeds_2" xml:lang="en-US">Fair Value Of Derivative Liability In Excess Of Proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_FairValueOfDerivativeLiabilityInExcessOfProceeds_3" xml:lang="en-US">Fair value of warrant liability in excess of proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_FairValueOfDerivativeLiabilityInExcessOfProceeds_4" xml:lang="en-US">Fair value of derivative liabilities in excess of proceeds recorded as other expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_FairValueOfUnderlyingShares_0" xml:lang="en-US">fair value of underlying shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_FairValueOfUnderlyingShares_1" xml:lang="en-US">Fair value of the underlying shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_FairValueOfUnderlyingShares_2" xml:lang="en-US">Fair value of underlying shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_FairValueOfWarrantsIssued_0" xml:lang="en-US">The fair value of warrants issued in noncash investing or financing activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_embi_FairValueOfWarrantsIssued_1" xml:lang="en-US">Initial fair value of Emerald Financing Warrant Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_FairValueOfWarrantsIssued_2" xml:lang="en-US">Fair Value Of Warrants Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_FairValueOfWarrantsIssued_3" xml:lang="en-US">Fair value of derivative liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_FairValueOfWarrantsIssued_4" xml:lang="en-US">Fair Value of Derivative Liabilities Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_FairValueOfWarrantsIssuedInConnectionWithFinancings_0" xml:lang="en-US">Amount of fair value of warrants issued in connection with financings.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_FairValueOfWarrantsIssuedInConnectionWithFinancings_1" xml:lang="en-US">Fair Value Of Warrants Issued In Connection With Financings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_FairValueOfWarrantsIssuedInConnectionWithFinancings_2" xml:lang="en-US">Fair value of warrants issued in connection with financings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_FeesAndExpensesForServicesProvided_0" xml:lang="en-US">Represents amount of fees and expenses for services provided.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_FeesAndExpensesForServicesProvided_1" xml:lang="en-US">Fees And Expenses For Services Provided</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_FeesAndExpensesForServicesProvided_2" xml:lang="en-US">Fees and expenses for the initial evaluation and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_FinancingSharesWarrantExercise_0" xml:lang="en-US">Financing shares Warrant Exercise</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_FinancingSharesWarrantExercise_1" xml:lang="en-US">Represents number of shares related to exercise of emerald financing warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_FinancingSharesWarrantExercise_2" xml:lang="en-US">Exercise of Emerald financing warrants (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_FinancingValueWarrantExercise_0" xml:lang="en-US">Financing Value Warrant Exercise</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_FinancingValueWarrantExercise_1" xml:lang="en-US">Represents amount related to Exercise of emerald financing warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_FinancingValueWarrantExercise_2" xml:lang="en-US">Exercise of Emerald financing warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_FixedAssetsProvidedToUniversityInLieuOfCash_0" xml:lang="en-US">Represents amount of fixed assets provided to university in lieu of cash.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_FixedAssetsProvidedToUniversityInLieuOfCash_1" xml:lang="en-US">Fixed Assets Provided To University In Lieu Of Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_FixedAssetsProvidedToUniversityInLieuOfCash_2" xml:lang="en-US">Fixed assets provided to university in lieu of cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_GlauconixBiosciencesIncMember_0" xml:lang="en-US">Represents information regarding Glauconix biosciences, inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_GlauconixBiosciencesIncMember_1" xml:lang="en-US">Glauconix Biosciences Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_GlauconixBiosciencesIncMember_2" xml:lang="en-US">Glauconix Biosciences, Inc</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_GuarantorFailedToPay_0" xml:lang="en-US">Represents information the guarantor failed to pay within 90 days of notice of purchaser.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_GuarantorFailedToPay_1" xml:lang="en-US">Guarantor Failed To Pay</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_GuarantorFailedToPay_2" xml:lang="en-US">Guarantor failed to pay within 90 days of notice of purchaser</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_IncomeTaxReconciliationChangeInCompoundDerivative_0" xml:lang="en-US">Income Tax Reconciliation Change in compound derivative</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_IncomeTaxReconciliationChangeInCompoundDerivative_1" xml:lang="en-US">Represents amount of Income Tax Reconciliation change in compound derivative related to the income tax reconciliation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_IncomeTaxReconciliationChangeInCompoundDerivative_2" xml:lang="en-US">Change in compound derivative</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_IncomeTaxReconciliationUncertainTaxPositions_0" xml:lang="en-US">Income Tax Reconciliation Uncertain tax positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_IncomeTaxReconciliationUncertainTaxPositions_1" xml:lang="en-US">Represents amount of uncertain tax positions related to Income Tax Reconciliation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_IncomeTaxReconciliationUncertainTaxPositions_2" xml:lang="en-US">Uncertain tax positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_IncreaseChangeInFairValueOfWarrantLiability_0" xml:lang="en-US">Amount increase of expense (income) related to warrant liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_IncreaseChangeInFairValueOfWarrantLiability_1" xml:lang="en-US">Increase Change In Fair Value Of Warrant Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_IncreaseChangeInFairValueOfWarrantLiability_2" xml:lang="en-US">Increase change in fair value of warrant liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_IncreaseDecreaseInDepositsAndOtherAssets_0" xml:lang="en-US">Represents amount of increase (decrease) in deposits and other assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_embi_IncreaseDecreaseInDepositsAndOtherAssets_1" xml:lang="en-US">Deposits and other assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_IncreaseDecreaseInDepositsAndOtherAssets_2" xml:lang="en-US">Increase Decrease In Deposits And Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_IncrementalAgreementFeesAndExpenses_0" xml:lang="en-US">Represent a incremental agreement fees and expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_IncrementalAgreementFeesAndExpenses_1" xml:lang="en-US">Incremental Agreement Fees And Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_IncrementalAgreementFeesAndExpenses_2" xml:lang="en-US">Incremental agreement fees and expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_IndependentContractorAgreementMember_0" xml:lang="en-US">Represents name of agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_IndependentContractorAgreementMember_1" xml:lang="en-US">Independent Contractor Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_IndependentContractorAgreementMember_2" xml:lang="en-US">Independent contractor agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_InitialTermOfAgreement_0" xml:lang="en-US">Represents the initial term of agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_InitialTermOfAgreement_1" xml:lang="en-US">Initial Term Of Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_InitialTermOfAgreement_2" xml:lang="en-US">Initial term of agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_IntrinsicValueOfWarrantExercises_0" xml:lang="en-US">Represents intrinsic value of warrant exercises.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_IntrinsicValueOfWarrantExercises_1" xml:lang="en-US">Intrinsic Value Of Warrant Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_IntrinsicValueOfWarrantExercises_2" xml:lang="en-US">Intrinsic value of warrant exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_IssuanceOfPreferredStockNetOfIssuanceCosts_0" xml:lang="en-US">Represents issuance cost of preferred cost net of issuance cost.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_IssuanceOfPreferredStockNetOfIssuanceCosts_1" xml:lang="en-US">Issuance Of Preferred Stock Net Of Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_IssuanceOfPreferredStockNetOfIssuanceCosts_2" xml:lang="en-US">Issuance of Series F Preferred Stock net of issuance costs of $118,855 and $103,364 put option liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_IssuanceOfPreferredStockNetOfIssuanceCostsShares_0" xml:lang="en-US">Represents issuance of preferred stock Series net of issuance costs shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_IssuanceOfPreferredStockNetOfIssuanceCostsShares_1" xml:lang="en-US">Issuance Of Preferred Stock Net Of Issuance Costs Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_IssuanceOfPreferredStockNetOfIssuanceCostsShares_2" xml:lang="en-US">Issuance of Series F Preferred Stock net of issuance costs of $118,855 and $103,364 put option liability (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_IssuanceOfPreferredStockSeriesNetOfIssuanceCostsShares_0" xml:lang="en-US">Represents issuance of Preferred Stock Series net of issuance costs shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_IssuanceOfPreferredStockSeriesNetOfIssuanceCostsShares_1" xml:lang="en-US">Issuance Of Preferred Stock Series Net Of Issuance Costs Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_IssuanceOfPreferredStockSeriesNetOfIssuanceCostsShares_2" xml:lang="en-US">Issuance of Series D Preferred Stock net of issuance costs of $183,343 (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_IssuanceOfPreferredStockSeriesNetOfIssuanceCostsValue_0" xml:lang="en-US">Represents issuance of Preferred Stock Series net of issuance costs value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_IssuanceOfPreferredStockSeriesNetOfIssuanceCostsValue_1" xml:lang="en-US">Issuance Of Preferred Stock Series Net Of Issuance Costs Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_IssuanceOfPreferredStockSeriesNetOfIssuanceCostsValue_2" xml:lang="en-US">Issuance of Series D Preferred Stock net of issuance costs of $183,343</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_K2CIncMember_0" xml:lang="en-US">Represents name of party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_K2CIncMember_1" xml:lang="en-US">K2C Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_K2CIncMember_2" xml:lang="en-US">K2C, Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_LeaseAgreementMember_0" xml:lang="en-US">Lease Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_LeaseAgreementMember_1" xml:lang="en-US">Lease Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_LetterAgreementMember_0" xml:lang="en-US">Represents letter agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_LetterAgreementMember_1" xml:lang="en-US">Letter Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_LetterAgreementMember_2" xml:lang="en-US">Letter agreement ("Agreement")</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_LicenseAgreementMember_0" xml:lang="en-US">Represents license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_LicenseAgreementMember_1" xml:lang="en-US">License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_LicenseAgreementMember_2" xml:lang="en-US">UM 8930 analogue agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_LicenseAgreementMember_3" xml:lang="en-US">License Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_LiquidationProvisionCommonStockEquivalentShares_0" xml:lang="en-US">Represents liquidation provision common stock equivalent shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_LiquidationProvisionCommonStockEquivalentShares_1" xml:lang="en-US">Liquidation Provision Common Stock Equivalent Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_LiquidationProvisionCommonStockEquivalentShares_2" xml:lang="en-US">Liquidation provision common stock equivalent shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_LiquidationProvisionCommonStockEquivalentValue_0" xml:lang="en-US">Represents liquidation provision common stock equivalent value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_LiquidationProvisionCommonStockEquivalentValue_1" xml:lang="en-US">Liquidation provision common stock equivalent value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_LossOnCommonStockIssuanceFromConversionOfAccruedInterest_0" xml:lang="en-US">Amount of loss on common stock issuance from conversion of accrued interest.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_LossOnCommonStockIssuanceFromConversionOfAccruedInterest_1" xml:lang="en-US">Loss On Common Stock Issuance From Conversion Of Accrued Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_LossOnCommonStockIssuanceFromConversionOfAccruedInterest_2" xml:lang="en-US">Loss on common stock issuance from conversion of accrued interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_LumpSumPaymentInAgreement_0" xml:lang="en-US">The amount related to lump sum payment in the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_LumpSumPaymentInAgreement_1" xml:lang="en-US">Lump Sum Payment In Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_LumpSumPaymentInAgreement_2" xml:lang="en-US">Lump sum payment in agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_MasterServiceAgreementMember_0" xml:lang="en-US">Represents information regarding master service agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_MasterServiceAgreementMember_1" xml:lang="en-US">Master Service Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_MasterServiceAgreementMember_2" xml:lang="en-US">Master service agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_Milestone1Member_0" xml:lang="en-US">Milestone 1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_Milestone1Member_1" xml:lang="en-US">It represents milestone 1 member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_Milestone1Member_2" xml:lang="en-US">Milestone 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_Milestone2Member_0" xml:lang="en-US">Milestone 2 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_Milestone2Member_1" xml:lang="en-US">It represents milestone 2 member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_Milestone2Member_2" xml:lang="en-US">Milestone 2</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_Milestone3Member_0" xml:lang="en-US">Milestone 3 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_Milestone3Member_1" xml:lang="en-US">It represents milestone 3 member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_Milestone3Member_2" xml:lang="en-US">Milestone 3</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_MilestonePaymentsPayableAxis_0" xml:lang="en-US">Milestone Payments Payable [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_MilestonePaymentsPayableAxis_1" xml:lang="en-US">It represents milestone payments payable axis.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_MilestonePaymentsPayableDomain_0" xml:lang="en-US">Milestone Payments Payable [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_MilestonePaymentsPayableDomain_1" xml:lang="en-US">It represents milestone payments payable domain.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_MinimumLitigationJudgementAmount_0" xml:lang="en-US">Represents minimum litigation judgement amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_MinimumLitigationJudgementAmount_1" xml:lang="en-US">Minimum Litigation Judgement Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_MinimumLitigationJudgementAmount_2" xml:lang="en-US">Value of final judgment rendered against company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_MonteCarloSimulationsMember_0" xml:lang="en-US">Represents monte carlo simulations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_MonteCarloSimulationsMember_1" xml:lang="en-US">Monte Carlo Simulations [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_MonteCarloSimulationsMember_2" xml:lang="en-US">Monte Carlo simulations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_MonthAndYearOfAgreementAxis_0" xml:lang="en-US">Information regarding month and year of agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_MonthAndYearOfAgreementAxis_1" xml:lang="en-US">Month And Year Of Agreement [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_MonthAndYearOfAgreementDomain_0" xml:lang="en-US">Represents month and year of agreement in which company entered into.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_MonthAndYearOfAgreementDomain_1" xml:lang="en-US">Month And Year Of Agreement [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_MonthlyFee_0" xml:lang="en-US">Represents amount of monthly fee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_MonthlyFee_1" xml:lang="en-US">Monthly Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_MonthlyFee_2" xml:lang="en-US">Monthly fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices_0" xml:lang="en-US">Monthly Fee Accruing From Effective Date In Exchange Of Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices_1" xml:lang="en-US">Represents amount of monthly fees accruing from the effective date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices_2" xml:lang="en-US">Monthly fee accruing from effective date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_MonthlyFeePaidEachMonthInExchangeOfServices_0" xml:lang="en-US">Monthly Fee Paid Each Month In Exchange Of Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_MonthlyFeePaidEachMonthInExchangeOfServices_1" xml:lang="en-US">Represents amount of monthly fee paid in exchange of services.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_MonthlyFeePaidEachMonthInExchangeOfServices_2" xml:lang="en-US">Monthly fee paid each month</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_MultiDrawCreditAgreementMember_0" xml:lang="en-US">Represents the information about Multi-Draw Credit Agreement (the "Credit Agreement").</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_MultiDrawCreditAgreementMember_1" xml:lang="en-US">Multi Draw Credit Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_MultiDrawCreditAgreementMember_2" xml:lang="en-US">Multi-Draw Credit Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_NatureOfOperationsAndBusinessActivitiesAbstract_0" xml:lang="en-US">Represents nature of operations and business activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_NatureOfOperationsAndBusinessActivitiesAbstract_1" xml:lang="en-US">Nature Of Operations And Business Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_NatureOfOperationsAndBusinessActivitiesLineItems_0" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_NatureOfOperationsAndBusinessActivitiesLineItems_1" xml:lang="en-US">Nature Of Operations And Business Activities [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_NatureOfOperationsAndBusinessActivitiesTable_0" xml:lang="en-US">Represents nature of operations and business activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_NatureOfOperationsAndBusinessActivitiesTable_1" xml:lang="en-US">Nature Of Operations And Business Activities [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_NetLossAdjustedBalance_0" xml:lang="en-US">Net Loss Adjusted Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_NetLossAdjustedBalance_1" xml:lang="en-US">Adjusted balance of net loss.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_NetLossAdjustedBalance_2" xml:lang="en-US">Net loss (as adjusted)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_NetLossAdjustedBalance_3" xml:lang="en-US">Loss available to common stockholders + assumed conversions, Income (Numerator)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_NonCashInterestExpenseAbstract_0" xml:lang="en-US">Non Cash Interest Expense [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_NonCashInterestExpenseAbstract_1" xml:lang="en-US">Non-cash interest expense:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_NoramcoAgreementMember_0" xml:lang="en-US">Represents information of noramco agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_NoramcoAgreementMember_1" xml:lang="en-US">Noramco Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_NoramcoAgreementMember_2" xml:lang="en-US">Noramco Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_NoticePeriodForTermination_0" xml:lang="en-US">This element represents written notice period for termination under agreement by either party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_NoticePeriodForTermination_1" xml:lang="en-US">Notice Period For Termination</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_NoticePeriodForTermination_2" xml:lang="en-US">Notice period for termination</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_NumberOfCommonStockIssuedUponConversionOfPreferredStock_0" xml:lang="en-US">Represents number of common stock issued upon conversion of preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_NumberOfCommonStockIssuedUponConversionOfPreferredStock_1" xml:lang="en-US">Number Of Common Stock Issued Upon Conversion Of Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_NumberOfCommonStockIssuedUponConversionOfPreferredStock_2" xml:lang="en-US">Number of common stock issued upon conversion of preferred stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_NumberOfInvestors_0" xml:lang="en-US">Represents the number of investors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_NumberOfInvestors_1" xml:lang="en-US">Number Of Investors</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_NumberOfInvestors_2" xml:lang="en-US">Number of investors</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_NumberOfLicenseAgreements_0" xml:lang="en-US">Represents number of license agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_NumberOfLicenseAgreements_1" xml:lang="en-US">Number Of License Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_NumberOfLicenseAgreements_2" xml:lang="en-US">Number of license agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_NumberOfWarrantsExercisable_0" xml:lang="en-US">Number of warrants exercisable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_NumberOfWarrantsExercisable_1" xml:lang="en-US">Number Of Warrants Exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_NumberOfWarrantsExercisable_2" xml:lang="en-US">Number of warrants exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_OctoberTwoThousandFifteenMember_0" xml:lang="en-US">Represents agreement date of the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_OctoberTwoThousandFifteenMember_1" xml:lang="en-US">October Two Thousand Fifteen [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_OctoberTwoThousandFifteenMember_2" xml:lang="en-US">October 2014</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_OmnibusIncentivePlan2014Member_0" xml:lang="en-US">Represents information of Omnibus Incentive Plan 2014.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_OmnibusIncentivePlan2014Member_1" xml:lang="en-US">Omnibus Incentive Plan 2014 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_OmnibusIncentivePlan2014Member_2" xml:lang="en-US">Omnibus Incentive Plan 2014</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_OneTimeUpfrontPayment_0" xml:lang="en-US">This element represents amount of one-time upfront payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_embi_OneTimeUpfrontPayment_1" xml:lang="en-US">One time up front payment payable in four equal monthly installments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_OneTimeUpfrontPayment_2" xml:lang="en-US">One Time Upfront Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_OneTimeUpfrontPayment_3" xml:lang="en-US">One-time up-front option payment under University of Mississippi option agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_OneTimeUpfrontPayment_4" xml:lang="en-US">One time up front payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_OptionAgreementMember_0" xml:lang="en-US">Represents information regarding option agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_OptionAgreementMember_1" xml:lang="en-US">Option Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_OptionAgreementMember_2" xml:lang="en-US">UM 5050 pro-drug agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_OptionAgreementMember_3" xml:lang="en-US">Option Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_OptionsMember_0" xml:lang="en-US">Options [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_OptionsMember_1" xml:lang="en-US">Represent the information of options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_OptionsMember_2" xml:lang="en-US">Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_PaymentForUpfrontFees_0" xml:lang="en-US">Payment For Upfront Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_PaymentForUpfrontFees_1" xml:lang="en-US">It represents payment for upfront fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_PaymentForUpfrontFees_2" xml:lang="en-US">Payment for upfront fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_PaymentOfUpfrontLicenseFee_0" xml:lang="en-US">Payment Of Upfront License Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_PaymentOfUpfrontLicenseFee_1" xml:lang="en-US">Represents cash outflow of payment of upfront license fee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_PaymentOfUpfrontLicenseFee_2" xml:lang="en-US">Payment of upfront license fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_PercentageOfAccruedInterestOnOutstandingBalance_0" xml:lang="en-US">Represents percentage of interest on accrued the outstanding balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_PercentageOfAccruedInterestOnOutstandingBalance_1" xml:lang="en-US">Percentage Of Accrued Interest On Outstanding Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_PercentageOfAccruedInterestOnOutstandingBalance_2" xml:lang="en-US">Percentage of accrued interest on outstanding balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase_0" xml:lang="en-US">Percentage of amount need to be issued against warrant purchase.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase_1" xml:lang="en-US">Percentage Of Amount Need To Be Issued Against Warrant Purchase</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase_2" xml:lang="en-US">Warrant coverage on the debt facility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_PercentageOfConversionAmount_0" xml:lang="en-US">Represents percentage of conversion amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_PercentageOfConversionAmount_1" xml:lang="en-US">Percentage Of Conversion Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_PercentageOfConversionAmount_2" xml:lang="en-US">Percentage of conversion amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_PercentageOfSharesToBeRedeemed_0" xml:lang="en-US">Represents percentage of shares to be redeemed.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_PercentageOfSharesToBeRedeemed_1" xml:lang="en-US">Percentage Of Shares To Be Redeemed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_PercentageOfSharesToBeRedeemed_2" xml:lang="en-US">Percentage of shares to be redeemed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_PeriodOfDiscretionaryAnnualBonusPayableToContractorAfterEachFiscalYearEnd_0" xml:lang="en-US">Period of discretionary annual bonus payable to contractor after each fiscal year end.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_PeriodOfDiscretionaryAnnualBonusPayableToContractorAfterEachFiscalYearEnd_1" xml:lang="en-US">Period Of Discretionary Annual Bonus Payable To Contractor After Each Fiscal Year End</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_PeriodOfDiscretionaryAnnualBonusPayableToContractorAfterEachFiscalYearEnd_2" xml:lang="en-US">Period of discretionary annual bonus payable to contractor after each fiscal year end</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_PharmaceuticalsInternationalInc.AgreementMember_0" xml:lang="en-US">Represents information regarding Pharmaceuticals International, Inc. agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_PharmaceuticalsInternationalInc.AgreementMember_1" xml:lang="en-US">Pharmaceuticals International, Inc. Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_PharmaceuticalsInternationalInc.AgreementMember_2" xml:lang="en-US">Pharmaceuticals International, Inc. Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_Pre2015CommonStockWarrantsMember_0" xml:lang="en-US">Represents Pre 2015 Common Stock Warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_Pre2015CommonStockWarrantsMember_1" xml:lang="en-US">Pre 2015 Common Stock Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_Pre2015CommonStockWarrantsMember_2" xml:lang="en-US">Pre 2015 Common Stock Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_PreferredStockPutOptionLiability_0" xml:lang="en-US">Represents the value of preferred stock put option liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_PreferredStockPutOptionLiability_1" xml:lang="en-US">Preferred Stock Put Option Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_PreferredStockPutOptionLiability_2" xml:lang="en-US">Series F put option liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_PricingModelAxis_0" xml:lang="en-US">Pricing Model [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_PricingModelDomain_0" xml:lang="en-US">Pricing Model [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_PricingModelMember_0" xml:lang="en-US">Represents option pricing model,</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_PricingModelMember_1" xml:lang="en-US">Pricing Model [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_PricingModelMember_2" xml:lang="en-US">Black-Scholes option pricing model</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_PricingModelMember_3" xml:lang="en-US">Black Scholes Merton Option Pricing Model</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement_0" xml:lang="en-US">Amount of proceeds allocated on a relative fair value basis to equity classified warrants issued with convertible multi-draw credit agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement_1" xml:lang="en-US">Proceeds Allocated To Equity Classified Warrants Issued With Convertible Multi Draw Credit Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement_2" xml:lang="en-US">Proceeds allocated to equity classified warrants issued with convertible multi-draw credit agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ProceedsFromConvertibleMultiDrawCreditAgreement_0" xml:lang="en-US">Amount of convertible multi-draw credit agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ProceedsFromConvertibleMultiDrawCreditAgreement_1" xml:lang="en-US">Proceeds From Convertible Multi Draw Credit Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ProceedsFromConvertibleMultiDrawCreditAgreement_2" xml:lang="en-US">Proceeds from convertible multi-draw credit agreement - related party, net of issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_ProceedsFromConvertibleMultiDrawCreditAgreement_3" xml:lang="en-US">Proceeds from convertible multi-draw credit agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ProceedsFromEmeraldFinancingNetOfIssuanceCosts_0" xml:lang="en-US">Amount of Proceeds from Emerald Financing, net of issuance costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ProceedsFromEmeraldFinancingNetOfIssuanceCosts_1" xml:lang="en-US">Proceeds From Emerald Financing, Net Of Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ProceedsFromEmeraldFinancingNetOfIssuanceCosts_2" xml:lang="en-US">Proceeds from Emerald Financing, net of $154,092 issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ProceedsFromFinancingBetweenConversionLiabilityAndWarrants_0" xml:lang="en-US">Represents the amount related to proceeds from financing between the conversion liability and the warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ProceedsFromFinancingBetweenConversionLiabilityAndWarrants_1" xml:lang="en-US">Proceeds From Financing Between Conversion Liability And Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ProceedsFromFinancingBetweenConversionLiabilityAndWarrants_2" xml:lang="en-US">Proceeds from financing between conversion liability and warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ProvisionForConversionOfPreferredStock_0" xml:lang="en-US">Represents the amount related to provision for conversion of preferred stock as of balance sheet date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ProvisionForConversionOfPreferredStock_1" xml:lang="en-US">Provision For Conversion Of Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_ProvisionForConversionOfPreferredStock_2" xml:lang="en-US">Fair value of the conversion feature</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ProvisionForConversionOfPreferredStock_3" xml:lang="en-US">Provision for conversion of Series B preferred stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ReclassificationOfDerivativesToEquity_0" xml:lang="en-US">Amount of derivatives reclassified to equity or the statement of operations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ReclassificationOfDerivativesToEquity_1" xml:lang="en-US">Reclassification Of Derivatives To Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_ReclassificationOfDerivativesToEquity_2" xml:lang="en-US">Reclassification of Derivatives to Equity or Extinguishment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ReclassificationOfDerivativesToEquity_3" xml:lang="en-US">Reduction of equity liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_RedemptionAmountPercentage_0" xml:lang="en-US">Represents redemption amount percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_RedemptionAmountPercentage_1" xml:lang="en-US">Redemption Amount Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_RedemptionAmountPercentage_2" xml:lang="en-US">Redemption amount percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ReductionToAdditionalPaidInCapitalFromTheIssuanceOfCommonStock_0" xml:lang="en-US">Amount of reduction to APIC from the issuance of common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ReductionToAdditionalPaidInCapitalFromTheIssuanceOfCommonStock_1" xml:lang="en-US">Reduction To Additional Paid In Capital From The Issuance Of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ReductionToAdditionalPaidInCapitalFromTheIssuanceOfCommonStock_2" xml:lang="en-US">Reduction to APIC from the issuance of common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_RepaymentOfConvertibleMultiDrawCreditAgreement_0" xml:lang="en-US">Repayment of Convertible Multi Draw Credit Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_RepaymentOfConvertibleMultiDrawCreditAgreement_1" xml:lang="en-US">Represents amount related to prepayment of convertible multi-draw credit agreement - related party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_embi_RepaymentOfConvertibleMultiDrawCreditAgreement_2" xml:lang="en-US">Prepayment of convertible multi-draw credit agreement - related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ResearchAgreementMember_0" xml:lang="en-US">Represents information regarding research agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ResearchAgreementMember_1" xml:lang="en-US">Research Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ResearchAgreementMember_2" xml:lang="en-US">Research Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_RestrictedStockAgreementsMember_0" xml:lang="en-US">Information of Restricted Stock Agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_RestrictedStockAgreementsMember_1" xml:lang="en-US">Restricted Stock Agreements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_RestrictedStockAgreementsMember_2" xml:lang="en-US">Restricted Stock Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_RisksAndUncertaintiesPolicyTextBlock_0" xml:lang="en-US">Represents policy for Risks and Uncertainties.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_RisksAndUncertaintiesPolicyTextBlock_1" xml:lang="en-US">Risks And Uncertainties [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_RisksAndUncertaintiesPolicyTextBlock_2" xml:lang="en-US">Risks and Uncertainties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_RrdInternationalAgreementMember_0" xml:lang="en-US">Represents information regarding RRD International agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_RrdInternationalAgreementMember_1" xml:lang="en-US">Rrd International Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_RrdInternationalAgreementMember_2" xml:lang="en-US">RRD International Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ScheduleOfAdjustmentForDifferenceBetweenFairValueOfWarrantLiabilitiesAndTotalProceedsReceivedTableTextBlock_0" xml:lang="en-US">Represent Schedule of the adjustment for the difference between the fair value of the warrant liabilities and the total proceeds received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ScheduleOfAdjustmentForDifferenceBetweenFairValueOfWarrantLiabilitiesAndTotalProceedsReceivedTableTextBlock_1" xml:lang="en-US">Schedule Of Adjustment For Difference Between Fair Value Of Warrant Liabilities And Total Proceeds Received Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ScheduleOfAdjustmentForDifferenceBetweenFairValueOfWarrantLiabilitiesAndTotalProceedsReceivedTableTextBlock_2" xml:lang="en-US">Schedule of the adjustment for the difference between the fair value of the warrant liabilities and the total proceeds received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ScheduleOfAssumptionsUsedToComputeFairValueOfWarrantsTableTextBlock_0" xml:lang="en-US">Tabular disclosure of Schedule of Assumptions Used to compute the fair value of the warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ScheduleOfAssumptionsUsedToComputeFairValueOfWarrantsTableTextBlock_1" xml:lang="en-US">Schedule Of Assumptions Used To Compute Fair Value Of Warrants Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ScheduleOfAssumptionsUsedToComputeFairValueOfWarrantsTableTextBlock_2" xml:lang="en-US">Schedule of Assumptions Used to compute the fair value of the warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ScheduleOfInterestExpenseTableTextBlock_0" xml:lang="en-US">Tabular disclosure of interest expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ScheduleOfInterestExpenseTableTextBlock_1" xml:lang="en-US">Schedule Of Interest Expense [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_ScheduleOfInterestExpenseTableTextBlock_2" xml:lang="en-US">Schedule of interest expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_SecondDrawOnMultiDrawCreditFacilityMember_0" xml:lang="en-US">Represents information regarding second draw on multi draw credit facility.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_SecondDrawOnMultiDrawCreditFacilityMember_1" xml:lang="en-US">Second Draw On Multi Draw Credit Facility [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_SecondDrawOnMultiDrawCreditFacilityMember_2" xml:lang="en-US">2nd Draw on Multi Draw Credit Facility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_SecuredPromissoryNoteAndSecurityAgreementMember_0" xml:lang="en-US">Represents Secured Promissory Note and Security Agreement for a convertible loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_SecuredPromissoryNoteAndSecurityAgreementMember_1" xml:lang="en-US">Secured Promissory Note And Security Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_SecuredPromissoryNoteAndSecurityAgreementMember_2" xml:lang="en-US">Secured Promissory Note and Security Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_SecuritiesPurchaseAgreementMember_0" xml:lang="en-US">Represents information regarding securities purchase agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_SecuritiesPurchaseAgreementMember_1" xml:lang="en-US">Securities Purchase Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_SecuritiesPurchaseAgreementMember_2" xml:lang="en-US">Securities Purchase Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_SecuritiesPurchaseAgreementMember_3" xml:lang="en-US">Securities purchase agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_SeparationAndReleaseAgreementMember_0" xml:lang="en-US">Represents separation and release agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_SeparationAndReleaseAgreementMember_1" xml:lang="en-US">Separation And Release Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_SeparationAndReleaseAgreementMember_2" xml:lang="en-US">Separation and release agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_SeriesBPreferredStockConversionLiabilityMember_0" xml:lang="en-US">Series B Preferred Stock Conversion Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_SeriesBPreferredStockConversionLiabilityMember_1" xml:lang="en-US">Series BPreferred Stock Conversion Liability Member</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_SeriesBPreferredStockConversionLiabilityMember_2" xml:lang="en-US">Series B Preferred Stock - conversion liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_SeriesBWarrantMember_0" xml:lang="en-US">Represents information regarding Series B warrant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_SeriesBWarrantMember_1" xml:lang="en-US">Series B Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_SeriesBWarrantMember_2" xml:lang="en-US">Series B - warrant liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_SeriesBWarrantMember_3" xml:lang="en-US">Series B Warrant Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_SeriesBWarrantsMember_0" xml:lang="en-US">Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_SeriesBWarrantsMember_1" xml:lang="en-US">Series B Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_SeriesBWarrantsMember_2" xml:lang="en-US">Series B Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_SeriesFPreferredStockPutOptionLiabilityMember_0" xml:lang="en-US">Series F Preferred Stock Put Option Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_SeriesFPreferredStockPutOptionLiabilityMember_1" xml:lang="en-US">Series F Preferred Stock Put Option Liability [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_SeriesFPreferredStockPutOptionLiabilityMember_2" xml:lang="en-US">Series F Preferred Stock Put Option Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ShareAndWarrantsIssuanceCosts_0" xml:lang="en-US">Share and warrants Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ShareAndWarrantsIssuanceCosts_1" xml:lang="en-US">Represents amount related to share and warrants issuance cost.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ShareAndWarrantsIssuanceCosts_2" xml:lang="en-US">Shares and warrants issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ShareIssuanceCosts_0" xml:lang="en-US">Represents costs related to issuance of shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ShareIssuanceCosts_1" xml:lang="en-US">Share Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ShareIssuanceCosts_2" xml:lang="en-US">Share issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_SignificantContractsAbstract_0" xml:lang="en-US">Significant Contracts [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_SignificantContractsLineItems_0" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_SignificantContractsLineItems_1" xml:lang="en-US">Significant Contracts [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_SignificantContractsTable_0" xml:lang="en-US">Significant Contracts [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_SignificantContractsTextBlock_0" xml:lang="en-US">Represents entire disclosure for significant contracts.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_SignificantContractsTextBlock_1" xml:lang="en-US">Significant Contracts [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_SignificantContractsTextBlock_2" xml:lang="en-US">Significant Contracts - University of Mississippi</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_SignificantContractsTextBlock_3" xml:lang="en-US">University of Mississippi Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants_0" xml:lang="en-US">Number of preferred stock and warrants for common stock issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants_1" xml:lang="en-US">Stock And Warrants Issued During Period Shares Preferred Stock And Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants_2" xml:lang="en-US">Number of preferred stock and warrants sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_StockBasedCompensationForNonEmployeesPolicyTextBlock_0" xml:lang="en-US">Represents policy for stock based compensation for Non Employees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_StockBasedCompensationForNonEmployeesPolicyTextBlock_1" xml:lang="en-US">Stock Based Compensation For Non Employees [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_StockBasedCompensationForNonEmployeesPolicyTextBlock_2" xml:lang="en-US">Stock-Based Compensation for Non-Employees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_StockIssuanceCosts_0" xml:lang="en-US">Represents amount of stock issuance costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_StockIssuanceCosts_1" xml:lang="en-US">Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_StockIssuanceCosts_2" xml:lang="en-US">Issuance costs (in dollars)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_StockIssuedDuringPeriodSharesIssuedForStockBasedCompensationExpense_0" xml:lang="en-US">Number of shares issued in lieu of cash for Stock based compensation expense contributed to the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_StockIssuedDuringPeriodSharesIssuedForStockBasedCompensationExpense_1" xml:lang="en-US">Stock Issued During Period Shares Issued For Stock Based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_StockIssuedDuringPeriodSharesIssuedForStockBasedCompensationExpense_2" xml:lang="en-US">Stock based compensation expense (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_StockIssuedDuringPeriodSharesNetOfIssuanceCosts_0" xml:lang="en-US">Number of shares of stock issued during the period net of issuance costs value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_StockIssuedDuringPeriodSharesNetOfIssuanceCosts_1" xml:lang="en-US">Stock Issued During Period Shares Net Of Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_StockIssuedDuringPeriodSharesNetOfIssuanceCosts_2" xml:lang="en-US">Issuance of common stock net of issuance costs of $16,900 (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_StockIssuedDuringPeriodSharesNetOfIssuanceCostsAndWarrants_0" xml:lang="en-US">Stock Issued During Period shares Net Of Issuance Costs and warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_StockIssuedDuringPeriodSharesNetOfIssuanceCostsAndWarrants_1" xml:lang="en-US">Represents number of shares related to issuance of common stock and warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_StockIssuedDuringPeriodSharesNetOfIssuanceCostsAndWarrants_2" xml:lang="en-US">Issuance of common stock and warrants, net of issuance costs of $80,628 (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_StockIssuedDuringPeriodSharesSeriesBWarrantExercises_0" xml:lang="en-US">Number of Series B warrant exercises for common stock issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_StockIssuedDuringPeriodSharesSeriesBWarrantExercises_1" xml:lang="en-US">Stock Issued During Period Shares Series B Warrant Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_StockIssuedDuringPeriodSharesSeriesBWarrantExercises_2" xml:lang="en-US">Series B warrant exercises (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_StockIssuedDuringPeriodValueNetOfIssuanceCosts_0" xml:lang="en-US">Value of shares of common stock issued during the period net of issuance costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_StockIssuedDuringPeriodValueNetOfIssuanceCosts_1" xml:lang="en-US">Stock Issued During Period Value Net Of Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_StockIssuedDuringPeriodValueNetOfIssuanceCosts_2" xml:lang="en-US">Issuance of common stock net of issuance costs of $16,900</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_StockIssuedDuringPeriodValueNetOfIssuanceCostsAndWarrants_0" xml:lang="en-US">Stock Issued During Period Value Net Of Issuance Costs and warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_StockIssuedDuringPeriodValueNetOfIssuanceCostsAndWarrants_1" xml:lang="en-US">Represents amount related to issuance of common stock and warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_StockIssuedDuringPeriodValueNetOfIssuanceCostsAndWarrants_2" xml:lang="en-US">Issuance of common stock and warrants, net of issuance costs of $80,628</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_StockIssuedDuringPeriodValueSeriesBWarrantExercises_0" xml:lang="en-US">Value of Series B warrant exercises for common stock issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_StockIssuedDuringPeriodValueSeriesBWarrantExercises_1" xml:lang="en-US">Stock Issued During Period Value Series B Warrant Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_StockIssuedDuringPeriodValueSeriesBWarrantExercises_2" xml:lang="en-US">Series B warrant exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_SubsequentFinancingPurchasePriceDescription_0" xml:lang="en-US">Represents subsequent financing purchase price description to protect against anti-dilution.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_SubsequentFinancingPurchasePriceDescription_1" xml:lang="en-US">Subsequent Financing Purchase Price Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_SubsequentFinancingPurchasePriceDescription_2" xml:lang="en-US">Subsequent financing purchase price, description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_TermOfAgreement_0" xml:lang="en-US">Represents term of agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_TermOfAgreement_1" xml:lang="en-US">Term Of Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_TermOfAgreement_2" xml:lang="en-US">Term of agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_TermOfWarrant_0" xml:lang="en-US">Represents term of warrant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_TermOfWarrant_1" xml:lang="en-US">Term Of Warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_TermOfWarrant_2" xml:lang="en-US">Term of warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_TermOfWarrant_3" xml:lang="en-US">Term (Years)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_TermOfWarrants_0" xml:lang="en-US">Represents term of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_TermOfWarrants_1" xml:lang="en-US">Term Of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_TermOfWarrants_2" xml:lang="en-US">Term of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_TermsOfAgreementRenewed_0" xml:lang="en-US">Represents tem of agreement renewed.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_TermsOfAgreementRenewed_1" xml:lang="en-US">Terms Of Agreement Renewed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_TermsOfAgreementRenewed_2" xml:lang="en-US">Terms of agreement renewed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_TotalExpenseIncurredUnderAgreement_0" xml:lang="en-US">Represents total expense incurred under the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_TotalExpenseIncurredUnderAgreement_1" xml:lang="en-US">Total Expense Incurred Under Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_TotalExpenseIncurredUnderAgreement_2" xml:lang="en-US">Total expense incurred under agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_TwoThousandEighteenEmeraldFinancingWarrantsMember_0" xml:lang="en-US">Represents 2018 Emerald Financing Warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_TwoThousandEighteenEmeraldFinancingWarrantsMember_1" xml:lang="en-US">Two Thousand Eighteen Emerald Financing Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_TwoThousandEighteenEmeraldFinancingWarrantsMember_2" xml:lang="en-US">2018 Emerald Financing Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_0" xml:lang="en-US">Information about 2018 emerald multi-draw credit agreement warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="lab_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_1" xml:lang="en-US">Emerald Multi-Draw Credit Agreement - compound derivative liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_2" xml:lang="en-US">Two Thousand Eighteen Emerald Multi Draw Credit Agreement Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_3" xml:lang="en-US">Emerald Multi-Draw Credit Agreement Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_4" xml:lang="en-US">Emerald Multi-Draw Credit Agreement Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_TwoThousandFifteenCommonStockWarrantsMember_0" xml:lang="en-US">Represents 2015 Common Stock Warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_TwoThousandFifteenCommonStockWarrantsMember_1" xml:lang="en-US">Two Thousand Fifteen Common Stock Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_TwoThousandFifteenCommonStockWarrantsMember_2" xml:lang="en-US">2015 Common Stock Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember_0" xml:lang="en-US">Represents two thousand fifteen series B financing Common Stock Warrants to Series B Stockholders.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember_1" xml:lang="en-US">Two Thousand Fifteen Series B Financing Common Stock Warrants To Series B Stockholders [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember_2" xml:lang="en-US">2015 series B financing Common Stock Warrants to Series B Stockholders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember_0" xml:lang="en-US">Represents two thousand fifteen series B financing Placement Agent Warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember_1" xml:lang="en-US">Two Thousand Fifteen Series B Financing Placement Agent Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember_2" xml:lang="en-US">2015 Series B financing Placement Agent Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_TwoThousandNineteenCommonStockWarrantsMember_0" xml:lang="en-US">Two Thousand Nineteen Common Stock Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_TwoThousandNineteenCommonStockWarrantsMember_1" xml:lang="en-US">Represents 2019 Common Stock Warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_TwoThousandNineteenCommonStockWarrantsMember_2" xml:lang="en-US">2019 Common Stock Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember_0" xml:lang="en-US">Represents two thousand seventeen Common Stock Warrants to Service Providers.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember_1" xml:lang="en-US">Two Thousand Seventeen Common Stock Warrants To Service Providers [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember_2" xml:lang="en-US">2017 Common Stock Warrants to Service Provider</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember_0" xml:lang="en-US">Represents two thousand sixteen Series D Placement Agent Warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember_1" xml:lang="en-US">Two Thousand Seventeen Series D Placement Agent Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember_2" xml:lang="en-US">2017 Series D Common Stock Warrants to Placement Agent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember_0" xml:lang="en-US">Represents two thousand sixteen Common Stock Warrants to Service Providers.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember_1" xml:lang="en-US">Two Thousand Sixteen Common Stock Warrants To Service Providers [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember_2" xml:lang="en-US">2016 Common Stock Warrants to Service Providers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember_0" xml:lang="en-US">Represents 2016 Series C Placement Agent Warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember_1" xml:lang="en-US">Two Thousand Sixteen Series C Placement Agent Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember_2" xml:lang="en-US">2016 Series C Common Stock Warrants to Placement Agent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_Um5050ProdrugAndUm8930AnalogAgreementsMember_0" xml:lang="en-US">Um 5050 Prodrug And Um 8930 Analog Agreements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_Um5050ProdrugAndUm8930AnalogAgreementsMember_1" xml:lang="en-US">It represents UM 5050 Pro-Drug and UM 8930 Analog Agreements member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_Um5050ProdrugAndUm8930AnalogAgreementsMember_2" xml:lang="en-US">Um 5050 Pro-Drug And Um 8930 Analog Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_Um5070LicenseAgreementMember_0" xml:lang="en-US">UM 5070 license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_Um5070LicenseAgreementMember_1" xml:lang="en-US">Um 5070 License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_Um5070LicenseAgreementMember_2" xml:lang="en-US">UM 5070 license agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_UnamortizedDebtDiscountPeriod_0" xml:lang="en-US">Period of unamortized discount of debt.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_UnamortizedDebtDiscountPeriod_1" xml:lang="en-US">Unamortized Debt Discount Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_UnamortizedDebtDiscountPeriod_2" xml:lang="en-US">Unamortized debt discount period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_UniversityOfMississippiAgreementsLineItems_0" xml:lang="en-US">University Of Mississippi Agreements [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_UniversityOfMississippiAgreementsLineItems_1" xml:lang="en-US">Line item represents information regarding University of Mississippi agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_UniversityOfMississippiAgreementsTable_0" xml:lang="en-US">University Of Mississippi Agreements [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_UniversityOfMississippiAgreementsTable_1" xml:lang="en-US">Tabular disclosure of information regarding University of Mississippi agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_UniversityOfMississippiMember_0" xml:lang="en-US">Represents information regarding university of mississippi.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_UniversityOfMississippiMember_1" xml:lang="en-US">University Of Mississippi [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_UniversityOfMississippiMember_2" xml:lang="en-US">University of Mississippi</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_UnvestedRestrictedStockMember_0" xml:lang="en-US">Unvested Restricted Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_UnvestedRestrictedStockMember_1" xml:lang="en-US">Represent the information of unvested restricted stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_UnvestedRestrictedStockMember_2" xml:lang="en-US">Unvested restricted stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_UpfrontPayment_0" xml:lang="en-US">This element represents amount of upfront payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_UpfrontPayment_1" xml:lang="en-US">Upfront Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_UpfrontPayment_2" xml:lang="en-US">Upfront payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ValueOfCommonStockCalledByWarrants_0" xml:lang="en-US">Represents amount of common stock called by warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ValueOfCommonStockCalledByWarrants_1" xml:lang="en-US">Value Of Common Stock Called By Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ValueOfCommonStockCalledByWarrants_2" xml:lang="en-US">Value of common stock called by warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_WarrantsAndDerivativeLiabilitiesAbstract_0" xml:lang="en-US">Warrants And Derivative Liabilities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_WarrantsAndDerivativeLiabilitiesTextBlock_0" xml:lang="en-US">The entire disclosure for Warrants and Derivative Liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_WarrantsAndDerivativeLiabilitiesTextBlock_1" xml:lang="en-US">Warrants And Derivative Liabilities [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_WarrantsAndDerivativeLiabilitiesTextBlock_2" xml:lang="en-US">Warrants and Derivative Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_0" xml:lang="en-US">Represents warrants issued in connection with convertible multi draw credit agreement related party value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_1" xml:lang="en-US">Warrants Issued In Connection With Convertible Multi Draw Credit Agreement Related Party Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_2" xml:lang="en-US">Warrants issued in connection with convertible multi-draw credit agreement, related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock_0" xml:lang="en-US">Disclosure of accounting policy for warrants issued in bundled transactions with other financial instruments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock_1" xml:lang="en-US">Warrants Issued In Connection With Financings [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock_2" xml:lang="en-US">Warrants Issued in Connection with Financings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_WarrantsLiabilityClassifiedMember_0" xml:lang="en-US">Warrants liability classified [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_WarrantsLiabilityClassifiedMember_1" xml:lang="en-US">Represent the information of warrants - liability classified.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_WarrantsLiabilityClassifiedMember_2" xml:lang="en-US">Warrants - liability classified</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_WarrantsMember_0" xml:lang="en-US">Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_WarrantsMember_1" xml:lang="en-US">Represent the information of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_WarrantsMember_2" xml:lang="en-US">Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_WarrantsVestedAndOutstanding_0" xml:lang="en-US">Represents warrants vested and outstanding as of balance sheet date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_WarrantsVestedAndOutstanding_1" xml:lang="en-US">Warrants Vested And Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_WarrantsVestedAndOutstanding_2" xml:lang="en-US">Amount Vested and Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_WorkingCapitalDeficit_0" xml:lang="en-US">Represent working capital deficit.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_embi_WorkingCapitalDeficit_1" xml:lang="en-US">Working capital deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_WorkingCapitalDeficit_2" xml:lang="en-US">Working Capital Deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_WorkingCapitalDeficit_3" xml:lang="en-US">Working capital deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_BoardOfDirectorsChairmanMember_0" xml:lang="en-US">Board of Directors Chairman [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_BoardOfDirectorsChairmanMember_1" xml:lang="en-US">Cosmas N. Lykos</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_srt_BoardOfDirectorsChairmanMember_2" xml:lang="en-US">Board of Directors Chairman [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ChiefExecutiveOfficerMember_0" xml:lang="en-US">Chief Executive Officer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ChiefExecutiveOfficerMember_1" xml:lang="en-US">Dr. Brian S. Murphy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_srt_ChiefExecutiveOfficerMember_2" xml:lang="en-US">Chief Executive Officer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ChiefFinancialOfficerMember_0" xml:lang="en-US">Chief Financial Officer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ChiefFinancialOfficerMember_1" xml:lang="en-US">Elizabeth Berecz, CFO</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MaximumMember_0" xml:lang="en-US">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MaximumMember_1" xml:lang="en-US">Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_srt_MaximumMember_2" xml:lang="en-US">Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MinimumMember_0" xml:lang="en-US">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MinimumMember_1" xml:lang="en-US">Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_srt_MinimumMember_2" xml:lang="en-US">Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeAxis_0" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeMember_0" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualAxis_0" xml:lang="en-US">Title of Individual [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xml:lang="en-US">Title of Individual [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_0" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_1" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableCurrent_0" xml:lang="en-US">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountsPayableCurrent_1" xml:lang="en-US">Accounts payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableRelatedPartiesCurrent_0" xml:lang="en-US">Accounts Payable, Related Parties, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountsPayableRelatedPartiesCurrent_1" xml:lang="en-US">Accounts payable to related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_0" xml:lang="en-US">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_1" xml:lang="en-US">Accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedSalariesCurrent_0" xml:lang="en-US">Accrued Salaries, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccruedSalariesCurrent_1" xml:lang="en-US">Accrued payroll and related expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_0" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_1" xml:lang="en-US">Additional paid-in-capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_1" xml:lang="en-US">Additional Paid-In Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentOfWarrantsGrantedForServices_0" xml:lang="en-US">Adjustment of Warrants Granted for Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentOfWarrantsGrantedForServices_1" xml:lang="en-US">Value of warrants issued to purchase shares of common stock for consulting services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_0" xml:lang="en-US">Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_1" xml:lang="en-US">Beneficial conversion feature upon issuance of Series C Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_0" xml:lang="en-US">Deemed dividend from beneficial conversion feature of Series C Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_1" xml:lang="en-US">Adjustments to Additional Paid in Capital, Dividends in Excess of Retained Earnings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_2" xml:lang="en-US">Deemed dividend from beneficial conversion feature of Series C Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1" xml:lang="en-US">Stock based compensation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0" xml:lang="en-US">Adjustments To Reconcile Net Income (Loss) To Cash Provided By (Used In) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1" xml:lang="en-US">Adjustments to reconcile net income (loss) to net cash used in operating activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_0" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_1" xml:lang="en-US">Recognized stock-based compensation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_2" xml:lang="en-US">Recognized additional stock based compensation expense of restricted stock and option awards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium_0" xml:lang="en-US">Amortization of Debt Discount (Premium)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium_1" xml:lang="en-US">Amortization of debt discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium_2" xml:lang="en-US">Amortization of convertible debt discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts_0" xml:lang="en-US">Amortization of Debt Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts_1" xml:lang="en-US">Amortization of debt discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts_2" xml:lang="en-US">Amortization of warrants and stock issued for services (1)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1" xml:lang="en-US">Anti-dilutive excluded from the calculation of diluted net loss per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0" xml:lang="en-US">Antidilutive Securities [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_0" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AreaOfLand_0" xml:lang="en-US">Area of Land</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AreaOfLand_1" xml:lang="en-US">Area of corporate office headquarters</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AreaOfLand_2" xml:lang="en-US">Area of land</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets_0" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets_1" xml:lang="en-US">Total assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Assets_2" xml:lang="en-US">Total Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract_0" xml:lang="en-US">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsAbstract_1" xml:lang="en-US">ASSETS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent_0" xml:lang="en-US">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent_1" xml:lang="en-US">Total current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsCurrent_2" xml:lang="en-US">Total current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract_0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract_1" xml:lang="en-US">Current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardTypeAxis_0" xml:lang="en-US">Award Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1" xml:lang="en-US">Basis of Presentation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BridgeLoan_0" xml:lang="en-US">Bridge Loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BridgeLoan_1" xml:lang="en-US">Aggregate gross proceeds secured by all of Nemus' assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BridgeLoan_2" xml:lang="en-US">Aggregate gross proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BridgeLoanMember_0" xml:lang="en-US">Bridge Loan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BridgeLoanMember_1" xml:lang="en-US">Bridge Loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Cash_0" xml:lang="en-US">Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_Cash_1" xml:lang="en-US">Cash, Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_Cash_2" xml:lang="en-US">Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Cash_3" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Cash_4" xml:lang="en-US">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Cash_5" xml:lang="en-US">Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2" xml:lang="en-US">Cash and Cash Equivalents, At Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_3" xml:lang="en-US">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_4" xml:lang="en-US">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_0" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_1" xml:lang="en-US">Net (decrease) increase in cash and restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_2" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_0" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1" xml:lang="en-US">Cash and Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_0" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_1" xml:lang="en-US">Restricted Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xml:lang="en-US">Total cash and restricted cash shown in the consolidated statements of cash flows</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1" xml:lang="en-US">Cash and restricted cash, beginning of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3" xml:lang="en-US">Total cash and restricted cash shown in the consolidated statements of cash flows</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4" xml:lang="en-US">Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_1" xml:lang="en-US">Reconciliation of cash and restricted cash:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_0" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1" xml:lang="en-US">Supplemental disclosures of non-cash financing activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockDomain_0" xml:lang="en-US">Class of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis_0" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain_0" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0" xml:lang="en-US">Warrant exercise price (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2" xml:lang="en-US">Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3" xml:lang="en-US">Warrant exercise price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems_0" xml:lang="en-US">Class of Warrant or Right [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_0" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_1" xml:lang="en-US">Number of warrants issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_0" xml:lang="en-US">Number of shares called by warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveVerboseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1" xml:lang="en-US">Total number of warrants issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3" xml:lang="en-US">Warrants to purchase shares of common stock issued and outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_4" xml:lang="en-US">Number of warrants issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_0" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_1" xml:lang="en-US">Number of warrant issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable_0" xml:lang="en-US">Class of Warrant or Right [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies_0" xml:lang="en-US">Commitments and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingencies_1" xml:lang="en-US">Commitments and contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1" xml:lang="en-US">Commitments and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_0" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1" xml:lang="en-US">Number of shares reserved for future grants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember_0" xml:lang="en-US">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockMember_1" xml:lang="en-US">Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_0" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_1" xml:lang="en-US">Par value of common stock issued (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_2" xml:lang="en-US">Common stock, par value (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_0" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_1" xml:lang="en-US">Common stock, shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued_0" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued_1" xml:lang="en-US">Common stock, shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_0" xml:lang="en-US">Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_1" xml:lang="en-US">Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_2" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_3" xml:lang="en-US">Common stock outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_4" xml:lang="en-US">Common stock, shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue_0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockValue_1" xml:lang="en-US">Common stock, $0.001 par value; 500,000,000 shares authorized; 182,895,247 and 133,907,747 shares issued and outstanding at December 31, 2019 and December 31, 2018, respectively</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_0" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_1" xml:lang="en-US">Comprehensive Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConversionOfStockAmountConverted1_0" xml:lang="en-US">Conversion of Stock, Amount Converted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConversionOfStockAmountConverted1_1" xml:lang="en-US">Conversion of outstanding preferred stock into common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ConversionOfStockAmountConverted1_2" xml:lang="en-US">Amount of shares converted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1_0" xml:lang="en-US">Conversion of Stock, Shares Converted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1_1" xml:lang="en-US">Number of shares converted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConversionOfStockSharesIssued1_0" xml:lang="en-US">Conversion of Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ConversionOfStockSharesIssued1_1" xml:lang="en-US">Number of shares issued in conversion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleDebt_0" xml:lang="en-US">Convertible Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ConvertibleDebt_1" xml:lang="en-US">Carrying value of total convertible debt - related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_ConvertibleDebtCurrent_0" xml:lang="en-US">Current convertible debt - related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleDebtCurrent_1" xml:lang="en-US">Convertible Debt, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConvertibleDebtCurrent_2" xml:lang="en-US">Convertible debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ConvertibleDebtCurrent_3" xml:lang="en-US">Secured convertible promissory note - related party, net of discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ConvertibleDebtCurrent_4" xml:lang="en-US">Carrying value of total convertible debt - related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleDebtMember_0" xml:lang="en-US">Convertible Debt [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConvertibleDebtMember_1" xml:lang="en-US">Convertible debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent_0" xml:lang="en-US">Less, noncurrent portion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent_1" xml:lang="en-US">Convertible Debt, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent_2" xml:lang="en-US">Convertible multi-draw credit agreement - related party, net of discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember_0" xml:lang="en-US">Convertible Debt Securities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember_1" xml:lang="en-US">Common shares underlying convertible debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock_0" xml:lang="en-US">Convertible Debt [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock_1" xml:lang="en-US">Schedule of convertible debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_0" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_1" xml:lang="en-US">Fair value of common stock issued in extinguishment of convertible debt and accrued interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_2" xml:lang="en-US">Number of shares issued in conversion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtDisclosureAbstract_0" xml:lang="en-US">Debt Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_0" xml:lang="en-US">Debt Instrument, Convertible, Beneficial Conversion Feature</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_1" xml:lang="en-US">Beneficial conversion feature</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_0" xml:lang="en-US">Debt Instrument, Convertible, Carrying Amount of Equity Component</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_1" xml:lang="en-US">Carrying value of the equity component</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_2" xml:lang="en-US">Total principal value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_0" xml:lang="en-US">Conversion price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_1" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_2" xml:lang="en-US">Conversion price, per share (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_3" xml:lang="en-US">Initial conversion price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_0" xml:lang="en-US">Debt Instrument, Convertible, Remaining Discount Amortization Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_1" xml:lang="en-US">Unamortized debt discount period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_0" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_1" xml:lang="en-US">Number of trading days as of financing close date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_1" xml:lang="en-US">Effective interest rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_0" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_1" xml:lang="en-US">Bridge loan interest rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentLineItems_0" xml:lang="en-US">Debt Instrument [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate_0" xml:lang="en-US">Debt Instrument, Maturity Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate_1" xml:lang="en-US">Bridge loan maturity date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate_2" xml:lang="en-US">Maturity date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentTable_0" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_0" xml:lang="en-US">Unamortized debt discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_1" xml:lang="en-US">Debt Instrument, Unamortized Discount, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_2" xml:lang="en-US">Unamortized debt discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtPolicyTextBlock_0" xml:lang="en-US">Debt, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtPolicyTextBlock_1" xml:lang="en-US">Debt Issuance Costs and Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredFinanceCostsCurrentGross_0" xml:lang="en-US">Unamortized debt issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredFinanceCostsCurrentGross_1" xml:lang="en-US">Debt Issuance Costs, Gross, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredFinanceCostsCurrentGross_2" xml:lang="en-US">Unamortized debt issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_0" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_1" xml:lang="en-US">Foreign</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_0" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_1" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_2" xml:lang="en-US">Total deferred tax assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_0" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_1" xml:lang="en-US">US</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_0" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_1" xml:lang="en-US">Gross deferred tax assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_2" xml:lang="en-US">Gross deferred tax assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_0" xml:lang="en-US">Deferred Tax Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_1" xml:lang="en-US">Net deferred tax assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_0" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_1" xml:lang="en-US">Net deferred tax assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract_0" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract_1" xml:lang="en-US">Current deferred tax assets/(liabilities):</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1" xml:lang="en-US">Net operating loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_1" xml:lang="en-US">California net operating loss carry forwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_0" xml:lang="en-US">Deferred Tax Assets, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_1" xml:lang="en-US">Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsStateTaxes_0" xml:lang="en-US">State taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsStateTaxes_1" xml:lang="en-US">Deferred Tax Assets, State Taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsStateTaxes_2" xml:lang="en-US">State taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_0" xml:lang="en-US">Valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_1" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_2" xml:lang="en-US">Valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilities_0" xml:lang="en-US">Deferred Tax Liabilities, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilities_1" xml:lang="en-US">Total deferred tax liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Depreciation_0" xml:lang="en-US">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Depreciation_1" xml:lang="en-US">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeContractTypeDomain_0" xml:lang="en-US">Derivative Contract [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis_0" xml:lang="en-US">Derivative Instrument [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_DerivativeLiabilities_0" xml:lang="en-US">Fair Value of Derivative Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_DerivativeLiabilities_1" xml:lang="en-US">Fair Value of Derivative Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeLiabilities_2" xml:lang="en-US">Derivative Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeLiabilities_3" xml:lang="en-US">Derivative liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent_0" xml:lang="en-US">Derivative Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent_1" xml:lang="en-US">Current balance of derivative liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent_2" xml:lang="en-US">Derivative liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent_0" xml:lang="en-US">Less, noncurrent portion of derivative liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent_1" xml:lang="en-US">Derivative Liabilities Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent_2" xml:lang="en-US">Derivative liabilities, non-current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent_3" xml:lang="en-US">Less, noncurrent portion of derivative liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock_0" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock_1" xml:lang="en-US">Convertible Instruments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DilutiveSecurities_0" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DilutiveSecurities_1" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DilutiveSecurities_2" xml:lang="en-US">Income (Numerator)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract_0" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract_1" xml:lang="en-US">Effect of Dilutive Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_0" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1" xml:lang="en-US">Stock-Based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_0" xml:lang="en-US">Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_1" xml:lang="en-US">Schedule of shares available for future grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DueFromRelatedParties_0" xml:lang="en-US">Due from Related Parties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DueFromRelatedParties_1" xml:lang="en-US">Amount of payments due under the contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareAbstract_0" xml:lang="en-US">Earnings Per Share [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasic_0" xml:lang="en-US">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic_1" xml:lang="en-US">Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic_2" xml:lang="en-US">Earnings Per Share, Basic, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic_3" xml:lang="en-US">Net income (loss) per share - basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic_4" xml:lang="en-US">Income available to common stockholders, Per-Share Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract_0" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract_1" xml:lang="en-US">Basic net loss per share:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract_2" xml:lang="en-US">Basic EPS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_0" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_1" xml:lang="en-US">Net loss per share - basic and diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_2" xml:lang="en-US">Basic and diluted net loss per common share (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_3" xml:lang="en-US">Earnings Per Share, Basic and Diluted, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_4" xml:lang="en-US">Loss available to common stockholders, Per-Share Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_0" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_1" xml:lang="en-US">Earnings (loss) per common share:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareDiluted_0" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted_1" xml:lang="en-US">Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted_2" xml:lang="en-US">Net loss per share - diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted_3" xml:lang="en-US">Loss available to common stockholders + assumed conversions, Per-Share Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract_0" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract_1" xml:lang="en-US">Diluted net loss per share:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract_2" xml:lang="en-US">Diluted EPS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareDilutedLineItems_0" xml:lang="en-US">Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_1" xml:lang="en-US">Net Income (Loss) Per Share of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_0" xml:lang="en-US">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_1" xml:lang="en-US">Net Income (Loss) Per Share of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1" xml:lang="en-US">Corporate tax rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1" xml:lang="en-US">Recognized weighted average period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2" xml:lang="en-US">Recognized period of non-vested stock options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_0" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1" xml:lang="en-US">Total amount of unrecognized compensation cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_2" xml:lang="en-US">Total amount of unrecognized compensation cost related to non-vested stock options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockOptionMember_0" xml:lang="en-US">Employee Stock Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeStockOptionMember_1" xml:lang="en-US">Stock Incentive Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EmployeeStockOptionMember_2" xml:lang="en-US">Stock options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityAbstract_0" xml:lang="en-US">Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EquityAbstract_1" xml:lang="en-US">Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain_0" xml:lang="en-US">Equity Component [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EquityComponentDomain_1" xml:lang="en-US">Equity Component [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ExtinguishmentOfDebtGainLossIncomeTax_0" xml:lang="en-US">Extinguishment of Debt, Gain (Loss), Income Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ExtinguishmentOfDebtGainLossIncomeTax_1" xml:lang="en-US">Loss on extinguishment of debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants_0" xml:lang="en-US">Change in fair market value at the re-measurement date recorded as non-operating income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants_1" xml:lang="en-US">Change in fair value of derivative liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants_2" xml:lang="en-US">Fair Value Adjustment of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants_3" xml:lang="en-US">Change in fair market value at the re-measurement date recorded as non-operating income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants_4" xml:lang="en-US">Change in Fair value of Derivative Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_0" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_1" xml:lang="en-US">Schedule of input and valuation technique used to value warrant liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_0" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_1" xml:lang="en-US">Fair Value Measurements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForeignCountryMember_0" xml:lang="en-US">Foreign Tax Authority [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ForeignCountryMember_1" xml:lang="en-US">Australia</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_0" xml:lang="en-US">Loss on disposal of assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_1" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_2" xml:lang="en-US">Loss on disposal of fixed assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_0" xml:lang="en-US">Loss on extinguishment of debt - related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_1" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_2" xml:lang="en-US">Loss on extinguishment of debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_3" xml:lang="en-US">Loss on extinguishment of secured convertible promissory note - related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_4" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_0" xml:lang="en-US">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_1" xml:lang="en-US">General and administrative</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_2" xml:lang="en-US">General and administrative</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_0" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2" xml:lang="en-US">Income (loss) before income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3" xml:lang="en-US">Pre-tax income (loss) from operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract_0" xml:lang="en-US">Income Statement [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeStatementAbstract_1" xml:lang="en-US">Income Statement [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_0" xml:lang="en-US">Income Statement Location [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_0" xml:lang="en-US">Income Statement Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_0" xml:lang="en-US">Income Tax Authority [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_0" xml:lang="en-US">Income Tax Authority [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_0" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_1" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_1" xml:lang="en-US">Income Taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxesPaid_0" xml:lang="en-US">Income Taxes Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxesPaid_1" xml:lang="en-US">Income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_0" xml:lang="en-US">Provision for income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_1" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_2" xml:lang="en-US">Provision (Benefit) for Income Taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_3" xml:lang="en-US">Provision for Income Taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_4" xml:lang="en-US">Provision for income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_0" xml:lang="en-US">Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_1" xml:lang="en-US">Reduction in deferred tax asset balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_0" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_1" xml:lang="en-US">Income Taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_1" xml:lang="en-US">Change in valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_1" xml:lang="en-US">Tax Cuts and Jobs Act</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_0" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_1" xml:lang="en-US">Expected income tax benefit at federal statutory tax rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_1" xml:lang="en-US">Other permanent difference</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_2" xml:lang="en-US">Other permanent difference</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_1" xml:lang="en-US">Stock Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_1" xml:lang="en-US">Rate adjustment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_1" xml:lang="en-US">State income taxes, net of federal benefit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_0" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_1" xml:lang="en-US">Accounts payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_0" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_1" xml:lang="en-US">Accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_0" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_1" xml:lang="en-US">Accounts payable to related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_0" xml:lang="en-US">Increase (Decrease) In Operating Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_1" xml:lang="en-US">Changes in assets and liabilities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_0" xml:lang="en-US">Other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_1" xml:lang="en-US">Increase (Decrease) in Other Current Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_0" xml:lang="en-US">Increase (Decrease) in Other Current Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_1" xml:lang="en-US">Other current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_0" xml:lang="en-US">Prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_1" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IntellectualPropertyMember_0" xml:lang="en-US">Intellectual Property [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IntellectualPropertyMember_1" xml:lang="en-US">Intellectual Property</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestExpense_0" xml:lang="en-US">Interest expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestExpenseOther_0" xml:lang="en-US">Interest Expense, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestExpenseOther_1" xml:lang="en-US">Other interest expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestPaidNet_0" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InterestPaidNet_1" xml:lang="en-US">Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_InvestmentIncomeInterest_0" xml:lang="en-US">Interest income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentIncomeInterest_1" xml:lang="en-US">Investment Income, Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InvestmentIncomeInterest_2" xml:lang="en-US">Interest income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestorMember_0" xml:lang="en-US">Investor [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestorMember_1" xml:lang="en-US">Accredited Investor</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IPOMember_0" xml:lang="en-US">IPO [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IPOMember_1" xml:lang="en-US">Direct offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseAndRentalExpense_0" xml:lang="en-US">Operating Leases, Rent Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseAndRentalExpense_1" xml:lang="en-US">Lease expenses per month</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities_0" xml:lang="en-US">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities_1" xml:lang="en-US">Total liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_0" xml:lang="en-US">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_1" xml:lang="en-US">Total liabilities and stockholders' equity (deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_2" xml:lang="en-US">Total Liabilities and Shareholders' Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent_0" xml:lang="en-US">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent_1" xml:lang="en-US">Total current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_1" xml:lang="en-US">Current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract_0" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract_1" xml:lang="en-US">Noncurrent liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_0" xml:lang="en-US">Line of Credit Facility, Average Outstanding Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_1" xml:lang="en-US">Maximum amount that can be borrowed over the life of the credit facility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_0" xml:lang="en-US">Line of Credit Facility, Commitment Fee Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_1" xml:lang="en-US">Unused portion of the credit facility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_0" xml:lang="en-US">Line of Credit Facility, Current Borrowing Capacity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_1" xml:lang="en-US">Principal amounts of borrowing capacity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_0" xml:lang="en-US">Line of Credit Facility, Fair Value of Amount Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_1" xml:lang="en-US">Fair value of advance under credit agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_0" xml:lang="en-US">Line of Credit Facility, Interest Rate at Period End</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_1" xml:lang="en-US">The annual stated interest rate on the debt instrument</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_0" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1" xml:lang="en-US">Maximum borrowing capacity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2" xml:lang="en-US">Maximum borrowing capacity of credit facility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputExercisePriceMember_0" xml:lang="en-US">Measurement Input, Exercise Price [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputExercisePriceMember_1" xml:lang="en-US">Closing price per share of common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember_0" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember_1" xml:lang="en-US">Dividend yield</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember_0" xml:lang="en-US">Measurement Input, Expected Term [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember_1" xml:lang="en-US">Expected term (years)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputOfferedPriceMember_0" xml:lang="en-US">Measurement Input, Offered Price [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_MeasurementInputOfferedPriceMember_1" xml:lang="en-US">Weighted-average fair value of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputOfferedPriceMember_2" xml:lang="en-US">Underlying common stock price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember_0" xml:lang="en-US">Measurement Input, Price Volatility [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember_1" xml:lang="en-US">Volatility factor</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_0" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_1" xml:lang="en-US">Risk-free interest rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputTypeAxis_0" xml:lang="en-US">Measurement Input Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputTypeDomain_0" xml:lang="en-US">Measurement Input Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1" xml:lang="en-US">Net cash provided by financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1" xml:lang="en-US">Cash flows from financing activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1" xml:lang="en-US">Net cash used in investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1" xml:lang="en-US">Cash flows from investing activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xml:lang="en-US">Net cash used in operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_2" xml:lang="en-US">Cash used in operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xml:lang="en-US">Cash flows from operating activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="lab_us-gaap_NetIncomeLoss_0" xml:lang="en-US">Net income (loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_NetIncomeLoss_1" xml:lang="en-US">Loss from operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss_2" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLoss_3" xml:lang="en-US">Net loss for the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss_4" xml:lang="en-US">Net Income (Loss) Attributable to Parent, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetIncomeLoss_5" xml:lang="en-US">Net income (loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_us-gaap_NetIncomeLoss_6" xml:lang="en-US">Net income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_0" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_1" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2" xml:lang="en-US">Net loss applicable to common shareholders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_3" xml:lang="en-US">Net income (loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_4" xml:lang="en-US">Income available to common stockholders, Income (Numerator)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1" xml:lang="en-US">Recent Accounting Pronouncements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_0" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_1" xml:lang="en-US">Total other expense (income), net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_2" xml:lang="en-US">Total other expense (income), net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_0" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_1" xml:lang="en-US">Other expense (income)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseMember_0" xml:lang="en-US">Nonoperating Income (Expense) [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseMember_1" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NumberOfReportableSegments_0" xml:lang="en-US">Number of Reportable Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NumberOfReportableSegments_1" xml:lang="en-US">Number of reportable segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenses_0" xml:lang="en-US">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingExpenses_1" xml:lang="en-US">Total operating expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingExpenses_2" xml:lang="en-US">Total operating expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract_0" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingExpensesAbstract_1" xml:lang="en-US">Operating expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss_0" xml:lang="en-US">Loss from operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss_1" xml:lang="en-US">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss_2" xml:lang="en-US">Operating loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss_3" xml:lang="en-US">Loss from operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems_0" xml:lang="en-US">Operating Leased Assets [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet_0" xml:lang="en-US">Operating Leases, Rent Expense, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet_1" xml:lang="en-US">Rent expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwards_0" xml:lang="en-US">Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLossCarryforwards_1" xml:lang="en-US">Operating loss carry forwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems_0" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable_0" xml:lang="en-US">Operating Loss Carryforwards [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_0" xml:lang="en-US">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_1" xml:lang="en-US">Nature of Operations and Business Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsCurrent_0" xml:lang="en-US">Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAssetsCurrent_1" xml:lang="en-US">Other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_0" xml:lang="en-US">Other Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_1" xml:lang="en-US">Other Liabilities, Current, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_2" xml:lang="en-US">Other current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsOfDerivativeIssuanceCosts_0" xml:lang="en-US">Financing transaction costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_PaymentsOfDerivativeIssuanceCosts_1" xml:lang="en-US">Warrant liability, issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfDerivativeIssuanceCosts_2" xml:lang="en-US">Payments of Derivative Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PaymentsOfDerivativeIssuanceCosts_3" xml:lang="en-US">Financing transaction costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsOfDerivativeIssuanceCosts_4" xml:lang="en-US">Payments of derivative issuance cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_0" xml:lang="en-US">Payments of Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_1" xml:lang="en-US">Common stock issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_2" xml:lang="en-US">Common stock issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireFurnitureAndFixtures_0" xml:lang="en-US">Payments to Acquire Furniture and Fixtures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsToAcquireFurnitureAndFixtures_1" xml:lang="en-US">Value of furniture lease payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0" xml:lang="en-US">Purchases of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1" xml:lang="en-US">Payments To Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2" xml:lang="en-US">Purchases of equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameAxis_0" xml:lang="en-US">Plan Name [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameDomain_0" xml:lang="en-US">Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockConversionBasis_0" xml:lang="en-US">Preferred Stock, Conversion Basis</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockConversionBasis_1" xml:lang="en-US">Preferred stock, conversion rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockConvertibleConversionPriceDecrease_0" xml:lang="en-US">Preferred Stock, Convertible, Conversion Price, Decrease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockConvertibleConversionPriceDecrease_1" xml:lang="en-US">Reduction of conversion price of preferred stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockLiquidationPreferenceValue_0" xml:lang="en-US">Preferred Stock, Liquidation Preference, Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockLiquidationPreferenceValue_1" xml:lang="en-US">Liquidation preference value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_0" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_1" xml:lang="en-US">Preferred stock (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_2" xml:lang="en-US">Preferred stock (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_0" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_1" xml:lang="en-US">Preferred stock, shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_2" xml:lang="en-US">Preferred stock, shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesIssued_0" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PreferredStockSharesIssued_1" xml:lang="en-US">Preferred Stock, Shares Issued, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockSharesIssued_2" xml:lang="en-US">Preferred stock, shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesIssued_3" xml:lang="en-US">Preferred stock, shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_0" xml:lang="en-US">Convertible preferred stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_1" xml:lang="en-US">Preferred Stock, Shares Outstanding, Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_2" xml:lang="en-US">Preferred Stock, Shares Outstanding, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_3" xml:lang="en-US">Preferred stock, shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockValue_0" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PreferredStockValue_1" xml:lang="en-US">Preferred Stock, Value, Issued, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_PreferredStockValue_2" xml:lang="en-US">Preferred Stock, Value, Issued, Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_PreferredStockValue_3" xml:lang="en-US">Preferred Stock, Value, Issued, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockValue_4" xml:lang="en-US">Preferred stock, $0.001 par value; 20,000,000 shares authorized; no shares issued and outstanding at December 31, 2019 and December 31, 2018</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseCurrent_0" xml:lang="en-US">Prepaid Expense, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PrepaidExpenseCurrent_1" xml:lang="en-US">Prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrivatePlacementMember_0" xml:lang="en-US">Private Placement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PrivatePlacementMember_1" xml:lang="en-US">Private placement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt_0" xml:lang="en-US">Proceeds from Convertible Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt_1" xml:lang="en-US">Proceeds from secured convertible promissory note - related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt_2" xml:lang="en-US">Proceeds from convertible debt issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_0" xml:lang="en-US">Less: proceeds from the Emerald Financing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_1" xml:lang="en-US">Common stock gross proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_2" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_3" xml:lang="en-US">Proceeds from the issuance of common stock and warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_4" xml:lang="en-US">Common stock gross proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveVerboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_5" xml:lang="en-US">Proceeds from the issuance of Common stock and warrants, net of $80,628 and $154,092 of issuance costs in 2019 and 2018, respectively</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_0" xml:lang="en-US">Proceeds from Issuance of Convertible Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_1" xml:lang="en-US">Proceeds from triggering transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_0" xml:lang="en-US">Proceeds from Issuance of Preferred Stock and Preference Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_1" xml:lang="en-US">Aggregate gross proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_2" xml:lang="en-US">Proceeds from preferred stock issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveVerboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_3" xml:lang="en-US">Proceeds from Common stock issuance, net of $80,628 and 154,092 of issuance costs in 2019 and 2018, respectively</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_0" xml:lang="en-US">Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_1" xml:lang="en-US">Proceeds from issuance of preferred stock and warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_2" xml:lang="en-US">Proceeds received from the Series B financing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants_0" xml:lang="en-US">Proceeds from Issuance of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants_1" xml:lang="en-US">Proceeds from warrant exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants_2" xml:lang="en-US">Proceeds from issuance of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_0" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_1" xml:lang="en-US">Excess over proceeds adjustment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_2" xml:lang="en-US">Excess over proceeds adjustment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromOtherDebt_0" xml:lang="en-US">Proceeds from Other Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromOtherDebt_1" xml:lang="en-US">Amount of cash inflow from convertible debt - related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromRelatedPartyDebt_0" xml:lang="en-US">Proceeds from Related Party Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromRelatedPartyDebt_1" xml:lang="en-US">Proceeds from related party debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises_0" xml:lang="en-US">Proceeds from Warrant Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises_1" xml:lang="en-US">Proceeds from warrant exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDepreciationMethods_0" xml:lang="en-US">Property, Plant and Equipment, Depreciation Methods</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDepreciationMethods_1" xml:lang="en-US">Property, plant and equipment, depreciation methods</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_0" xml:lang="en-US">Property, Plant and Equipment, Estimated Useful Lives</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_1" xml:lang="en-US">Estimated useful life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_0" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_0" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_1" xml:lang="en-US">Net equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_2" xml:lang="en-US">Net equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_3" xml:lang="en-US">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_0" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1" xml:lang="en-US">Property and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_0" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_1" xml:lang="en-US">Estimated useful life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RedeemablePreferredStockDividends_0" xml:lang="en-US">Redeemable Preferred Stock Dividends</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RedeemablePreferredStockDividends_1" xml:lang="en-US">Less: Preferred deemed dividend</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RedeemablePreferredStockDividends_2" xml:lang="en-US">Preferred deemed dividend</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyDomain_0" xml:lang="en-US">Related Party [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems_0" xml:lang="en-US">Related Party Transaction [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract_0" xml:lang="en-US">Related Party Transactions [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0" xml:lang="en-US">Related Party [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_0" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1" xml:lang="en-US">Related Party Matters</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt_0" xml:lang="en-US">Funding of remaining bridge loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt_1" xml:lang="en-US">Repayments of Convertible Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt_2" xml:lang="en-US">Payments received from convertible bridge loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt_3" xml:lang="en-US">Funds received under the Secured Promissory Note</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_0" xml:lang="en-US">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_1" xml:lang="en-US">Research and development expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_2" xml:lang="en-US">Research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_1" xml:lang="en-US">Research and Development Expenses and Licensed Technology</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_0" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_1" xml:lang="en-US">Restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2" xml:lang="en-US">Restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_3" xml:lang="en-US">Restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedStockExpense_0" xml:lang="en-US">Restricted Stock or Unit Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedStockExpense_1" xml:lang="en-US">Stock compensation expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedStockMember_0" xml:lang="en-US">Restricted Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedStockMember_1" xml:lang="en-US">Unvested restricted stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RestrictedStockMember_2" xml:lang="en-US">Restricted Stock Awards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0" xml:lang="en-US">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_2" xml:lang="en-US">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_3" xml:lang="en-US">Retained earnings during the development stage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember_0" xml:lang="en-US">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RetainedEarningsMember_1" xml:lang="en-US">Accumulated Deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_0" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_1" xml:lang="en-US">Revenue Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_0" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1" xml:lang="en-US">Net proceeds from the transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_0" xml:lang="en-US">Sale of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_0" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1" xml:lang="en-US">Shares issued, price per share (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2" xml:lang="en-US">Number of stock sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockPricePerShare_0" xml:lang="en-US">Sale of Stock, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockPricePerShare_1" xml:lang="en-US">Common stock, par value (per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1" xml:lang="en-US">Schedule of anti-dilutive securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_0" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_1" xml:lang="en-US">Schedule of components of income (loss) before the income tax provision (benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_0" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1" xml:lang="en-US">Schedule for significant portions of deferred income tax assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_0" xml:lang="en-US">Schedule of Derivative Liabilities at Fair Value [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_1" xml:lang="en-US">Schedule summary of the activity of derivative liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1" xml:lang="en-US">Schedule of basic and diluted net loss per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_0" xml:lang="en-US">Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_0" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1" xml:lang="en-US">Schedule of provision for income taxes on earnings subject to income taxes differs from the statutory Federal rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_0" xml:lang="en-US">Schedule of Nonvested Share Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_1" xml:lang="en-US">Schedule of RSA activity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_0" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0" xml:lang="en-US">Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1" xml:lang="en-US">Schedule of summary of stock option activity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1" xml:lang="en-US">Schedule of fair value assumptions of stock option granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTable_0" xml:lang="en-US">Schedule of Short-term Debt [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_0" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_1" xml:lang="en-US">Schedule of warrants vested and outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_0" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_1" xml:lang="en-US">Schedule of reconciliation of beginning and ending amounts of unrecognized tax positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_0" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_1" xml:lang="en-US">Segment Information</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeriesAPreferredStockMember_0" xml:lang="en-US">Series A Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SeriesAPreferredStockMember_1" xml:lang="en-US">Convertible Series A Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SeriesAPreferredStockMember_2" xml:lang="en-US">Series F Preferred stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeriesBPreferredStockMember_0" xml:lang="en-US">Series B Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SeriesBPreferredStockMember_1" xml:lang="en-US">Redeemable Convertible Series B Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SeriesBPreferredStockMember_2" xml:lang="en-US">Series B Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeriesCPreferredStockMember_0" xml:lang="en-US">Series C Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SeriesCPreferredStockMember_1" xml:lang="en-US">Convertible Series C Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SeriesCPreferredStockMember_2" xml:lang="en-US">Series C Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeriesDPreferredStockMember_0" xml:lang="en-US">Series D Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SeriesDPreferredStockMember_1" xml:lang="en-US">Convertible Series D Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SeriesDPreferredStockMember_2" xml:lang="en-US">Series D Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeriesEPreferredStockMember_0" xml:lang="en-US">Series E Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SeriesEPreferredStockMember_1" xml:lang="en-US">Series E Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeriesFPreferredStockMember_0" xml:lang="en-US">Series F Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SeriesFPreferredStockMember_1" xml:lang="en-US">Convertible Series F Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SeriesFPreferredStockMember_2" xml:lang="en-US">Series F Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation_0" xml:lang="en-US">Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation_1" xml:lang="en-US">Stock-based compensation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation_2" xml:lang="en-US">Total stock-based compensation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1" xml:lang="en-US">Restricted stock vesting percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_2" xml:lang="en-US">Vesting percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_1" xml:lang="en-US">Description of stock option agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1" xml:lang="en-US">Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2" xml:lang="en-US">Number of restricted common stock granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1" xml:lang="en-US">Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2" xml:lang="en-US">Weighted-average fair value of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0" xml:lang="en-US">Unvested, December 31, 2019</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1" xml:lang="en-US">Unvested, December 31, 2018</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1" xml:lang="en-US">Number of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0" xml:lang="en-US">Unvested, December 31, 2019</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1" xml:lang="en-US">Unvested, December 31, 2018</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1" xml:lang="en-US">Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0" xml:lang="en-US">Released</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2" xml:lang="en-US">Released</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3" xml:lang="en-US">Number of restricted common stock vested</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1" xml:lang="en-US">Released</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1" xml:lang="en-US">Dividend Yield</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1" xml:lang="en-US">Expected term (in years)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1" xml:lang="en-US">Volatility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1" xml:lang="en-US">Risk-free interest rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, options, additional disclosures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2" xml:lang="en-US">Aggregate intrinsic value of the awards exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1" xml:lang="en-US">Options to purchase shares of common stock, exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2" xml:lang="en-US">Exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1" xml:lang="en-US">Exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1" xml:lang="en-US">Weighted Average Remaining Contractual Term (Years), Exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_0" xml:lang="en-US">Cancelled</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2" xml:lang="en-US">Cancelled</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0" xml:lang="en-US">Forfeited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2" xml:lang="en-US">Options cancelled</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_3" xml:lang="en-US">Forfeited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0" xml:lang="en-US">Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1" xml:lang="en-US">Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3" xml:lang="en-US">Aggregate number of shares granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4" xml:lang="en-US">Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1" xml:lang="en-US">Weighted-average fair value of stock options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1" xml:lang="en-US">Aggregate Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xml:lang="en-US">Balance at the ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1" xml:lang="en-US">Balance at the beginning</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3" xml:lang="en-US">Options outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" xml:lang="en-US">Options outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Period Increase (Decrease)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_1" xml:lang="en-US">Share pool increase</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1" xml:lang="en-US">Number of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_2" xml:lang="en-US">Shares Available for Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" xml:lang="en-US">Balance at the ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1" xml:lang="en-US">Balance at the beginning</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1" xml:lang="en-US">Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1" xml:lang="en-US">Remaining contractual life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2" xml:lang="en-US">Weighted Average Remaining Contractual Term (Years)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_1" xml:lang="en-US">Aggregate intrinsic value of the awards expected to vest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_2" xml:lang="en-US">Aggregate intrinsic value of options exercisable, and vested and expected to vest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_1" xml:lang="en-US">Aggregate intrinsic value of options outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2" xml:lang="en-US">Aggregate Intrinsic Value, Vested and Expected to Vest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_1" xml:lang="en-US">Vested and Expected to Vest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_2" xml:lang="en-US">Expected to vest, September 30, 2018</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1" xml:lang="en-US">Vested and expected to vest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2" xml:lang="en-US">Expected to vest, September 30, 2018</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_1" xml:lang="en-US">Weighted Average Remaining Contractual Term (Years), Vested and Expected to Vest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1" xml:lang="en-US">Fair value of stock options vested</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_1" xml:lang="en-US">Options vested</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xml:lang="en-US">Award Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_0" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1" xml:lang="en-US">Cancelled</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1" xml:lang="en-US">Forfeited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_2" xml:lang="en-US">Options cancelled</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1" xml:lang="en-US">Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2" xml:lang="en-US">Options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_0" xml:lang="en-US">Share-based Compensation Award, Tranche One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_1" xml:lang="en-US">Immediate vesting</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_2" xml:lang="en-US">January 18, 2018</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_0" xml:lang="en-US">Share-based Compensation Award, Tranche Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_1" xml:lang="en-US">November 21, 2014</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_0" xml:lang="en-US">Share-based Compensation Award, Tranche Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_1" xml:lang="en-US">October 20, 2015</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1" xml:lang="en-US">Stock-Based Compensation for Employees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2" xml:lang="en-US">Stock-Based Compensation Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharesIssued_0" xml:lang="en-US">Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharesIssued_1" xml:lang="en-US">Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesIssued_2" xml:lang="en-US">Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharesIssued_3" xml:lang="en-US">Number of additional shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesIssuedPricePerShare_0" xml:lang="en-US">Shares Issued, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharesIssuedPricePerShare_1" xml:lang="en-US">Underlying common stock price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharesIssuedPricePerShare_2" xml:lang="en-US">Shares issued, price per share (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_SharesIssuedPricePerShare_3" xml:lang="en-US">Weighted average fair value of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermDebtLineItems_0" xml:lang="en-US">Short-term Debt [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis_0" xml:lang="en-US">Short-term Debt, Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain_0" xml:lang="en-US">Short-term Debt, Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_1" xml:lang="en-US">Summary of Significant Accounting Policies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementClassOfStockAxis_0" xml:lang="en-US">Class of Stock [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_0" xml:lang="en-US">Equity Components [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_1" xml:lang="en-US">Equity Components [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems_0" xml:lang="en-US">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_0" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_1" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_0" xml:lang="en-US">Statement Of Financial Position [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_1" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_0" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable_0" xml:lang="en-US">Statement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_0" xml:lang="en-US">Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_1" xml:lang="en-US">Common stock warrants issued for services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_2" xml:lang="en-US">Value of warrants issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_StockholdersEquity_0" xml:lang="en-US">Stockholders' deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquity_1" xml:lang="en-US">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquity_2" xml:lang="en-US">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity_3" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquity_4" xml:lang="en-US">Stockholders' deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity_5" xml:lang="en-US">Total stockholders' equity (deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquity_6" xml:lang="en-US">Total shareholders' equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract_0" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquityAbstract_1" xml:lang="en-US">Stockholders' equity (deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1" xml:lang="en-US">Stockholders' Equity (Deficit) and Capitalization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_0" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Units</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_1" xml:lang="en-US">Number of notes converted into common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_0" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_1" xml:lang="en-US">Common stock issued for services (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_2" xml:lang="en-US">Number of common shares issued to founders and one board member</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0" xml:lang="en-US">Common stock issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2" xml:lang="en-US">Issuance of common stock to investors in prior entity (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3" xml:lang="en-US">Number of shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1" xml:lang="en-US">Expired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2" xml:lang="en-US">Options exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_0" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_1" xml:lang="en-US">Common stock issued for services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_2" xml:lang="en-US">Issuance of common stock for services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventLineItems_0" xml:lang="en-US">Subsequent Event [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventMember_0" xml:lang="en-US">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SubsequentEventMember_1" xml:lang="en-US">Subsequent Event</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsAbstract_0" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_1" xml:lang="en-US">Subsequent Events</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTable_0" xml:lang="en-US">Subsequent Event [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_0" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_0" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_0" xml:lang="en-US">Sale of Stock [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract_0" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract_1" xml:lang="en-US">Supplemental disclosures of cash-flow information:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxCreditCarryforwardLimitationsOnUse_0" xml:lang="en-US">Tax Credit Carryforward, Limitations on Use</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_TaxCreditCarryforwardLimitationsOnUse_1" xml:lang="en-US">Tax credit limitation on use</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_0" xml:lang="en-US">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_1" xml:lang="en-US">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_2" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_3" xml:lang="en-US">Redeemable Convertible Preferred Stock, value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityLiquidationPreference_0" xml:lang="en-US">Temporary Equity, Liquidation Preference</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquityLiquidationPreference_1" xml:lang="en-US">Liquidation preference value (in dollars)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_0" xml:lang="en-US">Temporary Equity, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_1" xml:lang="en-US">Preferred stock, par value (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized_0" xml:lang="en-US">Temporary Equity, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized_1" xml:lang="en-US">Preferred stock, shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued_0" xml:lang="en-US">Temporary Equity, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued_1" xml:lang="en-US">Preferred stock, shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding_0" xml:lang="en-US">Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding_1" xml:lang="en-US">Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding_2" xml:lang="en-US">Temporary Equity, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding_3" xml:lang="en-US">Preferred stock, shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfArrangementAxis_0" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_0" xml:lang="en-US">Unrecognized Tax Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_1" xml:lang="en-US">Unrecognized tax positions, beginning of the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_2" xml:lang="en-US">Unrecognized tax positions, end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_0" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_1" xml:lang="en-US">Gross increase - current period tax positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UseOfEstimates_0" xml:lang="en-US">Use Of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_UseOfEstimates_1" xml:lang="en-US">Use of Estimates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VestingAxis_0" xml:lang="en-US">Vesting [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VestingDomain_0" xml:lang="en-US">Vesting [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantMember_0" xml:lang="en-US">Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WarrantMember_1" xml:lang="en-US">Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WarrantMember_2" xml:lang="en-US">Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0" xml:lang="en-US">Warrants and Rights Note Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding_0" xml:lang="en-US">Warrants and Rights Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding_1" xml:lang="en-US">Value of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding_2" xml:lang="en-US">Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_0" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_1" xml:lang="en-US">Warrants and rights outstanding measurement input (in percent)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_2" xml:lang="en-US">Measurement input</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm_0" xml:lang="en-US">Warrants and Rights Outstanding, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm_1" xml:lang="en-US">Expected Term (years)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm_2" xml:lang="en-US">Term of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1" xml:lang="en-US">Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2" xml:lang="en-US">Weighted average common shares outstanding - diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3" xml:lang="en-US">Loss available to common stockholders + assumed conversions, Shares (Denominator)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1" xml:lang="en-US">Weighted average common shares outstanding - basic and diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2" xml:lang="en-US">Weighted average shares of common stock outstanding: basic and diluted (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_3" xml:lang="en-US">Loss available to common stockholders, Shares (Denominator)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1" xml:lang="en-US">Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3" xml:lang="en-US">Weighted average common shares outstanding - basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4" xml:lang="en-US">Income available to common stockholders Shares (Denominator)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_0" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_1" xml:lang="en-US">Weighted average shares of common stock outstanding used to compute earnings (loss) per share:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_1" xlink:to="lab_dei_AmendmentFlag_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_1" xlink:to="lab_dei_AmendmentFlag_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_2" xlink:to="lab_dei_CurrentFiscalYearEndDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_2" xlink:to="lab_dei_CurrentFiscalYearEndDate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_3" xlink:to="lab_dei_DocumentFiscalPeriodFocus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_3" xlink:to="lab_dei_DocumentFiscalPeriodFocus_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_4" xlink:to="lab_dei_DocumentFiscalYearFocus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_4" xlink:to="lab_dei_DocumentFiscalYearFocus_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_5" xlink:to="lab_dei_DocumentPeriodEndDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_5" xlink:to="lab_dei_DocumentPeriodEndDate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_6" xlink:to="lab_dei_DocumentType_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_6" xlink:to="lab_dei_DocumentType_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_7" xlink:to="lab_dei_EntityCentralIndexKey_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_7" xlink:to="lab_dei_EntityCentralIndexKey_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_8" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_8" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_9" xlink:to="lab_dei_EntityCurrentReportingStatus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain_10" xlink:to="lab_dei_EntityDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_11" xlink:to="lab_dei_EntityEmergingGrowthCompany_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod_12" xlink:to="lab_dei_EntityExTransitionPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_13" xlink:to="lab_dei_EntityFilerCategory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_13" xlink:to="lab_dei_EntityFilerCategory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent_14" xlink:to="lab_dei_EntityInteractiveDataCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat_15" xlink:to="lab_dei_EntityPublicFloat_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_16" xlink:to="lab_dei_EntityRegistrantName_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_16" xlink:to="lab_dei_EntityRegistrantName_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany_17" xlink:to="lab_dei_EntityShellCompany_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness_18" xlink:to="lab_dei_EntitySmallBusiness_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers_19" xlink:to="lab_dei_EntityVoluntaryFilers_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer_20" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis_21" xlink:to="lab_dei_LegalEntityAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle_22" xlink:to="lab_dei_Security12bTitle_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_23" xlink:to="lab_dei_TradingSymbol_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_23" xlink:to="lab_dei_TradingSymbol_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AccruedExpenseUnderAgreement_24" xlink:to="lab_embi_AccruedExpenseUnderAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AccruedExpenseUnderAgreement_24" xlink:to="lab_embi_AccruedExpenseUnderAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AccruedExpenseUnderAgreement_24" xlink:to="lab_embi_AccruedExpenseUnderAgreement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AdditionalConversionLiability_25" xlink:to="lab_embi_AdditionalConversionLiability_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AdditionalConversionLiability_25" xlink:to="lab_embi_AdditionalConversionLiability_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AdditionalConversionLiability_25" xlink:to="lab_embi_AdditionalConversionLiability_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AggregateMilestonePaymentsIfMilestonesAchieved_26" xlink:to="lab_embi_AggregateMilestonePaymentsIfMilestonesAchieved_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AggregateMilestonePaymentsIfMilestonesAchieved_26" xlink:to="lab_embi_AggregateMilestonePaymentsIfMilestonesAchieved_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AggregateMilestonePaymentsIfMilestonesAchieved_26" xlink:to="lab_embi_AggregateMilestonePaymentsIfMilestonesAchieved_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AlbanyMolecularResearchIncMember_27" xlink:to="lab_embi_AlbanyMolecularResearchIncMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AlbanyMolecularResearchIncMember_27" xlink:to="lab_embi_AlbanyMolecularResearchIncMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AllocationOfDebtOnBasisOfRelativeFairValue_28" xlink:to="lab_embi_AllocationOfDebtOnBasisOfRelativeFairValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AllocationOfDebtOnBasisOfRelativeFairValue_28" xlink:to="lab_embi_AllocationOfDebtOnBasisOfRelativeFairValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AllocationOfDebtOnBasisOfRelativeFairValue_28" xlink:to="lab_embi_AllocationOfDebtOnBasisOfRelativeFairValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AllocationOfWarrantOnBasisOfRelativeFairValue_29" xlink:to="lab_embi_AllocationOfWarrantOnBasisOfRelativeFairValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AllocationOfWarrantOnBasisOfRelativeFairValue_29" xlink:to="lab_embi_AllocationOfWarrantOnBasisOfRelativeFairValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AllocationOfWarrantOnBasisOfRelativeFairValue_29" xlink:to="lab_embi_AllocationOfWarrantOnBasisOfRelativeFairValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AmortizationOfDebtDiscount_30" xlink:to="lab_embi_AmortizationOfDebtDiscount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AmortizationOfDebtDiscount_30" xlink:to="lab_embi_AmortizationOfDebtDiscount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AmortizationOfDebtDiscount_30" xlink:to="lab_embi_AmortizationOfDebtDiscount_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AmortizationOfTransactionCosts_31" xlink:to="lab_embi_AmortizationOfTransactionCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AmortizationOfTransactionCosts_31" xlink:to="lab_embi_AmortizationOfTransactionCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AmortizationOfTransactionCosts_31" xlink:to="lab_embi_AmortizationOfTransactionCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AmountOfEachWarrantOutstanding_32" xlink:to="lab_embi_AmountOfEachWarrantOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AmountOfEachWarrantOutstanding_32" xlink:to="lab_embi_AmountOfEachWarrantOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AmountOfEachWarrantOutstanding_32" xlink:to="lab_embi_AmountOfEachWarrantOutstanding_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AmountOfPassThroughExpensesAndConsultingFees_33" xlink:to="lab_embi_AmountOfPassThroughExpensesAndConsultingFees_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AmountOfPassThroughExpensesAndConsultingFees_33" xlink:to="lab_embi_AmountOfPassThroughExpensesAndConsultingFees_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AmountOfPassThroughExpensesAndConsultingFees_33" xlink:to="lab_embi_AmountOfPassThroughExpensesAndConsultingFees_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AnnualFeeForAgreement_34" xlink:to="lab_embi_AnnualFeeForAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AnnualFeeForAgreement_34" xlink:to="lab_embi_AnnualFeeForAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AnnualFeeForAgreement_34" xlink:to="lab_embi_AnnualFeeForAgreement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AnnualFeesForLicenseAgreement_35" xlink:to="lab_embi_AnnualFeesForLicenseAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AnnualFeesForLicenseAgreement_35" xlink:to="lab_embi_AnnualFeesForLicenseAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AnnualFeesForLicenseAgreement_35" xlink:to="lab_embi_AnnualFeesForLicenseAgreement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AnnualMaintenanceFeePayable_36" xlink:to="lab_embi_AnnualMaintenanceFeePayable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AnnualMaintenanceFeePayable_36" xlink:to="lab_embi_AnnualMaintenanceFeePayable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AvtarDhillonMember_37" xlink:to="lab_embi_AvtarDhillonMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AvtarDhillonMember_37" xlink:to="lab_embi_AvtarDhillonMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AvtarDhillonMember_37" xlink:to="lab_embi_AvtarDhillonMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AwardsGrantedOutside2014PlanMember_38" xlink:to="lab_embi_AwardsGrantedOutside2014PlanMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AwardsGrantedOutside2014PlanMember_38" xlink:to="lab_embi_AwardsGrantedOutside2014PlanMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AwardsGrantedOutside2014PlanMember_38" xlink:to="lab_embi_AwardsGrantedOutside2014PlanMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AwardsGrantedOutsideThe2014PlanMember_39" xlink:to="lab_embi_AwardsGrantedOutsideThe2014PlanMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AwardsGrantedOutsideThe2014PlanMember_39" xlink:to="lab_embi_AwardsGrantedOutsideThe2014PlanMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AwardsGrantedOutsideThe2014PlanMember_39" xlink:to="lab_embi_AwardsGrantedOutsideThe2014PlanMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_40" xlink:to="lab_embi_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_40" xlink:to="lab_embi_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_40" xlink:to="lab_embi_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement_41" xlink:to="lab_embi_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement_41" xlink:to="lab_embi_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement_41" xlink:to="lab_embi_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_BeneficialConversionFeatureUponIssuanceofSeriesDPreferredStock_42" xlink:to="lab_embi_BeneficialConversionFeatureUponIssuanceofSeriesDPreferredStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_BeneficialConversionFeatureUponIssuanceofSeriesDPreferredStock_42" xlink:to="lab_embi_BeneficialConversionFeatureUponIssuanceofSeriesDPreferredStock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_BeneficialConversionFeatureUponIssuanceofSeriesDPreferredStock_42" xlink:to="lab_embi_BeneficialConversionFeatureUponIssuanceofSeriesDPreferredStock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_BeneficialConversionFeatureUponIssuanceofSeriesFPreferredStock_43" xlink:to="lab_embi_BeneficialConversionFeatureUponIssuanceofSeriesFPreferredStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_BeneficialConversionFeatureUponIssuanceofSeriesFPreferredStock_43" xlink:to="lab_embi_BeneficialConversionFeatureUponIssuanceofSeriesFPreferredStock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_BeneficialConversionFeatureUponIssuanceofSeriesFPreferredStock_43" xlink:to="lab_embi_BeneficialConversionFeatureUponIssuanceofSeriesFPreferredStock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CashPaidDuringPeriodForAbstract_44" xlink:to="lab_embi_CashPaidDuringPeriodForAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CashPaidDuringPeriodForAbstract_44" xlink:to="lab_embi_CashPaidDuringPeriodForAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ChangeInFairValueOfDerivativeLiabilities_45" xlink:to="lab_embi_ChangeInFairValueOfDerivativeLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ChangeInFairValueOfDerivativeLiabilities_45" xlink:to="lab_embi_ChangeInFairValueOfDerivativeLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ChangeInFairValueOfDerivativeLiabilities_45" xlink:to="lab_embi_ChangeInFairValueOfDerivativeLiabilities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ChangeInFairValueOfWarrantLiability_46" xlink:to="lab_embi_ChangeInFairValueOfWarrantLiability_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ChangeInFairValueOfWarrantLiability_46" xlink:to="lab_embi_ChangeInFairValueOfWarrantLiability_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ChangeInFairValueOfWarrantLiability_46" xlink:to="lab_embi_ChangeInFairValueOfWarrantLiability_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ClassOfWarrantOrRightWarrantsAggregateExercisePrice_47" xlink:to="lab_embi_ClassOfWarrantOrRightWarrantsAggregateExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ClassOfWarrantOrRightWarrantsAggregateExercisePrice_47" xlink:to="lab_embi_ClassOfWarrantOrRightWarrantsAggregateExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ClassOfWarrantOrRightWarrantsAggregateExercisePrice_47" xlink:to="lab_embi_ClassOfWarrantOrRightWarrantsAggregateExercisePrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ClassOfWarrantOrRightWarrantsExercise_48" xlink:to="lab_embi_ClassOfWarrantOrRightWarrantsExercise_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ClassOfWarrantOrRightWarrantsExercise_48" xlink:to="lab_embi_ClassOfWarrantOrRightWarrantsExercise_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ClassOfWarrantOrRightWarrantsExercise_48" xlink:to="lab_embi_ClassOfWarrantOrRightWarrantsExercise_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CommonSharesUnderlyingConvertiblePreferredStockMember_49" xlink:to="lab_embi_CommonSharesUnderlyingConvertiblePreferredStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CommonSharesUnderlyingConvertiblePreferredStockMember_49" xlink:to="lab_embi_CommonSharesUnderlyingConvertiblePreferredStockMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CommonSharesUnderlyingConvertiblePreferredStockMember_49" xlink:to="lab_embi_CommonSharesUnderlyingConvertiblePreferredStockMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CommonStockAggregatePurchasePrice_50" xlink:to="lab_embi_CommonStockAggregatePurchasePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CommonStockAggregatePurchasePrice_50" xlink:to="lab_embi_CommonStockAggregatePurchasePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CommonStockAggregatePurchasePrice_50" xlink:to="lab_embi_CommonStockAggregatePurchasePrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CommonStockIssuedForServices_51" xlink:to="lab_embi_CommonStockIssuedForServices_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CommonStockIssuedForServices_51" xlink:to="lab_embi_CommonStockIssuedForServices_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CommonStockWarrantsToSeriesBStockholdersMember_52" xlink:to="lab_embi_CommonStockWarrantsToSeriesBStockholdersMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CommonStockWarrantsToSeriesBStockholdersMember_52" xlink:to="lab_embi_CommonStockWarrantsToSeriesBStockholdersMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CommonStockWarrantsToSeriesBStockholdersMember_52" xlink:to="lab_embi_CommonStockWarrantsToSeriesBStockholdersMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConsultingAgreementMember_53" xlink:to="lab_embi_ConsultingAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConsultingAgreementMember_53" xlink:to="lab_embi_ConsultingAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConsultingAgreementMember_53" xlink:to="lab_embi_ConsultingAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ContractPayableDue_54" xlink:to="lab_embi_ContractPayableDue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ContractPayableDue_54" xlink:to="lab_embi_ContractPayableDue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ContractPayableDue_54" xlink:to="lab_embi_ContractPayableDue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionLiabilityIntoCommonStockPerShare_55" xlink:to="lab_embi_ConversionLiabilityIntoCommonStockPerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionLiabilityIntoCommonStockPerShare_55" xlink:to="lab_embi_ConversionLiabilityIntoCommonStockPerShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionLiabilityIntoCommonStockPerShare_55" xlink:to="lab_embi_ConversionLiabilityIntoCommonStockPerShare_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock_56" xlink:to="lab_embi_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock_56" xlink:to="lab_embi_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock_56" xlink:to="lab_embi_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares_57" xlink:to="lab_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares_57" xlink:to="lab_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares_57" xlink:to="lab_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares_57" xlink:to="lab_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue_58" xlink:to="lab_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue_58" xlink:to="lab_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue_58" xlink:to="lab_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue_58" xlink:to="lab_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest_59" xlink:to="lab_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest_59" xlink:to="lab_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest_59" xlink:to="lab_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterestShares_60" xlink:to="lab_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterestShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterestShares_60" xlink:to="lab_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterestShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterestShares_60" xlink:to="lab_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterestShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfSeriesCPreferredStockToCommonStockShares_61" xlink:to="lab_embi_ConversionOfSeriesCPreferredStockToCommonStockShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfSeriesCPreferredStockToCommonStockShares_61" xlink:to="lab_embi_ConversionOfSeriesCPreferredStockToCommonStockShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfSeriesCPreferredStockToCommonStockShares_61" xlink:to="lab_embi_ConversionOfSeriesCPreferredStockToCommonStockShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfSeriesCPreferredStockToCommonStockShares_61" xlink:to="lab_embi_ConversionOfSeriesCPreferredStockToCommonStockShares_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfSeriesCPreferredStockToCommonStockSharesValue_62" xlink:to="lab_embi_ConversionOfSeriesCPreferredStockToCommonStockSharesValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfSeriesCPreferredStockToCommonStockSharesValue_62" xlink:to="lab_embi_ConversionOfSeriesCPreferredStockToCommonStockSharesValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfSeriesCPreferredStockToCommonStockSharesValue_62" xlink:to="lab_embi_ConversionOfSeriesCPreferredStockToCommonStockSharesValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfSeriesDPreferredStockToCommonStock_63" xlink:to="lab_embi_ConversionOfSeriesDPreferredStockToCommonStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfSeriesDPreferredStockToCommonStock_63" xlink:to="lab_embi_ConversionOfSeriesDPreferredStockToCommonStock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfSeriesDPreferredStockToCommonStock_63" xlink:to="lab_embi_ConversionOfSeriesDPreferredStockToCommonStock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfSeriesDPreferredStockToCommonStock_63" xlink:to="lab_embi_ConversionOfSeriesDPreferredStockToCommonStock_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfSeriesDPreferredStockToCommonStockShares_64" xlink:to="lab_embi_ConversionOfSeriesDPreferredStockToCommonStockShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfSeriesDPreferredStockToCommonStockShares_64" xlink:to="lab_embi_ConversionOfSeriesDPreferredStockToCommonStockShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfSeriesDPreferredStockToCommonStockShares_64" xlink:to="lab_embi_ConversionOfSeriesDPreferredStockToCommonStockShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfSeriesDPreferredStockToCommonStockShares_64" xlink:to="lab_embi_ConversionOfSeriesDPreferredStockToCommonStockShares_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfSeriesFPreferredStockToCommonStockShares_65" xlink:to="lab_embi_ConversionOfSeriesFPreferredStockToCommonStockShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfSeriesFPreferredStockToCommonStockShares_65" xlink:to="lab_embi_ConversionOfSeriesFPreferredStockToCommonStockShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfSeriesFPreferredStockToCommonStockShares_65" xlink:to="lab_embi_ConversionOfSeriesFPreferredStockToCommonStockShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfSeriesFPreferredStockToCommonStockValue_66" xlink:to="lab_embi_ConversionOfSeriesFPreferredStockToCommonStockValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfSeriesFPreferredStockToCommonStockValue_66" xlink:to="lab_embi_ConversionOfSeriesFPreferredStockToCommonStockValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfSeriesFPreferredStockToCommonStockValue_66" xlink:to="lab_embi_ConversionOfSeriesFPreferredStockToCommonStockValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionPrice_67" xlink:to="lab_embi_ConversionPrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionPrice_67" xlink:to="lab_embi_ConversionPrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionPrice_67" xlink:to="lab_embi_ConversionPrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionPricePerShare_68" xlink:to="lab_embi_ConversionPricePerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionPricePerShare_68" xlink:to="lab_embi_ConversionPricePerShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionPricePerShare_68" xlink:to="lab_embi_ConversionPricePerShare_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConvertedRate10000001Member_69" xlink:to="lab_embi_ConvertedRate10000001Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConvertedRate10000001Member_69" xlink:to="lab_embi_ConvertedRate10000001Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConvertedRate10000001Member_69" xlink:to="lab_embi_ConvertedRate10000001Member_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConvertedRate100001Member_70" xlink:to="lab_embi_ConvertedRate100001Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConvertedRate100001Member_70" xlink:to="lab_embi_ConvertedRate100001Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConvertedRate100001Member_70" xlink:to="lab_embi_ConvertedRate100001Member_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConvertedRateAxis_71" xlink:to="lab_embi_ConvertedRateAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConvertedRateAxis_71" xlink:to="lab_embi_ConvertedRateAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConvertedRateDomain_72" xlink:to="lab_embi_ConvertedRateDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConvertedRateDomain_72" xlink:to="lab_embi_ConvertedRateDomain_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConvertibleDebtRelatedPartyTextBlock_73" xlink:to="lab_embi_ConvertibleDebtRelatedPartyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConvertibleDebtRelatedPartyTextBlock_73" xlink:to="lab_embi_ConvertibleDebtRelatedPartyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConvertibleDebtRelatedPartyTextBlock_73" xlink:to="lab_embi_ConvertibleDebtRelatedPartyTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConvertibleMultiDrawCreditAgreementIssuanceCosts_74" xlink:to="lab_embi_ConvertibleMultiDrawCreditAgreementIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConvertibleMultiDrawCreditAgreementIssuanceCosts_74" xlink:to="lab_embi_ConvertibleMultiDrawCreditAgreementIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConvertibleMultiDrawCreditAgreementIssuanceCosts_74" xlink:to="lab_embi_ConvertibleMultiDrawCreditAgreementIssuanceCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CouponInterestExpense_75" xlink:to="lab_embi_CouponInterestExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CouponInterestExpense_75" xlink:to="lab_embi_CouponInterestExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CouponInterestExpense_75" xlink:to="lab_embi_CouponInterestExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CurrentConvertibleDebtExcludingNoncurrentPortion_76" xlink:to="lab_embi_CurrentConvertibleDebtExcludingNoncurrentPortion_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CurrentConvertibleDebtExcludingNoncurrentPortion_76" xlink:to="lab_embi_CurrentConvertibleDebtExcludingNoncurrentPortion_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CurrentConvertibleDebtExcludingNoncurrentPortion_76" xlink:to="lab_embi_CurrentConvertibleDebtExcludingNoncurrentPortion_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CurrentConvertibleDebtExcludingNoncurrentPortion_76" xlink:to="lab_embi_CurrentConvertibleDebtExcludingNoncurrentPortion_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_December2015Member_77" xlink:to="lab_embi_December2015Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_December2015Member_77" xlink:to="lab_embi_December2015Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_December2015Member_77" xlink:to="lab_embi_December2015Member_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_DeemedDividendFromBeneficialConversionFeatureOfSeriesDPreferredStock_78" xlink:to="lab_embi_DeemedDividendFromBeneficialConversionFeatureOfSeriesDPreferredStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_DeemedDividendFromBeneficialConversionFeatureOfSeriesDPreferredStock_78" xlink:to="lab_embi_DeemedDividendFromBeneficialConversionFeatureOfSeriesDPreferredStock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_DeemedDividendFromBeneficialConversionFeatureOfSeriesDPreferredStock_78" xlink:to="lab_embi_DeemedDividendFromBeneficialConversionFeatureOfSeriesDPreferredStock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_DeemedDividendFromBeneficialConversionFeatureOfSeriesDPreferredStock_78" xlink:to="lab_embi_DeemedDividendFromBeneficialConversionFeatureOfSeriesDPreferredStock_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_DeemedDividendFromBeneficialConversionFeatureOfSeriesFPreferredStock_79" xlink:to="lab_embi_DeemedDividendFromBeneficialConversionFeatureOfSeriesFPreferredStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_DeemedDividendFromBeneficialConversionFeatureOfSeriesFPreferredStock_79" xlink:to="lab_embi_DeemedDividendFromBeneficialConversionFeatureOfSeriesFPreferredStock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_DeemedDividendFromBeneficialConversionFeatureOfSeriesFPreferredStock_79" xlink:to="lab_embi_DeemedDividendFromBeneficialConversionFeatureOfSeriesFPreferredStock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_DeemedDividendFromBeneficialConversionFeatureOfSeriesFPreferredStock_79" xlink:to="lab_embi_DeemedDividendFromBeneficialConversionFeatureOfSeriesFPreferredStock_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_80" xlink:to="lab_embi_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_80" xlink:to="lab_embi_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_80" xlink:to="lab_embi_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_DeferredTaxLiabilitiesNoteDiscount_81" xlink:to="lab_embi_DeferredTaxLiabilitiesNoteDiscount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_DeferredTaxLiabilitiesNoteDiscount_81" xlink:to="lab_embi_DeferredTaxLiabilitiesNoteDiscount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_DeferredTaxLiabilitiesNoteDiscount_81" xlink:to="lab_embi_DeferredTaxLiabilitiesNoteDiscount_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_82" xlink:to="lab_embi_DerivativeLiabilitiesLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_82" xlink:to="lab_embi_DerivativeLiabilitiesLineItems_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_DerivativeLiabilitiesTable_83" xlink:to="lab_embi_DerivativeLiabilitiesTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_DerivativeLiabilitiesTable_83" xlink:to="lab_embi_DerivativeLiabilitiesTable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_DilutedSecuritiesAxis_84" xlink:to="lab_embi_DilutedSecuritiesAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_DilutedSecuritiesDomain_85" xlink:to="lab_embi_DilutedSecuritiesDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_DilutedSecuritiesDomain_85" xlink:to="lab_embi_DilutedSecuritiesDomain_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_DilutiveSecuritiesEffectOnBasicEarningsPerShareShares_86" xlink:to="lab_embi_DilutiveSecuritiesEffectOnBasicEarningsPerShareShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_DilutiveSecuritiesEffectOnBasicEarningsPerShareShares_86" xlink:to="lab_embi_DilutiveSecuritiesEffectOnBasicEarningsPerShareShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_DilutiveSecuritiesEffectOnBasicEarningsPerShareShares_86" xlink:to="lab_embi_DilutiveSecuritiesEffectOnBasicEarningsPerShareShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_DocumentAndEntityInformationAbstract_87" xlink:to="lab_embi_DocumentAndEntityInformationAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_DocumentAndEntityInformationAbstract_87" xlink:to="lab_embi_DocumentAndEntityInformationAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_DouglasCesarioMember_88" xlink:to="lab_embi_DouglasCesarioMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_DouglasCesarioMember_88" xlink:to="lab_embi_DouglasCesarioMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_DouglasCesarioMember_88" xlink:to="lab_embi_DouglasCesarioMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrant_89" xlink:to="lab_embi_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrant_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrant_89" xlink:to="lab_embi_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrant_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrant_89" xlink:to="lab_embi_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrant_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrant_89" xlink:to="lab_embi_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrant_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_90" xlink:to="lab_embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_90" xlink:to="lab_embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_90" xlink:to="lab_embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_90" xlink:to="lab_embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldFinancingIssuanceCosts_91" xlink:to="lab_embi_EmeraldFinancingIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldFinancingIssuanceCosts_91" xlink:to="lab_embi_EmeraldFinancingIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldFinancingIssuanceCosts_91" xlink:to="lab_embi_EmeraldFinancingIssuanceCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldFinancingMember_92" xlink:to="lab_embi_EmeraldFinancingMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldFinancingMember_92" xlink:to="lab_embi_EmeraldFinancingMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldFinancingMember_92" xlink:to="lab_embi_EmeraldFinancingMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldFinancingMember_92" xlink:to="lab_embi_EmeraldFinancingMember_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldHealthSciencesIncMember_93" xlink:to="lab_embi_EmeraldHealthSciencesIncMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldHealthSciencesIncMember_93" xlink:to="lab_embi_EmeraldHealthSciencesIncMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldHealthSciencesIncMember_93" xlink:to="lab_embi_EmeraldHealthSciencesIncMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldHealthSciencesIncMember_93" xlink:to="lab_embi_EmeraldHealthSciencesIncMember_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_94" xlink:to="lab_embi_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_94" xlink:to="lab_embi_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_94" xlink:to="lab_embi_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_94" xlink:to="lab_embi_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_94" xlink:to="lab_embi_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldWarrantLiabilityMember_95" xlink:to="lab_embi_EmeraldWarrantLiabilityMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldWarrantLiabilityMember_95" xlink:to="lab_embi_EmeraldWarrantLiabilityMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldWarrantLiabilityMember_95" xlink:to="lab_embi_EmeraldWarrantLiabilityMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldWarrantLiabilityMember_95" xlink:to="lab_embi_EmeraldWarrantLiabilityMember_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EquityLineItems_96" xlink:to="lab_embi_EquityLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EquityLineItems_96" xlink:to="lab_embi_EquityLineItems_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EquityTable_97" xlink:to="lab_embi_EquityTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EquityTable_97" xlink:to="lab_embi_EquityTable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EstimatedAgreementFeesAndExpenses_98" xlink:to="lab_embi_EstimatedAgreementFeesAndExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EstimatedAgreementFeesAndExpenses_98" xlink:to="lab_embi_EstimatedAgreementFeesAndExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EstimatedAgreementFeesAndExpenses_98" xlink:to="lab_embi_EstimatedAgreementFeesAndExpenses_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EstimatedInitialPaymentForContract_99" xlink:to="lab_embi_EstimatedInitialPaymentForContract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EstimatedInitialPaymentForContract_99" xlink:to="lab_embi_EstimatedInitialPaymentForContract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EstimatedInitialPaymentForContract_99" xlink:to="lab_embi_EstimatedInitialPaymentForContract_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ExerciseOfWarrants_100" xlink:to="lab_embi_ExerciseOfWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ExerciseOfWarrants_100" xlink:to="lab_embi_ExerciseOfWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ExerciseOfWarrants_100" xlink:to="lab_embi_ExerciseOfWarrants_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairMarketValueOfSharesGranted_101" xlink:to="lab_embi_FairMarketValueOfSharesGranted_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairMarketValueOfSharesGranted_101" xlink:to="lab_embi_FairMarketValueOfSharesGranted_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairMarketValueOfSharesGranted_101" xlink:to="lab_embi_FairMarketValueOfSharesGranted_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairMarketValueOfStockOptions_102" xlink:to="lab_embi_FairMarketValueOfStockOptions_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairMarketValueOfStockOptions_102" xlink:to="lab_embi_FairMarketValueOfStockOptions_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairMarketValueOfStockOptions_102" xlink:to="lab_embi_FairMarketValueOfStockOptions_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfCommonStockWarrantsIssued_103" xlink:to="lab_embi_FairValueOfCommonStockWarrantsIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfCommonStockWarrantsIssued_103" xlink:to="lab_embi_FairValueOfCommonStockWarrantsIssued_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfCommonStockWarrantsIssued_103" xlink:to="lab_embi_FairValueOfCommonStockWarrantsIssued_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement_104" xlink:to="lab_embi_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement_104" xlink:to="lab_embi_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement_104" xlink:to="lab_embi_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfDerivativeLiabilitiesRollForward_105" xlink:to="lab_embi_FairValueOfDerivativeLiabilitiesRollForward_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfDerivativeLiabilitiesRollForward_105" xlink:to="lab_embi_FairValueOfDerivativeLiabilitiesRollForward_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfDerivativeLiabilityExcessOfProceeds_106" xlink:to="lab_embi_FairValueOfDerivativeLiabilityExcessOfProceeds_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfDerivativeLiabilityExcessOfProceeds_106" xlink:to="lab_embi_FairValueOfDerivativeLiabilityExcessOfProceeds_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfDerivativeLiabilityExcessOfProceeds_106" xlink:to="lab_embi_FairValueOfDerivativeLiabilityExcessOfProceeds_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfDerivativeLiabilityExcessOfProceeds_106" xlink:to="lab_embi_FairValueOfDerivativeLiabilityExcessOfProceeds_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfDerivativeLiabilityExcessOfProceeds_106" xlink:to="lab_embi_FairValueOfDerivativeLiabilityExcessOfProceeds_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfDerivativeLiabilityInExcessOfProceeds_107" xlink:to="lab_embi_FairValueOfDerivativeLiabilityInExcessOfProceeds_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfDerivativeLiabilityInExcessOfProceeds_107" xlink:to="lab_embi_FairValueOfDerivativeLiabilityInExcessOfProceeds_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfDerivativeLiabilityInExcessOfProceeds_107" xlink:to="lab_embi_FairValueOfDerivativeLiabilityInExcessOfProceeds_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfDerivativeLiabilityInExcessOfProceeds_107" xlink:to="lab_embi_FairValueOfDerivativeLiabilityInExcessOfProceeds_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfDerivativeLiabilityInExcessOfProceeds_107" xlink:to="lab_embi_FairValueOfDerivativeLiabilityInExcessOfProceeds_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfUnderlyingShares_108" xlink:to="lab_embi_FairValueOfUnderlyingShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfUnderlyingShares_108" xlink:to="lab_embi_FairValueOfUnderlyingShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfUnderlyingShares_108" xlink:to="lab_embi_FairValueOfUnderlyingShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfWarrantsIssued_109" xlink:to="lab_embi_FairValueOfWarrantsIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfWarrantsIssued_109" xlink:to="lab_embi_FairValueOfWarrantsIssued_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfWarrantsIssued_109" xlink:to="lab_embi_FairValueOfWarrantsIssued_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfWarrantsIssued_109" xlink:to="lab_embi_FairValueOfWarrantsIssued_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfWarrantsIssued_109" xlink:to="lab_embi_FairValueOfWarrantsIssued_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfWarrantsIssuedInConnectionWithFinancings_110" xlink:to="lab_embi_FairValueOfWarrantsIssuedInConnectionWithFinancings_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfWarrantsIssuedInConnectionWithFinancings_110" xlink:to="lab_embi_FairValueOfWarrantsIssuedInConnectionWithFinancings_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfWarrantsIssuedInConnectionWithFinancings_110" xlink:to="lab_embi_FairValueOfWarrantsIssuedInConnectionWithFinancings_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FeesAndExpensesForServicesProvided_111" xlink:to="lab_embi_FeesAndExpensesForServicesProvided_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FeesAndExpensesForServicesProvided_111" xlink:to="lab_embi_FeesAndExpensesForServicesProvided_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FeesAndExpensesForServicesProvided_111" xlink:to="lab_embi_FeesAndExpensesForServicesProvided_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FinancingSharesWarrantExercise_112" xlink:to="lab_embi_FinancingSharesWarrantExercise_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FinancingSharesWarrantExercise_112" xlink:to="lab_embi_FinancingSharesWarrantExercise_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FinancingSharesWarrantExercise_112" xlink:to="lab_embi_FinancingSharesWarrantExercise_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FinancingValueWarrantExercise_113" xlink:to="lab_embi_FinancingValueWarrantExercise_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FinancingValueWarrantExercise_113" xlink:to="lab_embi_FinancingValueWarrantExercise_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FinancingValueWarrantExercise_113" xlink:to="lab_embi_FinancingValueWarrantExercise_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FixedAssetsProvidedToUniversityInLieuOfCash_114" xlink:to="lab_embi_FixedAssetsProvidedToUniversityInLieuOfCash_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FixedAssetsProvidedToUniversityInLieuOfCash_114" xlink:to="lab_embi_FixedAssetsProvidedToUniversityInLieuOfCash_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FixedAssetsProvidedToUniversityInLieuOfCash_114" xlink:to="lab_embi_FixedAssetsProvidedToUniversityInLieuOfCash_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_GlauconixBiosciencesIncMember_115" xlink:to="lab_embi_GlauconixBiosciencesIncMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_GlauconixBiosciencesIncMember_115" xlink:to="lab_embi_GlauconixBiosciencesIncMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_GlauconixBiosciencesIncMember_115" xlink:to="lab_embi_GlauconixBiosciencesIncMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_GuarantorFailedToPay_116" xlink:to="lab_embi_GuarantorFailedToPay_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_GuarantorFailedToPay_116" xlink:to="lab_embi_GuarantorFailedToPay_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_GuarantorFailedToPay_116" xlink:to="lab_embi_GuarantorFailedToPay_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_IncomeTaxReconciliationChangeInCompoundDerivative_117" xlink:to="lab_embi_IncomeTaxReconciliationChangeInCompoundDerivative_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_IncomeTaxReconciliationChangeInCompoundDerivative_117" xlink:to="lab_embi_IncomeTaxReconciliationChangeInCompoundDerivative_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_IncomeTaxReconciliationChangeInCompoundDerivative_117" xlink:to="lab_embi_IncomeTaxReconciliationChangeInCompoundDerivative_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_IncomeTaxReconciliationUncertainTaxPositions_118" xlink:to="lab_embi_IncomeTaxReconciliationUncertainTaxPositions_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_IncomeTaxReconciliationUncertainTaxPositions_118" xlink:to="lab_embi_IncomeTaxReconciliationUncertainTaxPositions_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_IncomeTaxReconciliationUncertainTaxPositions_118" xlink:to="lab_embi_IncomeTaxReconciliationUncertainTaxPositions_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_IncreaseChangeInFairValueOfWarrantLiability_119" xlink:to="lab_embi_IncreaseChangeInFairValueOfWarrantLiability_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_IncreaseChangeInFairValueOfWarrantLiability_119" xlink:to="lab_embi_IncreaseChangeInFairValueOfWarrantLiability_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_IncreaseChangeInFairValueOfWarrantLiability_119" xlink:to="lab_embi_IncreaseChangeInFairValueOfWarrantLiability_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_IncreaseDecreaseInDepositsAndOtherAssets_120" xlink:to="lab_embi_IncreaseDecreaseInDepositsAndOtherAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_IncreaseDecreaseInDepositsAndOtherAssets_120" xlink:to="lab_embi_IncreaseDecreaseInDepositsAndOtherAssets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_IncreaseDecreaseInDepositsAndOtherAssets_120" xlink:to="lab_embi_IncreaseDecreaseInDepositsAndOtherAssets_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_IncrementalAgreementFeesAndExpenses_121" xlink:to="lab_embi_IncrementalAgreementFeesAndExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_IncrementalAgreementFeesAndExpenses_121" xlink:to="lab_embi_IncrementalAgreementFeesAndExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_IncrementalAgreementFeesAndExpenses_121" xlink:to="lab_embi_IncrementalAgreementFeesAndExpenses_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_IndependentContractorAgreementMember_122" xlink:to="lab_embi_IndependentContractorAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_IndependentContractorAgreementMember_122" xlink:to="lab_embi_IndependentContractorAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_IndependentContractorAgreementMember_122" xlink:to="lab_embi_IndependentContractorAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_InitialTermOfAgreement_123" xlink:to="lab_embi_InitialTermOfAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_InitialTermOfAgreement_123" xlink:to="lab_embi_InitialTermOfAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_InitialTermOfAgreement_123" xlink:to="lab_embi_InitialTermOfAgreement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_IntrinsicValueOfWarrantExercises_124" xlink:to="lab_embi_IntrinsicValueOfWarrantExercises_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_IntrinsicValueOfWarrantExercises_124" xlink:to="lab_embi_IntrinsicValueOfWarrantExercises_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_IntrinsicValueOfWarrantExercises_124" xlink:to="lab_embi_IntrinsicValueOfWarrantExercises_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_IssuanceOfPreferredStockNetOfIssuanceCosts_125" xlink:to="lab_embi_IssuanceOfPreferredStockNetOfIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_IssuanceOfPreferredStockNetOfIssuanceCosts_125" xlink:to="lab_embi_IssuanceOfPreferredStockNetOfIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_IssuanceOfPreferredStockNetOfIssuanceCosts_125" xlink:to="lab_embi_IssuanceOfPreferredStockNetOfIssuanceCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_IssuanceOfPreferredStockNetOfIssuanceCostsShares_126" xlink:to="lab_embi_IssuanceOfPreferredStockNetOfIssuanceCostsShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_IssuanceOfPreferredStockNetOfIssuanceCostsShares_126" xlink:to="lab_embi_IssuanceOfPreferredStockNetOfIssuanceCostsShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_IssuanceOfPreferredStockNetOfIssuanceCostsShares_126" xlink:to="lab_embi_IssuanceOfPreferredStockNetOfIssuanceCostsShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_IssuanceOfPreferredStockSeriesNetOfIssuanceCostsShares_127" xlink:to="lab_embi_IssuanceOfPreferredStockSeriesNetOfIssuanceCostsShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_IssuanceOfPreferredStockSeriesNetOfIssuanceCostsShares_127" xlink:to="lab_embi_IssuanceOfPreferredStockSeriesNetOfIssuanceCostsShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_IssuanceOfPreferredStockSeriesNetOfIssuanceCostsShares_127" xlink:to="lab_embi_IssuanceOfPreferredStockSeriesNetOfIssuanceCostsShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_IssuanceOfPreferredStockSeriesNetOfIssuanceCostsValue_128" xlink:to="lab_embi_IssuanceOfPreferredStockSeriesNetOfIssuanceCostsValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_IssuanceOfPreferredStockSeriesNetOfIssuanceCostsValue_128" xlink:to="lab_embi_IssuanceOfPreferredStockSeriesNetOfIssuanceCostsValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_IssuanceOfPreferredStockSeriesNetOfIssuanceCostsValue_128" xlink:to="lab_embi_IssuanceOfPreferredStockSeriesNetOfIssuanceCostsValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_K2CIncMember_129" xlink:to="lab_embi_K2CIncMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_K2CIncMember_129" xlink:to="lab_embi_K2CIncMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_K2CIncMember_129" xlink:to="lab_embi_K2CIncMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_LeaseAgreementMember_130" xlink:to="lab_embi_LeaseAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_LeaseAgreementMember_130" xlink:to="lab_embi_LeaseAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_LetterAgreementMember_131" xlink:to="lab_embi_LetterAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_LetterAgreementMember_131" xlink:to="lab_embi_LetterAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_LetterAgreementMember_131" xlink:to="lab_embi_LetterAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_LicenseAgreementMember_132" xlink:to="lab_embi_LicenseAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_LicenseAgreementMember_132" xlink:to="lab_embi_LicenseAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_LicenseAgreementMember_132" xlink:to="lab_embi_LicenseAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_LicenseAgreementMember_132" xlink:to="lab_embi_LicenseAgreementMember_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_LiquidationProvisionCommonStockEquivalentShares_133" xlink:to="lab_embi_LiquidationProvisionCommonStockEquivalentShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_LiquidationProvisionCommonStockEquivalentShares_133" xlink:to="lab_embi_LiquidationProvisionCommonStockEquivalentShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_LiquidationProvisionCommonStockEquivalentShares_133" xlink:to="lab_embi_LiquidationProvisionCommonStockEquivalentShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_LiquidationProvisionCommonStockEquivalentValue_134" xlink:to="lab_embi_LiquidationProvisionCommonStockEquivalentValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_LiquidationProvisionCommonStockEquivalentValue_134" xlink:to="lab_embi_LiquidationProvisionCommonStockEquivalentValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_LossOnCommonStockIssuanceFromConversionOfAccruedInterest_135" xlink:to="lab_embi_LossOnCommonStockIssuanceFromConversionOfAccruedInterest_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_LossOnCommonStockIssuanceFromConversionOfAccruedInterest_135" xlink:to="lab_embi_LossOnCommonStockIssuanceFromConversionOfAccruedInterest_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_LossOnCommonStockIssuanceFromConversionOfAccruedInterest_135" xlink:to="lab_embi_LossOnCommonStockIssuanceFromConversionOfAccruedInterest_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_LumpSumPaymentInAgreement_136" xlink:to="lab_embi_LumpSumPaymentInAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_LumpSumPaymentInAgreement_136" xlink:to="lab_embi_LumpSumPaymentInAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_LumpSumPaymentInAgreement_136" xlink:to="lab_embi_LumpSumPaymentInAgreement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MasterServiceAgreementMember_137" xlink:to="lab_embi_MasterServiceAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MasterServiceAgreementMember_137" xlink:to="lab_embi_MasterServiceAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MasterServiceAgreementMember_137" xlink:to="lab_embi_MasterServiceAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_Milestone1Member_138" xlink:to="lab_embi_Milestone1Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_Milestone1Member_138" xlink:to="lab_embi_Milestone1Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_Milestone1Member_138" xlink:to="lab_embi_Milestone1Member_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_Milestone2Member_139" xlink:to="lab_embi_Milestone2Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_Milestone2Member_139" xlink:to="lab_embi_Milestone2Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_Milestone2Member_139" xlink:to="lab_embi_Milestone2Member_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_Milestone3Member_140" xlink:to="lab_embi_Milestone3Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_Milestone3Member_140" xlink:to="lab_embi_Milestone3Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_Milestone3Member_140" xlink:to="lab_embi_Milestone3Member_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MilestonePaymentsPayableAxis_141" xlink:to="lab_embi_MilestonePaymentsPayableAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MilestonePaymentsPayableAxis_141" xlink:to="lab_embi_MilestonePaymentsPayableAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MilestonePaymentsPayableDomain_142" xlink:to="lab_embi_MilestonePaymentsPayableDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MilestonePaymentsPayableDomain_142" xlink:to="lab_embi_MilestonePaymentsPayableDomain_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MinimumLitigationJudgementAmount_143" xlink:to="lab_embi_MinimumLitigationJudgementAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MinimumLitigationJudgementAmount_143" xlink:to="lab_embi_MinimumLitigationJudgementAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MinimumLitigationJudgementAmount_143" xlink:to="lab_embi_MinimumLitigationJudgementAmount_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MonteCarloSimulationsMember_144" xlink:to="lab_embi_MonteCarloSimulationsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MonteCarloSimulationsMember_144" xlink:to="lab_embi_MonteCarloSimulationsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MonteCarloSimulationsMember_144" xlink:to="lab_embi_MonteCarloSimulationsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MonthAndYearOfAgreementAxis_145" xlink:to="lab_embi_MonthAndYearOfAgreementAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MonthAndYearOfAgreementAxis_145" xlink:to="lab_embi_MonthAndYearOfAgreementAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MonthAndYearOfAgreementDomain_146" xlink:to="lab_embi_MonthAndYearOfAgreementDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MonthAndYearOfAgreementDomain_146" xlink:to="lab_embi_MonthAndYearOfAgreementDomain_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MonthlyFee_147" xlink:to="lab_embi_MonthlyFee_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MonthlyFee_147" xlink:to="lab_embi_MonthlyFee_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MonthlyFee_147" xlink:to="lab_embi_MonthlyFee_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices_148" xlink:to="lab_embi_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices_148" xlink:to="lab_embi_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices_148" xlink:to="lab_embi_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MonthlyFeePaidEachMonthInExchangeOfServices_149" xlink:to="lab_embi_MonthlyFeePaidEachMonthInExchangeOfServices_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MonthlyFeePaidEachMonthInExchangeOfServices_149" xlink:to="lab_embi_MonthlyFeePaidEachMonthInExchangeOfServices_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MonthlyFeePaidEachMonthInExchangeOfServices_149" xlink:to="lab_embi_MonthlyFeePaidEachMonthInExchangeOfServices_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MultiDrawCreditAgreementMember_150" xlink:to="lab_embi_MultiDrawCreditAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MultiDrawCreditAgreementMember_150" xlink:to="lab_embi_MultiDrawCreditAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MultiDrawCreditAgreementMember_150" xlink:to="lab_embi_MultiDrawCreditAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesAbstract_151" xlink:to="lab_embi_NatureOfOperationsAndBusinessActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesAbstract_151" xlink:to="lab_embi_NatureOfOperationsAndBusinessActivitiesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_152" xlink:to="lab_embi_NatureOfOperationsAndBusinessActivitiesLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_152" xlink:to="lab_embi_NatureOfOperationsAndBusinessActivitiesLineItems_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesTable_153" xlink:to="lab_embi_NatureOfOperationsAndBusinessActivitiesTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesTable_153" xlink:to="lab_embi_NatureOfOperationsAndBusinessActivitiesTable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NetLossAdjustedBalance_154" xlink:to="lab_embi_NetLossAdjustedBalance_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NetLossAdjustedBalance_154" xlink:to="lab_embi_NetLossAdjustedBalance_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NetLossAdjustedBalance_154" xlink:to="lab_embi_NetLossAdjustedBalance_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NetLossAdjustedBalance_154" xlink:to="lab_embi_NetLossAdjustedBalance_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NonCashInterestExpenseAbstract_155" xlink:to="lab_embi_NonCashInterestExpenseAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NonCashInterestExpenseAbstract_155" xlink:to="lab_embi_NonCashInterestExpenseAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NoramcoAgreementMember_156" xlink:to="lab_embi_NoramcoAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NoramcoAgreementMember_156" xlink:to="lab_embi_NoramcoAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NoramcoAgreementMember_156" xlink:to="lab_embi_NoramcoAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NoticePeriodForTermination_157" xlink:to="lab_embi_NoticePeriodForTermination_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NoticePeriodForTermination_157" xlink:to="lab_embi_NoticePeriodForTermination_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NoticePeriodForTermination_157" xlink:to="lab_embi_NoticePeriodForTermination_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NumberOfCommonStockIssuedUponConversionOfPreferredStock_158" xlink:to="lab_embi_NumberOfCommonStockIssuedUponConversionOfPreferredStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NumberOfCommonStockIssuedUponConversionOfPreferredStock_158" xlink:to="lab_embi_NumberOfCommonStockIssuedUponConversionOfPreferredStock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NumberOfCommonStockIssuedUponConversionOfPreferredStock_158" xlink:to="lab_embi_NumberOfCommonStockIssuedUponConversionOfPreferredStock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NumberOfInvestors_159" xlink:to="lab_embi_NumberOfInvestors_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NumberOfInvestors_159" xlink:to="lab_embi_NumberOfInvestors_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NumberOfInvestors_159" xlink:to="lab_embi_NumberOfInvestors_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NumberOfLicenseAgreements_160" xlink:to="lab_embi_NumberOfLicenseAgreements_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NumberOfLicenseAgreements_160" xlink:to="lab_embi_NumberOfLicenseAgreements_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NumberOfLicenseAgreements_160" xlink:to="lab_embi_NumberOfLicenseAgreements_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NumberOfWarrantsExercisable_161" xlink:to="lab_embi_NumberOfWarrantsExercisable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NumberOfWarrantsExercisable_161" xlink:to="lab_embi_NumberOfWarrantsExercisable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NumberOfWarrantsExercisable_161" xlink:to="lab_embi_NumberOfWarrantsExercisable_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_OctoberTwoThousandFifteenMember_162" xlink:to="lab_embi_OctoberTwoThousandFifteenMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_OctoberTwoThousandFifteenMember_162" xlink:to="lab_embi_OctoberTwoThousandFifteenMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_OctoberTwoThousandFifteenMember_162" xlink:to="lab_embi_OctoberTwoThousandFifteenMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_OmnibusIncentivePlan2014Member_163" xlink:to="lab_embi_OmnibusIncentivePlan2014Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_OmnibusIncentivePlan2014Member_163" xlink:to="lab_embi_OmnibusIncentivePlan2014Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_OmnibusIncentivePlan2014Member_163" xlink:to="lab_embi_OmnibusIncentivePlan2014Member_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_OneTimeUpfrontPayment_164" xlink:to="lab_embi_OneTimeUpfrontPayment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_OneTimeUpfrontPayment_164" xlink:to="lab_embi_OneTimeUpfrontPayment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_OneTimeUpfrontPayment_164" xlink:to="lab_embi_OneTimeUpfrontPayment_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_OneTimeUpfrontPayment_164" xlink:to="lab_embi_OneTimeUpfrontPayment_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_OneTimeUpfrontPayment_164" xlink:to="lab_embi_OneTimeUpfrontPayment_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_OptionAgreementMember_165" xlink:to="lab_embi_OptionAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_OptionAgreementMember_165" xlink:to="lab_embi_OptionAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_OptionAgreementMember_165" xlink:to="lab_embi_OptionAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_OptionAgreementMember_165" xlink:to="lab_embi_OptionAgreementMember_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_OptionsMember_166" xlink:to="lab_embi_OptionsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_OptionsMember_166" xlink:to="lab_embi_OptionsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_OptionsMember_166" xlink:to="lab_embi_OptionsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PaymentForUpfrontFees_167" xlink:to="lab_embi_PaymentForUpfrontFees_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PaymentForUpfrontFees_167" xlink:to="lab_embi_PaymentForUpfrontFees_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PaymentForUpfrontFees_167" xlink:to="lab_embi_PaymentForUpfrontFees_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PaymentOfUpfrontLicenseFee_168" xlink:to="lab_embi_PaymentOfUpfrontLicenseFee_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PaymentOfUpfrontLicenseFee_168" xlink:to="lab_embi_PaymentOfUpfrontLicenseFee_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PaymentOfUpfrontLicenseFee_168" xlink:to="lab_embi_PaymentOfUpfrontLicenseFee_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PercentageOfAccruedInterestOnOutstandingBalance_169" xlink:to="lab_embi_PercentageOfAccruedInterestOnOutstandingBalance_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PercentageOfAccruedInterestOnOutstandingBalance_169" xlink:to="lab_embi_PercentageOfAccruedInterestOnOutstandingBalance_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PercentageOfAccruedInterestOnOutstandingBalance_169" xlink:to="lab_embi_PercentageOfAccruedInterestOnOutstandingBalance_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase_170" xlink:to="lab_embi_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase_170" xlink:to="lab_embi_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase_170" xlink:to="lab_embi_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PercentageOfConversionAmount_171" xlink:to="lab_embi_PercentageOfConversionAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PercentageOfConversionAmount_171" xlink:to="lab_embi_PercentageOfConversionAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PercentageOfConversionAmount_171" xlink:to="lab_embi_PercentageOfConversionAmount_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PercentageOfSharesToBeRedeemed_172" xlink:to="lab_embi_PercentageOfSharesToBeRedeemed_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PercentageOfSharesToBeRedeemed_172" xlink:to="lab_embi_PercentageOfSharesToBeRedeemed_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PercentageOfSharesToBeRedeemed_172" xlink:to="lab_embi_PercentageOfSharesToBeRedeemed_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PeriodOfDiscretionaryAnnualBonusPayableToContractorAfterEachFiscalYearEnd_173" xlink:to="lab_embi_PeriodOfDiscretionaryAnnualBonusPayableToContractorAfterEachFiscalYearEnd_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PeriodOfDiscretionaryAnnualBonusPayableToContractorAfterEachFiscalYearEnd_173" xlink:to="lab_embi_PeriodOfDiscretionaryAnnualBonusPayableToContractorAfterEachFiscalYearEnd_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PeriodOfDiscretionaryAnnualBonusPayableToContractorAfterEachFiscalYearEnd_173" xlink:to="lab_embi_PeriodOfDiscretionaryAnnualBonusPayableToContractorAfterEachFiscalYearEnd_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PharmaceuticalsInternationalInc.AgreementMember_174" xlink:to="lab_embi_PharmaceuticalsInternationalInc.AgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PharmaceuticalsInternationalInc.AgreementMember_174" xlink:to="lab_embi_PharmaceuticalsInternationalInc.AgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PharmaceuticalsInternationalInc.AgreementMember_174" xlink:to="lab_embi_PharmaceuticalsInternationalInc.AgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_Pre2015CommonStockWarrantsMember_175" xlink:to="lab_embi_Pre2015CommonStockWarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_Pre2015CommonStockWarrantsMember_175" xlink:to="lab_embi_Pre2015CommonStockWarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_Pre2015CommonStockWarrantsMember_175" xlink:to="lab_embi_Pre2015CommonStockWarrantsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PreferredStockPutOptionLiability_176" xlink:to="lab_embi_PreferredStockPutOptionLiability_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PreferredStockPutOptionLiability_176" xlink:to="lab_embi_PreferredStockPutOptionLiability_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PreferredStockPutOptionLiability_176" xlink:to="lab_embi_PreferredStockPutOptionLiability_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PricingModelAxis_177" xlink:to="lab_embi_PricingModelAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PricingModelDomain_178" xlink:to="lab_embi_PricingModelDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PricingModelMember_179" xlink:to="lab_embi_PricingModelMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PricingModelMember_179" xlink:to="lab_embi_PricingModelMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PricingModelMember_179" xlink:to="lab_embi_PricingModelMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PricingModelMember_179" xlink:to="lab_embi_PricingModelMember_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement_180" xlink:to="lab_embi_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement_180" xlink:to="lab_embi_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement_180" xlink:to="lab_embi_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ProceedsFromConvertibleMultiDrawCreditAgreement_181" xlink:to="lab_embi_ProceedsFromConvertibleMultiDrawCreditAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ProceedsFromConvertibleMultiDrawCreditAgreement_181" xlink:to="lab_embi_ProceedsFromConvertibleMultiDrawCreditAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ProceedsFromConvertibleMultiDrawCreditAgreement_181" xlink:to="lab_embi_ProceedsFromConvertibleMultiDrawCreditAgreement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ProceedsFromConvertibleMultiDrawCreditAgreement_181" xlink:to="lab_embi_ProceedsFromConvertibleMultiDrawCreditAgreement_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ProceedsFromEmeraldFinancingNetOfIssuanceCosts_182" xlink:to="lab_embi_ProceedsFromEmeraldFinancingNetOfIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ProceedsFromEmeraldFinancingNetOfIssuanceCosts_182" xlink:to="lab_embi_ProceedsFromEmeraldFinancingNetOfIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ProceedsFromEmeraldFinancingNetOfIssuanceCosts_182" xlink:to="lab_embi_ProceedsFromEmeraldFinancingNetOfIssuanceCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ProceedsFromFinancingBetweenConversionLiabilityAndWarrants_183" xlink:to="lab_embi_ProceedsFromFinancingBetweenConversionLiabilityAndWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ProceedsFromFinancingBetweenConversionLiabilityAndWarrants_183" xlink:to="lab_embi_ProceedsFromFinancingBetweenConversionLiabilityAndWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ProceedsFromFinancingBetweenConversionLiabilityAndWarrants_183" xlink:to="lab_embi_ProceedsFromFinancingBetweenConversionLiabilityAndWarrants_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ProvisionForConversionOfPreferredStock_184" xlink:to="lab_embi_ProvisionForConversionOfPreferredStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ProvisionForConversionOfPreferredStock_184" xlink:to="lab_embi_ProvisionForConversionOfPreferredStock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ProvisionForConversionOfPreferredStock_184" xlink:to="lab_embi_ProvisionForConversionOfPreferredStock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ProvisionForConversionOfPreferredStock_184" xlink:to="lab_embi_ProvisionForConversionOfPreferredStock_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ReclassificationOfDerivativesToEquity_185" xlink:to="lab_embi_ReclassificationOfDerivativesToEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ReclassificationOfDerivativesToEquity_185" xlink:to="lab_embi_ReclassificationOfDerivativesToEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ReclassificationOfDerivativesToEquity_185" xlink:to="lab_embi_ReclassificationOfDerivativesToEquity_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ReclassificationOfDerivativesToEquity_185" xlink:to="lab_embi_ReclassificationOfDerivativesToEquity_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_RedemptionAmountPercentage_186" xlink:to="lab_embi_RedemptionAmountPercentage_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_RedemptionAmountPercentage_186" xlink:to="lab_embi_RedemptionAmountPercentage_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_RedemptionAmountPercentage_186" xlink:to="lab_embi_RedemptionAmountPercentage_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ReductionToAdditionalPaidInCapitalFromTheIssuanceOfCommonStock_187" xlink:to="lab_embi_ReductionToAdditionalPaidInCapitalFromTheIssuanceOfCommonStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ReductionToAdditionalPaidInCapitalFromTheIssuanceOfCommonStock_187" xlink:to="lab_embi_ReductionToAdditionalPaidInCapitalFromTheIssuanceOfCommonStock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ReductionToAdditionalPaidInCapitalFromTheIssuanceOfCommonStock_187" xlink:to="lab_embi_ReductionToAdditionalPaidInCapitalFromTheIssuanceOfCommonStock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_RepaymentOfConvertibleMultiDrawCreditAgreement_188" xlink:to="lab_embi_RepaymentOfConvertibleMultiDrawCreditAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_RepaymentOfConvertibleMultiDrawCreditAgreement_188" xlink:to="lab_embi_RepaymentOfConvertibleMultiDrawCreditAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_RepaymentOfConvertibleMultiDrawCreditAgreement_188" xlink:to="lab_embi_RepaymentOfConvertibleMultiDrawCreditAgreement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ResearchAgreementMember_189" xlink:to="lab_embi_ResearchAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ResearchAgreementMember_189" xlink:to="lab_embi_ResearchAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ResearchAgreementMember_189" xlink:to="lab_embi_ResearchAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_RestrictedStockAgreementsMember_190" xlink:to="lab_embi_RestrictedStockAgreementsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_RestrictedStockAgreementsMember_190" xlink:to="lab_embi_RestrictedStockAgreementsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_RestrictedStockAgreementsMember_190" xlink:to="lab_embi_RestrictedStockAgreementsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_RisksAndUncertaintiesPolicyTextBlock_191" xlink:to="lab_embi_RisksAndUncertaintiesPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_RisksAndUncertaintiesPolicyTextBlock_191" xlink:to="lab_embi_RisksAndUncertaintiesPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_RisksAndUncertaintiesPolicyTextBlock_191" xlink:to="lab_embi_RisksAndUncertaintiesPolicyTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_RrdInternationalAgreementMember_192" xlink:to="lab_embi_RrdInternationalAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_RrdInternationalAgreementMember_192" xlink:to="lab_embi_RrdInternationalAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_RrdInternationalAgreementMember_192" xlink:to="lab_embi_RrdInternationalAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ScheduleOfAdjustmentForDifferenceBetweenFairValueOfWarrantLiabilitiesAndTotalProceedsReceivedTableTextBlock_193" xlink:to="lab_embi_ScheduleOfAdjustmentForDifferenceBetweenFairValueOfWarrantLiabilitiesAndTotalProceedsReceivedTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ScheduleOfAdjustmentForDifferenceBetweenFairValueOfWarrantLiabilitiesAndTotalProceedsReceivedTableTextBlock_193" xlink:to="lab_embi_ScheduleOfAdjustmentForDifferenceBetweenFairValueOfWarrantLiabilitiesAndTotalProceedsReceivedTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ScheduleOfAdjustmentForDifferenceBetweenFairValueOfWarrantLiabilitiesAndTotalProceedsReceivedTableTextBlock_193" xlink:to="lab_embi_ScheduleOfAdjustmentForDifferenceBetweenFairValueOfWarrantLiabilitiesAndTotalProceedsReceivedTableTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ScheduleOfAssumptionsUsedToComputeFairValueOfWarrantsTableTextBlock_194" xlink:to="lab_embi_ScheduleOfAssumptionsUsedToComputeFairValueOfWarrantsTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ScheduleOfAssumptionsUsedToComputeFairValueOfWarrantsTableTextBlock_194" xlink:to="lab_embi_ScheduleOfAssumptionsUsedToComputeFairValueOfWarrantsTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ScheduleOfAssumptionsUsedToComputeFairValueOfWarrantsTableTextBlock_194" xlink:to="lab_embi_ScheduleOfAssumptionsUsedToComputeFairValueOfWarrantsTableTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ScheduleOfInterestExpenseTableTextBlock_195" xlink:to="lab_embi_ScheduleOfInterestExpenseTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ScheduleOfInterestExpenseTableTextBlock_195" xlink:to="lab_embi_ScheduleOfInterestExpenseTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ScheduleOfInterestExpenseTableTextBlock_195" xlink:to="lab_embi_ScheduleOfInterestExpenseTableTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SecondDrawOnMultiDrawCreditFacilityMember_196" xlink:to="lab_embi_SecondDrawOnMultiDrawCreditFacilityMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SecondDrawOnMultiDrawCreditFacilityMember_196" xlink:to="lab_embi_SecondDrawOnMultiDrawCreditFacilityMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SecondDrawOnMultiDrawCreditFacilityMember_196" xlink:to="lab_embi_SecondDrawOnMultiDrawCreditFacilityMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SecuredPromissoryNoteAndSecurityAgreementMember_197" xlink:to="lab_embi_SecuredPromissoryNoteAndSecurityAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SecuredPromissoryNoteAndSecurityAgreementMember_197" xlink:to="lab_embi_SecuredPromissoryNoteAndSecurityAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SecuredPromissoryNoteAndSecurityAgreementMember_197" xlink:to="lab_embi_SecuredPromissoryNoteAndSecurityAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SecuritiesPurchaseAgreementMember_198" xlink:to="lab_embi_SecuritiesPurchaseAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SecuritiesPurchaseAgreementMember_198" xlink:to="lab_embi_SecuritiesPurchaseAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SecuritiesPurchaseAgreementMember_198" xlink:to="lab_embi_SecuritiesPurchaseAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SecuritiesPurchaseAgreementMember_198" xlink:to="lab_embi_SecuritiesPurchaseAgreementMember_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SeparationAndReleaseAgreementMember_199" xlink:to="lab_embi_SeparationAndReleaseAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SeparationAndReleaseAgreementMember_199" xlink:to="lab_embi_SeparationAndReleaseAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SeparationAndReleaseAgreementMember_199" xlink:to="lab_embi_SeparationAndReleaseAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SeriesBPreferredStockConversionLiabilityMember_200" xlink:to="lab_embi_SeriesBPreferredStockConversionLiabilityMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SeriesBPreferredStockConversionLiabilityMember_200" xlink:to="lab_embi_SeriesBPreferredStockConversionLiabilityMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SeriesBPreferredStockConversionLiabilityMember_200" xlink:to="lab_embi_SeriesBPreferredStockConversionLiabilityMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SeriesBWarrantMember_201" xlink:to="lab_embi_SeriesBWarrantMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SeriesBWarrantMember_201" xlink:to="lab_embi_SeriesBWarrantMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SeriesBWarrantMember_201" xlink:to="lab_embi_SeriesBWarrantMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SeriesBWarrantMember_201" xlink:to="lab_embi_SeriesBWarrantMember_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SeriesBWarrantsMember_202" xlink:to="lab_embi_SeriesBWarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SeriesBWarrantsMember_202" xlink:to="lab_embi_SeriesBWarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SeriesBWarrantsMember_202" xlink:to="lab_embi_SeriesBWarrantsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SeriesFPreferredStockPutOptionLiabilityMember_203" xlink:to="lab_embi_SeriesFPreferredStockPutOptionLiabilityMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SeriesFPreferredStockPutOptionLiabilityMember_203" xlink:to="lab_embi_SeriesFPreferredStockPutOptionLiabilityMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SeriesFPreferredStockPutOptionLiabilityMember_203" xlink:to="lab_embi_SeriesFPreferredStockPutOptionLiabilityMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ShareAndWarrantsIssuanceCosts_204" xlink:to="lab_embi_ShareAndWarrantsIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ShareAndWarrantsIssuanceCosts_204" xlink:to="lab_embi_ShareAndWarrantsIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ShareAndWarrantsIssuanceCosts_204" xlink:to="lab_embi_ShareAndWarrantsIssuanceCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ShareIssuanceCosts_205" xlink:to="lab_embi_ShareIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ShareIssuanceCosts_205" xlink:to="lab_embi_ShareIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ShareIssuanceCosts_205" xlink:to="lab_embi_ShareIssuanceCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SignificantContractsAbstract_206" xlink:to="lab_embi_SignificantContractsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SignificantContractsLineItems_207" xlink:to="lab_embi_SignificantContractsLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SignificantContractsLineItems_207" xlink:to="lab_embi_SignificantContractsLineItems_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SignificantContractsTable_208" xlink:to="lab_embi_SignificantContractsTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SignificantContractsTextBlock_209" xlink:to="lab_embi_SignificantContractsTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SignificantContractsTextBlock_209" xlink:to="lab_embi_SignificantContractsTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SignificantContractsTextBlock_209" xlink:to="lab_embi_SignificantContractsTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SignificantContractsTextBlock_209" xlink:to="lab_embi_SignificantContractsTextBlock_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants_210" xlink:to="lab_embi_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants_210" xlink:to="lab_embi_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants_210" xlink:to="lab_embi_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockBasedCompensationForNonEmployeesPolicyTextBlock_211" xlink:to="lab_embi_StockBasedCompensationForNonEmployeesPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockBasedCompensationForNonEmployeesPolicyTextBlock_211" xlink:to="lab_embi_StockBasedCompensationForNonEmployeesPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockBasedCompensationForNonEmployeesPolicyTextBlock_211" xlink:to="lab_embi_StockBasedCompensationForNonEmployeesPolicyTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockIssuanceCosts_212" xlink:to="lab_embi_StockIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockIssuanceCosts_212" xlink:to="lab_embi_StockIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockIssuanceCosts_212" xlink:to="lab_embi_StockIssuanceCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockIssuedDuringPeriodSharesIssuedForStockBasedCompensationExpense_213" xlink:to="lab_embi_StockIssuedDuringPeriodSharesIssuedForStockBasedCompensationExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockIssuedDuringPeriodSharesIssuedForStockBasedCompensationExpense_213" xlink:to="lab_embi_StockIssuedDuringPeriodSharesIssuedForStockBasedCompensationExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockIssuedDuringPeriodSharesIssuedForStockBasedCompensationExpense_213" xlink:to="lab_embi_StockIssuedDuringPeriodSharesIssuedForStockBasedCompensationExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockIssuedDuringPeriodSharesNetOfIssuanceCosts_214" xlink:to="lab_embi_StockIssuedDuringPeriodSharesNetOfIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockIssuedDuringPeriodSharesNetOfIssuanceCosts_214" xlink:to="lab_embi_StockIssuedDuringPeriodSharesNetOfIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockIssuedDuringPeriodSharesNetOfIssuanceCosts_214" xlink:to="lab_embi_StockIssuedDuringPeriodSharesNetOfIssuanceCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockIssuedDuringPeriodSharesNetOfIssuanceCostsAndWarrants_215" xlink:to="lab_embi_StockIssuedDuringPeriodSharesNetOfIssuanceCostsAndWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockIssuedDuringPeriodSharesNetOfIssuanceCostsAndWarrants_215" xlink:to="lab_embi_StockIssuedDuringPeriodSharesNetOfIssuanceCostsAndWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockIssuedDuringPeriodSharesNetOfIssuanceCostsAndWarrants_215" xlink:to="lab_embi_StockIssuedDuringPeriodSharesNetOfIssuanceCostsAndWarrants_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockIssuedDuringPeriodSharesSeriesBWarrantExercises_216" xlink:to="lab_embi_StockIssuedDuringPeriodSharesSeriesBWarrantExercises_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockIssuedDuringPeriodSharesSeriesBWarrantExercises_216" xlink:to="lab_embi_StockIssuedDuringPeriodSharesSeriesBWarrantExercises_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockIssuedDuringPeriodSharesSeriesBWarrantExercises_216" xlink:to="lab_embi_StockIssuedDuringPeriodSharesSeriesBWarrantExercises_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockIssuedDuringPeriodValueNetOfIssuanceCosts_217" xlink:to="lab_embi_StockIssuedDuringPeriodValueNetOfIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockIssuedDuringPeriodValueNetOfIssuanceCosts_217" xlink:to="lab_embi_StockIssuedDuringPeriodValueNetOfIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockIssuedDuringPeriodValueNetOfIssuanceCosts_217" xlink:to="lab_embi_StockIssuedDuringPeriodValueNetOfIssuanceCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockIssuedDuringPeriodValueNetOfIssuanceCostsAndWarrants_218" xlink:to="lab_embi_StockIssuedDuringPeriodValueNetOfIssuanceCostsAndWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockIssuedDuringPeriodValueNetOfIssuanceCostsAndWarrants_218" xlink:to="lab_embi_StockIssuedDuringPeriodValueNetOfIssuanceCostsAndWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockIssuedDuringPeriodValueNetOfIssuanceCostsAndWarrants_218" xlink:to="lab_embi_StockIssuedDuringPeriodValueNetOfIssuanceCostsAndWarrants_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockIssuedDuringPeriodValueSeriesBWarrantExercises_219" xlink:to="lab_embi_StockIssuedDuringPeriodValueSeriesBWarrantExercises_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockIssuedDuringPeriodValueSeriesBWarrantExercises_219" xlink:to="lab_embi_StockIssuedDuringPeriodValueSeriesBWarrantExercises_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockIssuedDuringPeriodValueSeriesBWarrantExercises_219" xlink:to="lab_embi_StockIssuedDuringPeriodValueSeriesBWarrantExercises_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SubsequentFinancingPurchasePriceDescription_220" xlink:to="lab_embi_SubsequentFinancingPurchasePriceDescription_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SubsequentFinancingPurchasePriceDescription_220" xlink:to="lab_embi_SubsequentFinancingPurchasePriceDescription_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SubsequentFinancingPurchasePriceDescription_220" xlink:to="lab_embi_SubsequentFinancingPurchasePriceDescription_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TermOfAgreement_221" xlink:to="lab_embi_TermOfAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TermOfAgreement_221" xlink:to="lab_embi_TermOfAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TermOfAgreement_221" xlink:to="lab_embi_TermOfAgreement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TermOfWarrant_222" xlink:to="lab_embi_TermOfWarrant_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TermOfWarrant_222" xlink:to="lab_embi_TermOfWarrant_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TermOfWarrant_222" xlink:to="lab_embi_TermOfWarrant_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TermOfWarrant_222" xlink:to="lab_embi_TermOfWarrant_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TermOfWarrants_223" xlink:to="lab_embi_TermOfWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TermOfWarrants_223" xlink:to="lab_embi_TermOfWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TermOfWarrants_223" xlink:to="lab_embi_TermOfWarrants_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TermsOfAgreementRenewed_224" xlink:to="lab_embi_TermsOfAgreementRenewed_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TermsOfAgreementRenewed_224" xlink:to="lab_embi_TermsOfAgreementRenewed_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TermsOfAgreementRenewed_224" xlink:to="lab_embi_TermsOfAgreementRenewed_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TotalExpenseIncurredUnderAgreement_225" xlink:to="lab_embi_TotalExpenseIncurredUnderAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TotalExpenseIncurredUnderAgreement_225" xlink:to="lab_embi_TotalExpenseIncurredUnderAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TotalExpenseIncurredUnderAgreement_225" xlink:to="lab_embi_TotalExpenseIncurredUnderAgreement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandEighteenEmeraldFinancingWarrantsMember_226" xlink:to="lab_embi_TwoThousandEighteenEmeraldFinancingWarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandEighteenEmeraldFinancingWarrantsMember_226" xlink:to="lab_embi_TwoThousandEighteenEmeraldFinancingWarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandEighteenEmeraldFinancingWarrantsMember_226" xlink:to="lab_embi_TwoThousandEighteenEmeraldFinancingWarrantsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_227" xlink:to="lab_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_227" xlink:to="lab_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_227" xlink:to="lab_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_227" xlink:to="lab_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_227" xlink:to="lab_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandFifteenCommonStockWarrantsMember_228" xlink:to="lab_embi_TwoThousandFifteenCommonStockWarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandFifteenCommonStockWarrantsMember_228" xlink:to="lab_embi_TwoThousandFifteenCommonStockWarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandFifteenCommonStockWarrantsMember_228" xlink:to="lab_embi_TwoThousandFifteenCommonStockWarrantsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember_229" xlink:to="lab_embi_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember_229" xlink:to="lab_embi_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember_229" xlink:to="lab_embi_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember_230" xlink:to="lab_embi_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember_230" xlink:to="lab_embi_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember_230" xlink:to="lab_embi_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandNineteenCommonStockWarrantsMember_231" xlink:to="lab_embi_TwoThousandNineteenCommonStockWarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandNineteenCommonStockWarrantsMember_231" xlink:to="lab_embi_TwoThousandNineteenCommonStockWarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandNineteenCommonStockWarrantsMember_231" xlink:to="lab_embi_TwoThousandNineteenCommonStockWarrantsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember_232" xlink:to="lab_embi_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember_232" xlink:to="lab_embi_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember_232" xlink:to="lab_embi_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember_233" xlink:to="lab_embi_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember_233" xlink:to="lab_embi_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember_233" xlink:to="lab_embi_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember_234" xlink:to="lab_embi_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember_234" xlink:to="lab_embi_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember_234" xlink:to="lab_embi_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember_235" xlink:to="lab_embi_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember_235" xlink:to="lab_embi_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember_235" xlink:to="lab_embi_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_Um5050ProdrugAndUm8930AnalogAgreementsMember_236" xlink:to="lab_embi_Um5050ProdrugAndUm8930AnalogAgreementsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_Um5050ProdrugAndUm8930AnalogAgreementsMember_236" xlink:to="lab_embi_Um5050ProdrugAndUm8930AnalogAgreementsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_Um5050ProdrugAndUm8930AnalogAgreementsMember_236" xlink:to="lab_embi_Um5050ProdrugAndUm8930AnalogAgreementsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_Um5070LicenseAgreementMember_237" xlink:to="lab_embi_Um5070LicenseAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_Um5070LicenseAgreementMember_237" xlink:to="lab_embi_Um5070LicenseAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_Um5070LicenseAgreementMember_237" xlink:to="lab_embi_Um5070LicenseAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_UnamortizedDebtDiscountPeriod_238" xlink:to="lab_embi_UnamortizedDebtDiscountPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_UnamortizedDebtDiscountPeriod_238" xlink:to="lab_embi_UnamortizedDebtDiscountPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_UnamortizedDebtDiscountPeriod_238" xlink:to="lab_embi_UnamortizedDebtDiscountPeriod_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_UniversityOfMississippiAgreementsLineItems_239" xlink:to="lab_embi_UniversityOfMississippiAgreementsLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_UniversityOfMississippiAgreementsLineItems_239" xlink:to="lab_embi_UniversityOfMississippiAgreementsLineItems_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_UniversityOfMississippiAgreementsTable_240" xlink:to="lab_embi_UniversityOfMississippiAgreementsTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_UniversityOfMississippiAgreementsTable_240" xlink:to="lab_embi_UniversityOfMississippiAgreementsTable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_UniversityOfMississippiMember_241" xlink:to="lab_embi_UniversityOfMississippiMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_UniversityOfMississippiMember_241" xlink:to="lab_embi_UniversityOfMississippiMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_UniversityOfMississippiMember_241" xlink:to="lab_embi_UniversityOfMississippiMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_UnvestedRestrictedStockMember_242" xlink:to="lab_embi_UnvestedRestrictedStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_UnvestedRestrictedStockMember_242" xlink:to="lab_embi_UnvestedRestrictedStockMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_UnvestedRestrictedStockMember_242" xlink:to="lab_embi_UnvestedRestrictedStockMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_UpfrontPayment_243" xlink:to="lab_embi_UpfrontPayment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_UpfrontPayment_243" xlink:to="lab_embi_UpfrontPayment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_UpfrontPayment_243" xlink:to="lab_embi_UpfrontPayment_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ValueOfCommonStockCalledByWarrants_244" xlink:to="lab_embi_ValueOfCommonStockCalledByWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ValueOfCommonStockCalledByWarrants_244" xlink:to="lab_embi_ValueOfCommonStockCalledByWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ValueOfCommonStockCalledByWarrants_244" xlink:to="lab_embi_ValueOfCommonStockCalledByWarrants_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_WarrantsAndDerivativeLiabilitiesAbstract_245" xlink:to="lab_embi_WarrantsAndDerivativeLiabilitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_WarrantsAndDerivativeLiabilitiesTextBlock_246" xlink:to="lab_embi_WarrantsAndDerivativeLiabilitiesTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_WarrantsAndDerivativeLiabilitiesTextBlock_246" xlink:to="lab_embi_WarrantsAndDerivativeLiabilitiesTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_WarrantsAndDerivativeLiabilitiesTextBlock_246" xlink:to="lab_embi_WarrantsAndDerivativeLiabilitiesTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_247" xlink:to="lab_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_247" xlink:to="lab_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_247" xlink:to="lab_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock_248" xlink:to="lab_embi_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock_248" xlink:to="lab_embi_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock_248" xlink:to="lab_embi_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_WarrantsLiabilityClassifiedMember_249" xlink:to="lab_embi_WarrantsLiabilityClassifiedMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_WarrantsLiabilityClassifiedMember_249" xlink:to="lab_embi_WarrantsLiabilityClassifiedMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_WarrantsLiabilityClassifiedMember_249" xlink:to="lab_embi_WarrantsLiabilityClassifiedMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_WarrantsMember_250" xlink:to="lab_embi_WarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_WarrantsMember_250" xlink:to="lab_embi_WarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_WarrantsMember_250" xlink:to="lab_embi_WarrantsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_WarrantsVestedAndOutstanding_251" xlink:to="lab_embi_WarrantsVestedAndOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_WarrantsVestedAndOutstanding_251" xlink:to="lab_embi_WarrantsVestedAndOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_WarrantsVestedAndOutstanding_251" xlink:to="lab_embi_WarrantsVestedAndOutstanding_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_WorkingCapitalDeficit_252" xlink:to="lab_embi_WorkingCapitalDeficit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_WorkingCapitalDeficit_252" xlink:to="lab_embi_WorkingCapitalDeficit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_WorkingCapitalDeficit_252" xlink:to="lab_embi_WorkingCapitalDeficit_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_WorkingCapitalDeficit_252" xlink:to="lab_embi_WorkingCapitalDeficit_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_BoardOfDirectorsChairmanMember_253" xlink:to="lab_srt_BoardOfDirectorsChairmanMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_BoardOfDirectorsChairmanMember_253" xlink:to="lab_srt_BoardOfDirectorsChairmanMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_BoardOfDirectorsChairmanMember_253" xlink:to="lab_srt_BoardOfDirectorsChairmanMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefExecutiveOfficerMember_254" xlink:to="lab_srt_ChiefExecutiveOfficerMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefExecutiveOfficerMember_254" xlink:to="lab_srt_ChiefExecutiveOfficerMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefExecutiveOfficerMember_254" xlink:to="lab_srt_ChiefExecutiveOfficerMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefFinancialOfficerMember_255" xlink:to="lab_srt_ChiefFinancialOfficerMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefFinancialOfficerMember_255" xlink:to="lab_srt_ChiefFinancialOfficerMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_256" xlink:to="lab_srt_MaximumMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_256" xlink:to="lab_srt_MaximumMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_256" xlink:to="lab_srt_MaximumMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_257" xlink:to="lab_srt_MinimumMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_257" xlink:to="lab_srt_MinimumMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_257" xlink:to="lab_srt_MinimumMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_258" xlink:to="lab_srt_RangeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember_259" xlink:to="lab_srt_RangeMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis_260" xlink:to="lab_srt_TitleOfIndividualAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_261" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_262" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_262" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_263" xlink:to="lab_us-gaap_AccountsPayableCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_263" xlink:to="lab_us-gaap_AccountsPayableCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_264" xlink:to="lab_us-gaap_AccountsPayableRelatedPartiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_264" xlink:to="lab_us-gaap_AccountsPayableRelatedPartiesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_265" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_265" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalariesCurrent_266" xlink:to="lab_us-gaap_AccruedSalariesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalariesCurrent_266" xlink:to="lab_us-gaap_AccruedSalariesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock_267" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock_267" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_268" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_268" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices_269" xlink:to="lab_us-gaap_AdjustmentOfWarrantsGrantedForServices_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices_269" xlink:to="lab_us-gaap_AdjustmentOfWarrantsGrantedForServices_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_270" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_270" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_271" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_271" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_271" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_272" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_272" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_273" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_273" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_274" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_274" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_274" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium_275" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium_275" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium_275" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts_276" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts_276" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts_276" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_277" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_277" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_278" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_279" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_280" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfLand_281" xlink:to="lab_us-gaap_AreaOfLand_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfLand_281" xlink:to="lab_us-gaap_AreaOfLand_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfLand_281" xlink:to="lab_us-gaap_AreaOfLand_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_282" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_283" xlink:to="lab_us-gaap_Assets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_283" xlink:to="lab_us-gaap_Assets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_283" xlink:to="lab_us-gaap_Assets_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_284" xlink:to="lab_us-gaap_AssetsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_284" xlink:to="lab_us-gaap_AssetsAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_285" xlink:to="lab_us-gaap_AssetsCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_285" xlink:to="lab_us-gaap_AssetsCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_285" xlink:to="lab_us-gaap_AssetsCurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_286" xlink:to="lab_us-gaap_AssetsCurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_286" xlink:to="lab_us-gaap_AssetsCurrentAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_287" xlink:to="lab_us-gaap_AwardTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_288" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_288" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BridgeLoan_289" xlink:to="lab_us-gaap_BridgeLoan_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BridgeLoan_289" xlink:to="lab_us-gaap_BridgeLoan_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BridgeLoan_289" xlink:to="lab_us-gaap_BridgeLoan_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BridgeLoanMember_290" xlink:to="lab_us-gaap_BridgeLoanMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BridgeLoanMember_290" xlink:to="lab_us-gaap_BridgeLoanMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash_291" xlink:to="lab_us-gaap_Cash_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash_291" xlink:to="lab_us-gaap_Cash_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash_291" xlink:to="lab_us-gaap_Cash_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash_291" xlink:to="lab_us-gaap_Cash_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash_291" xlink:to="lab_us-gaap_Cash_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash_291" xlink:to="lab_us-gaap_Cash_5"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_292" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_292" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_292" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_292" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_292" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_293" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_293" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_293" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_294" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_294" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_295" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_295" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_296" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_296" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_296" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_296" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_296" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_297" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_297" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_298" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_298" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain_299" xlink:to="lab_us-gaap_ClassOfStockDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_300" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_301" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_302" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_302" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_302" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_302" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_303" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_304" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_304" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_305" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_305" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_305" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_305" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_305" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding_306" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding_306" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_307" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_308" xlink:to="lab_us-gaap_CommitmentsAndContingencies_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_308" xlink:to="lab_us-gaap_CommitmentsAndContingencies_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_309" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_310" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_310" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_311" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_311" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_312" xlink:to="lab_us-gaap_CommonStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_312" xlink:to="lab_us-gaap_CommonStockMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_313" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_313" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_313" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_314" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_314" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_315" xlink:to="lab_us-gaap_CommonStockSharesIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_315" xlink:to="lab_us-gaap_CommonStockSharesIssued_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_316" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_316" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_316" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_316" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_316" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_317" xlink:to="lab_us-gaap_CommonStockValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_317" xlink:to="lab_us-gaap_CommonStockValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_318" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_318" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockAmountConverted1_319" xlink:to="lab_us-gaap_ConversionOfStockAmountConverted1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockAmountConverted1_319" xlink:to="lab_us-gaap_ConversionOfStockAmountConverted1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockAmountConverted1_319" xlink:to="lab_us-gaap_ConversionOfStockAmountConverted1_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesConverted1_320" xlink:to="lab_us-gaap_ConversionOfStockSharesConverted1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesConverted1_320" xlink:to="lab_us-gaap_ConversionOfStockSharesConverted1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesIssued1_321" xlink:to="lab_us-gaap_ConversionOfStockSharesIssued1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesIssued1_321" xlink:to="lab_us-gaap_ConversionOfStockSharesIssued1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebt_322" xlink:to="lab_us-gaap_ConvertibleDebt_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebt_322" xlink:to="lab_us-gaap_ConvertibleDebt_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtCurrent_323" xlink:to="lab_us-gaap_ConvertibleDebtCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtCurrent_323" xlink:to="lab_us-gaap_ConvertibleDebtCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtCurrent_323" xlink:to="lab_us-gaap_ConvertibleDebtCurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtCurrent_323" xlink:to="lab_us-gaap_ConvertibleDebtCurrent_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtCurrent_323" xlink:to="lab_us-gaap_ConvertibleDebtCurrent_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember_324" xlink:to="lab_us-gaap_ConvertibleDebtMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember_324" xlink:to="lab_us-gaap_ConvertibleDebtMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtNoncurrent_325" xlink:to="lab_us-gaap_ConvertibleDebtNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtNoncurrent_325" xlink:to="lab_us-gaap_ConvertibleDebtNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtNoncurrent_325" xlink:to="lab_us-gaap_ConvertibleDebtNoncurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtSecuritiesMember_326" xlink:to="lab_us-gaap_ConvertibleDebtSecuritiesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtSecuritiesMember_326" xlink:to="lab_us-gaap_ConvertibleDebtSecuritiesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtTableTextBlock_327" xlink:to="lab_us-gaap_ConvertibleDebtTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtTableTextBlock_327" xlink:to="lab_us-gaap_ConvertibleDebtTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_328" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_328" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_328" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract_329" xlink:to="lab_us-gaap_DebtDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_330" xlink:to="lab_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_330" xlink:to="lab_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_331" xlink:to="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_331" xlink:to="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_331" xlink:to="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_332" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_332" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_332" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_332" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_333" xlink:to="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_333" xlink:to="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_334" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_334" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_335" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_335" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_336" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_336" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_337" xlink:to="lab_us-gaap_DebtInstrumentLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDate_338" xlink:to="lab_us-gaap_DebtInstrumentMaturityDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDate_338" xlink:to="lab_us-gaap_DebtInstrumentMaturityDate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDate_338" xlink:to="lab_us-gaap_DebtInstrumentMaturityDate_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_339" xlink:to="lab_us-gaap_DebtInstrumentTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_340" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_340" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_340" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtPolicyTextBlock_341" xlink:to="lab_us-gaap_DebtPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtPolicyTextBlock_341" xlink:to="lab_us-gaap_DebtPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsCurrentGross_342" xlink:to="lab_us-gaap_DeferredFinanceCostsCurrentGross_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsCurrentGross_342" xlink:to="lab_us-gaap_DeferredFinanceCostsCurrentGross_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsCurrentGross_342" xlink:to="lab_us-gaap_DeferredFinanceCostsCurrentGross_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_343" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_343" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_344" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_344" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_344" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_345" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_345" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_346" xlink:to="lab_us-gaap_DeferredTaxAssetsGross_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_346" xlink:to="lab_us-gaap_DeferredTaxAssetsGross_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_346" xlink:to="lab_us-gaap_DeferredTaxAssetsGross_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_347" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_347" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_348" xlink:to="lab_us-gaap_DeferredTaxAssetsNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_348" xlink:to="lab_us-gaap_DeferredTaxAssetsNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_349" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_349" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_350" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_350" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_350" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_351" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_351" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther_352" xlink:to="lab_us-gaap_DeferredTaxAssetsOther_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther_352" xlink:to="lab_us-gaap_DeferredTaxAssetsOther_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsStateTaxes_353" xlink:to="lab_us-gaap_DeferredTaxAssetsStateTaxes_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsStateTaxes_353" xlink:to="lab_us-gaap_DeferredTaxAssetsStateTaxes_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsStateTaxes_353" xlink:to="lab_us-gaap_DeferredTaxAssetsStateTaxes_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_354" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_354" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_354" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities_355" xlink:to="lab_us-gaap_DeferredTaxLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities_355" xlink:to="lab_us-gaap_DeferredTaxLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_356" xlink:to="lab_us-gaap_Depreciation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_356" xlink:to="lab_us-gaap_Depreciation_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_357" xlink:to="lab_us-gaap_DerivativeContractTypeDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_358" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities_359" xlink:to="lab_us-gaap_DerivativeLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities_359" xlink:to="lab_us-gaap_DerivativeLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities_359" xlink:to="lab_us-gaap_DerivativeLiabilities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities_359" xlink:to="lab_us-gaap_DerivativeLiabilities_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesCurrent_360" xlink:to="lab_us-gaap_DerivativeLiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesCurrent_360" xlink:to="lab_us-gaap_DerivativeLiabilitiesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesCurrent_360" xlink:to="lab_us-gaap_DerivativeLiabilitiesCurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesNoncurrent_361" xlink:to="lab_us-gaap_DerivativeLiabilitiesNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesNoncurrent_361" xlink:to="lab_us-gaap_DerivativeLiabilitiesNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesNoncurrent_361" xlink:to="lab_us-gaap_DerivativeLiabilitiesNoncurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesNoncurrent_361" xlink:to="lab_us-gaap_DerivativeLiabilitiesNoncurrent_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock_362" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock_362" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecurities_363" xlink:to="lab_us-gaap_DilutiveSecurities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecurities_363" xlink:to="lab_us-gaap_DilutiveSecurities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecurities_363" xlink:to="lab_us-gaap_DilutiveSecurities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_364" xlink:to="lab_us-gaap_DilutiveSecuritiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_364" xlink:to="lab_us-gaap_DilutiveSecuritiesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_365" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_366" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_366" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_367" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_367" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromRelatedParties_368" xlink:to="lab_us-gaap_DueFromRelatedParties_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromRelatedParties_368" xlink:to="lab_us-gaap_DueFromRelatedParties_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_369" xlink:to="lab_us-gaap_EarningsPerShareAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_370" xlink:to="lab_us-gaap_EarningsPerShareBasic_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_370" xlink:to="lab_us-gaap_EarningsPerShareBasic_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_370" xlink:to="lab_us-gaap_EarningsPerShareBasic_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_370" xlink:to="lab_us-gaap_EarningsPerShareBasic_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_370" xlink:to="lab_us-gaap_EarningsPerShareBasic_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_371" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_371" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_371" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_372" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_372" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_372" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_372" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_372" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_373" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_373" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_374" xlink:to="lab_us-gaap_EarningsPerShareDiluted_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_374" xlink:to="lab_us-gaap_EarningsPerShareDiluted_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_374" xlink:to="lab_us-gaap_EarningsPerShareDiluted_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_374" xlink:to="lab_us-gaap_EarningsPerShareDiluted_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_375" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_375" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_375" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_376" xlink:to="lab_us-gaap_EarningsPerShareDilutedLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_377" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_377" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_378" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_378" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_379" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_379" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_380" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_380" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_380" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_381" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_381" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_381" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_382" xlink:to="lab_us-gaap_EmployeeStockOptionMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_382" xlink:to="lab_us-gaap_EmployeeStockOptionMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_382" xlink:to="lab_us-gaap_EmployeeStockOptionMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_383" xlink:to="lab_us-gaap_EquityAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_383" xlink:to="lab_us-gaap_EquityAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_384" xlink:to="lab_us-gaap_EquityComponentDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_384" xlink:to="lab_us-gaap_EquityComponentDomain_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtinguishmentOfDebtGainLossIncomeTax_385" xlink:to="lab_us-gaap_ExtinguishmentOfDebtGainLossIncomeTax_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtinguishmentOfDebtGainLossIncomeTax_385" xlink:to="lab_us-gaap_ExtinguishmentOfDebtGainLossIncomeTax_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants_386" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants_386" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants_386" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants_386" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants_386" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_387" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_387" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_388" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_388" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_389" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_390" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember_391" xlink:to="lab_us-gaap_ForeignCountryMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember_391" xlink:to="lab_us-gaap_ForeignCountryMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_392" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_392" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_392" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_393" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_393" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_393" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_393" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_393" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_394" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_394" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_394" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_395" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_395" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_395" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_395" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_396" xlink:to="lab_us-gaap_IncomeStatementAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_396" xlink:to="lab_us-gaap_IncomeStatementAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_397" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_398" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_399" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_400" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_401" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_401" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_402" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_402" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid_403" xlink:to="lab_us-gaap_IncomeTaxesPaid_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid_403" xlink:to="lab_us-gaap_IncomeTaxesPaid_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_404" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_404" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_404" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_404" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_404" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_405" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_405" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock_406" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock_406" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_407" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_407" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_408" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_408" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_409" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_409" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_410" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_410" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_410" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_411" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_411" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_412" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_412" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_413" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_413" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable_414" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable_414" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_415" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_415" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_416" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_416" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_417" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_417" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_418" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_418" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_419" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_419" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_420" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_420" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_421" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntellectualPropertyMember_422" xlink:to="lab_us-gaap_IntellectualPropertyMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntellectualPropertyMember_422" xlink:to="lab_us-gaap_IntellectualPropertyMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_423" xlink:to="lab_us-gaap_InterestExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseOther_424" xlink:to="lab_us-gaap_InterestExpenseOther_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseOther_424" xlink:to="lab_us-gaap_InterestExpenseOther_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet_425" xlink:to="lab_us-gaap_InterestPaidNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet_425" xlink:to="lab_us-gaap_InterestPaidNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest_426" xlink:to="lab_us-gaap_InvestmentIncomeInterest_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest_426" xlink:to="lab_us-gaap_InvestmentIncomeInterest_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest_426" xlink:to="lab_us-gaap_InvestmentIncomeInterest_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestorMember_427" xlink:to="lab_us-gaap_InvestorMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestorMember_427" xlink:to="lab_us-gaap_InvestorMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember_428" xlink:to="lab_us-gaap_IPOMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember_428" xlink:to="lab_us-gaap_IPOMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAndRentalExpense_429" xlink:to="lab_us-gaap_LeaseAndRentalExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAndRentalExpense_429" xlink:to="lab_us-gaap_LeaseAndRentalExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_430" xlink:to="lab_us-gaap_Liabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_430" xlink:to="lab_us-gaap_Liabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_431" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_431" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_431" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_432" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_432" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_433" xlink:to="lab_us-gaap_LiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_433" xlink:to="lab_us-gaap_LiabilitiesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_434" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_434" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_435" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_435" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_436" xlink:to="lab_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_436" xlink:to="lab_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_437" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_437" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_438" xlink:to="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_438" xlink:to="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_439" xlink:to="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_439" xlink:to="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_440" xlink:to="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_440" xlink:to="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_441" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_441" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_441" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExercisePriceMember_442" xlink:to="lab_us-gaap_MeasurementInputExercisePriceMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExercisePriceMember_442" xlink:to="lab_us-gaap_MeasurementInputExercisePriceMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedDividendRateMember_443" xlink:to="lab_us-gaap_MeasurementInputExpectedDividendRateMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedDividendRateMember_443" xlink:to="lab_us-gaap_MeasurementInputExpectedDividendRateMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember_444" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember_444" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputOfferedPriceMember_445" xlink:to="lab_us-gaap_MeasurementInputOfferedPriceMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputOfferedPriceMember_445" xlink:to="lab_us-gaap_MeasurementInputOfferedPriceMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputOfferedPriceMember_445" xlink:to="lab_us-gaap_MeasurementInputOfferedPriceMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember_446" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember_446" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_447" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_447" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_448" xlink:to="lab_us-gaap_MeasurementInputTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_449" xlink:to="lab_us-gaap_MeasurementInputTypeDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_450" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_450" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_451" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_451" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_452" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_452" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_453" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_453" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_454" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_454" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_454" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_455" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_455" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_456" xlink:to="lab_us-gaap_NetIncomeLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_456" xlink:to="lab_us-gaap_NetIncomeLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_456" xlink:to="lab_us-gaap_NetIncomeLoss_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_456" xlink:to="lab_us-gaap_NetIncomeLoss_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_456" xlink:to="lab_us-gaap_NetIncomeLoss_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_456" xlink:to="lab_us-gaap_NetIncomeLoss_5"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_456" xlink:to="lab_us-gaap_NetIncomeLoss_6"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_457" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_457" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_457" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_457" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_457" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_458" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_458" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_459" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_459" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_459" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_460" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_460" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseMember_461" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseMember_461" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments_462" xlink:to="lab_us-gaap_NumberOfReportableSegments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments_462" xlink:to="lab_us-gaap_NumberOfReportableSegments_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_463" xlink:to="lab_us-gaap_OperatingExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_463" xlink:to="lab_us-gaap_OperatingExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_463" xlink:to="lab_us-gaap_OperatingExpenses_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_464" xlink:to="lab_us-gaap_OperatingExpensesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_464" xlink:to="lab_us-gaap_OperatingExpensesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_465" xlink:to="lab_us-gaap_OperatingIncomeLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_465" xlink:to="lab_us-gaap_OperatingIncomeLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_465" xlink:to="lab_us-gaap_OperatingIncomeLoss_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_465" xlink:to="lab_us-gaap_OperatingIncomeLoss_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_466" xlink:to="lab_us-gaap_OperatingLeasedAssetsLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseNet_467" xlink:to="lab_us-gaap_OperatingLeasesRentExpenseNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseNet_467" xlink:to="lab_us-gaap_OperatingLeasesRentExpenseNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards_468" xlink:to="lab_us-gaap_OperatingLossCarryforwards_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards_468" xlink:to="lab_us-gaap_OperatingLossCarryforwards_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_469" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_470" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_471" xlink:to="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_471" xlink:to="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent_472" xlink:to="lab_us-gaap_OtherAssetsCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent_472" xlink:to="lab_us-gaap_OtherAssetsCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_473" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_473" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_473" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDerivativeIssuanceCosts_474" xlink:to="lab_us-gaap_PaymentsOfDerivativeIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDerivativeIssuanceCosts_474" xlink:to="lab_us-gaap_PaymentsOfDerivativeIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDerivativeIssuanceCosts_474" xlink:to="lab_us-gaap_PaymentsOfDerivativeIssuanceCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDerivativeIssuanceCosts_474" xlink:to="lab_us-gaap_PaymentsOfDerivativeIssuanceCosts_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDerivativeIssuanceCosts_474" xlink:to="lab_us-gaap_PaymentsOfDerivativeIssuanceCosts_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_475" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_475" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_475" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireFurnitureAndFixtures_476" xlink:to="lab_us-gaap_PaymentsToAcquireFurnitureAndFixtures_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireFurnitureAndFixtures_476" xlink:to="lab_us-gaap_PaymentsToAcquireFurnitureAndFixtures_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_477" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_477" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_477" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis_478" xlink:to="lab_us-gaap_PlanNameAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain_479" xlink:to="lab_us-gaap_PlanNameDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockConversionBasis_480" xlink:to="lab_us-gaap_PreferredStockConversionBasis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockConversionBasis_480" xlink:to="lab_us-gaap_PreferredStockConversionBasis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockConvertibleConversionPriceDecrease_481" xlink:to="lab_us-gaap_PreferredStockConvertibleConversionPriceDecrease_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockConvertibleConversionPriceDecrease_481" xlink:to="lab_us-gaap_PreferredStockConvertibleConversionPriceDecrease_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockLiquidationPreferenceValue_482" xlink:to="lab_us-gaap_PreferredStockLiquidationPreferenceValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockLiquidationPreferenceValue_482" xlink:to="lab_us-gaap_PreferredStockLiquidationPreferenceValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_483" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_483" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_483" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_484" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_484" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_484" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_485" xlink:to="lab_us-gaap_PreferredStockSharesIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_485" xlink:to="lab_us-gaap_PreferredStockSharesIssued_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_485" xlink:to="lab_us-gaap_PreferredStockSharesIssued_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_485" xlink:to="lab_us-gaap_PreferredStockSharesIssued_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding_486" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding_486" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding_486" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding_486" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_487" xlink:to="lab_us-gaap_PreferredStockValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_487" xlink:to="lab_us-gaap_PreferredStockValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_487" xlink:to="lab_us-gaap_PreferredStockValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_487" xlink:to="lab_us-gaap_PreferredStockValue_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_487" xlink:to="lab_us-gaap_PreferredStockValue_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent_488" xlink:to="lab_us-gaap_PrepaidExpenseCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent_488" xlink:to="lab_us-gaap_PrepaidExpenseCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember_489" xlink:to="lab_us-gaap_PrivatePlacementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember_489" xlink:to="lab_us-gaap_PrivatePlacementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt_490" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt_490" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt_490" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_491" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_491" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_491" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_491" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_491" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_491" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_5"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_492" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_492" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_493" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_493" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_493" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_493" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_494" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_494" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_494" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfWarrants_495" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfWarrants_495" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfWarrants_495" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfWarrants_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_496" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_496" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_496" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromOtherDebt_497" xlink:to="lab_us-gaap_ProceedsFromOtherDebt_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromOtherDebt_497" xlink:to="lab_us-gaap_ProceedsFromOtherDebt_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRelatedPartyDebt_498" xlink:to="lab_us-gaap_ProceedsFromRelatedPartyDebt_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRelatedPartyDebt_498" xlink:to="lab_us-gaap_ProceedsFromRelatedPartyDebt_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises_499" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises_499" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDepreciationMethods_500" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDepreciationMethods_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDepreciationMethods_500" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDepreciationMethods_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_501" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_501" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_502" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_503" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_503" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_503" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_503" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_504" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_504" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_505" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_505" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemablePreferredStockDividends_506" xlink:to="lab_us-gaap_RedeemablePreferredStockDividends_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemablePreferredStockDividends_506" xlink:to="lab_us-gaap_RedeemablePreferredStockDividends_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemablePreferredStockDividends_506" xlink:to="lab_us-gaap_RedeemablePreferredStockDividends_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain_507" xlink:to="lab_us-gaap_RelatedPartyDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_508" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_509" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_510" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_511" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_511" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfConvertibleDebt_512" xlink:to="lab_us-gaap_RepaymentsOfConvertibleDebt_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfConvertibleDebt_512" xlink:to="lab_us-gaap_RepaymentsOfConvertibleDebt_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfConvertibleDebt_512" xlink:to="lab_us-gaap_RepaymentsOfConvertibleDebt_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfConvertibleDebt_512" xlink:to="lab_us-gaap_RepaymentsOfConvertibleDebt_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_513" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_513" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_513" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_514" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_514" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_515" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_515" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_515" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_515" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockExpense_516" xlink:to="lab_us-gaap_RestrictedStockExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockExpense_516" xlink:to="lab_us-gaap_RestrictedStockExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember_517" xlink:to="lab_us-gaap_RestrictedStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember_517" xlink:to="lab_us-gaap_RestrictedStockMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember_517" xlink:to="lab_us-gaap_RestrictedStockMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_518" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_518" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_518" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_518" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_519" xlink:to="lab_us-gaap_RetainedEarningsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_519" xlink:to="lab_us-gaap_RetainedEarningsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock_520" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock_520" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_521" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_521" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_522" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_523" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_523" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_523" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare_524" xlink:to="lab_us-gaap_SaleOfStockPricePerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare_524" xlink:to="lab_us-gaap_SaleOfStockPricePerShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_525" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_526" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_526" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_527" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_527" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_528" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_528" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_529" xlink:to="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_529" xlink:to="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_530" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_530" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_531" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_532" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_532" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_533" xlink:to="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_533" xlink:to="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_534" xlink:to="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_535" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_536" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_537" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_538" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_538" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_539" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_539" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_540" xlink:to="lab_us-gaap_ScheduleOfShortTermDebtTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_541" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_541" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_542" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_542" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_543" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_543" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember_544" xlink:to="lab_us-gaap_SeriesAPreferredStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember_544" xlink:to="lab_us-gaap_SeriesAPreferredStockMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember_544" xlink:to="lab_us-gaap_SeriesAPreferredStockMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesBPreferredStockMember_545" xlink:to="lab_us-gaap_SeriesBPreferredStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesBPreferredStockMember_545" xlink:to="lab_us-gaap_SeriesBPreferredStockMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesBPreferredStockMember_545" xlink:to="lab_us-gaap_SeriesBPreferredStockMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesCPreferredStockMember_546" xlink:to="lab_us-gaap_SeriesCPreferredStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesCPreferredStockMember_546" xlink:to="lab_us-gaap_SeriesCPreferredStockMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesCPreferredStockMember_546" xlink:to="lab_us-gaap_SeriesCPreferredStockMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesDPreferredStockMember_547" xlink:to="lab_us-gaap_SeriesDPreferredStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesDPreferredStockMember_547" xlink:to="lab_us-gaap_SeriesDPreferredStockMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesDPreferredStockMember_547" xlink:to="lab_us-gaap_SeriesDPreferredStockMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesEPreferredStockMember_548" xlink:to="lab_us-gaap_SeriesEPreferredStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesEPreferredStockMember_548" xlink:to="lab_us-gaap_SeriesEPreferredStockMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesFPreferredStockMember_549" xlink:to="lab_us-gaap_SeriesFPreferredStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesFPreferredStockMember_549" xlink:to="lab_us-gaap_SeriesFPreferredStockMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesFPreferredStockMember_549" xlink:to="lab_us-gaap_SeriesFPreferredStockMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_550" xlink:to="lab_us-gaap_ShareBasedCompensation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_550" xlink:to="lab_us-gaap_ShareBasedCompensation_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_550" xlink:to="lab_us-gaap_ShareBasedCompensation_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_551" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_551" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_551" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_552" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_552" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_553" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_553" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_553" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_554" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_554" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_554" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_555" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_555" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_555" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_556" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_556" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_557" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_557" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_557" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_558" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_558" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_559" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_559" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_559" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_559" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_560" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_560" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_561" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_561" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_562" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_562" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_563" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_563" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_564" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_564" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_565" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_566" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_566" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_567" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_567" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_567" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_568" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_568" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_568" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_569" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_569" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_570" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_570" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_571" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_571" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_571" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_572" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_572" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_572" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_572" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_573" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_573" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_573" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_573" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_573" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_574" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_574" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_575" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_575" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_576" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_576" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_576" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_576" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_576" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_577" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_577" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_578" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_578" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_578" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_579" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_579" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_579" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_580" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_580" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_581" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_581" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_581" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_582" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_582" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_582" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_583" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_583" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_583" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_584" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_584" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_584" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_585" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_585" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_585" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_586" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_586" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_587" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_587" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_588" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_588" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_589" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_590" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_590" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_591" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_591" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_591" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_592" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_592" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_592" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_593" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_593" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_593" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_594" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_594" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_595" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_595" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_596" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_596" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_596" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_597" xlink:to="lab_us-gaap_SharesIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_597" xlink:to="lab_us-gaap_SharesIssued_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_597" xlink:to="lab_us-gaap_SharesIssued_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_597" xlink:to="lab_us-gaap_SharesIssued_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare_598" xlink:to="lab_us-gaap_SharesIssuedPricePerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare_598" xlink:to="lab_us-gaap_SharesIssuedPricePerShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare_598" xlink:to="lab_us-gaap_SharesIssuedPricePerShare_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare_598" xlink:to="lab_us-gaap_SharesIssuedPricePerShare_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtLineItems_599" xlink:to="lab_us-gaap_ShortTermDebtLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_600" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_601" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_602" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_602" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis_603" xlink:to="lab_us-gaap_StatementClassOfStockAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_604" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_604" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_605" xlink:to="lab_us-gaap_StatementLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_606" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_606" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_607" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_607" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_608" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_609" xlink:to="lab_us-gaap_StatementTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_610" xlink:to="lab_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_610" xlink:to="lab_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_610" xlink:to="lab_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_611" xlink:to="lab_us-gaap_StockholdersEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_611" xlink:to="lab_us-gaap_StockholdersEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_611" xlink:to="lab_us-gaap_StockholdersEquity_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_611" xlink:to="lab_us-gaap_StockholdersEquity_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_611" xlink:to="lab_us-gaap_StockholdersEquity_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_611" xlink:to="lab_us-gaap_StockholdersEquity_5"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_611" xlink:to="lab_us-gaap_StockholdersEquity_6"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_612" xlink:to="lab_us-gaap_StockholdersEquityAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_612" xlink:to="lab_us-gaap_StockholdersEquityAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_613" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_613" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_614" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_614" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_615" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_615" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_615" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_616" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_616" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_616" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_616" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_617" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_617" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_617" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_618" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_618" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_618" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems_619" xlink:to="lab_us-gaap_SubsequentEventLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_620" xlink:to="lab_us-gaap_SubsequentEventMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_620" xlink:to="lab_us-gaap_SubsequentEventMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract_621" xlink:to="lab_us-gaap_SubsequentEventsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_622" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_622" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable_623" xlink:to="lab_us-gaap_SubsequentEventTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_624" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_625" xlink:to="lab_us-gaap_SubsequentEventTypeDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_626" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_627" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_627" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardLimitationsOnUse_628" xlink:to="lab_us-gaap_TaxCreditCarryforwardLimitationsOnUse_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardLimitationsOnUse_628" xlink:to="lab_us-gaap_TaxCreditCarryforwardLimitationsOnUse_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_629" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_629" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_629" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_629" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityLiquidationPreference_630" xlink:to="lab_us-gaap_TemporaryEquityLiquidationPreference_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityLiquidationPreference_630" xlink:to="lab_us-gaap_TemporaryEquityLiquidationPreference_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_631" xlink:to="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_631" xlink:to="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesAuthorized_632" xlink:to="lab_us-gaap_TemporaryEquitySharesAuthorized_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesAuthorized_632" xlink:to="lab_us-gaap_TemporaryEquitySharesAuthorized_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesIssued_633" xlink:to="lab_us-gaap_TemporaryEquitySharesIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesIssued_633" xlink:to="lab_us-gaap_TemporaryEquitySharesIssued_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding_634" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding_634" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding_634" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding_634" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_635" xlink:to="lab_us-gaap_TypeOfArrangementAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_636" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_636" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_636" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_637" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_637" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_638" xlink:to="lab_us-gaap_UseOfEstimates_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_638" xlink:to="lab_us-gaap_UseOfEstimates_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis_639" xlink:to="lab_us-gaap_VestingAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain_640" xlink:to="lab_us-gaap_VestingDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember_641" xlink:to="lab_us-gaap_WarrantMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember_641" xlink:to="lab_us-gaap_WarrantMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember_641" xlink:to="lab_us-gaap_WarrantMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_642" xlink:to="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstanding_643" xlink:to="lab_us-gaap_WarrantsAndRightsOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstanding_643" xlink:to="lab_us-gaap_WarrantsAndRightsOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstanding_643" xlink:to="lab_us-gaap_WarrantsAndRightsOutstanding_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_644" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_644" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_644" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm_645" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm_645" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm_645" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_646" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_646" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_646" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_646" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_647" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_647" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_647" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_647" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_648" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_648" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_648" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_648" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_648" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_649" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_649" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_1"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>embi-20191231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#DocumentAndEntityInformation" roleURI="http://www.emeraldbio.life/role/DocumentAndEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#ConsolidatedBalanceSheets" roleURI="http://www.emeraldbio.life/role/ConsolidatedBalanceSheets"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#Consolidatedbalancesheetsparentheticals" roleURI="http://www.emeraldbio.life/role/Consolidatedbalancesheetsparentheticals"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.emeraldbio.life/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.emeraldbio.life/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWSParentheticals" roleURI="http://www.emeraldbio.life/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSParentheticals"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#ConsolidatedStatementsOfStockholdersEquityDeficit" roleURI="http://www.emeraldbio.life/role/ConsolidatedStatementsOfStockholdersEquityDeficit"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#ConsolidatedStatementsOfStockholdersEquityDeficitParentheticals" roleURI="http://www.emeraldbio.life/role/ConsolidatedStatementsOfStockholdersEquityDeficitParentheticals"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#NatureOfOperationsAndBusinessActivities" roleURI="http://www.emeraldbio.life/role/NatureOfOperationsAndBusinessActivities"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#WarrantsAndDerivativeLiabilities" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#ConvertibleDebtRelatedParty" roleURI="http://www.emeraldbio.life/role/ConvertibleDebtRelatedParty"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#StockholdersEquityDeficitAndCapitalization" roleURI="http://www.emeraldbio.life/role/StockholdersEquityDeficitAndCapitalization"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#StockBasedCompensation" roleURI="http://www.emeraldbio.life/role/StockBasedCompensation"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#NetIncomeLossPerShareOfCommonStock" roleURI="http://www.emeraldbio.life/role/NetIncomeLossPerShareOfCommonStock"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#IncomeTaxes" roleURI="http://www.emeraldbio.life/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#SignificantContractsUniversityOfMississippi" roleURI="http://www.emeraldbio.life/role/SignificantContractsUniversityOfMississippi"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#COMMITMENTSANDCONTINGENCIES" roleURI="http://www.emeraldbio.life/role/COMMITMENTSANDCONTINGENCIES"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#RelatedPartyMatters" roleURI="http://www.emeraldbio.life/role/RelatedPartyMatters"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#SubsequentEvents" roleURI="http://www.emeraldbio.life/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPoliciesPolicies"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#WarrantsAndDerivativeLiabilitiesTables" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesTables"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#ConvertibleDebtRelatedPartyTables" roleURI="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyTables"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#StockBasedCompensationTables" roleURI="http://www.emeraldbio.life/role/StockBasedCompensationTables"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#Incometaxestables" roleURI="http://www.emeraldbio.life/role/Incometaxestables"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#NetIncomeLossPerShareOfCommonStockTables" roleURI="http://www.emeraldbio.life/role/NetIncomeLossPerShareOfCommonStockTables"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#NatureOfOperationsAndBusinessActivitiesDetailTextuals" roleURI="http://www.emeraldbio.life/role/NatureOfOperationsAndBusinessActivitiesDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#SummaryOfSignificantAccountingPoliciesDetailTextuals" roleURI="http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPoliciesDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#WarrantsAndDerivativeLiabilitiesDetails1" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails1"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#WarrantsAndDerivativeLiabilitiesDetails5" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails5"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#WarrantsAndDerivativeLiabilitiesDetails6" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails6"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#WarrantsAndDerivativeLiabilitiesDetails7" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails7"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#ConvertibleDebtRelatedPartyDetails" roleURI="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetails"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#ConvertibleDebtRelatedPartyDetails1" roleURI="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetails1"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#ConvertibleDebtRelatedPartyDetailTextuals" roleURI="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#ConvertibleDebtRelatedPartyDetailTextuals1" roleURI="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetailTextuals1"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#StockholdersEquityDeficitAndCapitalizationDetailTextuals" roleURI="http://www.emeraldbio.life/role/StockholdersEquityDeficitAndCapitalizationDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#StockholdersEquityDeficitAndCapitalizationDetailTextuals1" roleURI="http://www.emeraldbio.life/role/StockholdersEquityDeficitAndCapitalizationDetailTextuals1"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#StockBasedCompensationDetails" roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetails"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#StockBasedCompensationDetails1" roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetails1"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#StockBasedCompensationDetails2" roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetails2"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#StockBasedCompensationDetails3" roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetails3"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#StockBasedCompensationDetails4" roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetails4"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#StockBasedCompensationDetailTextuals" roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#StockBasedCompensationDetailTextuals1" roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetailTextuals1"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#StockBasedCompensationDetailTextuals2" roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetailTextuals2"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#SignificantContractsUniversityOfMississippiDetailTextuals" roleURI="http://www.emeraldbio.life/role/SignificantContractsUniversityOfMississippiDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#RelatedPartyMattersDetails" roleURI="http://www.emeraldbio.life/role/RelatedPartyMattersDetails"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#IncomeTaxesDetails1" roleURI="http://www.emeraldbio.life/role/IncomeTaxesDetails1"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#IncomeTaxesDetails2" roleURI="http://www.emeraldbio.life/role/IncomeTaxesDetails2"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#IncomeTaxesDetailTextuals" roleURI="http://www.emeraldbio.life/role/IncomeTaxesDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#NetIncomeLossPerShareOfCommonStockDetails" roleURI="http://www.emeraldbio.life/role/NetIncomeLossPerShareOfCommonStockDetails"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#NetIncomeLossPerShareOfCommonStockDetails1" roleURI="http://www.emeraldbio.life/role/NetIncomeLossPerShareOfCommonStockDetails1"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#WarrantsAndDerivativeLiabilitiesDetails2" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails2"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#WarrantsAndDerivativeLiabilitiesDetails3" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails3"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#WarrantsAndDerivativeLiabilitiesDetails4" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails4"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#WarrantsAndDerivativeLiabilitiesDetails" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#IncomeTaxesDetails" roleURI="http://www.emeraldbio.life/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#WarrantsAndDerivativeLiabilitiesDetailsTextuals" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetailsTextuals"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#IncomeTaxesDetails3" roleURI="http://www.emeraldbio.life/role/IncomeTaxesDetails3"/>
  <roleRef xlink:type="simple" xlink:href="embi-20191231.xsd#SubsequentEventsDetailTextuals" roleURI="http://www.emeraldbio.life/role/SubsequentEventsDetailTextuals"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_DocumentAndEntityInformationAbstract" xlink:label="loc_embi_DocumentAndEntityInformationAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_20"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityRegistrantName_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityCentralIndexKey_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_TradingSymbol_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityCurrentReportingStatus_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityVoluntaryFilers_5" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_CurrentFiscalYearEndDate_6" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityFilerCategory_7" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_8" order="70" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_9" order="80" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityPublicFloat_10" order="90" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentType_11" order="100" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentPeriodEndDate_12" order="110" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_AmendmentFlag_13" order="120" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentFiscalYearFocus_14" order="130" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_15" order="140" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntitySmallBusiness_16" order="150" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityEmergingGrowthCompany_17" order="160" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityExTransitionPeriod_18" order="170" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityShellCompany_19" order="180" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityInteractiveDataCurrent_20" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/ConsolidatedBalanceSheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_22"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_25"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_27"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_AssetsAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_AssetsCurrentAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_Cash_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_OtherAssetsCurrent_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_AssetsCurrent_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_Assets_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_10" xlink:to="loc_us-gaap_AccountsPayableCurrent_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_10" xlink:to="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_10" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_10" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_10" xlink:to="loc_us-gaap_LiabilitiesCurrent_14" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_16" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_16" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_16" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_17" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10" xlink:to="loc_us-gaap_Liabilities_19" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10" xlink:to="loc_us-gaap_CommitmentsAndContingencies_20" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10" xlink:to="loc_us-gaap_StockholdersEquityAbstract_21" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_21" xlink:to="loc_us-gaap_PreferredStockValue_21" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_21" xlink:to="loc_us-gaap_CommonStockValue_22" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_21" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_23" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_21" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_24" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_21" xlink:to="loc_us-gaap_StockholdersEquity_25" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_27" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/Consolidatedbalancesheetsparentheticals">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_PreferredStockSharesIssued_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesIssued_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ChangeInFairValueOfDerivativeLiabilities" xlink:label="loc_embi_ChangeInFairValueOfDerivativeLiabilities_6"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_FairValueOfDerivativeLiabilityInExcessOfProceeds" xlink:label="loc_embi_FairValueOfDerivativeLiabilityInExcessOfProceeds_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDerivativeIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDerivativeIssuanceCosts_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_21"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OperatingExpensesAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1" xlink:to="loc_us-gaap_OperatingExpenses_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OperatingIncomeLoss_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6" xlink:to="loc_embi_ChangeInFairValueOfDerivativeLiabilities_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6" xlink:to="loc_embi_FairValueOfDerivativeLiabilityInExcessOfProceeds_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6" xlink:to="loc_us-gaap_PaymentsOfDerivativeIssuanceCosts_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6" xlink:to="loc_us-gaap_InterestExpense_10" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6" xlink:to="loc_us-gaap_InvestmentIncomeInterest_11" order="50" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_12" order="60" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_15" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_NetIncomeLoss_16" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_17" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_17" xlink:to="loc_us-gaap_EarningsPerShareBasic_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_17" xlink:to="loc_us-gaap_EarningsPerShareDiluted_18" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_20" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_20" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_20" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_20" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_21" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_5"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_FairValueOfDerivativeLiabilityExcessOfProceeds" xlink:label="loc_embi_FairValueOfDerivativeLiabilityExcessOfProceeds_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDerivativeIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDerivativeIssuanceCosts_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_8"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_LossOnCommonStockIssuanceFromConversionOfAccruedInterest" xlink:label="loc_embi_LossOnCommonStockIssuanceFromConversionOfAccruedInterest_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_10"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_CommonStockIssuedForServices" xlink:label="loc_embi_CommonStockIssuedForServices_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_22"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_25"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_26"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ProceedsFromConvertibleMultiDrawCreditAgreement" xlink:label="loc_embi_ProceedsFromConvertibleMultiDrawCreditAgreement_27"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_RepaymentOfConvertibleMultiDrawCreditAgreement" xlink:label="loc_embi_RepaymentOfConvertibleMultiDrawCreditAgreement_28"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_29"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_31"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_32"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_33"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_34"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_34"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_34"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_35"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_36"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_CashPaidDuringPeriodForAbstract" xlink:label="loc_embi_CashPaidDuringPeriodForAbstract_38"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_38"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_39"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_41"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement" xlink:label="loc_embi_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement_41"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement" xlink:label="loc_embi_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement_42"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement" xlink:label="loc_embi_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement_43"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ExerciseOfWarrants" xlink:label="loc_embi_ExerciseOfWarrants_44"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_FairValueOfWarrantsIssuedInConnectionWithFinancings" xlink:label="loc_embi_FairValueOfWarrantsIssuedInConnectionWithFinancings_45"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_46"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_47"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock" xlink:label="loc_embi_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock_48"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_NetIncomeLoss_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_Depreciation_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_ShareBasedCompensation_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_5" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_embi_FairValueOfDerivativeLiabilityExcessOfProceeds_6" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_PaymentsOfDerivativeIssuanceCosts_7" order="50" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_8" order="60" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_embi_LossOnCommonStockIssuanceFromConversionOfAccruedInterest_9" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_10" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_embi_CommonStockIssuedForServices_11" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_12" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_12" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_12" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_13" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_12" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_14" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_12" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_15" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_12" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_16" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_19" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_21" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_21" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_21" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_21" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_22" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_24" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveVerboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_25" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_26" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24" xlink:to="loc_embi_ProceedsFromConvertibleMultiDrawCreditAgreement_27" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24" xlink:to="loc_embi_RepaymentOfConvertibleMultiDrawCreditAgreement_28" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_29" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_31" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_32" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_33" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_SupplementalCashFlowElementsAbstract_34" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_34" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_34" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_34" xlink:to="loc_us-gaap_Cash_34" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_34" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_35" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_34" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_36" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_34" xlink:to="loc_embi_CashPaidDuringPeriodForAbstract_38" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_CashPaidDuringPeriodForAbstract_38" xlink:to="loc_us-gaap_InterestPaidNet_38" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_CashPaidDuringPeriodForAbstract_38" xlink:to="loc_us-gaap_IncomeTaxesPaid_39" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_34" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_41" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_41" xlink:to="loc_embi_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement_41" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_41" xlink:to="loc_embi_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement_42" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_41" xlink:to="loc_embi_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement_43" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_41" xlink:to="loc_embi_ExerciseOfWarrants_44" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_41" xlink:to="loc_embi_FairValueOfWarrantsIssuedInConnectionWithFinancings_45" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_41" xlink:to="loc_us-gaap_ConversionOfStockAmountConverted1_46" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_41" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_47" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_41" xlink:to="loc_embi_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock_48" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSParentheticals">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_1"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ConvertibleMultiDrawCreditAgreementIssuanceCosts" xlink:label="loc_embi_ConvertibleMultiDrawCreditAgreementIssuanceCosts_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_embi_ConvertibleMultiDrawCreditAgreementIssuanceCosts_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/ConsolidatedStatementsOfStockholdersEquityDeficit">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="loc_us-gaap_SeriesFPreferredStockMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_16"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_StockIssuedDuringPeriodSharesIssuedForStockBasedCompensationExpense" xlink:label="loc_embi_StockIssuedDuringPeriodSharesIssuedForStockBasedCompensationExpense_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_19"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_StockIssuedDuringPeriodValueNetOfIssuanceCosts" xlink:label="loc_embi_StockIssuedDuringPeriodValueNetOfIssuanceCosts_20"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_StockIssuedDuringPeriodSharesNetOfIssuanceCosts" xlink:label="loc_embi_StockIssuedDuringPeriodSharesNetOfIssuanceCosts_21"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_StockIssuedDuringPeriodValueNetOfIssuanceCostsAndWarrants" xlink:label="loc_embi_StockIssuedDuringPeriodValueNetOfIssuanceCostsAndWarrants_22"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_StockIssuedDuringPeriodSharesNetOfIssuanceCostsAndWarrants" xlink:label="loc_embi_StockIssuedDuringPeriodSharesNetOfIssuanceCostsAndWarrants_23"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue" xlink:label="loc_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue_24"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares" xlink:label="loc_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares_25"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ConversionOfSeriesDPreferredStockToCommonStock" xlink:label="loc_embi_ConversionOfSeriesDPreferredStockToCommonStock_26"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ConversionOfSeriesDPreferredStockToCommonStockShares" xlink:label="loc_embi_ConversionOfSeriesDPreferredStockToCommonStockShares_27"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ConversionOfSeriesFPreferredStockToCommonStockValue" xlink:label="loc_embi_ConversionOfSeriesFPreferredStockToCommonStockValue_28"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ConversionOfSeriesFPreferredStockToCommonStockShares" xlink:label="loc_embi_ConversionOfSeriesFPreferredStockToCommonStockShares_29"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest" xlink:label="loc_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest_30"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterestShares" xlink:label="loc_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterestShares_31"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue" xlink:label="loc_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_32"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue" xlink:label="loc_embi_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_33"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_StockIssuedDuringPeriodValueSeriesBWarrantExercises" xlink:label="loc_embi_StockIssuedDuringPeriodValueSeriesBWarrantExercises_34"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_StockIssuedDuringPeriodSharesSeriesBWarrantExercises" xlink:label="loc_embi_StockIssuedDuringPeriodSharesSeriesBWarrantExercises_35"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_FinancingValueWarrantExercise" xlink:label="loc_embi_FinancingValueWarrantExercise_36"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_FinancingSharesWarrantExercise" xlink:label="loc_embi_FinancingSharesWarrantExercise_37"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_38"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_39"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_40"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_41"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_42"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1" xlink:to="loc_us-gaap_SeriesFPreferredStockMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1" xlink:to="loc_us-gaap_SeriesDPreferredStockMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1" xlink:to="loc_us-gaap_ClassOfStockDomain_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6" xlink:to="loc_us-gaap_CommonStockMember_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6" xlink:to="loc_us-gaap_WarrantMember_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6" xlink:to="loc_us-gaap_RetainedEarningsMember_9" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6" xlink:to="loc_us-gaap_EquityComponentDomain_10" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_12" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_12" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_12" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_13" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_12" xlink:to="loc_us-gaap_StockholdersEquity_14" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_12" xlink:to="loc_us-gaap_SharesIssued_15" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_12" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_16" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_12" xlink:to="loc_embi_StockIssuedDuringPeriodSharesIssuedForStockBasedCompensationExpense_17" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_12" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_18" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_12" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_19" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_12" xlink:to="loc_embi_StockIssuedDuringPeriodValueNetOfIssuanceCosts_20" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_12" xlink:to="loc_embi_StockIssuedDuringPeriodSharesNetOfIssuanceCosts_21" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_12" xlink:to="loc_embi_StockIssuedDuringPeriodValueNetOfIssuanceCostsAndWarrants_22" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_12" xlink:to="loc_embi_StockIssuedDuringPeriodSharesNetOfIssuanceCostsAndWarrants_23" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_12" xlink:to="loc_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue_24" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_12" xlink:to="loc_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares_25" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_12" xlink:to="loc_embi_ConversionOfSeriesDPreferredStockToCommonStock_26" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_12" xlink:to="loc_embi_ConversionOfSeriesDPreferredStockToCommonStockShares_27" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_12" xlink:to="loc_embi_ConversionOfSeriesFPreferredStockToCommonStockValue_28" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_12" xlink:to="loc_embi_ConversionOfSeriesFPreferredStockToCommonStockShares_29" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_12" xlink:to="loc_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest_30" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_12" xlink:to="loc_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterestShares_31" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_12" xlink:to="loc_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_32" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_12" xlink:to="loc_embi_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_33" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_12" xlink:to="loc_embi_StockIssuedDuringPeriodValueSeriesBWarrantExercises_34" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_12" xlink:to="loc_embi_StockIssuedDuringPeriodSharesSeriesBWarrantExercises_35" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_12" xlink:to="loc_embi_FinancingValueWarrantExercise_36" order="240" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_12" xlink:to="loc_embi_FinancingSharesWarrantExercise_37" order="250" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_12" xlink:to="loc_us-gaap_NetIncomeLoss_38" order="260" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_12" xlink:to="loc_us-gaap_StockholdersEquity_39" order="270" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_12" xlink:to="loc_us-gaap_SharesIssued_40" order="280" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_12" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_41" order="290" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_12" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_42" order="300" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/ConsolidatedStatementsOfStockholdersEquityDeficitParentheticals">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="loc_us-gaap_SeriesFPreferredStockMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_6"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ShareIssuanceCosts" xlink:label="loc_embi_ShareIssuanceCosts_6"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ShareAndWarrantsIssuanceCosts" xlink:label="loc_embi_ShareAndWarrantsIssuanceCosts_7"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ConversionPricePerShare" xlink:label="loc_embi_ConversionPricePerShare_8"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ConversionLiabilityIntoCommonStockPerShare" xlink:label="loc_embi_ConversionLiabilityIntoCommonStockPerShare_9"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1" xlink:to="loc_us-gaap_ClassOfStockDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1" xlink:to="loc_us-gaap_SeriesFPreferredStockMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1" xlink:to="loc_us-gaap_SeriesDPreferredStockMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_embi_ShareIssuanceCosts_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_embi_ShareAndWarrantsIssuanceCosts_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_embi_ConversionPricePerShare_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_embi_ConversionLiabilityIntoCommonStockPerShare_9" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/NatureOfOperationsAndBusinessActivities">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilities">
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_WarrantsAndDerivativeLiabilitiesAbstract" xlink:label="loc_embi_WarrantsAndDerivativeLiabilitiesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_WarrantsAndDerivativeLiabilitiesTextBlock" xlink:label="loc_embi_WarrantsAndDerivativeLiabilitiesTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_WarrantsAndDerivativeLiabilitiesAbstract_0" xlink:to="loc_embi_WarrantsAndDerivativeLiabilitiesTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/ConvertibleDebtRelatedParty">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ConvertibleDebtRelatedPartyTextBlock" xlink:label="loc_embi_ConvertibleDebtRelatedPartyTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_embi_ConvertibleDebtRelatedPartyTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockholdersEquityDeficitAndCapitalization">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockBasedCompensation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/NetIncomeLossPerShareOfCommonStock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/IncomeTaxes">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/SignificantContractsUniversityOfMississippi">
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_SignificantContractsAbstract" xlink:label="loc_embi_SignificantContractsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_SignificantContractsTextBlock" xlink:label="loc_embi_SignificantContractsTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_SignificantContractsAbstract_0" xlink:to="loc_embi_SignificantContractsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/COMMITMENTSANDCONTINGENCIES">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/RelatedPartyMatters">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPoliciesPolicies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_2"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_RisksAndUncertaintiesPolicyTextBlock" xlink:label="loc_embi_RisksAndUncertaintiesPolicyTextBlock_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_9"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock" xlink:label="loc_embi_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="loc_us-gaap_DebtPolicyTextBlock_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_16"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_UseOfEstimates_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_embi_RisksAndUncertaintiesPolicyTextBlock_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_9" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_embi_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock_10" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_DebtPolicyTextBlock_11" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_12" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_13" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_14" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_15" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_16" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesTables">
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_WarrantsAndDerivativeLiabilitiesAbstract" xlink:label="loc_embi_WarrantsAndDerivativeLiabilitiesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_DerivativeLiabilitiesTable" xlink:label="loc_embi_DerivativeLiabilitiesTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_EmeraldFinancingMember" xlink:label="loc_embi_EmeraldFinancingMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_4"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_TwoThousandNineteenCommonStockWarrantsMember" xlink:label="loc_embi_TwoThousandNineteenCommonStockWarrantsMember_4"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_SeriesBWarrantMember" xlink:label="loc_embi_SeriesBWarrantMember_5"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" xlink:label="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_6"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember" xlink:label="loc_embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_7"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_DerivativeLiabilitiesLineItems" xlink:label="loc_embi_DerivativeLiabilitiesLineItems_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_12"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ScheduleOfAdjustmentForDifferenceBetweenFairValueOfWarrantLiabilitiesAndTotalProceedsReceivedTableTextBlock" xlink:label="loc_embi_ScheduleOfAdjustmentForDifferenceBetweenFairValueOfWarrantLiabilitiesAndTotalProceedsReceivedTableTextBlock_13"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ScheduleOfAssumptionsUsedToComputeFairValueOfWarrantsTableTextBlock" xlink:label="loc_embi_ScheduleOfAssumptionsUsedToComputeFairValueOfWarrantsTableTextBlock_14"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_WarrantsAndDerivativeLiabilitiesAbstract_0" xlink:to="loc_embi_DerivativeLiabilitiesTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DerivativeLiabilitiesTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_embi_EmeraldFinancingMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DerivativeLiabilitiesTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4" xlink:to="loc_embi_TwoThousandNineteenCommonStockWarrantsMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4" xlink:to="loc_embi_SeriesBWarrantMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4" xlink:to="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4" xlink:to="loc_embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DerivativeLiabilitiesTable_1" xlink:to="loc_embi_DerivativeLiabilitiesLineItems_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_10" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_10" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_10" xlink:to="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_10" xlink:to="loc_embi_ScheduleOfAdjustmentForDifferenceBetweenFairValueOfWarrantLiabilitiesAndTotalProceedsReceivedTableTextBlock_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_10" xlink:to="loc_embi_ScheduleOfAssumptionsUsedToComputeFairValueOfWarrantsTableTextBlock_14" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ScheduleOfInterestExpenseTableTextBlock" xlink:label="loc_embi_ScheduleOfInterestExpenseTableTextBlock_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_ConvertibleDebtTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_embi_ScheduleOfInterestExpenseTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockBasedCompensationTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_5"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_OmnibusIncentivePlan2014Member" xlink:label="loc_embi_OmnibusIncentivePlan2014Member_5"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_AwardsGrantedOutside2014PlanMember" xlink:label="loc_embi_AwardsGrantedOutside2014PlanMember_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_12"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:to="loc_us-gaap_RestrictedStockMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_PlanNameAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_5" xlink:to="loc_us-gaap_PlanNameDomain_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_5" xlink:to="loc_embi_OmnibusIncentivePlan2014Member_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_5" xlink:to="loc_embi_AwardsGrantedOutside2014PlanMember_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" xlink:to="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/Incometaxestables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/NetIncomeLossPerShareOfCommonStockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/NatureOfOperationsAndBusinessActivitiesDetailTextuals">
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_NatureOfOperationsAndBusinessActivitiesAbstract" xlink:label="loc_embi_NatureOfOperationsAndBusinessActivitiesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_NatureOfOperationsAndBusinessActivitiesTable" xlink:label="loc_embi_NatureOfOperationsAndBusinessActivitiesTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_EmeraldFinancingMember" xlink:label="loc_embi_EmeraldFinancingMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_MultiDrawCreditAgreementMember" xlink:label="loc_embi_MultiDrawCreditAgreementMember_4"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_NatureOfOperationsAndBusinessActivitiesLineItems" xlink:label="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_12"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ProceedsFromConvertibleMultiDrawCreditAgreement" xlink:label="loc_embi_ProceedsFromConvertibleMultiDrawCreditAgreement_13"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesAbstract_0" xlink:to="loc_embi_NatureOfOperationsAndBusinessActivitiesTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_embi_EmeraldFinancingMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4" xlink:to="loc_embi_MultiDrawCreditAgreementMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesTable_1" xlink:to="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_7" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_7" xlink:to="loc_us-gaap_Cash_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_7" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_7" xlink:to="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_11" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_7" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_12" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_7" xlink:to="loc_embi_ProceedsFromConvertibleMultiDrawCreditAgreement_13" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPoliciesDetailTextuals">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:label="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDepreciationMethods" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDepreciationMethods_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_5"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDepreciationMethods_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_TwoThousandNineteenCommonStockWarrantsMember" xlink:label="loc_embi_TwoThousandNineteenCommonStockWarrantsMember_1"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_PricingModelAxis" xlink:label="loc_embi_PricingModelAxis_4"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_PricingModelDomain" xlink:label="loc_embi_PricingModelDomain_4"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_PricingModelMember" xlink:label="loc_embi_PricingModelMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputOfferedPriceMember" xlink:label="loc_us-gaap_MeasurementInputOfferedPriceMember_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_20"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandNineteenCommonStockWarrantsMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_embi_PricingModelAxis_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_PricingModelAxis_4" xlink:to="loc_embi_PricingModelDomain_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_PricingModelDomain_4" xlink:to="loc_embi_PricingModelMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_7" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_7" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_7" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_7" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_7" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_7" xlink:to="loc_us-gaap_MeasurementInputOfferedPriceMember_11" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_srt_RangeAxis_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_14" xlink:to="loc_srt_RangeMember_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_14" xlink:to="loc_srt_MinimumMember_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_14" xlink:to="loc_srt_MaximumMember_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_18" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_18" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_18" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_19" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_18" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_20" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails5">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_4"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_PricingModelAxis" xlink:label="loc_embi_PricingModelAxis_7"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_PricingModelDomain" xlink:label="loc_embi_PricingModelDomain_7"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_PricingModelMember" xlink:label="loc_embi_PricingModelMember_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_10"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember" xlink:label="loc_embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_15"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_embi_PricingModelAxis_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_PricingModelAxis_7" xlink:to="loc_embi_PricingModelDomain_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_PricingModelDomain_7" xlink:to="loc_embi_PricingModelMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_10" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_10" xlink:to="loc_embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_13" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_13" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_13" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_15" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails6">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_DerivativeLiabilitiesTable" xlink:label="loc_embi_DerivativeLiabilitiesTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_EmeraldFinancingMember" xlink:label="loc_embi_EmeraldFinancingMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_4"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_SeriesBPreferredStockConversionLiabilityMember" xlink:label="loc_embi_SeriesBPreferredStockConversionLiabilityMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_7"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember" xlink:label="loc_embi_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_7"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_SeriesBWarrantMember" xlink:label="loc_embi_SeriesBWarrantMember_8"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember" xlink:label="loc_embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_9"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_DerivativeLiabilitiesLineItems" xlink:label="loc_embi_DerivativeLiabilitiesLineItems_12"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_FairValueOfDerivativeLiabilitiesRollForward" xlink:label="loc_embi_FairValueOfDerivativeLiabilitiesRollForward_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_12"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_FairValueOfWarrantsIssued" xlink:label="loc_embi_FairValueOfWarrantsIssued_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_14"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ReclassificationOfDerivativesToEquity" xlink:label="loc_embi_ReclassificationOfDerivativesToEquity_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_18"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0" xlink:to="loc_embi_DerivativeLiabilitiesTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DerivativeLiabilitiesTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_embi_EmeraldFinancingMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DerivativeLiabilitiesTable_1" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_4" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4" xlink:to="loc_embi_SeriesBPreferredStockConversionLiabilityMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DerivativeLiabilitiesTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7" xlink:to="loc_embi_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7" xlink:to="loc_embi_SeriesBWarrantMember_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7" xlink:to="loc_embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DerivativeLiabilitiesTable_1" xlink:to="loc_embi_DerivativeLiabilitiesLineItems_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_12" xlink:to="loc_embi_FairValueOfDerivativeLiabilitiesRollForward_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_FairValueOfDerivativeLiabilitiesRollForward_12" xlink:to="loc_us-gaap_DerivativeLiabilities_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_FairValueOfDerivativeLiabilitiesRollForward_12" xlink:to="loc_embi_FairValueOfWarrantsIssued_13" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_FairValueOfDerivativeLiabilitiesRollForward_12" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_14" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_FairValueOfDerivativeLiabilitiesRollForward_12" xlink:to="loc_embi_ReclassificationOfDerivativesToEquity_15" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_FairValueOfDerivativeLiabilitiesRollForward_12" xlink:to="loc_us-gaap_DerivativeLiabilities_16" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_FairValueOfDerivativeLiabilitiesRollForward_12" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_17" order="50" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_FairValueOfDerivativeLiabilitiesRollForward_12" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_18" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails7">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_DerivativeLiabilitiesTable" xlink:label="loc_embi_DerivativeLiabilitiesTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_EmeraldFinancingMember" xlink:label="loc_embi_EmeraldFinancingMember_1"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_DerivativeLiabilitiesLineItems" xlink:label="loc_embi_DerivativeLiabilitiesLineItems_4"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_FairValueOfWarrantsIssued" xlink:label="loc_embi_FairValueOfWarrantsIssued_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_6"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0" xlink:to="loc_embi_DerivativeLiabilitiesTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DerivativeLiabilitiesTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_embi_EmeraldFinancingMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DerivativeLiabilitiesTable_1" xlink:to="loc_embi_DerivativeLiabilitiesLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_4" xlink:to="loc_embi_FairValueOfWarrantsIssued_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_4" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_4" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_4"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_EmeraldHealthSciencesIncMember" xlink:label="loc_embi_EmeraldHealthSciencesIncMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaap_ShortTermDebtLineItems_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsCurrentGross" xlink:label="loc_us-gaap_DeferredFinanceCostsCurrentGross_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaap_ConvertibleDebt_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_12"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_1" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_1" xlink:to="loc_us-gaap_ConvertibleDebtMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_dei_LegalEntityAxis_4" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_4" xlink:to="loc_dei_EntityDomain_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4" xlink:to="loc_embi_EmeraldHealthSciencesIncMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_us-gaap_ShortTermDebtLineItems_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_7" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_7" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_7" xlink:to="loc_us-gaap_DeferredFinanceCostsCurrentGross_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_7" xlink:to="loc_us-gaap_ConvertibleDebt_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_7" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_11" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_7" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_12" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_CouponInterestExpense" xlink:label="loc_embi_CouponInterestExpense_1"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_NonCashInterestExpenseAbstract" xlink:label="loc_embi_NonCashInterestExpenseAbstract_2"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_AmortizationOfDebtDiscount" xlink:label="loc_embi_AmortizationOfDebtDiscount_2"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_AmortizationOfTransactionCosts" xlink:label="loc_embi_AmortizationOfTransactionCosts_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseOther" xlink:label="loc_us-gaap_InterestExpenseOther_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_5"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_embi_CouponInterestExpense_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_embi_NonCashInterestExpenseAbstract_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NonCashInterestExpenseAbstract_2" xlink:to="loc_embi_AmortizationOfDebtDiscount_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NonCashInterestExpenseAbstract_2" xlink:to="loc_embi_AmortizationOfTransactionCosts_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NonCashInterestExpenseAbstract_2" xlink:to="loc_us-gaap_InterestExpenseOther_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NonCashInterestExpenseAbstract_2" xlink:to="loc_us-gaap_InterestExpense_5" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetailTextuals">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_EmeraldFinancingMember" xlink:label="loc_embi_EmeraldFinancingMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_MultiDrawCreditAgreementMember" xlink:label="loc_embi_MultiDrawCreditAgreementMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityAverageOutstandingAmount" xlink:label="loc_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_11"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase" xlink:label="loc_embi_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_13"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_AmountOfEachWarrantOutstanding" xlink:label="loc_embi_AmountOfEachWarrantOutstanding_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_17"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_AllocationOfDebtOnBasisOfRelativeFairValue" xlink:label="loc_embi_AllocationOfDebtOnBasisOfRelativeFairValue_18"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_AllocationOfWarrantOnBasisOfRelativeFairValue" xlink:label="loc_embi_AllocationOfWarrantOnBasisOfRelativeFairValue_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_21"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_FairValueOfDerivativeLiabilityInExcessOfProceeds" xlink:label="loc_embi_FairValueOfDerivativeLiabilityInExcessOfProceeds_22"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_25"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ConvertibleMultiDrawCreditAgreementIssuanceCosts" xlink:label="loc_embi_ConvertibleMultiDrawCreditAgreementIssuanceCosts_26"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_27"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_FairValueOfUnderlyingShares" xlink:label="loc_embi_FairValueOfUnderlyingShares_28"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_29"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_DebtInstrumentTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_embi_EmeraldFinancingMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4" xlink:to="loc_embi_MultiDrawCreditAgreementMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_DebtInstrumentLineItems_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7" xlink:to="loc_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_11" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7" xlink:to="loc_embi_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase_12" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_13" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7" xlink:to="loc_embi_AmountOfEachWarrantOutstanding_14" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_15" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_16" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_17" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7" xlink:to="loc_embi_AllocationOfDebtOnBasisOfRelativeFairValue_18" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7" xlink:to="loc_embi_AllocationOfWarrantOnBasisOfRelativeFairValue_19" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7" xlink:to="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_20" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7" xlink:to="loc_us-gaap_DerivativeLiabilities_21" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7" xlink:to="loc_embi_FairValueOfDerivativeLiabilityInExcessOfProceeds_22" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_23" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_24" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_25" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7" xlink:to="loc_embi_ConvertibleMultiDrawCreditAgreementIssuanceCosts_26" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7" xlink:to="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_27" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7" xlink:to="loc_embi_FairValueOfUnderlyingShares_28" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_29" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetailTextuals1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BridgeLoanMember" xlink:label="loc_us-gaap_BridgeLoanMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_SecuredPromissoryNoteAndSecurityAgreementMember" xlink:label="loc_embi_SecuredPromissoryNoteAndSecurityAgreementMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_7"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_EmeraldHealthSciencesIncMember" xlink:label="loc_embi_EmeraldHealthSciencesIncMember_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaap_ShortTermDebtLineItems_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BridgeLoan" xlink:label="loc_us-gaap_BridgeLoan_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_18"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_AdditionalConversionLiability" xlink:label="loc_embi_AdditionalConversionLiability_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_22"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_23"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_1" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_1" xlink:to="loc_us-gaap_BridgeLoanMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4" xlink:to="loc_embi_SecuredPromissoryNoteAndSecurityAgreementMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_dei_LegalEntityAxis_7" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_7" xlink:to="loc_dei_EntityDomain_7" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_7" xlink:to="loc_embi_EmeraldHealthSciencesIncMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_10" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_10" xlink:to="loc_us-gaap_SubsequentEventMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_us-gaap_ShortTermDebtLineItems_13" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_13" xlink:to="loc_us-gaap_BridgeLoan_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_13" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_13" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_15" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_13" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_16" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_13" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_17" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_13" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_18" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_13" xlink:to="loc_embi_AdditionalConversionLiability_19" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_13" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_20" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_13" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_21" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_13" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_22" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_13" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_23" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockholdersEquityDeficitAndCapitalizationDetailTextuals">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_EquityTable" xlink:label="loc_embi_EquityTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_SecuritiesPurchaseAgreementMember" xlink:label="loc_embi_SecuritiesPurchaseAgreementMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_4"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_EmeraldHealthSciencesIncMember" xlink:label="loc_embi_EmeraldHealthSciencesIncMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaap_InvestorMember_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_14"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_TwoThousandEighteenEmeraldFinancingWarrantsMember" xlink:label="loc_embi_TwoThousandEighteenEmeraldFinancingWarrantsMember_14"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_SeriesBWarrantsMember" xlink:label="loc_embi_SeriesBWarrantsMember_15"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_EquityLineItems" xlink:label="loc_embi_EquityLineItems_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_21"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ClassOfWarrantOrRightWarrantsExercise" xlink:label="loc_embi_ClassOfWarrantOrRightWarrantsExercise_22"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_IntrinsicValueOfWarrantExercises" xlink:label="loc_embi_IntrinsicValueOfWarrantExercises_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_25"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_26"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_27"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BridgeLoan" xlink:label="loc_us-gaap_BridgeLoan_28"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_SubsequentFinancingPurchasePriceDescription" xlink:label="loc_embi_SubsequentFinancingPurchasePriceDescription_29"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_TermOfWarrants" xlink:label="loc_embi_TermOfWarrants_30"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_EmeraldFinancingIssuanceCosts" xlink:label="loc_embi_EmeraldFinancingIssuanceCosts_31"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDerivativeIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDerivativeIssuanceCosts_32"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ReductionToAdditionalPaidInCapitalFromTheIssuanceOfCommonStock" xlink:label="loc_embi_ReductionToAdditionalPaidInCapitalFromTheIssuanceOfCommonStock_33"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_embi_EquityTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_embi_SecuritiesPurchaseAgreementMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityTable_1" xlink:to="loc_dei_LegalEntityAxis_4" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_4" xlink:to="loc_dei_EntityDomain_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4" xlink:to="loc_embi_EmeraldHealthSciencesIncMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7" xlink:to="loc_us-gaap_RelatedPartyDomain_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_7" xlink:to="loc_us-gaap_InvestorMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_10" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_10" xlink:to="loc_us-gaap_IPOMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_10" xlink:to="loc_us-gaap_PrivatePlacementMember_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_14" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_14" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_14" xlink:to="loc_embi_TwoThousandEighteenEmeraldFinancingWarrantsMember_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_14" xlink:to="loc_embi_SeriesBWarrantsMember_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityTable_1" xlink:to="loc_embi_EquityLineItems_18" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityLineItems_18" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityLineItems_18" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_19" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityLineItems_18" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_20" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityLineItems_18" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_21" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityLineItems_18" xlink:to="loc_embi_ClassOfWarrantOrRightWarrantsExercise_22" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityLineItems_18" xlink:to="loc_embi_IntrinsicValueOfWarrantExercises_23" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityLineItems_18" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_24" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityLineItems_18" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_25" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityLineItems_18" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_26" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityLineItems_18" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_27" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityLineItems_18" xlink:to="loc_us-gaap_BridgeLoan_28" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityLineItems_18" xlink:to="loc_embi_SubsequentFinancingPurchasePriceDescription_29" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityLineItems_18" xlink:to="loc_embi_TermOfWarrants_30" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityLineItems_18" xlink:to="loc_embi_EmeraldFinancingIssuanceCosts_31" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityLineItems_18" xlink:to="loc_us-gaap_PaymentsOfDerivativeIssuanceCosts_32" order="140" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityLineItems_18" xlink:to="loc_embi_ReductionToAdditionalPaidInCapitalFromTheIssuanceOfCommonStock_33" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockholdersEquityDeficitAndCapitalizationDetailTextuals1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_EquityTable" xlink:label="loc_embi_EquityTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="loc_us-gaap_SeriesFPreferredStockMember_3"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_EquityLineItems" xlink:label="loc_embi_EquityLineItems_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_11"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_embi_EquityTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1" xlink:to="loc_us-gaap_ClassOfStockDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1" xlink:to="loc_us-gaap_SeriesDPreferredStockMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1" xlink:to="loc_us-gaap_SeriesFPreferredStockMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityTable_1" xlink:to="loc_embi_EquityLineItems_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityLineItems_6" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityLineItems_6" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityLineItems_6" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityLineItems_6" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_9" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityLineItems_6" xlink:to="loc_us-gaap_PreferredStockSharesIssued_10" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityLineItems_6" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_11" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockBasedCompensationDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_OmnibusIncentivePlan2014Member" xlink:label="loc_embi_OmnibusIncentivePlan2014Member_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_PlanNameAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1" xlink:to="loc_us-gaap_PlanNameDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1" xlink:to="loc_embi_OmnibusIncentivePlan2014Member_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockBasedCompensationDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_OmnibusIncentivePlan2014Member" xlink:label="loc_embi_OmnibusIncentivePlan2014Member_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_25"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_26"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_27"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_28"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_PlanNameAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1" xlink:to="loc_us-gaap_PlanNameDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1" xlink:to="loc_embi_OmnibusIncentivePlan2014Member_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_11" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_12" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_13" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_16" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_17" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_18" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_19" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_20" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_21" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_23" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_23" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_23" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_23" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_24" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_23" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_25" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_26" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_23" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_27" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_28" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockBasedCompensationDetails2">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_8"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_OmnibusIncentivePlan2014Member" xlink:label="loc_embi_OmnibusIncentivePlan2014Member_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_14"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_srt_RangeAxis_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_4" xlink:to="loc_srt_RangeMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4" xlink:to="loc_srt_MinimumMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4" xlink:to="loc_srt_MaximumMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_PlanNameAxis_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_8" xlink:to="loc_us-gaap_PlanNameDomain_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_8" xlink:to="loc_embi_OmnibusIncentivePlan2014Member_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockBasedCompensationDetails3">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_4"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_AwardsGrantedOutsideThe2014PlanMember" xlink:label="loc_embi_AwardsGrantedOutsideThe2014PlanMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_10"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_PlanNameAxis_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_4" xlink:to="loc_us-gaap_PlanNameDomain_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_4" xlink:to="loc_embi_AwardsGrantedOutsideThe2014PlanMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockBasedCompensationDetails4">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_12"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:to="loc_us-gaap_RestrictedStockMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockBasedCompensationDetailTextuals">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ChiefFinancialOfficerMember" xlink:label="loc_srt_ChiefFinancialOfficerMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_4"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_OmnibusIncentivePlan2014Member" xlink:label="loc_embi_OmnibusIncentivePlan2014Member_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_10"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_RestrictedStockAgreementsMember" xlink:label="loc_embi_RestrictedStockAgreementsMember_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_13"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_K2CIncMember" xlink:label="loc_embi_K2CIncMember_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_us-gaap_RestrictedStockExpense_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_21"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_srt_TitleOfIndividualAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_1" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:to="loc_srt_ChiefFinancialOfficerMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_PlanNameAxis_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_4" xlink:to="loc_us-gaap_PlanNameDomain_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_4" xlink:to="loc_embi_OmnibusIncentivePlan2014Member_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_10" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_10" xlink:to="loc_embi_RestrictedStockAgreementsMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_dei_LegalEntityAxis_13" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_13" xlink:to="loc_dei_EntityDomain_13" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_13" xlink:to="loc_embi_K2CIncMember_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_17" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_18" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16" xlink:to="loc_us-gaap_RestrictedStockExpense_19" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_20" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_21" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockBasedCompensationDetailTextuals1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_DouglasCesarioMember" xlink:label="loc_embi_DouglasCesarioMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_RestrictedStockAgreementsMember" xlink:label="loc_embi_RestrictedStockAgreementsMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_FairMarketValueOfStockOptions" xlink:label="loc_embi_FairMarketValueOfStockOptions_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_15"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_srt_TitleOfIndividualAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_1" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:to="loc_embi_DouglasCesarioMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4" xlink:to="loc_embi_RestrictedStockAgreementsMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7" xlink:to="loc_embi_FairMarketValueOfStockOptions_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_11" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_12" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_13" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_14" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_15" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockBasedCompensationDetailTextuals2">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srt_ChiefExecutiveOfficerMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ChiefFinancialOfficerMember" xlink:label="loc_srt_ChiefFinancialOfficerMember_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="loc_srt_BoardOfDirectorsChairmanMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_9"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_K2CIncMember" xlink:label="loc_embi_K2CIncMember_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_12"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_FairMarketValueOfSharesGranted" xlink:label="loc_embi_FairMarketValueOfSharesGranted_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_us-gaap_RestrictedStockExpense_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_18"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:to="loc_us-gaap_RestrictedStockMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_srt_TitleOfIndividualAxis_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_4" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4" xlink:to="loc_srt_ChiefExecutiveOfficerMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4" xlink:to="loc_srt_ChiefFinancialOfficerMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4" xlink:to="loc_srt_BoardOfDirectorsChairmanMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_dei_LegalEntityAxis_9" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_9" xlink:to="loc_dei_EntityDomain_9" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_9" xlink:to="loc_embi_K2CIncMember_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_12" xlink:to="loc_embi_FairMarketValueOfSharesGranted_13" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_12" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_14" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_12" xlink:to="loc_us-gaap_RestrictedStockExpense_15" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_12" xlink:to="loc_us-gaap_ShareBasedCompensation_16" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_12" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_17" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_12" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_18" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/SignificantContractsUniversityOfMississippiDetailTextuals">
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_SignificantContractsAbstract" xlink:label="loc_embi_SignificantContractsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_UniversityOfMississippiAgreementsTable" xlink:label="loc_embi_UniversityOfMississippiAgreementsTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_OptionAgreementMember" xlink:label="loc_embi_OptionAgreementMember_1"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_LicenseAgreementMember" xlink:label="loc_embi_LicenseAgreementMember_2"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_Um5070LicenseAgreementMember" xlink:label="loc_embi_Um5070LicenseAgreementMember_3"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_Um5050ProdrugAndUm8930AnalogAgreementsMember" xlink:label="loc_embi_Um5050ProdrugAndUm8930AnalogAgreementsMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_7"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_UniversityOfMississippiMember" xlink:label="loc_embi_UniversityOfMississippiMember_7"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_MonthAndYearOfAgreementAxis" xlink:label="loc_embi_MonthAndYearOfAgreementAxis_10"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_MonthAndYearOfAgreementDomain" xlink:label="loc_embi_MonthAndYearOfAgreementDomain_10"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_December2015Member" xlink:label="loc_embi_December2015Member_10"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_OctoberTwoThousandFifteenMember" xlink:label="loc_embi_OctoberTwoThousandFifteenMember_11"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_MilestonePaymentsPayableAxis" xlink:label="loc_embi_MilestonePaymentsPayableAxis_14"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_MilestonePaymentsPayableDomain" xlink:label="loc_embi_MilestonePaymentsPayableDomain_14"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_Milestone1Member" xlink:label="loc_embi_Milestone1Member_14"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_Milestone2Member" xlink:label="loc_embi_Milestone2Member_15"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_Milestone3Member" xlink:label="loc_embi_Milestone3Member_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:label="loc_us-gaap_IntellectualPropertyMember_19"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_UniversityOfMississippiAgreementsLineItems" xlink:label="loc_embi_UniversityOfMississippiAgreementsLineItems_22"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_AnnualMaintenanceFeePayable" xlink:label="loc_embi_AnnualMaintenanceFeePayable_22"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_TermOfAgreement" xlink:label="loc_embi_TermOfAgreement_23"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_PaymentForUpfrontFees" xlink:label="loc_embi_PaymentForUpfrontFees_24"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_NumberOfLicenseAgreements" xlink:label="loc_embi_NumberOfLicenseAgreements_25"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_NoticePeriodForTermination" xlink:label="loc_embi_NoticePeriodForTermination_26"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_AnnualFeesForLicenseAgreement" xlink:label="loc_embi_AnnualFeesForLicenseAgreement_27"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_AggregateMilestonePaymentsIfMilestonesAchieved" xlink:label="loc_embi_AggregateMilestonePaymentsIfMilestonesAchieved_28"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_SignificantContractsAbstract_0" xlink:to="loc_embi_UniversityOfMississippiAgreementsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_embi_OptionAgreementMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_embi_LicenseAgreementMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_embi_Um5070LicenseAgreementMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_embi_Um5050ProdrugAndUm8930AnalogAgreementsMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_dei_LegalEntityAxis_7" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_7" xlink:to="loc_dei_EntityDomain_7" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_7" xlink:to="loc_embi_UniversityOfMississippiMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_embi_MonthAndYearOfAgreementAxis_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_MonthAndYearOfAgreementAxis_10" xlink:to="loc_embi_MonthAndYearOfAgreementDomain_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_MonthAndYearOfAgreementDomain_10" xlink:to="loc_embi_December2015Member_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_MonthAndYearOfAgreementDomain_10" xlink:to="loc_embi_OctoberTwoThousandFifteenMember_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_embi_MilestonePaymentsPayableAxis_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_MilestonePaymentsPayableAxis_14" xlink:to="loc_embi_MilestonePaymentsPayableDomain_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_MilestonePaymentsPayableDomain_14" xlink:to="loc_embi_Milestone1Member_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_MilestonePaymentsPayableDomain_14" xlink:to="loc_embi_Milestone2Member_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_MilestonePaymentsPayableDomain_14" xlink:to="loc_embi_Milestone3Member_16" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_19" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_19" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_19" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_19" xlink:to="loc_us-gaap_IntellectualPropertyMember_19" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_embi_UniversityOfMississippiAgreementsLineItems_22" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_UniversityOfMississippiAgreementsLineItems_22" xlink:to="loc_embi_AnnualMaintenanceFeePayable_22" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_UniversityOfMississippiAgreementsLineItems_22" xlink:to="loc_embi_TermOfAgreement_23" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_UniversityOfMississippiAgreementsLineItems_22" xlink:to="loc_embi_PaymentForUpfrontFees_24" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_UniversityOfMississippiAgreementsLineItems_22" xlink:to="loc_embi_NumberOfLicenseAgreements_25" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_UniversityOfMississippiAgreementsLineItems_22" xlink:to="loc_embi_NoticePeriodForTermination_26" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_UniversityOfMississippiAgreementsLineItems_22" xlink:to="loc_embi_AnnualFeesForLicenseAgreement_27" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_UniversityOfMississippiAgreementsLineItems_22" xlink:to="loc_embi_AggregateMilestonePaymentsIfMilestonesAchieved_28" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/RelatedPartyMattersDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_IndependentContractorAgreementMember" xlink:label="loc_embi_IndependentContractorAgreementMember_1"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_SeparationAndReleaseAgreementMember" xlink:label="loc_embi_SeparationAndReleaseAgreementMember_2"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ConsultingAgreementMember" xlink:label="loc_embi_ConsultingAgreementMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_6"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_K2CIncMember" xlink:label="loc_embi_K2CIncMember_6"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_EmeraldHealthSciencesIncMember" xlink:label="loc_embi_EmeraldHealthSciencesIncMember_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_15"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_AvtarDhillonMember" xlink:label="loc_embi_AvtarDhillonMember_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_18"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_MonthlyFee" xlink:label="loc_embi_MonthlyFee_18"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_LumpSumPaymentInAgreement" xlink:label="loc_embi_LumpSumPaymentInAgreement_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_21"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_InitialTermOfAgreement" xlink:label="loc_embi_InitialTermOfAgreement_22"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_TotalExpenseIncurredUnderAgreement" xlink:label="loc_embi_TotalExpenseIncurredUnderAgreement_23"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_AccruedExpenseUnderAgreement" xlink:label="loc_embi_AccruedExpenseUnderAgreement_24"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_PercentageOfAccruedInterestOnOutstandingBalance" xlink:label="loc_embi_PercentageOfAccruedInterestOnOutstandingBalance_25"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_AnnualFeeForAgreement" xlink:label="loc_embi_AnnualFeeForAgreement_26"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_PeriodOfDiscretionaryAnnualBonusPayableToContractorAfterEachFiscalYearEnd" xlink:label="loc_embi_PeriodOfDiscretionaryAnnualBonusPayableToContractorAfterEachFiscalYearEnd_27"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_MonthlyFeePaidEachMonthInExchangeOfServices" xlink:label="loc_embi_MonthlyFeePaidEachMonthInExchangeOfServices_28"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices" xlink:label="loc_embi_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices_29"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_embi_IndependentContractorAgreementMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_embi_SeparationAndReleaseAgreementMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_embi_ConsultingAgreementMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_dei_LegalEntityAxis_6" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_6" xlink:to="loc_dei_EntityDomain_6" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_6" xlink:to="loc_embi_K2CIncMember_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_6" xlink:to="loc_embi_EmeraldHealthSciencesIncMember_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_VestingAxis_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_10" xlink:to="loc_us-gaap_VestingDomain_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_10" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_10" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_10" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_15" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_15" xlink:to="loc_us-gaap_RelatedPartyDomain_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_15" xlink:to="loc_embi_AvtarDhillonMember_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_18" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_18" xlink:to="loc_embi_MonthlyFee_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_18" xlink:to="loc_embi_LumpSumPaymentInAgreement_19" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_18" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_20" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_21" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_18" xlink:to="loc_embi_InitialTermOfAgreement_22" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_18" xlink:to="loc_embi_TotalExpenseIncurredUnderAgreement_23" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_18" xlink:to="loc_embi_AccruedExpenseUnderAgreement_24" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_18" xlink:to="loc_embi_PercentageOfAccruedInterestOnOutstandingBalance_25" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_18" xlink:to="loc_embi_AnnualFeeForAgreement_26" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_18" xlink:to="loc_embi_PeriodOfDiscretionaryAnnualBonusPayableToContractorAfterEachFiscalYearEnd_27" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_18" xlink:to="loc_embi_MonthlyFeePaidEachMonthInExchangeOfServices_28" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_18" xlink:to="loc_embi_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices_29" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/IncomeTaxesDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsStateTaxes" xlink:label="loc_us-gaap_DeferredTaxAssetsStateTaxes_1"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:label="loc_embi_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_7"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_DeferredTaxLiabilitiesNoteDiscount" xlink:label="loc_embi_DeferredTaxLiabilitiesNoteDiscount_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_10"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsStateTaxes_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1" xlink:to="loc_embi_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1" xlink:to="loc_embi_DeferredTaxLiabilitiesNoteDiscount_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1" xlink:to="loc_us-gaap_DeferredTaxLiabilities_9" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_10" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/IncomeTaxesDetails2">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_2"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrant" xlink:label="loc_embi_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrant_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_4"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_IncomeTaxReconciliationUncertainTaxPositions" xlink:label="loc_embi_IncomeTaxReconciliationUncertainTaxPositions_5"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_IncomeTaxReconciliationChangeInCompoundDerivative" xlink:label="loc_embi_IncomeTaxReconciliationChangeInCompoundDerivative_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ExtinguishmentOfDebtGainLossIncomeTax" xlink:label="loc_us-gaap_ExtinguishmentOfDebtGainLossIncomeTax_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_11"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_embi_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrant_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_embi_IncomeTaxReconciliationUncertainTaxPositions_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_embi_IncomeTaxReconciliationChangeInCompoundDerivative_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_ExtinguishmentOfDebtGainLossIncomeTax_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_9" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_10" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_11" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/IncomeTaxesDetailTextuals">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:label="loc_us-gaap_TaxCreditCarryforwardLimitationsOnUse_11"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1" xlink:to="loc_us-gaap_ForeignCountryMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4" xlink:to="loc_us-gaap_OperatingLossCarryforwards_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_9" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_10" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_TaxCreditCarryforwardLimitationsOnUse_11" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/NetIncomeLossPerShareOfCommonStockDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_1"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_DilutedSecuritiesAxis" xlink:label="loc_embi_DilutedSecuritiesAxis_1"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_DilutedSecuritiesDomain" xlink:label="loc_embi_DilutedSecuritiesDomain_1"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_UnvestedRestrictedStockMember" xlink:label="loc_embi_UnvestedRestrictedStockMember_1"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_OptionsMember" xlink:label="loc_embi_OptionsMember_2"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_WarrantsMember" xlink:label="loc_embi_WarrantsMember_3"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_WarrantsLiabilityClassifiedMember" xlink:label="loc_embi_WarrantsLiabilityClassifiedMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDilutedLineItems" xlink:label="loc_us-gaap_EarningsPerShareDilutedLineItems_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DilutiveSecurities" xlink:label="loc_us-gaap_DilutiveSecurities_7"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_DilutiveSecuritiesEffectOnBasicEarningsPerShareShares" xlink:label="loc_embi_DilutiveSecuritiesEffectOnBasicEarningsPerShareShares_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_17"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_NetLossAdjustedBalance" xlink:label="loc_embi_NetLossAdjustedBalance_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_19"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_1" xlink:to="loc_embi_DilutedSecuritiesAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DilutedSecuritiesAxis_1" xlink:to="loc_embi_DilutedSecuritiesDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DilutedSecuritiesDomain_1" xlink:to="loc_embi_UnvestedRestrictedStockMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DilutedSecuritiesDomain_1" xlink:to="loc_embi_OptionsMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DilutedSecuritiesDomain_1" xlink:to="loc_embi_WarrantsMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DilutedSecuritiesDomain_1" xlink:to="loc_embi_WarrantsLiabilityClassifiedMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_1" xlink:to="loc_us-gaap_EarningsPerShareDilutedLineItems_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_7" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_7" xlink:to="loc_us-gaap_DilutiveSecurities_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_7" xlink:to="loc_embi_DilutiveSecuritiesEffectOnBasicEarningsPerShareShares_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_NetIncomeLoss_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_13" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_13" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_13" xlink:to="loc_us-gaap_EarningsPerShareBasic_15" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_17" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_17" xlink:to="loc_embi_NetLossAdjustedBalance_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_17" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_18" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_17" xlink:to="loc_us-gaap_EarningsPerShareDiluted_19" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/NetIncomeLossPerShareOfCommonStockDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_3"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_CommonSharesUnderlyingConvertiblePreferredStockMember" xlink:label="loc_embi_CommonSharesUnderlyingConvertiblePreferredStockMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:to="loc_us-gaap_RestrictedStockMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:to="loc_embi_CommonSharesUnderlyingConvertiblePreferredStockMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:to="loc_us-gaap_WarrantMember_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails2">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputOfferedPriceMember" xlink:label="loc_us-gaap_MeasurementInputOfferedPriceMember_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_12"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" xlink:label="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_12"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_PricingModelAxis" xlink:label="loc_embi_PricingModelAxis_15"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_PricingModelDomain" xlink:label="loc_embi_PricingModelDomain_15"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_PricingModelMember" xlink:label="loc_embi_PricingModelMember_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_20"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputOfferedPriceMember_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_srt_RangeAxis_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_8" xlink:to="loc_srt_RangeMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8" xlink:to="loc_srt_MinimumMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8" xlink:to="loc_srt_MaximumMember_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_12" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_12" xlink:to="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_embi_PricingModelAxis_15" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_PricingModelAxis_15" xlink:to="loc_embi_PricingModelDomain_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_PricingModelDomain_15" xlink:to="loc_embi_PricingModelMember_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_18" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_18" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_18" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_19" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_18" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_20" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails3">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_4"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_PricingModelAxis" xlink:label="loc_embi_PricingModelAxis_7"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_PricingModelDomain" xlink:label="loc_embi_PricingModelDomain_7"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_MonteCarloSimulationsMember" xlink:label="loc_embi_MonteCarloSimulationsMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_10"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_EmeraldFinancingMember" xlink:label="loc_embi_EmeraldFinancingMember_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_19"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_embi_PricingModelAxis_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_PricingModelAxis_7" xlink:to="loc_embi_PricingModelDomain_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_PricingModelDomain_7" xlink:to="loc_embi_MonteCarloSimulationsMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_dei_LegalEntityAxis_10" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_10" xlink:to="loc_dei_EntityDomain_10" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_10" xlink:to="loc_embi_EmeraldFinancingMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_srt_RangeAxis_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_13" xlink:to="loc_srt_RangeMember_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_13" xlink:to="loc_srt_MinimumMember_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_13" xlink:to="loc_srt_MaximumMember_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_17" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_17" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_17" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_18" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_17" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_19" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails4">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputOfferedPriceMember" xlink:label="loc_us-gaap_MeasurementInputOfferedPriceMember_5"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_PricingModelAxis" xlink:label="loc_embi_PricingModelAxis_8"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_PricingModelDomain" xlink:label="loc_embi_PricingModelDomain_8"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_PricingModelMember" xlink:label="loc_embi_PricingModelMember_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_11"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_SeriesBWarrantMember" xlink:label="loc_embi_SeriesBWarrantMember_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_20"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputOfferedPriceMember_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_embi_PricingModelAxis_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_PricingModelAxis_8" xlink:to="loc_embi_PricingModelDomain_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_PricingModelDomain_8" xlink:to="loc_embi_PricingModelMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_11" xlink:to="loc_us-gaap_ClassOfStockDomain_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_11" xlink:to="loc_embi_SeriesBWarrantMember_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_srt_RangeAxis_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_14" xlink:to="loc_srt_RangeMember_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_14" xlink:to="loc_srt_MinimumMember_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_14" xlink:to="loc_srt_MaximumMember_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_18" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_18" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_18" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_19" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_18" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_20" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_Pre2015CommonStockWarrantsMember" xlink:label="loc_embi_Pre2015CommonStockWarrantsMember_1"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_TwoThousandFifteenCommonStockWarrantsMember" xlink:label="loc_embi_TwoThousandFifteenCommonStockWarrantsMember_2"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_CommonStockWarrantsToSeriesBStockholdersMember" xlink:label="loc_embi_CommonStockWarrantsToSeriesBStockholdersMember_3"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember" xlink:label="loc_embi_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember_4"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember" xlink:label="loc_embi_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember_5"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember" xlink:label="loc_embi_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember_6"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember" xlink:label="loc_embi_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember_7"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_TwoThousandEighteenEmeraldFinancingWarrantsMember" xlink:label="loc_embi_TwoThousandEighteenEmeraldFinancingWarrantsMember_8"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" xlink:label="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_9"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_TwoThousandNineteenCommonStockWarrantsMember" xlink:label="loc_embi_TwoThousandNineteenCommonStockWarrantsMember_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_17"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_TermOfWarrant" xlink:label="loc_embi_TermOfWarrant_18"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_WarrantsVestedAndOutstanding" xlink:label="loc_embi_WarrantsVestedAndOutstanding_19"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_Pre2015CommonStockWarrantsMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandFifteenCommonStockWarrantsMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_CommonStockWarrantsToSeriesBStockholdersMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandEighteenEmeraldFinancingWarrantsMember_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_9" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandNineteenCommonStockWarrantsMember_10" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_srt_RangeAxis_13" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_13" xlink:to="loc_srt_RangeMember_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_13" xlink:to="loc_srt_MinimumMember_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_13" xlink:to="loc_srt_MaximumMember_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_17" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_17" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_17" xlink:to="loc_embi_TermOfWarrant_18" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_17" xlink:to="loc_embi_WarrantsVestedAndOutstanding_19" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetailsTextuals">
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_WarrantsAndDerivativeLiabilitiesAbstract" xlink:label="loc_embi_WarrantsAndDerivativeLiabilitiesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_DerivativeLiabilitiesTable" xlink:label="loc_embi_DerivativeLiabilitiesTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_EmeraldFinancingMember" xlink:label="loc_embi_EmeraldFinancingMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_4"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_TwoThousandNineteenCommonStockWarrantsMember" xlink:label="loc_embi_TwoThousandNineteenCommonStockWarrantsMember_4"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" xlink:label="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_5"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_TwoThousandEighteenEmeraldFinancingWarrantsMember" xlink:label="loc_embi_TwoThousandEighteenEmeraldFinancingWarrantsMember_6"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_SeriesBWarrantMember" xlink:label="loc_embi_SeriesBWarrantMember_7"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember" xlink:label="loc_embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_11"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_SeriesBPreferredStockConversionLiabilityMember" xlink:label="loc_embi_SeriesBPreferredStockConversionLiabilityMember_11"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_DerivativeLiabilitiesLineItems" xlink:label="loc_embi_DerivativeLiabilitiesLineItems_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_16"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_NumberOfWarrantsExercisable" xlink:label="loc_embi_NumberOfWarrantsExercisable_17"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ClassOfWarrantOrRightWarrantsAggregateExercisePrice" xlink:label="loc_embi_ClassOfWarrantOrRightWarrantsAggregateExercisePrice_18"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ClassOfWarrantOrRightWarrantsExercise" xlink:label="loc_embi_ClassOfWarrantOrRightWarrantsExercise_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_21"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_FairValueOfCommonStockWarrantsIssued" xlink:label="loc_embi_FairValueOfCommonStockWarrantsIssued_22"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDerivativeIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDerivativeIssuanceCosts_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_24"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_ReclassificationOfDerivativesToEquity" xlink:label="loc_embi_ReclassificationOfDerivativesToEquity_25"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_WarrantsAndDerivativeLiabilitiesAbstract_0" xlink:to="loc_embi_DerivativeLiabilitiesTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DerivativeLiabilitiesTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_embi_EmeraldFinancingMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DerivativeLiabilitiesTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4" xlink:to="loc_embi_TwoThousandNineteenCommonStockWarrantsMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4" xlink:to="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4" xlink:to="loc_embi_TwoThousandEighteenEmeraldFinancingWarrantsMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4" xlink:to="loc_embi_SeriesBWarrantMember_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4" xlink:to="loc_embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DerivativeLiabilitiesTable_1" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_11" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_11" xlink:to="loc_embi_SeriesBPreferredStockConversionLiabilityMember_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DerivativeLiabilitiesTable_1" xlink:to="loc_embi_DerivativeLiabilitiesLineItems_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_14" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_14" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_14" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_16" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_14" xlink:to="loc_embi_NumberOfWarrantsExercisable_17" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_14" xlink:to="loc_embi_ClassOfWarrantOrRightWarrantsAggregateExercisePrice_18" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_14" xlink:to="loc_embi_ClassOfWarrantOrRightWarrantsExercise_19" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_14" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_20" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_14" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_21" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_14" xlink:to="loc_embi_FairValueOfCommonStockWarrantsIssued_22" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_14" xlink:to="loc_us-gaap_PaymentsOfDerivativeIssuanceCosts_23" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_14" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_24" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_14" xlink:to="loc_embi_ReclassificationOfDerivativesToEquity_25" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/IncomeTaxesDetails3">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_3"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/SubsequentEventsDetailTextuals">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_4"/>
    <loc xlink:type="locator" xlink:href="embi-20191231.xsd#embi_PaymentOfUpfrontLicenseFee" xlink:label="loc_embi_PaymentOfUpfrontLicenseFee_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1" xlink:to="loc_us-gaap_SubsequentEventMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_4" xlink:to="loc_embi_PaymentOfUpfrontLicenseFee_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6813883792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Deficit) and Capitalization (Detail Textuals) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 20, 2019</div></th>
<th class="th"><div>Nov. 30, 2019</div></th>
<th class="th"><div>Feb. 16, 2018</div></th>
<th class="th"><div>Jan. 19, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Nov. 15, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Common stock gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,919,372<span></span>
</td>
<td class="nump">$ 3,095,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDerivativeIssuanceCosts', window );">Warrant liability, issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandEighteenEmeraldFinancingWarrantsMember', window );">2018 Emerald Financing Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_ClassOfWarrantOrRightWarrantsExercise', window );">Warrants exercise</a></td>
<td class="nump">40,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_IntrinsicValueOfWarrantExercises', window );">Intrinsic value of warrant exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,284,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_SeriesBWarrantsMember', window );">Series B Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_IntrinsicValueOfWarrantExercises', window );">Intrinsic value of warrant exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 144,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Direct offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of stock sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Common stock, par value (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from the transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,919,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_EmeraldFinancingIssuanceCosts', window );">Emerald financing issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 154,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDerivativeIssuanceCosts', window );">Warrant liability, issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_ReductionToAdditionalPaidInCapitalFromTheIssuanceOfCommonStock', window );">Reduction to APIC from the issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=embi_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement | Emerald Health Sciences Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,400,000<span></span>
</td>
<td class="nump">20,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Common stock gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_SubsequentFinancingPurchasePriceDescription', window );">Subsequent financing purchase price, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Securities Purchase Agreement also provides that in the case of a subsequent financing in which the purchase price is less than $0.10 per share, Emerald Health Sciences shall be issued additional shares in order to protect against anti-dilution.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TermOfWarrants', window );">Term of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=embi_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement | Emerald Health Sciences Inc | Accredited Investor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Common stock gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TermOfWarrants', window );">Term of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_ClassOfWarrantOrRightWarrantsExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents number of warrants exercise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_ClassOfWarrantOrRightWarrantsExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_EmeraldFinancingIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost incurred for Emerald Financing, issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_EmeraldFinancingIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_EquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_EquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_IntrinsicValueOfWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents intrinsic value of warrant exercises.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_IntrinsicValueOfWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_ReductionToAdditionalPaidInCapitalFromTheIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of reduction to APIC from the issuance of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_ReductionToAdditionalPaidInCapitalFromTheIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_SubsequentFinancingPurchasePriceDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents subsequent financing purchase price description to protect against anti-dilution.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_SubsequentFinancingPurchasePriceDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_TermOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents term of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_TermOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDerivativeIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of a derivative security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDerivativeIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandEighteenEmeraldFinancingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandEighteenEmeraldFinancingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=embi_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=embi_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=embi_EmeraldHealthSciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=embi_EmeraldHealthSciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6799895568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details 2) - Stock options - Omnibus Incentive Plan 2014<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend Yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.49%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 7 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">93.72%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.06%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 3 months 7 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months 29 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93.60%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=embi_OmnibusIncentivePlan2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=embi_OmnibusIncentivePlan2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6800837024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Detail Textuals)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_PaymentOfUpfrontLicenseFee', window );">Payment of upfront license fee</a></td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_PaymentOfUpfrontLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents cash outflow of payment of upfront license fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_PaymentOfUpfrontLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6803670896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations and Business Activities (Detail Textuals) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 16, 2018</div></th>
<th class="th"><div>Jan. 19, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Oct. 05, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_NatureOfOperationsAndBusinessActivitiesLineItems', window );"><strong>Nature Of Operations And Business Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,173,282<span></span>
</td>
<td class="nump">$ 33,225,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,829,977<span></span>
</td>
<td class="nump">1,853,373<span></span>
</td>
<td class="nump">$ 667,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,027,941)<span></span>
</td>
<td class="num">(3,943,014)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock and warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,919,372<span></span>
</td>
<td class="nump">3,095,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_ProceedsFromConvertibleMultiDrawCreditAgreement', window );">Proceeds from convertible multi-draw credit agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,990,699<span></span>
</td>
<td class="nump">1,946,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=embi_EmeraldFinancingMember', window );">Emerald Financing Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_NatureOfOperationsAndBusinessActivitiesLineItems', window );"><strong>Nature Of Operations And Business Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock and warrants</a></td>
<td class="num">$ (1,750,000)<span></span>
</td>
<td class="num">$ (1,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,250,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=embi_EmeraldFinancingMember', window );">Emerald Financing Warrant Liability | Multi-Draw Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_NatureOfOperationsAndBusinessActivitiesLineItems', window );"><strong>Nature Of Operations And Business Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity', window );">Principal amounts of borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock and warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,919,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_ProceedsFromConvertibleMultiDrawCreditAgreement', window );">Proceeds from convertible multi-draw credit agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,990,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_NatureOfOperationsAndBusinessActivitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_NatureOfOperationsAndBusinessActivitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_ProceedsFromConvertibleMultiDrawCreditAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of convertible multi-draw credit agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_ProceedsFromConvertibleMultiDrawCreditAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=embi_EmeraldFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=embi_EmeraldFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=embi_MultiDrawCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=embi_MultiDrawCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6735221968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt - Related Party (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Schedule of convertible debt</a></td>
<td class="text"><table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN;margin:auto" width="85%"><tbody><tr><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="6" style="BORDER-BOTTOM:black 1px solid;text-align:center" valign="bottom"><p style="MARGIN:0px 0px 0px 12pt;TEXT-INDENT:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>As of December 31, </strong></span></span></p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px 0px 0px 12pt;TEXT-INDENT:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2019</strong></span></span></p></td><td style="PADDING-BOTTOM:1px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px 0px 0px 12pt;TEXT-INDENT:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2018</strong></span></span></p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#cceeff"><td valign="top"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total principal value</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,014,500</span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:6px" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td><td style="text-align:right;width:62px" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,000,000</span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#ffffff"><td valign="top"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unamortized debt discount</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(1,622,344</span></span></td><td style="width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:6px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:62px" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(587,617</span></span></td><td style="width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td></tr><tr style="background-color:#cceeff"><td valign="top"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unamortized debt issuance costs</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:black 1px solid;width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:black 1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(5,086</span></span></td><td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-bottom:1px solid black;width:6px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-bottom:1px solid black;text-align:right;width:62px" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(51,423</span></span></td><td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></p></td></tr><tr style="background-color:#ffffff"><td valign="top"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Carrying value of total convertible debt -&#160;related party</strong></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:black 1px solid;width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td><td style="BORDER-BOTTOM:black 1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>387,070</strong></span></span></td><td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-bottom:1px solid black;width:6px" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td><td style="border-bottom:1px solid black;text-align:right;width:62px" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>1,360,960</strong></span></span></td><td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></p></td></tr><tr style="background-color:#cceeff"><td valign="top"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Less, noncurrent portion</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:black 1px solid;width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:black 1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(387,070</span></span></td><td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-bottom:1px solid black;width:6px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-bottom:1px solid black;text-align:right;width:62px" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(1,360,960</span></span></td><td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></p></td></tr><tr style="background-color:#ffffff"><td valign="top"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Current convertible debt &#x2013; related party</strong></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-bottom:2.5pt double black;width:1%;border-top:none;border-right:none;border-left:none;border-image:initial" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td><td style="border-bottom:2.5pt double black;text-align:right;width:9%;border-top:none;border-right:none;border-left:none;border-image:initial" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#x2014;</strong></span></span></td><td style="PADDING-BOTTOM:3px;width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-bottom:2.5pt double black;width:6px;border-top:none;border-right:none;border-left:none;border-image:initial" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td><td style="border-bottom:2.5pt double black;text-align:right;width:62px;border-top:none;border-right:none;border-left:none;border-image:initial" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#x2014;</strong></span></span></td><td style="PADDING-BOTTOM:3px;width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_ScheduleOfInterestExpenseTableTextBlock', window );">Schedule of interest expense</a></td>
<td class="text"><table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN;margin:auto" width="85%"><tbody><tr><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="6" style="BORDER-BOTTOM:black 1px solid;text-align:center" valign="bottom"><p style="MARGIN:0px 0px 0px 12pt;TEXT-INDENT:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Year&#160;Ended December 31,</strong></span></span></p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px 0px 0px 12pt;TEXT-INDENT:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2019</strong></span></span></p></td><td style="PADDING-BOTTOM:1px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border:1pt none" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="border-width:1pt;border-style:none none solid;border-top-color:initial;border-right-color:initial;border-bottom-color:black;border-left-color:initial;border-image:initial;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px 0px 0px 12pt;TEXT-INDENT:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2018</strong></span></span></p></td><td style="PADDING-BOTTOM:1px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#cceeff"><td valign="top"><p style="margin-top:0px;margin-right:0px;margin-bottom:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Interest expense - stated rate&#160;</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">371,420</span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">26,433</span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#ffffff"><td valign="top"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Non-cash interest expense:</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#cceeff"><td valign="top"><p style="margin-top:0px;margin-right:0px;margin-bottom:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Amortization of debt discount</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">616,383</span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">56,253</span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#ffffff"><td valign="top"><p style="margin-top:0px;margin-right:0px;margin-bottom:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Amortization of transaction costs</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">12,910</span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,283</span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#cceeff"><td valign="top"><p style="margin-top:0px;margin-right:0px;margin-bottom:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other interest expense</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border:1pt none;width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border:1pt none;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#x2014;</span></span></td><td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border:1pt none;width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border:1pt none;text-align:right;width:9%" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">9,794</span></span></p></td><td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#ffffff"><td><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-top:1pt solid black;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td><td style="border-top:1pt solid black;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>1,000,713</strong></span></span></td><td style="PADDING-BOTTOM:3px;width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-top:1pt solid black;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td><td style="border-top:1pt solid black;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>94,763</strong></span></span></td><td style="PADDING-BOTTOM:3px;width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_ScheduleOfInterestExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_ScheduleOfInterestExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder. Disclosures include, but are not limited to, principal amount, amortized premium or discount, and amount of liability and equity components.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6801835760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Matters<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Matters</a></td>
<td class="text"><p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><strong>11. </strong><strong>Related Party Matters</strong></span></span></span></span></span></span></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><strong><i>K2C, Inc.</i></strong></span></span></span></span></span></span></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span>In June 2014, the Company&#x2019;s U.S. subsidiary entered into an independent contractor agreement with K2C, Inc. (&#x201c;K2C&#x201d;), which is wholly owned by the Company&#x2019;s former Executive Chairman and Co-Founder, Mr. Cosmas N. Lykos, pursuant to which the Company paid K2C a monthly fee for services performed by Mr. Lykos for the Company. The agreement expired on June 1, 2017, and was automatically renewed for one year pursuant to the terms of the agreement. The monthly fee under the agreement was $10,000 and increased to $20,000 effective April 1, 2017.</span></span></span></span></span></span></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span>In February 2018, the Company entered into a separation and release agreement with K2C, which provided for a lump sum payment of $180,000 and the immediate vesting of 900,000 shares of restricted common stock granted on January 18, 2018, 325,000 shares of restricted common stock granted on October 20, 2015, and 125,000 options granted on November 21, 2014, in exchange for a release of claims and certain other agreements. During the year ended December 31, 2018, the Company recognized additional stock-based compensation expense of $112,270 for these restricted stock and option awards.</span></span></span></span></span></span></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span>For the year ended December 31, 2019, no expense was incurred under this agreement. For the year ended December 31, 2018, total expense incurred under this agreement was $220,000 (including the previously discussed lump sum payment). Under the separation agreement, Mr. Lykos was allowed to participate in the Company&#x2019;s health, death and disability insurance plans for six months subsequent to K2C&#x2019;s separation.</span></span></span></span></span></span></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><strong><i>Emerald Health Sciences</i></strong></span></span></span></span></span></span></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>On February 1, 2018, the Company entered into an Independent Contractor Agreement with Emerald Health Sciences, pursuant to which Emerald Health Sciences agreed to provide such services as are mutually agreed between the Company and Emerald Health Sciences, including reimbursement for reasonable expenses incurred in the performance of the Independent Contractor Agreement. These services included, but were not limited to, corporate advisory services and technical expertise in the areas of business development, marketing, investor relations, information technology and product development. The Independent Contractor Agreement had an initial term of 10 years and specified compensation which was agreed upon between the Company&#x2019;s Chief Executive Officer and Emerald Health Sciences&#x2019; Chairman, CEO and President on a month-to-month basis. The fee due under this agreement was payable on a monthly basis. Under this agreement, for the years ended December 31, 2019 and 2018, the Company incurred expenses of $542,000 and $550,000, respectively. At December 31, 2019, the Company has accrued $10,000 in expense under this agreement. Effective December 31, 2019, the Independent Contractor Agreement has been terminated.</span></span></span></span></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On February 6, 2018, the Company entered into a Consulting Agreement with Dr. Avtar Dhillon, the Chairman, Chief Executive Officer and President of Emerald Health Sciences. The services under the Consulting Agreement included corporate finance and strategic business advisory services. The Consulting Agreement had an initial term of one year and was renewable automatically unless terminated by either party.<span><span><span><span> </span></span></span></span>The agreement specified an annual fee of<span><span><span><span> $60,000,&#160;</span></span></span></span>payable semi-monthly in installments, and included reimbursement for reasonable expenses incurred in the performance of the services. Under the agreement, Dr. Avtar Dhillon was also entitled to a discretionary annual bonus, payable<span><span><span><span> 120 days </span></span></span></span>after each fiscal year-end, to be determined by the Board upon its annual review. Under this agreement, for the year ended December 31, 2018, the Company incurred<span><span><span><span> $45,000. </span></span></span></span>The Consulting Agreement was canceled on October 5, 2018 in connection with the Company&#x2019;s entry into the Credit Agreement with Emerald Health Sciences (See Note 4)&#160;and Dr. Avtar Dhillon&#x2019;s appointment as the Executive Chairman of the Company&#x2019;s Board.</span></span></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On December 17, 2019, Dr. Avtar Dhillon resigned as the Chairman of the Board and the position of Chairman of the Finance and Business Development Committee of the Board. Concurrently, the Company entered into a Board Observer Agreement with Emerald Health Sciences to allow Dr. Dhillon to continue as a representative of Emerald Health Sciences as a non-voting observer in future meetings of the Board.</span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On December 19, 2019, the Company entered into an Independent Contractor Services Agreement with Dr. Avtar Dhillon, pursuant to which Dr. Dhillon will provide ongoing corporate finance and strategic business advisory services to the Company. In exchange for his services, Dr. Dhillon will receive a monthly fee of $10,000, with (i) $5,000 paid each month and (ii) $5,000 accruing from the effective date and payable upon the Company&#x2019;s completion of a material financing. The Board will review the monthly rate paid to Dr. Dhillon within 90 days of the end of each fiscal year. The Independent Contractor Services Agreement has an initial term of one year and will renew automatically thereafter unless terminated earlier by either party. The Independent Contractor Services Agreement may be terminated by either party for cause upon written notice to the other party if the other party defaults in the performance of the agreement in any material respect or materially breaches the terms of the agreement, or without cause upon 30 days&#x2019; prior written notice to the other party.</span></span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6801836448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share of Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Income (Loss) Per Share of Common Stock</a></td>
<td class="text"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>7. </strong><strong>Net Income (Loss) Per Share of Common Stock</strong></span></span></span></span></p><p style="MARGIN:0px 0px 0px 0in">&#160;</p><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The following tables are a reconciliation of the numerators and denominators used in the calculation of basic and diluted net income (loss) per share computations:</span></span></p><div><p style="margin:0px;text-align:justify">&#160;</p><div><table style="font:10pt/normal times new roman;width:100%;text-align:justify;border-collapse:collapse;font-size-adjust:none;font-stretch:normal"><tbody><tr><td style="vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td colspan="10" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:black;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>For the Year Ended</strong> <strong>December 31, 2019</strong></span></span></p></td><td style="vertical-align:bottom"><p style="margin:0px">&#160;</p></td></tr><tr><td style="vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Income</strong></span></span></p><p style="margin:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>(Numerator)</strong></span></span></p></td><td style="padding-bottom:1px;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:black;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Shares</strong></span></span></p><p style="margin:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>(Denominator)</strong></span></span></p></td><td style="vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Per-Share</strong></span></span></p><p style="margin:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Amount</strong></span></span></p></td><td style="padding-bottom:1px;vertical-align:bottom"><p style="margin:0px">&#160;</p></td></tr><tr><td><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Net income</span></span></p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:black;border-bottom-width:1px;border-bottom-style:solid"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:black;border-bottom-width:1px;border-bottom-style:solid"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">1,051,825</span></span></td><td style="width:1%;padding-bottom:1px;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">&#160;</td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">&#160;</td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td></tr><tr style="background-color:rgb(255, 255, 255)"><td><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Basic EPS</strong></span></span></p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;padding-bottom:1px;vertical-align:bottom"><p style="margin:0px">&#160;</p></td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Income available to common stockholders</span></span></p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:black;border-bottom-width:3px;border-bottom-style:double"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:black;border-bottom-width:3px;border-bottom-style:double"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">1,051,825</span></span></td><td style="width:1%;padding-bottom:3px;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:black;border-bottom-width:3px;border-bottom-style:double"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:black;border-bottom-width:3px;border-bottom-style:double"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">135,154,931</span></span></td><td style="width:1%;padding-bottom:3px;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:black;border-bottom-width:3px;border-bottom-style:double"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>$</strong></span></span></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:black;border-bottom-width:3px;border-bottom-style:double"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>0.01</strong></span></span></td><td style="width:1%;padding-bottom:3px;vertical-align:bottom"><p style="margin:0px">&#160;</p></td></tr><tr style="background-color:rgb(204, 238, 255)"><td><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Effect of Dilutive Securities</strong></span></span></p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Unvested restricted stock</span></span></p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">858,856</span></span></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Options</span></span></p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">392,784</span></span></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Warrants</span></span></p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">447,431</span></span></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Warrants &#x2013; liability classified</span></span></p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(9,250,612</span></span></td><td style="width:1%;padding-bottom:1px;vertical-align:bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">32,706,263</span></span></td><td style="width:1%;padding-bottom:1px;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td></tr><tr style="background-color:rgb(204, 238, 255)"><td><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Diluted EPS</strong></span></span></p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;padding-bottom:1px;vertical-align:bottom"><p style="margin:0px">&#160;</p></td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Loss available to common stockholders + assumed conversions</span></span></p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(8,198,787</span></span></td><td style="width:1%;padding-bottom:3px;vertical-align:bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">169,560,265</span></span></td><td style="width:1%;padding-bottom:3px;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>$</strong></span></span></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>(0.05</strong></span></span></td><td style="width:1%;padding-bottom:3px;vertical-align:bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>)</strong></span></span></td></tr></tbody></table><p style="margin:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">&#160;&#160;</span></span></p><table style="font:10pt/normal times new roman;width:100%;text-align:justify;border-collapse:collapse;font-size-adjust:none;font-stretch:normal"><tbody><tr><td style="vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td colspan="10" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:black;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>For the Year Ended</strong> <strong>December 31, 2018</strong></span></span></p></td><td style="vertical-align:bottom"><p style="margin:0px">&#160;</p></td></tr><tr><td style="vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Income</strong></span></span></p><p style="margin:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>(Numerator)</strong></span></span></p></td><td style="padding-bottom:1px;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:black;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Shares</strong></span></span></p><p style="margin:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>(Denominator)</strong></span></span></p></td><td style="padding-bottom:1px;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Per-Share</strong></span></span></p><p style="margin:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Amount</strong></span></span></p></td><td style="padding-bottom:1px;vertical-align:bottom"><p style="margin:0px">&#160;</p></td></tr><tr><td><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Net loss</span></span></p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(19,194,236</span></span></td><td style="width:1%;padding-bottom:1px;vertical-align:bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">&#160;</td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">&#160;</td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td></tr><tr style="background-color:rgb(255, 255, 255)"><td><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Basic and Diluted EPS</strong></span></span></p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Loss available to common stockholders</span></span></p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:black;border-bottom-width:3px;border-bottom-style:double"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">$</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:black;border-bottom-width:3px;border-bottom-style:double"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(19,194,236</span></span></td><td style="width:1%;padding-bottom:3px;vertical-align:bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:black;border-bottom-width:3px;border-bottom-style:double"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:black;border-bottom-width:3px;border-bottom-style:double"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">121,154,334</span></span></td><td style="width:1%;padding-bottom:3px;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:black;border-bottom-width:3px;border-bottom-style:double"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>$</strong></span></span></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:black;border-bottom-width:3px;border-bottom-style:double"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>(0.16</strong></span></span></td><td style="width:1%;padding-bottom:3px;vertical-align:bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>)</strong></span></span></td></tr></tbody></table></div></div><p style="MARGIN:0px">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been anti-dilutive:</span></span></span></span></p><p style="MARGIN:0px">&#160;</p><table border="0" cellpadding="0" cellspacing="0" style="font:10pt Times New Roman;margin:auto;text-align:justify;width:100%" width="85%"><tbody><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="6" style="border-bottom:1px solid black;text-align:center;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Year Ended</strong></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>December 31,</strong></span></span></span></span></p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="border-bottom:1px solid black;text-align:center;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>2019</strong></span></span></span></span></p></td><td style="padding-bottom:1px;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="border-bottom:1px solid black;text-align:center;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>2018</strong></span></span></span></span></p></td><td style="padding-bottom:1px;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="background-color:rgb(204, 238, 255)" valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Stock options</span></span></span></span></p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>4,119,931</span></span></span></span></td><td style="padding-bottom:1px;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>3,600,073</span></span></span></span></td><td style="padding-bottom:1px;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Unvested restricted stock</span></span></span></span></p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>234,645</span></span></span></span></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>1,543,501</span></span></span></span></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="background-color:rgb(204, 238, 255)" valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Common shares underlying convertible debt</span></span></span></span></p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>5,036,250</span></span></span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>5,000,000</span></span></span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Warrants</span></span></span></span></p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>20,712,000</span></span></span></span></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>53,130,750</span></span></span></span></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6733659696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants and Derivative Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_WarrantsAndDerivativeLiabilitiesAbstract', window );"><strong>Warrants And Derivative Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_WarrantsAndDerivativeLiabilitiesTextBlock', window );">Warrants and Derivative Liabilities</a></td>
<td class="text"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>3. Warrants and Derivative Liabilities</strong></span></span></span></span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong><i>Warrants</i></strong></span></span></span></span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>There are significant judgments and estimates inherent in the determination of the fair value of the Company&#x2019;s warrants. These judgments and estimates include assumptions regarding the Company&#x2019;s future operating performance, the time to completing a liquidity event and the determination of the appropriate valuation methods. If the Company had made different assumptions, the fair value of the warrants could have been significantly different (See Note 2).</span></span></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Warrants vested and outstanding as of December 31, 2019 are summarized as follows:</span></span></span></span></p><p style="MARGIN:0px">&#160;</p><table border="0" cellpadding="0" cellspacing="0" style="WIDTH:100%;TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN" width="100%"><tbody><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="text-align:center;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="text-align:center;width:85px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="width:8px;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="text-align:center;background-color:rgb(255, 255, 255)" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong><strong>Number of</strong></strong></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong>Warrantsv</strong></p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="text-align:center;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Exercise</strong></span></span></span></span></p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="text-align:center;width:85px;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Term</strong></span></span></span></span></p></td><td style="width:8px;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="text-align:center;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong><strong>Vested</strong> and</strong></span></span></span></span></p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="border:1pt none;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Source</strong></span></span></span></span></p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="border-bottom:1px solid black;text-align:center;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Price</strong></span></span></span></span></p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="border-bottom:1px solid black;text-align:center;width:85px;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>(Years)</strong></span></span></span></span></p></td><td style="width:8px;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="border-bottom:1px solid black;text-align:center;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Outstanding</strong></span></span></span></span></p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="background-color:rgb(204, 238, 255)" valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Pre 2015 Common Stock Warrants</span></span></span></span></p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>1.00</span></span></span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="width:85px;background-color:rgb(204, 238, 255)"><p style="MARGIN:0px;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>6&#x2014;10</span></span></span></span></p></td><td style="width:8px;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>4,000,000</span></span></span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>2015 Common Stock Warrants</span></span></span></span></p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="background-color:rgb(255, 255, 255)"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></td><td style="background-color:rgb(255, 255, 255)"><p style="MARGIN:0px;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>1.15&#x2014;5.00</span></span></span></span></p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="width:85px;background-color:rgb(255, 255, 255)"><p style="MARGIN:0px;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>5&#x2014;10</span></span></span></span></p></td><td style="width:8px;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>442,000</span></span></span></span></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="background-color:rgb(204, 238, 255)" valign="top"><p style="margin-top:0px;margin-right:0px;margin-bottom:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Common Stock Warrants to Series B Stockholders</span></span></span></span></p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>0.00</span></span></span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:77px;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>5</span></span></span></span></td><td style="width:8px;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>1,031,250</span></span></span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>2016 Common Stock Warrants to Service Providers</span></span></span></span></p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>1.15</span></span></span></span></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:77px;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>10</span></span></span></span></td><td style="width:8px;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>40,000</span></span></span></span></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="background-color:rgb(204, 238, 255)" valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>2016 Series C Common Stock Warrants to Placement Agent</span></span></span></span></p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>0.40</span></span></span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:77px;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>5</span></span></span></span></td><td style="width:8px;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>125,000</span></span></span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>2017 Series D Common Stock Warrants to Placement Agent</span></span></span></span></p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>0.25</span></span></span></span></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:77px;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>5</span></span></span></span></td><td style="width:8px;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>480,000</span></span></span></span></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="background-color:rgb(204, 238, 255)" valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>2017 Common Stock Warrants to Service Provider</span></span></span></span></p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>0.41</span></span></span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:77px;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>5</span></span></span></span></td><td style="width:8px;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>125,000</span></span></span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>2018 Emerald Financing Warrants</span></span></span></span></p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>0.10</span></span></span></span></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:77px;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>5</span></span></span></span></td><td style="width:8px;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>3,400,000</span></span></span></span></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="border:1pt none;background-color:rgb(204, 238, 255)" valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Emerald Multi Draw Credit Agreement Warrants</span></span></span></span></p></td><td style="width:1%;border:1pt none;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border:1pt none;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></td><td style="border:1pt none;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>0.50</span></span></span></span></td><td style="padding-bottom:1px;width:1%;border:1pt none;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;border:1pt none;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border:1pt none;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border:1pt none;text-align:right;width:77px;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>5</span></span></span></span></td><td style="padding-bottom:1px;width:8px;border:1pt none;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;border:1pt none;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border:1pt none;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border:1pt none;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>7,500,000</span></span></span></span></td><td style="padding-bottom:1px;width:1%;border:1pt none;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="top"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">2019 Common Stock Warrants</span></span></p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(255, 255, 255);border-bottom:1pt solid black" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255);border-bottom:1pt solid black" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">0.35</span></span></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="text-align:right;width:77px;background-color:rgb(255, 255, 255);border-bottom:1pt solid black" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">5</span></span></td><td style="width:8px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="border-bottom:1pt solid black;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="border-bottom:1pt solid black;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">8,000,000</span></span></p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="background-color:rgb(204, 238, 255)" valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Total warrants vested and outstanding as of December 31, 2019</strong></span></span></span></span></p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:77px;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:8px;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>&#160;</strong></span></span></span></span></p></td><td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>25,143,250</strong></span></span></span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>&#160;</strong></span></span></span></span></p></td></tr></tbody></table><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><em>2019 Common Stock Warrants</em></span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">During the year ended December 31, 2019, the Company issued 8,000,000 fully vested common stock warrants to investors, in conjunction with the November 2019 Common Stock Offering discussed below (See Note 5). The warrants are equity classified at issuance and the Company allocated an aggregate of $722,208 of the gross proceeds to the warrants on a relative fair value basis. The warrants vested immediately and had an estimated aggregate fair value of $1,130,400 utilizing the Black-Scholes option pricing model with the following assumptions:</span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#160;</p><div><table border="0" cellpadding="0" cellspacing="0" style="border:0px" width="100%"><tbody><tr><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="bottom">&#160;</td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="bottom">&#160;</td><td colspan="2" style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>At Issuance</strong></span></span></td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="bottom">&#160;</td></tr><tr style="background-color:#cceeff"><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="top"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Dividend yield</span></span></td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom">&#160;</td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom">&#160;</td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">0.00</span></span></td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">%</span></span></td></tr><tr style="background-color:#ffffff"><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="top"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Volatility factor</span></span></td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom">&#160;</td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom">&#160;</td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">93.08</span></span></td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">%</span></span></td></tr><tr style="background-color:#cceeff"><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="top"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Risk-free interest rate</span></span></td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom">&#160;</td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom">&#160;</td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">1.62</span></span></td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">%</span></span></td></tr><tr style="background-color:#ffffff"><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="top"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Expected term (years)</span></span></td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom">&#160;</td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom">&#160;</td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">5.0</span></span></td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom">&#160;</td></tr><tr style="background-color:#cceeff"><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="top"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Underlying common stock price</span></span></td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom">&#160;</td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">0.22</span></span></td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom">&#160;</td></tr></tbody></table></div><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><i>Emerald Multi-Draw Credit Agreement Warrants</i></span></span></span></span><br/>&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">During the year ended December 31, 2019, the Company issued 5,000,000 fully vested common stock warrants to Emerald Health Sciences, in conjunction with advances under the Credit Agreement discussed below (See Note 4). The warrants are equity classified at issuance and the Company allocated an aggregate of $716,110 of the gross proceeds to the warrants on a relative fair value basis. The proceeds allocated to the warrants were recorded as discounts to each advance and are being amortized over the term of the debt. The warrants vested immediately and had an estimated aggregate fair value of $1,830,573 utilizing the Black-Scholes option pricing model with the following assumptions:</span></span></p><div><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#160;</p></div><div><div><table border="0" cellpadding="0" cellspacing="0" style="border:0px" width="100%"><tbody><tr><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="bottom">&#160;</td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="bottom">&#160;</td><td colspan="2" style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>At Issuance</strong></span></span></td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="bottom">&#160;</td></tr><tr style="background-color:#cceeff"><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="top"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Dividend yield</span></span></td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom">&#160;</td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom">&#160;</td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">0.00</span></span></td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">%</span></span></td></tr><tr style="background-color:#ffffff"><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="top"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Volatility factor</span></span></td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom">&#160;</td><td colspan="2" style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">91.6&#x2014;92.1</span></span></td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">%</span></span></td></tr><tr style="background-color:#cceeff"><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="top"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Risk-free interest rate</span></span></td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom">&#160;</td><td colspan="2" style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">2.23&#x2014;2.51</span></span></td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">%</span></span></td></tr><tr style="background-color:#ffffff"><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="top"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Expected term (years)</span></span></td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom">&#160;</td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom">&#160;</td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">5.0</span></span></td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom">&#160;</td></tr><tr style="background-color:#cceeff"><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="top"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Underlying common stock price</span></span></td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom">&#160;</td><td colspan="2" style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$0.33&#x2014;0.69</span></span></td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom">&#160;</td></tr></tbody></table></div></div><p style="MARGIN:0px;text-align:justify"><br/><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span>On November 1, 2018, the Company issued 2,500,000 </span></span>fully vested common stock warrants to Emerald Health Sciences, in conjunction with the first advance on the Credit Agreement discussed below (See Note 4). The warrants are equity classified at issuance and the Company allocated<span><span> $315,080 </span></span>of the gross proceeds to the warrants on a relative fair value basis. The proceeds allocated to the warrants was recorded as a discount to the November 1, 2018 advance and are being amortized over the term of the debt. The warrants vested immediately and had an estimated fair value of<span><span> $593,629 </span></span>utilizing the Black-Scholes option pricing model with the following assumptions:</span></span></span></span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><div><table border="0" cellpadding="0" cellspacing="0" style="font:10pt Times New Roman;margin:auto;text-align:justify;width:100%" width="85%"><tbody><tr><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong><strong>At</strong></strong></span></span></span></span></p><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong><strong>Issuance</strong></strong></span></span></span></span></td><td style="PADDING-BOTTOM:1px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Dividend yield</span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>0.00</span></span></span></span></td><td style="width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>%</span></span></span></span></td></tr><tr style="background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Volatility factor</span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>92.5</span></span></span></span></td><td style="width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>%</span></span></span></span></td></tr><tr style="background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Risk-free interest rate</span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>2.96</span></span></span></span></td><td style="width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>%</span></span></span></span></td></tr><tr style="background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Expected term (years)</span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>5.0</span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Underlying common stock price</span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>0.36</span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr></tbody></table></div><p style="MARGIN:0px;text-align:justify">&#160;</p><p><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><i>2018 Emerald Financing Warrants </i></span></span></span></span></p><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>In January and February 2018, the Company issued an aggregate of 40,800,000 and 3,400,000 </span></span><span><span>fully vested common stock warrants to Emerald Health Sciences and an accredited investor, respectively, in conjunction with the Emerald Financing discussed below (See Note 5). The Company reviewed the warrants for liability or equity classification under the guidance of ASC 480-10, <em>Distinguishing Liabilities from Equity</em>, and concluded that these warrants should be classified as liabilities. See the additional discussion below, <em>Derivative Liabilities- Emerald Financing Warrant Liability</em>. On December 20, 2019, Emerald Health Sciences paid the aggregate exercise price of $4,080,000 in the form of a reduction of the corresponding amount of obligations outstanding under the Credit Agreement to exercise 40,800,000 Emerald Financing Warrants.</span></span></span></span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong><i>Derivative Liabilities</i></strong></span></span></span></span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>The following tables summarize the activity of derivative liabilities for the periods indicated:</span></span></span></span></p><div><p style="MARGIN:0px">&#160;</p><table border="0" cellpadding="0" cellspacing="0" style="WIDTH:100%;TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN" width="100%"><tbody><tr><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="18" style="border:1pt none;text-align:center" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Year Ended December 31, 2019</strong></span></span></span></span></p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>December 31,</strong></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>2018, Fair</strong></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Value of</strong></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Derivative Liabilities</strong></span></span></span></span></p></td><td valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Fair Value of Derivative Liabilities Issued</strong></span></span></span></span></p></td><td valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td><td colspan="2" style="border-bottom:1px solid black;text-align:center;width:80px" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Change in</strong></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Fair value of&#160;Liabilities</strong></span></span></span></span></p></td><td style="width:8px" valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Reclassification</strong></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>of Derivatives</strong></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>to Equity&#160;or Extinguishment</strong></span></span></span></span></p></td><td valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>December 31,</strong></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>2019, Fair</strong></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Value of</strong></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Derivative Liabilities</strong></span></span></span></span></p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#cceeff"><td valign="top"><p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Emerald Multi Draw Credit Agreement - compound derivative liability (1)</span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:9px" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></td><td style="text-align:right;width:108px" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">219,453</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>516,058</span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></td><td style="text-align:right;width:72px" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(484,147</span></span></span></span></td><td style="width:8px" valign="bottom"><p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></td><td style="text-align:right;width:9%" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(160,567</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)*</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:6px" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></td><td style="text-align:right;width:73px" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>90,797</span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#ffffff"><td valign="top"><p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Emerald Financing - warrant liability (2)</span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:9px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:108px" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">15,251,413</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>&#x2014;</span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:72px" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(9,042,066</span></span></span></span></td><td style="width:8px" valign="bottom"><p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(5,933,323</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:6px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:73px" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>276,024</span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#cceeff"><td valign="top"><p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Series B - warrant liability (3)</span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:9px;border-bottom:1pt solid black" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:108px;border-bottom:1pt solid black" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>487,500</span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;border-bottom:1pt solid black" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;border-bottom:1pt solid black" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>&#x2014;</span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;border-bottom:1pt solid black" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:72px;border-bottom:1pt solid black" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(208,546</span></span></span></span></td><td style="width:8px" valign="bottom"><p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;border-bottom:1pt solid black" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;border-bottom:1pt solid black" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(144,375</span></span></span></span></td><td style="width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>)</span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:6px;border-bottom:1pt solid black" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:73px;border-bottom:1pt solid black" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>134,579</span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Total derivative liabilities</strong></span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-bottom:3px double black;width:9px" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>$</strong></span></span></span></span></td><td style="border-bottom:3px double black;text-align:right;width:108px" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>15,958,366</strong></span></span></span></span></td><td style="PADDING-BOTTOM:3px;width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>&#160;</strong></span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:black 3px double;width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>$</strong></span></span></span></span></td><td style="BORDER-BOTTOM:black 3px double;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>516,058</strong></span></span></span></span></td><td style="PADDING-BOTTOM:3px;width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>&#160;</strong></span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:black 3px double;width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>$</strong></span></span></span></span></td><td style="border-bottom:3px double black;text-align:right;width:72px" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>(9,734,759</strong></span></span></span></span></td><td style="padding-bottom:3px;width:8px" valign="bottom"><p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>)</strong></span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:black 3px double;width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>$</strong></span></span></span></span></td><td style="BORDER-BOTTOM:black 3px double;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>(6,238,265</strong></span></span></span></span></td><td style="PADDING-BOTTOM:3px;width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>)</strong></span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-bottom:3px double black;width:6px" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>$</strong></span></span></span></span></td><td style="border-bottom:3px double black;text-align:right;width:73px" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>501,400</strong></span></span></span></span></td><td style="PADDING-BOTTOM:3px;width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>&#160;</strong></span></span></span></span></p></td></tr><tr style="background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Less, noncurrent portion of derivative liabilities</span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:9px;border-bottom:1pt solid black" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:108px;border-bottom:1pt solid black" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(219,453</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:72px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:8px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-bottom:1px solid black;width:6px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-bottom:1px solid black;text-align:right;width:73px" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(90,797</span></span></span></span></td><td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>)</span></span></span></span></td></tr><tr style="background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Current balance of derivative liabilities</strong></span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:9px;border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial" valign="bottom"><p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>$</strong></span></span></p></td><td style="text-align:right;width:108px;border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>15,738,913</strong></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:72px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:8px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;border:1pt none" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;border:1pt none" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;width:6px" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>$</strong></span></span></span></span></td><td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;text-align:right;width:73px" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>410,603</strong></span></span></span></span></td><td style="PADDING-BOTTOM:3px;width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>&#160;</strong></span></span></span></span></p></td></tr></tbody></table><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><em>*This amount has been included in the calculation of the extinguishment loss recorded in connection with the prepayment of the Emerald Credit Agreement as described in Note 4 below.</em></span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#160;</p><table border="0" cellpadding="0" cellspacing="0" style="WIDTH:100%;TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN" width="100%"><tbody><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td colspan="18" style="border-bottom:1px solid black;text-align:center;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Year Ended December 31, 2018</strong></span></span></span></span></p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td colspan="2" style="border-bottom:1px solid black;text-align:center;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>December 31,</strong></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>2017, Fair</strong></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Value of</strong></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Derivative Liabilities</strong></span></span></span></span></p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td><td colspan="2" style="border-bottom:1px solid black;text-align:center;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Fair Value of Derivative Liabilities Issued</strong></span></span></span></span></p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td><td colspan="2" style="border-bottom:1px solid black;text-align:center;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Change in</strong></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Fair value of Derivative Liabilities</strong></span></span><span><span><strong>**</strong></span></span></span></span></p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td><td colspan="2" style="border-bottom:1px solid black;text-align:center;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Reclassification</strong></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>of Derivatives</strong></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>to Equity</strong></span></span></span></span></p></td><td style="background-color:rgb(255, 255, 255);width:6px" valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td><td style="width:12px;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td><td colspan="2" style="border-bottom:1px solid black;text-align:center;width:82px;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>December 31,</strong></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>2018, Fair</strong></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Value of</strong></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Derivative Liabilities</strong></span></span></span></span></p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="background-color:rgb(204, 238, 255)" valign="top"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Emerald Multi Draw Credit Agreement - compound derivative liability (1)</span></span></p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">&#x2014;</span></span></p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">204,102</span></span></p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">15,351</span></span></p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">&#x2014;</span></span></p></td><td style="width:6px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="width:12px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="width:11px;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">219,453</span></span></p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="top"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Emerald Financing - warrant liability (2)</span></span></p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">&#x2014;</span></span></p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">10,424,634</span></span></p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">4,826,779</span></span></p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">&#x2014;</span></span></p></td><td style="width:6px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="width:12px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="width:11px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">15,251,413</span></span></p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="background-color:rgb(204, 238, 255)" valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Series B - warrant liability (3)</span></span></span></span></p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>551,322</span></span></span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>&#x2014;</span></span></span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>1,476,044</span></span></span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(1,539,866</span></span></p></td><td style="width:6px;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></p></td><td style="width:12px;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:11px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>487,500</span></span></span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="top"><p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Emerald Convertible Promissory Note - conversion liability (4)</span></span></span></span></p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">265,000</span></span></p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>360,000</span></span></span></span></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">185,000</span></span></p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(810,000</span></span></p></td><td style="width:6px;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></p></td><td style="width:12px;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:11px;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>&#x2014;</span></span></span></span></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="background-color:rgb(204, 238, 255)" valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Series B Preferred Stock - conversion liability (5)</span></span></span></span></p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>6,715</span></span></span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>&#x2014;</span></span></span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>&#x2014;</span></span></span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(6,715</span></span></span></span></td><td style="width:6px;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>)</span></span></span></span></td><td style="width:12px;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:11px;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>&#x2014;</span></span></span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr><td style="background-color:rgb(255, 255, 255)" valign="top"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Total derivative liabilities</strong></span></span></p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="border-bottom:2.5pt double black;width:1%;background-color:rgb(255, 255, 255);border-top:1pt solid black;border-right:none;border-left:none;border-image:initial" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>$</strong></span></span></td><td style="border-bottom:2.5pt double black;text-align:right;width:9%;background-color:rgb(255, 255, 255);border-top:1pt solid black;border-right:none;border-left:none;border-image:initial" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>823,037</strong></span></span></td><td style="padding-bottom:3px;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="border-bottom:2.5pt double black;width:1%;background-color:rgb(255, 255, 255);border-top:1pt solid black;border-right:none;border-left:none;border-image:initial" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>$</strong></span></span></td><td style="border-bottom:2.5pt double black;text-align:right;width:9%;background-color:rgb(255, 255, 255);border-top:1pt solid black;border-right:none;border-left:none;border-image:initial" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>10,988,736</strong></span></span></td><td style="padding-bottom:3px;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="border-bottom:2.5pt double black;width:1%;background-color:rgb(255, 255, 255);border-top:1pt solid black;border-right:none;border-left:none;border-image:initial" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>$</strong></span></span></td><td style="border-bottom:2.5pt double black;text-align:right;width:9%;background-color:rgb(255, 255, 255);border-top:1pt solid black;border-right:none;border-left:none;border-image:initial" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>6,503,174</strong></span></span></td><td style="padding-bottom:3px;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="border-bottom:2.5pt double black;width:1%;background-color:rgb(255, 255, 255);border-top:1pt solid black;border-right:none;border-left:none;border-image:initial" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>$</strong></span></span></td><td style="border-bottom:2.5pt double black;text-align:right;width:9%;background-color:rgb(255, 255, 255);border-top:1pt solid black;border-right:none;border-left:none;border-image:initial" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>(2,356,581</strong></span></span></td><td style="padding-bottom:3px;width:6px;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>)</strong></span></span></td><td style="width:12px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="border-bottom:2.5pt double black;width:11px;background-color:rgb(255, 255, 255);border-top:1pt solid black;border-right:none;border-left:none;border-image:initial" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>$</strong></span></span></td><td style="border-bottom:2.5pt double black;text-align:right;width:9%;background-color:rgb(255, 255, 255);border-top:1pt solid black;border-right:none;border-left:none;border-image:initial" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>15,958,366</strong></span></span></td><td style="padding-bottom:3px;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="background-color:rgb(204, 238, 255)" valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Less, noncurrent portion of derivative liabilities</span></span></span></span></p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(551,322</span></span></p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:6px;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:12px;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border:1pt none;width:11px;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border:1pt none;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(219,453</span></span></span></span></td><td style="padding-bottom:1px;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>)</span></span></span></span></td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Current balance of derivative liabilities</strong></span></span></span></span></p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="width:1%;border-bottom:2.5pt double black;background-color:rgb(255, 255, 255);border-top:1pt solid black;border-right:none;border-left:none;border-image:initial" valign="bottom"><p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>$</strong></span></span></p></td><td style="text-align:right;width:9%;border-bottom:2.5pt double black;background-color:rgb(255, 255, 255);border-top:1pt solid black;border-right:none;border-left:none;border-image:initial" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>271,715</strong></span></span></p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:6px;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:12px;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-bottom:2.5pt double black;width:11px;background-color:rgb(255, 255, 255);border-top:1pt solid black;border-right:none;border-left:none;border-image:initial" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>$</strong></span></span></span></span></td><td style="border-bottom:2.5pt double black;text-align:right;width:9%;background-color:rgb(255, 255, 255);border-top:1pt solid black;border-right:none;border-left:none;border-image:initial" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>15,738,913</strong></span></span></span></span></td><td style="padding-bottom:3px;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>&#160;</strong></span></span></span></span></p></td></tr></tbody></table></div><p style="MARGIN:0px">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><em>**The change in fair value of derivative liabilities for the year ended December 31, 2018, relate partially to the Company determining it had sufficient trading activity to utilize the actual volatility of the trading of the Company&#x2019;s common stock as an input to the volatility assumption when computing the fair value of derivative liabilities. The volatility assumption was updated as of October 1, 2018 to incorporate the Company&#x2019;s own volatility with six similar companies to develop a blended average. The Company had previously estimated the volatility assumption by averaging the volatility of six similar entities which had resulted in a lower volatility. The increase in value of the volatility assumption has led to a higher valuation of the derivative liabilities as disclosed below.</em></span></span></span></span></p>&#160;<p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><i>Emerald Multi-Draw Credit Agreement Compound Derivative Liability (1)</i></span></span></span></span><br/>&#160;</p><p style="MARGIN:0px 0px 0px 0in;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>In connection with the advances under the Credit Agreement (See Note 4), the Company bifurcated a compound derivative liability related to a contingent interest feature and acceleration upon default provision (contingent put option) provided to Emerald Health Sciences. The Company&#x2019;s estimate of fair value of the compound derivative liability was determined by using a differential cash flows valuation model, wherein the fair value of the underlying debt facility and its conversion right are estimated both with and without the presence of the contingent interest feature, holding all other assumptions constant. The resulting difference between the estimated fair values in both scenarios is the estimated fair value of the compound derivative. The fair value of the underlying debt facility is estimated by calculating the expected cash flows with consideration of the estimated probability of a change in control transaction, defined as an event of default by the agreement, and applying the expected default interest rate from the date of such default through maturity. The expected cash flows are then discounted back to the reporting date using a benchmark market yield. The conversion right component of the compound derivative is measured using a standard Black-Scholes model for each payment period. Because Emerald Health Sciences would forgo the contingent interest if the contingent put option was exercised upon an event of default, the value ascribed to the contingent put option within the compound derivative is de minimis.</span></span></span></span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><i>Emerald Financing Warrant Liability (2)</i></span></span></span></span><br/>&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>In January and February 2018, the Company issued 44,200,000 warrants to purchase common stock in conjunction with the Emerald Financing discussed above. The warrants vest immediately and have an exercise price of $0.10 per share with a term of five years and are exercisable in cash or through a cashless exercise provision. The warrants contain an anti-dilution protection feature provided to the investors if the Company subsequently issues or sells any shares of common stock, stock options, or convertible securities at a price less than the exercise price of $0.10. The exercise price is automatically adjusted down to the price of the instrument being issued. </span></span><span><span>In addition, the warrants contain a contingent put option if the Company undergoes a subsequent financing that results in a change in control. The warrant holders also have the right to participate in subsequent financing transactions on an as-if converted basis.</span></span><br/><br/><span><span>In December 2019, Emerald Health Sciences paid the aggregate exercise price of $4,080,000 in the form of a reduction of the corresponding amount of obligations outstanding under the Credit Agreement to exercise 40,800,000 Emerald Financing Warrants. Under the Warrant Exercise Agreement between the Company and Emerald Health Sciences, the proceeds from the warrants were first applied directly to the accrued interest balance at the exercise date with the remainder applied to the oldest outstanding principal balances under the Credit Agreement. Immediately prior to exercise, the warrants were adjusted to fair value which considered the closing trading price on the exercise date (See Note 4).</span></span></span></span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>The Company reviewed the warrants for liability or equity classification under the guidance of ASC 480-10, <i>Distinguishing Liabilities from Equity</i>, and concluded that the warrants should be classified as a liability and re-measured to fair value at the end of each reporting period. </span></span><span><span>The Company also reviewed the warrants under ASC 815, <em>Derivatives and Hedging/Contracts in Entity&#x2019;s Own Equity</em>, and determined that the warrants also meet the definition of a derivative. With the assistance of a third-party valuation specialist, the Company valued the warrant liabilities utilizing the Monte Carlo valuation method pursuant to the accounting guidance of ASC 820-10, <em>Fair Value Measurement</em>s. On the closing dates, the Company estimated that the fair value of the warrants issued on January 19, 2018 and February 16, 2018 was</span></span><span><span> $4,717,211&#160;and $5,707,423, respectively.</span></span></span></span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The warrant liabilities were valued using Monte Carlo simulations conducted at the closing dates of January 19, 2018 and February 16, 2018 and at the balance sheet dates using the following assumptions:</span></span></p><p style="MARGIN:0px">&#160;</p><table border="0" cellpadding="0" cellspacing="0" style="WIDTH:100%;TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN;margin:auto" width="100%"><tbody><tr><td style="width:null" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>December 31,</strong></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>2019</strong></span></span></span></span></p></td><td style="PADDING-BOTTOM:1px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>December 31,</strong></span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>2018</strong></span></span></p></td><td style="PADDING-BOTTOM:1px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%">&#160;</td><td style="width:1%">&#160;</td><td style="border-bottom:1pt solid black;width:8%"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>At Issuance</strong></span></span></p></td><td style="width:1%">&#160;</td></tr><tr style="background-color:#cceeff"><td style="width:null" valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Dividend yield</span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>0.00</span></span></span></span></td><td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>%</span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>0.00</span></span></span></span></td><td style="width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>%</span></span></span></span></td><td style="width:1%">&#160;</td><td style="width:1%">&#160;</td><td style="width:8%"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">0.00</span></span></p></td><td style="width:1%"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">%</span></span></td></tr><tr style="background-color:#ffffff"><td style="width:null" valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Volatility factor</span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2"><p style="MARGIN:0px;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>79.5</span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>%</span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">92.1&#x2014;92.4</span></span></p></td><td style="width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>%</span></span></span></span></td><td style="width:1%">&#160;</td><td style="width:1%">&#160;</td><td style="text-align:right;width:8%"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">70.0</span></span></td><td style="width:1%"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">%</span></span></td></tr><tr style="background-color:#cceeff"><td style="width:null" valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Risk-free interest rate</span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>1.62</span></span></span></span></td><td style="width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>%</span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">2.49</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>%</span></span></span></span></p></td><td style="width:1%">&#160;</td><td style="width:1%">&#160;</td><td style="width:8%"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">2.45&#x2014;2.60</span></span></p></td><td style="width:1%"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">%</span></span></td></tr><tr style="background-color:#ffffff"><td style="width:null" valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Expected term (years)</span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2"><p style="MARGIN:0px;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>3.13</span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">4.05&#x2014;4.13</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%">&#160;</td><td style="width:1%">&#160;</td><td style="text-align:right;width:8%"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">5.0</span></span></td><td style="width:1%">&#160;</td></tr><tr style="background-color:#cceeff"><td style="width:null" valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Underlying common stock price</span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>0.13</span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></td><td><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">0.40</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%">&#160;</td><td style="width:1%"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></td><td style="width:8%"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">0.29&#x2014;0.30</span></span></p></td><td style="width:1%">&#160;</td></tr></tbody></table><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Because fair value assigned to the warrants exceeded the proceeds received in the Emerald Financing, none of the consideration was allocated to common stock and the Company recorded an adjustment for the difference between the fair value of the warrant liabilities and the total proceeds received to other expense in the Consolidated Statements Comprehensive Income (Loss) for the year ended December 31, 2018 as follows:</span></span></p><p style="MARGIN:0px">&#160;</p><table border="0" cellpadding="0" cellspacing="0" style="WIDTH:100%;TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN" width="100%"><tbody><tr><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="6" style="BORDER-BOTTOM:black 1px solid;text-align:center" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Closing</strong></span></span></span></span></p></td><td valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td><td colspan="2" style="text-align:center" valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td></tr><tr><td valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>January </strong></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>2018</strong></span></span></span></span></p></td><td valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>February</strong></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>2018</strong></span></span></span></span></p></td><td valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Total</strong></span></span></span></span></p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#cceeff"><td valign="top"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">Initial fair value of Emerald Financing Warrant Liability</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>4,717,211</span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>5,707,423</span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>10,424,634</span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#ffffff"><td valign="top"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">Less: proceeds from the Emerald Financing</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border:1pt none;width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border:1pt none;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>1,500,000</span></span></span></span></td><td style="padding-bottom:1px;width:1%;border:1pt none" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;border:1pt none" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border:1pt none;width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border:1pt none;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>1,750,000</span></span></span></span></td><td style="padding-bottom:1px;width:1%;border:1pt none" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;border:1pt none" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border:1pt none;width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border:1pt none;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>3,250,000</span></span></span></span></td><td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Excess over proceeds adjustment</strong></span></span></span></span></p></td><td style="width:1%;border:1pt none" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border:1pt none;width:1%" valign="bottom">&#160;</td><td style="border:1pt none;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>3,217,211</strong></span></span></span></span></td><td style="padding-bottom:3px;width:1%;border:1pt none" valign="bottom"><p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>&#160;</strong></span></span></span></span></p></td><td style="width:1%;border:1pt none" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border:1pt none;width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>$</strong></span></span></span></span></td><td style="border:1pt none;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>3,957,423</strong></span></span></span></span></td><td style="padding-bottom:3px;width:1%;border:1pt none" valign="bottom"><p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>&#160;</strong></span></span></span></span></p></td><td style="width:1%;border:1pt none" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border:1pt none;width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>$</strong></span></span></span></span></td><td style="border:1pt none;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>7,174,634</strong></span></span></span></span></td><td style="padding-bottom:3px;width:1%;border:1pt none" valign="bottom"><p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>&#160;</strong></span></span></span></span></p></td></tr></tbody></table><p style="MARGIN:0px">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>In addition, because the aggregate proceeds were allocated to the fair value of the Emerald Financing warrant liability, issuance costs totaling<span><span> $137,192 </span></span>were charged to other expense during the year ended December 31, 2018.</span></span></span></span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><i>Series B Warrant Liability (3)</i></span></span></span></span><br/>&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">In conjunction with the Redeemable Convertible Series B Preferred Stock financing, the Company issued the 2015 Series B Financing Warrants originally exercisable at a price of $1.15 per share. The warrants are exercisable in cash or through a cashless exercise provision and contain certain cash redemption rights. The Series B warrants also had a &#x201c;down-round&#x201d; protection feature if the Company subsequently issued or sold any shares of common stock, stock options, or convertible securities at a price less than the current exercise price. The down round provision was triggered and automatically adjusted down to $0.10 on December 28, 2017, after the Company entered into the Convertible Promissory Note (See Note 4) and again to $0.00 on January 19, 2018, as a result of the Emerald Financing (See Note 5). The strike price for these warrants is now permanently reset. However, because the remaining warrant holders still have certain cash redemption rights upon the occurrence of certain fundamental transactions, as defined in the Series B warrant agreements, the warrants continue to require liability classification. Subsequent to the repricing that occurred as a result of the Emerald Financing, the warrants have been valued using a Black Scholes Merton Option Pricing Model.</span></span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>To compute the fair value of the warrants, the Company utilized the following assumptions in the Black Scholes Merton Option Pricing Model for the periods indicated:</span></span></span></span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN;margin:auto" width="85%"><tbody><tr><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center" valign="bottom"><p style="MARGIN:0px 0px 0px 0in;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>As of </strong></span></span></span></span></p><p style="MARGIN:0px 0px 0px 0in;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>December 31,</strong></span></span></span></span></p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>2019</strong></span></span></span></span></p></td><td style="PADDING-BOTTOM:1px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>2018</strong></span></span></span></span></p></td><td style="PADDING-BOTTOM:1px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Dividend yield</span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>0.00</span></span></span></span></td><td style="width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>%</span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>0.00</span></span></span></span></td><td style="width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>%</span></span></span></span></td></tr><tr style="background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Volatility factor</span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>79.2</span></span></span></span></td><td style="width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>%</span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>93.0</span></span></span></span></td><td style="width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>%</span></span></span></span></td></tr><tr style="background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Risk-free interest rate</span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2"><p style="MARGIN:0px;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>1.60</span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>%</span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>2.79</span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>%</span></span></span></span></p></td></tr><tr style="background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Expected term (years)</span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2"><p style="MARGIN:0px;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>0.64</span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>1.64&#x2014;1.65</span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#cceeff"><td valign="top"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Underlying common stock price</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>0.13</span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>0.40</span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr></tbody></table><p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>&#160;&#160;</span></span></span></span></p><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span>In January 2018, 987,000 Series B warrants were exercised at a price of $0.10 resulting in cash proceeds to the Company of $98,700. </span></span>Prior to exercise, these Series B Warrants were adjusted to fair value using a Black Scholes Merton Option Pricing Model which considered the closing trading price on the exercise dates.<span><span> </span></span>For the year ended December 31, 2019 and for the period from January 19, 2018 through December 31, 2018, 187,500 and<span><span> 4,231,750 </span></span>Series B warrants were exercised for no consideration. Prior to exercise, these Series B Warrants were adjusted to fair value using a Black Scholes Merton Option Pricing Model which considered the closing trading price on the exercise dates. Because the exercise price of these options had been reset to $0.00, the fair value derived from the valuation model approximated the market value of the Company&#x2019;s common stock on the exercise dates.</span></span></span></span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><i>Emerald Convertible Promissory Note Conversion Liability (4)</i></span></span></span></span><br/>&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">In connection with the Convertible Promissory Note (See Note 4), the Company bifurcated a conversion liability related to an embedded conversion feature with a down-round protection provision. The Company valued the conversion liability pursuant to the accounting guidance of ASC 820-10, <em>Fair Value Measurement</em>s, as of the financing date of each closing utilizing the Black Scholes valuation model and the following assumptions:</span></span></p><p style="MARGIN:0px">&#160;</p><table border="0" cellpadding="0" cellspacing="0" style="WIDTH:100%;TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN" width="100%"><tbody><tr><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>January 19,</strong></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>2018</strong></span></span></span></span></p></td><td style="PADDING-BOTTOM:1px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Dividend yield</span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>0.00</span></span></span></span></td><td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>%</span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Volatility factor</span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>70.00</span></span></span></span></td><td style="width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>%</span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Risk-free interest rate</span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>1.29</span></span></span></span></td><td style="width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>%</span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Expected term (years)</span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>0.003</span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Underlying common stock price</span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>0.19</span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr></tbody></table><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The fair value of the conversion liability on January 19, 2018 was<span><span> $360,000</span></span>. In connection with the Emerald Financing discussed in Note 5 below, the Convertible Promissory Note was converted, and the conversion liability was extinguished with the debt.</span></span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><i>Series B Preferred Stock Conversion Liability (5)</i></span></span></span></span><br/>&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>On August 20, 2015, in connection with the Redeemable Convertible Series B Preferred Stock financing, the Company bifurcated a conversion liability related to the down-round protection provided to the Series B investors. The value of this embedded derivative was determined utilizing a &#x201c;with and without&#x201d; method by valuing the Series B Preferred Stock with and without the down-round protection. During the first fiscal quarter of 2018, all the remaining Series B Preferred Stock was converted to common stock and as a result, the Series B conversion liability was reduced to zero. The reduction of this liability totaling<span><span> $6,715 </span></span>was recorded to equity during the year ended December 31, 2018.</span></span></span></span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_WarrantsAndDerivativeLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_WarrantsAndDerivativeLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_WarrantsAndDerivativeLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for Warrants and Derivative Liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_WarrantsAndDerivativeLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6812556416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants and Derivative Liabilities (Details 3) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 16, 2018</div></th>
<th class="th"><div>Jan. 19, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_FairValueOfDerivativeLiabilitiesRollForward', window );"><strong>Fair Value Of Derivative Liabilities [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 823,037<span></span>
</td>
<td class="nump">$ 15,958,366<span></span>
</td>
<td class="nump">$ 823,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_FairValueOfWarrantsIssued', window );">Fair Value of Derivative Liabilities Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">516,058<span></span>
</td>
<td class="nump">10,988,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in Fair value of Derivative Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,734,759)<span></span>
</td>
<td class="nump">6,503,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_ReclassificationOfDerivativesToEquity', window );">Reclassification of Derivatives to Equity or Extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,238,265)<span></span>
</td>
<td class="num">(2,356,581)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">501,400<span></span>
</td>
<td class="nump">15,958,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Less, noncurrent portion of derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(90,797)<span></span>
</td>
<td class="num">(219,453)<span></span>
</td>
<td class="num">$ (551,322)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Current balance of derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">410,603<span></span>
</td>
<td class="nump">15,738,913<span></span>
</td>
<td class="nump">$ 271,715<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember', window );">Emerald Multi-Draw Credit Agreement - compound derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_FairValueOfDerivativeLiabilitiesRollForward', window );"><strong>Fair Value Of Derivative Liabilities [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">219,453<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_FairValueOfWarrantsIssued', window );">Fair Value of Derivative Liabilities Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">516,058<span></span>
</td>
<td class="nump">204,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in Fair value of Derivative Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(484,147)<span></span>
</td>
<td class="nump">15,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_ReclassificationOfDerivativesToEquity', window );">Reclassification of Derivatives to Equity or Extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(160,567)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,797<span></span>
</td>
<td class="nump">219,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_SeriesBWarrantMember', window );">Series B - warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_FairValueOfDerivativeLiabilitiesRollForward', window );"><strong>Fair Value Of Derivative Liabilities [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">551,322<span></span>
</td>
<td class="nump">487,500<span></span>
</td>
<td class="nump">551,322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_FairValueOfWarrantsIssued', window );">Fair Value of Derivative Liabilities Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in Fair value of Derivative Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(208,546)<span></span>
</td>
<td class="nump">1,476,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_ReclassificationOfDerivativesToEquity', window );">Reclassification of Derivatives to Equity or Extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(144,375)<span></span>
</td>
<td class="num">(1,539,866)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134,579<span></span>
</td>
<td class="nump">487,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember', window );">Emerald Convertible Promissory Note - conversion liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_FairValueOfDerivativeLiabilitiesRollForward', window );"><strong>Fair Value Of Derivative Liabilities [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">265,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">265,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_FairValueOfWarrantsIssued', window );">Fair Value of Derivative Liabilities Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in Fair value of Derivative Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_ReclassificationOfDerivativesToEquity', window );">Reclassification of Derivatives to Equity or Extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(810,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=embi_SeriesBPreferredStockConversionLiabilityMember', window );">Series B Preferred Stock - conversion liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_FairValueOfDerivativeLiabilitiesRollForward', window );"><strong>Fair Value Of Derivative Liabilities [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,715<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_FairValueOfWarrantsIssued', window );">Fair Value of Derivative Liabilities Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in Fair value of Derivative Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_ReclassificationOfDerivativesToEquity', window );">Reclassification of Derivatives to Equity or Extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,715)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=embi_EmeraldFinancingMember', window );">Emerald Financing - Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_FairValueOfDerivativeLiabilitiesRollForward', window );"><strong>Fair Value Of Derivative Liabilities [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">15,251,413<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_FairValueOfWarrantsIssued', window );">Fair Value of Derivative Liabilities Issued</a></td>
<td class="nump">$ 5,707,423<span></span>
</td>
<td class="nump">$ 4,717,211<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,424,634<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in Fair value of Derivative Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,042,066)<span></span>
</td>
<td class="nump">4,826,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_ReclassificationOfDerivativesToEquity', window );">Reclassification of Derivatives to Equity or Extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,933,323)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 276,024<span></span>
</td>
<td class="nump">$ 15,251,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_FairValueOfDerivativeLiabilitiesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of derivative liabilities at fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_FairValueOfDerivativeLiabilitiesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_FairValueOfWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of warrants issued in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_FairValueOfWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_ReclassificationOfDerivativesToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of derivatives reclassified to equity or the statement of operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_ReclassificationOfDerivativesToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_SeriesBWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_SeriesBWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=embi_SeriesBPreferredStockConversionLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=embi_SeriesBPreferredStockConversionLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=embi_EmeraldFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=embi_EmeraldFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6796493344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Warrants and Derivative Liabilities (Details 7) - Black-Scholes option pricing model - Emerald Convertible Promissory Note - conversion liability<br></strong></div></th>
<th class="th">
<div>Jan. 19, 2018 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Underlying common stock price</a></td>
<td class="nump">$ 0.19<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input (in percent)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility factor</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input (in percent)</a></td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input (in percent)</a></td>
<td class="nump">1.29<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected Term (years)</a></td>
<td class="text">1 day<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_PricingModelAxis=embi_PricingModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_PricingModelAxis=embi_PricingModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6793887632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details 3) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax positions, beginning of the year</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Gross increase - current period tax positions</a></td>
<td class="nump">552,082<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax positions, end of year</a></td>
<td class="nump">$ 552,082<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=SL37586934-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6796461136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">182,895,247<span></span>
</td>
<td class="nump">133,907,747<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">182,895,247<span></span>
</td>
<td class="nump">133,907,747<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6664621360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share of Common Stock (Details 1) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive excluded from the calculation of diluted net loss per share</a></td>
<td class="nump">4,119,931<span></span>
</td>
<td class="nump">3,600,073<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Unvested restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive excluded from the calculation of diluted net loss per share</a></td>
<td class="nump">234,645<span></span>
</td>
<td class="nump">1,543,501<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Common shares underlying convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive excluded from the calculation of diluted net loss per share</a></td>
<td class="nump">5,036,250<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive excluded from the calculation of diluted net loss per share</a></td>
<td class="nump">20,712,000<span></span>
</td>
<td class="nump">53,130,750<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6813894176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)<br></strong></div></th>
<th class="th"><div>Convertible Series F Preferred Stock</div></th>
<th class="th"><div>Convertible Series D Preferred Stock</div></th>
<th class="th"><div>Redeemable Convertible Series B Preferred Stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2017</a></td>
<td class="nump">$ 1,777,781<span></span>
</td>
<td class="nump">$ 169,447<span></span>
</td>
<td class="nump">$ 822,201<span></span>
</td>
<td class="nump">$ 33,623<span></span>
</td>
<td class="nump">$ 10,427,742<span></span>
</td>
<td class="num">$ (14,030,871)<span></span>
</td>
<td class="num">$ (3,569,506)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2017</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">2,834<span></span>
</td>
<td class="nump">33,622,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">674,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">674,961<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common stock issued for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,143<span></span>
</td>
<td class="num">(3,143)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Common stock issued for services (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,143,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_StockIssuedDuringPeriodValueNetOfIssuanceCosts', window );">Issuance of common stock net of issuance costs of $16,900</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,500<span></span>
</td>
<td class="num">(49,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,900)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_StockIssuedDuringPeriodSharesNetOfIssuanceCosts', window );">Issuance of common stock net of issuance costs of $16,900 (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue', window );">Conversion of Series B Preferred Stock and conversion liability into common stock at $0.10 and $0.001 per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (822,201)<span></span>
</td>
<td class="nump">$ 28,385<span></span>
</td>
<td class="nump">800,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">828,915<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares', window );">Conversion of Series B Preferred Stock and conversion liability into common stock at $0.10 and $0.001 per share (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,834)<span></span>
</td>
<td class="nump">28,385,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_ConversionOfSeriesDPreferredStockToCommonStock', window );">Conversion of Series D Preferred Stock to common stock at $0.10 per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (169,447)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">167,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,447<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_ConversionOfSeriesDPreferredStockToCommonStockShares', window );">Conversion of Series D Preferred Stock to common stock at $0.10 per share (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_ConversionOfSeriesFPreferredStockToCommonStockValue', window );">Conversion of Series F Preferred Stock to common stock at $0.10 per share</a></td>
<td class="num">$ (1,777,781)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">1,757,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,777,781<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_ConversionOfSeriesFPreferredStockToCommonStockShares', window );">Conversion of Series F Preferred Stock to common stock at $0.10 per share (in shares)</a></td>
<td class="num">(2,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest', window );">Conversion of secured convertible promissory note - related party and accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,038<span></span>
</td>
<td class="nump">1,714,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,723,560<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterestShares', window );">Conversion of secured convertible promissory note - related party and accrued interest (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,037,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue', window );">Warrants issued in connection with convertible multi-draw credit agreement, related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">315,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">315,080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue', window );">Beneficial conversion feature in connection with convertible multi-draw credit agreement - related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_StockIssuedDuringPeriodValueSeriesBWarrantExercises', window );">Series B warrant exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,219<span></span>
</td>
<td class="nump">1,633,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,638,566<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_StockIssuedDuringPeriodSharesSeriesBWarrantExercises', window );">Series B warrant exercises (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,218,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,194,236)<span></span>
</td>
<td class="num">(19,194,236)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 133,908<span></span>
</td>
<td class="nump">17,528,947<span></span>
</td>
<td class="num">(33,225,107)<span></span>
</td>
<td class="num">(15,562,252)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133,907,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">680,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">680,455<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_StockIssuedDuringPeriodValueNetOfIssuanceCostsAndWarrants', window );">Issuance of common stock and warrants, net of issuance costs of $80,628</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="nump">1,911,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,919,372<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_StockIssuedDuringPeriodSharesNetOfIssuanceCostsAndWarrants', window );">Issuance of common stock and warrants, net of issuance costs of $80,628 (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue', window );">Warrants issued in connection with convertible multi-draw credit agreement, related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">716,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">716,110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue', window );">Beneficial conversion feature in connection with convertible multi-draw credit agreement - related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,584,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,584,850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_StockIssuedDuringPeriodValueSeriesBWarrantExercises', window );">Series B warrant exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 187<span></span>
</td>
<td class="nump">144,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_StockIssuedDuringPeriodSharesSeriesBWarrantExercises', window );">Series B warrant exercises (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_FinancingValueWarrantExercise', window );">Exercise of Emerald financing warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,800<span></span>
</td>
<td class="nump">9,972,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,013,323<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_FinancingSharesWarrantExercise', window );">Exercise of Emerald financing warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,051,825<span></span>
</td>
<td class="nump">1,051,825<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 182,895<span></span>
</td>
<td class="nump">$ 32,538,445<span></span>
</td>
<td class="num">$ (32,173,282)<span></span>
</td>
<td class="nump">$ 548,058<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">182,895,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents beneficial conversion feature in connection with convertible multi-draw credit agreement - related party value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents conversion of Preferred Stock Series and conversion liability into common stock, shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents conversion of Preferred Stock Series and conversion liability into common stock, value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents value conversion of secured convertible promissory note related party and accrued interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterestShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents value conversion of secured convertible promissory note related party and accrued interest shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterestShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_ConversionOfSeriesDPreferredStockToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents conversion of Preferred Stock Series and conversion of series D preferred stock to common stock, value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_ConversionOfSeriesDPreferredStockToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_ConversionOfSeriesDPreferredStockToCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents conversion of Preferred Stock Series and conversion series D preferred stock common stock, shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_ConversionOfSeriesDPreferredStockToCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_ConversionOfSeriesFPreferredStockToCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of series F preferred stock converted during the period into common stocks.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_ConversionOfSeriesFPreferredStockToCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_ConversionOfSeriesFPreferredStockToCommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of series F preferred stock converted into common stocks during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_ConversionOfSeriesFPreferredStockToCommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_FinancingSharesWarrantExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents number of shares related to exercise of emerald financing warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_FinancingSharesWarrantExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_FinancingValueWarrantExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount related to Exercise of emerald financing warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_FinancingValueWarrantExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_StockIssuedDuringPeriodSharesNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period net of issuance costs value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_StockIssuedDuringPeriodSharesNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_StockIssuedDuringPeriodSharesNetOfIssuanceCostsAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents number of shares related to issuance of common stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_StockIssuedDuringPeriodSharesNetOfIssuanceCostsAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_StockIssuedDuringPeriodSharesSeriesBWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Series B warrant exercises for common stock issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_StockIssuedDuringPeriodSharesSeriesBWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_StockIssuedDuringPeriodValueNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of common stock issued during the period net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_StockIssuedDuringPeriodValueNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_StockIssuedDuringPeriodValueNetOfIssuanceCostsAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount related to issuance of common stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_StockIssuedDuringPeriodValueNetOfIssuanceCostsAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_StockIssuedDuringPeriodValueSeriesBWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of Series B warrant exercises for common stock issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_StockIssuedDuringPeriodValueSeriesBWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents warrants issued in connection with convertible multi draw credit agreement related party value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116855982&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6813917600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>6. Stock-Based Compensation</strong><strong> </strong></span></span></span></span></span></span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong><i>Stock Incentive Plan</i></strong></span></span></span></span></span></span><br/>&#160;</p><p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>On October 31, 2014, after the closing of the Merger, the Board approved the Company&#x2019;s 2014 Omnibus Incentive Plan (the &#x201c;2014 Plan&#x201d;). The 2014 Plan initially reserved 3,200,000 shares for future grants. In October 2018, the Company increased the share reserve under the 2014 Plan to equal 10% of the number of issued and outstanding shares of common stock of the Company. The 2014 Plan authorizes the issuance of awards including stock options, stock appreciation rights, restricted stock, stock units and performance units to employees, directors, and consultants of the Company. As of December 31, 2019, the shares available for future grant under the 2014 Plan are as follows:</span></span></span></span></span></span></p><p style="MARGIN:0px">&#160;</p><table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN;margin:auto" width="85%"><tbody><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="border-bottom:1px solid black;text-align:center;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Shares Available for Grant</strong></span></span></span></span></span></span></p></td><td style="padding-bottom:1px;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="top"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Available as of December 31, 2018</strong></span></span></p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></p></td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>9,142,273</strong></span></span></span></span></span></span></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></p></td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="background-color:rgb(204, 238, 255)" valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Share pool increase</span></span></span></span></span></span></p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>4,898,750</span></span></span></span></span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Forfeited</span></span></span></span></span></span></p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>153,125</span></span></span></span></span></span></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="background-color:rgb(204, 238, 255)" valign="top"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cancelled</span></span></p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>196,875</span></span></span></span></span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Granted</span></span></span></span></span></span></p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-bottom:1px solid black;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-bottom:1px solid black;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>(1,262,642</span></span></span></span></span></span></td><td style="padding-bottom:1px;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>)</span></span></span></span></span></span></td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="background-color:rgb(204, 238, 255)" valign="top"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Available as of December 31, 2019</strong></span></span></p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-bottom:2.5pt double black;width:1%;background-color:rgb(204, 238, 255);border-top:none;border-right:none;border-left:none;border-image:initial" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></p></td><td style="border-bottom:2.5pt double black;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-top:none;border-right:none;border-left:none;border-image:initial" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>13,128,381</strong></span></span></span></span></span></span></td><td style="padding-bottom:3px;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></p></td></tr></tbody></table><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>&#160;&#160;</span></span></span></span></span></span></p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><i>Stock Options</i></span></span></span></span></span></span><br/>&#160;</p><p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Options granted under the 2014 Plan expire no later than ten&#160;years from the date of grant. Options granted under the 2014 Plan may be either incentive or non-qualified stock options. For incentive and non-qualified stock option grants, the option price shall be at least 100% of the fair value on the date of grants, as determined by the Company&#x2019;s Board of Directors. If at any time the Company grants an option, and the optionee directly or by attribution owns stock possessing more than 10% of the total combined voting power of all classes of stock of the Company, the option price shall be at least 110% of the fair value and shall not be exercisable more than five years after the date of grant.</span></span></span></span></span></span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Options granted under the 2014 Plan may be immediately exercisable if permitted in the specific grant approved by the Board of Directors and, if exercised early may be subject to repurchase provisions. The shares issued generally vest over a period of one to five years from the date of grant.</span></span></span></span></span></span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>The following is a summary of option activities under the Company&#x2019;s 2014 Plan for the year ended December 31, 2019:</span></span></span></span></span></span></p><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>&#160;&#160;</span></span></span></span></span></span></p><div><table border="0" cellpadding="0" cellspacing="0" style="font:10pt Times New Roman;margin:auto;text-align:justify;width:100%" width="85%"><tbody><tr><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:9px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="border-bottom:1px solid black;text-align:center;width:76px" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Number of</strong></span></span></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Shares</strong></span></span></span></span></span></span></p></td><td style="PADDING-BOTTOM:1px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Weighted</strong></span></span></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Average</strong></span></span></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Exercise Price</strong></span></span></span></span></span></span></p></td><td style="PADDING-BOTTOM:1px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Weighted</strong></span></span></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Average Remaining</strong></span></span></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Contractual</strong></span></span></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Term</strong></span></span></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>(Years)</strong></span></span></span></span></span></span></p></td><td style="PADDING-BOTTOM:1px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Aggregate Intrinsic Value*</strong></span></span></span></span></span></span></p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#cceeff"><td valign="top"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Outstanding, December 31, 2018</strong></span></span></p></td><td style="width:9px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:5px" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>2,405,000</strong></span></span></span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>$</strong></span></span></span></span></span></span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>0.33</strong></span></span></span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:6px" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></p></td><td style="text-align:right;width:72px" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>8.71</strong></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="text-align:right;width:9%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#ffffff"><td><p style="MARGIN:0px">&#160;</p></td><td style="width:9px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:5px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:6px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:72px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="text-align:right;width:9%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Granted</span></span></span></span></span></span></p></td><td style="width:9px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:5px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>1,262,642</span></span></span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>0.30</span></span></span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:6px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:72px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="text-align:right;width:9%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#ffffff"><td valign="top"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cancelled</span></span></p></td><td style="width:9px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:5px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>(196,875</span></span></span></span></span></span></td><td style="width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>)</span></span></span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>0.26</span></span></span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:6px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:72px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="text-align:right;width:9%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Forfeited</span></span></span></span></span></span></p></td><td style="width:9px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-bottom:1px solid black;width:5px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:black 1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>(153,125</span></span></span></span></span></span></td><td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>)</span></span></span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:black 1px solid;width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:black 1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>0.26</span></span></span></span></span></span></td><td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-bottom:1px solid black;width:6px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-bottom:1px solid black;text-align:right;width:72px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:black 1px solid;width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:right;width:9%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#ffffff"><td valign="top"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Outstanding, December 31, 2019</strong></span></span></p></td><td style="width:9px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-bottom:3px double black;width:5px" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></p></td><td style="BORDER-BOTTOM:black 3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>3,317,642</span></span></span></span></span></span></td><td style="PADDING-BOTTOM:3px;width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:black 3px double;width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>$</strong></span></span></span></span></span></span></td><td style="BORDER-BOTTOM:black 3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>0.33</span></span></span></span></span></span></td><td style="PADDING-BOTTOM:3px;width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-bottom:3px double black;width:6px" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></p></td><td style="border-bottom:3px double black;text-align:right;width:72px" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>8.34</span></span></span></span></span></span></td><td style="PADDING-BOTTOM:3px;width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:black 3px double;width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>$</strong></span></span></span></span></span></span></td><td style="BORDER-BOTTOM:black 3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>&#x2014;</span></span></span></span></span></span></td><td style="PADDING-BOTTOM:3px;width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></p></td></tr><tr style="background-color:#cceeff"><td valign="top"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Exercisable, December 31, 2019</strong></span></span></p></td><td style="width:9px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-bottom:1px solid black;width:5px" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></p></td><td style="BORDER-BOTTOM:black 1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>2,399,356</span></span></span></span></span></span></td><td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:black 1px solid;width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>$</strong></span></span></span></span></span></span></td><td style="BORDER-BOTTOM:black 1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>0.34</span></span></span></span></span></span></td><td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-bottom:1px solid black;width:6px" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></p></td><td style="border-bottom:1px solid black;text-align:right;width:72px" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>7.84</span></span></span></span></span></span></td><td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:black 1px solid;width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>$</strong></span></span></span></span></span></span></td><td style="BORDER-BOTTOM:black 1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>&#x2014;</span></span></span></span></span></span></td><td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></p></td></tr><tr style="background-color:#ffffff"><td valign="top"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Vested and expected to vest, December 31, 2019</strong></span></span></p></td><td style="width:9px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;width:5px" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></p></td><td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>3,317,642</span></span></span></span></span></span></td><td style="padding-bottom:1px;width:1%;border:1pt none" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></p></td><td style="width:1%;border:1pt none" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>$</strong></span></span></span></span></span></span></td><td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>0.33</span></span></span></span></span></span></td><td style="padding-bottom:1px;width:1%;border:1pt none" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></p></td><td style="width:1%;border:1pt none" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;width:6px" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></p></td><td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;text-align:right;width:72px" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>8.34</span></span></span></span></span></span></td><td style="padding-bottom:1px;width:1%;border:1pt none" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></p></td><td style="width:1%;border:1pt none" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>$</strong></span></span></span></span></span></span></td><td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>&#x2014;</span></span></span></span></span></span></td><td style="padding-bottom:1px;width:1%;border:1pt none" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></p></td></tr></tbody></table><p style="MARGIN:0px">&#160;</p><p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><i>*The aggregate intrinsic value is the sum of the amounts by which the quoted market price of the Company&#x2019;s stock exceeded the exercise price of the stock options at December 31, 2019&#160;for those stock options for which the quoted market price was in excess of the exercise price (&#x201c;in-the-money options&#x201d;).</i></span></span></span></span></span></span></p></div><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>The weighted-average grant-date fair value of stock options granted for the years ended December 31, 2019 and 2018 was $0.22 and $0.30, respectively. The total fair value of the stock options that vested during the years ended December 31, 2019 and 2018 was $473,030 and $418,688, respectively.</span></span></span></span></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="margin:0px 0px 0px 0in;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>The fair value of each stock option grant was estimated on the date of grant using the Black-Scholes option-pricing model under the following assumptions:</span></span></span></span></span></span></p><div><div><p style="MARGIN:0px">&#160;</p><table border="0" cellpadding="0" cellspacing="0" style="font:10pt Times New Roman;margin:auto;text-align:justify;width:100%" width="85%"><tbody><tr><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Year&#160;Ended December 31,</strong></span></span></p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2019</strong></span></span></p></td><td style="PADDING-BOTTOM:1px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2018</strong></span></span></p></td><td style="PADDING-BOTTOM:1px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dividend yield</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.00</span></span></td><td style="width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.00</span></span></td><td style="width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></td></tr><tr style="background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Risk-free interest rate</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.49</span></span></td><td style="width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td>&#160;</td><td><p style="MARGIN:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3.06&#x2014;3.10</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></p></td></tr><tr style="background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected term (years)</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5.65</span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td>&#160;</td><td><p style="MARGIN:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5.27&#x2014;5.58</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Volatility</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">93.72</span></span></td><td style="width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td>&#160;</td><td><p style="MARGIN:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">70.00&#x2014;93.60</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></p></td></tr></tbody></table></div><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><i>Restricted Stock Awards</i></span></span></span></span></span></span><br/>&#160;</p></div><p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>There was no restricted stock award (&#x201c;RSA&#x201d;) activity under the Company&#x2019;s 2014 Plan during the year ended December 31, 2019.</span></span></span></span></span></span></p><p style="margin:0px;text-align:justify"><br/><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>On February 28, 2018, in conjunction with the signing of the K2C separation agreement discussed in Note 11 below, Mr. Lykos&#x2019; RSAs amounting to </span>325,000<span> shares vested immediately resulting in a Type III award modification and a credit to stock compensation of $</span>98,042<span> for the year ended December 31, 2018 due to a lower fair value of those shares as of the modification date.</span></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>On May 25, 2018, in conjunction with the signing of her separation agreement, the former Nemus CFO, Ms. Elizabeth Berecz&#x2019;s RSA&#x2019;s amounting to 350,000 shares vested immediately resulting in a Type III award modification and a credit to stock compensation of $97,183 for the year ended December 31, 2018 due to a lower fair value of those shares as of the modification date as compared to the fair value immediately prior to acceleration.</span></span></span></span></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong><i>Awards Granted Outside the 2014 Plan</i></strong></span></span></span></span></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><i>Options</i></span></span></span></span></span></span></p><p style="margin:0px;text-align:justify"><br/><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>There was no option activity outside of the 2014 Plan during the year ended December 31, 2019.</span></span></span></span></span></span><br/>&#160;</p><p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>On May 25, 2018, the Company entered into Stock Option Agreement with Douglas Cesario, CFO, granting 1,195,073 stock options with an exercise price equal to $0.245 and a grant date fair value of $200,772 or $0.26 per share based on the following assumptions estimated on the date of grant using the Black-Scholes option-pricing model:</span></span></span></span></span></span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><table border="0" cellpadding="0" cellspacing="0" style="font:10pt Times New Roman;margin:auto;text-align:justify;width:100%" width="85%"><tbody><tr><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td>&#160;</td><td style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>At Issuance</strong></span></span></span></span></span></span></p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Dividend Yield</span></span></span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>0.00</span></span></span></span></span></span></td><td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"><p style="MARGIN:0px">%</p></td></tr><tr style="background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Risk-free interest rate</span></span></span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>2.79</span></span></span></span></span></span></td><td style="width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>%</span></span></span></span></span></span></td></tr><tr style="background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Expected term (in years)</span></span></span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>5.54</span></span></span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Volatility</span></span></span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>70</span></span></span></span></span></span></td><td style="width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>%</span></span></span></span></span></span></td></tr></tbody></table><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>The options vested 25% on July 23, 2018, and the remaining 75% will vest 1/33 on each of the next 33 months thereafter. Options will fully vest upon a triggering event, including a sale of the Company or a merger that results in a change of control. At December 31, 2019, these options have a remaining contractual life of 8.57 years. At December 31, 2019, 760,501 options are exercisable and have no intrinsic value. At December 31, 2019, 1,195,073 options are vested and are expected to vest and have no intrinsic value.<br/><br/>The total fair value of stock options that vested during the years ended December 31, 2019 and 2018 were $54,756 and $73,008, respectively.</span></span></span></span></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><i>Restricted Stock Awards</i></span></span></span></span></span></span><br/>&#160;</p><p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>On January 18, 2018, the Company entered into Restricted Stock Agreements with each of Dr. Murphy, Elizabeth Berecz, CFO, and Cosmas N. Lykos, the Company&#x2019;s Founder granting 900,000, 700,000, and 900,000 shares of restricted common stock, respectively, with a fair value of $475,000. These agreements were issued outside of the 2014 Omnibus Incentive Plan. The restricted stock vests in equal 50% installments on the first and second anniversaries of the grant date, subject to continued employment with the Company through the applicable vesting date. Each Restricted Stock Agreement provides that if an executive&#x2019;s employment or service is terminated by the Company without cause, or is terminated by the grantee for good reason, then the executive shall be entitled to receive a cash severance payment equal to six months of their base compensation, payable in substantially equal installments during the six-month period following the separation along with accelerated vesting of all outstanding stock awards.</span></span></span></span></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>On February 28, 2018, in conjunction with the signing of the K2C separation agreement discussed in Note 8 below, Mr. Lykos&#x2019; Restricted stock awards amounting to 900,000 shares became immediately vested resulting in a Type III award modification and stock compensation expense of $216,000 for the year ended December 31, 2018, due to an increase in the fair value of the award immediately before and after the modification date.</span></span></span></span></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On May 25, 2018, in conjunction with the signing of her separation agreement discussed above, the Company&#x2019;s former CFO, Ms. Elizabeth Berecz&#x2019;s Restricted stock awards amounting to 700,000 shares became immediately vested resulting in the recording of compensation expense of<span><span> $184,800 for the year ended December 31, 2018, due to an increase in the fair value of the award immediately before and after the modification date.</span></span></span></span></span></span></p><p style="margin:0px 0px 0px 0in;text-align:justify">&#160;</p><p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The following is a summary of RSA activity outside of the Company&#x2019;s 2014 Plan during the year ended December 31, 2019:</span></span></span></span></p><p style="MARGIN:0px">&#160;</p><table border="0" cellpadding="0" cellspacing="0" style="font:10pt Times New Roman;margin:auto;text-align:justify;width:100%" width="85%"><tbody><tr><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Number of</strong></span></span></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Shares</strong></span></span></span></span></span></span></p></td><td style="PADDING-BOTTOM:1px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Weighted </strong></span></span></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Average Grant </strong></span></span></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Date Fair Value</strong></span></span></span></span></span></span></p></td><td style="PADDING-BOTTOM:1px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#cceeff"><td valign="top"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Unvested, December 31, 2018</strong></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>900,000</strong></span></span></span></td><td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:7px" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>$</strong></span></span></span></span></span></span></td><td style="text-align:right;width:72px" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>0.19</span></span></span></td><td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></p></td></tr><tr style="background-color:#ffffff"><td><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:7px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:72px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Granted</span></span></span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>&#x2014;</span></span></span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:7px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:72px" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>&#x2014;</span></span></span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Released</span></span></span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border:1pt none;width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border:1pt none;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>(450,000</span></span></span></span></span></span></td><td style="padding-bottom:1px;width:1%;border:1pt none" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>)</span></span></span></span></span></span></td><td style="width:1%;border:1pt none" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border:1pt none;width:7px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border:1pt none;text-align:right;width:72px" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>0.19</span></span></span></span></span></span></td><td style="padding-bottom:1px;width:1%;border:1pt none" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#cceeff"><td valign="top"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Unvested, December 31, 2019</strong></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-top:1pt solid black;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></p></td><td style="border-top:1pt solid black;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>450,000</strong></span></span></span></span></span></span></td><td style="padding-bottom:3px;width:1%;border:1pt none" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></p></td><td style="width:1%;border:1pt none" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-top:1pt solid black;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;width:7px" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>$</strong></span></span></span></span></span></span></td><td style="border-top:1pt solid black;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;text-align:right;width:72px" valign="bottom"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>0.19</span></span></span></span></span></span></strong></td><td style="padding-bottom:3px;width:1%;border:1pt none" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></p></td></tr></tbody></table><p style="MARGIN:0px">&#160;</p><p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong><i>Stock-Based Compensation Expense</i></strong></span></span></span></span></span></span><br/>&#160;</p><p style="margin:0px 0px 0px 0in;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The Company recognizes stock-based compensation expense using the straight-line method over the requisite service period. For the years ended December 31, 2019 and 2018, the Company recognized stock-based compensation expense of<span><span> $680,455 and $674,961, </span></span>respectively (including compensation expense for RSAs discussed above), which was recorded as a general and administrative expense in the Consolidated Statements of Comprehensive Income (Loss). The total amount of unrecognized compensation cost was<span><span> $312,405 </span></span>as of December 31, 2019. This amount will be recognized over a weighted-average period of 2.07 years.</span></span></span></span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6801708704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span><span><span><strong>2. Summary of Significant Accounting Policies</strong></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><div><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span><span><span><strong><i>Basis of Presentation</i></strong></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span>The preparation of financial statements in conformity with U.S. Generally Accepted Accounting Principles (&#x201c;GAAP&#x201d;) requires management to make estimates and assumptions that affect the amounts reported in the Consolidated Financial Statements and the accompanying notes. Actual results could differ from those estimates. Certain reclassifications have been made to prior year amounts to conform to the current year&#x2019;s presentation. Such reclassifications had no net effect on the prior year&#x2019;s total assets, total liabilities, total stockholders&#x2019; deficit, net loss and cash flows.</span></span></span></span></span></span></span></span></span></span></span></span></p></div><p style="margin:0px;text-align:justify">&#160;</p><div><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span><span><span><strong><i>Use of Estimates</i></strong></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span>The preparation of the Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Consolidated Financial Statements and the reported amounts of income and expense during the reporting period. Actual results could differ from those estimates. The most significant accounting estimates inherent in the preparation of the Company&#x2019;s financial statements include estimates as to the appropriate carrying value of certain assets and liabilities which are not readily apparent from other sources. Such estimates and judgments are utilized for stock-based compensation expense, equity securities, derivative liabilities and debt with embedded features.</span></span></span></span></span></span></span></span></span></span></span></span></p></div><p style="margin:0px;text-align:justify">&#160;</p><div><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span><span><span><strong><i>Risks and Uncertainties</i></strong></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span>The Company&#x2019;s operations are subject to a number of risks and uncertainties, including but not limited to, changes in the general economy, the size and growth of the potential markets for any of the Company&#x2019;s product candidates, results of research and development activities, uncertainties surrounding regulatory developments in the United States and Australia and the Company&#x2019;s ability to attract new funding.</span></span></span></span></span></span></span></span></span></span></span></span></p></div><p style="margin:0px;text-align:justify">&#160;</p><div><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span><span><span><strong><i>Cash and Cash Equivalents</i></strong></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span>The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The carrying values of those investments approximate&#160;their fair value due to their short maturity and liquidity. Cash includes cash on hand and amounts on deposit with financial institutions, which amounts may at times exceed federally insured limits. The Company has not experienced any losses on such accounts and does not believe it is exposed to any significant credit risk. As of December 31, 2019, the Company has no cash equivalents.</span></span></span></span></span></span></span></span></span></span></span></span></p></div><p style="margin:0px;text-align:justify">&#160;</p><div><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span><span><span><strong><i>Restricted Cash</i></strong></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span><span><span>A deposit of $4,538 and $4,512 </span></span>as of December 31, 2019 and&#160;2018, respectively, was restricted from withdrawal and held by a bank in the form of a certificate of deposit. This certificate serves as collateral for payment of the Company&#x2019;s credit cards.</span></span></span></span></span></span></span></span></span></span></span></span></p></div><p style="margin:0px;text-align:justify">&#160;</p><div><p style="text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span><span><span><strong><i>Fair Value Measurements</i></strong></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span><span><span>Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (the &#x201c;exit price&#x201d;) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last is considered unobservable, is used to measure fair value:</span></span></span></span></span></span></span></span></span></span></span></span></span></span></p><p style="MARGIN:0px">&#160;</p><table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN" width="100%"><tbody><tr style="height:15"><td style="width:7%" valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span><span><span>Level 1:</span></span></span></span></span></span></span></span></span></span></span></span></span></span></p></td><td style="width:93%" valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span><span><span>Valuations for assets and liabilities traded in active markets from readily available pricing sources such as quoted prices in active markets for identical assets or liabilities.</span></span></span></span></span></span></span></span></span></span></span></span></span></span></p></td></tr><tr style="height:15"><td valign="top">&#160;</td><td valign="top">&#160;</td></tr><tr style="height:15"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span><span><span>Level 2:</span></span></span></span></span></span></span></span></span></span></span></span></span></span></p></td><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span><span><span>Observable inputs (other than Level 1 quoted prices) such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span></span></span></span></span></span></span></span></span></span></span></span></span></span></p></td></tr><tr style="height:15"><td valign="top">&#160;</td><td valign="top">&#160;</td></tr><tr style="height:15"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span><span><span>Level 3:</span></span></span></span></span></span></span></span></span></span></span></span></span></span></p></td><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span><span><span>Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span></span></span></span></span></span></span></span></span></span></span></span></span></span></p></td></tr></tbody></table><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span>The carrying values of the Company&#x2019;s financial instruments, with the exception of the Credit Agreement and derivative liabilities, including, cash, prepaid expenses, accounts payable, and other current liabilities approximate their fair value due to the short maturities of these financial instruments. The derivative liabilities are valued on a recurring basis utilizing Level 3 inputs.</span></span></span></span></span></span></span></span></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span>Advances under the Credit Agreement are not recorded at fair value. However, fair value can be approximated and disclosed utilizing Level 3 inputs and independent third-party valuation techniques (See Note 3). As of December 31, 2019 and 2018, the fair value of the advances under the Credit Agreement was $1,877,938 and $3,176,824, respectively. The carrying amount of the liability at December 31, 2019 and 2018, was $387,070 and $1,360,960, respectively, and is included in Convertible multi-draw credit agreement - related party, net of discount in the Company&#x2019;s Consolidated Balance Sheets.</span></span></span></span></span></span></span></span></span></span></p></div><p style="margin:0px;text-align:justify">&#160;</p><div><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span><span><span><strong><i>Property and Equipment, Net</i></strong></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span>Property and equipment, net, consist primarily of computers and equipment. Expenditures for additions, renewals and improvements are capitalized at cost. Depreciation is computed on a<span><span><span><span><span><span> straight-line method based on </span></span></span></span></span></span>the estimated useful life of the related asset currently ranging from two to three years. Maintenance and repairs that do not extend the life of assets are charged to expense when incurred. When properties are disposed of, the related costs and accumulated depreciation are removed from the accounts and any gain or loss is reported in the period the transaction takes place.</span></span></span></span></span></span></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span><span><span>Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted cash flows expected to be generated by the asset. If the carrying amount exceeds its estimated future undiscounted cash flows, an impairment charge is recognized by the amount by which the carrying amount exceeds the fair value of the asset.</span></span></span></span></span></span></span></span></span></span></span></span></span></span></p></div><p style="margin:0px;text-align:justify">&#160;</p><div><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span><span><span><strong><i>Income Taxes</i></strong></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span>The Company accounts for deferred income tax assets and liabilities based on differences between the financial reporting and tax bases of assets and liabilities, net operating loss carryforwards (the &#x201c;NOLs&#x201d;) and other tax credit carryforwards. These items are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the period that includes the enactment date. Any interest or penalties would be recorded in the Company&#x2019;s Consolidated Statements of Comprehensive Income (Loss) in the period incurred. When necessary, the Company recognizes interest and penalties related to income tax matters in income tax expense.</span></span></span></span></span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span>The Company records a valuation allowance against deferred tax assets to the extent that it is more likely than not that some portion or all of the deferred tax assets will not be realized. In making such determinations, management considers all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and recent financial operations. Due to the substantial doubt related to the Company&#x2019;s ability to utilize its deferred tax assets, a valuation allowance for the full amount of the deferred tax assets has been established at December 31, 2019 and 2018. As a result of this valuation allowance, there are no income tax benefits reflected in the accompanying Consolidated Statements of Comprehensive Income (Loss) to offset pre-tax losses.</span></span></span></span></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span>The Company recognizes a tax benefit from uncertain tax positions when it is more likely than not (50%) that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits of the position.</span></span></span></span></span></span></p></div><p style="margin:0px;text-align:justify">&#160;</p><div><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span><span><span><strong><i>Convertible Instruments</i></strong></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span>The Company accounts for hybrid contracts with embedded conversion features in accordance with GAAP. ASC 815, <em>Derivatives and Hedging Activities</em> (&#x201c;ASC 815&#x201d;) requires companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria includes circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.</span></span></span></span></span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span>The Company accounts for convertible debt instruments with embedded conversion features in accordance with ASC 470-20, Debt with Conversion and Other Options (&#x201c;ASC 470-20&#x201d;) if it is determined that the conversion feature should not be bifurcated from their host instruments. Under ASC 470-20, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the difference between the fair value of the underlying common stock at the commitment date and the embedded effective conversion price. When the Company determines that the embedded conversion option should be bifurcated from its host instrument, the embedded feature is accounted for in accordance with ASC 815. Under ASC 815, a portion of the proceeds received upon the issuance of the hybrid contract is allocated to the fair value of the derivative. The derivative is subsequently marked to market at each reporting date based on current fair value, with the changes in fair value reported in the results of operations.</span></span></span></span></span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span>The Company also follows ASC 480-10, <em>Distinguishing Liabilities from Equity</em> (&#x201c;ASC 480-10&#x201d;) when evaluating the accounting for its hybrid instruments. A financial instrument that embodies an unconditional obligation, or a financial instrument other than an outstanding share that embodies a conditional obligation, that the issuer must or may settle by issuing a variable number of its equity shares shall be classified as a liability (or an asset in some circumstances) if, at inception, the monetary value of the obligation is based solely or predominantly on any one of the following: (a) a fixed monetary amount known at inception (for example, a payable settled with a variable number of the issuer&#x2019;s equity shares); (b) variations in something other than the fair value of the issuer&#x2019;s equity shares (for example, a financial instrument indexed to the Standard and Poor&#x2019;s S&amp;P 500 Index and settled with a variable number of the issuer&#x2019;s equity shares); or (c) variations inversely related to changes in the fair value of the issuer&#x2019;s equity shares (for example, a written put option that could be net share settled). Hybrid instruments meeting these criteria are not further evaluated for any embedded derivatives and are carried as a liability at fair value at each balance sheet date with a re-measurement reported in other (income) expense in the accompanying Consolidated Statements of Comprehensive Income (Loss).</span></span></span></span></span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span>When determining short-term vs. long-term classification of derivative liabilities, the Company first evaluates the instruments&#x2019; exercise provisions. Generally, if a derivative is a liability and exercisable within one year, it will be classified as short-term. However, because of the unique provisions and circumstances that may impact the accounting for derivative instruments, the Company carefully evaluates all factors that could potentially restrict the instrument from being exercised or create a situation where exercise would be considered remote. The Company re-evaluates its derivative liabilities at each reporting period end and make&#160;updates for any changes in facts and circumstances that may impact classification.</span></span></span></span></span></span></p></div><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><div><p style="margin:0px 0px 0px 0.35pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span><span><span><strong><i>Warrants Issued in Connection with Financings</i></strong></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span>The Company generally accounts for warrants issued in connection with debt and equity financings as a component of equity, unless the warrants include a conditional obligation to issue a variable number of shares or there is a deemed possibility that the Company may need to settle the warrants in cash. For warrants issued with a conditional obligation to issue a variable number of shares or the deemed possibility of a cash settlement, the Company records the fair value of the warrants as a liability at each balance sheet date and records changes in fair value in other (income) expense in the Consolidated Statements of Comprehensive Income (Loss).</span></span></span></span></span></span></p></div><p style="margin:0px;text-align:justify">&#160;</p><div><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span><span><span><strong><i>Debt Issuance Costs and Interest</i></strong></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span>Discounts related to bifurcated derivatives, freestanding instruments issued in bundled transactions and issuance costs are recorded as a reduction to the carrying value of the debt and amortized over the life of the debt using the effective interest method. The Company makes changes to the effective interest rate, as necessary, on a prospective basis. For debt facilities that provide for multiple advances, the Company initially defers any issuance costs until the first advance is made and then amortizes the costs over the life of the facility.</span></span></span></span></span></span></p></div><p style="margin:0px;text-align:justify">&#160;</p><div><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span><span><span><strong><i>Research and Development Expenses and Licensed Technology</i></strong></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span>Research and development costs are expensed when incurred. These costs may consist of external research and development expenses incurred under agreements with third-party contract research organizations and investigative sites, third-party manufacturing organizations and consultants; license fees; employee-related expenses, which include salaries and benefits for the personnel involved in the Company&#x2019;s preclinical and clinical drug development activities; facilities expense, depreciation and other allocated expenses; and equipment and laboratory supplies.</span></span></span></span></span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span>Costs incurred for the rights to use licensed technologies in the research and development process, including licensing fees and milestone payments, are charged to research and development expense as incurred in situations where the Company has not identified an alternative future use for the acquired rights, and are capitalized in situations where there is an identified alternative future use. No cost associated with the use of licensed technologies has been capitalized to date.</span></span></span></span></span></span></p></div><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><div><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span><span><span><span><span><strong><i>Stock-Based Compensation&#160;</i></strong></span></span></span></span></span></span></span></span></span></span></span></span><em><strong>Expense</strong></em></span></span></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span><span><span>Stock-based compensation expense is estimated at the grant date based on the fair value of the award, and the cost is recognized as expense ratably over the vesting period with forfeitures accounted for as they occur. The Company uses the Black-Scholes Merton option pricing model for estimating the grant date fair value of stock options using the following assumptions:</span></span></span></span></span></span></span></span></span></span></span></span></span></span></p><p style="MARGIN:0px">&#160;</p><table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN" width="100%"><tbody><tr style="height:15"><td style="width:4%"><p style="MARGIN:0px;text-align:justify">&#160;</p></td><td style="width:4%" valign="top"><p style="margin:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">&#x2022;</span></span></p></td><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span><span><span>Volatility - Stock price volatility is estimated over the expected term based on a blended rate of industry peers and the Company&#x2019;s actual stock volatility adjusted for periods in which significant financial variability was identified.</span></span></span></span></span></span></span></span></span></span></span></span></span></span></p></td></tr><tr style="height:15"><td><p style="MARGIN:0px;text-align:justify">&#160;</p></td><td valign="top"><p style="margin:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">&#x2022;</span></span></p></td><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span><span><span>Expected term - The expected term is based on a simplified method which defines the life as the weighted average of the contractual term of the options and the vesting period for each award.</span></span></span></span></span></span></span></span></span></span></span></span></span></span></p></td></tr><tr style="height:15"><td><p style="MARGIN:0px;text-align:justify">&#160;</p></td><td valign="top"><p style="margin:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">&#x2022;</span></span></p></td><td valign="top"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Risk-free rate - The risk-free interest rate for the expected term of the option is based on the average market rate on U.S. Treasury securities in effect during the period in which the awards were granted.</span></span></p></td></tr><tr style="height:15"><td><p style="MARGIN:0px;text-align:justify">&#160;</p></td><td valign="top"><p style="margin:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">&#x2022;</span></span></p></td><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span><span><span>Dividends - </span></span></span></span></span></span></span></span>The dividend yield assumption is based on the Company&#x2019;s history and expectation of paying no dividends in the foreseeable future.</span></span></span></span></span></span></p></td></tr></tbody></table></div><p style="MARGIN:0px 0px 0px 0in">&#160;</p><div><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><strong><em>Comprehensive Income (Loss)</em></strong></span></span></span></span></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span>Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. ASC 220 <em>Comprehensive Income</em> requires that an entity records all components of comprehensive income (loss), net of their related tax effects, in its financial statements in the period in which they are recognized. For the years ended December 31, 2019 and 2018, the comprehensive income (loss) was equal to net income (loss).</span></span></span></span></span></span></p></div><p style="margin:0px;text-align:justify">&#160;</p><div><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><strong><em>Net Income (Loss) Per Share of Common Stock</em></strong></span></span></span></span></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span>The Company applies FASB ASC No. 260, <em>Earnings per Share</em> in calculating its basic and diluted net income (loss) per share. Basic net income (loss) per share of common stock is computed by dividing net income (loss) available to common stockholders by the weighted-average number of shares of common stock outstanding for the period. The diluted net loss per share of common stock is computed by giving effect to all potential common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, options to purchase common stock, restricted stock subject to vesting, warrants to purchase common stock and common shares underlying convertible debt instruments were considered to be common stock equivalents. In periods with a reported net loss, such common stock equivalents are excluded from the calculation of diluted net loss per share of common stock if their effect is anti-dilutive. For additional information regarding the net income (loss) per share, see Note 7 &#x201c;Net Income (Loss) per Share of Common Stock.&#x201d;</span></span></span></span></span></span></p></div><p style="margin:0px;text-align:justify">&#160;</p><div><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span><span><span><strong><i>Recent Accounting Pronouncements</i></strong></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>In December 2019, the FASB issued ASU No. 2019-12 Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes. The Board issued this Update as part of its Simplification Initiative to improve areas of GAAP and reduce cost and complexity while maintaining usefulness. The main provisions remove certain exceptions, including the exception to the general methodology for calculating income taxes in an interim period when a year-to-date loss exceeds the anticipated loss for the year. In addition, the amendments simplify income tax accounting in the areas such as income-based franchise taxes, eliminating the requirements to allocate consolidated current and deferred tax expense in certain instances and a requirement that an entity reflects the effect of enacted changes in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date. For public companies, the standard is effective for fiscal years beginning after December 15, 2019, and interim periods therein. The Company plans to adopt this ASU on the effective date of January 1, 2020. The amendments in the update related to foreign subsidiaries will be applied on a modified retrospective basis, the amendments to franchise taxes will be applied on either a retrospective or modified retrospective basis and all other amendments will be applied on a prospective basis. The Company is still evaluating the impact from adopting this standard. However, because the Company&#x2019;s deferred tax assets and liabilities are fully reserved, it does not expect a material impact from the adoption of this standard.</span></span></span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>In November 2018, the FASB issued ASU No. 2018-08 <em>Collaborative Arrangements</em> (Topic 808) intended to improve financial reporting around collaborative arrangements and align the current guidance under ASC 808 with ASC 606 <em>Revenue from Contracts with Customers</em>. The ASU affects all companies that enter into collaborative arrangements. The ASU clarifies when certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606 and changes certain presentation requirements for transactions with collaborative arrangement participants that are not directly related to sales to third parties. For public companies, the standard is effective for fiscal years beginning after December 15, 2019 and interim periods therein. Earlier adoption is permitted for any annual or interim period for which consolidated financial statements have not yet been issued. The Company has not entered into any collaborative arrangements and therefore does not currently expect the adoption of this standard to have a material effect on its Consolidated Financial Statements. The Company plans to adopt this ASU on the effective date of January 1, 2020. Upon adoption, the Company will utilize the retrospective transition approach, as prescribed within this ASU.</span></span></span></span></p><p style="margin:0px 0px 0px 0in;text-align:justify">&#160;</p><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span><span><span><strong><i>Recently Adopted Accounting Standards </i></strong></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception (&#x201c;ASU 2017-11&#x201d;). Part I of this update addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of the pricing of future equity offerings. Current accounting guidance creates cost and complexity for entities that issue financial instruments (such as warrants and convertible instruments) with down round features that require fair value measurement of the entire instrument or conversion option. Part II of this update addresses the difficulty of navigating Topic 480, Distinguishing Liabilities from Equity, because of the existence of extensive pending content in the FASB Accounting Standards Codification. This pending content is the result of the indefinite deferral of accounting requirements about mandatorily redeemable financial instruments of certain nonpublic entities and certain mandatorily redeemable non-controlling interests. The amendments in Part II of this update do not have an accounting effect. The Company adopted this ASU on the effective date of January 1, 2019. The adoption of this standard using a retrospective cumulative-effect adjustment approach had no impact on the Company&#x2019;s accumulated deficit. The outstanding warrants issued in the Emerald Financing contain a down-round provision. However, in the absence of the down-round provision, these warrants would still require liability accounting and be considered derivatives (See Note 3). As such, the adoption of ASU 2017-11 on January 1, 2019, did not have an impact on the Company&#x2019;s Consolidated Financial Statements and Notes thereto.</span></span></span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>In February 2016, the FASB issued ASU No. 2016-02 <em>Leases</em> (Topic 842). In January, July and December 2018, and in March 2019, the FASB issued additional amendments to the new lease guidance relating to transition and clarification. This ASU requires most lessees to recognize right of use assets and lease liabilities and recognize expenses in a manner similar to current accounting standards. For public companies, the standard is effective for fiscal years beginning after December 15, 2018 and interim periods therein. The Company adopted this ASU on the effective date of January 1, 2019. Pursuant to ASU 2018-11, issued in July 2018, the Company elected to use the effective date as of the date of application for transition. Upon adoption there was no cumulative effect recorded to the accumulated deficit, as the Company has no lease terms in excess of one year. The Company has elected the short-term lease practical expedient under the ASU which resulted in no change to the current recognition accounting under ASC 840.</span></span></span></span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6752863648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>10. Commitments and Contingencies</strong></span></span></span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong><em>Legal Matters</em></strong></span></span></span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><em>General Litigation and Disputes</em></span></span></span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>From time to time, in the normal course of our operations, we may be a party to litigation and other dispute matters and claims. Litigation can be expensive and disruptive to normal business operations. Moreover, the results of complex legal proceedings are difficult to predict. An unfavorable outcome to any legal matter, if material, could have a materially adverse effect on our operations or our financial position, liquidity or results of operations. As of December 31, 2019, there were no pending or threatened lawsuits or claims that could reasonably be expected to have a material effect on the Company&#x2019;s financial position or results of operations.</span></span></span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><em>Government Proceedings</em></span></span></span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Like other companies in the pharmaceutical industry, we are subject to extensive regulation by national, state and local government agencies in the United States. As a result, interaction with government agencies occurs in the normal course of our operations. It is possible that criminal charges and substantial fines and/or civil penalties or damages could result from any government investigation or proceeding. As of December 31, 2019, the Company had no proceedings or inquiries.</span></span></span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong style="font-size:10pt"><em>Change in Control Severance Plan</em></strong></span></span></span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>In February 2015, we adopted a change in control severance plan, in which our named executive officers participate, that provides for the payment of severance benefits if the executive&#x2019;s service is terminated within twelve months following a change in control, either due to a termination without cause or upon resignation for a good reason (as each term is defined in the plan).</span></span></span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>In either such event, and provided the executive timely executes and does not revoke a general release of claims against the Company, he or she will be entitled to receive: (i) a lump sum cash payment equal to at least six months of the executive&#x2019;s monthly compensation, plus an additional month for each full year of service over six years, (ii) Company-paid premiums for continued health insurance for a period equal to the length of the cash severance period or, if earlier, when executive becomes covered under a subsequent employer&#x2019;s healthcare plan, and (iii) full vesting of all then-outstanding unvested stock options and restricted stock awards.</span></span></span></span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6799450176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Warrants and Derivative Liabilities (Details 4) - Emerald Financing Warrant Liability<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Feb. 16, 2018 </div>
<div>USD_per_warrants </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jan. 19, 2018 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected Term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_PricingModelAxis=embi_MonteCarloSimulationsMember', window );">Monte Carlo simulations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Underlying common stock price</a></td>
<td class="nump">$ 0.13<span></span>
</td>
<td class="nump">$ 0.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_PricingModelAxis=embi_MonteCarloSimulationsMember', window );">Monte Carlo simulations | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Underlying common stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.29<span></span>
</td>
<td class="nump">$ 0.29<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_PricingModelAxis=embi_MonteCarloSimulationsMember', window );">Monte Carlo simulations | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Underlying common stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.30<span></span>
</td>
<td class="nump">$ 0.30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend yield | Monte Carlo simulations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input (in percent)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility factor | Monte Carlo simulations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input (in percent)</a></td>
<td class="nump">79.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.0<span></span>
</td>
<td class="nump">70.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility factor | Monte Carlo simulations | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility factor | Monte Carlo simulations | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate | Monte Carlo simulations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input (in percent)</a></td>
<td class="nump">1.62<span></span>
</td>
<td class="nump">2.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate | Monte Carlo simulations | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.45<span></span>
</td>
<td class="nump">2.45<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate | Monte Carlo simulations | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.60<span></span>
</td>
<td class="nump">2.60<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term (years) | Monte Carlo simulations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected Term (years)</a></td>
<td class="text">3 years 1 month 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term (years) | Monte Carlo simulations | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected Term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term (years) | Monte Carlo simulations | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected Term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 1 month 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=embi_EmeraldFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=embi_EmeraldFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_PricingModelAxis=embi_MonteCarloSimulationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_PricingModelAxis=embi_MonteCarloSimulationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6813555696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants and Derivative Liabilities (Details Textuals) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 01, 2018</div></th>
<th class="th"><div>Dec. 20, 2019</div></th>
<th class="th"><div>Jan. 31, 2018</div></th>
<th class="th"><div>Jan. 19, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Feb. 16, 2018</div></th>
<th class="th"><div>Dec. 28, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_DerivativeLiabilitiesLineItems', window );"><strong>Derivative Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,080,000<span></span>
</td>
<td class="nump">$ 98,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,734,759)<span></span>
</td>
<td class="nump">6,503,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDerivativeIssuanceCosts', window );">Payments of derivative issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(137,192)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_ReclassificationOfDerivativesToEquity', window );">Reduction of equity liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (6,238,265)<span></span>
</td>
<td class="num">(2,356,581)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=embi_SeriesBPreferredStockConversionLiabilityMember', window );">Series B Preferred Stock - conversion liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_DerivativeLiabilitiesLineItems', window );"><strong>Derivative Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_ReclassificationOfDerivativesToEquity', window );">Reduction of equity liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,715)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandNineteenCommonStockWarrantsMember', window );">2019 Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_DerivativeLiabilitiesLineItems', window );"><strong>Derivative Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 722,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,130,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember', window );">Emerald Multi-Draw Credit Agreement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_DerivativeLiabilitiesLineItems', window );"><strong>Derivative Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of warrants issued</a></td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of warrants</a></td>
<td class="nump">$ 315,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 716,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of derivative liabilities</a></td>
<td class="nump">$ 593,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,830,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandEighteenEmeraldFinancingWarrantsMember', window );">2018 Emerald Financing Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_DerivativeLiabilitiesLineItems', window );"><strong>Derivative Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_ClassOfWarrantOrRightWarrantsAggregateExercisePrice', window );">Warrants aggregate exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,080,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,080,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_ClassOfWarrantOrRightWarrantsExercise', window );">Warrants exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_SeriesBWarrantMember', window );">Series B Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_DerivativeLiabilitiesLineItems', window );"><strong>Derivative Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (208,546)<span></span>
</td>
<td class="nump">$ 1,476,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_ClassOfWarrantOrRightWarrantsExercise', window );">Warrants exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,231,750<span></span>
</td>
<td class="nump">187,500<span></span>
</td>
<td class="nump">987,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrant exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 98,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_ReclassificationOfDerivativesToEquity', window );">Reduction of equity liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (144,375)<span></span>
</td>
<td class="num">$ (1,539,866)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember', window );">Emerald Convertible Promissory Note Conversion Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_DerivativeLiabilitiesLineItems', window );"><strong>Derivative Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_ReclassificationOfDerivativesToEquity', window );">Reduction of equity liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(810,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=embi_EmeraldFinancingMember', window );">Emerald Financing Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_DerivativeLiabilitiesLineItems', window );"><strong>Derivative Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,042,066)<span></span>
</td>
<td class="nump">4,826,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_FairValueOfCommonStockWarrantsIssued', window );">Fair value of common stock warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,717,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,707,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_ReclassificationOfDerivativesToEquity', window );">Reduction of equity liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,933,323)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_ClassOfWarrantOrRightWarrantsAggregateExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of aggregate exercise price of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_ClassOfWarrantOrRightWarrantsAggregateExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_ClassOfWarrantOrRightWarrantsExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents number of warrants exercise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_ClassOfWarrantOrRightWarrantsExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_DerivativeLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line item represents derivative liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_DerivativeLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_FairValueOfCommonStockWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the fair value of the common stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_FairValueOfCommonStockWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_ReclassificationOfDerivativesToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of derivatives reclassified to equity or the statement of operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_ReclassificationOfDerivativesToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDerivativeIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of a derivative security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDerivativeIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=embi_SeriesBPreferredStockConversionLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=embi_SeriesBPreferredStockConversionLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandNineteenCommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandNineteenCommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandEighteenEmeraldFinancingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandEighteenEmeraldFinancingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_SeriesBWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_SeriesBWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=embi_EmeraldFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=embi_EmeraldFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6638176816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details 2) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Expected income tax benefit at federal statutory tax rate</a></td>
<td class="nump">$ 221,219<span></span>
</td>
<td class="num">$ (4,030,454)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit</a></td>
<td class="num">(434,881)<span></span>
</td>
<td class="num">(319,816)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrant', window );">Change in fair value of warrants</a></td>
<td class="num">(1,874,873)<span></span>
</td>
<td class="nump">2,869,116<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">1,469,187<span></span>
</td>
<td class="nump">1,286,995<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_IncomeTaxReconciliationUncertainTaxPositions', window );">Uncertain tax positions</a></td>
<td class="nump">436,145<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_IncomeTaxReconciliationChangeInCompoundDerivative', window );">Change in compound derivative</a></td>
<td class="num">(101,671)<span></span>
</td>
<td class="nump">3,224<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtGainLossIncomeTax', window );">Loss on extinguishment of debt</a></td>
<td class="nump">117,198<span></span>
</td>
<td class="nump">123,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock Compensation</a></td>
<td class="nump">121,289<span></span>
</td>
<td class="nump">67,966<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Rate adjustment</a></td>
<td class="nump">49,338<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense', window );">Other permanent difference</a></td>
<td class="num">(1,351)<span></span>
</td>
<td class="nump">629<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for Income Taxes</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="nump">$ 1,642<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount related to Change in fair value of warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_IncomeTaxReconciliationChangeInCompoundDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of Income Tax Reconciliation change in compound derivative related to the income tax reconciliation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_IncomeTaxReconciliationChangeInCompoundDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_IncomeTaxReconciliationUncertainTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of uncertain tax positions related to Income Tax Reconciliation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_IncomeTaxReconciliationUncertainTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtGainLossIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current period income tax expense or benefit pertaining to a gain (loss) on an extinguishment of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtGainLossIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6811813584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 1,829,977<span></span>
</td>
<td class="nump">$ 1,853,373<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">4,538<span></span>
</td>
<td class="nump">4,512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">152,695<span></span>
</td>
<td class="nump">93,193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">7,550<span></span>
</td>
<td class="nump">2,609<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,994,760<span></span>
</td>
<td class="nump">1,953,687<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,983<span></span>
</td>
<td class="nump">3,445<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,996,743<span></span>
</td>
<td class="nump">1,957,132<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">129,809<span></span>
</td>
<td class="nump">15,597<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesCurrent', window );">Accounts payable to related party</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">420,406<span></span>
</td>
<td class="nump">184,461<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liabilities</a></td>
<td class="nump">410,603<span></span>
</td>
<td class="nump">15,738,913<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">970,818<span></span>
</td>
<td class="nump">15,938,971<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Noncurrent liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible multi-draw credit agreement - related party, net of discount</a></td>
<td class="nump">387,070<span></span>
</td>
<td class="nump">1,360,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liabilities, non-current</a></td>
<td class="nump">90,797<span></span>
</td>
<td class="nump">219,453<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,448,685<span></span>
</td>
<td class="nump">17,519,384<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 20,000,000 shares authorized; no shares issued and outstanding at December 31, 2019 and December 31, 2018</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 500,000,000 shares authorized; 182,895,247 and 133,907,747 shares issued and outstanding at December 31, 2019 and December 31, 2018, respectively</a></td>
<td class="nump">182,895<span></span>
</td>
<td class="nump">133,908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in-capital</a></td>
<td class="nump">32,538,445<span></span>
</td>
<td class="nump">17,528,947<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(32,173,282)<span></span>
</td>
<td class="num">(33,225,107)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity (deficit)</a></td>
<td class="nump">548,058<span></span>
</td>
<td class="num">(15,562,252)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity (deficit)</a></td>
<td class="nump">$ 1,996,743<span></span>
</td>
<td class="nump">$ 1,957,132<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6812277920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share of Common Stock (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of Dilutive Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 1,051,825<span></span>
</td>
<td class="num">$ (19,194,236)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic EPS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Income available to common stockholders, Income (Numerator)</a></td>
<td class="nump">$ 1,051,825<span></span>
</td>
<td class="num">$ (19,194,236)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Income available to common stockholders Shares (Denominator)</a></td>
<td class="nump">135,154,931<span></span>
</td>
<td class="nump">121,154,334<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Income available to common stockholders, Per-Share Amount</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="num">$ (0.16)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted EPS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_NetLossAdjustedBalance', window );">Loss available to common stockholders + assumed conversions, Income (Numerator)</a></td>
<td class="num">$ (8,198,787)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Loss available to common stockholders + assumed conversions, Shares (Denominator)</a></td>
<td class="nump">169,560,265<span></span>
</td>
<td class="nump">121,154,334<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Loss available to common stockholders + assumed conversions, Per-Share Amount</a></td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="num">$ (0.16)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_DilutedSecuritiesAxis=embi_UnvestedRestrictedStockMember', window );">Unvested restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of Dilutive Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_DilutiveSecuritiesEffectOnBasicEarningsPerShareShares', window );">Shares (Denominator)</a></td>
<td class="nump">858,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_DilutedSecuritiesAxis=embi_OptionsMember', window );">Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of Dilutive Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_DilutiveSecuritiesEffectOnBasicEarningsPerShareShares', window );">Shares (Denominator)</a></td>
<td class="nump">392,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_DilutedSecuritiesAxis=embi_WarrantsMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of Dilutive Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_DilutiveSecuritiesEffectOnBasicEarningsPerShareShares', window );">Shares (Denominator)</a></td>
<td class="nump">447,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_DilutedSecuritiesAxis=embi_WarrantsLiabilityClassifiedMember', window );">Warrants - liability classified</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of Dilutive Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecurities', window );">Income (Numerator)</a></td>
<td class="num">$ (9,250,612)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_DilutiveSecuritiesEffectOnBasicEarningsPerShareShares', window );">Shares (Denominator)</a></td>
<td class="nump">32,706,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_DilutiveSecuritiesEffectOnBasicEarningsPerShareShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares for calculating diluted earnings per share (EPS), resulting from the assumed exercise stock options, restrictive stock units (RSUs), convertible preferred stock of an employee stock ownership plan (ESOP), and other dilutive convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_DilutiveSecuritiesEffectOnBasicEarningsPerShareShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_NetLossAdjustedBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjusted balance of net loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_NetLossAdjustedBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise stock options, restrictive stock units (RSUs), convertible preferred stock of an employee stock ownership plan (ESOP), and other dilutive convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_DilutedSecuritiesAxis=embi_UnvestedRestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_DilutedSecuritiesAxis=embi_UnvestedRestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_DilutedSecuritiesAxis=embi_OptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_DilutedSecuritiesAxis=embi_OptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_DilutedSecuritiesAxis=embi_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_DilutedSecuritiesAxis=embi_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_DilutedSecuritiesAxis=embi_WarrantsLiabilityClassifiedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_DilutedSecuritiesAxis=embi_WarrantsLiabilityClassifiedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6793888352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS (Parentheticals) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Common stock issuance costs</a></td>
<td class="nump">$ 80,628<span></span>
</td>
<td class="nump">$ 154,092<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6803532368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Deficit) and Capitalization (Detail Textuals 1) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted</a></td>
<td class="nump">2,833.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Number of shares issued in conversion</a></td>
<td class="nump">28,385,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Series D Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Number of shares issued in conversion</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember', window );">Series F Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Number of shares issued in conversion</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_EquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_EquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6607639040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details 3) - Stock options - Awards Granted Outside the 2014 Plan<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th"><div>May 25, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend Yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.79%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 6 months 14 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">70.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=embi_AwardsGrantedOutsideThe2014PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=embi_AwardsGrantedOutsideThe2014PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>245</ContextCount>
  <ElementCount>402</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>77</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="embi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="embi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/ConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="embi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0003 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/Consolidatedbalancesheetsparentheticals</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="embi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="embi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="embi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSParentheticals</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="embi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0007 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/ConsolidatedStatementsOfStockholdersEquityDeficit</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="embi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0008 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/ConsolidatedStatementsOfStockholdersEquityDeficitParentheticals</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="embi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0009 - Disclosure - Nature of Operations and Business Activities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/NatureOfOperationsAndBusinessActivities</Role>
      <ShortName>Nature of Operations and Business Activities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="embi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0010 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="embi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0011 - Disclosure - Warrants and Derivative Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilities</Role>
      <ShortName>Warrants and Derivative Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="embi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0012 - Disclosure - Convertible Debt - Related Party</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/ConvertibleDebtRelatedParty</Role>
      <ShortName>Convertible Debt - Related Party</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="embi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0013 - Disclosure - Stockholders' Equity (Deficit) and Capitalization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/StockholdersEquityDeficitAndCapitalization</Role>
      <ShortName>Stockholders' Equity (Deficit) and Capitalization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="embi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0014 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="embi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0015 - Disclosure - Net Income (Loss) Per Share of Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/NetIncomeLossPerShareOfCommonStock</Role>
      <ShortName>Net Income (Loss) Per Share of Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="embi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0016 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="embi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0017 - Disclosure - Significant Contracts - University of Mississippi</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/SignificantContractsUniversityOfMississippi</Role>
      <ShortName>Significant Contracts - University of Mississippi</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="embi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0018 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="embi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0019 - Disclosure - Related Party Matters</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/RelatedPartyMatters</Role>
      <ShortName>Related Party Matters</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="embi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0020 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="embi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0021 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="embi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0022 - Disclosure - Warrants and Derivative Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesTables</Role>
      <ShortName>Warrants and Derivative Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilities</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="embi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0023 - Disclosure - Convertible Debt - Related Party (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyTables</Role>
      <ShortName>Convertible Debt - Related Party (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/ConvertibleDebtRelatedParty</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="embi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0024 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/StockBasedCompensation</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="embi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0025 - Disclosure - Net Income (Loss) Per Share of Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/NetIncomeLossPerShareOfCommonStockTables</Role>
      <ShortName>Net Income (Loss) Per Share of Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/NetIncomeLossPerShareOfCommonStock</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="embi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0026 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/Incometaxestables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/IncomeTaxes</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="embi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0027 - Disclosure - Nature of Operations and Business Activities (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/NatureOfOperationsAndBusinessActivitiesDetailTextuals</Role>
      <ShortName>Nature of Operations and Business Activities (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/NatureOfOperationsAndBusinessActivities</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="embi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0028 - Disclosure - Summary of Significant Accounting Policies (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPoliciesDetailTextuals</Role>
      <ShortName>Summary of Significant Accounting Policies (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="embi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0029 - Disclosure - Warrants and Derivative Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails</Role>
      <ShortName>Warrants and Derivative Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="embi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0030 - Disclosure - Warrants and Derivative Liabilities (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails1</Role>
      <ShortName>Warrants and Derivative Liabilities (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="embi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0031 - Disclosure - Warrants and Derivative Liabilities (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails2</Role>
      <ShortName>Warrants and Derivative Liabilities (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="embi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0032 - Disclosure - Warrants and Derivative Liabilities (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails6</Role>
      <ShortName>Warrants and Derivative Liabilities (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="embi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0033 - Disclosure - Warrants and Derivative Liabilities (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails3</Role>
      <ShortName>Warrants and Derivative Liabilities (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="embi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0034 - Disclosure - Warrants and Derivative Liabilities (Details 5)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails7</Role>
      <ShortName>Warrants and Derivative Liabilities (Details 5)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="embi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0035 - Disclosure - Warrants and Derivative Liabilities (Details 6)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails4</Role>
      <ShortName>Warrants and Derivative Liabilities (Details 6)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="embi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0036 - Disclosure - Warrants and Derivative Liabilities (Details 7)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails5</Role>
      <ShortName>Warrants and Derivative Liabilities (Details 7)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="embi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0037 - Disclosure - Warrants and Derivative Liabilities (Details Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetailsTextuals</Role>
      <ShortName>Warrants and Derivative Liabilities (Details Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="embi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0038 - Disclosure - Convertible Debt - Related Party (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetails</Role>
      <ShortName>Convertible Debt - Related Party (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="embi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0039 - Disclosure - Convertible Debt - Related Party (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetails1</Role>
      <ShortName>Convertible Debt - Related Party (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="embi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0040 - Disclosure - Convertible Debt - Related Party (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetailTextuals</Role>
      <ShortName>Convertible Debt - Related Party (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="embi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0041 - Disclosure - Convertible Debt - Related Party (Detail Textuals 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetailTextuals1</Role>
      <ShortName>Convertible Debt - Related Party (Detail Textuals 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="embi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0042 - Disclosure - Stockholders' Equity (Deficit) and Capitalization (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/StockholdersEquityDeficitAndCapitalizationDetailTextuals</Role>
      <ShortName>Stockholders' Equity (Deficit) and Capitalization (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/StockholdersEquityDeficitAndCapitalization</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="embi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0043 - Disclosure - Stockholders' Equity (Deficit) and Capitalization (Detail Textuals 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/StockholdersEquityDeficitAndCapitalizationDetailTextuals1</Role>
      <ShortName>Stockholders' Equity (Deficit) and Capitalization (Detail Textuals 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/StockholdersEquityDeficitAndCapitalization</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="embi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0044 - Disclosure - Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/StockBasedCompensationDetails</Role>
      <ShortName>Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/StockBasedCompensationTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="embi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0045 - Disclosure - Stock-Based Compensation (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/StockBasedCompensationDetails1</Role>
      <ShortName>Stock-Based Compensation (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/StockBasedCompensationTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="embi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0046 - Disclosure - Stock-Based Compensation (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/StockBasedCompensationDetails2</Role>
      <ShortName>Stock-Based Compensation (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/StockBasedCompensationTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="embi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0047 - Disclosure - Stock-Based Compensation (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/StockBasedCompensationDetails3</Role>
      <ShortName>Stock-Based Compensation (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/StockBasedCompensationTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="embi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0048 - Disclosure - Stock-Based Compensation (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/StockBasedCompensationDetails4</Role>
      <ShortName>Stock-Based Compensation (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/StockBasedCompensationTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="embi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0049 - Disclosure - Stock-Based Compensation (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/StockBasedCompensationDetailTextuals</Role>
      <ShortName>Stock-Based Compensation (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/StockBasedCompensationTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="embi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0050 - Disclosure - Stock-Based Compensation (Detail Textuals 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/StockBasedCompensationDetailTextuals1</Role>
      <ShortName>Stock-Based Compensation (Detail Textuals 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/StockBasedCompensationTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="embi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0051 - Disclosure - Stock-Based Compensation (Detail Textuals 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/StockBasedCompensationDetailTextuals2</Role>
      <ShortName>Stock-Based Compensation (Detail Textuals 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/StockBasedCompensationTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="embi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0052 - Disclosure - Net Income (Loss) Per Share of Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/NetIncomeLossPerShareOfCommonStockDetails</Role>
      <ShortName>Net Income (Loss) Per Share of Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/NetIncomeLossPerShareOfCommonStockTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="embi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0053 - Disclosure - Net Income (Loss) Per Share of Common Stock (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/NetIncomeLossPerShareOfCommonStockDetails1</Role>
      <ShortName>Net Income (Loss) Per Share of Common Stock (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/NetIncomeLossPerShareOfCommonStockTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="embi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0054 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/Incometaxestables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="embi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0055 - Disclosure - Income Taxes (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/IncomeTaxesDetails1</Role>
      <ShortName>Income Taxes (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/Incometaxestables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="embi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0056 - Disclosure - Income Taxes (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/IncomeTaxesDetails2</Role>
      <ShortName>Income Taxes (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/Incometaxestables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="embi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0057 - Disclosure - Income Taxes (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/IncomeTaxesDetails3</Role>
      <ShortName>Income Taxes (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/Incometaxestables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="embi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0058 - Disclosure - Income Taxes (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/IncomeTaxesDetailTextuals</Role>
      <ShortName>Income Taxes (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/Incometaxestables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="embi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0059 - Disclosure - Significant Contracts - University of Mississippi (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/SignificantContractsUniversityOfMississippiDetailTextuals</Role>
      <ShortName>Significant Contracts - University of Mississippi (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/SignificantContractsUniversityOfMississippi</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="embi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0061 - Disclosure - Related Party Matters (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/RelatedPartyMattersDetails</Role>
      <ShortName>Related Party Matters (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/RelatedPartyMatters</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="embi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0063 - Disclosure - Subsequent Events (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/SubsequentEventsDetailTextuals</Role>
      <ShortName>Subsequent Events (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/SubsequentEvents</ParentRole>
      <Position>61</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>embi-20191231.xml</File>
    <File>embi-20191231.xsd</File>
    <File>embi-20191231_cal.xml</File>
    <File>embi-20191231_def.xml</File>
    <File>embi-20191231_lab.xml</File>
    <File>embi-20191231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6800235536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Matters (Detail Textuals) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 06, 2018</div></th>
<th class="th"><div>Apr. 01, 2017</div></th>
<th class="th"><div>Dec. 19, 2019</div></th>
<th class="th"><div>Feb. 28, 2018</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=embi_IndependentContractorAgreementMember', window );">Independent contractor agreement | Dr. Avtar Dhillon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_MonthlyFee', window );">Monthly fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_MonthlyFeePaidEachMonthInExchangeOfServices', window );">Monthly fee paid each month</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices', window );">Monthly fee accruing from effective date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=embi_IndependentContractorAgreementMember', window );">Independent contractor agreement | K2C, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_MonthlyFee', window );">Monthly fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TotalExpenseIncurredUnderAgreement', window );">Total expense incurred under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=embi_IndependentContractorAgreementMember', window );">Independent contractor agreement | Emerald Health Sciences Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_InitialTermOfAgreement', window );">Initial term of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TotalExpenseIncurredUnderAgreement', window );">Total expense incurred under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 542,000<span></span>
</td>
<td class="nump">550,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_AccruedExpenseUnderAgreement', window );">Accrued expense under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=embi_SeparationAndReleaseAgreementMember', window );">Separation and release agreement | K2C, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_LumpSumPaymentInAgreement', window );">Lump sum payment in agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Recognized additional stock based compensation expense of restricted stock and option awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,270<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=embi_SeparationAndReleaseAgreementMember', window );">Separation and release agreement | K2C, Inc. | January 18, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of restricted common stock vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=embi_SeparationAndReleaseAgreementMember', window );">Separation and release agreement | K2C, Inc. | October 20, 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of restricted common stock vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">325,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=embi_SeparationAndReleaseAgreementMember', window );">Separation and release agreement | K2C, Inc. | November 21, 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of restricted common stock vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=embi_ConsultingAgreementMember', window );">Consulting Agreement | Emerald Health Sciences Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_InitialTermOfAgreement', window );">Initial term of agreement</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TotalExpenseIncurredUnderAgreement', window );">Total expense incurred under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_AnnualFeeForAgreement', window );">Annual fee</a></td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_PeriodOfDiscretionaryAnnualBonusPayableToContractorAfterEachFiscalYearEnd', window );">Period of discretionary annual bonus payable to contractor after each fiscal year end</a></td>
<td class="text">120 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_AccruedExpenseUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents total accrued expense under the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_AccruedExpenseUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_AnnualFeeForAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of annual fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_AnnualFeeForAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_InitialTermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the initial term of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_InitialTermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_LumpSumPaymentInAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount related to lump sum payment in the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_LumpSumPaymentInAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_MonthlyFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of monthly fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_MonthlyFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of monthly fees accruing from the effective date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_MonthlyFeePaidEachMonthInExchangeOfServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of monthly fee paid in exchange of services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_MonthlyFeePaidEachMonthInExchangeOfServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_PeriodOfDiscretionaryAnnualBonusPayableToContractorAfterEachFiscalYearEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of discretionary annual bonus payable to contractor after each fiscal year end.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_PeriodOfDiscretionaryAnnualBonusPayableToContractorAfterEachFiscalYearEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_TotalExpenseIncurredUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents total expense incurred under the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_TotalExpenseIncurredUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=embi_IndependentContractorAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=embi_IndependentContractorAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=embi_AvtarDhillonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=embi_AvtarDhillonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=embi_K2CIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=embi_K2CIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=embi_EmeraldHealthSciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=embi_EmeraldHealthSciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=embi_SeparationAndReleaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=embi_SeparationAndReleaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=embi_ConsultingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=embi_ConsultingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>41
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M^L/O)NR\L7O[CXVO@K*%7W<AOP!02P,$%     @ N*QT4)E<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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MBOM^N'7IOKT><:^%OCE/Q_?B]A_"ZG]02P,$%     @ N*QT4+U2QQU$ @
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MF"3[PQ@X3Q7[)!2K6U"@H"P%]LA#C[R-*.#V!6Q?F(C(N22D@\:?AZ1%.C5
MY%6Q*R5TI02N4&*E-%8J)]A(!8U4P$@2RJHR1HK*J4]G$,A*#45FR0?H3C#N
M5*DWP9A9A%*T]"'QQPH+[X3*S"20P]O<69<DW>?.F!+FXFRZ#QX!71G]*23G
M4H8\9%TRILBN/RDI<,82)-!'8FO)I\&S#8J]F@T.=#XXR7J$B44"%JRDIL28
M"F7(#3)&&UFVD=,T=K5KC ,'XY#5^<KGR$88;639%E&:Z0+3C2S>E-*8++D6
M/OB4"FN@HU"QY#S"D"-+.4UW/%G*+32DCJ^1C N7P3]A'I(%HI:I/Y9TQ,ID
M1LCJ%G'6.;<0,1+),E'3)$N6=3%MG26NRVH#DXXMZ31AZHHMP9A]T'2S ]TB
M9B_*>81!QQ9TY-(BBRWI%H7CTBX0I)2@XB@S(XRIR PV8J9N8HPQ1ABK4G\M
MQA8J56:#,>88(XZEJ9(MG]ZSA/G$@$_9"<=\8E!^40HH1N"A(*6ICJU07(A)
MI\HXA1'%H!!+]_J*+7S451=[\.B4%8:JS&Y53"D&91NE28<M?M2]0P6,'[;X
M(4KS(%O^2 BN"&:A 5"%6#R'3-$J&%5B4464%B8"&"2A\CXW H(I)(!"E%)(
M+%L*%XOD,H40$'JO+KA,G2R806(K,Z(T48DMN18L4J9K$NC(!SG/^9<^94Z3
M &J4IBJQ4*/*EU5:5ZZ!,);44N56"L:? /Q1FM7$XH\J49\NJ3447CI_Z10F
MI0!2<FY18E**):68L  H*PZA+-.PD-#'A9(;:PQ* ;5<>G86P$DO:>:#*LJM
M1LQ(08PT0P1*.3SS2/C>S&.:2@ SG]GYBMFG@'V<IB,%)]*2E-.=#W01$+GS
MJ&) *@ DIV=D!0?2PF1'J-+,Q"M&HX+R+%=S*R:9 I*E!]J5 I+Y2BMO@@+'
M41>+@XQ+F5=M &2<9B&U?"JI.*_"CAY9G9#/NX0QIAZXE.:@H^@RXXNF)<0:
MZ-@IY5*08BPJ*"#9O)(\B,[?-1:N+(OTW>5:T4N\6$(4F8.[8BXJ*" YK8S4
M(H^<<O[ED&+L*<">F/D'- M:,F<J8\4T4U ;2EKP*"CY2I(R-X@>8\\#[$E:
M\1]%YS-;<14HA?3R["7_KND>I^\A_>RN?=D/X_OTLZ>G;RX?>?Q(D#Q?T=7Z
M\.7D9S>'#SE_UMWC9M_/OK;#T.ZF#P4/;3LTT4WW(0[&4U/?GVZVS<,P7I;Q
MNCM\0#G<#.WS\>/0\O2%ZO9_4$L#!!0    ( +BL=%#=9N^;X0$  &<$   8
M    >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL?53;CILP$/T5RQ^P!D/8- *D
M3:JJE5HIVJK;9P>&B];&U';"]N]K&Y8E">H+]HS/.3-CSY .4KWJ!L"@-\$[
MG>'&F'Y'B"X:$$P_R!XZ>U)))9BQIJJ)[A6PTI,$)S0($B)8V^$\];ZCRE-Y
M-KSMX*B0/@O!U-\]<#ED.,3OCN>V;HQSD#SM60T_P?SJC\I:9%8I6P&=;F6'
M%%09?@IWA]CA/>"EA4$O]LA5<I+RU1G?R@P'+B'@4!BGP.QR@0-P[H1L&G\F
M33R'=,3E_EW]BZ_=UG)B&@Z2_VY+TV1XBU$)%3MS\RR'KS#5L\%H*OX[7(!;
MN,O$QB@DU_Z+BK,V4DPJ-A7!WL:U[?PZC"?)9J*M$^A$H#,A3/Y+B"9"]$'P
MMTG&S'RIGYEA>:KD@-3X6#US/1'N(GN9A7/ZN_-GMEIMO9<\C**47)S0A-F/
M&+K$S ABU><0="W$GM[1Z76 PSTB>ER/$*T6$7E^=%5$O"X0KPK$7B"^$MC<
MW,*(23RF\YAMD-#M32GWJ' 3!Y_H339D\3X"5.U;6:-"GCOC;F+AG:?EB;KW
MO?'O[12-3?\A,X[@#Z;JMM/H)(WM'O_&E90&;);!@^WKQD[];'"HC-L^VKT:
M>W\TC.RGL2;SOR7_!U!+ P04    " "XK'10[;R=-W\%  #N&@  &    'AL
M+W=O<FMS:&5E=',O<VAE970W+GAM;(U9T6[;.!#\%</OKL5=D:**), UL>,#
M[H"@Q=T]*XF2&+4MGZ0DO;\_2E9=<W>4I ^UI<R2LTMJ9BF?O5;U]^:I+-O)
MC^UFUYQ/G]IV_WD^;^Z>RFW1?*KVY2[\Y:&JMT4;+NO'>;.OR^*^#]INYI0D
M;KXMUKOIQ5E_[Z:^.*N>V\UZ5][4D^9YNRWJ_[Z4F^KU?&JF/V]\73\^M=V-
M^<79OG@LOY7M7_N;.ES-CZ/<K[?EKEE7NTE=/IQ/?S.?5YQU 3WB[W7YVIQ\
MGW2IW%;5]^[B]_OS:=(Q*C?E7=L-482/E_*RW&RZD0*/?X=!I\<YN\#3[S]'
M7_;)AV1NBZ:\K#;_K._;I_.IGT[NRX?B>=-^K5Y7Y9"0G4Z&[/\H7\I-@'=,
MPAQWU:;I_Y_</3=MM1U&"52VQ8_#YWK7?[X.X_\,PP$T!- QX%"<T0 > OBC
M >D0D!X#4O]F@!T"[#' \)L!;@APQP!ZFU(V!&2_ MZNDA\"_"]*U*_X83GZ
M];TJVN+BK*Y>)_5AB^Z+[DDPGWW807?=S7[#]'\+2]R$NR\7AMW9_*4;:,!\
M.6 HPF0QYA)A?(RY0I@\QBP )DUBS!)A3(RY1AB*,2N$X2-F'NIV+![!XE$_
M0!H-D(KB'3"NQ^P.F"S\\X+P)<"Y/$U%G:\TS!-1(D9;:!BS(Q:%!',F*669
MK-2U!L["LG#B,S'Q"B#9NMPF#A>686$9%-:*PAXP]F2FH-ABJUQ"D"@IP'@6
MR[C0H*Z@Y"G'>:4PK[0?A:.\1@ICX0 6%$9LD:555%V6YDZNU+NPB(Z#=!R@
M(Y[ZA=-;\?0Q.W!VBLR,1Q_&#'+) !>I+IE>Q3"+34:2]G BKR>R8D\MO$Z:
MK-QY2Z^S3O-4PE8 %K3A!!:1SB'I')"6HI'KZG2DD[&93((M)0%S"46Y&D"1
M4$ E \#P>'JA!LL!=DK>)XEE64N$(Y\;.Y+BB&L:D"++%(U>-Z L -8G.%YV
M;$8&N)$5DUT:I.3 9Q8 J.5U.:!.N9N@(G*T%<1%L\898E<PP!:LE1EJI9XI
MS5\ %"5O;76LYR8%C%3[E(*:HQY@ 9"4@*JGNIJ9U>.M(#">.,X2FXX!KF,S
MF:7VDYG>,0L &PH_5GGL/ 98CY768[3WY(EL2Y=&FX_)0K]!JE]$0 KMS1AU
M;%0&.)55?;"VJD ]<V[LD<%>98!9.;6?M,%PL#2OM/-=7$P).Y$!5B2;DZ71
M7A0,3S-Z#Q8W\=BO"/B5$VN_(&U#EHQ8M25I=S&.F94@8J"W;J0;).Q#!'S(
ML:2N#290]YD=*]/(80?XBQ/^<DU:Z&<F-WE*\E2Y^A T)H9M@8 M."N+P/JL
MPYPG4@Q(&T/0UM AR"6\!L@9,Y$UB5IM  W.%<X/)WU1G"KV&P)^XYQ,%:A^
MEVHXUXV(!V'=)_OQXPIAF29T0I '%M*ZZGR22FM?O8^+*6'Y)2"_3K8_ R@Z
M9VLC)BW280<;SJ1S8&!^"HRI8S4GI.;2]$BKM'_+8 G+-"&95@70^IL%,3=2
MI]_'Q2\%L% S$FKI' R4U?K4RR/:Z@/ F!268$82+-UC $7JX^5CP%JG39H:
M[R5QB.-LY#%@+.>,Y%Q:!X.^O3..L1*-O,U! BT;'M8"G08GESN.M93F>19T
ME&65@) G21!"&GFKP%AR&4AN)KM:UI+;DQ]]Z!@K+H-.6WDLZQ;:)-9XDGKY
M 6!,"FLX PV7[_T6K%MMTQVLY3D=X)@L^U2^W[L&R!F3R9B\E%< M:E/3LX#
M<9[8&!@8@U3R!0,E[_,D9:[SDW?PW2]!?Q;UXWK73&ZKMJVV_4OWAZIJRS!L
M\BD,^%06]\>+3?G0=E^S\+T^_ )SN&BK_?#KTOSX$]?%_U!+ P04    " "X
MK'10+W]D73 "  #&!@  &    'AL+W=O<FMS:&5E=',O<VAE970X+GAM;(U5
MVXZ;,!#]%<0'!',)D(@@;5)5K=1*T59MGQTR!+0&4]L)V[^O+X0EQ*GR@NWA
M7&8,'F<]96^\ A#.>T-:OG$K(;JUY_&B@@;S!>V@E6]*RAHLY)*=/-XQP$=-
M:H@7(!1[#:Y;-\]T;,_RC)X%J5O8,X>?FP:SOUL@M-^XOGL-O-:G2JB EV<=
M/L$/$#^[/9,K;U0YU@VTO*:MPZ#<N"_^>N=K@D;\JJ'GD[FC2CE0^J867X\;
M%ZF,@$ AE 26PP5V0(A2DGG\&43=T5,1I_.K^F==O"SF@#GL*/E='T6U<5/7
M.4*)ST2\TOX+# 4M76>H_AM<@$BXRD1Z%)1P_72*,Q>T&51D*@U^-V/=ZK$?
M]*\T.R$8",%(\./_$L*!$'X0(EV\R4R7^@D+G&>,]@XS7ZO#ZJ?PUZ'<S$(%
M]=[I=[):+J.7W$_"S+LHH0&S-9A@BAD1GE0?+0*;Q3:XHP>W!KM[1)C8'4)K
M$:'F1S=%1#,/@XDUIC68>(60W2:RVD06F^5LKZ([FQ3%06JW65IMEA:;V"X0
M6P5BBT RVPZ#22=YHL6#KYI831*+R8,R4ZM ^D26!K-Z)LN5U61E,5G9!7QD
M/R#HB3P'T%.)^@\.HG_ODZ*YCP$E-SX(S9V\R>EO@)UTH^1.0<^M4.=L$AV;
M\4N@NL<LOE5-6G>5#QG3X;]C=JI;[ARHD+U)=Y"24@$R2[20?W E+Y5Q0: 4
M:IK(.3.=U2P$[89;PQNOKOP?4$L#!!0    ( +BL=%"%"T-MM $  -(#   8
M    >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL?5-A;]P@#/TKB!]0+ERZG4Y)
MI%ZG:9,VZ=1IZV<N<1)4B#,@E^[?#TB:9EO6+X"-W_.S,=F(YLFV (X\:]79
MG+;.]4?&;-F"%O8&>^C\38U&"^=-TS#;&Q!5!&G%^&[WCFDA.UIDT7<V18:#
M4[*#LR%VT%J87R=0..8TH2^.!]FT+CA8D?6B@6_@OO=GXRVVL%120V<E=L1
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MAV,2XF/ KQ8&NSB34,D9\2D87\N,;H(@D%"XP"#\=H$[D#(0>1F_)TXZIPS
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M'E\V]K\VQ@-*V5SA"+7XP69#0NW#\3.>[3AFH^%--_T@-G_CXB]02P,$%
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MO"4B3(%%)E!D @CFG@C T!2+3*'(%! 03P1A MLU@R(S0)!Y(@B38Y$"BA2
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M7@P!C0O;![\WTUN>#*?[>4S)\J\H_P!02P,$%     @ N*QT4$[FLNC; 0
M 04  !D   !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL=53K;ML@%'X5Q ,4
MAUS<1;:EIE6U29L4=5KWF]C'%Q6,!SCNWGZ '<_SZ)_ .?XNYQ .R2#5FZX!
M#'H7O-4IKHWICH3HO ;!])WLH+5?2JD$,S94%=&= E9XDN"$1M&!"-:T.$M\
M[JRR1/:&-RV<%=*]$$S]/@&70XHW^)9X::K:N 3)DHY5\!W,C^ZL;$1FE:(1
MT.I&MDA!F>*'S?$4.[P'O#8PZ,4>N4XN4KZYX$N1XL@5!!QRXQ287:[P")P[
M(5O&KTD3SY:.N-S?U)]][[:7"]/P*/G/IC!UBN\Q*J!D/3<O<O@,4S][C*;F
MO\(5N(6[2JQ'+KGVORCOM9%B4K&E"/8^KDWKUV'2O]'"!#H1Z(I 1B-?^1,S
M+$N4') :S[YC[B_>'*D]F]PE_5'X;[9X;;/7C'Z*$G)U0A/F-&+H K.9$<2J
MSQ8T9'&B_]%IF+X-5KCU].V2'GT@L L*[+S [I\6-ZL60Y@/3/9!DWU 8+LR
M"6%V89-#T.00$-BO3$*80]@D#IK$ 8%X91+"W*],R.(*"E"5'SZ-<MFW?O 7
MV7F^'ZB_PG_AX^/PC:FJ:36Z2&,'P5_74DH#MI3HSIYJ;=^C.>!0&K>-[5Z-
M4SD&1G;3@T/F5R_[ U!+ P04    " "XK'10,[)X_2(#  #C"P  &0   'AL
M+W=O<FMS:&5E=',O<VAE970R-RYX;6R55FUOFS 0_BN([RL^&VR(DDC-2[M)
MFU1UVO:9)DZ""C@#I^G^_<Q+*9A+UGT!;)[G[KGS^733LRJ>RX.4VGG-TKR<
MN0>MCQ//*S<'F<7EC3K*W/S9J2*+M5D6>Z\\%C+>UJ0L]2@AW,OB)'?GTWKO
MH9A/U4FG22X?"J<\95E<_%G(5)UG+KAO&X_)_J"K#6\^/<9[^5WJ'\>'PJR\
MSLHVR61>)BIW"KF;N;<PN0=1$6K$ST2>R]ZW4X7RI-1SM?BRG;FD4B13N=&5
MB=B\7N12IFEER>CXW1IU.Y\5L?_]9OVN#MX$\Q27<JG27\E6'V9NZ#I;N8M/
MJ7Y4Y\^R#2APG3;ZK_)%I@9>*3$^-BHMZZ>S.95:9:T5(R6+7YMWDM?O<_-'
ML):&$VA+H!W!^+Y&8"V!O1/\JP2_)?CO!'Z5$+2$X*,>>$O@'R6(EB L@M=D
MMSZN5:SC^;109Z=H*NX85X4-$V$*8E-MUN=?_S,G5IK=ESF-HJGW4AEJ,8L&
M0WL81L@0LQICH$-X1D$G@V(R%A1Q 4,72PQ#+1ECC(58(U;$$'*'.6)#S#V&
M\?&(&9IX5AM@ P,!;L!'#?BU ;]G@-O9:""\AN2-#PJ"T=!."@)DE 9 !*XH
M0!4%(T7,*J55 PEZCB T!2>L(UACN( Q81W#73 2SKD@O>H<R.:H;#Z63;BE
MFX_T?.*$BLBWBG2- %GDFV*^4!P"E20025:*5F*<H@@B)NRS'>,8B8*(A+B@
M$!44(H)"2U X=A1%A-OM9#W&0>1S&C%<4(0*BD:"*+^08B!XYR,?OX%PH7G"
MO\]IT8+Z-?H)1$"(W4.7*+(&6L@UAF1T:',8 -IV;X$B 4073.!]#/ZCD0'>
MR6#<RAA8(=_#N$>!3\B5D/$F!4B7 K"=C?O*U>SBC06PSF)?8QAW#/L>#WWA
M'0.PEF'?T!;$KUS1QI?7&Q\R6>SK:;%T-NJ4Z^JL>[O=1'I+J_'#VE_ 9 G(
M_@HFZV;>?#??C+_?XF*?Y*7SI+09>NK19*>4ED8_N3%9.IB)NUND<J>K3V&^
MBV;L;!9:'=N1VNOF^OE?4$L#!!0    ( +BL=% V(^E/*0(  #4&   9
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M"]R-O0BAP4B)'\PK;DP/GQ<,+MI.<S.78R<;%UKT4Y..YC]%]0=02P,$%
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MP*#"#*H0!A5BD$HL1E"%((A$9 &)#8X0!-4<02%_\>U?80;5G$&N*0O,H%K
MH,(,JA &%6*06$051E"%((A$5 4U1E"'(*CG"*[4+RJH,8-ZSB!71%HT9E O
M8%!C!G4(@QHQ2+UT:0RA#H$0B<@28@AU"(1Z#F$&M^"2R5YQ99JCWR5OHYV]
MU'Z+?G+UMA/_S/U>\__R81O_4]X<B[J-WJQSMO+[R@=KG>GZT^$01R>3[V\G
MI3FX_G#5'3?#]OEPXNQY_&D@N?T^L?T.4$L#!!0    ( +BL=%"9E(]U' (
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M:@/9-9 ?#=35!JIKH#X:F*L-=-= 3^W!= V,T\!K)ZN9_4U<QJMEGIUG>9M
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M53(T@B$HQ(3=UXF&/TPLT,HMRX"PVJ*&J9&J0V"L"H!5LO\$9>&"*R5]M^Z
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M]1A/:^D%42B(-@1L2$!]3, @ 6L(^$AM:"@!&&:HW5['C!KAL!%^21!R3!!
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M1_I!",V-?W1GZGXRWQ'#I.(';8>9&<ON,NTF6K3]AT(T?*TL_P)02P,$%
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MLWW5W\O]P,AV>'/(^/ 5_P!02P,$%     @ N*QT4+X93 T%!0  X!D  !D
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M&-7'W%$8W<?<8PR$\3P0&-N'S# D<#(_[^21BD7T,4_4G,P!$S6+?]@!2>^
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M?)\(TB55U4JM%%W5]K=#-@&=P=1VDNO;US8<QV&G?X*]GIV=69REO#'^(AH
MZ;UVM!<;OY%R> P"43?0$?' !NC5R8GQCDBUY>= #!S(T21U-,!AF 8=:7N_
M*DULSZN2721M>]AS3URZCO"_6Z#LMO&1_Q9X;L^-U(&@*@=RAA\@?PY[KG;!
MS')L.^A%RWJ/PVGC/Z''7:'Q!O"KA9M8K#WMY,#8B]Y\/6[\4 L""K74#$0]
MKK #2C61DO%GXO3GDCIQN7YC_VR\*R\'(F#'Z._V*)N-G_O>$4[D0N4SNWV!
MR4_B>Y/Y;W %JN!:B:I1,RK,KU=?A&3=Q**D=.1U?+:]>=[&DR29TMP)>$K
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MF:%R8DR"$AD^J&8UZC,S;RB<I%YF:LW'83MN)!NF[T@P?\RJ?U!+ P04
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MM3K^'9.&9\XN\/+\(_MC/_AV,"]9;99E_L]^T^SFH0Z#C=EF;WGSI3P]F7%
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M$!?-'=2@\3N(^<@ '^7  8%A/K([^,@P'QG@HS3.7DL&^.@+,C36&.8C&S%
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M^Y,P'/$UTAH0X,L?^D+F=D_\)!S=[@AL$@OD <E-1BC@+H ^T080W >0V0B
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M;Y0^EH[U4N[\P ):ST'!(_N&)K6& K^8*BN<DET;4^(GLV,EWYE"COZ:]\_
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MVV9[YEQ1'26:Z9+E>F#W!T;/RFP3O1?MU&H/BM?=1/;ZOP7KOU!+ P04
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M3S6@4;OG!8LFL^"L'5G,LL60'B9$Z!KS,,3@#A&H"+HP"!3&D@S,6<BN*58
MACJAK@%,[(8ZQ)!KQ&:("&,XFQ L:FCLPSY#',(.*.B &@?T*@WLI-%B(H,I
M#29*$&5.U38 +*:3:*0[# R' >$X-7M@ YX0$XH8S!.!/!' $SH\$(;")#%(
M$@,.1J),0 ?)[=V=@ XF0 21DV:+8;UR(I@"(UC7""")';584+]I-&8(C5&-
M/$(P0)6X5$,092.BPN SXAX3@&<RX@(6)OZ$,C$L30QIT^G>RH+Z[9L@-%Y8
M6'88T!US]+"QH#X5P=$X%:P\#,@J&7,!ZPK'GZ@MK"R<?%S;M07=7%M8@Q@0
M83+VRH(E1M#M"1-8.@22CI/PTH+Z"<?7"=MWWX>XZY!@E1% 98-#9T']!P=.
M:#)*!:N1A$ /R(@+6(V$?J('L,H(]'9S#QT9J@P\=$%O[BIX?3!3<^-MQ:F4
M.LS>;C>9WQ,]MSG[2SQ=8V#_04WR[=S]YK[]#/B>UH>L;+PG(=6T:&:ZO1"2
MJ_#1G0K\J+X\ND7.]U+?QNJ^;L?O=B%%93\M@N[[9O$?4$L#!!0    ( +BL
M=% [&Q([%P,  &T,   9    >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;)57
M[V^;,!#]5Q#?&^PSOUPED9I,TR9M4M5IVV>:. DJX R<I/OO9QM**3ZZ]$O
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M_:(0.V5N$WU?MP-PNU#RV WW0?\/8_D/4$L#!!0    ( +BL=%#T>-;3;0(
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MM^Y9-OYYZ688[<U@ ](;D,$ L[L&M#>@@4'2D?E4OW##%S,E+Y'J5JOE[J7
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M>2:88 ())N,[G4*"Z8A.&PR[Z)3>Z)2$V"<AR#3MFB#LB7HSU8 E23\5&Z+
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MF=?M?V]UJ)4L#(M>2I%^=,^L;)]'P_]IAAN ,8"3 8DN&E!C0,<:1,8@&FO
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M/ G=N05<L8 I=N*@P,4(T14!X^(!6SQ(P'8;I.!N48"K!Q#U<!<%KAZX0CV
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MZF(P:(S;WMJ]"L\U&$8.\R22Y7=0_@502P,$%     @ N*QT4$XW=0R"D0
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M 9/,P$RMLG66E(\QG8M=3P*79YOR[PI_(G ^[H,#_T_9]'"K\54R0=G\=*N
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MOUF+AZ/#-IQP 6ZX(]Z,I8,E+8*4Z=GP.PY0Y1FL"O3ZY"X-C)X@Q)WE)+5
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MM?4^8N24/S=J8>H\--I$@/#B>@'QQT?557U!A12M 7 5<-C(0WYT%?^W<+%
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M@05R\FY')C-;K,0*QN%M[ '"_DT(??9,0N_M@--%]L?4"_>3_/0?2_*@5(Z
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M"D>.J?X(->E^>)KGZ,]/'-MH,EA.OQNT\HTL[O6_N98YK[AE 8?<+X/X<W,
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M:F-\ %H$00_(1TZJTQ_I!#+:E.G1F^(ZKOY_=S,<SH+?"ZF!$&YH(A]KAN9
MM0W+?Q2T(.WF=IF+<6^S]1DR4DS!R>ZRN@%C1YD4C..8/ J[#YSLR.8;W-A!
MWW$\*'\T,@7=5('NB/NPW6_=DNP:NOI+^2 >F6/9]F:/!MF.^1+[9IWU O(
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MF6)^?9Y(BV_-N]#^1&PIV<Y%3*@<+Z7;+67LL(RB-* . 5#D&[<J QFI:E0
M_P!D0K%(3@K6&"L'][AH2(47-LYRTP2]21Q=0%P!;&>0/)VL4S;XD<,PPY?I
MLPI$J<;":C1#%!_SB6#F^)!! &5U?9#BA)AM& :6_7<]&B5YF134@W\R$$'Z
M*PO&IGP2 URKK(X]7C+#3E4@(;$XL$7NG]D3]UHW[:F_=]'G<4?;0;!(>K\1
MR3E2,Q *BHY%N9<>84E<78:/F!S?OG=JGWAY](I]KZOVW SZH)JL)DV*WR"$
M#H'_?S[QLUN?8H">C1GL#[^W67[/=7<J^;N.MR_](6!)9"W:4W,*+]7H :WC
M!A(*&D[!@2FI1[IG]UDM3\1#A4AS&9?])9RO3=#,', M]B49G70-0_+YZWY]
M)P=3&J1(<FT^X:R.J1BR1CU>,>QC"[K4(B]$5N(V56#+K"DXD29H^73$]++J
M%W[+ 4#5'?E6/8]UYB>;3)PF=B+V,Y .':4;<6]'M-Y)] RVG(*"_2?$HE%N
M!#DIMF*>5I2#!R/?E<6##]5Z!#[V_VD5^6,?F:FS;X4AU#7#Y)H<FU[L.=^4
M.@X7!WM1EACQ8]^K2\PW+W>GPD0A)&^CX+(+K0E[K"/Z"-H,M_S%=L8=,F;&
MYX5_O/;H^$<_&&0'$EPZX?=C /H^HU(33K@2-ZM4DDLG\;5K?%B4V1VEW&R1
M2@58@S!'7?I *4C;A/9-$L6@^3.["2^V*/L%.87]QXD3?*5[B5N8!>TO/6A<
MAKD0P 3]C)@K2/;8@'="6$[%$X(+>T^"(C>\%B&\R2O#B_6<"U,PLGJO&8#,
M8^0M-+F0YV=;0C;"W![%B]M(= 0C-G@M&H4,"J!-'G%RB*PYS8Z0J7 Z%%(0
M1MS(';E)-UAO(;AD,$11*?A'" (CW4CQ"A^=J$2-.UL'U\X>< $XW.&C>K T
MWHDNW):C*3"-9Y,%>WOAGZ-QJQ>!Z0/T+DUP:[===Z#G,:?E]8GND@D3;3 $
M$?3$QA80*B$#[D7D&I)KGI"X_)R'AMN"LFFA,*V^C%L0,7 :7'C C@R"\[VE
M]!+?HX2@D44#3[]FTC3<Z>%.$I.ZCM7Y)0OS9(U ^J G8;*Q)"FK\>>^[#\C
MT, E]9(($(<U>*$]RS5@:%H!;OTN"S*'Q]3DT,_?]JETP:%J2WK<[C!5]6P3
MN.TH$'#,O:0!DDM0<)AW"M)&Y3F-)_=YZUD$U3(?N<_@6@)#>[1-5I%S;9"I
MB[:%[\7X3Y_%P1G=]4/!)"*\$P?P'U0^3U4F666?LA.+\6_]^_!#]!:G$HU^
M\#LHLJ^;9FOT!3 L GOBG+Q$5<<I0*Z+BS9_%?5'6$RE?>F)MJJNX3!7D0H,
M5\[BL 1$&8P\]_$/XE>VAW9B4MMEB>$W3Y\U%04&[YQ(W!Y"WV5C0-1#&3=<
MVM.#8^8,+4:6YL8TU$!>-LKK7A6@1MP4I7KCS$-RH>#")+IWDQ] F6B3O/M$
MM=^)A4 E877-W\H+5X:@'=N8'O4U(Q" [A3:VL&=M)O*=2_=ZWM!$V%I4X%B
M*C4VI/0LPXBLJKNZM9XI'- '#AD3*)++O6 9N2(:E+^[P!IAZ7<1%@!UJN,!
MS!.N(6;S)O-!R=@+8_%SQR;?7TW^0*0<I\*$"HSOGEJEW4OF3>LS*TH!)E]S
M\+9$2X0,1H9B9'L&?Q::\\P2148CV-?:0&=;(;IJ4U(:1&ZS4+D*9C/6UK9&
M%MDS)TDA\_[O^CXKUV?LA_[2)6-.KM.4_8"3TUZ%IQ&%[J#_(W:",]WBQ7P>
M+U5MF<2C^7F\0 "U,$P=$'D(K>IE\!,XR?3!R6(>8_4^?6X43\Z'\?)\V&R_
M0=OF,S<DJ=SUAB*@]K-UF3RH?N@=]F>NAIYVV8$@.[3JGBRAP,L1MI-IJ8X?
MM5R?DAQ QY1DC_=I_8Q'H^!OJ?\;S#AV':& 4P%O1"DH13%[5XWC7AEPVT;8
M"#2\6=Y*@AK9D1A5W@@Q;@E"R+L'5@;B/&' G $<(_".5>8ZDLAWY49V=G9T
M*DGWJNA;' D3#1(Q*[.22?$>IHAQT_2+%K,:XWN5E:O]%K.+61JNT=>82DIT
MBR2=8HJ6C6FGA&G30#OH;9<?F&B]^XP-OGOL'$^^@HK+P47+(9$EO2+ &O$\
M^M <L&C%-;M'T[@M94(\V1OU,Y@&S#34 /%!NS['-EM%^(W^6Q)][ODD=?HP
M^\_E)QSJ<"F.^G7^#/SD%<J^.1P0QJT[U&JDYO+)5$8%/0XZ>@$T5$E'@!:K
MUV8N>5'DO8[2%(5>/N!*%2X2(O>'/0ZLG8/-/)R%XR4L?DCX5?"N9JQE=;J5
MO#NE.=].-<T3)A+!:Y4Y)@\-] =,#6)OL8L^!<T9&FWN!<"8.7SJ>EG:JA7_
M17(QM"%@FR<1TI&/LA)^+J&BJ3/#+<R87A>43]75^\M:HBR\C^'EQ_?I"F>J
M.5V#Z,^XD7E*F$7E8T].<!5U=TCK:7RG595A,SC1U$)'R_\U('B/ \]D=#0,
M_!5A<',_.FP5E9KZIBJV\8_0D6?L/,HNDFK2G#I0P0\I)J<0[)37Y*O5?;K>
M8_$0DW+"AG!?VPG4BHN_,OEW]DF*&3QXDS!>M.:ZI%J_LB)'O&,EML3O_Y_H
M]TZ#^^?!X'_C_3V,DM]Q8Y, %IM<#KY'8P-#&GG @<MS,AM^=\I7*,B.\WW/
M@JZ1IDE>F"2M(&DLC'*/" 761TJT7=IR;2K'K,BV,SZAU"0L;X&;^0Y8.J^.
MDGBO7E]Y2^W(Q_H%^/WC39FM70U4U0@6^1;#+F[$+A-D>0X@0ER7%]>7T0(K
M1EXYRY%OY1_3]1UE7+IH2/^$6CUFC5WZ;9/#:4WGPS-,BGGEXF&7_F6<(C<+
MT6;/FI+@7_4.T5LA,]/ RY%5>T9H>J-4%!Y\D]WNRQ6K@)+F!NK8/3I4 _N;
M4Z#MS)M"K5Q74DQH))]JDYHRX':2,A<<"P))" 8[-F7V@4\_<ZWQ<?N<Y>V3
M8&IV:7BFMTJ@TK64S:";L*E <ANH* P^YX]$I,[%YP2:&9,C3O0 NT_NB"I_
M1%W4(V4]<E0=QX0WM'%(<3B:'G?FNNNJ&=5-D'!/["G3M6DU0Y-B;I.4Y#;<
M-BO#GQOWF!'*L,C>R+3V:7@73\OED]GBFLTC.P#9K2RNP)H3'KVR3B?FV)P#
M,7-?-9XT8SZ:6373='I0# +>@4A= CC-]V4Q/!OA3<\J;3-$?A^C_]*1ON8X
M.M&,=5B2JXQZXT5?X%NN4UZCX2[K,-V./DN"[-M/60J+1FWND:;+I%\1S*4*
MFU"Z#"JJ($X:IV.#.)R]04.0JB3);A[Y)3/P<[XI/;; =,LUOC5M4^[N+/J^
MS-0XER<P^UVC3]/J(@F;QMCI6_>JW2XL:D8%Z=%L&0'34TYJ *#A8OA4=LIQ
MO\;V\DESYV7=X35Y+PBD UTE6;W7RAIN R_GX&P9$V@ITVU1MY3_,S]3U@B[
MO::MVZ(%Y1(FIC2C_8YR"UPV0G!-5O4Q&Q^2:4N/<-W9KSA?DSUW>6K --YH
MIG1+NWC6R\$VW;EDP$#8N]YEF1MPU1B0)(^ZJC##V'^ TOM7VM^=,K#I&8_C
M=I^:3TA2$*$DN>I0#YI&!B!.@_3W,J.+Y)-4M(BV%.69;N :G9IK00T1 T$%
MC45*RJ68#W3?>I,VYT6>'Z[\;&X(IT7\!C/NFBK[$1BU .?5AKY2T[9;>KC)
M)@UN)+1^(U[:"KVT7I[KH-TRP)4#G[!=<FJJ7-OI;D<;'ZV+0)K@E4K12\(A
MQ]E=B9?@N<\3TI1FFSI3TB@2GC$ S[LMT]3A,5B]RE^$&U"5"'/#XB:PXUTF
MP>#I[+C5: E;@)BK9+HBM//<F"+D9H$Q"BP)?4$$FL%!@]OP.>/H<AJ8<ZBP
MB[D)$/9+ZL]8/1WM=Z7I;&756/)B@[C1D(,6!KXA*7*#.L7*1:@-@@SQ%-<E
M5H,LS5+ 3(0&6=V,^M?84H_YR.);1B+C$K-T12O-W<Y5HKSBRYU[*!-NUP7\
M;#/'; G6:ZU4Q#^\56S(3ZX&]3<;*/KY<.-4]4C2:VQF.\\;^T7Y.>1S&A1!
M5OQ5FG/WYL:UBXH%_,1#2XN^Z&-R3K]UHS*8\-\3<S\\EM(7C$W73 )^D&V2
M[U&<<IIK>X 5UP@B:W--A0CE]4?%8DG/]([[V*V@@8B4H6H ]4HYMXJKC@#"
M0SF'4=<OB'/8ZRK%.,\F8U<!([S)#]3;J3O5\$=[/USBZ-K&C+S3VUL)NI0?
MFY$A\F-3C@%5D.T1P)2RVL/F#;HX0M2F*X\Z9!O6U(!\]=*&^$VL[Z4!N,MI
M.NW&0Q0SHWC)VN)K]U%?9!$9$#!6%<)*-,)VZEKMH+ IS@P[2)3.R1X2UZF\
MOR]9274*[PL'3YN1O9XOBYZ1!U_L_-P@>E_0143_88''K-J#26'J/@OG:;03
MPC0.=/>WJE(H0?DE&7F7-D$9E_M:;D=3<>Q.UNL=2C@6=X ]A-R1V9":J%V$
M3-(P17OB7AC<\2U+://"T$CBK@^**<+J<]Q=X5I$C>>4SJ*\327(&WH!.']/
MVI*'@G)?B?AXN4E@N=>K^P*K8MZE9>U=$T$^#"-?\<)5*IMEARL-,9Z\&#<(
M:+Z:X0>.D)W_&/VI0 P$4N?.I!4OYQQ^\7\(MM]MC(]>H=7LSB")0#NEHOU2
M:A<42A"V4"/FG9YW+CC@=9BO<^-?V5\^!>(KS(=M2I*/!K"6S.\3%HN[5@.W
M\M?!_,\X\!;\+JOLLJH,P7+I:DJHG6? J9N55P4DA_,A13Z U(51[CM'CBK:
M]J;T$W]OX;DZ",^AH!$Y^V5@FOX9JIF\W[R.TOTRT+\<KPK7&4P@6#5='YF^
MN(/X5'.N_?I44H#4EBF8P*>I+W&Q/!.]9G0=!@(1G"&_K%<9Q9C6V'VQ PFV
M3_U_QJ,-*T*;ZVXX!-E*R?5Q6#%0974.,8[]O$TEGH6OY%.TK7IZ"2O7$5/,
M5).@AVL\'G9:.LTU8@I+N+*/,-3U?<*U1I?L?N6[';C46+YS9V#\(/8 'F,2
MT&OMV+[3@=I:*,7?@D*_(B\P:M,9KWCJ>0Q5NHB7SR6GJ8FI='']F6<(?ST;
MC<,&WB>NE?%I=,T7]5%IK]'3V+YG:\3E,Q1,^[QC*Y91+(F)P1QE8/4,7I&%
MH>"ZDM#C<6BHUHSM8##31.ZPVDF(NL2;[C-*X,RHT2)A]E7H%\-:?BFHXDXR
MSB.'OBETBDMPS&4J5LU^)SZ'46PRK9OQV91:QKU9$8@K6:@KU[9>4KF)@61;
M)__('")O(P+"T#91%H;-/<& *V-!_9_>KO2WC>3*?\[^%0VLLTMYFYR^CS$P
M@"S9664MVY#L!$$^!+3$L8F12(&4//;"?_R^H\ZNJCXHS0+!Q&)WUUWO?K]W
MS0]-3!=R2\NPJ%C$ML!-YW,@J.QW*]!$;Z %]B,C??E5(4#\BBA27]"T1[.(
MH]7-FEU\*M6-Y#3N3B!14"#3E6EPD%9M%B<-MZUAI9";@'H]7V<2^<P>HDY9
M;.%OW1M:,BE1(JC$3'5"MRE&E2!0D<B:$XM+M4<\E8,Y.DP$BVVD!\C<O>&H
M#U2][Z@>A88(%BE6:,;@BV)TCCMK0"'LS3+3!%*@X35*F27"RILYL#T+P5@&
MU*10# 6&>X3HM'PUD0P(SM3!C8!U5-AX,>=:,\BA/EUB5=C\:MIO?'73E26=
M">6UQ#"Z9B%@M[KO6BZ<TXPMV^?1UZA 5EAVFJ0,C'!G?-@P+(2_UKUZQ^TQ
MLYA+C6Z@>_Q.6+GE;1'69L8RQEW@!_0ZGP>//\$GWHT)6$*.Q5X!H3Q<DT?#
M*5"M82#,X=':7V^-P&UKE&<FA*&*V0UPF&:>-#"%&Z$/$\0D&D$_"[IQ@1S]
M0=2 .;&=ZB<@K@(]VN%;5^Q4.Q;HR@8KNA0#LVI"U_Y!X9-YFAJ,67-XP?F
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M3FFWU:=%A D.N*;=AW]=;A;*N]9]>(X9[+E(,.X^?(?I.DGI_U+,])TUT^/
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ML1.KXJO9[3&^N]3(XX (OO2AYZ5)6YKAEDZ)73MHD]]NOX(,)@R)X4T.$)D
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MOFE]HWC[25QSC?VWAE_^!5!+ P04    " "XK'10L03XNA@"  #L)   &@
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M?KI_IG29MJ1P^;SZWW*9^B<BS"OR\V]02P,$%     @ N*QT4)>*BVSH 0
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M-Q36T]CY5/6QWO-X*=(\50/K%Q[S$:G?.B65!PU/K4_WP[Y9OQJ^[WOA7\7
MAL/_WOKQ<@B0'!(DAP+)H4%R3$%RG(/DN #)<0F2@T]0@J"(RE%(Y2BF<A14
M.8JJ'(55CN(J1X&5H\@J4&05*+(*%%D%BJP"15:!(JM D56@R"I09!4HLDH4
M626*K!)%5HDBJT215:+(*E%DE2BR2A19)8JL"D56A2*K0I%5H<BJ4&15*+(J
M%%D5BJP*15:%(JM&D56CR*I19-4HLFH4636*K!I%5HTBJT:15:/(.D61=7I"
M68=CWIJZ^RW)B[6KS_EL^(_1S3M02P$"% ,4    " "XK'10'R// \     3
M @  "P              @ $     7W)E;',O+G)E;'-02P$"% ,4    " "X
MK'10)^B'#H(   "Q    $               @ 'I    9&]C4')O<',O87!P
M+GAM;%!+ 0(4 Q0    ( +BL=% \SGVR[P   "L"   1              "
M 9D!  !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( +BL=%"97)PC$ 8
M )PG   3              "  ;<"  !X;"]T:&5M92]T:&5M93$N>&UL4$L!
M A0#%     @ N*QT4,\9P"K$ @  ,PL  !@              ( !^ @  'AL
M+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( +BL=%#(])?)P0,
M $\0   8              "  ?(+  !X;"]W;W)K<VAE971S+W-H965T,BYX
M;6Q02P$"% ,4    " "XK'10O5+''40"  "X!P  &               @ 'I
M#P  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ N*QT4(U8
MKPR2 P  N@X  !@              ( !8Q(  'AL+W=O<FMS:&5E=',O<VAE
M970T+GAM;%!+ 0(4 Q0    ( +BL=%"34?^M=P4  *T:   8
M  "  2L6  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " "X
MK'10W6;OF^$!  !G!   &               @ '8&P  >&PO=V]R:W-H965T
M<R]S:&5E=#8N>&UL4$L! A0#%     @ N*QT4.V\G3=_!0  [AH  !@
M         ( ![QT  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0
M   ( +BL=% O?V1=, (  ,8&   8              "  :0C  !X;"]W;W)K
M<VAE971S+W-H965T."YX;6Q02P$"% ,4    " "XK'10A0M#;;0!  #2 P
M&               @ $*)@  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L!
M A0#%     @ N*QT4$AX\!RT 0  T@,  !D              ( !]"<  'AL
M+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " "XK'10>LB!W;4!
M  #2 P  &0              @ '?*0  >&PO=V]R:W-H965T<R]S:&5E=#$Q
M+GAM;%!+ 0(4 Q0    ( +BL=%!)+R^@M0$  -(#   9              "
M <LK  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ N*QT
M4"I,_8&S 0  T@,  !D              ( !MRT  'AL+W=O<FMS:&5E=',O
M<VAE970Q,RYX;6Q02P$"% ,4    " "XK'10F PQJ[4!  #2 P  &0
M        @ &A+P  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0
M   ( +BL=%"\VQN^M@$  -(#   9              "  8TQ  !X;"]W;W)K
M<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ N*QT4*Q?.N*S 0  T@,
M !D              ( !>C,  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q0
M2P$"% ,4    " "XK'10BCY-9;0!  #2 P  &0              @ %D-0
M>&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( +BL=% 2[JZ.
MM0$  -(#   9              "  4\W  !X;"]W;W)K<VAE971S+W-H965T
M,3@N>&UL4$L! A0#%     @ N*QT4%5IE0BS 0  T@,  !D
M ( !.SD  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " "X
MK'10LS3Y/[4!  #2 P  &0              @ $E.P  >&PO=V]R:W-H965T
M<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( +BL=% [C_#;A@(  -P)   9
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M970R-2YX;6Q02P$"% ,4    " "XK'103N:RZ-L!   !!0  &0
M    @ &P2   >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    (
M +BL=% SLGC](@,  .,+   9              "  <)*  !X;"]W;W)K<VAE
M971S+W-H965T,C<N>&UL4$L! A0#%     @ N*QT4#8CZ4\I @  -08  !D
M             ( !&TX  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"
M% ,4    " "XK'10NJ1+VB $  "K&   &0              @ %[4   >&PO
M=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( +BL=%"9E(]U' (
M  <'   9              "  =)4  !X;"]W;W)K<VAE971S+W-H965T,S N
M>&UL4$L! A0#%     @ N*QT4)7(<9_L @  8@T  !D              ( !
M)5<  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " "XK'10
MSS%Z8",%  !%&@  &0              @ %(6@  >&PO=V]R:W-H965T<R]S
M:&5E=#,R+GAM;%!+ 0(4 Q0    ( +BL=%#E\;TLE@,  ((2   9
M      "  :)?  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%
M  @ N*QT4!37DW"A @  N0@  !D              ( !;V,  'AL+W=O<FMS
M:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " "XK'10#TFXX7D"  #&"0
M&0              @ %'9@  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+
M 0(4 Q0    ( +BL=%#R#O%*'0(   0'   9              "  ?=H  !X
M;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ N*QT4+X93 T%
M!0  X!D  !D              ( !2VL  'AL+W=O<FMS:&5E=',O<VAE970S
M-RYX;6Q02P$"% ,4    " "XK'10*8+=*DX"  "\!P  &0
M@ &'<   >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( +BL
M=%#QOSL[3@(  -@&   9              "  0QS  !X;"]W;W)K<VAE971S
M+W-H965T,SDN>&UL4$L! A0#%     @ N*QT4."]0LX/!   :Q,  !D
M         ( !D74  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4
M    " "XK'10L\8%7MH"  #>"@  &0              @ '7>0  >&PO=V]R
M:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( +BL=%"8HA %-00  #D5
M   9              "  >A\  !X;"]W;W)K<VAE971S+W-H965T-#(N>&UL
M4$L! A0#%     @ N*QT4#%.#SNC @  ^0D  !D              ( !5($
M 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    " "XK'10?15(
M<1T"  #E!0  &0              @ $NA   >&PO=V]R:W-H965T<R]S:&5E
M=#0T+GAM;%!+ 0(4 Q0    ( +BL=%"O-CD]>0,  ,H/   9
M  "  8*&  !X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @
MN*QT4)V3E>=O @  "@D  !D              ( !,HH  'AL+W=O<FMS:&5E
M=',O<VAE970T-BYX;6Q02P$"% ,4    " "XK'10D8@@ON8!   %!0  &0
M            @ '8C   >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4
M Q0    ( +BL=%!U4HR--0(  .L&   9              "  ?6.  !X;"]W
M;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ N*QT4$3"6T"Q @
MC D  !D              ( !89$  'AL+W=O<FMS:&5E=',O<VAE970T.2YX
M;6Q02P$"% ,4    " "XK'10MB(._'<"   B"   &0              @ %)
ME   >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( +BL=%!3
M@]#Q' ,  .L,   9              "  ?>6  !X;"]W;W)K<VAE971S+W-H
M965T-3$N>&UL4$L! A0#%     @ N*QT4#L;$CL7 P  ;0P  !D
M     ( !2IH  'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( +BL=%#;:]C/!0(  '(%   9              "
M 4>H  !X;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @ N*QT
M4*A@]  ^ @  H@8  !D              ( !@ZH  'AL+W=O<FMS:&5E=',O
M<VAE970U."YX;6Q02P$"% ,4    " "XK'105PD*O[H"   0#   &0
M        @ 'XK   >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0
M   ( +BL=%#C7"K57@,  ",0   9              "  >FO  !X;"]W;W)K
M<VAE971S+W-H965T-C N>&UL4$L! A0#%     @ N*QT4/-.A>S* 0  &@0
M !D              ( !?K,  'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q0
M2P$"% ,4    " "XK'103C=U#(*1  #2/0( %               @ %_M0
M>&PO<VAA<F5D4W1R:6YG<RYX;6Q02P$"% ,4    " "XK'10G; N F0"   D
M#0  #0              @ $S1P$ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    (
M +BL=%"YSU7'I 0  .\H   /              "  <)) 0!X;"]W;W)K8F]O
M:RYX;6Q02P$"% ,4    " "XK'10L03XNA@"  #L)   &@
M@ &33@$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " "X
MK'10EXJ+;.@!  !K)   $P              @ 'C4 $ 6T-O;G1E;G1?5'EP
=97-=+GAM;%!+!08     1@!& !P3  #\4@$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6801830944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of components of income (loss) before the income tax provision (benefit)</a></td>
<td class="text"><div><p style="MARGIN:0px;text-align:justify">&#160;</p><table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN" width="100%"><tbody><tr><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Year Ended </strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>December 31,</strong></span></span></p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2019</strong></span></span></p></td><td style="PADDING-BOTTOM:1px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2018</strong></span></span></p></td><td style="PADDING-BOTTOM:1px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">US</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,120,521</span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(19,192,594</span></span></td><td style="width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td></tr><tr style="background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Foreign</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(67,096</span></span></td><td style="width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#x2014;</span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#cceeff"><td valign="top"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">Pre-tax income (loss) from operations</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-top:1pt solid black;border-bottom:2.5pt double black;border-right:none;border-left:none;border-image:initial;width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td><td style="border-top:1pt solid black;border-bottom:2.5pt double black;border-right:none;border-left:none;border-image:initial;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>1,053,425</strong></span></span></td><td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-top:1pt solid black;border-bottom:2.5pt double black;border-right:none;border-left:none;border-image:initial;width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td><td style="border-top:1pt solid black;border-bottom:2.5pt double black;border-right:none;border-left:none;border-image:initial;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>(19,192,594</strong></span></span></td><td style="padding-bottom:1px;width:1%" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">)</p></td></tr></tbody></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule for significant portions of deferred income tax assets</a></td>
<td class="text"><table border="0" cellpadding="0" cellspacing="0" style="WIDTH:100%;TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN" width="100%"><tbody><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="background-color:rgb(255, 255, 255);width:6px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="6" style="border-bottom:1px solid;text-align:center;background-color:rgb(255, 255, 255);width:159px" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>As of December 31,</strong></span></span></p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px 0px 0px 0in;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Current deferred tax assets/(liabilities):</span></span></p></td><td style="background-color:rgb(255, 255, 255);width:6px" valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td><td colspan="2" style="border-bottom:1px solid;text-align:center;width:80px;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2019</strong></span></span></p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td colspan="2" style="border-bottom:1px solid;text-align:center;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2018</strong></span></span></p></td><td style="padding-bottom:1px;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="background-color:rgb(204, 238, 255)" valign="top"><p style="MARGIN:0px 0px 0px 15px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">State taxes</span></span></p></td><td style="width:6px;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:9px;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">336</span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="width:6px;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td><td style="text-align:right;width:73px;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">345</span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="top"><p style="MARGIN:0px 0px 0px 15px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Capitalized research and development costs</span></span></p></td><td style="width:6px;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:9px;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#x2014;</span></span></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="width:6px;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:73px;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">10,327</span></span></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="background-color:rgb(204, 238, 255)" valign="top"><p style="MARGIN:0px 0px 0px 15px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other</span></span></p></td><td style="width:6px;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:9px;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">112,222</span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="width:6px;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:73px;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">187,377</span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="top"><p style="MARGIN:0px 0px 0px 15px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net operating loss</span></span></p></td><td style="width:6px;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-bottom:1px solid;width:9px;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-bottom:1px solid;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6,434,544</span></span></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="border-bottom:1px solid;width:6px;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-bottom:1px solid;text-align:right;width:73px;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,104,432</span></span></td><td style="padding-bottom:1px;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="background-color:rgb(204, 238, 255)" valign="top"><p style="MARGIN:0px 0px 0px 0in;text-align:justify"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Gross deferred tax assets</span></span></strong></p></td><td style="width:6px;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:9px;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>6,547,102</strong></span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="width:6px;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:73px;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>5,302,481</strong></span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="top"><p style="MARGIN:0px 0px 0px 0in;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Valuation allowance</span></span></p></td><td style="width:6px;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-bottom:1px solid;width:9px;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-bottom:1px solid;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(6,206,450</span></span></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="border-bottom:1px solid;width:6px;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-bottom:1px solid;text-align:right;width:73px;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(5,302,481</span></span></td><td style="padding-bottom:1px;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="background-color:rgb(204, 238, 255)" valign="top"><p style="MARGIN:0px 0px 0px 0in;text-align:justify"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net&#160;deferred tax assets</span></span></strong></p></td><td style="width:6px;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border:1pt none;width:9px;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td><td style="border:1pt none;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>340,652</strong></span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="border:1pt none;width:6px;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td><td style="border:1pt none;text-align:right;width:73px;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#x2014;</strong></span></span></td><td style="padding-bottom:3px;width:1%;background-color:rgb(204, 238, 255);border:1pt none" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></p></td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="top">&#160;</td><td style="width:6px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="border-width:1pt;border-style:none none solid;border-top-color:initial;border-right-color:initial;border-bottom-color:black;border-left-color:initial;border-image:initial;width:9px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="border-width:1pt;border-style:none none solid;border-top-color:initial;border-right-color:initial;border-bottom-color:black;border-left-color:initial;border-image:initial;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="width:1%;border:1pt none;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="width:1%;border:1pt none;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="border-width:1pt;border-style:none none solid;border-top-color:initial;border-right-color:initial;border-bottom-color:black;border-left-color:initial;border-image:initial;width:6px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="border-width:1pt;border-style:none none solid;border-top-color:initial;border-right-color:initial;border-bottom-color:black;border-left-color:initial;border-image:initial;text-align:right;width:73px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="padding-bottom:3px;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="background-color:rgb(204, 238, 255)" valign="top"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Deferred tax liabilities</strong></span></span></p></td><td style="width:6px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="border:1pt none;width:9px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="border:1pt none;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="width:1%;border:1pt none;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="width:1%;border:1pt none;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="border:1pt none;width:6px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="border:1pt none;text-align:right;width:73px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="padding-bottom:3px;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="top"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160; &#160;&#160;Note discount</span></span></p></td><td style="width:6px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="border-bottom:1pt solid black;width:9px;background-color:rgb(255, 255, 255);border-top:1pt solid black" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td><td style="border-bottom:1pt solid black;text-align:right;width:9%;background-color:rgb(255, 255, 255);border-top:1pt solid black" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(340,652</span></span></p></td><td style="width:1%;border:1pt none;background-color:rgb(255, 255, 255)" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></p></td><td style="width:1%;border:1pt none;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="border-bottom:1pt solid black;width:6px;background-color:rgb(255, 255, 255);border-top:1pt solid black" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td><td style="border-bottom:1pt solid black;text-align:right;width:73px;background-color:rgb(255, 255, 255);border-top:1pt solid black" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#x2014;</span></span></p></td><td style="padding-bottom:3px;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="background-color:rgb(204, 238, 255)" valign="top"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Total deferred tax liabilities</strong></span></span></p></td><td style="width:6px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="border-bottom:1pt solid black;width:9px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="border-bottom:1pt solid black;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>(340,652</strong></span></span></p></td><td style="width:1%;border:1pt none;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>)</strong></span></span></td><td style="width:1%;border:1pt none;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="border-bottom:1pt solid black;width:6px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="border-bottom:1pt solid black;text-align:right;width:73px;background-color:rgb(204, 238, 255)" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#x2014;</span></span></p></td><td style="padding-bottom:3px;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="top"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Net deferred tax assets</strong></span></span></p></td><td style="width:6px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="border-bottom:2.5pt double black;width:9px;background-color:rgb(255, 255, 255);border-top:none;border-right:none;border-left:none;border-image:initial" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td><td style="border-bottom:2.5pt double black;text-align:right;width:9%;background-color:rgb(255, 255, 255);border-top:none;border-right:none;border-left:none;border-image:initial" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#x2014;</span></span></p></td><td style="width:1%;border:1pt none;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="width:1%;border:1pt none;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="border-bottom:2.5pt double black;width:6px;background-color:rgb(255, 255, 255);border-top:none;border-right:none;border-left:none;border-image:initial" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td><td style="border-bottom:2.5pt double black;text-align:right;width:73px;background-color:rgb(255, 255, 255);border-top:none;border-right:none;border-left:none;border-image:initial" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#x2014;</span></span></p></td><td style="padding-bottom:3px;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of provision for income taxes on earnings subject to income taxes differs from the statutory Federal rate</a></td>
<td class="text"><table border="0" cellpadding="0" cellspacing="0" style="WIDTH:100%;TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN" width="100%"><tbody><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="6" style="border-bottom:1px solid;text-align:center;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>As of December 31,</strong></span></span></p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td><td colspan="2" style="border-bottom:1px solid;text-align:center;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2019</strong></span></span></p></td><td style="padding-bottom:1px;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td><td colspan="2" style="border-bottom:1px solid;text-align:center;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2018</strong></span></span></p></td><td style="padding-bottom:1px;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="background-color:rgb(204, 238, 255)" valign="top"><p style="MARGIN:0px 0px 0px 0in;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected income tax benefit at federal statutory tax rate</span></span></p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">221,219</span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(4,030,454</span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="top"><p style="MARGIN:0px 0px 0px 0in;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">State income taxes, net of federal benefit</span></span></p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(434,881</span></span></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(319,816</span></span></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="background-color:rgb(204, 238, 255)" valign="top"><p style="MARGIN:0px 0px 0px 0in;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Change in fair value of warrants</span></span></p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(1,874,873</span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,869,116</span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="top"><p style="MARGIN:0px 0px 0px 0in;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Change in valuation allowance</span></span></p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,469,187</span></span></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,286,995</span></span></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="background-color:rgb(204, 238, 255)" valign="top"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Uncertain tax positions</span></span></p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">436,145</span></span></p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#x2014;</span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="top"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Change in compound derivative</span></span></p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(101,671</span></span></p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,224</span></span></p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="background-color:rgb(204, 238, 255)" valign="top"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Loss on extinguishment of debt</span></span></p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">117,198</span></span></p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">123,982</span></span></p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="top"><p style="MARGIN:0px 0px 0px 0in;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Stock compensation</span></span></p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">121,289</span></span></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">67,966</span></span></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="background-color:rgb(204, 238, 255)" valign="top"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Rate adjustment</span></span></p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">49,338</span></span></p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#x2014;</span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="top"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other permanent difference</span></span></p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(1,351</span></span></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255);border-bottom:1pt solid black" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255);border-bottom:1pt solid black" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">629</span></span></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="background-color:rgb(204, 238, 255)" valign="top"><p style="MARGIN:0px 0px 0px 0in;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Provision for Income Taxes</strong></span></span></p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-top:1pt solid black;border-right:none;border-bottom:2.5pt double black;border-left:none;width:1%;background-color:rgb(204, 238, 255);border-image:initial" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td><td style="border-top:1pt solid black;border-right:none;border-bottom:2.5pt double black;border-left:none;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-image:initial" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>1,600</strong></span></span></td><td style="padding-bottom:3px;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td><td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>1,642</strong></span></span></td><td style="padding-bottom:3px;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of reconciliation of beginning and ending amounts of unrecognized tax positions</a></td>
<td class="text"><div><p style="MARGIN:0px">&#160;</p><table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN" width="100%"><tbody><tr><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="6" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>As of December 31,</strong></span></span></p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2019</strong></span></span></p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2018</strong></span></span></p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unrecognized tax positions, beginning of the year</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#x2014;</span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#x2014;</span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Gross increase - current period tax positions</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:black 1px solid;width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:black 1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">552,082</span></span></td><td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:black 1px solid;width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:black 1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#x2014;</span></span></td><td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unrecognized tax positions, end of year</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td><td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>552,082</strong></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td><td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#x2014;</span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr></tbody></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=117331294&amp;loc=d3e36027-109320<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6796569744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants and Derivative Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_DerivativeLiabilitiesLineItems', window );"><strong>Derivative Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of warrants vested and outstanding</a></td>
<td class="text"><table border="0" cellpadding="0" cellspacing="0" style="WIDTH:100%;TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN" width="100%"><tbody><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="text-align:center;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="text-align:center;width:85px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="width:8px;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="text-align:center;background-color:rgb(255, 255, 255)" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong><strong>Number of</strong></strong></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong>Warrantsv</strong></p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="text-align:center;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Exercise</strong></span></span></span></span></p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="text-align:center;width:85px;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Term</strong></span></span></span></span></p></td><td style="width:8px;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="text-align:center;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong><strong>Vested</strong> and</strong></span></span></span></span></p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="border:1pt none;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Source</strong></span></span></span></span></p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="border-bottom:1px solid black;text-align:center;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Price</strong></span></span></span></span></p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="border-bottom:1px solid black;text-align:center;width:85px;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>(Years)</strong></span></span></span></span></p></td><td style="width:8px;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="border-bottom:1px solid black;text-align:center;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Outstanding</strong></span></span></span></span></p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="background-color:rgb(204, 238, 255)" valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Pre 2015 Common Stock Warrants</span></span></span></span></p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>1.00</span></span></span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="width:85px;background-color:rgb(204, 238, 255)"><p style="MARGIN:0px;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>6&#x2014;10</span></span></span></span></p></td><td style="width:8px;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>4,000,000</span></span></span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>2015 Common Stock Warrants</span></span></span></span></p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="background-color:rgb(255, 255, 255)"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></td><td style="background-color:rgb(255, 255, 255)"><p style="MARGIN:0px;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>1.15&#x2014;5.00</span></span></span></span></p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="width:85px;background-color:rgb(255, 255, 255)"><p style="MARGIN:0px;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>5&#x2014;10</span></span></span></span></p></td><td style="width:8px;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>442,000</span></span></span></span></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="background-color:rgb(204, 238, 255)" valign="top"><p style="margin-top:0px;margin-right:0px;margin-bottom:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Common Stock Warrants to Series B Stockholders</span></span></span></span></p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>0.00</span></span></span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:77px;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>5</span></span></span></span></td><td style="width:8px;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>1,031,250</span></span></span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>2016 Common Stock Warrants to Service Providers</span></span></span></span></p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>1.15</span></span></span></span></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:77px;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>10</span></span></span></span></td><td style="width:8px;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>40,000</span></span></span></span></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="background-color:rgb(204, 238, 255)" valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>2016 Series C Common Stock Warrants to Placement Agent</span></span></span></span></p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>0.40</span></span></span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:77px;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>5</span></span></span></span></td><td style="width:8px;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>125,000</span></span></span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>2017 Series D Common Stock Warrants to Placement Agent</span></span></span></span></p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>0.25</span></span></span></span></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:77px;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>5</span></span></span></span></td><td style="width:8px;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>480,000</span></span></span></span></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="background-color:rgb(204, 238, 255)" valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>2017 Common Stock Warrants to Service Provider</span></span></span></span></p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>0.41</span></span></span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:77px;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>5</span></span></span></span></td><td style="width:8px;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>125,000</span></span></span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>2018 Emerald Financing Warrants</span></span></span></span></p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>0.10</span></span></span></span></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:77px;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>5</span></span></span></span></td><td style="width:8px;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>3,400,000</span></span></span></span></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="border:1pt none;background-color:rgb(204, 238, 255)" valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Emerald Multi Draw Credit Agreement Warrants</span></span></span></span></p></td><td style="width:1%;border:1pt none;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border:1pt none;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></td><td style="border:1pt none;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>0.50</span></span></span></span></td><td style="padding-bottom:1px;width:1%;border:1pt none;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;border:1pt none;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border:1pt none;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border:1pt none;text-align:right;width:77px;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>5</span></span></span></span></td><td style="padding-bottom:1px;width:8px;border:1pt none;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;border:1pt none;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border:1pt none;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border:1pt none;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>7,500,000</span></span></span></span></td><td style="padding-bottom:1px;width:1%;border:1pt none;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="top"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">2019 Common Stock Warrants</span></span></p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(255, 255, 255);border-bottom:1pt solid black" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255);border-bottom:1pt solid black" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">0.35</span></span></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="text-align:right;width:77px;background-color:rgb(255, 255, 255);border-bottom:1pt solid black" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">5</span></span></td><td style="width:8px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="border-bottom:1pt solid black;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="border-bottom:1pt solid black;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">8,000,000</span></span></p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="background-color:rgb(204, 238, 255)" valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Total warrants vested and outstanding as of December 31, 2019</strong></span></span></span></span></p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:77px;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:8px;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>&#160;</strong></span></span></span></span></p></td><td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>25,143,250</strong></span></span></span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>&#160;</strong></span></span></span></span></p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock', window );">Schedule summary of the activity of derivative liabilities</a></td>
<td class="text"><div><p style="MARGIN:0px">&#160;</p><table border="0" cellpadding="0" cellspacing="0" style="WIDTH:100%;TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN" width="100%"><tbody><tr><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="18" style="border:1pt none;text-align:center" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Year Ended December 31, 2019</strong></span></span></span></span></p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>December 31,</strong></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>2018, Fair</strong></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Value of</strong></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Derivative Liabilities</strong></span></span></span></span></p></td><td valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Fair Value of Derivative Liabilities Issued</strong></span></span></span></span></p></td><td valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td><td colspan="2" style="border-bottom:1px solid black;text-align:center;width:80px" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Change in</strong></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Fair value of&#160;Liabilities</strong></span></span></span></span></p></td><td style="width:8px" valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Reclassification</strong></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>of Derivatives</strong></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>to Equity&#160;or Extinguishment</strong></span></span></span></span></p></td><td valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>December 31,</strong></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>2019, Fair</strong></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Value of</strong></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Derivative Liabilities</strong></span></span></span></span></p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#cceeff"><td valign="top"><p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Emerald Multi Draw Credit Agreement - compound derivative liability (1)</span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:9px" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></td><td style="text-align:right;width:108px" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">219,453</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>516,058</span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></td><td style="text-align:right;width:72px" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(484,147</span></span></span></span></td><td style="width:8px" valign="bottom"><p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></td><td style="text-align:right;width:9%" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(160,567</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)*</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:6px" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></td><td style="text-align:right;width:73px" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>90,797</span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#ffffff"><td valign="top"><p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Emerald Financing - warrant liability (2)</span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:9px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:108px" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">15,251,413</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>&#x2014;</span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:72px" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(9,042,066</span></span></span></span></td><td style="width:8px" valign="bottom"><p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(5,933,323</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:6px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:73px" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>276,024</span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#cceeff"><td valign="top"><p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Series B - warrant liability (3)</span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:9px;border-bottom:1pt solid black" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:108px;border-bottom:1pt solid black" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>487,500</span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;border-bottom:1pt solid black" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;border-bottom:1pt solid black" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>&#x2014;</span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;border-bottom:1pt solid black" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:72px;border-bottom:1pt solid black" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(208,546</span></span></span></span></td><td style="width:8px" valign="bottom"><p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;border-bottom:1pt solid black" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;border-bottom:1pt solid black" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(144,375</span></span></span></span></td><td style="width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>)</span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:6px;border-bottom:1pt solid black" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:73px;border-bottom:1pt solid black" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>134,579</span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Total derivative liabilities</strong></span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-bottom:3px double black;width:9px" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>$</strong></span></span></span></span></td><td style="border-bottom:3px double black;text-align:right;width:108px" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>15,958,366</strong></span></span></span></span></td><td style="PADDING-BOTTOM:3px;width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>&#160;</strong></span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:black 3px double;width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>$</strong></span></span></span></span></td><td style="BORDER-BOTTOM:black 3px double;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>516,058</strong></span></span></span></span></td><td style="PADDING-BOTTOM:3px;width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>&#160;</strong></span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:black 3px double;width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>$</strong></span></span></span></span></td><td style="border-bottom:3px double black;text-align:right;width:72px" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>(9,734,759</strong></span></span></span></span></td><td style="padding-bottom:3px;width:8px" valign="bottom"><p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>)</strong></span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:black 3px double;width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>$</strong></span></span></span></span></td><td style="BORDER-BOTTOM:black 3px double;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>(6,238,265</strong></span></span></span></span></td><td style="PADDING-BOTTOM:3px;width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>)</strong></span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-bottom:3px double black;width:6px" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>$</strong></span></span></span></span></td><td style="border-bottom:3px double black;text-align:right;width:73px" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>501,400</strong></span></span></span></span></td><td style="PADDING-BOTTOM:3px;width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>&#160;</strong></span></span></span></span></p></td></tr><tr style="background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Less, noncurrent portion of derivative liabilities</span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:9px;border-bottom:1pt solid black" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:108px;border-bottom:1pt solid black" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(219,453</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:72px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:8px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-bottom:1px solid black;width:6px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-bottom:1px solid black;text-align:right;width:73px" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(90,797</span></span></span></span></td><td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>)</span></span></span></span></td></tr><tr style="background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Current balance of derivative liabilities</strong></span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:9px;border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial" valign="bottom"><p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>$</strong></span></span></p></td><td style="text-align:right;width:108px;border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>15,738,913</strong></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:72px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:8px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;border:1pt none" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;border:1pt none" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;width:6px" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>$</strong></span></span></span></span></td><td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;text-align:right;width:73px" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>410,603</strong></span></span></span></span></td><td style="PADDING-BOTTOM:3px;width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>&#160;</strong></span></span></span></span></p></td></tr></tbody></table><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><em>*This amount has been included in the calculation of the extinguishment loss recorded in connection with the prepayment of the Emerald Credit Agreement as described in Note 4 below.</em></span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#160;</p><table border="0" cellpadding="0" cellspacing="0" style="WIDTH:100%;TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN" width="100%"><tbody><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td colspan="18" style="border-bottom:1px solid black;text-align:center;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Year Ended December 31, 2018</strong></span></span></span></span></p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td colspan="2" style="border-bottom:1px solid black;text-align:center;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>December 31,</strong></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>2017, Fair</strong></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Value of</strong></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Derivative Liabilities</strong></span></span></span></span></p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td><td colspan="2" style="border-bottom:1px solid black;text-align:center;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Fair Value of Derivative Liabilities Issued</strong></span></span></span></span></p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td><td colspan="2" style="border-bottom:1px solid black;text-align:center;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Change in</strong></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Fair value of Derivative Liabilities</strong></span></span><span><span><strong>**</strong></span></span></span></span></p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td><td colspan="2" style="border-bottom:1px solid black;text-align:center;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Reclassification</strong></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>of Derivatives</strong></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>to Equity</strong></span></span></span></span></p></td><td style="background-color:rgb(255, 255, 255);width:6px" valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td><td style="width:12px;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td><td colspan="2" style="border-bottom:1px solid black;text-align:center;width:82px;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>December 31,</strong></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>2018, Fair</strong></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Value of</strong></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Derivative Liabilities</strong></span></span></span></span></p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="background-color:rgb(204, 238, 255)" valign="top"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Emerald Multi Draw Credit Agreement - compound derivative liability (1)</span></span></p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">&#x2014;</span></span></p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">204,102</span></span></p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">15,351</span></span></p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">&#x2014;</span></span></p></td><td style="width:6px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="width:12px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="width:11px;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">219,453</span></span></p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="top"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Emerald Financing - warrant liability (2)</span></span></p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">&#x2014;</span></span></p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">10,424,634</span></span></p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">4,826,779</span></span></p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">&#x2014;</span></span></p></td><td style="width:6px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="width:12px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="width:11px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">15,251,413</span></span></p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="background-color:rgb(204, 238, 255)" valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Series B - warrant liability (3)</span></span></span></span></p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>551,322</span></span></span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>&#x2014;</span></span></span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>1,476,044</span></span></span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(1,539,866</span></span></p></td><td style="width:6px;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></p></td><td style="width:12px;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:11px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>487,500</span></span></span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="top"><p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Emerald Convertible Promissory Note - conversion liability (4)</span></span></span></span></p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">265,000</span></span></p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>360,000</span></span></span></span></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">185,000</span></span></p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;<p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(810,000</span></span></p></td><td style="width:6px;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></p></td><td style="width:12px;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:11px;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>&#x2014;</span></span></span></span></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="background-color:rgb(204, 238, 255)" valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Series B Preferred Stock - conversion liability (5)</span></span></span></span></p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>6,715</span></span></span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>&#x2014;</span></span></span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>&#x2014;</span></span></span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(6,715</span></span></span></span></td><td style="width:6px;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>)</span></span></span></span></td><td style="width:12px;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:11px;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>&#x2014;</span></span></span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr><td style="background-color:rgb(255, 255, 255)" valign="top"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Total derivative liabilities</strong></span></span></p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="border-bottom:2.5pt double black;width:1%;background-color:rgb(255, 255, 255);border-top:1pt solid black;border-right:none;border-left:none;border-image:initial" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>$</strong></span></span></td><td style="border-bottom:2.5pt double black;text-align:right;width:9%;background-color:rgb(255, 255, 255);border-top:1pt solid black;border-right:none;border-left:none;border-image:initial" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>823,037</strong></span></span></td><td style="padding-bottom:3px;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="border-bottom:2.5pt double black;width:1%;background-color:rgb(255, 255, 255);border-top:1pt solid black;border-right:none;border-left:none;border-image:initial" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>$</strong></span></span></td><td style="border-bottom:2.5pt double black;text-align:right;width:9%;background-color:rgb(255, 255, 255);border-top:1pt solid black;border-right:none;border-left:none;border-image:initial" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>10,988,736</strong></span></span></td><td style="padding-bottom:3px;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="border-bottom:2.5pt double black;width:1%;background-color:rgb(255, 255, 255);border-top:1pt solid black;border-right:none;border-left:none;border-image:initial" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>$</strong></span></span></td><td style="border-bottom:2.5pt double black;text-align:right;width:9%;background-color:rgb(255, 255, 255);border-top:1pt solid black;border-right:none;border-left:none;border-image:initial" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>6,503,174</strong></span></span></td><td style="padding-bottom:3px;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="border-bottom:2.5pt double black;width:1%;background-color:rgb(255, 255, 255);border-top:1pt solid black;border-right:none;border-left:none;border-image:initial" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>$</strong></span></span></td><td style="border-bottom:2.5pt double black;text-align:right;width:9%;background-color:rgb(255, 255, 255);border-top:1pt solid black;border-right:none;border-left:none;border-image:initial" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>(2,356,581</strong></span></span></td><td style="padding-bottom:3px;width:6px;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>)</strong></span></span></td><td style="width:12px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="border-bottom:2.5pt double black;width:11px;background-color:rgb(255, 255, 255);border-top:1pt solid black;border-right:none;border-left:none;border-image:initial" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>$</strong></span></span></td><td style="border-bottom:2.5pt double black;text-align:right;width:9%;background-color:rgb(255, 255, 255);border-top:1pt solid black;border-right:none;border-left:none;border-image:initial" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>15,958,366</strong></span></span></td><td style="padding-bottom:3px;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="background-color:rgb(204, 238, 255)" valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Less, noncurrent portion of derivative liabilities</span></span></span></span></p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(551,322</span></span></p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:6px;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:12px;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border:1pt none;width:11px;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border:1pt none;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>(219,453</span></span></span></span></td><td style="padding-bottom:1px;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>)</span></span></span></span></td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Current balance of derivative liabilities</strong></span></span></span></span></p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="width:1%;border-bottom:2.5pt double black;background-color:rgb(255, 255, 255);border-top:1pt solid black;border-right:none;border-left:none;border-image:initial" valign="bottom"><p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>$</strong></span></span></p></td><td style="text-align:right;width:9%;border-bottom:2.5pt double black;background-color:rgb(255, 255, 255);border-top:1pt solid black;border-right:none;border-left:none;border-image:initial" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>271,715</strong></span></span></p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:6px;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:12px;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-bottom:2.5pt double black;width:11px;background-color:rgb(255, 255, 255);border-top:1pt solid black;border-right:none;border-left:none;border-image:initial" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>$</strong></span></span></span></span></td><td style="border-bottom:2.5pt double black;text-align:right;width:9%;background-color:rgb(255, 255, 255);border-top:1pt solid black;border-right:none;border-left:none;border-image:initial" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>15,738,913</strong></span></span></span></span></td><td style="padding-bottom:3px;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>&#160;</strong></span></span></span></span></p></td></tr></tbody></table></div><p style="MARGIN:0px">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><em>**The change in fair value of derivative liabilities for the year ended December 31, 2018, relate partially to the Company determining it had sufficient trading activity to utilize the actual volatility of the trading of the Company&#x2019;s common stock as an input to the volatility assumption when computing the fair value of derivative liabilities. The volatility assumption was updated as of October 1, 2018 to incorporate the Company&#x2019;s own volatility with six similar companies to develop a blended average. The Company had previously estimated the volatility assumption by averaging the volatility of six similar entities which had resulted in a lower volatility. The increase in value of the volatility assumption has led to a higher valuation of the derivative liabilities as disclosed below.</em></span></span></span></span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_ScheduleOfAdjustmentForDifferenceBetweenFairValueOfWarrantLiabilitiesAndTotalProceedsReceivedTableTextBlock', window );">Schedule of the adjustment for the difference between the fair value of the warrant liabilities and the total proceeds received</a></td>
<td class="text"><table border="0" cellpadding="0" cellspacing="0" style="WIDTH:100%;TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN" width="100%"><tbody><tr><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="6" style="BORDER-BOTTOM:black 1px solid;text-align:center" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Closing</strong></span></span></span></span></p></td><td valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td><td colspan="2" style="text-align:center" valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td></tr><tr><td valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>January </strong></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>2018</strong></span></span></span></span></p></td><td valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>February</strong></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>2018</strong></span></span></span></span></p></td><td valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Total</strong></span></span></span></span></p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#cceeff"><td valign="top"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">Initial fair value of Emerald Financing Warrant Liability</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>4,717,211</span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>5,707,423</span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>10,424,634</span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#ffffff"><td valign="top"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">Less: proceeds from the Emerald Financing</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border:1pt none;width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border:1pt none;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>1,500,000</span></span></span></span></td><td style="padding-bottom:1px;width:1%;border:1pt none" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;border:1pt none" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border:1pt none;width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border:1pt none;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>1,750,000</span></span></span></span></td><td style="padding-bottom:1px;width:1%;border:1pt none" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;border:1pt none" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border:1pt none;width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border:1pt none;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>3,250,000</span></span></span></span></td><td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Excess over proceeds adjustment</strong></span></span></span></span></p></td><td style="width:1%;border:1pt none" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border:1pt none;width:1%" valign="bottom">&#160;</td><td style="border:1pt none;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>3,217,211</strong></span></span></span></span></td><td style="padding-bottom:3px;width:1%;border:1pt none" valign="bottom"><p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>&#160;</strong></span></span></span></span></p></td><td style="width:1%;border:1pt none" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border:1pt none;width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>$</strong></span></span></span></span></td><td style="border:1pt none;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>3,957,423</strong></span></span></span></span></td><td style="padding-bottom:3px;width:1%;border:1pt none" valign="bottom"><p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>&#160;</strong></span></span></span></span></p></td><td style="width:1%;border:1pt none" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border:1pt none;width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>$</strong></span></span></span></span></td><td style="border:1pt none;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>7,174,634</strong></span></span></span></span></td><td style="padding-bottom:3px;width:1%;border:1pt none" valign="bottom"><p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>&#160;</strong></span></span></span></span></p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandNineteenCommonStockWarrantsMember', window );">2019 Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_DerivativeLiabilitiesLineItems', window );"><strong>Derivative Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of input and valuation technique used to value warrant liabilities</a></td>
<td class="text"><div><table border="0" cellpadding="0" cellspacing="0" style="border:0px" width="100%"><tbody><tr><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="bottom">&#160;</td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="bottom">&#160;</td><td colspan="2" style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>At Issuance</strong></span></span></td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="bottom">&#160;</td></tr><tr style="background-color:#cceeff"><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="top"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Dividend yield</span></span></td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom">&#160;</td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom">&#160;</td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">0.00</span></span></td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">%</span></span></td></tr><tr style="background-color:#ffffff"><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="top"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Volatility factor</span></span></td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom">&#160;</td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom">&#160;</td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">93.08</span></span></td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">%</span></span></td></tr><tr style="background-color:#cceeff"><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="top"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Risk-free interest rate</span></span></td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom">&#160;</td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom">&#160;</td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">1.62</span></span></td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">%</span></span></td></tr><tr style="background-color:#ffffff"><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="top"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Expected term (years)</span></span></td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom">&#160;</td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom">&#160;</td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">5.0</span></span></td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom">&#160;</td></tr><tr style="background-color:#cceeff"><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="top"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Underlying common stock price</span></span></td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom">&#160;</td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">0.22</span></span></td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom">&#160;</td></tr></tbody></table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_SeriesBWarrantMember', window );">Series B Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_DerivativeLiabilitiesLineItems', window );"><strong>Derivative Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of input and valuation technique used to value warrant liabilities</a></td>
<td class="text"><table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN;margin:auto" width="85%"><tbody><tr><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center" valign="bottom"><p style="MARGIN:0px 0px 0px 0in;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>As of </strong></span></span></span></span></p><p style="MARGIN:0px 0px 0px 0in;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>December 31,</strong></span></span></span></span></p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>2019</strong></span></span></span></span></p></td><td style="PADDING-BOTTOM:1px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>2018</strong></span></span></span></span></p></td><td style="PADDING-BOTTOM:1px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Dividend yield</span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>0.00</span></span></span></span></td><td style="width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>%</span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>0.00</span></span></span></span></td><td style="width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>%</span></span></span></span></td></tr><tr style="background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Volatility factor</span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>79.2</span></span></span></span></td><td style="width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>%</span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>93.0</span></span></span></span></td><td style="width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>%</span></span></span></span></td></tr><tr style="background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Risk-free interest rate</span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2"><p style="MARGIN:0px;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>1.60</span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>%</span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>2.79</span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>%</span></span></span></span></p></td></tr><tr style="background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Expected term (years)</span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2"><p style="MARGIN:0px;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>0.64</span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>1.64&#x2014;1.65</span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#cceeff"><td valign="top"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Underlying common stock price</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>0.13</span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>0.40</span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember', window );">Emerald Multi-Draw Credit Agreement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_DerivativeLiabilitiesLineItems', window );"><strong>Derivative Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of input and valuation technique used to value warrant liabilities</a></td>
<td class="text"><div><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#160;</p><table border="0" cellpadding="0" cellspacing="0" style="border:0px" width="100%"><tbody><tr><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="bottom">&#160;</td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="bottom">&#160;</td><td colspan="2" style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom"><strong>At Issuance</strong></td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="bottom">&#160;</td></tr><tr style="background-color:#cceeff"><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="top">Dividend yield</td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom">&#160;</td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom">&#160;</td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right;width:9%" valign="bottom">0.00</td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom">%</td></tr><tr style="background-color:#ffffff"><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="top">Volatility factor</td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom">&#160;</td><td colspan="2" style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right">91.6-92.1%</td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom">&#160;</td></tr><tr style="background-color:#cceeff"><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="top">Risk-free interest rate</td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom">&#160;</td><td colspan="2" style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right">2.23-2.51%</td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom">&#160;</td></tr><tr style="background-color:#ffffff"><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="top">Expected term (years)</td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom">&#160;</td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right;width:1%" valign="bottom">&#160;</td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right;width:9%" valign="bottom">5.0</td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom">&#160;</td></tr><tr style="background-color:#cceeff"><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="top">Underlying common stock price</td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom">&#160;</td><td colspan="2" style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right">$0.33-0.69</td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom">&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#160;</p><table border="0" cellpadding="0" cellspacing="0" style="border:0px" width="100%"><tbody><tr><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="bottom">&#160;</td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="bottom">&#160;</td><td colspan="2" style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;border-bottom:1pt solid black;text-align:center;width:9%" valign="bottom"><strong>At Issuance</strong></td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="bottom">&#160;</td></tr><tr style="background-color:#cceeff"><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="top">Dividend yield</td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom">&#160;</td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom">&#160;</td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right;width:9%" valign="bottom">0.00</td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom">%</td></tr><tr style="background-color:#ffffff"><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="top">Volatility factor</td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom">&#160;</td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom">&#160;</td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right;width:9%" valign="bottom">92.5</td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom">%</td></tr><tr style="background-color:#cceeff"><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="top">Risk-free interest rate</td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom">&#160;</td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom">&#160;</td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right;width:9%" valign="bottom">2.96</td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom">%</td></tr><tr style="background-color:#ffffff"><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="top">Expected term (years)</td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom">&#160;</td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom">&#160;</td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right;width:9%" valign="bottom">5.0</td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom">&#160;</td></tr><tr style="background-color:#cceeff"><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt" valign="top">Underlying common stock price</td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom">&#160;</td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom">$</td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right;width:9%" valign="bottom">0.36</td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:1%" valign="bottom">&#160;</td></tr></tbody></table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember', window );">Emerald Convertible Promissory Note Conversion Liability</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_DerivativeLiabilitiesLineItems', window );"><strong>Derivative Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of input and valuation technique used to value warrant liabilities</a></td>
<td class="text"><table border="0" cellpadding="0" cellspacing="0" style="WIDTH:100%;TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN" width="100%"><tbody><tr><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>January 19,</strong></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>2018</strong></span></span></span></span></p></td><td style="PADDING-BOTTOM:1px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Dividend yield</span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>0.00</span></span></span></span></td><td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>%</span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Volatility factor</span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>70.00</span></span></span></span></td><td style="width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>%</span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Risk-free interest rate</span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>1.29</span></span></span></span></td><td style="width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>%</span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Expected term (years)</span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>0.003</span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Underlying common stock price</span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>0.19</span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=embi_EmeraldFinancingMember', window );">Emerald Financing Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_DerivativeLiabilitiesLineItems', window );"><strong>Derivative Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of input and valuation technique used to value warrant liabilities</a></td>
<td class="text"><table border="0" cellpadding="0" cellspacing="0" style="WIDTH:100%;TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN;margin:auto" width="100%"><tbody><tr><td style="width:null" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>December 31,</strong></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>2019</strong></span></span></span></span></p></td><td style="PADDING-BOTTOM:1px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>December 31,</strong></span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>2018</strong></span></span></p></td><td style="PADDING-BOTTOM:1px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%">&#160;</td><td style="width:1%">&#160;</td><td style="border-bottom:1pt solid black;width:8%"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>At Issuance</strong></span></span></p></td><td style="width:1%">&#160;</td></tr><tr style="background-color:#cceeff"><td style="width:null" valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Dividend yield</span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>0.00</span></span></span></span></td><td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>%</span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>0.00</span></span></span></span></td><td style="width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>%</span></span></span></span></td><td style="width:1%">&#160;</td><td style="width:1%">&#160;</td><td style="width:8%"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">0.00</span></span></p></td><td style="width:1%"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">%</span></span></td></tr><tr style="background-color:#ffffff"><td style="width:null" valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Volatility factor</span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2"><p style="MARGIN:0px;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>79.5</span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>%</span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">92.1&#x2014;92.4</span></span></p></td><td style="width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>%</span></span></span></span></td><td style="width:1%">&#160;</td><td style="width:1%">&#160;</td><td style="text-align:right;width:8%"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">70.0</span></span></td><td style="width:1%"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">%</span></span></td></tr><tr style="background-color:#cceeff"><td style="width:null" valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Risk-free interest rate</span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>1.62</span></span></span></span></td><td style="width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>%</span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">2.49</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>%</span></span></span></span></p></td><td style="width:1%">&#160;</td><td style="width:1%">&#160;</td><td style="width:8%"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">2.45&#x2014;2.60</span></span></p></td><td style="width:1%"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">%</span></span></td></tr><tr style="background-color:#ffffff"><td style="width:null" valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Expected term (years)</span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2"><p style="MARGIN:0px;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>3.13</span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">4.05&#x2014;4.13</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%">&#160;</td><td style="width:1%">&#160;</td><td style="text-align:right;width:8%"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">5.0</span></span></td><td style="width:1%">&#160;</td></tr><tr style="background-color:#cceeff"><td style="width:null" valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Underlying common stock price</span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>0.13</span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>$</span></span></span></span></td><td><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">0.40</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%">&#160;</td><td style="width:1%"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></td><td style="width:8%"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:right"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">0.29&#x2014;0.30</span></span></p></td><td style="width:1%">&#160;</td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_DerivativeLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line item represents derivative liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_DerivativeLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_ScheduleOfAdjustmentForDifferenceBetweenFairValueOfWarrantLiabilitiesAndTotalProceedsReceivedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent Schedule of the adjustment for the difference between the fair value of the warrant liabilities and the total proceeds received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_ScheduleOfAdjustmentForDifferenceBetweenFairValueOfWarrantLiabilitiesAndTotalProceedsReceivedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative liabilities at fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandNineteenCommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandNineteenCommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_SeriesBWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_SeriesBWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=embi_EmeraldFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=embi_EmeraldFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6803764480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Warrants and Derivative Liabilities (Details 2) - Emerald Multi-Draw Credit Agreement Warrants - Black-Scholes option pricing model<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 01, 2018 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Underlying common stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.36<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Underlying common stock price</a></td>
<td class="nump">$ 0.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Underlying common stock price</a></td>
<td class="nump">$ 0.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input (in percent)</a></td>
<td class="nump">0.0000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility factor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility factor | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input (in percent)</a></td>
<td class="nump">91.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility factor | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input (in percent)</a></td>
<td class="nump">0.921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.96<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input (in percent)</a></td>
<td class="nump">0.0223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input (in percent)</a></td>
<td class="nump">0.0251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected Term (years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_PricingModelAxis=embi_PricingModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_PricingModelAxis=embi_PricingModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6799661920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Warrants and Derivative Liabilities (Details 6) - Black Scholes Merton Option Pricing Model - Series B Warrant Liability<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Underlying common stock price</a></td>
<td class="nump">$ 0.13<span></span>
</td>
<td class="nump">$ 0.40<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input (in percent)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility factor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input (in percent)</a></td>
<td class="nump">79.2<span></span>
</td>
<td class="nump">93.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input (in percent)</a></td>
<td class="nump">1.60<span></span>
</td>
<td class="nump">2.79<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected Term (years)</a></td>
<td class="text">7 months 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term (years) | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected Term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 7 months 20 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term (years) | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected Term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 7 months 24 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_PricingModelAxis=embi_PricingModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_PricingModelAxis=embi_PricingModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=embi_SeriesBWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=embi_SeriesBWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6792420752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt - Related Party (Details 1) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_CouponInterestExpense', window );">Interest expense - stated rate</a></td>
<td class="nump">$ 371,420<span></span>
</td>
<td class="nump">$ 26,433<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_NonCashInterestExpenseAbstract', window );"><strong>Non-cash interest expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_AmortizationOfDebtDiscount', window );">Amortization of debt discount</a></td>
<td class="nump">616,383<span></span>
</td>
<td class="nump">56,253<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_AmortizationOfTransactionCosts', window );">Amortization of transaction costs</a></td>
<td class="nump">12,910<span></span>
</td>
<td class="nump">2,283<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseOther', window );">Other interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,794<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">$ 1,000,713<span></span>
</td>
<td class="nump">$ 94,763<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_AmortizationOfDebtDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_AmortizationOfDebtDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_AmortizationOfTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization of transaction costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_AmortizationOfTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_CouponInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as coupon interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_CouponInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_NonCashInterestExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_NonCashInterestExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6801805328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>8. Income Taxes </strong></span></span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The components of income (loss) before the income tax provision (benefit) consist of the following:</span></span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><div><p style="MARGIN:0px;text-align:justify">&#160;</p><table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN" width="100%"><tbody><tr><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Year Ended </strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>December 31,</strong></span></span></p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2019</strong></span></span></p></td><td style="PADDING-BOTTOM:1px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2018</strong></span></span></p></td><td style="PADDING-BOTTOM:1px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">US</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,120,521</span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(19,192,594</span></span></td><td style="width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td></tr><tr style="background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Foreign</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(67,096</span></span></td><td style="width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#x2014;</span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#cceeff"><td valign="top"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">Pre-tax income (loss) from operations</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-top:1pt solid black;border-bottom:2.5pt double black;border-right:none;border-left:none;border-image:initial;width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td><td style="border-top:1pt solid black;border-bottom:2.5pt double black;border-right:none;border-left:none;border-image:initial;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>1,053,425</strong></span></span></td><td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-top:1pt solid black;border-bottom:2.5pt double black;border-right:none;border-left:none;border-image:initial;width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td><td style="border-top:1pt solid black;border-bottom:2.5pt double black;border-right:none;border-left:none;border-image:initial;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>(19,192,594</strong></span></span></td><td style="padding-bottom:1px;width:1%" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">)</p></td></tr></tbody></table></div><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0in;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under the FASB&#x2019;s accounting guidance related to income tax positions, among other things, the impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. Additionally, the guidance provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.</span></span></p><p style="MARGIN:0px 0px 0px 0in;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>The Company had no accrual for interest or penalties on the Company&#x2019;s Balance Sheets at December 31, 2019 and 2018, and has not recognized interest and/or penalties in the Consolidated Statements of Comprehensive Income (Loss) for the years ended December 31, 2019 or 2018.</span></span></span></span></span></p><p style="MARGIN:0px 0px 0px 0in;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0in;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>The Company is subject to taxation in the United States and California. The Company&#x2019;s tax years for 2016 (federal) and 2015 (California) and 2019 (Australia) and forward are subject to examination by the United States, California and Australia tax authorities.</span></span></span></span></span></p><p style="MARGIN:0px 0px 0px 0in;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">At December 31, 2019, the Company had federal and California NOLs aggregating $13,213,037 and $24,481,423, respectively, which, if not used, it will begin to expire from 2033 and the Company had federal NOLs that do not expire but utilization is limited to 80% of taxable income for any given tax year in the amount of $11,275,349. At December 31, 2019, the Company had Australia NOLs aggregating $67,096 which do not expire.</span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Utilization of the domestic NOL will be subject to a substantial annual limitation due to ownership change limitations that may have occurred, or that could occur in the future, as required by Section 382 of the Internal Revenue Code of 1986, as amended (the Code), as well as similar state provisions. These ownership changes may limit the amount of NOLs that can be utilized annually to offset future taxable income and tax, respectively.&#160;In general, an &#x201c;ownership change&#x201d; as defined by Section 382 of the Code&#160;results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percentage points of the outstanding stock of a company by certain stockholders.</span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Upon the occurrence of an ownership change under Section 382 as outlined above, utilization of the NOLs are subject to an annual limitation under Section 382 of the Code, which is determined by first multiplying the value of the Company&#x2019;s stock at the time of the ownership change by the applicable long-term, tax-exempt rate, and then could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the NOL before utilization. The multiple ownership changes may have already occurred as the Company raised capital through the issuance of stock. However, due to the existence of the valuation allowance for deferred tax assets, any potential change in ownership will not impact the Company&#x2019;s effective tax rate.</span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The tax effects of temporary differences and carryforwards that give rise to significant portions of the deferred income tax assets are as follows:</span></span></p><p style="MARGIN:0px">&#160;</p><table border="0" cellpadding="0" cellspacing="0" style="WIDTH:100%;TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN" width="100%"><tbody><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="background-color:rgb(255, 255, 255);width:6px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="6" style="border-bottom:1px solid;text-align:center;background-color:rgb(255, 255, 255);width:159px" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>As of December 31,</strong></span></span></p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px 0px 0px 0in;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Current deferred tax assets/(liabilities):</span></span></p></td><td style="background-color:rgb(255, 255, 255);width:6px" valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td><td colspan="2" style="border-bottom:1px solid;text-align:center;width:80px;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2019</strong></span></span></p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td colspan="2" style="border-bottom:1px solid;text-align:center;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2018</strong></span></span></p></td><td style="padding-bottom:1px;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="background-color:rgb(204, 238, 255)" valign="top"><p style="MARGIN:0px 0px 0px 15px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">State taxes</span></span></p></td><td style="width:6px;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:9px;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">336</span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="width:6px;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td><td style="text-align:right;width:73px;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">345</span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="top"><p style="MARGIN:0px 0px 0px 15px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Capitalized research and development costs</span></span></p></td><td style="width:6px;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:9px;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#x2014;</span></span></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="width:6px;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:73px;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">10,327</span></span></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="background-color:rgb(204, 238, 255)" valign="top"><p style="MARGIN:0px 0px 0px 15px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other</span></span></p></td><td style="width:6px;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:9px;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">112,222</span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="width:6px;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:73px;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">187,377</span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="top"><p style="MARGIN:0px 0px 0px 15px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net operating loss</span></span></p></td><td style="width:6px;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-bottom:1px solid;width:9px;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-bottom:1px solid;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6,434,544</span></span></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="border-bottom:1px solid;width:6px;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-bottom:1px solid;text-align:right;width:73px;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5,104,432</span></span></td><td style="padding-bottom:1px;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="background-color:rgb(204, 238, 255)" valign="top"><p style="MARGIN:0px 0px 0px 0in;text-align:justify"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Gross deferred tax assets</span></span></strong></p></td><td style="width:6px;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:9px;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>6,547,102</strong></span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="width:6px;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:73px;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>5,302,481</strong></span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="top"><p style="MARGIN:0px 0px 0px 0in;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Valuation allowance</span></span></p></td><td style="width:6px;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-bottom:1px solid;width:9px;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-bottom:1px solid;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(6,206,450</span></span></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="border-bottom:1px solid;width:6px;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-bottom:1px solid;text-align:right;width:73px;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(5,302,481</span></span></td><td style="padding-bottom:1px;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="background-color:rgb(204, 238, 255)" valign="top"><p style="MARGIN:0px 0px 0px 0in;text-align:justify"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net&#160;deferred tax assets</span></span></strong></p></td><td style="width:6px;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border:1pt none;width:9px;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td><td style="border:1pt none;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>340,652</strong></span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="border:1pt none;width:6px;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td><td style="border:1pt none;text-align:right;width:73px;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#x2014;</strong></span></span></td><td style="padding-bottom:3px;width:1%;background-color:rgb(204, 238, 255);border:1pt none" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></p></td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="top">&#160;</td><td style="width:6px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="border-width:1pt;border-style:none none solid;border-top-color:initial;border-right-color:initial;border-bottom-color:black;border-left-color:initial;border-image:initial;width:9px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="border-width:1pt;border-style:none none solid;border-top-color:initial;border-right-color:initial;border-bottom-color:black;border-left-color:initial;border-image:initial;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="width:1%;border:1pt none;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="width:1%;border:1pt none;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="border-width:1pt;border-style:none none solid;border-top-color:initial;border-right-color:initial;border-bottom-color:black;border-left-color:initial;border-image:initial;width:6px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="border-width:1pt;border-style:none none solid;border-top-color:initial;border-right-color:initial;border-bottom-color:black;border-left-color:initial;border-image:initial;text-align:right;width:73px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="padding-bottom:3px;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="background-color:rgb(204, 238, 255)" valign="top"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Deferred tax liabilities</strong></span></span></p></td><td style="width:6px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="border:1pt none;width:9px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="border:1pt none;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="width:1%;border:1pt none;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="width:1%;border:1pt none;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="border:1pt none;width:6px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="border:1pt none;text-align:right;width:73px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="padding-bottom:3px;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="top"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160; &#160;&#160;Note discount</span></span></p></td><td style="width:6px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="border-bottom:1pt solid black;width:9px;background-color:rgb(255, 255, 255);border-top:1pt solid black" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td><td style="border-bottom:1pt solid black;text-align:right;width:9%;background-color:rgb(255, 255, 255);border-top:1pt solid black" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(340,652</span></span></p></td><td style="width:1%;border:1pt none;background-color:rgb(255, 255, 255)" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></p></td><td style="width:1%;border:1pt none;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="border-bottom:1pt solid black;width:6px;background-color:rgb(255, 255, 255);border-top:1pt solid black" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td><td style="border-bottom:1pt solid black;text-align:right;width:73px;background-color:rgb(255, 255, 255);border-top:1pt solid black" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#x2014;</span></span></p></td><td style="padding-bottom:3px;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="background-color:rgb(204, 238, 255)" valign="top"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Total deferred tax liabilities</strong></span></span></p></td><td style="width:6px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="border-bottom:1pt solid black;width:9px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="border-bottom:1pt solid black;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>(340,652</strong></span></span></p></td><td style="width:1%;border:1pt none;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>)</strong></span></span></td><td style="width:1%;border:1pt none;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="border-bottom:1pt solid black;width:6px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="border-bottom:1pt solid black;text-align:right;width:73px;background-color:rgb(204, 238, 255)" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#x2014;</span></span></p></td><td style="padding-bottom:3px;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="top"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Net deferred tax assets</strong></span></span></p></td><td style="width:6px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="border-bottom:2.5pt double black;width:9px;background-color:rgb(255, 255, 255);border-top:none;border-right:none;border-left:none;border-image:initial" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td><td style="border-bottom:2.5pt double black;text-align:right;width:9%;background-color:rgb(255, 255, 255);border-top:none;border-right:none;border-left:none;border-image:initial" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#x2014;</span></span></p></td><td style="width:1%;border:1pt none;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="width:1%;border:1pt none;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="border-bottom:2.5pt double black;width:6px;background-color:rgb(255, 255, 255);border-top:none;border-right:none;border-left:none;border-image:initial" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td><td style="border-bottom:2.5pt double black;text-align:right;width:73px;background-color:rgb(255, 255, 255);border-top:none;border-right:none;border-left:none;border-image:initial" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#x2014;</span></span></p></td><td style="padding-bottom:3px;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td></tr></tbody></table><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The provision for income taxes on earnings subject to income taxes differs from the statutory Federal rate at December 31, 2019 and 2018, due to the following:</span></span></p><p style="MARGIN:0px">&#160;</p><table border="0" cellpadding="0" cellspacing="0" style="WIDTH:100%;TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN" width="100%"><tbody><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="6" style="border-bottom:1px solid;text-align:center;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>As of December 31,</strong></span></span></p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td><td colspan="2" style="border-bottom:1px solid;text-align:center;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2019</strong></span></span></p></td><td style="padding-bottom:1px;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center">&#160;</p></td><td colspan="2" style="border-bottom:1px solid;text-align:center;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2018</strong></span></span></p></td><td style="padding-bottom:1px;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="background-color:rgb(204, 238, 255)" valign="top"><p style="MARGIN:0px 0px 0px 0in;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected income tax benefit at federal statutory tax rate</span></span></p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">221,219</span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(4,030,454</span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="top"><p style="MARGIN:0px 0px 0px 0in;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">State income taxes, net of federal benefit</span></span></p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(434,881</span></span></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(319,816</span></span></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="background-color:rgb(204, 238, 255)" valign="top"><p style="MARGIN:0px 0px 0px 0in;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Change in fair value of warrants</span></span></p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(1,874,873</span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,869,116</span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="top"><p style="MARGIN:0px 0px 0px 0in;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Change in valuation allowance</span></span></p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,469,187</span></span></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,286,995</span></span></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="background-color:rgb(204, 238, 255)" valign="top"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Uncertain tax positions</span></span></p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">436,145</span></span></p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#x2014;</span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="top"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Change in compound derivative</span></span></p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(101,671</span></span></p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,224</span></span></p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="background-color:rgb(204, 238, 255)" valign="top"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Loss on extinguishment of debt</span></span></p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">117,198</span></span></p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">123,982</span></span></p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="top"><p style="MARGIN:0px 0px 0px 0in;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Stock compensation</span></span></p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">121,289</span></span></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">67,966</span></span></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="background-color:rgb(204, 238, 255)" valign="top"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Rate adjustment</span></span></p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">49,338</span></span></p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#x2014;</span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="top"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other permanent difference</span></span></p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(1,351</span></span></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255);border-bottom:1pt solid black" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255);border-bottom:1pt solid black" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">629</span></span></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="background-color:rgb(204, 238, 255)" valign="top"><p style="MARGIN:0px 0px 0px 0in;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Provision for Income Taxes</strong></span></span></p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-top:1pt solid black;border-right:none;border-bottom:2.5pt double black;border-left:none;width:1%;background-color:rgb(204, 238, 255);border-image:initial" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td><td style="border-top:1pt solid black;border-right:none;border-bottom:2.5pt double black;border-left:none;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-image:initial" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>1,600</strong></span></span></td><td style="padding-bottom:3px;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td><td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>1,642</strong></span></span></td><td style="padding-bottom:3px;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></p></td></tr></tbody></table><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company records a valuation allowance against deferred tax assets to the extent that it is more likely than not that some portion, or all of, the deferred tax assets will not be realized. Due to the substantial doubt related to the Company&#x2019;s ability to utilize its deferred tax assets, a valuation allowance for the full amount of the deferred tax assets has been established at December 31, 2019. As a result of this valuation allowance, there are no income tax benefits reflected in the accompanying statement of operations to offset pre-tax losses.</span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Tax Cuts and Jobs Act of 2017 subjects a U.S. shareholder to tax on global intangible low-taxed income ("GILTI") earned by certain foreign subsidiaries. The FASB Staff Q&amp;A, Topic 740, No. 5, Accounting for Global Intangible Low-Taxed Income, states that an entity can make an accounting policy election to recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only. The Company elects to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only.</span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">A reconciliation of the beginning and ending amounts of unrecognized tax positions are as follows:</span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#160;</p><div><p style="MARGIN:0px">&#160;</p><table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN" width="100%"><tbody><tr><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="6" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>As of December 31,</strong></span></span></p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2019</strong></span></span></p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2018</strong></span></span></p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unrecognized tax positions, beginning of the year</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#x2014;</span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#x2014;</span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Gross increase - current period tax positions</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:black 1px solid;width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:black 1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">552,082</span></span></td><td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:black 1px solid;width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:black 1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#x2014;</span></span></td><td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unrecognized tax positions, end of year</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td><td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>552,082</strong></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td><td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#x2014;</span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr></tbody></table></div><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">If recognized, none of the unrecognized tax positions would impact the Company&#x2019;s income tax benefit or effective tax rate as long as the Company&#x2019;s net deferred tax assets remain subject to a full valuation allowance. The Company does not expect any significant increases or decreases to the Company&#x2019;s unrecognized tax positions within the next twelve months.</span></span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6801848416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt - Related Party<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_ConvertibleDebtRelatedPartyTextBlock', window );">Convertible Debt - Related Party</a></td>
<td class="text"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>4. Convertible Debt &#x2013; Related Party</strong></span></span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0in"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company&#x2019;s Convertible Debt with Emerald Health Sciences consists of the following:</span></span></p><p style="MARGIN:0px">&#160;</p><table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN;margin:auto" width="85%"><tbody><tr><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="6" style="BORDER-BOTTOM:black 1px solid;text-align:center" valign="bottom"><p style="MARGIN:0px 0px 0px 12pt;TEXT-INDENT:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>As of December 31, </strong></span></span></p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px 0px 0px 12pt;TEXT-INDENT:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2019</strong></span></span></p></td><td style="PADDING-BOTTOM:1px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px 0px 0px 12pt;TEXT-INDENT:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2018</strong></span></span></p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#cceeff"><td valign="top"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total principal value</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,014,500</span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:6px" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td><td style="text-align:right;width:62px" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,000,000</span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#ffffff"><td valign="top"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unamortized debt discount</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(1,622,344</span></span></td><td style="width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:6px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:62px" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(587,617</span></span></td><td style="width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td></tr><tr style="background-color:#cceeff"><td valign="top"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unamortized debt issuance costs</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:black 1px solid;width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:black 1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(5,086</span></span></td><td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-bottom:1px solid black;width:6px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-bottom:1px solid black;text-align:right;width:62px" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(51,423</span></span></td><td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></p></td></tr><tr style="background-color:#ffffff"><td valign="top"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Carrying value of total convertible debt -&#160;related party</strong></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:black 1px solid;width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td><td style="BORDER-BOTTOM:black 1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>387,070</strong></span></span></td><td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-bottom:1px solid black;width:6px" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td><td style="border-bottom:1px solid black;text-align:right;width:62px" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>1,360,960</strong></span></span></td><td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></p></td></tr><tr style="background-color:#cceeff"><td valign="top"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Less, noncurrent portion</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:black 1px solid;width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:black 1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(387,070</span></span></td><td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-bottom:1px solid black;width:6px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-bottom:1px solid black;text-align:right;width:62px" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(1,360,960</span></span></td><td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></p></td></tr><tr style="background-color:#ffffff"><td valign="top"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Current convertible debt &#x2013; related party</strong></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-bottom:2.5pt double black;width:1%;border-top:none;border-right:none;border-left:none;border-image:initial" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td><td style="border-bottom:2.5pt double black;text-align:right;width:9%;border-top:none;border-right:none;border-left:none;border-image:initial" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#x2014;</strong></span></span></td><td style="PADDING-BOTTOM:3px;width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-bottom:2.5pt double black;width:6px;border-top:none;border-right:none;border-left:none;border-image:initial" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td><td style="border-bottom:2.5pt double black;text-align:right;width:62px;border-top:none;border-right:none;border-left:none;border-image:initial" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#x2014;</strong></span></span></td><td style="PADDING-BOTTOM:3px;width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></p></td></tr></tbody></table><p style="MARGIN:0px 0px 0px 0in;TEXT-INDENT:0.5in">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company&#x2019;s interest expense consists of the following:</span></span></p><p style="MARGIN:0px">&#160;</p><table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN;margin:auto" width="85%"><tbody><tr><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="6" style="BORDER-BOTTOM:black 1px solid;text-align:center" valign="bottom"><p style="MARGIN:0px 0px 0px 12pt;TEXT-INDENT:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Year&#160;Ended December 31,</strong></span></span></p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px 0px 0px 12pt;TEXT-INDENT:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2019</strong></span></span></p></td><td style="PADDING-BOTTOM:1px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border:1pt none" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="border-width:1pt;border-style:none none solid;border-top-color:initial;border-right-color:initial;border-bottom-color:black;border-left-color:initial;border-image:initial;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px 0px 0px 12pt;TEXT-INDENT:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2018</strong></span></span></p></td><td style="PADDING-BOTTOM:1px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#cceeff"><td valign="top"><p style="margin-top:0px;margin-right:0px;margin-bottom:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Interest expense - stated rate&#160;</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">371,420</span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">26,433</span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#ffffff"><td valign="top"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Non-cash interest expense:</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#cceeff"><td valign="top"><p style="margin-top:0px;margin-right:0px;margin-bottom:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Amortization of debt discount</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">616,383</span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">56,253</span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#ffffff"><td valign="top"><p style="margin-top:0px;margin-right:0px;margin-bottom:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Amortization of transaction costs</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">12,910</span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,283</span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#cceeff"><td valign="top"><p style="margin-top:0px;margin-right:0px;margin-bottom:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other interest expense</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border:1pt none;width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border:1pt none;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#x2014;</span></span></td><td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border:1pt none;width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border:1pt none;text-align:right;width:9%" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">9,794</span></span></p></td><td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#ffffff"><td><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-top:1pt solid black;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td><td style="border-top:1pt solid black;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>1,000,713</strong></span></span></td><td style="PADDING-BOTTOM:3px;width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-top:1pt solid black;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>$</strong></span></span></td><td style="border-top:1pt solid black;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>94,763</strong></span></span></td><td style="PADDING-BOTTOM:3px;width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>&#160;</strong></span></span></p></td></tr></tbody></table><p style="MARGIN:0px">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><i>Multi-Draw Credit Agreement</i></span></span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On October 5, 2018, the Company entered into the Credit Agreement with Emerald Health Sciences, a related party (See Note 11). The Credit Agreement provides for a credit facility to the Company of up to $20,000,000 and is unsecured. Advances under the Credit Agreement bear interest at an annual rate of 7% (payable quarterly in arrears) and mature on October 5, 2022. At Emerald Health Sciences&#x2019; election, advances and unpaid interest may be converted into common stock at a fixed conversion price of $0.40, subject to customary adjustments for stock splits, stock dividends, recapitalizations, etc. As of December 31, 2019, the unused portion of the credit facility is $14,000,000.&#160;</span></span><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The drawdowns are subject to approval by the Company&#x2019;s Board, which is controlled by the directors of Emerald Health Sciences. As such, we do not consider the facility available until advance requests are approved, drawn down and funded. The Credit Agreement is still in place, however, there is no guarantee of continued funding.</span></span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Credit Agreement provides for customary events of default which may result in the acceleration of the maturity of the advances in addition to, but not limited to, cross acceleration to certain other indebtedness of the Company or a change in control. In the case of an event of default arising from specified events of bankruptcy or insolvency or reorganization, all outstanding advances will become due and payable immediately without further action or notice. If any other event of default under the Credit Agreement occurs or is continuing, Emerald Health Sciences may, by written notice, terminate its commitment to make any advances and/or declare all the advances with any other amounts payable due immediately. If any amount under the Credit Agreement is not paid when due, such overdue amount shall bear interest at an annual default interest rate of the applicable rate plus 10%, until such amount is paid in full.</span></span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In connection with each advance under the Credit Agreement, the Company agreed to issue to Emerald Health Sciences warrants to purchase shares of common stock in an amount equal to 50% of the number of shares of common stock that each advance may be converted into. The warrants have an exercise price of $0.50 per share, a term of five years and are immediately exercisable upon issuance. The exercise price is subject to adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events or upon any distributions of assets, including cash, stock or other property to the Company&#x2019;s stockholders (See Note 3).</span></span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In accounting for each convertible advance and the warrants issued under the Credit Agreement, the Company allocates the proceeds between the debt host and the freestanding warrants on a relative fair value basis for each advance. On the date of each advance, if the effective conversion rate of the debt is less than the market value of the Company&#x2019;s common stock, the Company records a beneficial conversion feature as a discount to the debt and an increase to additional paid-in capital. The debt discounts related to the warrants, beneficial conversion features and compound derivatives, if any, are being amortized over the term of the Credit Agreement using the effective interest rate method. Amortization of the debt discount is recognized as non-cash interest expense and the compound derivatives related to the contingent interest feature and acceleration upon default provision are remeasured at fair value in subsequent periods in the Company&#x2019;s Consolidated Balance Sheets.</span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#160;</p><p style="MARGIN:0px 0px 0px 1.4pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>On November 1, 2018, the&#160;initial advance under Credit Agreement was made for $2,000,000 and the Company issued 2,500,000 warrants (See Note 3). </span></span>In accounting for the convertible advances and warrants under the Credit Agreement, $<span><span>1,684,920 </span></span>of the proceeds was allocated to the debt and<span><span> $315,080 </span></span>was allocated to equity classified warrants. A beneficial conversion feature of<span><span> $90,080 </span></span>and a compound derivative liability of<span><span> $204,102 </span></span>were also recorded.</span></span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">During the year ended December 31, 2019, the Company initiated two advances under Credit Agreement, each in the amount of $2,000,000, for an aggregate principal amount of $4,000,000, and the Company issued an aggregate of 5,000,000 warrants to Emerald Health Sciences (See Note 3). In accounting for the convertible advances and warrants issued under the Credit Agreement, an aggregate amount of $3,283,890 was allocated to the debt and $716,110 was allocated to equity classified warrants. A beneficial conversion feature of $1,584,850 and compound derivative liabilities of an aggregate of $516,058 have been recorded (See Note 3). Of the $516,058 in compound derivatives, $322,644 was recorded as other expense in the Consolidated Statements of Comprehensive Income (Loss) for the year ended December 31, 2019, as the value of the beneficial conversion feature exceeded the proceeds allocated to the third draw.</span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="margin:0px 0px 0px 0in;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Aggregate financing costs of $63,007 incurred in connection with the Credit Agreement have been recorded as a discount to the debt host and are being amortized using the effective interest rate method and recognized as non-cash interest expense over the term of the Credit Agreement.</span></span></p><p style="MARGIN:0px 0px 0px 0in">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">During the year ended December 31, 2019, the Company used $3,985,500 in proceeds from the exercise of the 2018 Emerald Financing Warrants (Note 3) to prepay a portion of the principal balance on the Credit Agreement. In connection with the prepayment, the Company recorded an extinguishment loss of $725,425.&#160;</span></span>The extinguishment loss was calculated as the difference between the fair value of the consideration paid to extinguish the debt and carrying value of the debt host plus the related compound derivative liability.</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For the years ended December 31, 2019 and 2018, the effective interest rate related to the Credit Agreement was 32.05% and 10.57%, respectively. As of December 31, 2019, the unamortized debt discount will be amortized over a remaining period of 2.76 years. The fair value of the underlying shares of the Credit Agreement was $657,231 at December 31, 2019. As of December 31, 2019, the if-converted value did not exceed the principal balance.</span></span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><i>Secured Convertible Promissory Note</i></span></span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0in;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On December 28, 2017, the Company entered into a convertible Secured Promissory Note and Security Agreement with Emerald Health Sciences (the &#x201c;Convertible Promissory Note&#x201d;). The Convertible Promissory Note provided for aggregate gross proceeds to the Company of up to $900,000 and was secured by all the Company&#x2019;s assets. Drawdowns on the Convertible Promissory Note were interest-bearing at an annual rate of 12% (compounding semi-annually), payable at maturity. The Convertible Promissory Note matured upon the earlier of June 30, 2018 or upon a default event, as defined, and elected by Emerald Health Sciences. At Emerald Health Sciences&#x2019; election, drawdowns and unpaid interest were convertible into common stock at a conversion price of $0.10, subject to a full-ratchet antidilution right. The Convertible Promissory Note was automatically converted upon the occurrence of the private placement transaction with Emerald Health Sciences (the Emerald Financing) in January 2018.</span></span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company received proceeds of $500,000 on December 28, 2017, and on January 19, 2018 the Company received the remaining $400,000 in funding as it had satisfied the conditions required. These conditions required receipt of conversion notices from all the existing Series B stockholders to convert their preferred shares to common stock. Such conversions occurred in January and February of 2018. On each financing date, the Company bifurcated a conversion liability from the Convertible Promissory Note related to the embedded conversion feature with a down-round protection provision (See Note 3). This resulted in a conversion liability of $265,000 at the first financing date which was one trading day prior to December 31, 2017. The second funding in January 2018 resulted in an additional conversion liability of $360,000. The conversion liabilities were recorded as a discount to the debt at each draw down date and were being amortized to interest expense.</span></span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On January 19, 2018, in conjunction with the Emerald Financing (See Note 5), the Convertible Promissory Note was automatically converted into common stock at a conversion price of $0.10 per share for 9,000,000 shares of common stock. Upon conversion, the debt and associated conversion liability were extinguished, resulting in a loss on extinguishment of $590,392 which was recorded to&#160;other expense for the year ended December 31, 2018. For the year ended December 31, 2018, the effective interest rate related to the Convertible Promissory Note was 13.94%.</span></span></p><p style="MARGIN:0px 0px 0px 0in">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_ConvertibleDebtRelatedPartyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for convertible debt - related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_ConvertibleDebtRelatedPartyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6750644672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Detail Textuals) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carry forwards</a></td>
<td class="nump">$ 13,213,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">California net operating loss carry forwards</a></td>
<td class="nump">24,481,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss</a></td>
<td class="nump">$ 6,434,544<span></span>
</td>
<td class="nump">$ 5,104,432<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLimitationsOnUse', window );">Tax credit limitation on use</a></td>
<td class="text">In general, an &#x201c;ownership change&#x201d; as defined by Section 382 of the Code&#160;results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percentage points of the outstanding stock of a company by certain stockholders.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Australia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carry forwards</a></td>
<td class="nump">$ 67,096<span></span>
</td>
<td class="nump">$ 11,275,349<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLimitationsOnUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the limitation related to use of the tax credit carryforward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLimitationsOnUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6796874544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Parentheticals) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_ShareIssuanceCosts', window );">Share issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_ShareAndWarrantsIssuanceCosts', window );">Shares and warrants issuance costs</a></td>
<td class="nump">$ 80,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember', window );">Series F Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_ConversionPricePerShare', window );">Conversion of preferred stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Series D Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_ConversionPricePerShare', window );">Conversion of preferred stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_ConversionPricePerShare', window );">Conversion of preferred stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_ConversionLiabilityIntoCommonStockPerShare', window );">Conversion liability into common stock per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_ConversionLiabilityIntoCommonStockPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents conversion liability into common stock per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_ConversionLiabilityIntoCommonStockPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_ConversionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the value related to conversion of Series A Preferred Stock and conversion liability into common stock per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_ConversionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_ShareAndWarrantsIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount related to share and warrants issuance cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_ShareAndWarrantsIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_ShareIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents costs related to issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_ShareIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6792386128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">US</a></td>
<td class="nump">$ 1,120,521<span></span>
</td>
<td class="num">$ (19,192,594)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="num">(67,096)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Pre-tax income (loss) from operations</a></td>
<td class="nump">$ 1,053,425<span></span>
</td>
<td class="num">$ (19,192,594)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6803796576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 2,237,956<span></span>
</td>
<td class="nump">$ 329,966<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">4,394,622<span></span>
</td>
<td class="nump">4,362,557<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">6,632,578<span></span>
</td>
<td class="nump">4,692,523<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(6,632,578)<span></span>
</td>
<td class="num">(4,692,523)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other expense (income)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_ChangeInFairValueOfDerivativeLiabilities', window );">Change in fair value of derivative liabilities</a></td>
<td class="num">(9,734,759)<span></span>
</td>
<td class="nump">6,503,174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_FairValueOfDerivativeLiabilityInExcessOfProceeds', window );">Fair value of derivative liabilities in excess of proceeds</a></td>
<td class="nump">322,644<span></span>
</td>
<td class="nump">7,174,634<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDerivativeIssuanceCosts', window );">Financing transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,192<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt - related party</a></td>
<td class="nump">725,425<span></span>
</td>
<td class="nump">590,392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">1,000,713<span></span>
</td>
<td class="nump">94,763<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="num">(26)<span></span>
</td>
<td class="num">(84)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense (income), net</a></td>
<td class="num">(7,686,003)<span></span>
</td>
<td class="nump">14,500,071<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income (loss) before income taxes</a></td>
<td class="nump">1,053,425<span></span>
</td>
<td class="num">(19,192,594)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,642<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent, Total</a></td>
<td class="nump">$ 1,051,825<span></span>
</td>
<td class="num">$ (19,194,236)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Earnings (loss) per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="num">$ (0.16)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted</a></td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="num">$ (0.16)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Weighted average shares of common stock outstanding used to compute earnings (loss) per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic</a></td>
<td class="nump">135,154,931<span></span>
</td>
<td class="nump">121,154,334<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted</a></td>
<td class="nump">169,560,265<span></span>
</td>
<td class="nump">121,154,334<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_ChangeInFairValueOfDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of derivative liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_ChangeInFairValueOfDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_FairValueOfDerivativeLiabilityInExcessOfProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to fair value of derivative liability in excess of proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_FairValueOfDerivativeLiabilityInExcessOfProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDerivativeIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of a derivative security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDerivativeIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6794046112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Detail Textuals 1) - Douglas Cesario, CFO - Restricted Stock Agreements - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 25, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">1,195,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="nump">$ 0.245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_FairMarketValueOfStockOptions', window );">Fair market value of stock options</a></td>
<td class="nump">$ 200,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Description of stock option agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The options vested 25% on July 23, 2018, and the remaining 75% will vest 1/33 on each of the next 33 months thereafter.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining contractual life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 6 months 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">760,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,195,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of stock options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,756<span></span>
</td>
<td class="nump">$ 73,008<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_FairMarketValueOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the fair market value of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_FairMarketValueOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=embi_DouglasCesarioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=embi_DouglasCesarioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=embi_RestrictedStockAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=embi_RestrictedStockAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>54
<FILENAME>0001640334-20-000582-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001640334-20-000582-xbrl.zip
M4$L#!!0    ( +FL=%!J2>)3Y7,! -\D%0 1    96UB:2TR,#$Y,3(S,2YX
M;6SLO6ESX\BQ*/K]_ J^?C[WS420&BQ<9[NAUC*6W=U2M-3V.9\4$%&4X $!
M&HO4\J]_F5D%H+"1X"9Q*8?=ID@L55FYK[_^W^]3M_7,@M#QO=\^Z"?:AQ;S
MQK[M>(^_??AV=]D9?OB_O__7K_]/IW/UY>[BCZO_:3V\MB[^T_F?CU\_=3J_
M_U?KOW[]_A"X+7B,%_[VX2F*9C__]-/+R\L)?GWB!X\_&9IF_N1X861Y8_:!
M7_FSS9ST:KHR9..31__Y)_@![M!''4WOF'IR.9L^.+FGLRD++-=^</P3UYDP
MND4WLAN<T.\:^F#>BO@5R0VNX_TYYVK\^<$*T_6'091>/;'"![H2OJQ8>QQV
M'BUK5KY<_%!Q"[[;+@!(+*7_$_\QO;2T\!>3KM5'H]%/]&MZ:>A470@/U7_Z
MG\^?;L=/;&IUTI/Z_;_^JP7_4?^H?]0_ZA_UC_I'_:/^4?^H?]0_ZA_UC_I'
M_:/^4?^H?]0_ZI^#_.=7])_^'))G]"N;M,B?^O-3P":_?4"?="?Q.Y]\#^T/
MXN?H=<9^^Q ZTYG+/OS^ZT_Y9_R.CQW[7L2^1RW'_NW#&?]\?QK>7T_N-?W^
M;Y9W#\\=W&G:/?_OW?6]J=^?LW'A^W,6.,]6Y#RS*R^,@GC*O.BK$_YY^MT)
M[V_A1Q9^O('%LB!@]FWDC_^$EPEO_R?'>G!<)WK]#!MA0>+N37>?^_ K/!@N
ME:[)_5SZ ^YP;+QGXK"@17MG.=]SXNX_N_K[A]\U3=-[>K_7TW_]*;OM=_'$
M7T/VB!LKO+SBG>)Z[B#_F7V?N<[8B?C^6K8##^%A#N%X_WD>^#[\CN?[\W)
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M8 WT0T482VE-"P&LB.- B>/^'\ 5T:M)#WNR O81GF"?^=,9'!Q_,&D6\%K
M]6N/'311[3V5)2N1CE4:\]#\?!7!*X)'A+A[@D<KDC]@DI=.6!&](GI"B1=?
MD?PADWQROHK@MT3P?[.\BHC(L.+[!L[/PZ!"NOX]W)G;1BZ]$7+I'7TGD>O^
MSHE<8&=7GHW=WF*+ETQ\].'.Z\FY$[!QY ?AV9/E!%-+9<ORJJE*H/$*JOF0
MVR#S5R3ROB1R]N2PR<5W-HXQ._EZ,G'&[+##R/2 =>EC#M@4<1P6<8B<,LM5
MQ+$,<52#31''.Q+'J.)[E62ZYTFFC7%K].:XI9),=R0RJO+)D@-Y=^*)O8KR
M4*WB^[F>T&K* EG,9K!,^!O?'%AHNJD:F>6HI0D0C\+CV.UH_<7D05>9VH;(
MX[/U6A%BZ%5\W[ B6E3MYVJM$<IT>_@'=GQC]G4<A8"/=T\,-X37*EK9T7+J
M1N?VSD*EUTBH]#I&[YVI1IG"\[Z@!RA3^'B(HQKQS_WXT;7",Q9:\/JY^M>"
MW%Q%)]5T0HR]"LQO5&^S7DKUP1&,Z%13J.;O57S?S'=40RS'T"YIBV;*6OV3
M#L\-IFM-R 2OV@B9D/P(ROUO@'Q.9\7OE25?^TYER;\%>0PZFDGR84%/&*U+
M1+0^>9AU4D2__^(_-_(2'X-XH.O?7QILGS6;#5BSOB[N7?[O16UXHJJAX]HX
MM#FT>1^_MNAZ^(8@OS^%;=J.2TD365CBXOO8C6UF7P;^%+,]XXB2/:\G%U;@
M@8(1WK" YX.^5C\@:0N5#'/'OF79K\?+,K8([LS+L #N^Q#A.3!*./#^H'3]
M;M' JMYPA?V;QWZ5??Z6F+^+/N9CQ/K<^"J%[5O"]F6&A!TKEA_A' JZ_L \
MJGN*7W7-]!9-;U!-A553844Z*Y&."E8<0K!"$=3F""H7X5M$/BIK1'7$.V 2
M.8>'/UMH5%UY<% Q@@"GIHE:$)J]?!.P"0L"<8+<H8R@_^18#]+<Q,,@!;J^
M,>;/ U]^@'5#("HTK413E:11^\[#UGL4"U](&VI27>4[#ZRTXETGU>TK:81!
M5)TVCB"M3!U7YD#5%_0 E41^;.1S&\&;<-]G<&SA]83#KM8R."02H.L;HUXM
MH*2.>?404]BW$O:=*^Q;$OLJ(::P;R7LNU38MR3V54),8=]\[+OX=PS[Q=P(
MWT-]A3#PU+8=M#LL]\9R["OOS)HYD>4J'*P$5X:'<^&F,'$%3(0_I[ZG.& 3
M["O!2F'<"ACWE466XS$[R1!3:+< [:H!IG"O$O>X^T=H,B*=\#KXZCP^92X@
M$8J7"BOR0^]5@$Q"TEI0YO,:E@>F0N"5$5BX(HX^)WD1;E;!2:'=AM#NB 7W
M<GBG!/9BQ"LUD%L0!N5WY8.A_+OZ5G5A$'W%R )=#']\MKX[TWAZ2&B\*43'
M0% **]YI*P>M[??64D%:1<(-2-CQ% DW)V$96HJ$%0D72;@^:Z+);+D&R=H'
M2J+T@#V:#*>R]8!4J(N8IFMZY/-/^F(R^#;M:0/MDP.LI3'^?_,<<H!$K]>3
MSTX8XG]G,R<G!2^!,T?L$UQH7WD1O!;]**=AR*+PX^MGZU]^0":')"/A,N:Z
M;!S%EGL3^+#CPW)2;9KHEH!P)L'J@?Q&64_S\&VK?& NTKYSK[4&C(&NTE?L
MFDZ,03>,H?+%[;<O#@'G 9[  P@G=#Z[,_EN!9P W6F) $-=US@*],2 F6GM
MB8HS-(TSK S3M\<U5$Q6Q;5AJIC )WVT6F7Q,:'1(1?>KC$@IPJ75(BTB%YO
MP[H.,T2Z%>2\??*#Z(X%4^QX6/ .?@P<^Y%]\JW\")IYOHMQ#,(B#W,PKT43
MHM>&=MPQ\-I-4T;E.6;V5?$HW\BJ6A(A5%N(-V, #?5K97/MK,VU*91:QZLG
MH129;+5%A/##G %"JI2P\@MZP'[,;5(%A<N027U MGJ0F8KWO/GT,!7<>4/\
M%NR_4G((+44-[=M=YK]'0_O>CQJ4'_N=G$&[ZL?>$51=Z/)6?8YWI<]Q/O*1
M^@/6B'RH>,?>>I2V@@RXK1N0V8C1OLVR!D#RESFE304WYB#8VPBXC4<[FJR1
M%E!$%;&N,K+L(RTH]^A>NT??#2?N7OR[)S\.+<^^P!\8\XK:@JKK6H0P2P-Q
M?['I,[/".""3Y,J;Q<4@;/'GB^\SAC;U.1K[H/=_!;U?2&0EO7<Z1+O+XCQ9
M8QTR9EZ=YOBHM(QM\P",]RO:5[3_WK2?X:&B^6W1/&Z=_<-WK4@Z?47VBNS?
MGNPK45%1_K8H'X=D7 :,88U4P,)(:?R*_-^3_.OQ4?& 13S T)8,#"L/X\YZ
M&(M0+ =P#>T- K@*D5I[CD@5;&:]BC9#[ZN@_KX&]8V.WE_W\%6<8DTD.9@X
MQ;K8U$M+1GI&3^7W'VN*Y_[F]_<:E<'T.D9O'2ULD)+)(-7'ZM%=M;79/UM^
M/]O:J(8V.68P:,0,!FN:9,LQ ]ZO3_$"Q0NVS LJ$4VQ@AUB!=B$K*<!<MA!
M_'CJV=^FPY&IG7J6ZS\6U:I=X1#TTL^."TJ@[[$;ZY76"/]OX3.35:47Z,?%
M5XZ2T2R#QIL*&<S#0+&L(@XJUJ=8WUNR/D.Q/L7ZWIGU&8KU*=;W]JS/5*Q/
ML;YW9GVF8GW;9WVZ9G1%AHNN-4M,J ^AU57NJ[#DZF')9C!]7U35M8[179PY
MPQLDK(ZJ"D$5@LX!LAQ&%[BV<AC]S7!MF8S@P\#+_4;4QIK.KJ;$'B1E;*HJ
M[T I[/!)3I7$*0ZPJ1H]Q02.C@D<98'<!OG [K;$4+9@LR_HB8H9''>#C/?C
M"&]8,JLX0K,OZ(F*(QQW >WZ'$'OK4TPFZ.13<!#[ZT##]5?6O67;HIK:\Y)
ME'#M-@*.17OD(.)U/_,JC95?FC^@,?+5@GCU,N7]EQ[[@L&;5EH/E"+6))$=
M4[P4Y>91;(.4.THG:HR0AO=9 RRN(Y?Z,&HT]6&T;M.0 CA5JX@]:16Q][BS
M,!6V3I<^)-1;4^K-2\&<#[ZWF*ZJ" *A<>ZX,;9#X%-N0=H7BGT/RO5'US=3
M3RKADJM.W8'\PYW$FV_>,^BKS*Z<J:;P*)>"/0=2"J\*>)5XQ5/7%!DM>(:V
MPJT2;BV$EL*O&OQ2R%2+3$>+.6)*+&S$1C YSRR#T\7WL1O;S+X,_"DZTN/(
M0O7@>G)A!1ZHE^$-"VZ?K(!]?*U^@.1GD]KKGK.'*+OF^) RG=BZ/:!GWK<%
M<%<8OS6,OYC.7/^5,=)\N&*M<'VKN%X+<87E6\/RH[>%WA3#E3WUMMA]](VZ
MWP2K=Z9?_/MB\XL5V(7HM.*N"1[*P%'\L!J#YF>? :%.?8_@E%B]=[Z(@].W
M3[YKL^"(#;)%N6;+05"AH9IN]$;9CQN?773DR*DR=(\G0W=?4?4F8'!]KT(F
M*52L0\5%,%.HMA*JX>"1KY@)DTPA^6Q]=Z;Q8?=?H <TFAN2@H;/"LD!9X,I
MKPKY=P3Y'4\A?RWRR\!1R+_KR*_F%>[LO,)]12DU\>X )]X='C(>4]\ NGY?
MN@(H5 4:GR!4E>F_&E8N I]"P'414#D$]L$AH$CB74E"N0EVSTV@2&*#)/'%
M\9C24U;'P(7P4RBX" 5OV3-LNAJ&E+KQ[(PQ9(Y- 57F2R.L7 6D"E$;(RKW
M))[?N-:8%Y8_*J?#B@C: )0*,1<BIO-=\<^-HN?2 %5(VA!).<&?*=ZY+G(V
M .31(B4 Q?MB3;/YBI2:'OZ!L&'V=1R%<+9P3Q<OS'7<J4KP/_ BP34QMR;K
M?]4ZOV5>+1^SH)/%!ZV(8B-$<<!5+]LAB%7*8!0QO!DQ7$\]YR$.K[PQ[O&9
MX04(JT-";+I^'82:#R2%3,V02:D:^:7LJ:JAB*&2&-*NOA?_CK'Q$Y:.>/"G
M7+)]:ML.'I/EWEB.?>6=63,GL@ZJJSE=OWPKY"J@99@^%VX*X^9@G.3*45BV
M ,M*L%*8-0>SOK+(<CQF)VT5%'HM0*]J@!TOCL4/8)<Y5O!Z:[E,'K @E$LJ
MN62IG^^(\:L.4AEN50/K:''KSHD04%>>C2/U8BL;Q7'NQX^N%9ZQT((WY.R2
M^J;C!1=&FAM\4#QO123%C*A*< MKH0K@&[1/YC4[7W!LQTL=M8@.)\AF\#*&
MI>]>%%CCR \*3>(7-/3_*[/<Z.EV[#"P#]%(5#32"%F;@/XM^O/7G)\BEJ,<
M14'7O__DB<- K[XQW.?!1*W<R": 6K]C#-<8V:1GY*:;6D.KX.KF^GCIJX$A
MD,+G?2E*;T91>L?4UJ HA3=[AS=%)B)08'4F8F0R6Q]M1L%-_%LN(*5] QC\
M>@=/"N%:G#_S\57^)4LJ> 9</W]R7%>%KB34:P[%)'9?@N,;68L;4,"WS52-
MAFJ*/EJ'J4H496C+9CNJM@E'TC:A,3(::TGX/1_F61)W:XXY5=,X]VCXX/L?
M?OU(ZL_X]#,K</U;9QJ[UL$-'5P1A=B<(<ES8'9XDS.W@KRUZ%@[(7WY,>Q'
MC;YJQ'C^Z#:.P7.;A[Q)6Z=EB.A :6%%XMC-]B;;Z$.E:+4IK7YF5A@'!.$K
M;Q9'A;SDXL\(&/8/'V5_U@1<D?T[D;WB QM<:ATE9#[B1L2@.-/[<*:O3OCG
M)>#(%;PP8"$\/V**/2GV=+SLJ9XB%(]:A4?);<\43]D[2^?]N]8I2T>@UKO0
MJK)TJHYC3\A>\0%EZ2C.I"P=Q9X4>U*6SH9YU%$V^UD.)W=HQ/4644#-J%X/
M2_9J1O6[X=&Z,V<59NW='-]WPS4UB'?OQC&^&ZX<;C+59O'C'>8IOAM.J,S^
M \SLWT%L4A,-=]1Q<0BXIB;"'5@NPCN/O]I/G%8CW7;:ZZQP6LUDV_.9;'N!
M0RI\QQ^PBPBHPE'OC?&K1>0OOL\8!H'.L?T?\^PL_GB@%'18)+5ZX+G^X!6E
M'S2EW['@L$T)1>%U!ZXH^R INS+%41'W01.W2FL]'OJNSQ%41'[01*Z20]^2
MTE>90'\8!+@<'J\R,WUWQE+O%*8U&"6O,*P9AC4 Y3%@UM)3X!5^-9E<KOA7
M!98U&.>NL*L)=C4 Y/YBU94W]J?LSOI^&D=/?I!TON0_7OH!<QZ!O&(O"@[*
M<[$<SE0#*;,,JN"TORBQL1C52DU2C[$)[Z;Q=8_B3:KUZ]X0;:W#3.4F[[07
M;?_*KE7T>\\Y@FHN7?<%/7%?24<UP<ZCV&Y1;I9)H!3OO:/7-TL#40KWSA.I
M$JM+?T%/W#<R5>(TCUH[2ZFJ^]D^4/51F,0J773['*"Z0ZO2J?=%6+]']J52
MJ_>!5)5FO?07],0])%:E7.>Q:S?H=4Z+825?]X5DWRWQ60G9O2%:)6F7_H*>
MN*]DJ\1M'L6V1+DWKN5]L:8L)9CKJ><\Q.&5-\9%/C.\ .[I'A+I+(>!,H@$
M!LP'TM%@PYQ^[!?3F>N_,D;D>CU#P7I(&+0F2M4T::\%V@;YZ1%A\^V3'T3H
MWSQG#T65Y,SWGED0.0\NPU\;:?]_998;/=V.'0:00G IC,[$=!6L,\RN!/=;
MJ-@U9[;'2)WH0Q?_CF%)U"_=@S]#";E/;=M!YF&Y-Y9C7WEGULR)K(.*]2R)
MG?. EF'I7+@=-LI(%4\*31:@20E6AXT:7UED.1ZS+ZS  [/GH+*HMX(?U0#;
M7R1!<7X].44#^Y$7K"6*T95GLQGS\ A PD>!-8[\((UV*Z5J37RK!+S0;YJ
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M=67[?U=A<$$BA7FBDUA=A&%YN Q[/;-8)T]-]T&5,=\ +ICFUB6X#'6 T*[
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M?!K[P<P/T#"#/V GSY9MM7RO]=D*QD\MO=]NP8UZ"^[ZY%MVZX_8"FSX^.@
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M ]SS_"GH4/ 3@!=?2RL^:7T"YA*T$0 )U\X0AF\J>Q2N__0YLH+6^9/CNBE
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MY9J9O$[/CUJO#!]/I&V3U]J+&2=G7"MR!I2;H,]Y8V<&=.SGHU?$@+R8  +
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M3PD\N_['U7D'G>+HJI"M05B0S:;.6+8"3]#& Q)Y+7HP77*OH2/'">S.C-*
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M.HXP28\'#D)A%]D.9ADEEAL6[J7+/*&Z7(MB[&.<R\=+=&G%62;1U+)Y:"A
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MZHPE<U%<(')T^(L)75BRE.^;LHCQH*J8[@##OHEO/!3.<5G92X9%\I;-/)J
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M2F,!G=3 IM-NX$QGIO(CFS)&>X^Q.1^QNA-AX-BD''(Y)PTE[9C;9#D%QMG
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MC#O;T.935/B1W4QH=P\O-E^(B>G2Y%S2XV;NI[U\\M(*F^S,^"/INA$QDU9
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MYQ\S%X7^*SC><Z$3<-,+]89_,7E(6<&)L"IEH'5)G=J!5VW*%/@Y$X2J,FN
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M<.4R<3A_4S]4=1T'@.>@2&?K$%-->6Q:LAX'%1H9Y0*LFE>G[&Y@6Z&KGC"
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M^ \HV16SQ#([AV>$Z#PQ.?*X%Q,/_A+>-K$R4D,HMC/VET99\!*V7PQC"CP
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MQ[NX@$T\4LL$OERF%&U0AK!Q8N"==$LARH$7D^6_[-DZ>(L_+X3;'7*6H;?
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M=\*7H!PCUSG&GJ-6Z3P*-B?V6PJ<&Q79>!S+_7I!>$B=UJFX%)2!-LZJF<I
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MY;14EG7%4E-,K%CJAFZ:!=3&U17Q@_HU66*Q/J*.L*1:5S^T@<G5?53'VKI
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MCK&G&Z_3F-24OZ SR"(0LF4;1I$-S9"'^K8)K@(=!3K6CXZ&;&E#>;1U#)3
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M.Z)1^O#K6;0(E\ @OWK1WP0ZC%Z2[JBD.>I>X% M4UMC&L.1:C8#@!TPI&8
MK.*#J6N6R:_<V$;X3/CATZP>@>HG-5_K3?"\?JW%G[_.L15] 03_2*0^N<\R
ME6 # H]-4\'/-M3U(]-/:U9]BP\"?&O_P^19N&$HIJ$,U^Q.4QTJIK7+L6 7
M[Q*71,)@H^LH6B*WX%P8<]1%T+K]K5K*<(TGQ\?>?*A*SEV%*0JTNL9$&MA[
M/18F\0R8.L;&41%SK/]<)8:.J7U3E;%EC?1U0Z<^?+&2O?'DI-/QB^'07".<
MF U6# C&^S_]^VH_@5Z]Y6..C7453E4,S1CJ!C?GKH\P==4PC>&P 893Y]DK
M5?.QA3A>LQ#UH4)L'TZ TIAF2W%DK \Q_^861W;2;+%2M*Z<QP*@KI-\7$:+
M8%IZ&'5<\/GAWGC5&JMK*I\Q4D>:JM9_PD_HH>"$PX+/CSOAVB6:(V5D:/KN
M)_R*'& GWL1S2'PP&Y*+[H.K_RPANLBMBKL:=!D:BKINB9^##C,<,:CL=.3*
M(52QO-8,RU"M=6%U;HYU74\PH)VS5AW-P-JIJ8^M=2_\.;;N])'9YF'+0@?8
MFM;-H6FMA=+.AYIN:<-F-\VMJFVJRGJP36D,-MQHWYJFCL>E-B&_@*A3'8=0
MA+[FCCIGO* 7H*DU= $!S-&ZA "GBL(_9M7OLC>L;V-M/51^3AWW?(-G%SW?
M4+"EMBY_F%PZ[(09E?(C22DDD-_!TX/U^PK\@2-]_,U8LTA+]?K2+1Y_( VK
M\Q4=J" (6Z;&[W"@-+GNPH7$6Z";3T%XZ4TPJ:"9@SZ@Q0M"LW7C()N"-W/)
MA +,C1R$W AC"<((X>;S\790CL@Q+5M1M-&#<JZYR#I7562?VZYKG1LJ<D$?
M&2%M\N97DA!NDQ1]DB!/P.0@WV>YX<G[:&X[\7N6"?S7]>7];^\P8_OQ_?W5
M_]Z?7_Q^_<^;.._X_:?;FWN2(BS=7W^^NI-NKOZ2OMY^OKAY(Y$D\U_>P"_3
MRO=LDG1NDD4MM22U/-0) $SXJ<,$1A]NOUY>?3W_<'M_?_OY':E6D-3Y=UJ]
MD$W7=C#& +[NOK&"7W.39/_1#R*,+75FV.]UB66PJAA7CEHFP1[M34%Q6G7X
MP<V9RT;7].B(Q=>Z)U-(RJ3ZPAVPPK6TPU>I<O;0,3B 3B-8I*"E8W#H$WH(
M@9@$+0E:$K1T' X1ZXL;)#I(C2IM'_8_#K8I)RG ,EMI8>S?-2W 7BEL9#:\
ME!CQ$C.2I<2WM FT*[TEFNE@P5,-^0\'(^M>G3%X.K(AC]21K*EJI4?G!(4$
MHO8'44UYI(QD0ZNV_R8G*"00M3^(JBH82PUYJ!N=P=0=-: )^8<3#0C&=[R3
MYLS5+TW"8$IZ!*SI0-S09TG7YH97[08-R::BR(JB5$I"&YLMY\'45/>V)E<5
M^+<'_HU,@7\"_]K"/UW6:L"_+Q>7E]<W_XS]4UG\:U&KV-.OPG6SKM3M=?7=
MP0J*%#RC,%52["2W@5Y8<[W8^:7S72=$=HR"\]B Z3GK96FA&^&Q", #%)OI
M/-@M\N'A7AIHBMIQZA^;&=>5H'Y!_8+Z3X;Z1[(ZRK@#!?5S3/T[=!UFZ<T-
M)BSGNI3$7_T4!E-(HH:13[?AG0T[V9"IWW@=ZU#YIFLDP7VM$EMC>>^['ZE:
M"#14YSH<?].QW,=B?PT"]..F(=!\O1B&PLCZ-L+\#[._52BPCRN! B.MJ^\H
M=+RHL*-N6DNHJ%57>XY5U?PVMD;K?5_(A\5'7-WS$8<K+F6MKSN1J:J&8:EK
MI]7'EFGN=5["2S.%9)?H 3\/&I*[7^QP\;I_U<;X83)V#'5[U<:Q'J5B*7:P
MD$P$FC&0,@"1 ")2VD-<?R\Q^$@$0/M)PX-ZW^_>/E]*_O5F30#NOJS+^AH
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MZQZG3+IE#.IQ&X3CGUH(HUAE+,=IWGRT\&N4'ZS)+<4/RTCY!Y_<%N(UDVD
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MVIZX2(Z?DZ(+D9(UH)G 3"P79O(S6"*  MBQ%6+L NV<#$6C3)\^ANBSH9\
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MJ876<9N!IWR(MLDV2J#6:( VC42K4;!QM\=-^D!N@0@F5;ZG>6JI.$\@P:(
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M1S9*?1/2J+/2R#@W#M4U2Z1S58[-C=._!$=WEJ/[AW(CA'51('VV;+5T/.=
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MX0_Z9+G7P,31*[O^_ZJ7P-6K6__W-/E!4Y=U_F<_E("W+>'8 .0QA,A&;/C
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MZOECQ^-?3+&1GN.QZX:6.YRZZ:V/5N@,^1V..\624P]PY\2X<QGN0#T0YM,
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M_%UU(["AG0$Z<3+XAQ^&:_L"D/]-K#"<CJD=#RT-.Y0*LUL4IOX*S+JZA+8
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M#8#+[GNK&33Q?(PM0*%KO9Y6  IMH/9-O<6@2/K5;@,+P]2- ECH>E_7E [
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M\J"O%N4>*\I@@,G'I0*I:K#O6-3P4"52MD;'H"C7N0?JJZ^U#!UU<L'&51H
M<K,(Y*JF]W2C91!O(@-L@XE!47F,8NB:(;=-%M5)_)>S6.$5?8QFUZP OB++
M1< W9*VG&G++@-]$/M@-*86E+X;,_M<RI-3)$7$ 826H=;E(#<C@/+8/UDUD
M@(UPT"\B=PU<H'ZU0H@7HMY;/Z^<<.CZX7270J+!XXA:FQ02[1MQ*_8==W9-
MTT15\YQP0!" !-S'G<G=QUQLL+TEOF)S('3_C(5RXXGO42\*B3\B#@?1*?9!
M?TL>Z<@/*)NX%O\063_))/!?'!R534X?J4='3O06R2ATP@@?@5>/?-?U?P!=
MOC\@7.,"^Y*>MFM!W/WU_[L_N_CC]O<O::G;S=V7^[A&[O;S]7?RY?K?Y-O=
MYXLO:>4;*X-+W[QTZ&$E8:5#E9U]NOMV=?WM[-/=_?W=YUF"_8K4^JK2YJL2
M,;/JL8JD2UT;V[T8[& TMVQF8@M91CTBEMF^ &IU</SKQ=75[9??,R"K*!@O
M2*!$$BAU+.MA2&"SP^W_-1Q2.IKM.D,X99Y2EX>:/[_O!?OD[.4P9W&;'V:5
M!Z!=QM,L/;&K8P.*!$Z_9*CK,C ;C%Y!1'43$>\LJDK&8)]NBG6L?/,&HAM*
M^!'[7WLD_ UX]/#*+HCY:M,I:N&K7E^2!_MTZVTV3PD2JMZX9BO_"5:UOLZ.
M/C3$JK&9J^TC_C6@9QCTS =&1X$_)OX$A]>G!>]-H,2XB05N29E$N0X6^?X6
MZKD!O_.NLOD+& 6_]WR/)M^X=)3_PAE;3_2]XSF18[D?ZI0\>4^RA.Z^=0"P
M6>(C!U%%D@U-TE5C?\@NNN7K*:=%.D!PGN"\,B&ZX&'M ]L5;0/6<T6U^O7M
M)M;")GVUM_6R-C^<)>F_CE=76 Z+)=G)ZLW%]T\S$V_P(236<(A'_EA(^31U
M;-;]-*"NA2T&(C]W<.N'#K-7)&*-@9J(#T_$QV("@<2/><<3:\B.<6&A4WA4
M$%F.5_00 O_,'0P'-)H&'AD#7,@C+F+H/WD  YM8$;O6!1*@\*/%TSJB9_C>
M"<D87-(SU_F;NJ]G\)UWYOD1+AV>$<*S8 'PB.D$7FA-;0>>_<J>!IND+Q8^
MQ_J)N[>FT;,?.-'K.;E8M_@?CNL2?$U^G<Z(P/.?K9"X- QQ@?!.8LB_$+8\
MY]GW;03.(\47IHN#%P*#X8,MUWWED$QQP8[+;4!O^@V\']#)WXHW2608-\\=
M6OQO!T/Q#%*>3284'HM)(%(6UVQC<)4SA@L"Q[?A9SM-\& W1H'E\?V>;^KN
M[TK^Z[BI,B%29VY)04U#]C-F5V"NCN6] DG90&Z(OV!JN63D!S,<P^<4Q0E7
MQ??E.3WI;?S]F=(H1*;*'LP2O(KA'4]4)/8)*1FI/$OB&=)ZEWNUD[S:8\J7
M"9#O$?S?.,D.P54%])D"5;W0))WF] _N$OE<0+U2*P@)9:?@B\N#BW!UZ^AQ
MV]*WJLBV44I@6YH#R1I.'_^;#IDP!?''A$N"YC]!]B0(#AFQ7,*. (N>8YV3
M^V4TB%*4HWC$<=DCIR,*XLQRWR;$9Y#3V;/2;P?D] * !1<F7\(%/ZP M$-
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MCA<6C@9)&C[##C!D%#U;$7'@GY",_8 2U_F;NJ_XM4<\/_X]1$MYX@?X%HF
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M[_D5J'Q^T%9!,DX2]*92I956B1++4JUVD\J3"B*&$F(28 !0,O_]U]TSN B
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M+'F079C:XX"O?TS!LV:.Y))G394JS\QC(S>2[$@:,9 +>PQ/MJ-9Y =SNB
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M0=-SY 6B#ANCWING&+^S@ $$4X@U (3GN91]N#T>2R.7C1VJJIF%+/NJ/-6
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MR,_8X"E7JH*UR0F$=Q%%)].Q/V=!GE@<S"%ZR%R7(@.<8<,S3@]R]_B9 7%
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M\Q][TG4R=5G 2=_N@D!T>RIK[":([5=B2RSLQ'KS>NG.$JRI'56XMS6./N]
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MVE0R;>#'./\EE57KS%HIX5]7/]M=C%/EF,WL.U/@I\^SRP/LLTP:.L#U$H1
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MD5=]05ZU[UNTXJC%SZ,E0EYRB8]K0@>>/%(\>9_KGN,9$O9UK'A+J63%]VZ
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MB3S(%R?9>W@1%N$1YWDP9SH+O3/WR4_=8!LATZ!6$@N'EW_OFA-10&NF&D?
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M$IQ^A1D+N2MRN%D5\"$)3K^*^<IOT%H&SGQ9G>/'T^Z9!>;(5J&T;Z@$@U(
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ME:HVU9R[J5<36-NBVW8HXB&T02@TWM8PQONZ.9Y(^I1!(#0^EXYM>QRZ;U>
M1.,YZ?@RO5-S=P(8-#Y.ME['I3J<Q<QO(%.68MRA#8>Y%P"A\4S,+ WSS(;0
M ; T_HP/DUZ;UD&$YN^'YL@;#V[]_*Z)!\&M!,N?> S6987A12IUDP/Q(%H
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MO(V+?S@>'=BZ 10BOT"3F]T+0U?[B3P!#3,^IP/F;O/WH^1+'0>*U[VOHR<
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MPROM5L)M6ZS=81F9OZ?)[[DWE/R=RFS#4V522+G]?1 NC4>FP#6\.%\*&/L
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M\!<HIL<F'VCRFAK8T9GR]M%"/[97;:QMF>7'_A2(C- C ';\-]JF+@"!T"?
M6XS.=<?9"F-9KM+7Q7V_GCB(A=##,')^D8:8TMY]M32(#H"E]4"Z3!IFZ>[W
M;*-^!X1%Z^]T07S)THA%U8*G6'#O)0=0F7^@R<LZ@$7]/13>,XTC C-]$ ZM
MI]5EGC\V:M7J'0Z_3P$ TOI?7?;TKV6M(80#*0%@*O^M4ZGH*I5UR,"K?'$D
M3W#V!5!4/MTV8WG%(K_''C[= 1J5[]7C3=T%RV#572&:R0!4*A^MQV-3U=NW
M<J0W#0!)Y7'U&<2E4!5B=!7P].D.T*C\*PMON^JI@0: I/*+>@S>Y&P#&W(O
M9\C:=?Z!)@/M-E\\S 1S9[&\$*?3MUF27(H7TX,06BD!8"*OIF1)PA9E%2;J
M*LIY(6?N!#"(?!=QH>"C>9V6P#"1[]%AP_7&7=<<6"?R, 0O>/1FSX;1:PD,
M$_D-ZB)).)V*+2OG^BX @<@?0'ZRW&-JMAL"NS26_6;FYE2U 29);/0U+LN\
M7F%:AHE[Y="V!^9);*^?"]%Q$FCRNK98 -EMVT _[K5= 1*)S73QY>&;^Y(
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MY!FNQM'IR]<"W[6(;.+H[.,+;M<1B#^1^0>:G*_^''IL 8<3 ]@DGHF!4W&
M^<K1U1 !F"1^BC^'NX^NA1C )O%;#)PV-]"O&%T-$8!)XL?X<[C[Z%J( 6P2
M/P<X;=[MV!$U[8!9$K^EP\3)4Q@G_ UOUBK!*\]>7:FY!E("P"0>S!?V308C
M@=* -J7PUX7(4C?TD?!04@"9Q./Y IRI:2*&R'V?8^P#(&C\'1-#/FN'J^_\
M TV66R-CSJV"HR< HO%;*OSZ;'G+-EE>X@)PQQY=H9_F3@"#Q"^IK8H4JHW[
MK;; -(E7L<6(Q\PP]@$0)#[#K*O4#A.J:0V,DUC]IG $WH1'JDR+._.;O2/
M(?$+NEP5>*TO5<0>U6+M!V!(;/Y.!5$L]4\^T.1[-7,T3,^,O0$8B6TWL^8J
MT^?H.?] DQEVEC^&J:R?>I:E!?B!$?\'SYR#>2U8@8$R_$=5 ?(OBG-6+/*8
MI^S"E J-8XE.)&QK?#S2O7X7A$GB4X@G('Q9=(=;;#<&MFE\".1D4*B(H0<
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M*@]$SY-_-)@O"8!(Y57H^5,39&G?-SM[ S 2_^*618RMPRUG7KU3LDTN9U\
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MM'=_<^M;(+3OZ[9K&XB88U>IJ$;@4>!@[]\&H7Z7.Y\6L#U?-UD_".+[+O=
M+31$>R!/#D# W]>=T3!XJ$K+0^JN)S/SCS2U85Z[V3,C-6WVCO>X]=R!&Q#\
M=[F#$K>,^,Q07=AD^*/6YOOD\3%GC^!*'LS]VIDG&(3O<C=F -Q2P\D,@ILG
M&(3O<F?G!KQWU]F7!1#Q=[F7<^,C<FI>QQ@,!]VN\!5F;C!JBF/@\9B$8?HN
M[]RZ@4#U@<[^A;[]21 AW:[SU7BZ2=3V+K[NYT!TT]QQ&K,)B)0"P!_6Z/&M
MN[F/SX'HIKF7-&(QW[3LR\"-S,K\(TTEL5?CU-S14(E\("L@\FGN(%TXK1<1
M!Y.V/Q<@Z"GM$OFR!\PO5FR6,O=+6G\J '1*.[$6B_?PN3&@MN@ V"GMB=I,
M?LO&@*JH - )W4&)V0<F^RK%-[WQ$Q;73 MG9OD=J %P.O_=766WW0Q8I?.3
M)0_>Z7A-?0 $D<?:RN#C%]NJZP#L$WF-[01$Z,_:2YAHV\]_H:F(ML6,A\.O
M[0$ :+R9^#&-E_$"<^<M%EF5UMER,/^K3Z8=+P( C\:'P,KJZ/KP3)XR"Y1+
MP4Q]  2-?Z 8$F^@FLS%OD!T_0 ,C?U73'FM5%N-@6T::ZXXF2VQW,EEDGWS
M"HJW= ,H-/:YX>DR3L%9BL/D)BMX\/TP2,;N (W&GC>\;>=[&X;-W!_ T=AY
MQ9PSN5^G(;!+8]=[A9F%QW1>Y76,#C\CW2IO[5$R^;6DY[_0U#;;UBD7R$YC
M8)O&1]AM*IGG#TV=,GT&R&%UY;QI $@B7P$^OCT?Q*9%%(PK<..X_)K&[CGF
M30C@$GD3%B[%SR^S_([E3[!1VQGN%B& 2^2%6+C\PK[Q7^T,LR8 \(@\$PMW
M[7R\ZGS2>KXPF!C )O):M)QR&S:"#NOI %@:+Z9Z*-@?%>Y*GGQW 88N ('&
ML^GRXSZLU+6?_T)4+ZW+C-<FQM %(-#X(SU^O RWJ0^ H/%&N@PY?7I-<V"=
MQL?H\>)Q9J?O 0!HO(9M=MSG=J8^ (+&%P"&XB@.\Y=6@3B/<=#V 1 T%K_:
M;!*^5PT3=4!R(7[@MS*YNP,T$JM^'SZ?P=XS%M5P9;SY=;R.1<FU8I9^M3Z)
M\>H/X$BL^#U;;[(<]$@>+<J"OR=K/  ^*<L\?JA*GDD^NP%_*[4-XF!: )K$
M[O<8O8[ACX@/ACAI8*GURMZG^_P7FOI:/=Y SK.<'R/)DQ3WM9@G!0!(XC/T
MV!.[@).J7&4YUD+P!];O"8!(_ <M6\Y+5TLO $+B36A9:H6K#D73Z@J02/P+
M= YFRU8PCL,L:]L#\R1^A:%$B(5]0P\ 0.)3&-A1+T*+6U94"=Y2\B*H58XF
M1>R4H;6ZR=@![\ /@'A(_!+P&F;+BZ*,U[ X6V%V&@*[))Z&S(3OF$&M5L H
MB7<@67!N)#KMYK_0U%J2-R'.HXM..V"6Q':K:YN3-!(%$;IG[A[[!$\* )#$
MEF^QYV?^;-T "HDUM_'T&59'D#8:N*MT4PT:, L9@$IBY6T\8H#/CO"P*T B
ML?V],&#U(D-6Q1WBF@VD!(!)? 4#FYR_%GNGW9K(PW$[" )\$E_ QFW19W='
MU%MT "R))^'+I!R3QCSPRP8?*S/*!T \+?\%O](1$)#*JKPY:,BSA-42^O;M
MVT]<2BB@XW?OWO^,O_Z94^DS'C[,(Q;/3V =C7 MO4S"Q_D[:+5.H$WZ^&\_
ML/3MU[L?_D?=(L F_RJHC<H?R.LA*]BU-YM')&S:Q"C=_$L8TS#Y3Q;F%S"Y
M,3FN3J*R<2!:!]@\@/8!=B"2KY%_G:@/S;]-\.?9@N>#%[S(!YCPLT(K>=5:
ML2[:![P#D>3- '2B/S0 ?]&C%O@+GNO,=,3>,.\C]/TR[R-R,>RV-:;F66H(
M\?JB9]PJ[ ,P[B-J/)RS2QA;$(N5,VF5YKZ8M(GP(BWQ0H=A7H'D*HW8\[^S
M%ZTL1<M -@UXVP :$XE5S[A.OH=DW$/4V7HMB[MO;[%L<N?] M[Q32"Z!JV^
MM,-@ V4;$P)0'D,D?*>Z,C7>D1ELIL(AO:VZ2R#ZT/ OSRTM_/Y--/E_:?B[
M6+/\$83T>YY]*U?XYB5,K6N.ZA"('H'L0L3],SY?%3<$,F.RC?7GH&DN[24-
MWY=QPO(SL-*/66Z5-F\8J):DZTJ79\M"LG^>W0+F!5?"!3[Q!6<HE&N"3=*M
M'N@_A6H=H>'_IGI(XL5EDH56ID6S@+>C8?26/<9X$).6F%#%QFO3,L"FI+K<
MX]JBS ?@VBWDNQ5+$H^UF;>C79'OUF&2G%9%G++":J9YPT"UI&'V+UE2I668
MB[7-RF[=5"QO1 S_%<;WW]/L6WK'PB)+6<1C47(;X]CE[3^P3Z Z!:+7H2%<
ML\<P$5SQBV<=T[Q-H#PC;'9PO^B.+:H</G]T_' ?EXE^3>._";)E<'3\X\.?
M M7GT+R".X.N^=W+^B%+](R*%H%H0K3H=MG4K;;[9],D1K9^B.<GBT5>,9X#
M,"W85]B5YB>/.>.7IOI#?M$A8*)'P+L$=9]] (CDT00/@=P)B$[PL$L"9C
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MZ!<-WZW\I3 P4<,ZU7'IKD+6+U=28$ L$-2"%KE T>//LUL4]W=ZZC<-=Y.
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MHL*&P[TBX;9B"PM1LF8;$O?.<9(CXG$">;]U--<[M,*9E&;I(BQ6\-<G#($
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MS'R5DT=->(ZD#H^"'X_VLC0XE2XMXRA.>%S>'5M4.7<@8&>65.#37,(F"ZU
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MLTU92<A@C*ID$MS3@PUAU6]M\G?79=PJE<\+-A-HO[-?'+.X0-(3ERD96Y'
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M,K\#3^CX0-C,Z=% WLZ>I3>$3:QNP!^V9&D4OZU]K#9>F:*SEN2"?^VL]WW
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MG:\RVH+^$*O>T4W7GXH)EX\P8*J-MI&%ZGVU\ZX,%:_<&"8O4#NN#J14ATC
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MS\]LI[A^F12/-=<!S4*_.DP=8M0-0PHR5SVBM&ZK!E1&GCT_QV*1,L$@M]6
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M2T1'\U!Y\A %P4T4ERN&[A2H=RCVOD67#N_3R3O%:OO>ZF@S?KR^Z>?1HK*
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MP"V,T.G6@%Y7SF]_%1%$>PNPB>X3E"I<45F%S_PZZM(-/1($.W:^8P!IZ9I
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MR]97&9ME-;'VYI> U!DN-"!9A@L-2(_-!$NW81K51LE[$HMMP+<S32"\>P^
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MS@=A7K2)R:P._:N_AN+$&+)#<60,V8$Y,U_DPN3Q*?'ZX;TZH&YH LR>D5
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M18.D!>/)(&FAF"#2+,P7M<#KI1L$Q+]XJY[ZG:K#MQV:0C'&+BHH9ME%!<7
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MY$GB&1A] ,G0;+_00/),+Y8B)'=RJ ^"]>H(I_TJ0:L[!R='^J!9OYY^1LS
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M;8\)W$YEG2P&PA"S6_\4W!*#I,:CZR*'W,FQ(3RE;(%'\\,Q[(,=P.?$$3"
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M"NAKW:6LCOW.M+O[ ;WMA)TM8<=G=WG1=9/CVD! CU[PV=D>UIVP:XW3VKC
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MO8^RT?'O/RV@:_U-/_[0?^C?YI7O/_X'4$L#!!0    ( +FL=%#QU;1IAUL
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M:F.<V4OK4<":)QB32_?%PT:O]Y>JI:+0*8C\%_@,NKX,=R\HB+5D/>Z@];J
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M[3NA+FS\V"O8_C@DU 0J,UV8M""OC>N[%CZT>+*59H(6.G*1:BO/-5IXR<7
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MD3,6F\4+_B7IE["4+](8 Q7'APNK#3A&9ZL5\?N3D'OH>RO"GQ9[0]F-S+A
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M%G(=1E]>-A&V5K""S$]&?=@YAUGOBS()S8,-4QIF ^<<9@>X"Q/<=>G[(E_
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M:,Q&0U%"27BH D)''>='NT5PX<;>JOG]LS_XR[5J9V8B$S5;A0-\[3ER2\H
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M#SQQ B=.X,0)'"9H$R=PX@1.G,"!H3751I1G4-I2(Y&IG0"$TK=FA3W 44^
M@X45%-L8U5S_H5T5!/FJ<D]D#0^E%5-(H")E&K$<I3;:S"THG8 &RS"HC:5:
M#+6/67UVZ%W1ZUCS(S>S/?N)) !-7_:I<,BFZH:J^M*!FJH;3M4->\)KJFZ8
M43HG1F<OP=2Q,3J!;\@<C KM+L@$(B$A_,.?+\/=+@RR(Y;<_9>B=D#B52K
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M,C,Q+GAS9%!+ 0(4 Q0    ( +FL=% FD[MSN0L  *2C   5
M  "  8V. 0!E;6)I+3(P,3DQ,C,Q7V-A;"YX;6Q02P$"% ,4    " "YK'10
M:F&Z^.))  !B_@4 %0              @ %YF@$ 96UB:2TR,#$Y,3(S,5]D
M968N>&UL4$L! A0#%     @ N:QT4'>49!-?\@  MY@- !4
M ( !CN0! &5M8FDM,C Q.3$R,S%?;&%B+GAM;%!+ 0(4 Q0    ( +FL=%#Q
MU;1IAUL  '52!P 5              "  2#7 @!E;6)I+3(P,3DQ,C,Q7W!R
;92YX;6Q02P4&      8 !@"* 0  VC(#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6799670816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt - Related Party (Detail Textuals 1) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 19, 2018</div></th>
<th class="th"><div>Dec. 28, 2017</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible debt issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (725,425)<span></span>
</td>
<td class="num">$ (590,392)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=embi_EmeraldHealthSciencesIncMember', window );">Emerald Health Sciences Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Initial conversion price</a></td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Number of notes converted into common stock</a></td>
<td class="nump">9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.94%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_BridgeLoanMember', window );">Bridge Loan | Secured Promissory Note and Security Agreement | Emerald Health Sciences Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BridgeLoan', window );">Aggregate gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Bridge loan interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Initial conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible debt issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Funding of remaining bridge loan</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">265,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_AdditionalConversionLiability', window );">Additional conversion liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_AdditionalConversionLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to additional conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_AdditionalConversionLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BridgeLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Short-Term financing which is expected to be paid back relatively quickly, such as by a subsequent longer-term loan. Also called swing loan or bridge financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BridgeLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=embi_EmeraldHealthSciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=embi_EmeraldHealthSciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_BridgeLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_BridgeLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=embi_SecuredPromissoryNoteAndSecurityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=embi_SecuredPromissoryNoteAndSecurityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6813179728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details 1) - Omnibus Incentive Plan 2014 - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at the beginning</a></td>
<td class="nump">9,142,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">1,262,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Cancelled</a></td>
<td class="num">(196,875)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited</a></td>
<td class="num">(153,125)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at the ending</a></td>
<td class="nump">13,128,381<span></span>
</td>
<td class="nump">9,142,273<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=embi_OmnibusIncentivePlan2014Member', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at the beginning</a></td>
<td class="nump">2,405,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">1,262,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Cancelled</a></td>
<td class="num">(196,875)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited</a></td>
<td class="num">(153,125)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at the ending</a></td>
<td class="nump">3,317,642<span></span>
</td>
<td class="nump">2,405,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable</a></td>
<td class="nump">2,399,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and Expected to Vest</a></td>
<td class="nump">3,317,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at the beginning</a></td>
<td class="nump">$ 0.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="nump">0.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Cancelled</a></td>
<td class="nump">0.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited</a></td>
<td class="nump">0.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at the ending</a></td>
<td class="nump">0.33<span></span>
</td>
<td class="nump">$ 0.33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable</a></td>
<td class="nump">0.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest</a></td>
<td class="nump">$ 0.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based compensation arrangement by share-based payment award, options, additional disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (Years)</a></td>
<td class="text">8 years 4 months 2 days<span></span>
</td>
<td class="text">8 years 8 months 15 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (Years), Exercisable</a></td>
<td class="text">7 years 10 months 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (Years), Vested and Expected to Vest</a></td>
<td class="text">8 years 4 months 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and Expected to Vest</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=embi_OmnibusIncentivePlan2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=embi_OmnibusIncentivePlan2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6799974928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Detail Textuals) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 25, 2018</div></th>
<th class="th"><div>Feb. 28, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Oct. 31, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=embi_RestrictedStockAgreementsMember', window );">Restricted Stock Agreements | K2C, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of restricted common stock vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">325,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockExpense', window );">Stock compensation expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 98,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=embi_OmnibusIncentivePlan2014Member', window );">Omnibus Incentive Plan 2014 | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for future grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value of stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.22<span></span>
</td>
<td class="nump">$ 0.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of stock options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 473,030<span></span>
</td>
<td class="nump">$ 418,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember', window );">Elizabeth Berecz, CFO | Restricted Stock Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of restricted common stock vested</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockExpense', window );">Stock compensation expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for award of restricted stock or unit under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=embi_RestrictedStockAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=embi_RestrictedStockAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=embi_K2CIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=embi_K2CIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=embi_OmnibusIncentivePlan2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=embi_OmnibusIncentivePlan2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6796867776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Detail Textuals) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">$ 4,538<span></span>
</td>
<td class="nump">$ 4,512<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding', window );">Fair value of advance under credit agreement</a></td>
<td class="nump">1,877,938<span></span>
</td>
<td class="nump">3,176,824<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible multi-draw credit agreement - related party, net of discount</a></td>
<td class="nump">$ 387,070<span></span>
</td>
<td class="nump">$ 1,360,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDepreciationMethods', window );">Property, plant and equipment, depreciation methods</a></td>
<td class="text">straight-line method<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Estimated useful life</a></td>
<td class="text">two to three years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of the amount outstanding under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDepreciationMethods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the methodology for computing depreciation for classes of depreciable assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDepreciationMethods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68071081&amp;loc=d3e1205-110223<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6813099184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Omnibus Incentive Plan 2014</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Schedule of shares available for future grant</a></td>
<td class="text"><table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN;margin:auto" width="85%"><tbody><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="border-bottom:1px solid black;text-align:center;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Shares Available for Grant</strong></span></span></span></span></span></span></p></td><td style="padding-bottom:1px;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="top"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Available as of December 31, 2018</strong></span></span></p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></p></td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>9,142,273</strong></span></span></span></span></span></span></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></p></td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="background-color:rgb(204, 238, 255)" valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Share pool increase</span></span></span></span></span></span></p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>4,898,750</span></span></span></span></span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Forfeited</span></span></span></span></span></span></p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>153,125</span></span></span></span></span></span></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="background-color:rgb(204, 238, 255)" valign="top"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cancelled</span></span></p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>196,875</span></span></span></span></span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Granted</span></span></span></span></span></span></p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-bottom:1px solid black;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-bottom:1px solid black;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>(1,262,642</span></span></span></span></span></span></td><td style="padding-bottom:1px;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>)</span></span></span></span></span></span></td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="background-color:rgb(204, 238, 255)" valign="top"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Available as of December 31, 2019</strong></span></span></p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-bottom:2.5pt double black;width:1%;background-color:rgb(204, 238, 255);border-top:none;border-right:none;border-left:none;border-image:initial" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></p></td><td style="border-bottom:2.5pt double black;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-top:none;border-right:none;border-left:none;border-image:initial" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>13,128,381</strong></span></span></span></span></span></span></td><td style="padding-bottom:3px;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of summary of stock option activity</a></td>
<td class="text"><div><table border="0" cellpadding="0" cellspacing="0" style="font:10pt Times New Roman;margin:auto;text-align:justify;width:100%" width="85%"><tbody><tr><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:9px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="border-bottom:1px solid black;text-align:center;width:76px" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Number of</strong></span></span></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Shares</strong></span></span></span></span></span></span></p></td><td style="PADDING-BOTTOM:1px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Weighted</strong></span></span></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Average</strong></span></span></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Exercise Price</strong></span></span></span></span></span></span></p></td><td style="PADDING-BOTTOM:1px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Weighted</strong></span></span></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Average Remaining</strong></span></span></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Contractual</strong></span></span></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Term</strong></span></span></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>(Years)</strong></span></span></span></span></span></span></p></td><td style="PADDING-BOTTOM:1px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Aggregate Intrinsic Value*</strong></span></span></span></span></span></span></p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#cceeff"><td valign="top"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Outstanding, December 31, 2018</strong></span></span></p></td><td style="width:9px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:5px" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>2,405,000</strong></span></span></span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>$</strong></span></span></span></span></span></span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>0.33</strong></span></span></span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:6px" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></p></td><td style="text-align:right;width:72px" valign="bottom"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>8.71</strong></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="text-align:right;width:9%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#ffffff"><td><p style="MARGIN:0px">&#160;</p></td><td style="width:9px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:5px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:6px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:72px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="text-align:right;width:9%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Granted</span></span></span></span></span></span></p></td><td style="width:9px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:5px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>1,262,642</span></span></span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>0.30</span></span></span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:6px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:72px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="text-align:right;width:9%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#ffffff"><td valign="top"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cancelled</span></span></p></td><td style="width:9px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:5px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>(196,875</span></span></span></span></span></span></td><td style="width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>)</span></span></span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>0.26</span></span></span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:6px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:72px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="text-align:right;width:9%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Forfeited</span></span></span></span></span></span></p></td><td style="width:9px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-bottom:1px solid black;width:5px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:black 1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>(153,125</span></span></span></span></span></span></td><td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>)</span></span></span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:black 1px solid;width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:black 1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>0.26</span></span></span></span></span></span></td><td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-bottom:1px solid black;width:6px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-bottom:1px solid black;text-align:right;width:72px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:black 1px solid;width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:right;width:9%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#ffffff"><td valign="top"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Outstanding, December 31, 2019</strong></span></span></p></td><td style="width:9px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-bottom:3px double black;width:5px" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></p></td><td style="BORDER-BOTTOM:black 3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>3,317,642</span></span></span></span></span></span></td><td style="PADDING-BOTTOM:3px;width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:black 3px double;width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>$</strong></span></span></span></span></span></span></td><td style="BORDER-BOTTOM:black 3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>0.33</span></span></span></span></span></span></td><td style="PADDING-BOTTOM:3px;width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-bottom:3px double black;width:6px" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></p></td><td style="border-bottom:3px double black;text-align:right;width:72px" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>8.34</span></span></span></span></span></span></td><td style="PADDING-BOTTOM:3px;width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:black 3px double;width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>$</strong></span></span></span></span></span></span></td><td style="BORDER-BOTTOM:black 3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>&#x2014;</span></span></span></span></span></span></td><td style="PADDING-BOTTOM:3px;width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></p></td></tr><tr style="background-color:#cceeff"><td valign="top"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Exercisable, December 31, 2019</strong></span></span></p></td><td style="width:9px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-bottom:1px solid black;width:5px" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></p></td><td style="BORDER-BOTTOM:black 1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>2,399,356</span></span></span></span></span></span></td><td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:black 1px solid;width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>$</strong></span></span></span></span></span></span></td><td style="BORDER-BOTTOM:black 1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>0.34</span></span></span></span></span></span></td><td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-bottom:1px solid black;width:6px" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></p></td><td style="border-bottom:1px solid black;text-align:right;width:72px" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>7.84</span></span></span></span></span></span></td><td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:black 1px solid;width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>$</strong></span></span></span></span></span></span></td><td style="BORDER-BOTTOM:black 1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>&#x2014;</span></span></span></span></span></span></td><td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></p></td></tr><tr style="background-color:#ffffff"><td valign="top"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Vested and expected to vest, December 31, 2019</strong></span></span></p></td><td style="width:9px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;width:5px" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></p></td><td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>3,317,642</span></span></span></span></span></span></td><td style="padding-bottom:1px;width:1%;border:1pt none" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></p></td><td style="width:1%;border:1pt none" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>$</strong></span></span></span></span></span></span></td><td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>0.33</span></span></span></span></span></span></td><td style="padding-bottom:1px;width:1%;border:1pt none" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></p></td><td style="width:1%;border:1pt none" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;width:6px" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></p></td><td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;text-align:right;width:72px" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>8.34</span></span></span></span></span></span></td><td style="padding-bottom:1px;width:1%;border:1pt none" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></p></td><td style="width:1%;border:1pt none" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>$</strong></span></span></span></span></span></span></td><td style="border-top:none;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>&#x2014;</span></span></span></span></span></span></td><td style="padding-bottom:1px;width:1%;border:1pt none" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></p></td></tr></tbody></table><p style="MARGIN:0px">&#160;</p><p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><i>*The aggregate intrinsic value is the sum of the amounts by which the quoted market price of the Company&#x2019;s stock exceeded the exercise price of the stock options at December 31, 2019&#160;for those stock options for which the quoted market price was in excess of the exercise price (&#x201c;in-the-money options&#x201d;).</i></span></span></span></span></span></span></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of fair value assumptions of stock option granted</a></td>
<td class="text"><div><p style="MARGIN:0px">&#160;</p><table border="0" cellpadding="0" cellspacing="0" style="font:10pt Times New Roman;margin:auto;text-align:justify;width:100%" width="85%"><tbody><tr><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Year&#160;Ended December 31,</strong></span></span></p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2019</strong></span></span></p></td><td style="PADDING-BOTTOM:1px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2018</strong></span></span></p></td><td style="PADDING-BOTTOM:1px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dividend yield</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.00</span></span></td><td style="width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.00</span></span></td><td style="width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></td></tr><tr style="background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Risk-free interest rate</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.49</span></span></td><td style="width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td>&#160;</td><td><p style="MARGIN:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3.06&#x2014;3.10</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></p></td></tr><tr style="background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected term (years)</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5.65</span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td>&#160;</td><td><p style="MARGIN:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5.27&#x2014;5.58</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Volatility</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">93.72</span></span></td><td style="width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td>&#160;</td><td><p style="MARGIN:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">70.00&#x2014;93.60</span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></p></td></tr></tbody></table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Awards Granted Outside the 2014 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of fair value assumptions of stock option granted</a></td>
<td class="text"><table border="0" cellpadding="0" cellspacing="0" style="font:10pt Times New Roman;margin:auto;text-align:justify;width:100%" width="85%"><tbody><tr><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td>&#160;</td><td style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>At Issuance</strong></span></span></span></span></span></span></p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Dividend Yield</span></span></span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>0.00</span></span></span></span></span></span></td><td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"><p style="MARGIN:0px">%</p></td></tr><tr style="background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Risk-free interest rate</span></span></span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>2.79</span></span></span></span></span></span></td><td style="width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>%</span></span></span></span></span></span></td></tr><tr style="background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Expected term (in years)</span></span></span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>5.54</span></span></span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Volatility</span></span></span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>70</span></span></span></span></span></span></td><td style="width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>%</span></span></span></span></span></span></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock Awards | Awards Granted Outside the 2014 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock', window );">Schedule of RSA activity</a></td>
<td class="text"><table border="0" cellpadding="0" cellspacing="0" style="font:10pt Times New Roman;margin:auto;text-align:justify;width:100%" width="85%"><tbody><tr><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Number of</strong></span></span></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Shares</strong></span></span></span></span></span></span></p></td><td style="PADDING-BOTTOM:1px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:black 1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Weighted </strong></span></span></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Average Grant </strong></span></span></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>Date Fair Value</strong></span></span></span></span></span></span></p></td><td style="PADDING-BOTTOM:1px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#cceeff"><td valign="top"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Unvested, December 31, 2018</strong></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><strong>900,000</strong></span></span></span></td><td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:7px" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>$</strong></span></span></span></span></span></span></td><td style="text-align:right;width:72px" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>0.19</span></span></span></td><td style="PADDING-BOTTOM:1px;width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></p></td></tr><tr style="background-color:#ffffff"><td><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:7px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:72px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Granted</span></span></span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>&#x2014;</span></span></span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:7px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:72px" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>&#x2014;</span></span></span></span></span></span></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Released</span></span></span></span></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border:1pt none;width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border:1pt none;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>(450,000</span></span></span></span></span></span></td><td style="padding-bottom:1px;width:1%;border:1pt none" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>)</span></span></span></span></span></span></td><td style="width:1%;border:1pt none" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border:1pt none;width:7px" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border:1pt none;text-align:right;width:72px" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>0.19</span></span></span></span></span></span></td><td style="padding-bottom:1px;width:1%;border:1pt none" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:#cceeff"><td valign="top"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>Unvested, December 31, 2019</strong></span></span></p></td><td style="width:1%" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-top:1pt solid black;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;width:1%" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></p></td><td style="border-top:1pt solid black;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>450,000</strong></span></span></span></span></span></span></td><td style="padding-bottom:3px;width:1%;border:1pt none" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></p></td><td style="width:1%;border:1pt none" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="border-top:1pt solid black;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;width:7px" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>$</strong></span></span></span></span></span></span></td><td style="border-top:1pt solid black;border-right:none;border-bottom:2.5pt double black;border-left:none;border-image:initial;text-align:right;width:72px" valign="bottom"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>0.19</span></span></span></span></span></span></strong></td><td style="padding-bottom:3px;width:1%;border:1pt none" valign="bottom"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><strong>&#160;</strong></span></span></span></span></span></span></p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=embi_OmnibusIncentivePlan2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=embi_OmnibusIncentivePlan2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=embi_AwardsGrantedOutside2014PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=embi_AwardsGrantedOutside2014PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6752863648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>12. Subsequent Events</strong></span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In March 2020, the Company was notified by the United States Patent and Trademark Office, that a notice of allowance has been issued for the proprietary analog of cannabidiol, CBDVHS, under the UM 8930 License Agreement. As a result, the Company is required to pay UM a fee of $200,000 within 30 days from when the notice was received (Note 9).</span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Refer to Note 1 for disclosure of the salary deferral program that was put in place during March 2020.</span></span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6799467120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details 4) - Restricted Stock Awards<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested, December 31, 2018 | shares</a></td>
<td class="nump">900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Released | shares</a></td>
<td class="num">(450,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested, December 31, 2019 | shares</a></td>
<td class="nump">450,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested, December 31, 2018 | $ / shares</a></td>
<td class="nump">$ 0.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Released | $ / shares</a></td>
<td class="nump">0.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested, December 31, 2019 | $ / shares</a></td>
<td class="nump">$ 0.19<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6799777280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt - Related Party (Detail Textuals) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 01, 2018</div></th>
<th class="th"><div>Oct. 05, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Feb. 16, 2018</div></th>
<th class="th"><div>Jan. 19, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 501,400<span></span>
</td>
<td class="nump">$ 15,958,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 823,037<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_FairValueOfDerivativeLiabilityInExcessOfProceeds', window );">Fair value of derivative liabilities in excess of proceeds recorded as other expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(322,644)<span></span>
</td>
<td class="num">(7,174,634)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(725,425)<span></span>
</td>
<td class="num">$ (590,392)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=embi_MultiDrawCreditAgreementMember', window );">Multi-Draw Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_AmountOfEachWarrantOutstanding', window );">Amount of each warrant outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from related party debt</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrant issued</a></td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_AllocationOfDebtOnBasisOfRelativeFairValue', window );">Allocation of debt on the basis of relative fair value</a></td>
<td class="nump">$ 1,684,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,283,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_AllocationOfWarrantOnBasisOfRelativeFairValue', window );">Allocation of warrant on the basis of relative fair value</a></td>
<td class="nump">315,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">716,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">Beneficial conversion feature</a></td>
<td class="nump">90,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,584,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="nump">$ 204,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">516,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_FairValueOfDerivativeLiabilityInExcessOfProceeds', window );">Fair value of derivative liabilities in excess of proceeds recorded as other expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">322,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrant exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,985,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (725,425)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.05%<span></span>
</td>
<td class="nump">10.57%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_ConvertibleMultiDrawCreditAgreementIssuanceCosts', window );">Convertible multi-draw credit agreement issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1', window );">Unamortized debt discount period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 9 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_FairValueOfUnderlyingShares', window );">Fair value of underlying shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 657,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=embi_EmeraldFinancingMember', window );">Emerald Financing Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 276,024<span></span>
</td>
<td class="nump">$ 15,251,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=embi_EmeraldFinancingMember', window );">Emerald Financing Warrant Liability | Multi-Draw Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAverageOutstandingAmount', window );">Maximum amount that can be borrowed over the life of the credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">The annual stated interest rate on the debt instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct.  05,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeeAmount', window );">Unused portion of the credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase', window );">Warrant coverage on the debt facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_AllocationOfDebtOnBasisOfRelativeFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents allocation of debt on the basis of relative fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_AllocationOfDebtOnBasisOfRelativeFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_AllocationOfWarrantOnBasisOfRelativeFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents allocation of warrant on the basis of relative fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_AllocationOfWarrantOnBasisOfRelativeFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_AmountOfEachWarrantOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of each warrant outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_AmountOfEachWarrantOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_ConvertibleMultiDrawCreditAgreementIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of convertible multi-draw credit agreement issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_ConvertibleMultiDrawCreditAgreementIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_FairValueOfDerivativeLiabilityInExcessOfProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to fair value of derivative liability in excess of proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_FairValueOfDerivativeLiabilityInExcessOfProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_FairValueOfUnderlyingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of the underlying shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_FairValueOfUnderlyingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of amount need to be issued against warrant purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period for discount on the liability component of convertible debt which may be settled in cash upon conversion, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAverageOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average amount borrowed under the credit facility during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAverageOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=embi_MultiDrawCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=embi_MultiDrawCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=embi_EmeraldFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=embi_EmeraldFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6792429728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details) - Omnibus Incentive Plan 2014<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares Available for Grant</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at the beginning</a></td>
<td class="nump">9,142,273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease', window );">Share pool increase</a></td>
<td class="nump">4,898,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited</a></td>
<td class="nump">153,125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Cancelled</a></td>
<td class="nump">196,875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="num">(1,262,642)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at the ending</a></td>
<td class="nump">13,128,381<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase or decrease in number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding, including vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=embi_OmnibusIncentivePlan2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=embi_OmnibusIncentivePlan2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6601255040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share of Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of basic and diluted net loss per share</a></td>
<td class="text"><div><table style="font:10pt/normal times new roman;width:100%;text-align:justify;border-collapse:collapse;font-size-adjust:none;font-stretch:normal"><tbody><tr><td style="vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td colspan="10" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:black;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>For the Year Ended</strong> <strong>December 31, 2019</strong></span></span></p></td><td style="vertical-align:bottom"><p style="margin:0px">&#160;</p></td></tr><tr><td style="vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Income</strong></span></span></p><p style="margin:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>(Numerator)</strong></span></span></p></td><td style="padding-bottom:1px;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:black;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Shares</strong></span></span></p><p style="margin:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>(Denominator)</strong></span></span></p></td><td style="vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Per-Share</strong></span></span></p><p style="margin:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Amount</strong></span></span></p></td><td style="padding-bottom:1px;vertical-align:bottom"><p style="margin:0px">&#160;</p></td></tr><tr><td><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Net income</span></span></p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:black;border-bottom-width:1px;border-bottom-style:solid"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:black;border-bottom-width:1px;border-bottom-style:solid"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">1,051,825</span></span></td><td style="width:1%;padding-bottom:1px;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">&#160;</td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">&#160;</td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td></tr><tr style="background-color:rgb(255, 255, 255)"><td><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Basic EPS</strong></span></span></p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;padding-bottom:1px;vertical-align:bottom"><p style="margin:0px">&#160;</p></td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Income available to common stockholders</span></span></p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:black;border-bottom-width:3px;border-bottom-style:double"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:black;border-bottom-width:3px;border-bottom-style:double"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">1,051,825</span></span></td><td style="width:1%;padding-bottom:3px;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:black;border-bottom-width:3px;border-bottom-style:double"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:black;border-bottom-width:3px;border-bottom-style:double"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">135,154,931</span></span></td><td style="width:1%;padding-bottom:3px;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:black;border-bottom-width:3px;border-bottom-style:double"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>$</strong></span></span></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:black;border-bottom-width:3px;border-bottom-style:double"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>0.01</strong></span></span></td><td style="width:1%;padding-bottom:3px;vertical-align:bottom"><p style="margin:0px">&#160;</p></td></tr><tr style="background-color:rgb(204, 238, 255)"><td><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Effect of Dilutive Securities</strong></span></span></p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Unvested restricted stock</span></span></p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">858,856</span></span></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Options</span></span></p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">392,784</span></span></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Warrants</span></span></p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">447,431</span></span></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Warrants &#x2013; liability classified</span></span></p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(9,250,612</span></span></td><td style="width:1%;padding-bottom:1px;vertical-align:bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">32,706,263</span></span></td><td style="width:1%;padding-bottom:1px;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td></tr><tr style="background-color:rgb(204, 238, 255)"><td><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Diluted EPS</strong></span></span></p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;padding-bottom:1px;vertical-align:bottom"><p style="margin:0px">&#160;</p></td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Loss available to common stockholders + assumed conversions</span></span></p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(8,198,787</span></span></td><td style="width:1%;padding-bottom:3px;vertical-align:bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">169,560,265</span></span></td><td style="width:1%;padding-bottom:3px;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>$</strong></span></span></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>(0.05</strong></span></span></td><td style="width:1%;padding-bottom:3px;vertical-align:bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>)</strong></span></span></td></tr></tbody></table><p style="margin:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">&#160;&#160;</span></span></p><table style="font:10pt/normal times new roman;width:100%;text-align:justify;border-collapse:collapse;font-size-adjust:none;font-stretch:normal"><tbody><tr><td style="vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td colspan="10" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:black;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>For the Year Ended</strong> <strong>December 31, 2018</strong></span></span></p></td><td style="vertical-align:bottom"><p style="margin:0px">&#160;</p></td></tr><tr><td style="vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Income</strong></span></span></p><p style="margin:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>(Numerator)</strong></span></span></p></td><td style="padding-bottom:1px;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:black;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Shares</strong></span></span></p><p style="margin:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>(Denominator)</strong></span></span></p></td><td style="padding-bottom:1px;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Per-Share</strong></span></span></p><p style="margin:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Amount</strong></span></span></p></td><td style="padding-bottom:1px;vertical-align:bottom"><p style="margin:0px">&#160;</p></td></tr><tr><td><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Net loss</span></span></p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">$</span></span></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(19,194,236</span></span></td><td style="width:1%;padding-bottom:1px;vertical-align:bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">&#160;</td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">&#160;</td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td></tr><tr style="background-color:rgb(255, 255, 255)"><td><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>Basic and Diluted EPS</strong></span></span></p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Loss available to common stockholders</span></span></p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:black;border-bottom-width:3px;border-bottom-style:double"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">$</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:black;border-bottom-width:3px;border-bottom-style:double"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">(19,194,236</span></span></td><td style="width:1%;padding-bottom:3px;vertical-align:bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:black;border-bottom-width:3px;border-bottom-style:double"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:black;border-bottom-width:3px;border-bottom-style:double"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">121,154,334</span></span></td><td style="width:1%;padding-bottom:3px;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:black;border-bottom-width:3px;border-bottom-style:double"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>$</strong></span></span></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:black;border-bottom-width:3px;border-bottom-style:double"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>(0.16</strong></span></span></td><td style="width:1%;padding-bottom:3px;vertical-align:bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>)</strong></span></span></td></tr></tbody></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of anti-dilutive securities</a></td>
<td class="text"><table border="0" cellpadding="0" cellspacing="0" style="font:10pt Times New Roman;margin:auto;text-align:justify;width:100%" width="85%"><tbody><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="6" style="border-bottom:1px solid black;text-align:center;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>Year Ended</strong></span></span></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>December 31,</strong></span></span></span></span></p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="border-bottom:1px solid black;text-align:center;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>2019</strong></span></span></span></span></p></td><td style="padding-bottom:1px;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="border-bottom:1px solid black;text-align:center;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><strong>2018</strong></span></span></span></span></p></td><td style="padding-bottom:1px;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="background-color:rgb(204, 238, 255)" valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Stock options</span></span></span></span></p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>4,119,931</span></span></span></span></td><td style="padding-bottom:1px;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>3,600,073</span></span></span></span></td><td style="padding-bottom:1px;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Unvested restricted stock</span></span></span></span></p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>234,645</span></span></span></span></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>1,543,501</span></span></span></span></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="background-color:rgb(204, 238, 255)" valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Common shares underlying convertible debt</span></span></span></span></p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>5,036,250</span></span></span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>5,000,000</span></span></span></span></td><td style="width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="background-color:rgb(255, 255, 255)" valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Warrants</span></span></span></span></p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>20,712,000</span></span></span></span></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>53,130,750</span></span></span></span></td><td style="width:1%;background-color:rgb(255, 255, 255)" valign="bottom"><p style="MARGIN:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6811718352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span><span><span><strong><i>Basis of Presentation</i></strong></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span>The preparation of financial statements in conformity with U.S. Generally Accepted Accounting Principles (&#x201c;GAAP&#x201d;) requires management to make estimates and assumptions that affect the amounts reported in the Consolidated Financial Statements and the accompanying notes. Actual results could differ from those estimates. Certain reclassifications have been made to prior year amounts to conform to the current year&#x2019;s presentation. Such reclassifications had no net effect on the prior year&#x2019;s total assets, total liabilities, total stockholders&#x2019; deficit, net loss and cash flows.</span></span></span></span></span></span></span></span></span></span></span></span></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span><span><span><strong><i>Use of Estimates</i></strong></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span>The preparation of the Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Consolidated Financial Statements and the reported amounts of income and expense during the reporting period. Actual results could differ from those estimates. The most significant accounting estimates inherent in the preparation of the Company&#x2019;s financial statements include estimates as to the appropriate carrying value of certain assets and liabilities which are not readily apparent from other sources. Such estimates and judgments are utilized for stock-based compensation expense, equity securities, derivative liabilities and debt with embedded features.</span></span></span></span></span></span></span></span></span></span></span></span></p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_RisksAndUncertaintiesPolicyTextBlock', window );">Risks and Uncertainties</a></td>
<td class="text"><div><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span><span><span><strong><i>Risks and Uncertainties</i></strong></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span>The Company&#x2019;s operations are subject to a number of risks and uncertainties, including but not limited to, changes in the general economy, the size and growth of the potential markets for any of the Company&#x2019;s product candidates, results of research and development activities, uncertainties surrounding regulatory developments in the United States and Australia and the Company&#x2019;s ability to attract new funding.</span></span></span></span></span></span></span></span></span></span></span></span></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span><span><span><strong><i>Cash and Cash Equivalents</i></strong></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span>The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The carrying values of those investments approximate&#160;their fair value due to their short maturity and liquidity. Cash includes cash on hand and amounts on deposit with financial institutions, which amounts may at times exceed federally insured limits. The Company has not experienced any losses on such accounts and does not believe it is exposed to any significant credit risk. As of December 31, 2019, the Company has no cash equivalents.</span></span></span></span></span></span></span></span></span></span></span></span></p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><div><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span><span><span><strong><i>Restricted Cash</i></strong></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span><span><span>A deposit of $4,538 and $4,512 </span></span>as of December 31, 2019 and&#160;2018, respectively, was restricted from withdrawal and held by a bank in the form of a certificate of deposit. This certificate serves as collateral for payment of the Company&#x2019;s credit cards.</span></span></span></span></span></span></span></span></span></span></span></span></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div><p style="text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span><span><span><strong><i>Fair Value Measurements</i></strong></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span><span><span>Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (the &#x201c;exit price&#x201d;) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last is considered unobservable, is used to measure fair value:</span></span></span></span></span></span></span></span></span></span></span></span></span></span></p><p style="MARGIN:0px">&#160;</p><table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN" width="100%"><tbody><tr style="height:15"><td style="width:7%" valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span><span><span>Level 1:</span></span></span></span></span></span></span></span></span></span></span></span></span></span></p></td><td style="width:93%" valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span><span><span>Valuations for assets and liabilities traded in active markets from readily available pricing sources such as quoted prices in active markets for identical assets or liabilities.</span></span></span></span></span></span></span></span></span></span></span></span></span></span></p></td></tr><tr style="height:15"><td valign="top">&#160;</td><td valign="top">&#160;</td></tr><tr style="height:15"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span><span><span>Level 2:</span></span></span></span></span></span></span></span></span></span></span></span></span></span></p></td><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span><span><span>Observable inputs (other than Level 1 quoted prices) such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span></span></span></span></span></span></span></span></span></span></span></span></span></span></p></td></tr><tr style="height:15"><td valign="top">&#160;</td><td valign="top">&#160;</td></tr><tr style="height:15"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span><span><span>Level 3:</span></span></span></span></span></span></span></span></span></span></span></span></span></span></p></td><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span><span><span>Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span></span></span></span></span></span></span></span></span></span></span></span></span></span></p></td></tr></tbody></table><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span>The carrying values of the Company&#x2019;s financial instruments, with the exception of the Credit Agreement and derivative liabilities, including, cash, prepaid expenses, accounts payable, and other current liabilities approximate their fair value due to the short maturities of these financial instruments. The derivative liabilities are valued on a recurring basis utilizing Level 3 inputs.</span></span></span></span></span></span></span></span></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span>Advances under the Credit Agreement are not recorded at fair value. However, fair value can be approximated and disclosed utilizing Level 3 inputs and independent third-party valuation techniques (See Note 3). As of December 31, 2019 and 2018, the fair value of the advances under the Credit Agreement was $1,877,938 and $3,176,824, respectively. The carrying amount of the liability at December 31, 2019 and 2018, was $387,070 and $1,360,960, respectively, and is included in Convertible multi-draw credit agreement - related party, net of discount in the Company&#x2019;s Consolidated Balance Sheets.</span></span></span></span></span></span></span></span></span></span></p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><div><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span><span><span><strong><i>Property and Equipment, Net</i></strong></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span>Property and equipment, net, consist primarily of computers and equipment. Expenditures for additions, renewals and improvements are capitalized at cost. Depreciation is computed on a<span><span><span><span><span><span> straight-line method based on </span></span></span></span></span></span>the estimated useful life of the related asset currently ranging from two to three years. Maintenance and repairs that do not extend the life of assets are charged to expense when incurred. When properties are disposed of, the related costs and accumulated depreciation are removed from the accounts and any gain or loss is reported in the period the transaction takes place.</span></span></span></span></span></span></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span><span><span>Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted cash flows expected to be generated by the asset. If the carrying amount exceeds its estimated future undiscounted cash flows, an impairment charge is recognized by the amount by which the carrying amount exceeds the fair value of the asset.</span></span></span></span></span></span></span></span></span></span></span></span></span></span></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span><span><span><strong><i>Income Taxes</i></strong></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span>The Company accounts for deferred income tax assets and liabilities based on differences between the financial reporting and tax bases of assets and liabilities, net operating loss carryforwards (the &#x201c;NOLs&#x201d;) and other tax credit carryforwards. These items are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the period that includes the enactment date. Any interest or penalties would be recorded in the Company&#x2019;s Consolidated Statements of Comprehensive Income (Loss) in the period incurred. When necessary, the Company recognizes interest and penalties related to income tax matters in income tax expense.</span></span></span></span></span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span>The Company records a valuation allowance against deferred tax assets to the extent that it is more likely than not that some portion or all of the deferred tax assets will not be realized. In making such determinations, management considers all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and recent financial operations. Due to the substantial doubt related to the Company&#x2019;s ability to utilize its deferred tax assets, a valuation allowance for the full amount of the deferred tax assets has been established at December 31, 2019 and 2018. As a result of this valuation allowance, there are no income tax benefits reflected in the accompanying Consolidated Statements of Comprehensive Income (Loss) to offset pre-tax losses.</span></span></span></span></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span>The Company recognizes a tax benefit from uncertain tax positions when it is more likely than not (50%) that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits of the position.</span></span></span></span></span></span></p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Convertible Instruments</a></td>
<td class="text"><div><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span><span><span><strong><i>Convertible Instruments</i></strong></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span>The Company accounts for hybrid contracts with embedded conversion features in accordance with GAAP. ASC 815, <em>Derivatives and Hedging Activities</em> (&#x201c;ASC 815&#x201d;) requires companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria includes circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.</span></span></span></span></span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span>The Company accounts for convertible debt instruments with embedded conversion features in accordance with ASC 470-20, Debt with Conversion and Other Options (&#x201c;ASC 470-20&#x201d;) if it is determined that the conversion feature should not be bifurcated from their host instruments. Under ASC 470-20, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the difference between the fair value of the underlying common stock at the commitment date and the embedded effective conversion price. When the Company determines that the embedded conversion option should be bifurcated from its host instrument, the embedded feature is accounted for in accordance with ASC 815. Under ASC 815, a portion of the proceeds received upon the issuance of the hybrid contract is allocated to the fair value of the derivative. The derivative is subsequently marked to market at each reporting date based on current fair value, with the changes in fair value reported in the results of operations.</span></span></span></span></span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span>The Company also follows ASC 480-10, <em>Distinguishing Liabilities from Equity</em> (&#x201c;ASC 480-10&#x201d;) when evaluating the accounting for its hybrid instruments. A financial instrument that embodies an unconditional obligation, or a financial instrument other than an outstanding share that embodies a conditional obligation, that the issuer must or may settle by issuing a variable number of its equity shares shall be classified as a liability (or an asset in some circumstances) if, at inception, the monetary value of the obligation is based solely or predominantly on any one of the following: (a) a fixed monetary amount known at inception (for example, a payable settled with a variable number of the issuer&#x2019;s equity shares); (b) variations in something other than the fair value of the issuer&#x2019;s equity shares (for example, a financial instrument indexed to the Standard and Poor&#x2019;s S&amp;P 500 Index and settled with a variable number of the issuer&#x2019;s equity shares); or (c) variations inversely related to changes in the fair value of the issuer&#x2019;s equity shares (for example, a written put option that could be net share settled). Hybrid instruments meeting these criteria are not further evaluated for any embedded derivatives and are carried as a liability at fair value at each balance sheet date with a re-measurement reported in other (income) expense in the accompanying Consolidated Statements of Comprehensive Income (Loss).</span></span></span></span></span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span>When determining short-term vs. long-term classification of derivative liabilities, the Company first evaluates the instruments&#x2019; exercise provisions. Generally, if a derivative is a liability and exercisable within one year, it will be classified as short-term. However, because of the unique provisions and circumstances that may impact the accounting for derivative instruments, the Company carefully evaluates all factors that could potentially restrict the instrument from being exercised or create a situation where exercise would be considered remote. The Company re-evaluates its derivative liabilities at each reporting period end and make&#160;updates for any changes in facts and circumstances that may impact classification.</span></span></span></span></span></span></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock', window );">Warrants Issued in Connection with Financings</a></td>
<td class="text"><div><p style="margin:0px 0px 0px 0.35pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span><span><span><strong><i>Warrants Issued in Connection with Financings</i></strong></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span>The Company generally accounts for warrants issued in connection with debt and equity financings as a component of equity, unless the warrants include a conditional obligation to issue a variable number of shares or there is a deemed possibility that the Company may need to settle the warrants in cash. For warrants issued with a conditional obligation to issue a variable number of shares or the deemed possibility of a cash settlement, the Company records the fair value of the warrants as a liability at each balance sheet date and records changes in fair value in other (income) expense in the Consolidated Statements of Comprehensive Income (Loss).</span></span></span></span></span></span></p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Debt Issuance Costs and Interest</a></td>
<td class="text"><div><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span><span><span><strong><i>Debt Issuance Costs and Interest</i></strong></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span>Discounts related to bifurcated derivatives, freestanding instruments issued in bundled transactions and issuance costs are recorded as a reduction to the carrying value of the debt and amortized over the life of the debt using the effective interest method. The Company makes changes to the effective interest rate, as necessary, on a prospective basis. For debt facilities that provide for multiple advances, the Company initially defers any issuance costs until the first advance is made and then amortizes the costs over the life of the facility.</span></span></span></span></span></span></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses and Licensed Technology</a></td>
<td class="text"><div><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span><span><span><strong><i>Research and Development Expenses and Licensed Technology</i></strong></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span>Research and development costs are expensed when incurred. These costs may consist of external research and development expenses incurred under agreements with third-party contract research organizations and investigative sites, third-party manufacturing organizations and consultants; license fees; employee-related expenses, which include salaries and benefits for the personnel involved in the Company&#x2019;s preclinical and clinical drug development activities; facilities expense, depreciation and other allocated expenses; and equipment and laboratory supplies.</span></span></span></span></span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span>Costs incurred for the rights to use licensed technologies in the research and development process, including licensing fees and milestone payments, are charged to research and development expense as incurred in situations where the Company has not identified an alternative future use for the acquired rights, and are capitalized in situations where there is an identified alternative future use. No cost associated with the use of licensed technologies has been capitalized to date.</span></span></span></span></span></span></p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation for Employees</a></td>
<td class="text"><div><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span><span><span><span><span><strong><i>Stock-Based Compensation&#160;</i></strong></span></span></span></span></span></span></span></span></span></span></span></span><em><strong>Expense</strong></em></span></span></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span><span><span>Stock-based compensation expense is estimated at the grant date based on the fair value of the award, and the cost is recognized as expense ratably over the vesting period with forfeitures accounted for as they occur. The Company uses the Black-Scholes Merton option pricing model for estimating the grant date fair value of stock options using the following assumptions:</span></span></span></span></span></span></span></span></span></span></span></span></span></span></p><p style="MARGIN:0px">&#160;</p><table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN" width="100%"><tbody><tr style="height:15"><td style="width:4%"><p style="MARGIN:0px;text-align:justify">&#160;</p></td><td style="width:4%" valign="top"><p style="margin:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">&#x2022;</span></span></p></td><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span><span><span>Volatility - Stock price volatility is estimated over the expected term based on a blended rate of industry peers and the Company&#x2019;s actual stock volatility adjusted for periods in which significant financial variability was identified.</span></span></span></span></span></span></span></span></span></span></span></span></span></span></p></td></tr><tr style="height:15"><td><p style="MARGIN:0px;text-align:justify">&#160;</p></td><td valign="top"><p style="margin:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">&#x2022;</span></span></p></td><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span><span><span>Expected term - The expected term is based on a simplified method which defines the life as the weighted average of the contractual term of the options and the vesting period for each award.</span></span></span></span></span></span></span></span></span></span></span></span></span></span></p></td></tr><tr style="height:15"><td><p style="MARGIN:0px;text-align:justify">&#160;</p></td><td valign="top"><p style="margin:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">&#x2022;</span></span></p></td><td valign="top"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Risk-free rate - The risk-free interest rate for the expected term of the option is based on the average market rate on U.S. Treasury securities in effect during the period in which the awards were granted.</span></span></p></td></tr><tr style="height:15"><td><p style="MARGIN:0px;text-align:justify">&#160;</p></td><td valign="top"><p style="margin:0px;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">&#x2022;</span></span></p></td><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span><span><span>Dividends - </span></span></span></span></span></span></span></span>The dividend yield assumption is based on the Company&#x2019;s history and expectation of paying no dividends in the foreseeable future.</span></span></span></span></span></span></p></td></tr></tbody></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income (Loss)</a></td>
<td class="text"><div><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><strong><em>Comprehensive Income (Loss)</em></strong></span></span></span></span></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span>Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. ASC 220 <em>Comprehensive Income</em> requires that an entity records all components of comprehensive income (loss), net of their related tax effects, in its financial statements in the period in which they are recognized. For the years ended December 31, 2019 and 2018, the comprehensive income (loss) was equal to net income (loss).</span></span></span></span></span></span></p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Income (Loss) Per Share of Common Stock</a></td>
<td class="text"><div><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><strong><em>Net Income (Loss) Per Share of Common Stock</em></strong></span></span></span></span></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span>The Company applies FASB ASC No. 260, <em>Earnings per Share</em> in calculating its basic and diluted net income (loss) per share. Basic net income (loss) per share of common stock is computed by dividing net income (loss) available to common stockholders by the weighted-average number of shares of common stock outstanding for the period. The diluted net loss per share of common stock is computed by giving effect to all potential common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, options to purchase common stock, restricted stock subject to vesting, warrants to purchase common stock and common shares underlying convertible debt instruments were considered to be common stock equivalents. In periods with a reported net loss, such common stock equivalents are excluded from the calculation of diluted net loss per share of common stock if their effect is anti-dilutive. For additional information regarding the net income (loss) per share, see Note 7 &#x201c;Net Income (Loss) per Share of Common Stock.&#x201d;</span></span></span></span></span></span></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span><span><span><strong><i>Recent Accounting Pronouncements</i></strong></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>In December 2019, the FASB issued ASU No. 2019-12 Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes. The Board issued this Update as part of its Simplification Initiative to improve areas of GAAP and reduce cost and complexity while maintaining usefulness. The main provisions remove certain exceptions, including the exception to the general methodology for calculating income taxes in an interim period when a year-to-date loss exceeds the anticipated loss for the year. In addition, the amendments simplify income tax accounting in the areas such as income-based franchise taxes, eliminating the requirements to allocate consolidated current and deferred tax expense in certain instances and a requirement that an entity reflects the effect of enacted changes in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date. For public companies, the standard is effective for fiscal years beginning after December 15, 2019, and interim periods therein. The Company plans to adopt this ASU on the effective date of January 1, 2020. The amendments in the update related to foreign subsidiaries will be applied on a modified retrospective basis, the amendments to franchise taxes will be applied on either a retrospective or modified retrospective basis and all other amendments will be applied on a prospective basis. The Company is still evaluating the impact from adopting this standard. However, because the Company&#x2019;s deferred tax assets and liabilities are fully reserved, it does not expect a material impact from the adoption of this standard.</span></span></span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>In November 2018, the FASB issued ASU No. 2018-08 <em>Collaborative Arrangements</em> (Topic 808) intended to improve financial reporting around collaborative arrangements and align the current guidance under ASC 808 with ASC 606 <em>Revenue from Contracts with Customers</em>. The ASU affects all companies that enter into collaborative arrangements. The ASU clarifies when certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606 and changes certain presentation requirements for transactions with collaborative arrangement participants that are not directly related to sales to third parties. For public companies, the standard is effective for fiscal years beginning after December 15, 2019 and interim periods therein. Earlier adoption is permitted for any annual or interim period for which consolidated financial statements have not yet been issued. The Company has not entered into any collaborative arrangements and therefore does not currently expect the adoption of this standard to have a material effect on its Consolidated Financial Statements. The Company plans to adopt this ASU on the effective date of January 1, 2020. Upon adoption, the Company will utilize the retrospective transition approach, as prescribed within this ASU.</span></span></span></span></p><p style="margin:0px 0px 0px 0in;text-align:justify">&#160;</p><p style="margin:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span><span><span><span><span><span><span><span><strong><i>Recently Adopted Accounting Standards </i></strong></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception (&#x201c;ASU 2017-11&#x201d;). Part I of this update addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of the pricing of future equity offerings. Current accounting guidance creates cost and complexity for entities that issue financial instruments (such as warrants and convertible instruments) with down round features that require fair value measurement of the entire instrument or conversion option. Part II of this update addresses the difficulty of navigating Topic 480, Distinguishing Liabilities from Equity, because of the existence of extensive pending content in the FASB Accounting Standards Codification. This pending content is the result of the indefinite deferral of accounting requirements about mandatorily redeemable financial instruments of certain nonpublic entities and certain mandatorily redeemable non-controlling interests. The amendments in Part II of this update do not have an accounting effect. The Company adopted this ASU on the effective date of January 1, 2019. The adoption of this standard using a retrospective cumulative-effect adjustment approach had no impact on the Company&#x2019;s accumulated deficit. The outstanding warrants issued in the Emerald Financing contain a down-round provision. However, in the absence of the down-round provision, these warrants would still require liability accounting and be considered derivatives (See Note 3). As such, the adoption of ASU 2017-11 on January 1, 2019, did not have an impact on the Company&#x2019;s Consolidated Financial Statements and Notes thereto.</span></span></span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>In February 2016, the FASB issued ASU No. 2016-02 <em>Leases</em> (Topic 842). In January, July and December 2018, and in March 2019, the FASB issued additional amendments to the new lease guidance relating to transition and clarification. This ASU requires most lessees to recognize right of use assets and lease liabilities and recognize expenses in a manner similar to current accounting standards. For public companies, the standard is effective for fiscal years beginning after December 15, 2018 and interim periods therein. The Company adopted this ASU on the effective date of January 1, 2019. Pursuant to ASU 2018-11, issued in July 2018, the Company elected to use the effective date as of the date of application for transition. Upon adoption there was no cumulative effect recorded to the accumulated deficit, as the Company has no lease terms in excess of one year. The Company has elected the short-term lease practical expedient under the ASU which resulted in no change to the current recognition accounting under ASC 840.</span></span></span></span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_RisksAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents policy for Risks and Uncertainties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_RisksAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for warrants issued in bundled transactions with other financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41638-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579245-113959<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41675-113959<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32247-109318<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32280-109318<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6814019440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants and Derivative Liabilities (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_WarrantsVestedAndOutstanding', window );">Amount Vested and Outstanding | shares</a></td>
<td class="nump">25,143,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_Pre2015CommonStockWarrantsMember', window );">Pre 2015 Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 1.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_WarrantsVestedAndOutstanding', window );">Amount Vested and Outstanding | shares</a></td>
<td class="nump">4,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_Pre2015CommonStockWarrantsMember', window );">Pre 2015 Common Stock Warrants | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TermOfWarrant', window );">Term (Years)</a></td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_Pre2015CommonStockWarrantsMember', window );">Pre 2015 Common Stock Warrants | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TermOfWarrant', window );">Term (Years)</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandFifteenCommonStockWarrantsMember', window );">2015 Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_WarrantsVestedAndOutstanding', window );">Amount Vested and Outstanding | shares</a></td>
<td class="nump">442,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandFifteenCommonStockWarrantsMember', window );">2015 Common Stock Warrants | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 1.15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TermOfWarrant', window );">Term (Years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandFifteenCommonStockWarrantsMember', window );">2015 Common Stock Warrants | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 5.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TermOfWarrant', window );">Term (Years)</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_CommonStockWarrantsToSeriesBStockholdersMember', window );">Common Stock Warrants to Series B Stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 0.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TermOfWarrant', window );">Term (Years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_WarrantsVestedAndOutstanding', window );">Amount Vested and Outstanding | shares</a></td>
<td class="nump">1,031,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember', window );">2016 Common Stock Warrants to Service Providers</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 1.15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TermOfWarrant', window );">Term (Years)</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_WarrantsVestedAndOutstanding', window );">Amount Vested and Outstanding | shares</a></td>
<td class="nump">40,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember', window );">2016 Series C Common Stock Warrants to Placement Agent</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 0.40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TermOfWarrant', window );">Term (Years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_WarrantsVestedAndOutstanding', window );">Amount Vested and Outstanding | shares</a></td>
<td class="nump">125,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember', window );">2017 Series D Common Stock Warrants to Placement Agent</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 0.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TermOfWarrant', window );">Term (Years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_WarrantsVestedAndOutstanding', window );">Amount Vested and Outstanding | shares</a></td>
<td class="nump">480,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember', window );">2017 Common Stock Warrants to Service Provider</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 0.41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TermOfWarrant', window );">Term (Years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_WarrantsVestedAndOutstanding', window );">Amount Vested and Outstanding | shares</a></td>
<td class="nump">125,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandEighteenEmeraldFinancingWarrantsMember', window );">2018 Emerald Financing Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 0.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TermOfWarrant', window );">Term (Years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_WarrantsVestedAndOutstanding', window );">Amount Vested and Outstanding | shares</a></td>
<td class="nump">3,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember', window );">Emerald Multi-Draw Credit Agreement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 0.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TermOfWarrant', window );">Term (Years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_WarrantsVestedAndOutstanding', window );">Amount Vested and Outstanding | shares</a></td>
<td class="nump">7,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandNineteenCommonStockWarrantsMember', window );">2019 Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 0.35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TermOfWarrant', window );">Term (Years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_WarrantsVestedAndOutstanding', window );">Amount Vested and Outstanding | shares</a></td>
<td class="nump">8,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_TermOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents term of warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_TermOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_WarrantsVestedAndOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents warrants vested and outstanding as of balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_WarrantsVestedAndOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_Pre2015CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_Pre2015CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandFifteenCommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandFifteenCommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_CommonStockWarrantsToSeriesBStockholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_CommonStockWarrantsToSeriesBStockholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandEighteenEmeraldFinancingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandEighteenEmeraldFinancingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandNineteenCommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandNineteenCommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6813260848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Debt - Related Party (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Less, noncurrent portion</a></td>
<td class="num">$ (387,070)<span></span>
</td>
<td class="num">$ (1,360,960)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible debt | Emerald Health Sciences Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Total principal value</a></td>
<td class="nump">2,014,500<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountCurrent', window );">Unamortized debt discount</a></td>
<td class="num">(1,622,344)<span></span>
</td>
<td class="num">(587,617)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsCurrentGross', window );">Unamortized debt issuance costs</a></td>
<td class="num">(5,086)<span></span>
</td>
<td class="num">(51,423)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Carrying value of total convertible debt - related party</a></td>
<td class="nump">387,070<span></span>
</td>
<td class="nump">1,360,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Less, noncurrent portion</a></td>
<td class="num">(387,070)<span></span>
</td>
<td class="num">(1,360,960)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Current convertible debt - related party</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsCurrentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsCurrentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=embi_EmeraldHealthSciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=embi_EmeraldHealthSciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6813101392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Warrants and Derivative Liabilities (Details 1) - 2019 Common Stock Warrants - Black-Scholes option pricing model<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Underlying common stock price</a></td>
<td class="nump">$ 0.22<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandNineteenCommonStockWarrantsMember', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input (in percent)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandNineteenCommonStockWarrantsMember', window );">Volatility factor</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input (in percent)</a></td>
<td class="nump">93.08<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandNineteenCommonStockWarrantsMember', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input (in percent)</a></td>
<td class="nump">1.62<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandNineteenCommonStockWarrantsMember', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected Term (years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandNineteenCommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandNineteenCommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_PricingModelAxis=embi_PricingModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_PricingModelAxis=embi_PricingModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6814606848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants and Derivative Liabilities (Details 5) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 16, 2018</div></th>
<th class="th"><div>Jan. 19, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_DerivativeLiabilitiesLineItems', window );"><strong>Derivative Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_FairValueOfWarrantsIssued', window );">Initial fair value of Emerald Financing Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 516,058<span></span>
</td>
<td class="nump">$ 10,988,736<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Less: proceeds from the Emerald Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,919,372)<span></span>
</td>
<td class="num">(3,095,908)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=embi_EmeraldFinancingMember', window );">Emerald Financing - Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_DerivativeLiabilitiesLineItems', window );"><strong>Derivative Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_FairValueOfWarrantsIssued', window );">Initial fair value of Emerald Financing Warrant Liability</a></td>
<td class="nump">$ 5,707,423<span></span>
</td>
<td class="nump">$ 4,717,211<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">10,424,634<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Less: proceeds from the Emerald Financing</a></td>
<td class="nump">1,750,000<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,250,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Excess over proceeds adjustment</a></td>
<td class="nump">$ 3,957,423<span></span>
</td>
<td class="nump">$ 3,217,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,174,634<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_DerivativeLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line item represents derivative liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_DerivativeLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_FairValueOfWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of warrants issued in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_FairValueOfWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=embi_EmeraldFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=embi_EmeraldFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6636987152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Contracts - University of Mississippi<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_SignificantContractsAbstract', window );"><strong>Significant Contracts [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_SignificantContractsTextBlock', window );">Significant Contracts - University of Mississippi</a></td>
<td class="text"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>9. Significant Contracts - University of Mississippi</strong><strong> </strong></span></span></span></span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><em>UM 5050 Pro-Drug and UM 8930 Analog Agreements</em></strong></span></span></span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>In July 2018, the Company renewed its ocular licenses for UM 5050, related to the pro-drug formulation of tetrahydrocannabinol (&#x201c;THC&#x201d;), and UM 8930, related to an analog formulation of cannabidiol (&#x201c;CBD&#x201d;). On May 24, 2019, the ocular delivery licenses were replaced by &#x201c;all fields of use&#x201d; licenses for both UM 5050 and UM 8930 (collectively, the &#x201c;License Agreements&#x201d;). Pursuant to the License Agreements, UM granted the Company an exclusive, perpetual license, including, with the prior written consent of UM, the right to sublicense, to intellectual property related to UM 5050 and UM 8930 for all fields of use.</span></span></span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The License Agreements contain certain milestone payments, royalty and sublicensing fees payable by the Company, as defined therein. Each License Agreement provides for an annual maintenance fee of $75,000 payable on the anniversary of the effective date. The upfront payment for UM 5050 is $100,000 and the upfront payment for UM 8930 is $200,000. Additionally, there is also a $200,000 fee due within 30 days upon receipt of the first United States Patent and Trademark Office Notice of Allowance for UM 8930. The milestone payments payable for each license are as follows:</span></span></span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#160;</p><table border="0" cellpadding="0" cellspacing="0" style="border:0px" width="100%"><tbody><tr><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:3%" valign="top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>i)</span></span></span></span></td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:76%" valign="top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$100,000 paid within 30 days following the submission of the first Investigational New Drug Application to the Food and Drug Administration or an equivalent application to a regulatory agency anywhere in the world, for a product;</span></span></span></span></td></tr><tr><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:3%">&#160;</td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:76%">&#160;</td></tr><tr><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:3%" valign="top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>ii)</span></span></span></span></td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:76%" valign="top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$200,000 paid within 30 days following the first submission of an NDA, or an equivalent application to a regulatory agency anywhere in the world, for each product that is administered in a different route of administration from that of the early submitted product(s); and</span></span></span></span></td></tr><tr><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:3%">&#160;</td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:76%">&#160;</td></tr><tr><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:3%" valign="top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>iii)</span></span></span></span></td><td style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;width:76%" valign="top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$400,000 paid within 30 days following the approval of an NDA, or an equivalent application to a regulatory agency anywhere in the world, for each product that is administered in a different route of administration from that of the early approved product(s).</span></span></span></span></td></tr></tbody></table><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The royalty percentage due on net sales under each License Agreement is in the mid-single digits. The Company must also pay to UM a portion of all licensing fees received from any sublicensees, subject to a minimum royalty on net sales, and the Company is required to reimburse patent costs incurred by UM related to the licensed products. The royalty obligations apply by country and by licensed product, and end upon the later of the date that no valid claim of a licensed patent covers a licensed product in a given country, or ten&#160;years after the first commercial sale of such licensed product in such country.</span></span></span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Each License Agreement continues, unless terminated, until the later of the expiration of the last to expire of the patents or patent applications within the licensed technology or the expiration of the Company&#x2019;s payment obligations under such License Agreement. UM may terminate each License Agreement, by giving written notice of termination, upon the Company&#x2019;s material breach of such License Agreement, including failure to make payments or satisfy covenants, representations or warranties without cure, noncompliance, a bankruptcy event, the Company&#x2019;s dissolution or cessation of operations, the Company&#x2019;s failure to make reasonable efforts to commercialize at least one product or failure to keep at least one product on the market after the first commercial sale for a continuous period of one year, other than for reasons outside the Company&#x2019;s control, or the Company&#x2019;s failure to meet certain pre-established development milestones. The Company may terminate each License Agreement upon 60 days&#x2019; written notice to UM.</span></span></span></span><br/>&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">As of December 31, 2019, none of the milestones under the license agreements have been met.</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><em>UM 5070 License Agreement</em></strong></span></span></span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>In January 2017, the Company entered into a license agreement with UM pursuant to which UM granted us an exclusive, perpetual license, including the right to sublicense, to intellectual property related to a platform of cannabinoid-based molecules (&#x201c;UM 5070&#x201d;), to research, develop and commercialize products for the treatment of infectious diseases. The license agreement culminates roughly one year of screening and target molecule identification studies especially focused on therapy-resistant infectious organisms like Methicillin-resistant Staphylococcus aureus (&#x201c;MRSA&#x201d;).</span></span></span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The Company paid UM an upfront license fee under the license agreement. Under the license agreement, the Company is also responsible for annual maintenance fees that will be credited against royalties in the current fiscal year, contingent milestone payments upon achievement of development and regulatory milestones, and royalties on net sales of licensed products sold for commercial use. The aggregate milestone payments due under the license agreement if all the milestones are achieved is $700,000 and the royalty percentage due on net sales is in the mid-single digits. The Company must also pay to UM a percentage of all licensing fees we receive from any sublicensees, subject to a minimum royalty on net sales by such sublicensees. The Company&#x2019;s royalty obligations apply on a country by country and licensed product by licensed product basis, and end upon the later of the date that no valid claim of a licensed patent covers a licensed product in a given country, or ten years after first commercial sale of such licensed product in such country.</span></span></span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The license agreement continues, unless terminated, until the later of the expiration of the last to expire of the patents or patent applications within the licensed technology or expiration of the Company&#x2019;s payment obligations under the license. UM may terminate the license agreement, effective with the giving of notice, if: (a) the Company fails to pay any material amount payable to UM under the license agreement and do not cure such failure within 60 days after UM notifies us of such failure, (b) the Company materially breaches any covenant, representation or warranty in the license agreement and do not cure such breach within 60 days after UM notifies the Company of such breach, (c) the Company fails to comply in any material respect with the terms of the license and do not cure such noncompliance within 60 days after UM notifies us of such failure, (d) the Company is subject to a bankruptcy event, (e) the Company dissolves or ceases operations or (f) if after the first commercial sale of a product during the term of the license agreement, the Company materially fails to make reasonable efforts to commercialize at least one product or fail to keep at least one product on the market after the first commercial sale for a continuous period of one year, other than for reasons outside of the Company&#x2019;s control. The Company may terminate the license agreement upon 60 days&#x2019; written notice to UM.</span></span></span></span><br/><br/>As of December 31, 2019, none of the milestones under this license agreement have been met.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_SignificantContractsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_SignificantContractsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_SignificantContractsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents entire disclosure for significant contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_SignificantContractsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6801770432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Deficit) and Capitalization<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity (Deficit) and Capitalization</a></td>
<td class="text"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>5. Stockholders&#x2019; Equity (Deficit) and Capitalization</strong></span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><em>Common Stock</em></strong></span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">On November 14, 2018, the Company amended its articles of incorporation to increase the number of authorized shares of common stock available for issuance to 500,000,000.</span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><em>November 2019 Common Stock Offering</em></span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">In November 2019, the Company sold in a registered direct offering an aggregate of 8,000,000 shares of its common stock, par value $0.001 per share, and warrants to purchase 8,000,000 shares of common stock (Note 3). The aggregate net proceeds of the transaction were $1,919,372.</span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><em>Warrant Exercises</em></span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">During the year ended December 31, 2019, Emerald Health Sciences exercised 40,800,000 2018 Emerald Financing Warrants with an intrinsic value of $4,284,000, which resulted in the issuance of 40,800,000 shares of common stock.</span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">During the year ended December 31, 2018, the Series B warrant holders exercised warrants with an intrinsic value of $144,375, which resulted in the issuance of 187,500 shares of common stock.</span></span></p><p style="MARGIN:0px"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">&#160;&#160;</span></span></p><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><i>Emerald Financing</i></span></span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">On January 19, 2018, the Company entered into a Securities Purchase Agreement pursuant to which the Company sold to Emerald Health Sciences 15,000,000 shares of common stock and a warrant to purchase 20,400,000 shares of common stock at an exercise price of $0.10 for aggregate gross proceeds of $1,500,000 (the &#x201c;Emerald Financing&#x201d;). This transaction also resulted in the conversion of the $900,000&#160;Convertible Promissory Note (Note 4). As part of the transaction, the Company&#x2019;s Board members, with the exception of Dr. Brian Murphy, the Company&#x2019;s CEO/CMO, tendered their resignation and Emerald Health Sciences appointed two new nominees to the Board.&#160;The Securities Purchase Agreement also provides that in the case of a subsequent financing in which the purchase price is less than $0.10 per share, Emerald Health Sciences shall be issued additional shares in order to protect against anti-dilution.</span></span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The second closing under the Emerald Financing occurred on February 16, 2018, pursuant to which the Company issued and sold to Emerald Health Sciences 15,000,000 shares of the Company&#x2019;s common stock, and a warrant to purchase 20,400,000 shares of common stock at an exercise price of $0.10 per share for a term of five years. In addition, an accredited investor purchased 2,500,000 shares of common stock and a warrant to purchase 3,400,000 shares of common stock at an exercise price of&#160;$0.10 per share for a term of five years. The Company received aggregate gross proceeds of $1,750,000 from the second closing. In connection with the private placement, the Company incurred issuance costs of $154,092, of which $137,192 was allocated to the warrant liability and expensed during the period and $16,900 was recorded as a reduction to additional paid-in capital from the issuance of common stock.</span></span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><i>Conversion of Preferred Stock</i></span></span></p><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">During the year ended December 31, 2018 all remaining Preferred Series B, D, and F shares were converted to common stock as follows:</span></span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:justify;FONT:10pt TIMES NEW ROMAN" width="100%"><tbody><tr><td style="width:31px"><p style="MARGIN:0px">&#160;</p></td><td style="width:33px" valign="top"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center">&#x2022;</p></td><td valign="top"><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">For the year ended December 31, 2018,&#160;2,833.55<span>&#160;shares of Series B Preferred stock were converted, resulting in the issuance of </span>28,385,000<span>&#160;shares of common stock.</span></span></span></p></td></tr><tr><td style="width:31px"><p style="MARGIN:0px">&#160;</p></td><td style="width:33px;text-align:center" valign="top">&#x2022;</td><td valign="top"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">For the year ended December 31, 2018, 200&#160;shares of Series D Preferred stock were converted, resulting in the issuance of 2,000,000&#160;shares of common stock.</span></span></td></tr><tr><td style="width:31px"><p style="MARGIN:0px">&#160;</p></td><td style="width:33px;text-align:center" valign="top">&#x2022;</td><td valign="top"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">For the year ended December 31, 2018, 2,000&#160;shares of Series F Preferred stock were converted, resulting in the issuance of 20,000,000&#160;shares of common stock.</span></span></td></tr></tbody></table><p><br/><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><em>Preferred Stock</em></strong></span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The Company has 20,000,000 authorized shares of preferred stock, with a par value of $0.001 per share. As of December 31, 2019, there were no shares of preferred stock issued and outstanding.</span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">During the year ended December 31, 2018, all remaining Preferred Series B, D, and F shares that were previously issued and outstanding were converted to common stock.</span></span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6803801808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Mar. 16, 2020</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Emerald Bioscience, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001516551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183,207,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,116,620<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6799017264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details 1) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Current deferred tax assets/(liabilities):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsStateTaxes', window );">State taxes</a></td>
<td class="nump">$ 336<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts', window );">Capitalized research and development costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,327<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">112,222<span></span>
</td>
<td class="nump">187,377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss</a></td>
<td class="nump">6,434,544<span></span>
</td>
<td class="nump">5,104,432<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">6,547,102<span></span>
</td>
<td class="nump">5,302,481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(6,206,450)<span></span>
</td>
<td class="num">(5,302,481)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">340,652<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_DeferredTaxLiabilitiesNoteDiscount', window );">Note discount</a></td>
<td class="nump">340,652<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="nump">340,652<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalized research and development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_DeferredTaxLiabilitiesNoteDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of notes discount related to deferred tax liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_DeferredTaxLiabilitiesNoteDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsStateTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from state taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsStateTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31931-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6813101024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 1,051,825<span></span>
</td>
<td class="num">$ (19,194,236)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">1,462<span></span>
</td>
<td class="nump">1,544<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">803<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">680,455<span></span>
</td>
<td class="nump">674,961<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of derivative liabilities</a></td>
<td class="num">(9,734,759)<span></span>
</td>
<td class="nump">6,503,174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_FairValueOfDerivativeLiabilityExcessOfProceeds', window );">Fair value of derivative liabilities in excess of proceeds</a></td>
<td class="nump">322,644<span></span>
</td>
<td class="nump">7,174,634<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDerivativeIssuanceCosts', window );">Financing transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,192<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt - related party</a></td>
<td class="nump">725,425<span></span>
</td>
<td class="nump">590,392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_LossOnCommonStockIssuanceFromConversionOfAccruedInterest', window );">Loss on common stock issuance from conversion of accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,794<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">629,293<span></span>
</td>
<td class="nump">58,536<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="num">(59,502)<span></span>
</td>
<td class="nump">198,235<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets</a></td>
<td class="num">(4,941)<span></span>
</td>
<td class="num">(2,609)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">124,212<span></span>
</td>
<td class="num">(85,324)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accounts payable to related party</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="nump">225,945<span></span>
</td>
<td class="num">(10,110)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(6,027,941)<span></span>
</td>
<td class="num">(3,943,014)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,385)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,385)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of Common stock and warrants, net of $80,628 and $154,092 of issuance costs in 2019 and 2018, respectively</a></td>
<td class="nump">1,919,372<span></span>
</td>
<td class="nump">3,095,908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from warrant exercises</a></td>
<td class="nump">4,080,000<span></span>
</td>
<td class="nump">98,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from secured convertible promissory note - related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_ProceedsFromConvertibleMultiDrawCreditAgreement', window );">Proceeds from convertible multi-draw credit agreement - related party, net of issuance costs</a></td>
<td class="nump">3,990,699<span></span>
</td>
<td class="nump">1,946,293<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_RepaymentOfConvertibleMultiDrawCreditAgreement', window );">Prepayment of convertible multi-draw credit agreement - related party</a></td>
<td class="num">(3,985,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">6,004,571<span></span>
</td>
<td class="nump">5,540,901<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net (decrease) increase in cash and restricted cash</a></td>
<td class="num">(23,370)<span></span>
</td>
<td class="nump">1,593,502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and restricted cash, beginning of year</a></td>
<td class="nump">1,857,885<span></span>
</td>
<td class="nump">264,383<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash and restricted cash shown in the consolidated statements of cash flows</a></td>
<td class="nump">1,834,515<span></span>
</td>
<td class="nump">1,857,885<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Reconciliation of cash and restricted cash:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">1,829,977<span></span>
</td>
<td class="nump">1,853,373<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">4,538<span></span>
</td>
<td class="nump">4,512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash and restricted cash shown in the consolidated statements of cash flows</a></td>
<td class="nump">1,834,515<span></span>
</td>
<td class="nump">1,857,885<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_CashPaidDuringPeriodForAbstract', window );"><strong>Cash paid during the year for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="nump">371,420<span></span>
</td>
<td class="nump">23,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,642<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosures of non-cash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement', window );">Beneficial conversion feature on convertible multi-draw credit agreement</a></td>
<td class="nump">1,584,850<span></span>
</td>
<td class="nump">90,080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement', window );">Proceeds allocated to equity classified warrants issued with convertible multi-draw credit agreement</a></td>
<td class="nump">716,110<span></span>
</td>
<td class="nump">315,080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement', window );">Fair value of compound derivative liability bifurcated from convertible multi-draw credit agreement</a></td>
<td class="nump">193,414<span></span>
</td>
<td class="nump">204,102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_ExerciseOfWarrants', window );">Reclassification of warrant liabilities to equity from exercise of warrants</a></td>
<td class="nump">$ 6,077,698<span></span>
</td>
<td class="nump">1,539,866<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_FairValueOfWarrantsIssuedInConnectionWithFinancings', window );">Fair value of warrants issued in connection with financings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,424,634<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of outstanding preferred stock into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,947,228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Fair value of common stock issued in extinguishment of convertible debt and accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,713,766<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock', window );">Conversion of outstanding preferred stock subject to redemption into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 828,915<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of beneficial conversion feature recorded on advances under the convertible multi-draw credit agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_CashPaidDuringPeriodForAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_CashPaidDuringPeriodForAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of conversion of outstanding preferred stock subject to redemption into common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_ExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the fair value of derivative liabilities reclassified to equity upon the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_ExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the initial fair value of the compound derivative liability that was bifurcated from advances under the convertible multi-draw credit agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_FairValueOfDerivativeLiabilityExcessOfProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of fair value of derivative liability in excess of proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_FairValueOfDerivativeLiabilityExcessOfProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_FairValueOfWarrantsIssuedInConnectionWithFinancings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of fair value of warrants issued in connection with financings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_FairValueOfWarrantsIssuedInConnectionWithFinancings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_LossOnCommonStockIssuanceFromConversionOfAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss on common stock issuance from conversion of accrued interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_LossOnCommonStockIssuanceFromConversionOfAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of proceeds allocated on a relative fair value basis to equity classified warrants issued with convertible multi-draw credit agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_ProceedsFromConvertibleMultiDrawCreditAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of convertible multi-draw credit agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_ProceedsFromConvertibleMultiDrawCreditAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_RepaymentOfConvertibleMultiDrawCreditAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount related to prepayment of convertible multi-draw credit agreement - related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_RepaymentOfConvertibleMultiDrawCreditAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDerivativeIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of a derivative security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDerivativeIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6803582128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Detail Textuals 2) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 25, 2018</div></th>
<th class="th"><div>Feb. 28, 2018</div></th>
<th class="th"><div>Jan. 18, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 680,455<span></span>
</td>
<td class="nump">$ 674,961<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total amount of unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 312,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Recognized weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of restricted common stock granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_FairMarketValueOfSharesGranted', window );">Fair market value of shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 475,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Restricted stock vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock Awards | K2C, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of restricted common stock granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockExpense', window );">Stock compensation expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">216,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock Awards | Dr. Brian S. Murphy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of restricted common stock granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock Awards | Elizabeth Berecz, CFO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of restricted common stock granted</a></td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockExpense', window );">Stock compensation expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 184,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock Awards | Cosmas N. Lykos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of restricted common stock granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_FairMarketValueOfSharesGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of shares granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_FairMarketValueOfSharesGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for award of restricted stock or unit under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=embi_K2CIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=embi_K2CIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6800951392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Contracts - University of Mississippi (Detail Textuals) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 10, 2017</div></th>
<th class="th"><div>Jul. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_UniversityOfMississippiAgreementsLineItems', window );"><strong>University Of Mississippi Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_AnnualMaintenanceFeePayable', window );">Annual Maintenance Fee Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=embi_OptionAgreementMember', window );">UM 5050 pro-drug agreements | University of Mississippi | Intellectual Property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_UniversityOfMississippiAgreementsLineItems', window );"><strong>University Of Mississippi Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_PaymentForUpfrontFees', window );">Payment for upfront fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=embi_LicenseAgreementMember', window );">UM 8930 analogue agreements | University of Mississippi | Intellectual Property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_UniversityOfMississippiAgreementsLineItems', window );"><strong>University Of Mississippi Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_PaymentForUpfrontFees', window );">Payment for upfront fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_AnnualFeesForLicenseAgreement', window );">Annual fees for license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=embi_Um5070LicenseAgreementMember', window );">UM 5070 license agreement | University of Mississippi | Intellectual Property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_UniversityOfMississippiAgreementsLineItems', window );"><strong>University Of Mississippi Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TermOfAgreement', window );">Term of agreement</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_NoticePeriodForTermination', window );">Notice period for termination</a></td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_AggregateMilestonePaymentsIfMilestonesAchieved', window );">Aggregate milestone payments if milestones achieved</a></td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=embi_Um5050ProdrugAndUm8930AnalogAgreementsMember', window );">Um 5050 Pro-Drug And Um 8930 Analog Agreements | University of Mississippi | Milestone 1 | Intellectual Property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_UniversityOfMississippiAgreementsLineItems', window );"><strong>University Of Mississippi Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TermOfAgreement', window );">Term of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_AggregateMilestonePaymentsIfMilestonesAchieved', window );">Aggregate milestone payments if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=embi_Um5050ProdrugAndUm8930AnalogAgreementsMember', window );">Um 5050 Pro-Drug And Um 8930 Analog Agreements | University of Mississippi | Milestone 2 | Intellectual Property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_UniversityOfMississippiAgreementsLineItems', window );"><strong>University Of Mississippi Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TermOfAgreement', window );">Term of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_AggregateMilestonePaymentsIfMilestonesAchieved', window );">Aggregate milestone payments if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=embi_Um5050ProdrugAndUm8930AnalogAgreementsMember', window );">Um 5050 Pro-Drug And Um 8930 Analog Agreements | University of Mississippi | Milestone 3 | Intellectual Property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_UniversityOfMississippiAgreementsLineItems', window );"><strong>University Of Mississippi Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TermOfAgreement', window );">Term of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_AggregateMilestonePaymentsIfMilestonesAchieved', window );">Aggregate milestone payments if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_AggregateMilestonePaymentsIfMilestonesAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents amount of aggregate milestone payments under the license agreements if the milestones are achieved.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_AggregateMilestonePaymentsIfMilestonesAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_AnnualFeesForLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents annual fees for license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_AnnualFeesForLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_AnnualMaintenanceFeePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of annual maintenance fee payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_AnnualMaintenanceFeePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_NoticePeriodForTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents written notice period for termination under agreement by either party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_NoticePeriodForTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_PaymentForUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents payment for upfront fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_PaymentForUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_TermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents term of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_TermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_UniversityOfMississippiAgreementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line item represents information regarding University of Mississippi agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_UniversityOfMississippiAgreementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=embi_OptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=embi_OptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=embi_UniversityOfMississippiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=embi_UniversityOfMississippiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=embi_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=embi_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=embi_Um5070LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=embi_Um5070LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=embi_Um5050ProdrugAndUm8930AnalogAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=embi_Um5050ProdrugAndUm8930AnalogAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_MilestonePaymentsPayableAxis=embi_Milestone1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_MilestonePaymentsPayableAxis=embi_Milestone1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_MilestonePaymentsPayableAxis=embi_Milestone2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_MilestonePaymentsPayableAxis=embi_Milestone2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_MilestonePaymentsPayableAxis=embi_Milestone3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_MilestonePaymentsPayableAxis=embi_Milestone3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6801718896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations and Business Activities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">Nature of Operations and Business Activities</a></td>
<td class="text"><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><strong>1. Nature of Operations and Business Activities</strong></span></span></span></span></span></span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><strong><i>Nature of Operations</i></strong></span></span></span></span></span></span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span>Emerald Bioscience, Inc. (the &#x201c;Company&#x201d;) was initially incorporated in Nevada on March 16, 2011 as Load Guard Logistics, Inc. On October 31, 2014, the Company closed a reverse merger transaction (the &#x201c;Merger&#x201d;) pursuant to which Nemus, a California corporation (&#x201c;Nemus Sub&#x201d;), became the Company&#x2019;s wholly-owned subsidiary, and the Company assumed the operations of Nemus Sub. Nemus Sub was incorporated in the State of California on July 17, 2012. On November 3, 2014, the Company changed its name to Nemus Bioscience, Inc. by merging with Nemus Sub.</span></span></span></span></span></span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span>In January 2018, the Company entered into a securities purchase agreement with Emerald Health Sciences, Inc. (&#x201c;Emerald Health Sciences&#x201d;) discussed in Note 5, pursuant to which Emerald Health Sciences purchased a majority of the equity interest in the Company, resulting in a change in control. As part of the transaction, the Company&#x2019;s Board members, with the exception of Dr. Brian Murphy, the Company&#x2019;s CEO/CMO, tendered their resignation and Emerald Health Sciences appointed two new nominees to the Board. Later, in October 2018, the Board appointed Dr. Avtar Dhillon, the Chairman, Chief Executive Officer and President of Emerald Health Sciences, as the Executive Chairman of the Company&#x2019;s Board.</span></span></span></span></span></span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span>On February 11, 2019, the Company&#x2019;s Board of Directors (the &#x201c;Board&#x201d;) and majority stockholder unanimously approved an amendment to the Company&#x2019;s articles of incorporation to change the name of the Company to Emerald Bioscience, Inc. Effective March 25, 2019, the Company filed a Certificate of Amendment with the Nevada Secretary of State changing the Company&#x2019;s name to Emerald Bioscience, Inc.</span></span></span></span></span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span>In August 2019, the Company formed a new subsidiary in Australia, EMBI Australia Pty Ltd., an Australian proprietary limited company (&#x201c;EMBI Australia&#x201d;), in order to qualify for the Australian government&#x2019;s research and development tax credit for research and development dollars spent in Australia. The primary purpose of EMBI Australia is to conduct clinical trials for the Company&#x2019;s product candidates.</span></span></span></span></span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span>On December 17, 2019, Dr. Avtar Dhillon resigned as the Chairman of the Company&#x2019;s Board and the Company entered into a Board Observer Agreement with Emerald Health Sciences. Refer to Note 11 - Related Party Matters for additional information.</span></span></span></span></span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span>The Company, is a biopharmaceutical company located in Long Beach, California that plans to research, develop and commercialize therapeutics derived from cannabinoids through several license agreements with the University of Mississippi (&#x201c;UM&#x201d;). UM is the only entity federally permitted and licensed to cultivate cannabis for research purposes in the United States.</span></span></span></span></span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span>As of December 31, 2019, the Company has devoted substantially all its efforts to securing product licenses, carrying out research and development, building infrastructure and raising capital. The Company has not yet realized revenue from its planned principal operations and is a number of years from potentially being able to do so.</span></span></span></span></span></span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><strong><i>Liquidity and Going Concern</i></strong></span></span></span></span></span></span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>The Company has incurred operating losses and negative cash flows from operations since inception and as of December 31, 2019, had an accumulated deficit of<span><span> $32,173,282.&#160;</span></span>The Company anticipates that it will continue to incur operating losses into the foreseeable future in order to advance and develop a number of potential drug candidates into preclinical and clinical development activities and support its corporate infrastructure which includes the costs associated with being a public company. </span></span></span></span><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">As of December 31, 2019 and filing date of our 2019 Annual Report on Form 10K, the Company had cash in the amount of<span><span><span><span> $1,829,977&#160;</span></span></span></span>and approximately $667,000, respectively.</span></span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>During the year ended December 31, 2019, the Company received net cash proceeds of $3,990,699 from the Credit Agreement (defined below) with Emerald Health Sciences and raised $1,919,372 in net proceeds pursuant to the sale of common stock and warrants under a registered direct offering. However, the Company&#x2019;s cash flows from its financing efforts have been offset by cash used in operating activities of $6,027,941 for the year ended December 31, 2019. </span></span></span></span>As the Company approaches its first clinical trial, it expects to ramp up research and development spending and projects to increase cash used in operating activities. However, based on the Company&#x2019;s current cash position and expected cash requirements, without obtaining additional funding in the second quarter of 2020, management believes that the Company will not have enough funds to meet its obligations. These conditions give rise to substantial doubt as to the Company&#x2019;s ability to continue as a going concern. The accompanying Consolidated Financial Statements do not include any adjustments that might result from the outcome of this uncertainty.</p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>The Company&#x2019;s continued existence is dependent on its ability to raise sufficient additional funding to cover operating expenses and to invest in research and development activities. On October 5, 2018, the Company entered into a Multi-Draw Credit Agreement (the &#x201c;Credit Agreement&#x201d;) with Emerald Health Sciences (See Note 4). As of December 31, 2019, under the Credit Agreement, the Company may&#160;draw down up to the remaining amount under the Credit Agreement of&#160;<span><span>$14,000,000 </span></span>from time to time in principal amounts of at least<span><span> $250,000. </span></span></span></span></span></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The drawdowns are subject to approval by the Company&#x2019;s Board, which is controlled by the directors of Emerald Health Sciences. We do not consider the facility available until advance requests are approved, drawn down and funded. The Credit Agreement is still in place, however, there is no guarantee of continued funding.</span></span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>The Company plans to continue to pursue funding through public or private equity or debt financings, licensing arrangements, asset sales, government grants or other arrangements. However, the Company cannot provide any assurances that such additional funds will be available on reasonable terms, or at all. If the Company raises additional funds by issuing equity securities, substantial dilution to existing stockholders would result.</span></span></span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>Effective March 23, 2020, the Company approved a plan to defer 50% of senior management&#x2019;s compensation indefinitely. If the members of senior management accept the plan, the aggregate deferred compensation, together with a retention bonus of 10% of the amount being deferred will be payable to senior management when decided by the Board. This measure, in conjunction with management&#x2019;s plan to negotiate extended payment terms with its vendors and service providers, is intended to slow cash burn. The Company&#x2019;s Board plans on further assessing the financial condition of the Company to determine what additional measures, if any, will be implemented. If the Company is unable to secure adequate additional funding, the Company may be forced to reduce spending further, liquidate assets where possible, suspend or curtail planned programs or cease operations.</span></span></span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>On March 11, 2020, the World Health Organization declared the outbreak of a respiratory disease caused by a new COVID-19 as a &#x201c;pandemic&#x201d;. Notably, the Company relies on third-party manufacturers to produce its product candidates. The manufacturing of the active pharmaceutical ingredient of NB1111 is conducted in the United States. Formulation of the eye drop for testing is also performed in the United States but can rely on regulatory-accepted excipients that can be sourced from countries outside the United States, such as China. In lieu of the recent pandemic of a COVID-19, there could possibly be an impact on sourcing materials that are part of the eye drop formulation, as well as impacting volunteer and/or patient recruitment in Australia for clinical studies. Therefore, the Company anticipates shifting its first-in-human studies of the lead drug candidate, NB1111, from the second half of 2020, to the 2021 timeframe. Additionally, COVID-19 has caused significant disruptions to the global financial markets which could impact the Company&#x2019;s ability to raise additional capital.</span></span></span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">After considering the plans to alleviate substantial doubt, management has concluded that there is substantial doubt about the Company's ability to continue as a going concern within one year after the date that the financial statements are issued.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
